2015 ESC/ERS Guidelines for the diagnosis and treatme

European Heart Journal

37, 67-119

DOI: 10.1093/eurheartj/ehv317

Citation Report

#	Article	IF	Citations
1	Pulmonary Hypertension in the Cardiothoracic Intensive CareÂUnit. , 0, , 272-277.		0
2	Alzheimer?s disease: the impact of age-related changes in reproductive hormones. Cellular and Molecular Life Sciences, 2005, 62, 257-270.	2.4	144
3	The Second Tomoh Masaki Award (2013). Life Sciences, 2014, 118, 87-90.	2.0	5
4	Pulmonary Veno-Occlusive Disease: An 80-Year-Old Mystery. Respiration, 2014, 88, 148-157.	1.2	8
5	The significance of natriuretic peptide in treatment of pulmonary hypertension after mitral valve replacement. Journal of Thoracic and Cardiovascular Surgery, 2014, 147, 1362-1367.	0.4	2
7	Pulmonary Arterial Hypertension in HIV Infection: A Concise Review. Heart Lung and Circulation, 2014, 23, 299-302.	0.2	9
9	Increase of pulmonary artery wedge pressure above 15 mm Hg in patients with pre-capillary pulmonary hypertension. International Journal of Cardiology Heart & Vessels, 2014, 4, 161-169.	0.5	2
10	Should we pursue pulmonary vasodilation in patients with COPD?. Lancet Respiratory Medicine,the, 2014, 2, 252-254.	5.2	0
11	Role of cardiovascular magnetic resonance in the guidelines of the European Society of Cardiology. Journal of Cardiovascular Magnetic Resonance, 2016, 18, 6.	1.6	125
13	Health-Related Quality of Life in Patients With Chronic Thromboembolic Pulmonary Hypertension. Circulation Journal, 2015, 79, 2553-2554.	0.7	0
14	Interstitial pneumonia and pulmonary hypertension associated with suspected ehrlichiosis in a dog. Acta Veterinaria Scandinavica, 2015, 58, 46.	0.5	5
15	AMBITION: An important piece in the therapeutic puzzle of pulmonary arterial hypertension. Global Cardiology Science & Practice, 2015, 2015, 48.	0.3	0
16	Early Observations on the Use of Riociguat in a Large, Metropolitan Pulmonary Arterial Hypertension/Chronic Thromboembolic Pulmonary Hypertension Treatment Center. Cardiology and Therapy, 2015, 4, 209-218.	1.1	9
17	Pulmonary Hypertension Complicating Fibrosing Mediastinitis. Medicine (United States), 2015, 94, e1800.	0.4	46
18	Metabolic Connection between Incretins and Pulmonary Hypertension. Journal of Diabetes & Metabolism, 2015, s13, .	0.2	0
19	Lung transplantation in chronic obstructive pulmonary disease: patient selection and special considerations. International Journal of COPD, 2015, 10, 2137.	0.9	13
20	Pharmacological Treatment of Idiopathic Pulmonary Fibrosis: Current Approaches, Unsolved Issues, and Future Perspectives. BioMed Research International, 2015, 2015, 1-10.	0.9	60
21	Biomarkers for pediatric pulmonary arterial hypertension: challenges and recommendations. Paediatric Respiratory Reviews, 2015, 16, 225-231.	1.2	10

#	Article	IF	Citations
22	Recent advances in targeting the prostacyclin pathway in pulmonary arterial hypertension. European Respiratory Review, 2015, 24, 630-641.	3.0	78
23	Challenges in pulmonary hypertension: managing the unexpected. European Respiratory Review, 2015, 24, 674-681.	3.0	9
25	Pulmonary arterial hypertension: the burden of disease and impact on quality of life. European Respiratory Review, 2015, 24, 621-629.	3.0	128
26	To decipher the hypoxic pulmonary hypertension: Vascular heterogeneity and the hypothesis of hypoxic responsive threshold. Journal of Medical Hypotheses and Ideas, 2015, 9, 29-37.	0.7	0
27	Pulmonary embolism: An update. Presse Medicale, 2015, 44, e373-e376.	0.8	1
28	Echocardiography and Other Noninvasive Imaging Techniques in the Selection and Management of Patients with Cardiac Resynchronization Therapy. , 2016, , .		0
29	Prevalence of Pulmonary Arterial Hypertension in Korean Adult Patients with Systemic Sclerosis: Result of a Pilot Echocardiographic Screening Study. Journal of Cardiovascular Imaging, 2016, 24, 312.	0.8	9
30	Treatment of patients with chronic thromboembolic pulmonary hypertension: focus on riociguat. Therapeutics and Clinical Risk Management, 2016, 12, 957.	0.9	6
31	Pulmonary Hypertension - New Trends of Diagnostic and Therapy. Medicinski Arhiv = Medical Archives = Archives De MÃ©decine, 2016, 70, 303.	0.4	10
32	Cardiopulmonary laboratory biomarkers in the evaluation of acute dyspnea. Open Access Emergency Medicine, 2016, 8, 35.	0.6	16
33	Where do we go from here? Reappraising the data on anticoagulation in pulmonary arterial hypertension. Journal of Thoracic Disease, 2016, 8, E298-E304.	0.6	4
34	Role of Biomarkers in the Diagnosis, Risk Assessment, and Management of Pulmonary Hypertension. Biomarker Insights, 2016, 11, BMI.S38323.	1.0	8
35	New Therapeutic Paradigms and Guidelines in the Management of Pulmonary Arterial Hypertension. Journal of Managed Care & Specialty Pharmacy, 2016, 22, s3-s21.	0.5	13
36	Pulmonary Hypertension and Indicators of Right Ventricular Function. Frontiers in Medicine, 2016, 3, 23.	1.2	14
37	Pulmonary Hypertension Due to Common Respiratory Conditions: Classification, Evaluation and Management Strategies. Journal of Clinical Medicine, 2016, 5, 75.	1.0	12
38	Cardiac manifestations of idiopathic pulmonary fibrosis. Intractable and Rare Diseases Research, 2016, 5, 70-75.	0.3	28
39	Statins Have No Additional Benefit for Pulmonary Hypertension: A Meta-Analysis of Randomized Controlled Trials. PLoS ONE, 2016, 11, e0168101.	1.1	7
40	4-Phenylbutyric Acid Induces Protection against Pulmonary Arterial Hypertension in Rats. PLoS ONE, 2016, 11, e0157538.	1.1	30

#	Article	IF	Citations
41	Recognizing systemic sclerosis: comparative analysis of various sets of classification criteria. Reumatologia, 2016, 54, 296-305.	0.5	11
42	Update on pharmacotherapy for pulmonary hypertension. Medical Journal of Australia, 2016, 205, 271-276.	0.8	11
43	Comparative Efficacy and Safety of Prostacyclin Analogs for Pulmonary Arterial Hypertension. Medicine (United States), 2016, 95, e2575.	0.4	12
44	Association between endothelial function and micro-vascular remodeling measured by synchrotron radiation pulmonary micro-angiography in pulmonary arterial hypertension. General Thoracic and Cardiovascular Surgery, 2016, 64, 597-603.	0.4	11
45	Group 2 Pulmonary Hypertension Special Issue. Progress in Cardiovascular Diseases, 2016, 59, 1-2.	1.6	10
46	Heart rate response during 6-minute walking testing predicts outcome in operable chronic thromboembolic pulmonary hypertension. BMC Pulmonary Medicine, 2016, 16, 96.	0.8	12
47	Heart Rate Variability and Arrhythmic Burden in Pulmonary Hypertension. Advances in Experimental Medicine and Biology, 2016, 934, 9-22.	0.8	16
48	Pulmonary Hypertension in Aortic Stenosis and Mitral Regurgitation: Rest and Exercise Echocardiography Significance. Progress in Cardiovascular Diseases, 2016, 59, 59-70.	1.6	9
49	Implications of edoxaban in the prevention and treatment of thromboembolic complications in clinical practice. Future Cardiology, 2016, 12, 419-433.	0.5	4
50	Exercise echocardiography for the assessment of pulmonary hypertension in systemic sclerosis: a systematic review. Arthritis Research and Therapy, 2016, 18, 153.	1.6	12
51	Group 2 PH: Medical Therapy. Progress in Cardiovascular Diseases, 2016, 59, 71-77.	1.6	5
52	Inhaled Iloprost for Chronic Thromboembolic Pulmonary Hypertension (CTEPH) During Pregnancy: A Case Report. Pharmacotherapy, 2016, 36, e142-7.	1.2	4
53	Undiagnosed connective tissue diseases. Medicine (United States), 2016, 95, e4827.	0.4	15
54	Biological Phenotyping of Combined Post-Capillary and Pre-Capillary Pulmonary Hypertension. Journal of the American College of Cardiology, 2016, 68, 2537-2539.	1.2	12
55	Beyond a single pathway: combination therapy in pulmonary arterial hypertension. European Respiratory Review, 2016, 25, 408-417.	3.0	53
56	Pulmonary hypertension: the importance of correctly diagnosing the cause. European Respiratory Review, 2016, 25, 372-380.	3.0	9
57	Multimodality imaging in congenital heart disease-related pulmonary arterial hypertension. Heart, 2016, 102, 910-918.	1.2	30
58	Case report: a patient with pulmonary arterial hypertension transitioning from a PDE-5 inhibitor to Riociguat. BMC Pulmonary Medicine, 2016, 16, 82.	0.8	7

#	Article	IF	Citations
59	Riociguat for the treatment of pulmonary hypertension: Chinese subgroup analyses and comparison. Heart Asia, 2016, 8, 74-82.	1.1	12
60	Treatment of children with pulmonary hypertension. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK. Heart, 2016, 102, ii67-ii85.	1.2	55
61	Patients with Down syndrome and congenital heart disease: survival is improving, but challenges remain: TableÂ1. Heart, 2016, 102, 1515-1517.	1.2	12
62	A case of progressive breathlessness post partum. Thorax, 2016, 71, 871-872.	2.7	0
63	Hypertension pulmonaire. Revue Des Maladies Respiratoires Actualites, 2016, 8, S24-S28.	0.0	0
64	Patient engagement and self-management in pulmonary arterial hypertension. European Respiratory Review, 2016, 25, 399-407.	3.0	39
65	Pulmonary hypertension in children with congenital heart disease (PAH-CHD, PPHVD-CHD). Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK. Heart, 2016, 102, ii42-ii48.	1.2	62
66	Treatment update: pulmonary arterial hypertension. British Journal of Cardiac Nursing, 2016, 11, 536-542.	0.0	1
67	Treatment of Chronic Thromboembolic Pulmonary Hypertension: The Role of Medical Therapy and Balloon Pulmonary Angioplasty. Methodist DeBakey Cardiovascular Journal, 2016, 12, 205-212.	0.5	10
68	Left Heart Disease and Pulmonary Hypertension: Controversy Redefined. Methodist DeBakey Cardiovascular Journal, 2016, 12, 14-15.	0.5	4
69	Pulmonary Hypertension in the Era of Mechanical Circulatory Support. ASAIO Journal, 2016, 62, 505-512.	0.9	17
70	Cardiac MR and CT imaging in children with suspected or confirmed pulmonary hypertension/pulmonary hypertensive vascular disease. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK. Heart, 2016, 102, ii30-ii35.	1.2	39
71	Risk assessment in pulmonary arterial hypertension. European Respiratory Review, 2016, 25, 390-398.	3.0	39
72	Pulmonary hypertension in heart failure with preserved ejection fraction: a plea for proper phenotyping and further researchâ€. European Heart Journal, 2017, 38, ehw597.	1.0	83
73	Pregnancy in pulmonary arterial hypertension. European Respiratory Review, 2016, 25, 431-437.	3.0	103
74	A case of balloon pulmonary angioplasty as a palliative therapy in chronic thromboembolic pulmonary hypertension. Hellenic Journal of Cardiology, 2016, 57, 363-365.	0.4	3
76	Long-Term Outcomes After Percutaneous Transluminal Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension. Circulation, 2016, 134, 2030-2032.	1.6	93
77	Relevance of Angiopoietinâ€2 and Soluble Pâ€Selectin Levels in Patients with Pulmonary Arterial Hypertension Receiving Combination Therapy with Oral Treprostinil: A FREEDOMâ€C2 Biomarker Substudy. Pulmonary Circulation, 2016, 6, 516-523.	0.8	7

#	Article	IF	Citations
78	A Correlative Study of Spirometric Parameters and Markers of Right Ventricular Dysfunction in Pediatric Patients with Pulmonary Arterial Hypertension. Journal of Interdisciplinary Medicine, 2016, 1, 153-158.	0.1	1
79	Cas clinique nÂ° 2 : Interactions cÅ“ur-poumons â€“ hypertension pulmonaire et maladies cardiaques gauches. Revue Des Maladies Respiratoires Actualites, 2016, 8, 15-19.	0.0	0
81	Hypertension pulmonaire au cours des pneumopathies interstitielles diffuses. Revue Des Maladies Respiratoires Actualites, 2016, 8, 129-132.	0.0	0
82	Practical considerations for therapies targeting the prostacyclin pathway. European Respiratory Review, 2016, 25, 418-430.	3.0	33
83	Pulmonary Pulse Wave Transit Time is Associated with Right Ventricularâ€“Pulmonary Artery Coupling in Pulmonary Arterial Hypertension. Pulmonary Circulation, 2016, 6, 576-585.	0.8	30
84	Right Heart Failure. , 2016, , 455-484.		0
85	In Situ Expression of Bclâ€2Âin Pulmonary Artery Endothelial Cells Associates with Pulmonary Arterial Hypertension Relative to Heart Failure with Preserved Ejection Fraction. Pulmonary Circulation, 2016, 6, 551-556.	0.8	10
86	Pulmonary hypertension in thyroid diseases. Endocrine, 2016, 54, 578-587.	1.1	33
87	Initial dual oral combination therapy in pulmonary arterial hypertension. European Respiratory Journal, 2016, 47, 1727-1736.	3.1	124
88	First data from Latvian chronic thromboembolic pulmonary hypertension registry. European Journal of Internal Medicine, 2016, 32, e23-e24.	1.0	2
89	Pulmonary vascular resistance estimated by Doppler echocardiography predicts mortality in patients with interstitial lung disease. Journal of Cardiology, 2016, 68, 300-307.	0.8	11
90	ePLAR â€" The echocardiographic Pulmonary to Left Atrial Ratio â€" A novel non-invasive parameter to differentiate pre-capillary and post-capillary pulmonary hypertension. International Journal of Cardiology, 2016, 212, 379-386.	0.8	46
91	Cardiovascular changes in patients with non-severe Plasmodium vivax malaria. IJC Heart and Vasculature, 2016, 11, 12-16.	0.6	8
92	Physiological Techniques and Pulmonary Hypertension â€“ Left Heart Disease. Progress in Cardiovascular Diseases, 2016, 59, 30-41.	1.6	2
93	Remodelado cardÃaco inverso en pacientes con hipertensiÃ³n pulmonar tras trasplante bipulmonar. Estudio con tomografÃa computarizada multidetector. Radiologia, 2016, 58, 277-282.	0.3	3
94	Prognostic Implications of Elevated Pulmonary Artery Pressure After ST-Segment Elevation Myocardial Infarction. American Journal of Cardiology, 2016, 118, 326-331.	0.7	15
95	The Diagnostic Challenge of Group 2 Pulmonary Hypertension. Progress in Cardiovascular Diseases, 2016, 59, 22-29.	1.6	17
96	Regional contribution to ventricular stroke volume is affected on the left side, but not on the right in patients with pulmonary hypertension. International Journal of Cardiovascular Imaging, 2016, 32, 1243-1253.	0.7	20

#	Article	IF	Citations
97	Use of Parenteral Prostanoids. Chest, 2016, 149, 615-616.	0.4	0
98	Right sided heart failure and pulmonary hypertension: New insights into disease mechanisms and treatment modalities. Progress in Pediatric Cardiology, 2016, 43, 71-80.	0.2	2
99	ActualizaciÃ³n en hipertensiÃ³n arterial pulmonar. Revista Clinica Espanola, 2016, 216, 436-444.	0.2	5
100	Exercise intolerance in pulmonary hypertension: mechanism, evaluation and clinical implications. Expert Review of Respiratory Medicine, 2016, 10, 979-990.	1.0	27
101	Pulmonary hypertension complicating pulmonary sarcoidosis. Netherlands Heart Journal, 2016, 24, 390-399.	0.3	31
102	COPD-associated pulmonary hypertension: clinical implications and current methods for treatment. Expert Review of Respiratory Medicine, 2016, 10, 755-766.	1.0	5
103	Comprendre le cÅ“ur droit dÃ©faillant. Archives Des Maladies Du Coeur Et Des Vaisseaux - Pratique, 2016, 2016, 2-8.	0.0	0
104	Using Registries to Understand ClinicalÂPractice. Journal of the American College of Cardiology, 2016, 67, 1324-1326.	1.2	3
105	Mixed connective tissue disease. Best Practice and Research in Clinical Rheumatology, 2016, 30, 95-111.	1.4	88
106	Elevated Levels of Circulating Bone Morphogenetic Protein 7 Predict Mortality in Pulmonary Arterial Hypertension. Chest, 2016, 150, 367-373.	0.4	7
107	The heart and pulmonary arterial hypertension in systemic sclerosis. Acta Clinica Belgica, 2016, 71, 1-18.	0.5	13
108	Transcatheter Therapies for Treating Tricuspid Regurgitation. Journal of the American College of Cardiology, 2016, 67, 1829-1845.	1.2	189
109	Frontiers in congenital heart disease: pulmonary hypertension, heart failure, and arrhythmias. European Heart Journal, 2016, 37, 1407-1409.	1.0	7
110	Syncope and collapse in acute pulmonary embolism. American Journal of Emergency Medicine, 2016, 34, 1251-1257.	0.7	24
111	Predictors of long-term survival in pulmonary hypertension. Lancet Respiratory Medicine,the, 2016, 4, 338-339.	5.2	1
112	Right heart/pulmonary circulation unit assessment during exercise, a need for a global view of the loop. International Journal of Cardiology, 2016, 203, 1147-1148.	0.8	0
114	Right Ventricular Functional Reserve in Pulmonary Arterial Hypertension. Circulation, 2016, 133, 2413-2422.	1.6	149
115	How to define pulmonary hypertension due to left heart disease. European Respiratory Journal, 2016, 48, 553-555.	3.1	36

#	Article	IF	Citations
116	The Pulmonary Hypertension Consult. Chest, 2016, 150, 705-713.	0.4	6
117	Pulmonary Hypertension in the Dog. Acta Veterinaria, 2016, 66, 1-25.	0.2	4
118	Prognostic Factors in Patients With Pulmonary Hypertensionâ€"A Nationwide Cohort Study. Journal of the American Heart Association, 2016, 5, .	1.6	32
119	Near infrared spectroscopy for the assessment of peripheral tissue oxygenation in pulmonary arterial hypertension. European Respiratory Journal, 2016, 48, 1224-1227.	3.1	6
120	Macitentan: A Review in Pulmonary Arterial Hypertension. American Journal of Cardiovascular Drugs, 2016, 16, 453-460.	1.0	12
121	Pulmonary arterial hypertension: Basic knowledge for clinicians. Archives of Cardiovascular Diseases, 2016, 109, 550-561.	0.7	34
122	Initial combination therapy with ambrisentan and tadalafil and mortality in patients with pulmonary arterial hypertension: a secondary analysis of the results from the randomised, controlled AMBITION study. Lancet Respiratory Medicine,the, 2016, 4, 894-901.	5.2	59
123	Bleeding Complications After Endoscopic Lung Volume Reduction Coil Treatment: A Retrospective Observational Study. Archivos De Bronconeumologia, 2016, 52, 590-595.	0.4	3
124	Echocardiographic B-mode evaluation of the right heart in older people: The ActiFE Study. Archives of Gerontology and Geriatrics, 2016, 67, 145-152.	1.4	2
125	Pulmonary arterial hypertension and quality of life in cardiology. Do we really need more studies?. Hellenic Journal of Cardiology, 2016, 57, 215-217.	0.4	4
126	Identification of genetic defects in pulmonary arterial hypertension by a new gene panel diagnostic tool. Clinical Science, 2016, 130, 2043-2052.	1.8	25
127	Hemodynamic Evidence of Vascular Remodeling in Combined Postâ€•and Precapillary Pulmonary Hypertension. Pulmonary Circulation, 2016, 6, 313-321.	0.8	38
129	Prevalence of Anxiety and Depression in Pulmonary Hypertension and Changes during Therapy. Respiration, 2016, 91, 359-366.	1.2	33
130	Comparison of echocardiographic parameters between pre-clinical and clinical advanced diastolic dysfunction patients. International Journal of Cardiology, 2016, 224, 165-169.	0.8	5
131	Aerobic exercise-related attenuation of arterial pulmonary hypertension: A right arrow targets the disease?. Vascular Pharmacology, 2016, 87, 6-9.	1.0	4
132	Clinical characteristics and determinants of exercise-induced pulmonary hypertension in patients with preserved left ventricular ejection fraction. European Heart Journal Cardiovascular Imaging, 2017, 18, jew199.	0.5	5
133	Zalecenia dotyczÄ…ce oceny schorzeÅ„ wspÃ³Å‚istniejÄ…cych u chorych na przewlekÅ‚Ä… biaÅ‚aczkÄ™ szpikowÄ… w procesie wyboru inhibitora kinaz tyrozynowych. Acta Haematologica Polonica, 2016, 47, 184-196.	0.1	1
134	2-D Speckle tracking in the assessment of left and right ventricular functions in hemodialysis versus recently diagnosed uremic patients with preserved systolic function. Egyptian Journal of Critical Care Medicine, 2016, 4, 139-144.	0.2	2

#	Article	IF	Citations
135	Multidetector computed tomography shows reverse cardiac remodeling after double lung transplantation for pulmonary hypertension. Radiologia, 2016, 58, 277-282.	0.3	1
136	Portuguese validation of the Cambridge pulmonary hypertension outcome review (CAMPHOR) questionnaire. Health and Quality of Life Outcomes, 2016, 14, 110.	1.0	8
137	Contemporary diagnosis and management of pulmonary hypertension. Heart, 2016, 102, 1680-1691.	1.2	3
138	Selexipag for the treatment of pulmonary arterial hypertension. Expert Opinion on Pharmacotherapy, 2016, 17, 1825-1834.	0.9	3
139	The difficult diagnosis of pulmonary vascular disease in heart failure. European Respiratory Journal, 2016, 48, 311-314.	3.1	10
140	Elevated levels of plasma transforming growth factor-Î²1 in idiopathic and heritable pulmonary arterial hypertension. International Journal of Cardiology, 2016, 222, 368-374.	0.8	23
141	Left Ventricular Function in Patients with Pulmonary Arterial Hypertension: The Role of Twoâ€Ðimensional Speckle Tracking Strain. Echocardiography, 2016, 33, 1326-1334.	0.3	14
142	A Contemporary Approach to Pulmonary Arterial Hypertension. Current Atherosclerosis Reports, 2016, 18, 58.	2.0	1
143	Contemporary management of acute right ventricular failure: a statement from the Heart Failure Association and the Working Group on Pulmonary Circulation and Right Ventricular Function of the European Society of Cardiology. European Journal of Heart Failure, 2016, 18, 226-241.	2.9	455
144	Group 5 Pulmonary Hypertension. Cardiology Clinics, 2016, 34, 443-449.	0.9	20
145	Group 2 Pulmonary Hypertension. Cardiology Clinics, 2016, 34, 401-411.	0.9	14
146	Pharmacokinetic and Pharmacodynamic Comparison of Sildenafilâ€Bosentan and Sildenafilâ€Ambrisentan Combination Therapies for Pulmonary Hypertension. Clinical and Translational Science, 2016, 9, 29-35.	1.5	7
147	New targeted therapies in the treatment of pulmonary arterial hypertension: getting to the heart of the problem. Respirology, 2016, 21, 406-407.	1.3	2
148	2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. European Heart Journal, 2016, 37, 2768-2801.	1.0	1,996
149	Biomarkers of tissue remodeling predict survival in patients with pulmonary hypertension. International Journal of Cardiology, 2016, 223, 821-826.	0.8	20
150	Late outcomes after acute pulmonary embolism: rationale and design of FOCUS, a prospective observational multicenter cohort study. Journal of Thrombosis and Thrombolysis, 2016, 42, 600-609.	1.0	50
151	Left Ventricular Diastolic Dysfunction in Pediatric Pulmonary Hypertension. Circulation: Cardiovascular Imaging, 2016, 9, .	1.3	9
152	Correlation between JAK2 allele burden and pulmonary arterial hypertension and hematological parameters in Philadelphia negative JAK2 positive myeloproliferative neoplasms. An Egyptian experience. Annals of Hematology, 2016, 95, 1611-1616.	0.8	18

#	Article	IF	Citations
153	Echocardiography Combined With Cardiopulmonary Exercise Testing for the Prediction of Outcome in Idiopathic Pulmonary Arterial Hypertension. Chest, 2016, 150, 1313-1322.	0.4	51
154	CTA-derived left to right atrial size ratio distinguishes between pulmonary hypertension due to heart failure and idiopathic pulmonary arterial hypertension. International Journal of Cardiology, 2016, 223, 723-728.	0.8	14
156	Plasma Proteomic Study in Pulmonary Arterial Hypertension Associated with Congenital Heart Diseases. Scientific Reports, 2016, 6, 36541.	1.6	26
158	Novel Therapeutic Targets of Pulmonary Hypertension. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, e97-e102.	1.1	14
159	EIF2AK4 mutation as â€œsecond hitâ€•in hereditary pulmonary arterial hypertension. Respiratory Research, 2016, 17, 141.	1.4	33
160	Balloon Pulmonary Angioplasty Improves Biventricular Functions and Pulmonary Flow in Chronic Thromboembolic Pulmonary Hypertension. Circulation Journal, 2016, 80, 1470-1477.	0.7	53
161	Efficacy and Safety of a Novel Endothelin Receptor Antagonist, Macitentan, in Japanese Patients With Pulmonary Arterial Hypertension. Circulation Journal, 2016, 80, 1478-1483.	0.7	8
162	Beneficial Therapeutic Effects of Balloon Pulmonary Angioplasty on Biventricular Function in Patients With Chronic Thromboembolic Pulmonary Hypertension. Circulation Journal, 2016, 80, 1326-1327.	0.7	3
163	Pulmonary hypertension in adults with congenital heart disease: First data from Latvian PAH registry. European Journal of Internal Medicine, 2016, 36, e20-e21.	1.0	2
164	Pulmonary arterial hypertension in congenital heart disease: Current perspectives and future challenges. Hellenic Journal of Cardiology, 2016, 57, 218-222.	0.4	29
165	An unusual cause of pulmonary hypertension: Swyerâ€“Jamesâ€“Macleod syndrome. International Journal of Cardiology, 2016, 223, 212-214.	0.8	4
166	Right ventricular dysfunction in heart failure with preserved ejection fraction: a systematic review and metaâ€analysis. European Journal of Heart Failure, 2016, 18, 1472-1487.	2.9	200
167	The time difference between clinical improvement and exercise tolerance increase following pulmonary thromboendarterectomy. International Journal of Cardiology, 2016, 222, 267-269.	0.8	1
168	Trends in pregnancy outcomes in patients with pulmonary hypertension: still a long way to go. European Journal of Heart Failure, 2016, 18, 1129-1131.	2.9	14
169	Effects of Age and Sex on the Pharmacokinetics of the Soluble Guanylate Cyclase Stimulator Riociguat (BAY 63-2521). Pulmonary Circulation, 2016, 6, S58-S65.	0.8	10
170	Pharmacokinetic Interaction Study between Riociguat and the Combined Oral Contraceptives Levonorgestrel and Ethinylestradiol in Healthy Postmenopausal Women. Pulmonary Circulation, 2016, 6, S97-S102.	0.8	12
171	Why We Should Care about the Mysteries of Pulmonary Hypertension. Pulmonary Circulation, 2016, 6, 249-250.	0.8	0
172	Managing the Patient with Pulmonary Hypertension. Cardiology Clinics, 2016, 34, 489-500.	0.9	14

#	Article	IF	Citations
173	Expression Profiling Elucidates a Molecular Gene Signature for Pulmonary Hypertension in Sarcoidosis. Pulmonary Circulation, 2016, 6, 465-471.	0.8	10
174	Pre-Capillary, Combined, and Post-Capillary Pulmonary Hypertension. Journal of the American College of Cardiology, 2016, 68, 368-378.	1.2	244
175	High-Risk Cardiac Disease in Pregnancy. Journal of the American College of Cardiology, 2016, 68, 502-516.	1.2	97
176	Pulmonary hypertension and pregnancy outcomes: data from the Registry Of Pregnancy and Cardiac Disease (<scp>ROPAC</scp>) of the European Society of Cardiology. European Journal of Heart Failure, 2016, 18, 1119-1128.	2.9	164
177	Medical Therapy in Chronic Thromboembolic Pulmonary Hypertension. Annals of the American Thoracic Society, 2016, 13, S248-S254.	1.5	15
178	Pulmonary hypertension in the changing landscape of congenital heart disease: Global differences and aÂpossible driver of end-stage heart failure. Netherlands Heart Journal, 2016, 24, 372-373.	0.3	2
179	Pulmonary Artery Denervation for Treatment of a Patient with Pulmonary Hypertension Secondary to Left Heart Disease. Pulmonary Circulation, 2016, 6, 240-243.	0.8	14
180	Arterial-ventricular and interventricular interaction in isolated post-capillary and combined pulmonary hypertension in severe mitral stenosis. European Journal of Applied Physiology, 2016, 116, 1545-1554.	1.2	1
181	Pulmonary Hypertension in Children. Cardiology Clinics, 2016, 34, 451-472.	0.9	43
182	Epidemiology of Pulmonary Hypertension in Left Heart Disease. Progress in Cardiovascular Diseases, 2016, 59, 3-10.	1.6	17
183	Recall of patients discharged from follow-up after repair of isolated congenital shunt lesions. International Journal of Cardiology, 2016, 221, 314-320.	0.8	10
184	Complicaciones hemorrÃ¡gicas tras el tratamiento endoscÃ³pico de reducciÃ³n del volumen pulmonar con espiral: estudio observacional retrospectivo. Archivos De Bronconeumologia, 2016, 52, 590-595.	0.4	5
185	Echocardiographic pulmonary hypertension probability is associated with clinical outcomes after transcatheter aortic valve implantation. International Journal of Cardiology, 2016, 225, 218-225.	0.8	15
186	Trends and Outcomes of Pulmonary Arterial Hypertensionâ€“Related Hospitalizations in the United States. JAMA Cardiology, 2016, 1, 1021.	3.0	69
187	Diagnosis, Treatment, and Clinical Management of Pulmonary Arterial Hypertension in the Contemporary Era. JAMA Cardiology, 2016, 1, 1056.	3.0	99
188	Pulmonary Hypertension in Heart Failure Patients: Pathophysiology and Prognostic Implications. Current Heart Failure Reports, 2016, 13, 281-294.	1.3	21
190	C-Arm Computed Tomography Adds Diagnostic Information in Patients with Chronic Thromboembolic Pulmonary Hypertension and a Positive V/Q SPECT. RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren, 2016, 189, 49-56.	0.7	6
191	Non-invasive monitoring of pulmonary artery pressure at the bedside. , 2016, 2016, 4236-4239.		1

#	Article	IF	Citations
192	Computed tomography for planning transcatheter tricuspid valve therapy. European Heart Journal, 2017, 38, ehw499.	1.0	63
193	Update on novel targets and potential treatment avenues in pulmonary hypertension. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2016, 311, L811-L831.	1.3	19
194	Letter by Kataoka et al Regarding Article, â€œDynamic Risk Stratification of Patient Long-Term Outcome After Pulmonary Endarterectomy: Results From the United Kingdom National Cohortâ€• Circulation, 2016, 134, e299-e300.	1.6	0
195	Obstructive Ventilatory Disorder in Heart Failureâ€"Caused by the Heart or the Lung?. Current Heart Failure Reports, 2016, 13, 310-318.	1.3	5
196	Effects of Longterm Treatment with Bosentan and Iloprost on Nailfold Absolute Capillary Number, Fingertip Blood Perfusion, and Clinical Status in Systemic Sclerosis. Journal of Rheumatology, 2016, 43, 2033-2041.	1.0	64
197	Efficacy of Statin Therapy in Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis. Scientific Reports, 2016, 6, 30060.	1.6	25
198	Transthoracic Echocardiography and Chest Computed Tomography Arteriography in Patients with Acute Pulmonary Embolism: A Two-Year Follow-Up Study. Respiration, 2016, 92, 235-240.	1.2	5
199	The clinical use of stress echocardiography in non-ischaemic heart disease: recommendations from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. European Heart Journal Cardiovascular Imaging, 2016, 17, 1191-1229.	0.5	300
200	Incidence and predictors of vasoplegia after heart failure surgery. European Journal of Cardio-thoracic Surgery, 2017, 51, ezw316.	0.6	21
202	Sarcoidosis-associated Pulmonary Hypertension. The Japanese Journal of Sarcoidosis and Other Granulomatous Disorders, 2016, 36, 63-66.	0.1	0
204	Risk of Direct Oral Anticoagulant Bioaccumulation in Patients with Pulmonary Hypertension. Respiration, 2016, 91, 307-315.	1.2	18
205	Significance of Serum Uric Acid in Children with Pulmonary Arterial Hypertension. Journal of Interdisciplinary Medicine, 2016, 1, 46-50.	0.1	2
206	Limited Cutaneous Scleroderma-Related Pulmonary Arterial Hypertension â€" a Case Report. Journal of Interdisciplinary Medicine, 2016, 1, 97-102.	0.1	0
207	Pulmonary hypertension: the importance of aÂmultidisciplinary approach. Netherlands Heart Journal, 2016, 24, 369-371.	0.3	3
208	Right heart imaging in patients with heart failure. Current Opinion in Cardiology, 2016, 31, 469-482.	0.8	39
209	Prognostic value of TAPSE after therapy optimisation in patients with pulmonary arterial hypertension is independent of the haemodynamic effects of therapy. Open Heart, 2016, 3, e000408.	0.9	36
210	Subspecificities of anticentromeric protein A antibodies identify systemic sclerosis patients at higher risk of pulmonary vascular disease. Medicine (United States), 2016, 95, e3931.	0.4	13
211	EIF2AK4 mutation in pulmonary veno-occlusive disease. Medicine (United States), 2016, 95, e5030.	0.4	6

#	Article	IF	Citations
212	Clinical study of right ventricular longitudinal strain for assessing right ventricular dysfunction and hemodynamics in pulmonary hypertension. Medicine (United States), 2016, 95, e5668.	0.4	9
213	Non-invasive monitoring of pulmonary artery pressure from timing information by EIT: experimental evaluation during induced hypoxia. Physiological Measurement, 2016, 37, 713-726.	1.2	22
215	The prognostic impact of thyroid function in pulmonary hypertension. Journal of Heart and Lung Transplantation, 2016, 35, 1427-1434.	0.3	25
216	Balloon pulmonary angioplasty: applicability of C-Arm CT for procedure guidance. European Radiology, 2016, 26, 4064-4071.	2.3	36
217	Non-invasive screening for pulmonary hypertension in idiopathic pulmonary fibrosis. Respiratory Medicine, 2016, 117, 65-72.	1.3	30
218	Pulmonary hypertension begets pulmonary hypertension: mutually reinforcing roles for haemodynamics, inflammation, and cancer-like phenotypes. Cardiovascular Research, 2016, 111, 1-4.	1.8	8
219	Echocardiography in the Assessment of Patients with Rheumatologic Diseases. Current Cardiology Reports, 2016, 18, 72.	1.3	11
220	Update on pulmonary arterial hypertension. Revista Clínica Espanõla, 2016, 216, 436-444.	0.3	0
221	Pressure-Flow During Exercise Catheterization Predicts Survival inÂPulmonary Hypertension. Chest, 2016, 150, 57-67.	0.4	56
222	The Need for Comprehensive Cardiac Catheterization in Children With Pulmonary Hypertension. Journal of the American College of Cardiology, 2016, 67, 1009-1010.	1.2	11
223	Treatment and Prognosis of Pulmonary Hypertension in the Left Ventricular Assist Device Patient. Current Heart Failure Reports, 2016, 13, 140-150.	1.3	4
224	Epigenetic mechanisms in pulmonary arterial hypertension: the need for global perspectives. European Respiratory Review, 2016, 25, 135-140.	3.0	35
225	Case report: Subjective loss of performance after pulmonary embolism in an athleteâ€“ beyond normal values. BMC Pulmonary Medicine, 2016, 16, 21.	0.8	5
226	Pulmonary Veno-occlusive Disease and Pulmonary Hypertension in Dogs. Veterinary Pathology, 2016, 53, 707-710.	0.8	5
227	Functional performance and quality of life in high-risk comorbid patients undergoing transcatheter aortic valve implantation for symptomatic aortic valve stenosis. European Heart Journal Quality of Care & Clinical Outcomes, 2016, 2, 184-192.	1.8	13
228	BSR and BHPR guideline for the treatment of systemic sclerosis. Rheumatology, 2016, 55, 1906-1910.	0.9	147
229	Theory and practical based approach to chronic total occlusions. BMC Cardiovascular Disorders, 2016, 16, 33.	0.7	27
230	Neurohormonal activation and pharmacological inhibition in pulmonary arterial hypertension and related right ventricular failure. Heart Failure Reviews, 2016, 21, 539-547.	1.7	27

#	Article	IF	Citations
231	The Role of Cardiac Magnetic Resonance Imaging in Pulmonary Hypertension. Current Cardiovascular Imaging Reports, 2016, 9, 1.	0.4	1
232	Endothelin-Receptor Antagonists beyond Pulmonary Arterial Hypertension: Cancer and Fibrosis. Journal of Medicinal Chemistry, 2016, 59, 8168-8188.	2.9	27
233	Resting arterial hypoxaemia in subjects with chronic heart failure, pulmonary hypertension and patent foramen ovale. Experimental Physiology, 2016, 101, 657-670.	0.9	5
234	Effects of ventricular conduction block patterns on mortality in hospitalized patients with dilated cardiomyopathy: a single-center cohort study. BMC Cardiovascular Disorders, 2016, 16, 136.	0.7	6
235	The Prognostic Impact of the Evolution ofÂRV Function in IdiopathicÂDCM. JACC: Cardiovascular Imaging, 2016, 9, 1034-1042.	2.3	92
236	Development of Pulmonary Hypertension in Heart Failure With Preserved Ejection Fraction. Progress in Cardiovascular Diseases, 2016, 59, 52-58.	1.6	14
237	Echocardiography and cardiac catheterism as complementary tools for the assessment of pulmonary circulation during exercise. International Journal of Cardiology, 2016, 203, 1149-1150.	0.8	0
238	Cardiopulmonary exercise testing in patients with pulmonary hypertension: clinical recommendations based on a review of the evidence. Expert Review of Respiratory Medicine, 2016, 10, 279-295.	1.0	22
239	The Quest for Metabolic Biomarkers ofÂPulmonary Hypertension âˆ—. Journal of the American College of Cardiology, 2016, 67, 190-192.	1.2	3
240	BMPR2 mutation is a potential predisposing genetic risk factor for congenital heart disease associated pulmonary vascular disease. International Journal of Cardiology, 2016, 211, 132-136.	0.8	30
241	Anesthesia for pregnant women with pulmonary hypertension. Current Opinion in Anaesthesiology, 2016, 29, 273-281.	0.9	29
242	Screening of Mechanical Complications of Dilated Pulmonary Artery Related to the Risk for Sudden Cardiac Death in Patients with Pulmonary Arterial Hypertension by Transthoracic Echocardiography. Journal of the American Society of Echocardiography, 2016, 29, 561-566.	1.2	11
243	Combination Therapy for Pulmonary Arterial Hypertension: A Systematic Review and Meta-analysis. Canadian Journal of Cardiology, 2016, 32, 1520-1530.	0.8	50
244	Update on hypertension: target blood pressure, comorbidities, and outcome. European Heart Journal, 2016, 37, 921-923.	1.0	1
245	Six-minute walk test in systemic sclerosis: A systematic review and meta-analysis. International Journal of Cardiology, 2016, 212, 265-273.	0.8	32
246	Definition of pulmonary hypertension challenged?. Nature Reviews Cardiology, 2016, 13, 250-251.	6.1	9
247	Derivation of a clinical prediction score for chronic thromboembolic pulmonary hypertension after acute pulmonary embolism. Journal of Thrombosis and Haemostasis, 2016, 14, 121-128.	1.9	129
248	Clinical Cardiology, Geriatric Cardiology, Heart Failure, and Transplantation 2015: A Selection of Topical Issues. Revista Espanola De Cardiologia (English Ed), 2016, 69, 159-166.	0.4	5

#	Article	IF	Citations
249	SelecciÃ³n de temas de actualidad en cardiologÃa clÃnica, cardiologÃa geriÃ¡trica e insuficiencia cardiaca y trasplante 2015. Revista Espanola De Cardiologia, 2016, 69, 159-166.	0.6	9
250	Î²-blockers in pulmonary arterial hypertension: generation might matter. European Respiratory Journal, 2016, 47, 682-684.	3.1	3
251	Treatment of pulmonary hypertension. Lancet Respiratory Medicine,the, 2016, 4, 323-336.	5.2	97
252	A global view of pulmonary hypertension. Lancet Respiratory Medicine,the, 2016, 4, 306-322.	5.2	523
253	Aortic and/or mitral valve surgery in patients with pulmonary hypertension performed via a minimally invasive approach. Interactive Cardiovascular and Thoracic Surgery, 2016, 22, 668-670.	0.5	9
254	Novel approaches to pulmonary arterial hypertension drug discovery. Expert Opinion on Drug Discovery, 2016, 11, 407-414.	2.5	6
255	Update in treatment options in pulmonary hypertension. Journal of Heart and Lung Transplantation, 2016, 35, 695-703.	0.3	21
256	40-Year-Old Woman With Breathlessness and Fatigue. Mayo Clinic Proceedings, 2016, 91, e49-e53.	1.4	0
257	2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Summary document prepared by the Czech Society of Cardiology. Cor Et Vasa, 2016, 58, e129-e152.	0.1	1
258	Insuffisance ventriculaire droiteÂ: comment la prendre en chargeÂ?. Archives Des Maladies Du Coeur Et Des Vaisseaux - Pratique, 2016, 2016, 9-13.	0.0	0
259	Combined post- and pre-capillary pulmonary hypertension in heart failure with preserved ejection fraction. Heart Failure Reviews, 2016, 21, 285-297.	1.7	25
260	Pulmonary hypertension, gender issues, and quality of care. European Heart Journal, 2016, 37, 1-3.	1.0	22
261	Genetic counselling in a national referral centre for pulmonary hypertension. European Respiratory Journal, 2016, 47, 541-552.	3.1	87
262	Rest and exercise echocardiography for early detection of pulmonary hypertension. Journal of Echocardiography, 2016, 14, 2-12.	0.4	12
263	Left ventricular heart failure and pulmonary hypertension. European Heart Journal, 2016, 37, 942-954.	1.0	486
264	Anticoagulation in patients with pulmonary arterial hypertension: An update on current knowledge. Journal of Heart and Lung Transplantation, 2016, 35, 151-164.	0.3	23
265	Rapid improvement of pulmonary hemodynamics following combined tadalafil and inotropic treatment in a patient with pulmonary hypertension secondary to left ventricular dysfunction. International Journal of Cardiology, 2016, 203, 212-213.	0.8	0
266	Exercise training in pulmonary hypertension: improving performance but waiting for outcome. European Heart Journal, 2016, 37, 45-48.	1.0	18

#	Article	IF	Citations
267	Direct oral anticoagulants: Current indications and unmet needs in the treatment of venous thromboembolism. Pharmacological Research, 2017, 118, 33-42.	3.1	31
268	Riociguat: Mode of Action and Clinical Development in Pulmonary Hypertension. Chest, 2017, 151, 468-480.	0.4	79
269	Moderate-to-severe obstructive sleep apnea is associated with subclinical myocardial injury and impaired hemodynamics in pulmonary hypertension patients. Sleep Medicine, 2017, 30, 121-127.	0.8	11
270	Ambrisentan use for pulmonary arterial hypertension in a post-authorization drug registry: The VOLibris Tracking Study. Journal of Heart and Lung Transplantation, 2017, 36, 399-406.	0.3	13
271	T<scp>ranslational</scp> A<scp>dvances</scp> <scp>in</scp> <scp>the</scp> F<scp>ield</scp> <scp>of</scp> P<scp>ulmonary</scp> H<scp>ypertension</scp> Molecular Medicine of Pulmonary Arterial Hypertension. From Population Genetics to Precision Medicine and Gene Editing. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 23-31.	2.5	32
272	The benefit of exercise training in pulmonary hypertension: a clinical review. Internal Medicine Journal, 2017, 47, 361-369.	0.5	19
274	Exercise-based rehabilitation programmes for pulmonary hypertension. The Cochrane Library, 2017, 2017, CD011285.	1.5	54
275	Pulmonary arterial hypertension associated with connective tissue disease: Insights from Latvian PAH registry. European Journal of Internal Medicine, 2017, 40, e13-e14.	1.0	4
276	Novel putative pharmacological therapies to protect the right ventricle in pulmonary hypertension: a review of current literature. British Journal of Pharmacology, 2017, 174, 497-511.	2.7	13
277	Selexipag, an orally available IP receptor agonist, in the treatment of pulmonary arterial hypertension: current evidence and future prospects. Expert Opinion on Orphan Drugs, 2017, 5, 193-200.	0.5	0
278	Algoritmo para el diagnÃ³stico y el seguimiento de la tromboembolia pulmonar aguda. Radiologia, 2017, 59, 75-87.	0.3	2
279	POINT: Should Wireless Pulmonary Artery Hemodynamic Monitoring Be Used to Monitor Patients With Pulmonary Hypertension? Yes. Chest, 2017, 152, 13-15.	0.4	1
280	Comparison of hemodynamic parameters in treatment-naÃ¯ve and pre-treated patients with pulmonary arterial hypertension in the randomized phase III PATENT-1 study. Journal of Heart and Lung Transplantation, 2017, 36, 509-519.	0.3	22
281	Prognostic relevance of pulmonary arterial compliance after therapy initiation or escalation in patients with pulmonary arterial hypertension. International Journal of Cardiology, 2017, 230, 53-58.	0.8	32
283	Pulmonary Endarterectomy for Chronic Thromboembolic Pulmonary Hypertension. , 2017, , 203-214.		2
284	Diagnosis: Imaging. , 2017, , 13-27.		0
285	Stress echo 2020: the international stress echo study in ischemic and non-ischemic heart disease. Cardiovascular Ultrasound, 2017, 15, 3.	0.5	82
286	The Clinical Use of Stress Echocardiography in Non-Ischaemic Heart Disease: Recommendations from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. Journal of the American Society of Echocardiography, 2017, 30, 101-138.	1.2	207

#	Article	IF	Citations
287	Right heart function during simulated altitude in patients with pulmonary arterial hypertension. Open Heart, 2017, 4, e000532.	0.9	20
288	Osteoprotegerin Disruption Attenuates HySu-Induced Pulmonary Hypertension Through Integrin Î± _v Î² ₃ /FAK/AKT Pathway Suppression. Circulation: Cardiovascular Genetics, 2017, 10, .	5.1	27
289	Adipokines: A Possible Contribution to Vascular and Bone Remodeling in Idiopathic Pulmonary Arterial Hypertension. Calcified Tissue International, 2017, 100, 325-331.	1.5	9
290	Integrative Cardiopulmonary Ultrasound for Interstitial Lung Disease Assessment: Correlation between Lung Ultrasound Performance and Cardiac Involvement. Ultrasound in Medicine and Biology, 2017, 43, 744-752.	0.7	6
291	Cardiopulmonary Disease Development in Anti-RNA Polymerase III-positive Systemic Sclerosis: Comparative Analyses from an Unselected, Prospective Patient Cohort. Journal of Rheumatology, 2017, 44, 459-465.	1.0	24
292	Clinical Classification. , 2017, , 3-11.		0
293	Balloon Pulmonary Angioplasty. , 2017, , 193-202.		0
294	Right Ventricular Function. , 2017, , 217-236.		1
295	Human Pathology. , 2017, , 101-113.		3
296	Downhill exercise training in monocrotaline-injected rats: Effects on echocardiographic and haemodynamic variables and survival. Archives of Cardiovascular Diseases, 2017, 110, 106-115.	0.7	5
297	Early detection of pulmonary hypertension in primary myelofibrosis: The role of echocardiography, cardiopulmonary exercise testing, and biomarkers. American Journal of Hematology, 2017, 92, E47-E48.	2.0	5
298	Treatment of Pulmonary Arterial Hypertension Using Initial Combination Therapy of Bosentan and Iloprost. Respiratory Care, 2017, 62, 489-496.	0.8	13
299	New Cardiac Imaging Tools and Invasive Techniques in Systemic Autoimmune Diseases (Part II). Handbook of Systemic Autoimmune Diseases, 2017, 14, 209-226.	0.1	0
300	Enfermedad venooclusiva pulmonar y hemangiomatosis capilar pulmonar. Medicina ClÃnica, 2017, 148, 265-270.	0.3	10
301	Cardio-Onco-HematologÃa en la prÃ¡ctica clÃnica. Documento deÂconsenso yÂrecomendaciones. Revista Espanola De Cardiologia, 2017, 70, 474-486.	0.6	72
302	Myocardial injury in severe heritable pulmonary veno-occlusive disease. Journal of Heart and Lung Transplantation, 2017, 36, 818-820.	0.3	0
303	The Giessen Pulmonary Hypertension Registry: Survival in pulmonary hypertension subgroups. Journal of Heart and Lung Transplantation, 2017, 36, 957-967.	0.3	221
304	Cardiopulmonary exercise testing for detecting pulmonary arterial hypertension in systemic sclerosis. Heart, 2017, 103, 774-782.	1.2	59

#	Article	IF	Citations
305	Impact of Pulmonary Hypertension on Outcome in Patients with Severe Aortic Stenosis and Preserved Left Ventricular Ejection Fraction. Clinical Research in Cardiology, 2017, 106, 542-550.	1.5	7
306	Sarcoplasmic reticulumâ€“mitochondria communication in cardiovascular pathophysiology. Nature Reviews Cardiology, 2017, 14, 342-360.	6.1	114
307	Oscillatory whole-body vibration improves exercise capacity and physical performance in pulmonary arterial hypertension: a randomised clinical study. Heart, 2017, 103, 592-598.	1.2	34
308	Safety and effectiveness of tadalafil in patients with pulmonary arterial hypertension: Japanese post-marketing surveillance data. Current Medical Research and Opinion, 2017, 33, 963-971.	0.9	3
309	Integrated Use of Perfusion SPECT/CTA Fusion Imaging and Pulmonary BalloonÂAngioplasty for Chronic Pulmonary Thromboembolism. JACC: Cardiovascular Interventions, 2017, 10, 532-534.	1.1	6
310	Randomised controlled trial examining the effect of an outpatient exercise training programme on haemodynamics and cardiac MR parameters of right ventricular function in patients with pulmonary arterial hypertension: the ExPAH study protocol. BMJ Open, 2017, 7, e014037.	0.8	13
311	Six-Minute Walk Test in Evaluation of Children with Pulmonary Arterial Hypertension. Pediatric Cardiology, 2017, 38, 754-761.	0.6	6
312	Early Experience of Macitentan for Pulmonary Arterial Hypertension in Adult Congenital Heart Disease. Heart Lung and Circulation, 2017, 26, 1113-1116.	0.2	24
313	Hemodynamic phenotyping based on exercise catheterization predicts outcome in patients with heart failure and reduced ejection fraction. Journal of Heart and Lung Transplantation, 2017, 36, 880-889.	0.3	16
314	Epoprostenol and pulmonary arterial hypertension: 20â€…years of clinical experience. European Respiratory Review, 2017, 26, 160055.	3.0	70
315	Physical Activity in Pediatric Pulmonary Arterial Hypertension Measured by Accelerometry. A Candidate Clinical Endpoint. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 220-227.	2.5	34
316	Usefulness of the Continuous-Wave Doppler-Derived Pulmonary Arterialâ€“Right Ventricular Pressure Gradient Just before Atrial Contraction for the Estimation of Pulmonary Arterial Diastolic and Wedge Pressures. Ultrasound in Medicine and Biology, 2017, 43, 958-966.	0.7	2
317	First identification of KrÃ¼ppel-like factor 2 mutation in heritable pulmonary arterial hypertension. Clinical Science, 2017, 131, 689-698.	1.8	38
318	Benefits of skeletal-muscle exercise training in pulmonary arterial hypertension: The WHOLEi+12 trial. International Journal of Cardiology, 2017, 231, 277-283.	0.8	76
319	Haemodynamic effects of riociguat in inoperable/recurrent chronic thromboembolic pulmonary hypertension. Heart, 2017, 103, 599-606.	1.2	34
320	Mechanism of Progressive Heart Failure and Significance of Pulmonary Hypertension in Obstructive Hypertrophic Cardiomyopathy. Circulation: Heart Failure, 2017, 10, e003689.	1.6	43
321	HAND1 loss-of-function mutation contributes to congenital double outlet right ventricle. International Journal of Molecular Medicine, 2017, 39, 711-718.	1.8	16
322	Pulmonary Hypertension in Pregnancy. Obstetrics and Gynecology, 2017, 129, 511-520.	1.2	93

#	Article	IF	Citations
323	Lung perfusion: MRI vs. SPECT for screening in suspected chronic thromboembolic pulmonary hypertension. Journal of Magnetic Resonance Imaging, 2017, 46, 1693-1697.	1.9	71
324	Echocardiographic pulmonary artery pressure estimation and heart failure rehospitalization burden in patients with acute heart failure. International Journal of Cardiology, 2017, 241, 407-410.	0.8	20
325	Ambrisentan: a review of its use in pulmonary arterial hypertension. Therapeutic Advances in Respiratory Disease, 2017, 11, 233-244.	1.0	29
326	RAGE-mediated extracellular matrix proteins accumulation exacerbates HySu-induced pulmonary hypertension. Cardiovascular Research, 2017, 113, 586-597.	1.8	42
327	Pulmonary hypertension due to left heart disease. Archives of Cardiovascular Diseases, 2017, 110, 420-431.	0.7	10
328	Importance of combined left atrial size and estimated pulmonary pressure for clinical outcome in patients presenting with heart failure with preserved ejection fraction. European Heart Journal Cardiovascular Imaging, 2017, 18, 629-635.	0.5	40
329	Healthcare burden of pulmonary hypertension owing to lung disease and/or hypoxia. BMC Pulmonary Medicine, 2017, 17, 58.	0.8	23
330	Antiphospholipid antibodies can identify lupus patients at risk of pulmonary hypertension: A systematic review and meta-analysis. Autoimmunity Reviews, 2017, 16, 576-586.	2.5	48
331	Sex-specific cardiopulmonary exercise testing indices related to hemodynamics in idiopathic pulmonary arterial hypertension. Therapeutic Advances in Respiratory Disease, 2017, 11, 135-145.	1.0	8
332	Drug-induced pulmonary arterial hypertension: a review. Heart Failure Reviews, 2017, 22, 289-297.	1.7	24
333	The European Association of Preventive Cardiology Exercise Prescription in Everyday Practice and Rehabilitative Training (EXPERT) tool: A digital training and decision support system for optimized exercise prescription in cardiovascular disease. Concept, definitions and construction methodology. European Journal of Preventive Cardiology, 2017, 24, 1017-1031.	0.8	141
334	Plasma Drug Concentrations in Patients with Pulmonary Arterial Hypertension on Combination Treatment. Respiration, 2017, 94, 26-37.	1.2	19
335	Clinical pharmacology, efficacy, and safety of selexipag for the treatment of pulmonary arterial hypertension. Expert Opinion on Drug Safety, 2017, 16, 743-751.	1.0	13
336	Changes in right ventricular function assessed by echocardiography in dog models of mild <scp>RV</scp> pressure overload. Echocardiography, 2017, 34, 1040-1049.	0.3	12
337	Identification of Pulmonary Hypertension Caused by Left-Sided Heart Disease (World Health) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 187 T 152, 792-799.	0.4	17
338	Pulmonary Hypertension in Infants, Children, and Young Adults. Journal of the American College of Cardiology, 2017, 69, 2551-2569.	1.2	128
339	Reduced carboxylesterase 1 is associated with endothelial injury in methamphetamine-induced pulmonary arterial hypertension. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2017, 313, L252-L266.	1.3	35
340	ACR Appropriateness CriteriaÂ® Suspected Pulmonary Hypertension. Journal of the American College of Radiology, 2017, 14, S350-S361.	0.9	18

#	Article	IF	Citations
341	Selexipag, an Oral Prostacyclin-Receptor Agonist for Pulmonary Arterial Hypertension. Annals of Pharmacotherapy, 2017, 51, 488-495.	0.9	7
342	Effect of Weight on Parenteral Prostacyclin Analogues Dosing in Pulmonary Hypertension. Chest, 2017, 151, 1189-1192.	0.4	0
343	Obstructive sleep apnoea and right ventricular function: A combined assessment by speckle tracking and three-dimensional echocardiography. International Journal of Cardiology, 2017, 243, 544-549.	0.8	28
344	Refined balloon pulmonary angioplastyâ€"A therapeutic option in very elderly patients with chronic thromboembolic pulmonary hypertension. Journal of Interventional Cardiology, 2017, 30, 249-255.	0.5	19
345	The Effect of Clinical and Physiological Instability at Discharge Following Hospitalization for Acute Exacerbation of COPD on Early Readmission. Chest, 2017, 151, 1192-1194.	0.4	2
346	Epidemiological changes in Eisenmenger syndrome in the Nordic region in 1977â€"2012. Heart, 2017, 103, 1353-1358.	1.2	26
347	High-risk echocardiographic features predict mortality in pulmonary arterial hypertension. American Heart Journal, 2017, 189, 167-176.	1.2	12
348	PPARÎ³ Links BMP2 and TGFÎ²1 Pathways in Vascular Smooth Muscle Cells, Regulating Cell Proliferation and Glucose Metabolism. Cell Metabolism, 2017, 25, 1118-1134.e7.	7.2	163
349	Challenge of Pregnancy in Patients With Pre-Capillary Pulmonary Hypertension: Veno-Arterial Extracorporeal Membrane Oxygenation as an Innovative Support for Delivery. Journal of Cardiothoracic and Vascular Anesthesia, 2017, 31, 2152-2155.	0.6	14
350	Is it time to recognize a new phenotype? Heart failure with preserved ejection fraction with pulmonary vascular disease. European Heart Journal, 2017, 38, 2874-2878.	1.0	62
351	Pulmonary Hypertension and Cancer: Etiology, Diagnosis, and Management. Current Treatment Options in Cardiovascular Medicine, 2017, 19, 44.	0.4	6
352	Breathâ€hold and freeâ€breathing 2D phaseâ€contrast MRI for quantification of oxygenâ€induced changes of pulmonary circulation dynamics in healthy volunteers. Journal of Magnetic Resonance Imaging, 2017, 46, 1698-1706.	1.9	2
353	Past and current cause-specific mortality in Eisenmenger syndrome. European Heart Journal, 2017, 38, 2060-2067.	1.0	68
354	Trends in Pulmonary Hypertension Over a Period of 30 Years: Experience From a Single Referral Centre. Revista Espanola De Cardiologia (English Ed), 2017, 70, 915-923.	0.4	7
355	Clinical and hemodynamic improvements after adding ambrisentan to background PDE5i therapy in patients with pulmonary arterial hypertension exhibiting a suboptimal therapeutic response (ATHENA-1). Respiratory Medicine, 2017, 126, 84-92.	1.3	15
356	Early pulmonary arterial hypertension immediately after closure of a ventricular or complete atrioventricular septal defect beyond 6 months of age. International Journal of Cardiology, 2017, 228, 313-318.	0.8	2
357	Impact of pulmonary hypertension on biventricular functions tissue doppler echocardiographic study. The Egyptian Journal of Chest Diseases and Tuberculosis, 2017, 66, 137-144.	0.1	1
358	Pulmonary Hypertension and Precision Medicine through the â€œOmicsâ€•Looking Glass. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 1558-1560.	2.5	5

#	Article	IF	Citations
359	High sensitivity and negative predictive value of theÂDETECT algorithm for an early diagnosis of pulmonary arterial hypertension in systemic sclerosis: application in a single center. Arthritis Research and Therapy, 2017, 19, 135.	1.6	19
360	Nailfold capillaroscopic changes in patients with idiopathic pulmonary arterial hypertension and systemic sclerosis-related pulmonary arterial hypertension. Microvascular Research, 2017, 114, 46-51.	1.1	42
361	Twoâ€dimensional knowledgeâ€based volumetric reconstruction of the right ventricle documents shortâ€term improvement in pulmonary hypertension. Echocardiography, 2017, 34, 817-824.	0.3	0
362	An association between volumes of the cardiac chambers and troponin levels in individuals submitted to cardiac coronary computed tomography. Clinical Cardiology, 2017, 40, 879-885.	0.7	2
363	Evaluation and management approaches for scleroderma lung disease. Therapeutic Advances in Respiratory Disease, 2017, 11, 327-340.	1.0	19
364	Current management of pulmonary arterial hypertension. The Prescriber, 2017, 28, 27-33.	0.1	1
365	Lung Cancer in Patients With Combined Pulmonary Fibrosis and Emphysema and Idiopathic Pulmonary Fibrosis. A Descriptive Study in a Spanish Series. Archivos De Bronconeumologia, 2017, 53, 304-310.	0.4	7
366	Selexipag, a selective prostacyclin receptor agonist in pulmonary arterial hypertension: a pharmacology review. Expert Review of Clinical Pharmacology, 2017, 10, 753-762.	1.3	16
367	Effect of iloprost on biomarkers in patients with congenital heart diseaseâ€pulmonary arterial hypertension. Clinical and Experimental Pharmacology and Physiology, 2017, 44, 914-923.	0.9	6
368	Identifying â€œsuper respondersâ€•in pulmonary arterial hypertension. Pulmonary Circulation, 2017, 7, 300-311.	0.8	19
369	Pulmonary hemodynamics and effects of phosphodiesterase type 5 inhibition in heart failure: a meta-analysis of randomized trials. BMC Cardiovascular Disorders, 2017, 17, 150.	0.7	32
370	Aptamer-based proteomic profiling for prognostication in pulmonary arterial hypertension. Lancet Respiratory Medicine,the, 2017, 5, 671-672.	5.2	3
371	Load Adaptability in Patients With Pulmonary Arterial Hypertension. American Journal of Cardiology, 2017, 120, 874-882.	0.7	15
372	Phosphodiesterase type 5Âinhibitor to riociguat transition is associated with hemodynamic and symptomatic improvement in pulmonary hypertension. Pulmonary Circulation, 2017, 7, 539-542.	0.8	9
373	Effects of exercise training on pulmonary hemodynamics, functional capacity and inflammation in pulmonary hypertension. Pulmonary Circulation, 2017, 7, 20-37.	0.8	33
374	The ultimate diagnosis of unexplained dyspnoea on exertion: Stay tuned on invasive cardiopulmonary exercise testing and beyond. European Journal of Preventive Cardiology, 2017, 24, 1308-1310.	0.8	5
376	Pediatric pulmonary arterial hypertension. Current Opinion in Pulmonary Medicine, 2017, 23, 398-403.	1.2	2
377	Right Heart End-Systolic Remodeling Index Strongly Predicts Outcomes in Pulmonary Arterial Hypertension. Circulation: Cardiovascular Imaging, 2017, 10, .	1.3	72

#	Article	IF	Citations
378	Left Main Coronary Artery Compression in Patients With Pulmonary Arterial Hypertension andÂAngina. Journal of the American College of Cardiology, 2017, 69, 2808-2817.	1.2	91
379	Left Main Coronary Artery Compression inÂPatients With Pulmonary Arterial Hypertension â^—. Journal of the American College of Cardiology, 2017, 69, 2818-2820.	1.2	5
380	A long way to go after the initial experience with balloon pulmonary angioplasty. European Respiratory Journal, 2017, 49, 1700718.	3.1	15
381	Pulmonary arterial wall disease in COPD and interstitial lung diseases candidates for lung transplantation. Respiratory Research, 2017, 18, 85.	1.4	11
382	Pre-anaesthetic evaluation of the patient with end-stage lung disease. Bailliere's Best Practice and Research in Clinical Anaesthesiology, 2017, 31, 249-260.	1.7	2
383	Ventricular Diastolic Pressure Ratio as a Marker of Treatment Response in Pulmonary Hypertension. Chest, 2017, 152, 980-989.	0.4	2
385	Cardiopulmonary assessment of patients with systemic sclerosis for hematopoietic stem cell transplantation: recommendations from the European Society for Blood and Marrow Transplantation Autoimmune Diseases Working Party and collaborating partners. Bone Marrow Transplantation, 2017, 52, 1495-1503.	1.3	88
386	Pulmonary Hypertensionâ€“Back to the Future. Revista Espanola De Cardiologia (English Ed), 2017, 70, 901-904.	0.4	1
387	The role of platelets in autoimmunity, vasculopathy, and fibrosis: Implications for systemic sclerosis. Seminars in Arthritis and Rheumatism, 2017, 47, 409-417.	1.6	41
388	Recent advances in connective tissue disease related interstitial lung disease. Expert Review of Respiratory Medicine, 2017, 11, 591-603.	1.0	21
389	Diameter of the Pulmonary Artery in Relation to the Ascending Aorta: Association with Cardiovascular Outcome. Radiology, 2017, 284, 685-693.	3.6	11
390	Assessment of right ventricular longitudinal strain by 2D speckle tracking imaging compared with RV function and hemodynamics in pulmonary hypertension. International Journal of Cardiovascular Imaging, 2017, 33, 1737-1748.	0.7	12
391	Outcomes of pulmonary arterial hypertension therapy in Australia: is monotherapy adequate?. Internal Medicine Journal, 2017, 47, 1124-1128.	0.5	0
392	Risk of cardiovascular events and pulmonary hypertension following splenectomy â€” a Danish population-based cohort study from 1996â€“2012. Haematologica, 2017, 102, 1333-1341.	1.7	25
393	Novel approach to classifying patients with pulmonary arterial hypertension using cluster analysis. Pulmonary Circulation, 2017, 7, 486-493.	0.8	12
394	Balloon pulmonary angioplasty for inoperable patients with chronic thromboembolic pulmonary hypertension: the initial German experience. European Respiratory Journal, 2017, 49, 1602409.	3.1	178
395	Survival in pulmonary hypertension: Experiences from a referral center. Journal of Heart and Lung Transplantation, 2017, 36, 938-939.	0.3	0
396	Circulating Endothelial Cell Quantification by Microfluidics Chip in Pulmonary Arterial Hypertension. American Journal of Respiratory Cell and Molecular Biology, 2017, 56, 680-682.	1.4	2

#	Article	IF	Citations
397	Simultaneous quantification of endothelin receptor antagonists and phosphodiesterase 5 inhibitors currently used in pulmonary arterial hypertension. Journal of Pharmaceutical and Biomedical Analysis, 2017, 143, 291-298.	1.4	14
398	Mortality in pulmonary arterial hypertension due to congenital heart disease: Serial changes improve prognostication. International Journal of Cardiology, 2017, 243, 449-453.	0.8	22
399	Chronic thromboembolic pulmonary hypertension: Evaluation of 2D-perfusion angiography in patients who undergo balloon pulmonary angioplasty. European Radiology, 2017, 27, 4264-4270.	2.3	24
400	Follistatin-like 1 protects against hypoxia-induced pulmonary hypertension in mice. Scientific Reports, 2017, 7, 45820.	1.6	19
401	Use of Î²-Blockers in Pulmonary Hypertension. Circulation: Heart Failure, 2017, 10, .	1.6	56
402	Pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis. Medicina ClÃnica (English Edition), 2017, 148, 265-270.	0.1	2
403	Effect of breathing oxygen-enriched air on exercise performance in patients with precapillary pulmonary hypertension: randomized, sham-controlled cross-over trial. European Heart Journal, 2017, 38, 1159-1168.	1.0	67
404	A simple hemodynamic parameter to predict clinical worsening in pulmonary arterial hypertension: The parameter is simple but interpreting the results is difficult. Journal of Critical Care, 2017, 42, 350.	1.0	0
405	Pulmonary arterial hypertension in congenital heart disease: translational opportunities to study the reversibility of pulmonary vascular disease. European Heart Journal, 2017, 38, 2034-2041.	1.0	66
406	Just air good enough in pulmonary hypertension?. European Heart Journal, 2017, 38, 1169-1171.	1.0	1
407	Why septal motion is a marker of right ventricular failure in pulmonary arterial hypertension: mechanistic analysis using a computer model. American Journal of Physiology - Heart and Circulatory Physiology, 2017, 312, H691-H700.	1.5	38
408	Resultados de la tromboendarterectomÃa pulmonar en la hipertensiÃ³n pulmonar tromboembÃ³lica crÃ³nica. Medicina ClÃnica, 2017, 149, 1-8.	0.3	7
411	Mazindol: a risk factor for pulmonary arterial hypertension?. Sleep Medicine, 2017, 34, 168-169.	0.8	5
412	Impact of postoperative pulmonary hypertension on outcome after heart transplantation. Scandinavian Cardiovascular Journal, 2017, 51, 172-181.	0.4	10
413	Magnetic Resonance Imaging in the Prognostic Evaluation of Patients with Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 228-239.	2.5	122
414	Right ventricular freeâ€wall longitudinal speckle tracking strain in patients with pulmonary arterial hypertension under specific treatment. Echocardiography, 2017, 34, 530-536.	0.3	12
415	Australian and <scp>N</scp>ew <scp>Z</scp>ealand <scp>P</scp>ulmonary <scp>R</scp>ehabilitation <scp>G</scp>uidelines. Respirology, 2017, 22, 800-819.	1.3	198
416	Pulmonary Hypertension in Heart Failure. Journal of the American College of Cardiology, 2017, 69, 1718-1734.	1.2	247

#	Article	IF	Citations
418	Randomized controlled trials: a solid platform for observational research. European Heart Journal, 2017, 38, 1156-1158.	1.0	2
419	Prognostic Significance of Reduced Blood Pressure Response to Exercise in Pediatric Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 1478-1481.	2.5	1
420	The Year in Thoracic Anesthesia: Selected Highlights from 2016. Journal of Cardiothoracic and Vascular Anesthesia, 2017, 31, 791-799.	0.6	10
421	Impact of advanced medical therapy for the outcome of an adult patient with Eisenmenger syndrome. Respiratory Medicine Case Reports, 2017, 21, 16-20.	0.2	3
423	Advances in treatment of pulmonary arterial hypertension: patent review. Expert Opinion on Therapeutic Patents, 2017, 27, 907-918.	2.4	13
424	Steps forward in the treatment of pulmonary arterial hypertension: latest developments and clinical opportunities. Therapeutic Advances in Chronic Disease, 2017, 8, 47-64.	1.1	26
425	Retrospective evaluation of pimobendan and sildenafil therapy for severe pulmonary hypertension due to lung disease and hypoxia in 28 dogs (2007-2013). Veterinary Medicine and Science, 2017, 3, 99-106.	0.6	14
426	Withdrawal of longâ€term epoprostenol therapy in pulmonary arterial hypertension (PAH). Pulmonary Circulation, 2017, 7, 439-447.	0.8	11
427	Impact of Thrombolytic Therapy onÂtheÂLong-Term Outcome of Intermediate-Risk PulmonaryÂEmbolism. Journal of the American College of Cardiology, 2017, 69, 1536-1544.	1.2	258
428	Real-world, long-term survival of incident patients with pulmonary arterial hypertension. Revista Portuguesa De Pneumologia, 2017, 23, 124-131.	0.7	9
429	Effects of reduction of pressure overload on right ventricular function in patients with Eisenmenger syndrome. Journal of Cardiology, 2017, 69, 739-740.	0.8	0
430	Cardio-Onco-Hematology in Clinical Practice. Position Paper and Recommendations. Revista Espanola De Cardiologia (English Ed), 2017, 70, 474-486.	0.4	54
431	Noninvasive pulmonary artery pressure monitoring by EIT: a model-based feasibility study. Medical and Biological Engineering and Computing, 2017, 55, 949-963.	1.6	12
432	Overestimation by echocardiography of the peak systolic pressure gradient between the right ventricle and right atrium due to tricuspid regurgitation and the usefulness of the early diastolic transpulmonary valve pressure gradient for estimating pulmonary artery pressure. Heart and Vessels, 2017, 32, 833-842.	0.5	12
433	Bucindolol improves right ventricle function in rats with pulmonary arterial hypertension through the reversal of autonomic imbalance. European Journal of Pharmacology, 2017, 798, 57-65.	1.7	10
434	Treatment of pulmonary arterial hypertension in Eisenmenger syndrome: Practice makes (almost) perfect. Journal of Heart and Lung Transplantation, 2017, 36, 376-377.	0.3	0
435	The Influence of Age on Hemodynamic Parameters During Rest andÂExercise inÂHealthy Individuals. JACC: Heart Failure, 2017, 5, 337-346.	1.9	108
436	Evaluation of left ventricular diastolic function profile in patients with pulmonary hypertension due to heart failure with preserved ejection fraction. Clinical Cardiology, 2017, 40, 356-363.	0.7	9

#	Article	IF	Citations
437	Application of Cardiac Troponin in Cardiovascular Diseases Other Than Acute Coronary Syndrome. Clinical Chemistry, 2017, 63, 223-235.	1.5	77
438	Cardiac dysfunction of pulmonary artery aneurysm in patients with pulmonary arterial hypertension. International Journal of Cardiology, 2017, 228, 1035-1040.	0.8	9
439	Persistent pulmonary hypertension and right ventricular function after percutaneous mechanical thrombectomy in severe acute pulmonary embolism. European Respiratory Journal, 2017, 49, 1600910.	3.1	3
440	Diagnosis and Treatment of Pulmonary Hypertension. , 2017, , .		1
441	Enterosalivary nitrate metabolism and the microbiome: Intersection of microbial metabolism, nitric oxide and diet in cardiac and pulmonary vascular health. Free Radical Biology and Medicine, 2017, 105, 48-67.	1.3	123
442	Adaptation and Validation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) for Use in Spain. Revista Espanola De Cardiologia (English Ed), 2017, 70, 467-473.	0.4	4
443	Update of EULAR recommendations for the treatment of systemic sclerosis. Annals of the Rheumatic Diseases, 2017, 76, 1327-1339.	0.5	794
444	Selexipag: A Review in Pulmonary Arterial Hypertension. American Journal of Cardiovascular Drugs, 2017, 17, 73-80.	1.0	17
445	Targeting Vascular Remodeling to Treat Pulmonary Arterial Hypertension. Trends in Molecular Medicine, 2017, 23, 31-45.	3.5	171
446	HAND1 Loss-of-Function Mutation Causes Tetralogy of Fallot. Pediatric Cardiology, 2017, 38, 547-557.	0.6	13
447	A simple hemodynamic parameter to predict clinical worsening in pulmonary arterial hypertension. Journal of Critical Care, 2017, 38, 324-327.	1.0	2
448	Utility of FVC/DLCO ratio to stratify the risk of mortality in unselected subjects with pulmonary hypertension. Internal and Emergency Medicine, 2017, 12, 319-326.	1.0	11
449	Management of tricuspid valve regurgitation. European Journal of Cardio-thoracic Surgery, 2017, 52, 1022-1030.	0.6	129
450	Inhibition of pyruvate dehydrogenase kinase improves pulmonary arterial hypertension in genetically susceptible patients. Science Translational Medicine, 2017, 9, .	5.8	206
451	Comprehensive evaluation of the effectiveness and safety of balloon pulmonary angioplasty for inoperable chronic thrombo-embolic pulmonary hypertension: long-term effects and procedure-related complications. European Heart Journal, 2017, 38, 3152-3159.	1.0	130
452	What Is the Role of Oral Prostacyclin Pathway Medications in Pulmonary Arterial Hypertension Management?. Current Hypertension Reports, 2017, 19, 97.	1.5	9
453	Invited Commentary. Annals of Thoracic Surgery, 2017, 104, 1185-1186.	0.7	0
454	Late Onset Postcapillary Pulmonary Hypertension in Patients With Transposition of the Great Arteries and Mustard or Senning Baffles. Journal of the American Heart Association, 2017, 6, .	1.6	21

#	Article	IF	Citations
456	Contribution of central and peripheral factors at peak exercise in heart failure patients with progressive severity of exercise limitation. International Journal of Cardiology, 2017, 248, 252-256.	0.8	20
457	Myocardial fibrosis detected by magnetic resonance in systemic sclerosis patients â€“ Relationship with biochemical and echocardiography parameters. International Journal of Cardiology, 2017, 249, 448-453.	0.8	36
458	Wave reflection correlates with pulmonary vascular wall thickening in rats with pulmonary arterial hypertension. International Journal of Cardiology, 2017, 249, 396-401.	0.8	6
461	Severe idiopathic pulmonary fibrosis: what can be done?. European Respiratory Review, 2017, 26, 170047.	3.0	33
462	Cardiac complications of systemic sclerosis and management: recent progress. Current Opinion in Rheumatology, 2017, 29, 574-584.	2.0	31
463	Is pulmonary artery wedge pressure a Fib in Aâ€Fib?. European Journal of Heart Failure, 2017, 19, 1491-1494.	2.9	4
464	Heart rate and risk of death among patients with Pulmonary Hypertension: A 12-lead ECG analysis. Respiratory Medicine, 2017, 132, 42-49.	1.3	9
467	3-Dimensional SPECT/CT Fusion Imaging-Guided Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension. JACC: Cardiovascular Interventions, 2017, 10, e193-e194.	1.1	6
469	Pulmonary Hypertension Due to Left Ventricular Cardiomyopathy: Is it the Result or Cause of Disease Progression?. Current Heart Failure Reports, 2017, 14, 507-513.	1.3	11
470	Evidence on Exercise Training in Pulmonary Hypertension. Advances in Experimental Medicine and Biology, 2017, 1000, 153-172.	0.8	14
471	Contrast microsphere enhancement of the tricuspid regurgitant spectral Doppler signal - Is it still necessary with contemporary scanners?. IJC Heart and Vasculature, 2017, 17, 1-10.	0.6	7
472	Echocardiographic estimation of left ventricular and pulmonary pressures in patients with heart failure and preserved ejection fraction: a study utilizing simultaneous echocardiography and invasive measurements. European Journal of Heart Failure, 2017, 19, 1651-1660.	2.9	89
473	Anxiety, Depression, and Health-Related QOL in Patients Diagnosed with PAH or CTEPH. Lung, 2017, 195, 759-768.	1.4	26
475	Echocardiography in the Diagnosis and Follow-Up of Patients with Pulmonary Arterial Hypertension Associated with Congenital Heart Disease. Congenital Heart Disease in Adolescents and Adults, 2017, , 163-178.	0.2	3
476	Atrial fibrillation modifies the association between pulmonary artery wedge pressure and left ventricular endâ€diastolic pressure. European Journal of Heart Failure, 2017, 19, 1483-1490.	2.9	42
478	Definition and Classification of Pulmonary Hypertension in Congenital Heart Disease. Congenital Heart Disease in Adolescents and Adults, 2017, , 23-28.	0.2	0
479	Anticoagulation for Thromboembolic Risk Reduction in Adults With Congenital Heart Disease. Canadian Journal of Cardiology, 2017, 33, 1597-1603.	0.8	10
480	The Prevalence, Correlates, and ImpactÂonÂCardiac Mortality of RightÂVentricular Dysfunction in NonischemicÂCardiomyopathy. JACC: Cardiovascular Imaging, 2017, 10, 1225-1236.	2.3	67

#	Article	IF	Citations
481	Exercise Training in Pulmonary Hypertension and Right Heart Failure: Insights from Pre-clinical Studies. Advances in Experimental Medicine and Biology, 2017, 999, 307-324.	0.8	9
482	The Nitric Oxide Pathway in Pulmonary Vascular Disease. American Journal of Cardiology, 2017, 120, S71-S79.	0.7	79
483	The Nitric Oxide Pathwayâ€"A Potential Target for Precision Medicine in Pulmonary Arterial Hypertension. American Journal of Cardiology, 2017, 120, S69-S70.	0.7	3
484	Pulmonary Arterial Hypertension Complicating Congenital Heart Disease: Advances in Therapy. Seminars in Respiratory and Critical Care Medicine, 2017, 38, 636-650.	0.8	7
485	Lung Transplantation for Pulmonary Hypertension and Strategies to Bridge to Transplant. Seminars in Respiratory and Critical Care Medicine, 2017, 38, 701-710.	0.8	5
486	Chronic Thromboembolic Pulmonary Hypertension: Advances in Therapy. Seminars in Respiratory and Critical Care Medicine, 2017, 38, 677-685.	0.8	0
487	Idiopathic Pulmonary Arterial Hypertension: Evolving Therapeutic Strategies. Seminars in Respiratory and Critical Care Medicine, 2017, 38, 606-618.	0.8	5
488	Pulmonary Hypertension Due to Left Heart Disease. Seminars in Respiratory and Critical Care Medicine, 2017, 38, 662-676.	0.8	1
489	Pulmonary Hypertension: Definition, Classification, and Diagnosis. Seminars in Respiratory and Critical Care Medicine, 2017, 38, 561-570.	0.8	7
490	Medical Treatment of Pulmonary Arterial Hypertension. Seminars in Respiratory and Critical Care Medicine, 2017, 38, 686-700.	0.8	9
491	Evolving Concepts in Pulmonary Hypertension. Seminars in Respiratory and Critical Care Medicine, 2017, 38, 559-560.	0.8	0
492	Management and long-term outcomes of sarcoidosis-associated pulmonary hypertension. European Respiratory Journal, 2017, 50, 1700465.	3.1	111
493	Evaluation of the hemodynamics and right ventricular function in pulmonary hypertension by echocardiography compared with right-sided heart catheterization. Experimental and Therapeutic Medicine, 2017, 14, 3616-3622.	0.8	6
494	Medical Management of Pulmonary Hypertension with Unclear and/or Multifactorial Mechanisms (Group 5): Is There a Role for Pulmonary Arterial Hypertension Medications?. Current Hypertension Reports, 2017, 19, 86.	1.5	19
495	Endothelial Cell Reactive Oxygen Species and Ca2+ Signaling in Pulmonary Hypertension. Advances in Experimental Medicine and Biology, 2017, 967, 299-314.	0.8	14
497	Treatment strategies for the right heart in pulmonary hypertension. Cardiovascular Research, 2017, 113, 1465-1473.	1.8	55
498	Pulmonary veno-occlusive disease: An important consideration in patients with pulmonary hypertension. Respiratory Medicine, 2017, 132, 203-209.	1.3	13
499	Endothelial to haematopoietic transition contributes to pulmonary arterial hypertension. Cardiovascular Research, 2017, 113, 1560-1573.	1.8	20

#	Article	IF	Citations
500	RV pressure overload: from hypertrophy to failure. Cardiovascular Research, 2017, 113, 1423-1432.	1.8	66
502	The Circulating MicroRNA-206 Level Predicts the Severity of Pulmonary Hypertension in Patients with Left Heart Diseases. Cellular Physiology and Biochemistry, 2017, 41, 2150-2160.	1.1	32
503	Management of combined pre- and post-capillary pulmonary hypertension in advanced heart failure with reduced ejection fraction. Respiratory Medicine, 2017, 131, 94-100.	1.3	3
504	Echocardiographic assessment of the right ventricle in the current era: Application in clinical practice. Echocardiography, 2017, 34, 1930-1947.	0.3	40
505	Right atrial function and prognosis in idiopathic pulmonary arterial hypertension. International Journal of Cardiology, 2017, 248, 320-325.	0.8	35
506	Treatment of idiopathic pulmonary fibrosis in <scp>A</scp>ustralia and <scp>N</scp>ew Zealand: <scp>A</scp> position statement from the <scp>T</scp>horacic <scp>S</scp>ociety of <scp>A</scp>ustralia and <scp>N</scp>ew <scp>Z</scp>ealand and the <scp>L</scp>ung <scp>F</scp>oundation <scp>A</scp>ustralia. Respirology, 2017, 22, 1436-1458.	1.3	39
509	Hemodynamic Phenotyping of Pulmonary Hypertension in Left Heart Failure. Circulation: Heart Failure, 2017, 10, .	1.6	84
510	What We Talk About When We Talk About the Wedge Pressure. Circulation: Heart Failure, 2017, 10, .	1.6	34
511	Cardiopulmonary Exercise Testing. Journal of the American College of Cardiology, 2017, 70, 1618-1636.	1.2	294
512	Therapeutic benefits of phosphodiesterase-5 inhibition in chronic heart failure: A meta-analysis. Interventional Medicine & Applied Science, 2017, 9, 123-135.	0.2	2
513	Mortality in adults with congenital heart disease. International Journal of Cardiology, 2017, 245, 125-130.	0.8	32
514	Prostaglandin E1 Attenuates Pulmonary Artery Remodeling by Activating Phosphorylation of CREB and the PTEN Signaling Pathway. Scientific Reports, 2017, 7, 9974.	1.6	6
515	Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study. Lancet Respiratory Medicine,the, 2017, 5, 785-794.	5.2	201
516	Macitentan for treatment of CTEPH: why MERIT merits attention. Lancet Respiratory Medicine,the, 2017, 5, 762-763.	5.2	1
517	The Impact of Heterozygous KCNK3 Mutations Associated With Pulmonary Arterial Hypertension on Channel Function and Pharmacological Recovery. Journal of the American Heart Association, 2017, 6, .	1.6	34
518	Challenging the concept of adding more drugs in pulmonary arterial hypertension. European Respiratory Journal, 2017, 50, 1701527.	3.1	7
519	Conservative Management and Recommendations for Pulmonary Arterial Hypertension Related to Congenital Heart Disease. Congenital Heart Disease in Adolescents and Adults, 2017, , 229-251.	0.2	0
520	Efficacy and safety of long-term imatinib therapy for patients with pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis. Respiratory Medicine, 2017, 131, 215-219.	1.3	20

#	Article	IF	Citations
521	Interstitial Pneumonia With Autoimmune Features: Overview of Proposed Criteria and Recent Cohort Characterization. Clinical Pulmonary Medicine, 2017, 24, 191-196.	0.3	11
522	Decoupling Between Diastolic Pulmonary Artery Pressure and Pulmonary Capillary Wedge Pressure as a Prognostic Factor After Continuous Flow Ventricular Assist Device Implantation. Circulation: Heart Failure, 2017, 10, .	1.6	57
523	Diastolic Pressure Difference to Classify Pulmonary Hypertension in the Assessment of Heart Transplant Candidates. Circulation: Heart Failure, 2017, 10, .	1.6	32
524	Palliative Care and End-of-Life Considerations in Patients with PAHâ€“CHD. Congenital Heart Disease in Adolescents and Adults, 2017, , 341-361.	0.2	0
525	Evaluation of criteria for exercise-induced pulmonary hypertension in patients with resting pulmonary hypertension. European Respiratory Journal, 2017, 50, 1700784.	3.1	7
527	Increased Epicardial Fat Volume Is Independently Associated with the Presence and Severity of Systemic Sclerosis. Academic Radiology, 2017, 24, 1473-1481.	1.3	15
528	Pulmonary Hypertension in a Large Cohort with Hereditary Hemorrhagic Telangiectasia. Respiration, 2017, 94, 242-250.	1.2	20
529	2017 Comprehensive Update of the Canadian Cardiovascular Society Guidelines for the Management of Heart Failure. Canadian Journal of Cardiology, 2017, 33, 1342-1433.	0.8	503
530	Long-term management of end-stage heart failure. Bailliere's Best Practice and Research in Clinical Anaesthesiology, 2017, 31, 153-166.	1.7	22
531	Importance of kynurenine in pulmonary hypertension. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2017, 313, L741-L751.	1.3	31
532	HipertensiÃ³n arterial pulmonar reversible en una paciente con esclerosis mÃºltiple asociada a tratamiento con interferÃ³n. Archivos De Bronconeumologia, 2017, 53, 596-597.	0.4	4
533	Decreased pulmonary arterial proportional pulse pressure is associated with increased mortality in group 1 pulmonary hypertension. Clinical Cardiology, 2017, 40, 988-992.	0.7	5
534	Broader implications for the widened pulmonary artery?. Respirology, 2017, 22, 1495-1496.	1.3	2
535	Is there a vanishing pulmonary capillary syndrome?. Lancet Respiratory Medicine,the, 2017, 5, 676-678.	5.2	22
536	Pulmonary hypertensionâ€™s variegated landscape: a snapshot. Pulmonary Circulation, 2017, 7, 67-81.	0.8	2
537	Complications associated with the use of oral anticoagulation in patients with pulmonary arterial hypertension from two referral centers. Pulmonary Circulation, 2017, 7, 692-701.	0.8	9
538	Novel echocardiographic prognostic markers for cardiac tamponade in patients with large malignant pericardial effusions: A paradigm shift from flow to tissue imaging. Echocardiography, 2017, 34, 1315-1323.	0.3	4
539	HipertensiÃ³n pulmonar. Regreso al futuro. Revista Espanola De Cardiologia, 2017, 70, 901-904.	0.6	2

#	Article	IF	Citations
540	Comprehensive Multi-Dimensional MRI for the Simultaneous Assessment of Cardiopulmonary Anatomy and Physiology. Scientific Reports, 2017, 7, 5330.	1.6	36
541	Cor pulmonale. Medicine, 2017, 12, 2116-2126.	0.0	0
542	Pulmonary endarterectomy outputs in chronic thromboembolic pulmonary hypertension. Medicina ClÃ¤nica (English Edition), 2017, 149, 1-8.	0.1	3
543	A natriuretic peptides clearance receptorâ€™s agonist reduces pulmonary artery pressures and enhances cardiac performance in preclinical models: New hope for patients with pulmonary hypertension due to left ventricular heart failure. Biomedicine and Pharmacotherapy, 2017, 93, 1144-1150.	2.5	12
544	The safety and tolerability of inhaled treprostinil in patients with pulmonary hypertension and chronic obstructive pulmonary disease. Pulmonary Circulation, 2017, 7, 82-88.	0.8	20
545	Healthcare resource utilization and costs for patients with pulmonary arterial hypertension: real-world documentation of functional class. Journal of Medical Economics, 2017, 20, 1178-1186.	1.0	30
546	Consensus Document of the Italian Association of Hospital Cardiologists (ANMCO), Italian Society of Pediatric Cardiology (SICP), and Italian Society of Gynaecologists and Obstetrics (SIGO): pregnancy and congenital heart diseases. European Heart Journal Supplements, 2017, 19, D256-D292.	0.0	13
547	Selexipag for the treatment of pulmonary arterial hypertension. American Journal of Health-System Pharmacy, 2017, 74, 1135-1141.	0.5	12
550	Renal Transplantation After Laparoscopic Radical Nephrectomy due to Neoplastic Disease â€“ Case Report. Transplantation, 2017, 101, S16.	0.5	0
551	Bilateral Lung Transplantation With Interventional Occlusion of an Atrial Septal Defect in a Patient With Eisenmenger Syndrome. Transplantation, 2017, 101, S16.	0.5	0
552	Effects of Pulmonary Hypertension on Kidney Function. Clinical Pulmonary Medicine, 2017, 24, 26-28.	0.3	4
553	Plasma acylcarnitines are associated with pulmonary hypertension. Pulmonary Circulation, 2017, 7, 211-218.	0.8	21
554	Safety and Efficacy of Immunoadsorption as an Add-On to Medical Treatment in Patients with Severe Idiopathic Pulmonary Arterial Hypertension. Respiration, 2017, 94, 263-271.	1.2	2
555	Multispecialty pulmonary hypertension clinic in the VA. Pulmonary Circulation, 2017, 7, 758-767.	0.8	4
556	How I treat idiopathic patients with inflammatory myopathies in the clinical practice. Autoimmunity Reviews, 2017, 16, 999-1007.	2.5	22
557	Angiogenic and inflammatory biomarkers in the differentiation of pulmonary hypertension. Scandinavian Cardiovascular Journal, 2017, 51, 261-270.	0.4	32
558	Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model. European Respiratory Journal, 2017, 50, 1700740.	3.1	489
559	Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension. European Respiratory Journal, 2017, 50, 1700889.	3.1	527

#	Article	IF	Citations
560	Left atrial phasic function and heart rate variability in patients with systemic sclerosis: A new part of the old puzzle. Echocardiography, 2017, 34, 1447-1455.	0.3	5
561	More on idiopathic pulmonary arterial hypertension with a low diffusing capacity. European Respiratory Journal, 2017, 50, 1700354.	3.1	25
562	Prostacyclin Therapy for Pulmonary Arterial Hypertension Evolves Again With the Development of an Implantable Delivery System. Chest, 2017, 152, 1100-1102.	0.4	2
563	Multi-view approach for the diagnosis of pulmonary hypertension using transthoracic echocardiography. International Journal of Cardiovascular Imaging, 2017, 34, 695-700.	0.7	13
564	The potential effects of pregnancy in a patient with idiopathic pulmonary arterial hypertension responding to calcium channel blockade. European Respiratory Journal, 2017, 50, 1701141.	3.1	8
565	Lesson of the month 1: Obesity hypoventilation (Pickwickian) syndrome: a reversible cause of severe pulmonary hypertension. Clinical Medicine, 2017, 17, 578-581.	0.8	4
566	Clinical Application of Genetic Testing in Heart Failure. Current Heart Failure Reports, 2017, 14, 543-553.	1.3	6
567	Acute decompensated pulmonary hypertension. European Respiratory Review, 2017, 26, 170092.	3.0	48
568	Pulmonary hypertension as a manifestation of mitochondrial disease. Medicine (United States), 2017, 96, e8716.	0.4	10
569	Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension. Circulation: Cardiovascular Quality and Outcomes, 2017, 10, .	0.9	227
570	Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension. Circulation: Cardiovascular Quality and Outcomes, 2017, 10, .	0.9	4
571	Î±-Solanine as potential therapeutic target in pulmonary artery hypertension. Journal of Hypertension, 2017, 35, 2377-2379.	0.3	3
572	Management of prostacyclin side effects in adult patients with pulmonary arterial hypertension. Pulmonary Circulation, 2017, 7, 598-608.	0.8	39
573	Invasive Hemodynamics of Pulmonary Disease and the Right Ventricle. Interventional Cardiology Clinics, 2017, 6, 329-343.	0.2	2
574	Diagnosis and management of myocardial involvement in systemic immune-mediated diseases: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Disease. European Heart Journal, 2017, 38, 2649-2662.	1.0	163
575	Supplemental Oxygen in Interstitial Lung Disease: An Art in Need of Science. Annals of the American Thoracic Society, 2017, 14, 1373-1377.	1.5	30
577	Congenital heart disease: some progress, but still the challenge of a lifetime!. European Heart Journal, 2017, 38, 2021-2023.	1.0	2
578	Safety and effectiveness of tadalafil in pediatric patients with pulmonary arterial hypertension: a sub-group analysis based on Japan post-marketing surveillance. Current Medical Research and Opinion, 2017, 33, 2241-2249.	0.9	14

#	Article	IF	Citations
579	Switching from sildenafil to riociguat for the treatment of PAH and inoperable CTEPH: Real-life experiences. Respiratory Medicine Case Reports, 2017, 22, 39-43.	0.2	11
580	Addressing the challenges of phenotyping pediatric pulmonary vascular disease. Pulmonary Circulation, 2017, 7, 7-19.	0.8	15
581	Pulmonary arterial hypertension in the USA: an epidemiological study in a large insured pediatric population. Pulmonary Circulation, 2017, 7, 126-136.	0.8	54
582	Prognostic value of tricuspid regurgitation velocity and probability of pulmonary hypertension in patients undergoing transcatheter aortic valve implantation. International Journal of Cardiovascular Imaging, 2017, 33, 1931-1938.	0.7	13
584	Collaborative Care: A Defining Characteristic for a Pulmonary Hypertension Center. Pulmonary Therapy, 2017, 3, 93-111.	1.1	10
585	Markers as predictors of clinical worsening in pulmonary arterial hypertension. Progress in Pediatric Cardiology, 2017, 46, 87-93.	0.2	2
586	Riociguat in PAH and CTEPH: Strategies for Patient Management. Pulmonary Therapy, 2017, 3, 31-43.	1.1	2
587	Imatinib relaxes the pulmonary venous bed of guinea pigs. Respiratory Research, 2017, 18, 32.	1.4	17
588	Chronic hypoxia aggravates monocrotaline-induced pulmonary arterial hypertension: a rodent relevant model to the human severe form of the disease. Respiratory Research, 2017, 18, 47.	1.4	7
589	The predictive capabilities of a novel cardiovascular magnetic resonance derived marker of cardiopulmonary reserve on established prognostic surrogate markers in patients with pulmonary vascular disease: results of a longitudinal pilot study. Journal of Cardiovascular Magnetic Resonance, 2016, 19, 3.	1.6	8
590	Survival and quality of life in incident systemic sclerosis-related pulmonary arterial hypertension. Arthritis Research and Therapy, 2017, 19, 122.	1.6	53
591	Afterload Dependence of Right Ventricular Myocardial Strain. Journal of the American Society of Echocardiography, 2017, 30, 676-684.e1.	1.2	20
592	Left atrial strain predicts hemodynamic parameters in cardiovascular patients. Echocardiography, 2017, 34, 1170-1178.	0.3	28
593	Familial clustering of congenital deafness, patent ductus arteriosus, Eisenmenger complex, and differential cyanosis. Medicine (United States), 2017, 96, e7105.	0.4	0
594	Oxygen Uptake Efficiency Slope Predicts Poor Outcome in Patients With Idiopathic Pulmonary Arterial Hypertension. Journal of the American Heart Association, 2017, 6, .	1.6	27
595	Pulmonary Hypertension and Atrial Septal Defect: Management Dilemma. American Journal of Therapeutics, 2017, 24, e602-e605.	0.5	3
597	A socialâ€technological epistemology of clinical decisionâ€making as mediated by imaging. Journal of Evaluation in Clinical Practice, 2017, 23, 949-958.	0.9	19
598	Pulmonary Hypertension Care CenterÂNetwork. Chest, 2017, 151, 749-754.	0.4	23

#	Article	IF	Citations
599	Independent predictors of developing pulmonary hypertension in heart failure with reduced versus preserved ejection fraction. Journal of the Saudi Heart Association, 2017, 29, 185-194.	0.2	1
600	A Clinical and Echocardiographic Score to Identify Pulmonary Hypertension Due to HFpEF. Journal of Cardiac Failure, 2017, 23, 29-35.	0.7	25
601	From bosentan to macitentan for pulmonary arterial hypertension and adult congenital heart disease: Further improvement?. International Journal of Cardiology, 2017, 227, 51-52.	0.8	43
602	Treatment of idiopathic pulmonary fibrosis: a position paper from a Nordic expert group. Journal of Internal Medicine, 2017, 281, 149-166.	2.7	27
603	Diagnostics in Children and Adolescents with Suspected or Confirmed Pulmonary Hypertension. Paediatric Respiratory Reviews, 2017, 23, 3-15.	1.2	8
604	Right ventricular relative wall thickness as a predictor of outcomes and of right ventricular reverse remodeling for patients with pulmonary hypertension. International Journal of Cardiovascular Imaging, 2017, 33, 313-321.	0.7	13
605	Acute effect of iloprost inhalation on right atrial function and ventricular dyssynchrony in patients with pulmonary artery hypertension. Echocardiography, 2017, 34, 53-60.	0.3	13
606	Lung perfusion characteristics in pulmonary arterial hypertension (PAH) and peripheral forms of chronic thromboembolic pulmonary hypertension (pCTEPH): Dual-energy CT experience in 31 patients. European Radiology, 2017, 27, 1631-1639.	2.3	63
607	Right ventricular function assessed by tissue Doppler echocardiography in older subjects without evidence for structural cardiac disease. Aging Clinical and Experimental Research, 2017, 29, 557-562.	1.4	3
608	Pulmonary Hypertension in Diffuse Parenchymal Lung Diseases. Chest, 2017, 151, 204-214.	0.4	15
609	2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. European Journal of Heart Failure, 2017, 19, 9-42.	2.9	920
610	Diagnostic and prognostic value of right ventricular strain in patients with pulmonary arterial hypertension and relatively preserved functional capacity studied with echocardiography and magnetic resonance. International Journal of Cardiovascular Imaging, 2017, 33, 39-46.	0.7	33
611	Incidence of right heart catheterization in patients initiated on pulmonary arterial hypertension therapies: A population-based study. Journal of Heart and Lung Transplantation, 2017, 36, 220-226.	0.3	10
612	A new method to estimate pulmonary vascular resistance using diastolic pulmonary artery-right ventricular pressure gradients derived from continuous-wave Doppler velocity measurements of pulmonary regurgitation. International Journal of Cardiovascular Imaging, 2017, 33, 31-38.	0.7	2
613	Clinical Relevance of Fluid ChallengeÂinÂPatients Evaluated forÂPulmonary Hypertension. Chest, 2017, 151, 119-126.	0.4	90
614	A review of therapeutic agents for the management of pulmonary arterial hypertension. Therapeutic Advances in Respiratory Disease, 2017, 11, 46-63.	1.0	11
615	An homozygous mutation in KCNK3 is associated with an aggressive form of hereditary pulmonary arterial hypertension. Clinical Genetics, 2017, 91, 453-457.	1.0	54
616	Macitentan Improves Health-Related QualityÂof Life for Patients With Pulmonary Arterial Hypertension. Chest, 2017, 151, 106-118.	0.4	46

#	Article	IF	Citations
617	Why Is Your Patient Still Short of Breath? Understanding the Complex Pathophysiology of Dyspnea in Chronic Kidney Disease. Seminars in Dialysis, 2017, 30, 50-57.	0.7	31
618	The strengths and weaknesses of non-invasive parameters obtained by echocardiography and cardiopulmonary exercise testing in comparison with the hemodynamic assessment by the right heart catheterization in patients with pulmonary hypertension. Advances in Medical Sciences, 2017, 62, 39-44.	0.9	9
619	Pulmonary hypertension secondary to pulmonary veno-occlusive disease complicated by right heart failure, hypotension and acute kidney injury. Respiratory Medicine Case Reports, 2017, 20, 10-13.	0.2	1
620	Right ventricular performance using myocardial deformation imaging in infants with bronchopulmonary dysplasia. Journal of Perinatology, 2017, 37, 81-87.	0.9	13
621	Persistent right ventricular dysfunction, functional capacity limitation, exercise intolerance, and quality of life impairment following pulmonary embolism: Systematic review with meta-analysis. Vascular Medicine, 2017, 22, 37-43.	0.8	104
622	Reference ranges and determinants of right ventricle outflow tract acceleration time in healthy adults by two-dimensional echocardiography. International Journal of Cardiovascular Imaging, 2017, 33, 219-226.	0.7	17
623	Procedural safety of a fully implantable intravenous prostanoid pump for pulmonary hypertension. Clinical Research in Cardiology, 2017, 106, 174-182.	1.5	16
624	The principal pathways involved in the inÂvivo modulation of hypoxic pulmonary vasoconstriction, pulmonary arterial remodelling and pulmonary hypertension. Acta Physiologica, 2017, 219, 728-756.	1.8	69
625	Precapillary Pulmonary Hypertension and Sleep-Disordered Breathing: Is There a Link?. Respiration, 2017, 93, 65-77.	1.2	22
626	Effects of sildenafil on cardiac structure and function, cardiopulmonary exercise testing and healthâ€related quality of life measures in heart failure patients with preserved ejection fraction and pulmonary hypertension. European Journal of Heart Failure, 2017, 19, 116-125.	2.9	50
627	Idiopathic pre-capillary pulmonary hypertension in patients with end-stage kidney disease: effect of endothelin receptor antagonists. Clinical and Experimental Nephrology, 2017, 21, 1088-1096.	0.7	7
628	Detection of elevated pulmonary pressures by the ECG-derived ventricular gradient: A comparison of conversion matrices in patients with suspected pulmonary hypertension. Journal of Electrocardiology, 2017, 50, 115-122.	0.4	0
629	Comparative Effectiveness of Pharmacologic Interventions for Pulmonary Arterial Hypertension. Chest, 2017, 151, 90-105.	0.4	39
630	Right ventricular recovery after bilateral lung transplantation for pulmonary arterial hypertensionâ€. Interactive Cardiovascular and Thoracic Surgery, 2017, 24, 890-897.	0.5	42
631	Integrated Transitions of Care for Patients With Rare Pulmonary Diseases. Professional Case Management, 2017, 22, 54-63.	0.2	11
633	Helicity and Vorticity of Pulmonary Arterial Flow in Patients With Pulmonary Hypertension: Quantitative Analysis of Flow Formations. Journal of the American Heart Association, 2017, 6, .	1.6	51
634	A systematic review of genetic mutations in pulmonary arterial hypertension. BMC Medical Genetics, 2017, 18, 82.	2.1	59
635	Incidence and risk of respiratory tract infection associated with specific drug therapy in pulmonary arterial hypertension: a systematic review. Scientific Reports, 2017, 7, 16218.	1.6	13

#	Article	IF	Citations
637	59-Year-Old Woman With Fatigue, Dyspnea, and Lower Extremity Edema. Mayo Clinic Proceedings, 2017, 92, e167-e171.	1.4	0
639	SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension. European Heart Journal, 2017, 38, 1147-1155.	1.0	65
640	ANMCO Position Paper: long-term follow-up of patients with pulmonary thromboembolism. European Heart Journal Supplements, 2017, 19, D309-D332.	0.0	10
641	From thrombosis to fibrosis in chronic thromboembolic pulmonary hypertension. Thrombosis and Haemostasis, 2017, 117, 769-783.	1.8	53
642	EACVI appropriateness criteria for the use of transthoracic echocardiography in adults: a report of literature and current practice review. European Heart Journal Cardiovascular Imaging, 2017, 18, 1191-1204.	0.5	63
643	Optimizing percutaneous coronary interventions: Heart Team, SYNTAX II Score, physiology and imaging guidance, modern stents, and guideline-based medication. European Heart Journal, 2017, 38, 3109-3113.	1.0	5
644	Advanced pulmonary arterial hypertension: mechanical support and lung transplantation. European Respiratory Review, 2017, 26, 170089.	3.0	23
645	Pulmonary arterial hypertension: tailoring treatment to risk in the current era. European Respiratory Review, 2017, 26, 170095.	3.0	32
647	The changing landscape of chronic thromboembolic pulmonary hypertension management. European Respiratory Review, 2017, 26, 170105.	3.0	69
648	Echocardiography in pulmonary hypertension: current evidence and future perspectives. Continuing Cardiology Education, 2017, 3, 153-162.	0.4	0
649	Standardization of adult transthoracic echocardiography reporting in agreement with recent chamber quantification, diastolic function, and heart valve disease recommendations: an expert consensus document of the European Association of Cardiovascular Imaging. European Heart Journal Cardiovascular Imaging, 2017, 18, 1301-1310.	0.5	477
650	Surgical results of mitral valve repair for congenital mitral valve stenosis in paediatric patients. Interactive Cardiovascular and Thoracic Surgery, 2017, 25, 877-882.	0.5	3
651	Complex Pathophysiology of Pulmonary Hypertension Associated with Systemic Sclerosis: Potential Unfavorable Effects of Vasodilators. Journal of Scleroderma and Related Disorders, 2017, 2, 92-99.	1.0	7
652	Pulmonary Complications of Liver Cirrhosis: A Concise Review. , 0, , .		1
653	Interferon Therapy Exacerbated Pulmonary Hypertension in a Patient with Hepatitis C Virus Infection: Pathogenic Interplay among Multiple Risk Factors. Internal Medicine, 2017, 56, 1061-1065.	0.3	8
654	Pulmonary Hypertension in Systemic Sclerosis. , 2017, , .		0
655	A nationwide evaluation of off-label drug utilization in Turkey. Turkish Journal of Medical Sciences, 2017, 47, 1229-1238.	0.4	3
656	What have multicentre registries across the world taught us about the disease features of systemic sclerosis?. Journal of Scleroderma and Related Disorders, 2017, 2, 169-182.	1.0	18

#	Article	IF	Citations
657	Pulmonary Artery Occlusion and Mediastinal Fibrosis in a Patient on Dopamine Agonist Treatment for Hyperprolactinemia. Frontiers in Pharmacology, 2017, 8, 492.	1.6	5
658	Adenosine Receptors As Drug Targets for Treatment of Pulmonary Arterial Hypertension. Frontiers in Pharmacology, 2017, 8, 858.	1.6	27
659	Efficacy and Safety of an Orally Administered Selective Prostacyclin Receptor Agonist, Selexipag, in Japanese Patients With Pulmonary Arterial Hypertension. Circulation Journal, 2017, 81, 1360-1367.	0.7	19
660	Right heart catheterization procedures in patients with suspicion of pulmonary hypertension â€“ experiences of a tertiary center. Postepy W Kardiologii Interwencyjnej, 2017, 4, 295-301.	0.1	5
661	Treatment of pulmonary hypertension with left heart disease: a concise review. Vascular Health and Risk Management, 2017, Volume 13, 415-420.	1.0	8
662	A review of pediatric pulmonary hypertension with new guidelines. Turkish Journal of Medical Sciences, 2017, 47, 375-380.	0.4	5
663	The Changing Landscape of Pulmonary Arterial Hypertension in the Adult with Congenital Heart Disease. Journal of Clinical Medicine, 2017, 6, 40.	1.0	17
664	Nanoparticle-Mediated Drug Delivery System for Pulmonary Arterial Hypertension. Journal of Clinical Medicine, 2017, 6, 48.	1.0	21
665	Potential of Bioactive Glasses for Cardiac and Pulmonary Tissue Engineering. Materials, 2017, 10, 1429.	1.3	64
666	Pulmonary Hypertension and Cancer. , 2017, , 257-265.		0
667	Sildenafil in Infants and Children. Children, 2017, 4, 60.	0.6	14
668	Arginase Inhibition Reverses Monocrotaline-Induced Pulmonary Hypertension. International Journal of Molecular Sciences, 2017, 18, 1609.	1.8	17
669	The Role of Transient Receptor Potential Channel 6 Channels in the Pulmonary Vasculature. Frontiers in Immunology, 2017, 8, 707.	2.2	39
670	Comorbid Conditions in Idiopathic Pulmonary Fibrosis: Recognition and Management. Frontiers in Medicine, 2017, 4, 123.	1.2	67
671	Hemodynamic and Pathologic Characterization of the TASK-1â^'/â^' Mouse Does Not Demonstrate Pulmonary Hypertension. Frontiers in Medicine, 2017, 4, 177.	1.2	17
672	Echocardiographic Assessment of Pulmonary Arterial Hypertension for Pediatricians and Neonatologists. Frontiers in Pediatrics, 2017, 5, 168.	0.9	17
673	Clinical, Epidemiological, and Histopathological Features of Respiratory Involvement in Rheumatoid Arthritis. BioMed Research International, 2017, 2017, 1-8.	0.9	31
674	Microarray Analysis and Detection of MicroRNAs Associated with Chronic Thromboembolic Pulmonary Hypertension. BioMed Research International, 2017, 2017, 1-9.	0.9	17

#	Article	IF	Citations
675	The Effect of Left Ventricular Assist Device Therapy in Patients with Heart Failure and Mixed Pulmonary Hypertension. International Journal of Artificial Organs, 2017, 40, 67-73.	0.7	5
676	Treatment of Vasodilator-resistant Mixed Connective Tissue Disease-associated Pulmonary Arterial Hypertension with Glucocorticoid and Cyclophosphamide. Internal Medicine, 2017, 56, 445-448.	0.3	8
677	Early intervention in the management of pulmonary arterial hypertension: clinical and economic outcomes. ClinicoEconomics and Outcomes Research, 2017, Volume 9, 731-739.	0.7	23
678	Role for Functional SOD2 Polymorphism in Pulmonary Arterial Hypertension in a Chinese Population. International Journal of Environmental Research and Public Health, 2017, 14, 266.	1.2	22
679	Comparison of linear and non-linear regression analysis to determine Pulmonary Pressure in Hyperthyroidism. Pakistan Journal of Medical Sciences, 2017, 33, 111-120.	0.3	4
680	Expression profile of matricellular proteins in hypertrophied right ventricle of monocrotaline-induced pulmonary hypertensive rats. Journal of Veterinary Medical Science, 2017, 79, 1096-1102.	0.3	17
681	Early Accrual of Organ Damage in Systemic Sclerosis: Rationale for Development of a Disease Damage Index. Journal of Scleroderma and Related Disorders, 2017, 2, 127-134.	1.0	4
682	An implantable pump Lenus proÂ® in the treatment of pulmonary arterial hypertension with intravenous treprostinil. BMC Pulmonary Medicine, 2017, 17, 162.	0.8	16
683	The association of N-terminal pro-brain-type natriuretic peptide with hemodynamics and functional capacity in therapy-naive precapillary pulmonary hypertension: results from a cohort study. BMC Pulmonary Medicine, 2017, 17, 167.	0.8	11
684	CMR fluoroscopy right heart catheterization for cardiac output and pulmonary vascular resistance: results in 102 patients. Journal of Cardiovascular Magnetic Resonance, 2016, 19, 54.	1.6	41
685	Pulmonary arterial hypertension in a patient treated with dasatinib: a case report. Journal of Medical Case Reports, 2017, 11, 362.	0.4	2
686	Reverse Right Ventricular Remodeling After Lung Transplantation in Patients With Pulmonary Arterial Hypertension Under Combination Therapy of Targeted Medical Drugs. Circulation Journal, 2017, 81, 383-390.	0.7	20
687	Reproducibility of peak filling and peak emptying rate determined by cardiovascular magnetic resonance imaging for assessment of biventricular systolic and diastolic dysfunction in patients with pulmonary arterial hypertension. International Journal of Cardiovascular Imaging, 2018, 34, 777-786.	0.7	10
689	Diversity of borderline pulmonary arterial pressure associated with systemic sclerosis: 3 case series. Modern Rheumatology Case Reports, 2017, 1, 9-14.	0.3	3
690	Right Ventricular Dyssynchrony to Measure the Effects of Pulmonary Endarterectomy in Chronic Thromboembolic Pulmonary Hypertension. Structural Heart, 2017, 1, 160-161.	0.2	0
691	Systolic time ratio measured by impedance cardiography accurately screens left ventricular diastolic dysfunction in patients with arterial hypertension. Clinical Hypertension, 2017, 23, 28.	0.7	8
692	The spectrum of pulmonary arterial hypertension in adults with congenital heart disease: management from a physician and nurse specialist perspective. Journal of Congenital Cardiology, 2017, 1, .	0.5	0
694	Changing face of pulmonary arterial hypertension in Canada. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2017, 1, 242-252.	0.2	5

#	Article	IF	Citations
695	Pulmonary hypertension associated with antiphospholipid antibody: Call for a screening tool?. Intractable and Rare Diseases Research, 2017, 6, 163-171.	0.3	13
696	Risk factors detection in chronic thromboembolic pulmonary hypertension, a tool for risk quantification?. Bratislava Medical Journal, 2017, 117, 577-582.	0.4	7
697	Mechanisms of N-acetylcysteine in reducing monocrotaline-induced pulmonary hypertension in rats: Inhibiting the expression of Nox1 in pulmonary vascular smooth muscle cells. Molecular Medicine Reports, 2017, 16, 6148-6155.	1.1	5
698	A novel scoring index by Doppler echocardiography for predicting severe pulmonary hypertension due to chronic lung diseases: a cross-sectional diagnostic accuracy study. International Journal of COPD, 2017, Volume 12, 1741-1751.	0.9	7
699	TBX20 loss-of-function mutation responsible for familial tetralogy of Fallot or sporadic persistent truncus arteriosus. International Journal of Medical Sciences, 2017, 14, 323-332.	1.1	57
700	Cardiopulmonary exercise test and PaO₂ in evaluation of pulmonary hypertension in COPD. International Journal of COPD, 2018, Volume 13, 91-100.	0.9	10
701	A Review of Clinical Trial Endpoints of Patients with Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension and How They Relate to Patient Outcomes in the United States. Journal of Managed Care & Specialty Pharmacy, 2017, 23, 92-104.	0.5	12
702	Inducible pluripotent stem cells and pulmonary arterial hypertension: the future is now!. Stem Cell Investigation, 2017, 4, 53-53.	1.3	0
705	Clinical Significance of Pulmonary Arterial Capacitance Calculated by Echocardiography in Patients With Advanced Heart Failure. Circulation Journal, 2017, 81, 1871-1878.	0.7	7
706	Statins may be beneficial for patients with pulmonary hypertension secondary to lung diseases. Journal of Thoracic Disease, 2017, 9, 2437-2446.	0.6	12
707	Reversible pulmonary hypertension with unclear etiology associated with suspected viral infection. Journal of Thoracic Disease, 2017, 9, E1074-E1078.	0.6	1
708	Pulmonary hypertension: diagnosis, imaging techniques, and novel therapies. Cardiovascular Diagnosis and Therapy, 2017, 7, 405-417.	0.7	19
709	Pediatric Idiopathic Pulmonary Arterial Hypertension with Mental Retardation Successfully Treated with the Introduction and Maintenance of a Continuous Subcutaneous Infusion of Treprostinil. Nihon Shoni Junkanki Gakkai Zasshi = Pediatric Cardiology and Cardiac Surgery, 2017, 33, 234-238.	0.0	0
710	Sildenafil-Bosentan Drug-Drug Interaction: A Word of Caution Regarding the Most Common Combination Therapy in Children with Advanced Pulmonary Arterial Hypertension. Respiration, 2018, 96, 302-302.	1.2	3
711	Lung Function, Inflammation, and Endothelinâ€1 in Congenital Heart Diseaseâ€“Associated Pulmonary Arterial Hypertension. Journal of the American Heart Association, 2018, 7, .	1.6	17
712	Ventilatory response to exercise in cardiopulmonary disease: the role of chemosensitivity and dead space. European Respiratory Journal, 2018, 51, 1700860.	3.1	73
713	A case report of acute pulmonary hypertension after hyperthermic intraperitoneal chemotherapy (HIPEC) and review of the literature. Annals of Medicine and Surgery, 2018, 27, 26-31.	0.5	1
714	Detection and treatment of chronic thromboembolic pulmonary hypertension: Still a lot of homework to do. Hellenic Journal of Cardiology, 2018, 59, 24-25.	0.4	6

#	Article	IF	Citations
715	The right ventricular outflow tract in pediatric pulmonary hypertensionâ€"Data from the European Pediatric Pulmonary Vascular Disease Network. Echocardiography, 2018, 35, 841-848.	0.3	4
716	Determination of Cardiac Output in Pulmonary Hypertension Using Impedance Cardiography. Respiration, 2018, 96, 500-506.	1.2	17
717	Role of a clinical prediction score in a chronic thromboembolic pulmonary hypertension rule-out strategy. European Respiratory Journal, 2018, 51, 1702576.	3.1	7
718	Pulmonary Arterial Hypertension: Combination Therapy in Practice. American Journal of Cardiovascular Drugs, 2018, 18, 249-257.	1.0	51
719	Implications of cardiac variability with cardiovascular magnetic resonance imaging for calculating trial sample size in pulmonary arterial hypertension. International Journal of Cardiology, 2018, 257, 332-338.	0.8	7
720	Right Ventricular Dysfunction and Its Contribution to Morbidity and Mortality in Left Ventricular Heart Failure. Current Heart Failure Reports, 2018, 15, 94-105.	1.3	19
721	The contribution of left heart disease in COPD patients with pulmonary hypertension. Hellenic Journal of Cardiology, 2018, 59, 160-165.	0.4	9
722	Pulmonary Arterial Enlargement is Associated With Acute Chest Pain in Patients Without Obstructive Coronary Artery Disease. Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine, 2018, 12, 117954841875802.	0.5	2
723	Role of right ventricular reverse remodeling in risk assessment of pulmonary hypertension. Journal of Heart and Lung Transplantation, 2018, 37, 182-183.	0.3	0
724	Systemic-pulmonary arteriovenous fistulae with pulmonary hypertension. Medicine (United States), 2018, 97, e9959.	0.4	4
725	Changes in hemodynamic classification over time are common in systemic sclerosisâ€associated pulmonary hypertension: insights from the PHAROS cohort. Pulmonary Circulation, 2018, 8, 1-7.	0.8	12
726	Real-World Switching to Riociguat: Management and Practicalities in Patients with PAH and CTEPH. Lung, 2018, 196, 305-312.	1.4	18
727	Treatment of Pediatric Pulmonary Hypertension. Current Treatment Options in Cardiovascular Medicine, 2018, 20, 8.	0.4	1
728	Fill in the Gaps of Secondary Mitral Regurgitation: a Continuum Challenge From Pathophysiology to Prognosis. Current Heart Failure Reports, 2018, 15, 106-115.	1.3	4
729	Pre-operative Evaluation of Patients with Pulmonary Hypertension. Current Anesthesiology Reports, 2018, 8, 44-51.	0.9	0
730	Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers: A Promising Medication for Chronic Obstructive Pulmonary Disease?. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2018, 15, 148-156.	0.7	23
731	GPCRs in pulmonary arterial hypertension: tipping the balance. British Journal of Pharmacology, 2018, 175, 3063-3079.	2.7	18
732	The clinical characteristics and longâ€term prognosis of pulmonary arterial hypertension associated with hereditary hemorrhagic telangiectasia. Pulmonary Circulation, 2018, 8, 1-11.	0.8	15

#	Article	IF	Citations
733	A case of ruptured sinus of Valsalva aneurysm and reversible flowâ€induced pulmonary hypertension. Pulmonary Circulation, 2018, 8, 1-5.	0.8	1
734	Reappraisal of the reliability of Doppler echocardiographic estimations for mean pulmonary artery pressure in patients with pulmonary hypertension: a study from a tertiary centre comparing four formulae. Pulmonary Circulation, 2018, 8, 1-9.	0.8	4
735	Wholeâ€exome sequencing improves genetic testing accuracy in pulmonary artery hypertension. Pulmonary Circulation, 2018, 8, 1-9.	0.8	3
736	Assessment of Right Atrium Function in Patients With Systemic Lupus Erythematosus With Different Pulmonary Artery Systolic Pressures by 2â€Dimensional Speckleâ€Tracking Echocardiography. Journal of Ultrasound in Medicine, 2018, 37, 2345-2351.	0.8	3
737	Balloon Pulmonary Angioplasty in Patients With Thromboembolic Pulmonary Hypertension. Current Treatment Options in Cardiovascular Medicine, 2018, 20, 13.	0.4	2
738	Sarcoidosis-associated Pulmonary Hypertension: Pathophysiology, Diagnosis, and Treatment. Clinical Pulmonary Medicine, 2018, 25, 52-60.	0.3	31
739	Bucindolol attenuates the vascular remodeling of pulmonary arteries by modulating the expression of the endothelin-1 A receptor in rats with pulmonary arterial hypertension. Biomedicine and Pharmacotherapy, 2018, 99, 704-714.	2.5	6
740	Pulmonary hypertension in chronic hemolytic anemias: Pathophysiology and treatment. Respiratory Medicine, 2018, 137, 191-200.	1.3	16
741	The outcome of reoperative pulmonary endarterectomy surgery. Interactive Cardiovascular and Thoracic Surgery, 2018, 26, 932-937.	0.5	11
742	Chronic obstructive pulmonary disease in patients with chronic thromboembolic pulmonary hypertension: Prevalence and implications for surgical treatment outcome. Clinical Respiratory Journal, 2018, 12, 2242-2248.	0.6	4
743	Preoperative right heart hemodynamics predict postoperative acute kidney injury after heart transplantation. Intensive Care Medicine, 2018, 44, 588-597.	3.9	52
744	Effect of abnormal right heart structures on the diagnosis of pulmonary hypertension. Pulmonary Circulation, 2018, 8, 1-8.	0.8	3
745	Reversible pulmonary artery perfusion abnormalities in the postpartum period as a precursor to the development of pulmonary arterial hypertension. Pulmonary Circulation, 2018, 8, 1-6.	0.8	1
746	Pulmonary hypertension in chronic lung diseases: comparison to other pulmonary hypertension groups. Pulmonary Circulation, 2018, 8, 1-10.	0.8	30
747	CCL21 as a Potential Serum Biomarker for Pulmonary Arterial Hypertension in Systemic Sclerosis. Arthritis and Rheumatology, 2018, 70, 1644-1653.	2.9	28
748	Nitric Oxide in Cardiac Surgery: A Meta-Analysis of Randomized Controlled Trials. Journal of Cardiothoracic and Vascular Anesthesia, 2018, 32, 2512-2519.	0.6	28
749	Realâ€life practices of chronic thromboembolic pulmonary hypertension screening: Results from the REMOTEV observational study. Clinical Respiratory Journal, 2018, 12, 2303-2306.	0.6	2
750	PPARÎ³ agonist pioglitazone reverses pulmonary hypertension and prevents right heart failure via fatty acid oxidation. Science Translational Medicine, 2018, 10, .	5.8	198

#	Article	IF	Citations
751	Creation of a restrictive atrial communication in pulmonary arterial hypertension (PAH): effective palliation of syncope and endâ€stage heart failure. Pulmonary Circulation, 2018, 8, 1-9.	0.8	17
752	After the Dawnã€€â€• Balloon Pulmonary Angioplasty for Patients With Chronic Thromboembolic Pulmonary Hypertension â€•. Circulation Journal, 2018, 82, 1222-1230.	0.7	32
753	Depression and Anxiety in Patients With Pulmonary Hypertension: The Role of Life Satisfaction and Optimism. Psychosomatics, 2018, 59, 575-583.	2.5	21
754	Sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: A Phase IIb, randomised, double-blind, placebo-controlled study â€“ Rationale and study design. Respiratory Medicine, 2018, 138, 13-20.	1.3	27
755	Creation of a restrictive atrial communication in heart failure with preserved and mid-range ejection fraction: effective palliation of left atrial hypertension and pulmonary congestion. Clinical Research in Cardiology, 2018, 107, 845-857.	1.5	16
756	Pulmonary arterial hypertension and atrial arrhythmias: incidence, risk factors, and clinical impact. Pulmonary Circulation, 2018, 8, 1-8.	0.8	43
757	Risk assessment in pulmonary arterial hypertension. European Respiratory Journal, 2018, 51, 1702606.	3.1	67
758	Diagnosis, Treatment, and Management of Orthotopic Liver Transplant Candidates With Portopulmonary Hypertension. Cardiology in Review, 2018, 26, 169-176.	0.6	18
759	Chronic thromboembolic pulmonary hypertension from the perspective of patients with pulmonary embolism. Journal of Thrombosis and Haemostasis, 2018, 16, 1040-1051.	1.9	45
760	S100A12 as a marker of worse cardiac output and mortality in pulmonary hypertension. Respirology, 2018, 23, 771-779.	1.3	18
761	Novel Insights and Treatment Strategies for Right Heart Failure. Current Heart Failure Reports, 2018, 15, 141-155.	1.3	9
762	Chronic thromboembolic pulmonary hypertension. What we are missing?. Hellenic Journal of Cardiology, 2018, 59, 1-2.	0.4	3
763	Strengths and weaknesses of echocardiography for the diagnosis of pulmonary hypertension. International Journal of Cardiology, 2018, 263, 177-183.	0.8	25
764	Impact of age and comorbidity on risk stratification in idiopathic pulmonary arterial hypertension. European Respiratory Journal, 2018, 51, 1702310.	3.1	79
765	Ca2+ handling remodeling and STIM1L/Orai1/TRPC1/TRPC4 upregulation in monocrotaline-induced right ventricular hypertrophy. Journal of Molecular and Cellular Cardiology, 2018, 118, 208-224.	0.9	58
766	National trends and outcomes of hospitalizations for pulmonary hypertension in Spain (2001â€“2014). International Journal of Cardiology, 2018, 263, 125-131.	0.8	2
767	Extended-release oral treprostinil in the management of pulmonary arterial hypertension: clinical evidence and experience. Therapeutic Advances in Respiratory Disease, 2018, 12, 175346661876649.	1.0	8
768	Evaluation and Management of Right-Sided Heart Failure: A Scientific Statement From the American Heart Association. Circulation, 2018, 137, e578-e622.	1.6	503

#	Article	IF	Citations
769	Lung Transplantation in Pulmonary Hypertension: A Multidisciplinary Unit's Management Experience. Transplantation Proceedings, 2018, 50, 1496-1503.	0.3	12
770	Sildenafil for improving outcomes in patients with corrected valvular heart disease and persistent pulmonary hypertension: a multicenter, double-blind, randomized clinical trial. European Heart Journal, 2018, 39, 1255-1264.	1.0	166
771	Mitral valve disease: news from the frontier in valvular heart disease. European Heart Journal, 2018, 39, 1211-1214.	1.0	0
772	Sex differences in hemodynamic responses and long-term survival to optimal medical therapy in patients with pulmonary arterial hypertension. Heart and Vessels, 2018, 33, 939-947.	0.5	18
773	Cardio-oncology: conflicting priorities of anticancer treatment and cardiovascular outcome. Clinical Research in Cardiology, 2018, 107, 271-280.	1.5	37
774	Percutaneous Mechanical Circulation Support Combined with Extracorporeal Membrane Oxygenation (oxyRVAD) in Secondary Right Heart Failure. ASAIO Journal, 2018, 64, e64-e67.	0.9	9
775	Pulmonary arterial hypertension in four patients treated by leflunomide. Joint Bone Spine, 2018, 85, 761-763.	0.8	11
776	Right atrial function in patients with pulmonary hypertension: A study with two-dimensional speckle-tracking echocardiography. International Journal of Cardiology, 2018, 255, 200-205.	0.8	19
777	Comparison of thermodilution and indirect Fick cardiac outputs in pulmonary hypertension. International Journal of Cardiology, 2018, 258, 228-231.	0.8	12
778	Pulmonary Arterial Hypertension-Related Morbidity Is Prognostic for Mortality. Journal of the American College of Cardiology, 2018, 71, 752-763.	1.2	82
779	Surrogate Endpoints for Pulmonary Hypertension Management and Trial Design. Journal of the American College of Cardiology, 2018, 71, 764-765.	1.2	1
780	Subcutaneous treprostinil in congenital heart disease-related pulmonary arterial hypertension. Heart, 2018, 104, 1195-1199.	1.2	25
781	Pulmonary Diseases in Refugees and Migrants in Europe. Respiration, 2018, 95, 273-286.	1.2	6
782	Right atrium enlargement predicts clinically significant supraventricular arrhythmia in patients with pulmonary arterial hypertension. Heart and Lung: Journal of Acute and Critical Care, 2018, 47, 237-242.	0.8	16
783	Risk Assessment Tools in Pulmonary Arterial Hypertension. Prognosis for Prospective Trials?. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 843-845.	2.5	12
784	Impact of systolic pulmonary artery pressure on all-cause mortality in elderly cardiac patients. Scandinavian Cardiovascular Journal, 2018, 52, 80-84.	0.4	1
785	Adherence and medication belief in patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension: A nationwide populationâ€based cohort survey. Clinical Respiratory Journal, 2018, 12, 2029-2035.	0.6	11
786	Echocardiographic Evaluation of the Right Atrial Area Index in Dogs with Pulmonary Hypertension. Journal of Veterinary Internal Medicine, 2018, 32, 42-47.	0.6	19

#	Article	IF	Citations
787	Coping, social support and information in patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension: A 2-year retrospective cohort study. SAGE Open Medicine, 2018, 6, 205031211774915.	0.7	9
788	Dasatinibâ€induced pulmonary arterial hypertension. British Journal of Clinical Pharmacology, 2018, 84, 835-845.	1.1	48
789	In search of markers of pulmonary vascular remodelling in pulmonary hypertension due to left heart disease. European Journal of Heart Failure, 2018, 20, 735-737.	2.9	2
790	Pulmonary Vascular Disease: Hemodynamic Assessment and Treatment Selectionâ€"Focus on Group II Pulmonary Hypertension. Current Heart Failure Reports, 2018, 15, 81-93.	1.3	5
791	Macitentan in pulmonary hypertension due to left ventricular dysfunction. European Respiratory Journal, 2018, 51, 1701886.	3.1	139
792	Lessons from the COMPASSâ€3 Study. Pulmonary Circulation, 2018, 8, 1-3.	0.8	0
793	Acute Effect of Inhaled Iloprost in Children with Pulmonary Arterial Hypertension Associated with Simple Congenital Heart Defects. Pediatric Cardiology, 2018, 39, 757-762.	0.6	6
794	Multiparametric Magnetic Resonance Imaging in the Assessment of Pulmonary Hypertension: Initial Experience of a One-Stop Study. Lung, 2018, 196, 165-171.	1.4	3
795	Pulmonary Arterial Hemodynamic Assessment by a Novel Index in Systemic Sclerosis Patients: Pulmonary Pulse Transit Time. Lung, 2018, 196, 173-178.	1.4	9
796	Frequencies of borderline pulmonary hypertension before and after the DETECT algorithm: results from a prospective systemic sclerosis cohort. Rheumatology, 2018, 57, 480-487.	0.9	30
798	Pulmonary hypertension and exercise training: a synopsis on the more recent evidences. Annals of Medicine, 2018, 50, 226-233.	1.5	13
799	Pharmacokinetics of singleâ€dose sildenafil administered orally in clinically healthy dogs: Effect of feeding and dose proportionality. Journal of Veterinary Pharmacology and Therapeutics, 2018, 41, 457-462.	0.6	11
800	Functional assessment of the <scp>BMPR</scp>2 gene in lymphoblastoid cell lines from Gravesâ€™ disease patients. Journal of Cellular and Molecular Medicine, 2018, 22, 1538-1547.	1.6	4
801	Inhaled Treprostinil in Pulmonary Hypertension Associated with Lung Disease. Lung, 2018, 196, 139-146.	1.4	15
802	Comparative Safety of Drugs Targeting the Nitric Oxide Pathway in Pulmonary Hypertension. Chest, 2018, 154, 136-147.	0.4	18
803	Clinical Complications and Their Management. Hematology/Oncology Clinics of North America, 2018, 32, 223-236.	0.9	14
804	Pulmonary tumour thrombotic microangiopathy due to adenocarcinoma of the lung. A cause of pulmonary hypertension. Pulmonology, 2018, 24, 57-58.	1.0	0
805	Treatment Effect of Balloon Pulmonary Angioplasty in Chronic Thromboembolic Pulmonary Hypertension Quantified by Automatic Comparative Imaging in Computed Tomography Pulmonary Angiography. Investigative Radiology, 2018, 53, 286-292.	3.5	11

#	Article	IF	Citations
806	Macitentan in Pulmonary Arterial Hypertension: A Focus on Combination Therapy in the SERAPHIN Trial. American Journal of Cardiovascular Drugs, 2018, 18, 1-11.	1.0	37
807	Surveillance on The Safety and Efficacy of Ambrisentan (Volibris Tablet 2.5 mg) in Patients with Pulmonary Arterial Hypertension in Real Clinical Practice: Post-marketing Surveillance (Interim) Tj ETQq1 1 0.784314 rgBT /Overlock 1	1.1	4
808	Trial Duration and Risk Reduction in Combination Therapy Trials for Pulmonary Arterial Hypertension. Chest, 2018, 153, 1142-1152.	0.4	4
809	Pulmonary arterial hypertension associated with connective tissue diseases: A review focusing on distinctive clinical aspects. European Journal of Clinical Investigation, 2018, 48, e12876.	1.7	23
810	Clinical implications of hemodynamic assessment during left ventricular assist device therapy. Journal of Cardiology, 2018, 71, 352-358.	0.8	37
811	Hemodynamic profile of pulmonary hypertension (PH) in ARDS. Pulmonary Circulation, 2018, 8, 204589321775341.	0.8	13
812	The clinical value of assessing right ventricular diastolic function after balloon pulmonary angioplasty in patients with chronic thromboembolic pulmonary hypertension. International Journal of Cardiovascular Imaging, 2018, 34, 875-882.	0.7	14
813	Who Is an Appropriate Candidate for Long-Term MCS?: The Art of Patient Selection. , 2018, , 15-34.		0
814	Does HIV Really Augment the Frequency or Mortality Risk of Increased Pulmonary Artery Systolic Pressures?. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 854-855.	2.5	0
815	The impact of delayed treatment on 6-minute walk distance test in patients with pulmonary arterial hypertension: A meta-analysis. International Journal of Cardiology, 2018, 254, 299-301.	0.8	14
816	The Low-Risk Profile in Pulmonary Arterial Hypertension. Time for a Paradigm Shift to Goal-oriented Clinical Trial Endpoints?. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 860-868.	2.5	45
818	Current and emerging imaging techniques in the diagnosis and assessment of pulmonary hypertension. Expert Review of Respiratory Medicine, 2018, 12, 145-160.	1.0	7
819	Initial tadalafil and ambrisentan combination therapy in pulmonary arterial hypertension. Journal of Cardiovascular Medicine, 2018, 19, 12-17.	0.6	16
820	Management of the Critically Ill Adult With Congenital Heart Disease. Journal of Cardiothoracic and Vascular Anesthesia, 2018, 32, 1682-1700.	0.6	7
821	Morphologic and Functional Changes in Rightâ€Sided Cardiac Chambers in Patients With Chronic Liver Disease and Normal Pulmonary Artery Pressure. Journal of Ultrasound in Medicine, 2018, 37, 1681-1691.	0.8	8
822	Echocardiographic assessment of regional right ventricular systolic function using two-dimensional strain echocardiography and evaluation of the predictive ability of longitudinal 2D-strain imaging for pulmonary arterial hypertension in systemic sclerosis patients. International Journal of Cardiovascular Imaging, 2018, 34, 883-892.	0.7	16
823	Single center experience with the Potts shunt in severe pulmonary arterial hypertension. Progress in Pediatric Cardiology, 2018, 48, 111-115.	0.2	1
824	Targeting the Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension Receiving Double Combination Therapy: Insights from the Randomized Controlled GRIPHON Study. American Journal of Cardiovascular Drugs, 2018, 18, 37-47.	1.0	69

#	Article	IF	Citations
825	Balloon pulmonary angioplasty for inoperable patients with chronic thromboembolic disease. Pulmonary Circulation, 2018, 8, 1-6.	0.8	54
826	Functional analysis of a novel ENG variant in a patient with hereditary hemorrhagic telangiectasia (HHT) identifies a new Sp1 binding-site. Gene, 2018, 647, 85-92.	1.0	9
827	Modern Invasive Hemodynamic Assessment of Pulmonary Hypertension. Respiration, 2018, 95, 201-211.	1.2	1
828	Right Ventricular Function in Heart Failure. Circulation: Cardiovascular Imaging, 2018, 11, e007396.	1.3	5
829	Heart Rate and Oxygen Saturation Change Patterns During 6-min Walk Test in Subjects With Chronic Thromboembolic Pulmonary Hypertension. Respiratory Care, 2018, 63, 573-583.	0.8	8
830	Right Ventricular Structure and Function in the Veteran Ultramarathon Runner: Is There Evidence for Chronic Maladaptation?. Journal of the American Society of Echocardiography, 2018, 31, 598-605.e1.	1.2	5
831	Aiming at the appropriate target for the treatment of pulmonary hypertension due to left heart disease. European Heart Journal, 2018, 39, 1265-1268.	1.0	11
832	N-terminal proâ€“B-type natriuretic peptide for monitoring after balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension. Journal of Heart and Lung Transplantation, 2018, 37, 639-646.	0.3	36
833	Pulmonary arterial hypertension in adult congenital heart disease. Heart, 2018, 104, 1568-1574.	1.2	58
834	Predictors of Favorable Responses to Immunosuppressive Treatment in Pulmonary Arterial Hypertension Associated With Connective Tissue Disease. Circulation Journal, 2018, 82, 546-554.	0.7	33
835	A Focus on Macitentan in the Treatment of Pulmonary Arterial Hypertension. Basic and Clinical Pharmacology and Toxicology, 2018, 123, 103-113.	1.2	30
836	Clinical practice guidelines in China. BMJ: British Medical Journal, 2018, 360, j5158.	2.4	59
837	The role of cardiopulmonary exercise tests in pulmonary arterial hypertension. European Respiratory Review, 2018, 27, 170134.	3.0	53
838	Associations between comorbidities, their treatment and survival in patients with interstitial lung diseases â€“ a claims data analysis. Respiratory Research, 2018, 19, 73.	1.4	47
839	Acquired peripheral pulmonary artery aneurysms: morphological spectrum of disease and multidetector computed tomography angiography findingsâ€”cases series and literature review. Radiologia Medica, 2018, 123, 664-675.	4.7	8
840	Right ventriculoâ€“arterial uncoupling and impaired contractile reserve in obese patients with unexplained exercise intolerance. European Journal of Applied Physiology, 2018, 118, 1415-1426.	1.2	6
841	Prognostic Value of Right Ventricular Strain Using Speckle-Tracking Echocardiography in Pulmonary Hypertension: AÂSystematic Review and Meta-analysis. Canadian Journal of Cardiology, 2018, 34, 1069-1078.	0.8	54
842	Rare variants in RNF213, a susceptibility gene for moyamoya disease, are found in patients with pulmonary hypertension and aggravate hypoxiaâ€induced pulmonary hypertension in mice. Pulmonary Circulation, 2018, 8, 1-13.	0.8	33

#	Article	IF	Citations
843	Quantitation of Perfused Lung Volume Using Hybrid SPECT/CT Allows Refining the Assessment of Lung Perfusion and Estimating Disease Extent in Chronic Thromboembolic Pulmonary Hypertension. Clinical Nuclear Medicine, 2018, 43, e170-e177.	0.7	24
844	Vascular smooth muscle cell proliferation as a therapeutic target. Part 1: molecular targets and pathways. Biotechnology Advances, 2018, 36, 1586-1607.	6.0	78
845	Pulmonary arterial hypertension: pathogenesis and clinical management. BMJ: British Medical Journal, 2018, 360, j5492.	2.4	553
846	Use of supplemental oxygen in patients with pulmonary arterial hypertension in REVEAL. Journal of Heart and Lung Transplantation, 2018, 37, 948-955.	0.3	18
848	Positioning document on incorporating point-of-care ultrasound in Internal Medicine departments. Revista Clínica Espanõla, 2018, 218, 192-198.	0.3	10
849	Usefulness of scoring right ventricular function for assessment of prognostic factors in patients with chronic thromboembolic pulmonary hypertension. Heart and Vessels, 2018, 33, 1220-1228.	0.5	9
850	Treat-and-repair strategy is a feasible therapeutic choice in adult patients with severe pulmonary arterial hypertension associated with a ventricular septal defect: case series. European Heart Journal - Case Reports, 2018, 2, yty033.	0.3	9
851	Change in R wave in lead V1 predicts survival of patients with pulmonary arterial hypertension. Pulmonary Circulation, 2018, 8, 1-7.	0.8	14
852	Pulmonary hypertension due to unclassified interstitial lung disease in a Pembroke Welsh corgi. Journal of Veterinary Medical Science, 2018, 80, 939-944.	0.3	3
853	Prognostic Value of Serial Nâ€Terminal Proâ€Bâ€Type Natriuretic Peptide Measurements in Adults With Congenital Heart Disease. Journal of the American Heart Association, 2018, 7, .	1.6	20
854	Pulmonary hypertension in patients with interstitial lung disease. Pulmonary Pharmacology and Therapeutics, 2018, 50, 38-46.	1.1	21
855	In-depth haemodynamic phenotyping of pulmonary hypertension due to left heart disease. European Respiratory Journal, 2018, 51, 1800067.	3.1	18
856	Risk assessment in pulmonary arterial hypertension. European Respiratory Journal, 2018, 51, 1800279.	3.1	26
857	CT derived left atrial size identifies left heart disease in suspected pulmonary hypertension: Derivation and validation of predictive thresholds. International Journal of Cardiology, 2018, 260, 172-177.	0.8	17
858	Central versus peripheral cannulation of extracorporeal membrane oxygenation support during double lung transplant for pulmonary hypertension. European Journal of Cardio-thoracic Surgery, 2018, 54, 341-347.	0.6	30
859	Hematocrit-corrected Pulmonary Vascular Resistance. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 305-309.	2.5	33
860	A case of sarcoidosisâ€associated pulmonary hypertension masquerading as chronic thromboembolic pulmonary hypertension. Pulmonary Circulation, 2018, 8, 1-6.	0.8	4
861	The transpulmonary ratio of endothelin 1 is elevated in patients with preserved left ventricular ejection fraction and combined preâ€and postâ€capillary pulmonary hypertension. Pulmonary Circulation, 2018, 8, 1-8.	0.8	27

#	Article	IF	Citations
862	Successful treatment of severe combined postâ€•and preâ€•capillary pulmonary hypertension in a patient with idiopathic restrictive cardiomyopathy. Pulmonary Circulation, 2018, 8, 1-5.	0.8	1
863	Urocortin-2 improves right ventricular function and attenuates pulmonary arterial hypertension. Cardiovascular Research, 2018, 114, 1165-1177.	1.8	19
864	Prevalence of pulmonary hypertension in patients with chronic kidney disease without dialysis: a meta-analysis. International Urology and Nephrology, 2018, 50, 1497-1504.	0.6	13
865	Grossly Abnormal Ventilation/Perfusion SPECT Study in Idiopathic Pulmonary Arterial Hypertension Without Thromboembolism. Heart Lung and Circulation, 2018, 27, e101-e104.	0.2	2
866	Documento de posicionamiento sobre la incorporaciÃ³n de la ecografÃa clÃnica en los servicios de Medicina Interna. Revista Clinica Espanola, 2018, 218, 192-198.	0.2	27
867	Echocardiographic evaluation of the right heart. Wiener Klinische Wochenschrift, 2018, 130, 413-420.	1.0	34
868	Systolic pulmonary artery pressure assessed during routine exercise Doppler echocardiography: insights of a real-world setting in patients with elevated pulmonary pressures. International Journal of Cardiovascular Imaging, 2018, 34, 1215-1225.	0.7	2
869	Clinical prediction score for identifying patients with pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis. Journal of Cardiology, 2018, 72, 255-260.	0.8	19
870	Stressing the Cardiopulmonary Vascular System: The Role of Echocardiography. Journal of the American Society of Echocardiography, 2018, 31, 527-550.e11.	1.2	45
871	Fluid challenge predicts clinical worsening in pulmonary arterial hypertension. International Journal of Cardiology, 2018, 261, 167-171.	0.8	18
872	Characteristics of Infants With Congenital Diaphragmatic Hernia Who Need Follow-Up of Pulmonary Hypertension. Pediatric Critical Care Medicine, 2018, 19, e219-e226.	0.2	17
873	Incidence of pulmonary hypertension and determining factors in patients with systemic sclerosis. European Respiratory Journal, 2018, 51, 1701197.	3.1	76
874	In Vitro Assessment of Pharmacokinetic Drug-Drug Interactions of Direct Oral Anticoagulants: Type 5-Phosphodiesterase Inhibitors Are Inhibitors of Rivaroxaban and Apixaban Efflux by P-Glycoprotein. Journal of Pharmacology and Experimental Therapeutics, 2018, 365, 519-525.	1.3	21
875	Multicentre observational screening survey for the detection of CTEPH following pulmonary embolism. European Respiratory Journal, 2018, 51, 1702505.	3.1	58
876	Outcomes following balloon mitral valvuloplasty in pregnant females with mitral stenosis and significant sub valve disease with severe decompensated heart failure. Journal of Interventional Cardiology, 2018, 31, 525-531.	0.5	13
877	Nitric Oxide Attenuates Arterial Pulse Wave Reflection in a Vasodilator Responding Pulmonary Arterial Hypertension Patient. Circulation: Cardiovascular Interventions, 2018, 11, e006242.	1.4	10
878	Rationale and design of the screening of pulmonary hypertension in systemic lupus erythematosus (SOPHIE) study. ERJ Open Research, 2018, 4, 00135-2017.	1.1	10
879	Association Between Hemodynamic Markers of Pulmonary Hypertension and Outcomes in Heart Failure With Preserved Ejection Fraction. JAMA Cardiology, 2018, 3, 298.	3.0	162

#	Article	IF	Citations
880	Calcium mishandling impairs contraction in right ventricular hypertrophy prior to overt heart failure. Pflugers Archiv European Journal of Physiology, 2018, 470, 1115-1126.	1.3	17
881	Pulmonary hypertension due to left heart disease: analysis of survival according to the haemodynamic classification of the 2015 <scp>ESC</scp>/<scp>ERS</scp> guidelines and insights for future changes. European Journal of Heart Failure, 2018, 20, 248-255.	2.9	85
882	Pulmonary hypertension in advanced lung diseases: Echocardiography as an important part of patient evaluation for lung transplantation. Clinical Respiratory Journal, 2018, 12, 930-938.	0.6	23
883	Discriminatory ability of right atrial volumes with twoâ€•and threeâ€dimensional echocardiography to detect elevated right atrial pressure in pulmonary hypertension. Clinical Physiology and Functional Imaging, 2018, 38, 192-199.	0.5	4
884	Pulmonary arterial stiffness indices assessed by intravascular ultrasound in children with early pulmonary vascular disease: prediction of advanced disease and mortality during 20-year follow-up. European Heart Journal Cardiovascular Imaging, 2018, 19, 216-224.	0.5	23
885	Can MRI detect pulmonary hypertension in a population pre-selected by echocardiography?. Acta Radiologica, 2018, 59, 180-187.	0.5	1
886	Validation of a risk assessment instrument for pulmonary arterial hypertension. European Heart Journal, 2018, 39, 4182-4185.	1.0	16
887	Three-dimensional right-ventricular regional deformation and survival in pulmonary hypertension. European Heart Journal Cardiovascular Imaging, 2018, 19, 450-458.	0.5	62
888	Epidemiology and management of chronic thromboembolic pulmonary hypertension: experience from two expert centers. Hellenic Journal of Cardiology, 2018, 59, 16-23.	0.4	12
889	Right ventricular-vascular coupling in heart failure with preserved ejection fraction and pre- vs. post-capillary pulmonary hypertension. European Heart Journal Cardiovascular Imaging, 2018, 19, 425-432.	0.5	93
890	A comprehensive risk stratification at early follow-up determines prognosis in pulmonary arterial hypertension. European Heart Journal, 2018, 39, 4175-4181.	1.0	389
891	Attenuated post-exercise heart rate recovery in patients with systemic lupus erythematosus: the role of disease severity and beta-blocker treatment. Lupus, 2018, 27, 217-224.	0.8	9
892	Pulmonary hypertension nosography: are all patients classifiable?. Internal and Emergency Medicine, 2018, 13, 35-40.	1.0	0
893	Late consequences of venous thromboembolism: Measuring quality of life after deep vein thrombosis and pulmonary embolism. Thrombosis Research, 2018, 164, 170-176.	0.8	32
894	The metabolism and drugâ€“drug interaction potential of the selective prostacyclin receptor agonist selexipag. Xenobiotica, 2018, 48, 704-719.	0.5	13
895	Pulmonary endarterectomy in chronic thromboembolic pulmonary hypertension. Journal of Heart and Lung Transplantation, 2018, 37, 250-258.	0.3	32
897	Acute hemodynamic effects of intravenous adenosine in patients with associated pulmonary arterial hypertension: Comparison with intravenous epoprostenol. Pulmonary Pharmacology and Therapeutics, 2018, 49, 147-151.	1.1	3
898	Variable Expressivity of a Founder Mutation in the EIF2AK4 Gene in Hereditary Pulmonary Veno-occlusive Disease and Its Impact on Survival. Revista Espanola De Cardiologia (English Ed), 2018, 71, 86-94.	0.4	5

#	Article	IF	Citations
899	Right heart dysfunction and failure in heart failure with preserved ejection fraction: mechanisms and management. Position statement on behalf of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2018, 20, 16-37.	2.9	239
900	Pulmonary vascular disease due to left heart disease: how to achieve a more accurate approach beyond the haemodynamic phenotype: reply. European Journal of Heart Failure, 2018, 20, 943-943.	2.9	0
901	Pulmonary Arterial Hypertension With Abnormal V/Q Single-Photon Emission Computed Tomography. JACC: Cardiovascular Imaging, 2018, 11, 1487-1493.	2.3	20
902	Pulmonary vascular indices and survival in left heart disease: illusion of conclusion?. European Journal of Heart Failure, 2018, 20, 256-259.	2.9	3
903	MicroRNA-424(322) as a new marker of disease progression in pulmonary arterial hypertension and its role in right ventricular hypertrophy by targeting SMURF1. Cardiovascular Research, 2018, 114, 53-64.	1.8	72
904	Echocardiographic Assessment of Pulmonary Artery Pressure, Tips and Tricks. , 2018, , 235-251.		0
905	Lessons learned in acute heart failure. European Journal of Heart Failure, 2018, 20, 630-641.	2.9	33
906	Pulmonary vascular remodeling patterns and expression of general control nonderepressible 2 (GCN2) in pulmonary veno-occlusive disease. Journal of Heart and Lung Transplantation, 2018, 37, 647-655.	0.3	50
907	Temporary treatment interruptions with oral selexipag in pulmonary arterial hypertension: Insights from the Prostacyclin (PGI 2) Receptor Agonist in Pulmonary Arterial Hypertension (GRIPHON) study. Journal of Heart and Lung Transplantation, 2018, 37, 401-408.	0.3	15
908	Left Heart Disease and Pulmonary Hypertension: Are We Seeing the Full Picture?. Heart Lung and Circulation, 2018, 27, 301-309.	0.2	10
909	Prognostic Value of Follow-Up Hemodynamic Variables After Initial Management in Pulmonary Arterial Hypertension. Circulation, 2018, 137, 693-704.	1.6	155
910	Bosentanâ€based, treatâ€toâ€target therapy in patients with pulmonary arterial hypertension: results from the COMPASSâ€3 study. Pulmonary Circulation, 2018, 8, 1-13.	0.8	10
911	Cell deathâ€inducing <scp>DFF</scp>45â€like effector C gene silencing alleviates pulmonary vascular remodeling in a type 2 diabetic rat model. Journal of Diabetes Investigation, 2018, 9, 741-752.	1.1	5
912	Right ventricular speckle tracking assessment for differentiation of pressureâ€versus volumeâ€overloaded right ventricle. Clinical Physiology and Functional Imaging, 2018, 38, 763-771.	0.5	18
913	Distinction Between Precapillary and Postcapillary Pulmonary Hypertension by the Atrial Volume Ratio on Transthoracic Echocardiography. Journal of Ultrasound in Medicine, 2018, 37, 891-896.	0.8	5
914	Hypoxia induces the dysfunction of human endothelial colony-forming cells via HIF-1Î± signaling. Respiratory Physiology and Neurobiology, 2018, 247, 87-95.	0.7	20
915	Outcomes of persistent pulmonary hypertension following transcatheter aortic valve replacement. Heart, 2018, 104, 821-827.	1.2	47
916	Prevalence and associated factors of renal dysfunction and proteinuria in cyanotic congenital heart disease. Pediatric Nephrology, 2018, 33, 493-501.	0.9	18

#	Article	IF	Citations
917	The Development of Pulmonary Hypertension Results in Decreased Post-Transplant Survival. ASAIO Journal, 2018, 64, 508-514.	0.9	5
918	A novel single-beat approach to assess right ventricular systolic function. Journal of Applied Physiology, 2018, 124, 283-290.	1.2	31
919	Right Ventricular Perfusion. Anesthesiology, 2018, 128, 202-218.	1.3	66
920	Plasma l-arginine levels distinguish pulmonary arterial hypertension from left ventricular systolic dysfunction. Heart and Vessels, 2018, 33, 255-263.	0.5	20
921	Pulmonary Arterial Hypertension Associated With Systemic Lupus Erythematosus. Chest, 2018, 153, 143-151.	0.4	68
922	Influence of various therapeutic strategies on right ventricular morphology, function and hemodynamics in pulmonary arterial hypertension. Journal of Heart and Lung Transplantation, 2018, 37, 365-375.	0.3	49
923	Red Blood Cells Distribution Width as a Potential Prognostic Biomarker in Patients With Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension. Heart Lung and Circulation, 2018, 27, 842-848.	0.2	28
924	Pathophysiology of exercise intolerance in pulmonary arterial hypertension. Respirology, 2018, 23, 148-159.	1.3	31
925	Exercise right heart catheterization for pulmonary hypertension identified on screening echocardiography in adult survivors of childhood cancer: A report from the St. Jude Lifetime Cohort. Pediatric Blood and Cancer, 2018, 65, e26769.	0.8	3
926	Relationship between matrix metalloproteinase-3 serum level and pulmonary artery systolic pressure in patients with rheumatoid arthritis. Heart and Vessels, 2018, 33, 191-197.	0.5	3
927	Exercise training in patients with pulmonary and systemic hypertension: A unique therapy for two different diseases. European Journal of Internal Medicine, 2018, 47, 17-24.	1.0	18
928	Survival of Idiopathic Pulmonary Arterial Hypertension Patients in the Modern Era in Australia and New Zealand. Heart Lung and Circulation, 2018, 27, 1368-1375.	0.2	26
929	Pulmonary Hypertension and Related Disorders. , 2018, , 163-181.		0
930	Risk factors for perinatal cardiac complications in pregnancy with pulmonary hypertension. Pregnancy Hypertension, 2018, 12, 207-213.	0.6	8
931	Tricuspid Valve Interventions: Heart Team Discussion, When, Who and What?. , 2018, , 279-303.		0
932	Echocardiographic Estimation of Mean Pulmonary Artery Pressure: A Comparison of Different Approaches to Assign the Likelihood of Pulmonary Hypertension. Journal of the American Society of Echocardiography, 2018, 31, 89-98.	1.2	32
933	Red blood cell distribution width as a related factor of pulmonary arterial hypertension in patients with systemic sclerosis. Clinical Rheumatology, 2018, 37, 979-985.	1.0	19
934	Macitentan in daily clinical practice: A single centre, 1-year experience. Pulmonology, 2018, 24, 170-173.	1.0	4

#	Article	IF	Citations
935	Additive and independent prognostic role of abnormal right ventricle and pulmonary hypertension in mitral-tricuspid surgery. International Journal of Cardiology, 2018, 252, 39-43.	0.8	19
936	Threeâ€dimensional echocardiography to evaluate right atrial volume and phasic function in pulmonary hypertension. Echocardiography, 2018, 35, 153-161.	0.3	4
937	REVEAL risk scores applied to riociguat-treated patients in PATENT-2: Impact of changes in risk score on survival. Journal of Heart and Lung Transplantation, 2018, 37, 513-519.	0.3	29
938	Management of Adults With Congenital Heart Disease and Pulmonary Arterial Hypertension in the UK: Survey of Current Practice, Unmet Needs and Expert Commentary. Heart Lung and Circulation, 2018, 27, 1018-1027.	0.2	7
939	Pilot multiâ€centre randomised trial of the impact of preâ€operative focused cardiac ultrasound on mortality and morbidity in patients having surgery for femoral neck fractures (<scp>ECHONOF</scp>â€2) Tj ETQq1 1 0 rgBT /Overlock 1	1.8	10
940	Diastolic dysfunction in pulmonary artery hypertension: Creatine kinase and the potential therapeutic benefit of betaâ€blockers. Clinical and Experimental Pharmacology and Physiology, 2018, 45, 384-389.	0.9	9
941	The significance of diminished sTWEAK and P-selectin content in platelets of patients with pulmonary arterial hypertension. Cytokine, 2018, 107, 52-58.	1.4	8
942	Oesophageal or transgastric views for estimating mean pulmonary artery pressure with transoesophageal echocardiography. European Journal of Anaesthesiology, 2018, 35, 349-355.	0.7	1
943	Down-regulation of lncRNA MEG3 promotes hypoxia-induced human pulmonary artery smooth muscle cell proliferation and migration via repressing PTEN by sponging miR-21. Biochemical and Biophysical Research Communications, 2018, 495, 2125-2132.	1.0	62
944	Firstâ€inâ€child use of the oral soluble guanylate cyclase stimulator riociguat in pulmonary arterial hypertension. Pulmonary Circulation, 2018, 8, 1-6.	0.8	31
945	Limited Exercise Capacity in Patients with Systemic Sclerosis: Identifying Contributing Factors with Cardiopulmonary Exercise Testing. Journal of Rheumatology, 2018, 45, 95-102.	1.0	14
946	Impact of declining renal function on outcomes in pulmonary arterial hypertension: A REVEAL registry analysis. Journal of Heart and Lung Transplantation, 2018, 37, 696-705.	0.3	28
947	Current Trends and Future Perspectives in the Treatment of Pulmonary Arterial Hypertension. Current Problems in Cardiology, 2018, 43, 191-216.	1.1	4
948	Current Trends and Future Perspectives in the Treatment of Pulmonary Hypertension: WHO Group II-V. Current Problems in Cardiology, 2018, 43, 217-231.	1.1	3
949	Haemodynamic effects of an acute vasodilator challenge in heart failure patients with reduced ejection fraction and different forms of postâ€capillary pulmonary hypertension. European Journal of Heart Failure, 2018, 20, 725-734.	2.9	27
950	Subclinical Hypothyroidism Is Associated With Adverse Prognosis in Heart Failure Patients. Canadian Journal of Cardiology, 2018, 34, 80-87.	0.8	30
951	Pulmonology in Pregnancy. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 127-129.	2.5	0
952	Models and Molecular Mechanisms of World Health Organization Group 2 to 4 Pulmonary Hypertension. Hypertension, 2018, 71, 34-55.	1.3	18

#	Article	IF	Citations
953	Implication of pulmonary hypertension in patients undergoing <scp>MitraClip</scp> therapy: results from the German transcatheter mitral valve interventions (<scp>TRAMI</scp>) registry. European Journal of Heart Failure, 2018, 20, 585-594.	2.9	62
954	Recent advances in pulmonary arterial hypertension. F1000Research, 2018, 7, 1128.	0.8	27
955	Assessment of noggin level in pulmonary arterial hypertension patients. Current Issues in Pharmacy and Medical Sciences, 2018, 31, 122-130.	0.1	1
956	Novel imaging techniques in pulmonary hypertension. Current Opinion in Cardiology, 2018, 33, 587-593.	0.8	5
957	Methamphetamine and the risk of pulmonary arterial hypertension. Current Opinion in Pulmonary Medicine, 2018, 24, 416-424.	1.2	28
958	Pulmonary Arterial Hypertension and Pregnancy. Indian Journal of Cardiovascular Disease in Women WINCARS, 2018, 03, 139-148.	0.1	1
959	The aetiology, clinical presentation and treatment of patients with pulmonary hypertension in Cape Town: A preliminary report from the Groote Schuur Hospital Pulmonary Hypertension Registry. African Journal of Thoracic and Critical Care Medicine, 2018, 24, 133.	0.3	2
960	Atrial septal defect (ASD) device trans-catheter closure: limitations. Journal of Thoracic Disease, 2018, 10, S2923-S2930.	0.6	21
961	Pulmonary veno-occlusive disease as a cause of severe pulmonary hypertension in a dog. Acta Veterinaria Scandinavica, 2018, 60, 78.	0.5	3
962	Atrial septal defects and pulmonary arterial hypertension. Journal of Thoracic Disease, 2018, 10, S2953-S2965.	0.6	27
964	Improving medical care and prevention in adults with congenital heart diseaseâ€"reflections on a global problemâ€"part II: infective endocarditis, pulmonary hypertension, pulmonary arterial hypertension and aortopathy. Cardiovascular Diagnosis and Therapy, 2018, 8, 716-724.	0.7	14
965	Imaging of pulmonary hypertension: an update. Cardiovascular Diagnosis and Therapy, 2018, 8, 279-296.	0.7	32
966	Key topics in pulmonary vascular diseases (assembly 13) from the European Respiratory Society 2018 Parisian Congress. Journal of Thoracic Disease, 2018, 10, S3029-S3033.	0.6	1
967	Focused Cardiac Ultrasound Determines Cause of Cardiovascular Collapse During Thoracic Surgery in a Patient With Undiagnosed Pulmonary Hypertension: A Case Report. A&A Practice, 2018, 11, 128-130.	0.2	0
968	Tricuspid annular displacement measured by 2-dimensional speckle tracking echocardiography for predicting right ventricular function in pulmonary hypertension. Medicine (United States), 2018, 97, e11710.	0.4	15
970	Protocolo diagnÃ³stico de la hipertensiÃ³n pulmonar sin cardiopatÃa izquierda. Medicine, 2018, 12, 4021-4024.	0.0	0
971	Mujer de 57 aÃ±os con disnea progresiva. Medicine, 2018, 12, 4025.e1-4025.e4.	0.0	0
972	Effects of human relaxin-2 (serelaxin) on hypoxic pulmonary vasoconstriction during acute hypoxia in a sheep model. Hypoxia (Auckland, N Z), 2018, Volume 6, 11-22.	1.9	5

#	Article	IF	Citations
973	Elicitation of health state utilities associated with the mode of administration of drugs acting on the prostacyclin pathway in pulmonary arterial hypertension. Patient Preference and Adherence, 2018, Volume 12, 1079-1088.	0.8	9
974	Noncardiac Surgery in Adult Congenital Heart Disease. , 2018, , 200-208.		3
975	Idiopathic Pulmonary Hypertension. , 2018, , 670-677.		0
976	Systemic sclerosis: severe pulmonary arterial hypertension and pericardial effusion at diagnosis. BMJ Case Reports, 2018, 2018, bcr-2017-223972.	0.2	0
977	Hemodynamics of the Right Heart in Health and Disease. , 2018, , 497-507.		1
978	New Possibilities of Antithrombotic Therapy of Patients with Peripheral and Widespread Atherosclerotic Lesion. Rational Pharmacotherapy in Cardiology, 2018, 14, 272-283.	0.3	3
979	Primary biliary cholangitis in Spain. Results of a Delphi study of epidemiology, diagnosis, follow-up and treatment. Revista Espanola De Enfermedades Digestivas, 2018, 110, 641-649.	0.1	3
980	Chronic Thromboembolic Pulmonary Hypertension and Antiphospholipid Syndrome with Immune Thrombocytopenia: A Case Report. American Journal of Case Reports, 2018, 19, 1245-1248.	0.3	2
981	Progenitor Endothelial Cells in Pulmonary Arterial Hypertension. Journal of General Practice (Los) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 4	0.1	0
982	Treatment Approaches for Pulmonary Hypertension in Kyphoscoliosis Related Alveolar Hypoventilation. International Journal of Neurorehabilitation, 2018, 05, .	0.1	0
983	Pulmonary Valve Stenosis Combined with Patent Foramen Ovale in Adult Patients: To Close or Not?. Journal of Clinical Case Reports, 2018, 08, .	0.0	0
984	OBSOLETE: Hemodynamics of the Right Heart in Health and Disease. , 2018, , .		0
985	Pulmonary Hypertension Associated With Left-Sided Heart Disease. , 2018, , 223-229.		0
986	PrÃkapillÃre pulmonale Hypertonie und schlafbezogene AtmungsstÃ¶rungen: Gibt es einen Zusammenhang?. Karger Kompass Pneumologie, 2018, 6, 216-228.	0.0	0
987	Drug abuse and HIV-related pulmonary hypertension. Aids, 2018, 32, 2651-2667.	1.0	14
988	Determinants of diagnostic delay in chronic thromboembolic pulmonary hypertension: results from the European CTEPH Registry. European Respiratory Journal, 2018, 52, 1801687.	3.1	78
989	Novel Noninvasive Assessment of Pulmonary Arterial Stiffness Using Velocity Transfer Function. Journal of the American Heart Association, 2018, 7, e009459.	1.6	15
990	Low plasma stem cell factor combined with high transforming growth factor-Î± identifies high-risk patients in pulmonary arterial hypertension. ERJ Open Research, 2018, 4, 00035-2018.	1.1	10

#	Article	IF	Citations
991	Echocardiographic evaluation of prevalence of pulmonary hypertension in Î²-thalassemia major: A cross sectional study. Pediatric Hematology and Oncology, 2018, 35, 322-330.	0.3	3
992	Exercise capacity in COPD patients with exercise-induced pulmonary hypertension. International Journal of COPD, 2018, Volume 13, 3599-3610.	0.9	9
993	Echocardiographic Screening for Pulmonary Hypertension in CongenitalÂHeart Disease. Journal of the American College of Cardiology, 2018, 72, 2778-2788.	1.2	38
994	Augmented concentrations of CX3CL1 are associated with interstitial lung disease in systemic sclerosis. PLoS ONE, 2018, 13, e0206545.	1.1	25
995	Caring for adults with congenital heart disease in a regional setting. Australian Journal of Rural Health, 2018, 26, 441-446.	0.7	0
996	Right heart size and function significantly correlate in patients with pulmonary arterial hypertension â€“ a cross-sectional study. Respiratory Research, 2018, 19, 216.	1.4	11
997	Impaired right ventricular ejection fraction after cardiac surgery is associated with a complicated ICU stay. Journal of Intensive Care, 2018, 6, 85.	1.3	14
998	A Very Uncommon Case of Pulmonary Hypertension. Case, 2018, 2, 279-281.	0.1	6
999	Iron deficiency in pulmonary arterial hypertension associated with congenital heart disease. Scandinavian Cardiovascular Journal, 2018, 52, 378-382.	0.4	11
1000	Quantitative videocapillaroscopy correlates with functional respiratory parameters: a clue for vasculopathy as a pathogenic mechanism for lung injury in systemic sclerosis. Arthritis Research and Therapy, 2018, 20, 281.	1.6	26
1001	Updates in heart failure: what last year brought to us. ESC Heart Failure, 2018, 5, 989-1007.	1.4	10
1002	Determining the value contribution of selexipag for the treatment of pulmonary arterial hypertension (PAH) in Spain using reflective multi-criteria decision analysis (MCDA). Orphanet Journal of Rare Diseases, 2018, 13, 220.	1.2	11
1003	Demographics, treatment trends, and survival rate in incident pulmonary artery hypertension in Korea: A nationwide study based on the health insurance review and assessment service database. PLoS ONE, 2018, 13, e0209148.	1.1	22
1004	The Role of G Protein-Coupled Receptors in the Right Ventricle in Pulmonary Hypertension. Frontiers in Cardiovascular Medicine, 2018, 5, 179.	1.1	12
1005	Arterial and pulmonary hypertension: risk assessment and current pharmacological and interventional management. European Heart Journal, 2018, 39, 4127-4131.	1.0	5
1006	Hypertension Is an Independent Predictor of Multivessel Coronary Artery Disease in Young Adults with Acute Coronary Syndrome. International Journal of Hypertension, 2018, 2018, 1-9.	0.5	17
1007	Idiopathic Pulmonary Fibrosis: Epidemiology, Natural History, Phenotypes. Medical Sciences (Basel,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	1.3	68
1008	Utility of the amplitude of RV1+SV5/6 in assessment of pulmonary hypertension. PLoS ONE, 2018, 13, e0206856.	1.1	8

#	Article	IF	Citations
1009	A Man with Severe Pulmonary Hypertension and Right Ventricular Failure. Annals of the American Thoracic Society, 2018, 15, 1472-1476.	1.5	0
1010	Heart failure in the spotlight. Interactive Cardiovascular and Thoracic Surgery, 2018, 27, 795-796.	0.5	1
1011	Exercise training in pulmonary arterial hypertension. Journal of Thoracic Disease, 2018, 10, 508-521.	0.6	26
1012	Anxiety and depression in patients with pulmonary hypertension: impact and management challenges. Vascular Health and Risk Management, 2018, Volume 14, 349-360.	1.0	48
1013	Prostacyclin Use Among Patients with Pulmonary Arterial Hypertension in the United States: A Retrospective Analysis of a Large Health Care Claims Database. Journal of Managed Care & Specialty Pharmacy, 2018, 24, 291-302.	0.5	14
1014	Good response to PAH-targeted drugs in a PVOD patient carrying Biallelic EIF2AK4 mutation. Respiratory Research, 2018, 19, 192.	1.4	7
1015	Risk assessment in scleroderma patients with newly diagnosed pulmonary arterial hypertension: application of the ESC/ERS risk prediction model. European Respiratory Journal, 2018, 52, 1800497.	3.1	32
1016	Pulmonary microvascular remodeling in chronic thrombo-embolic pulmonary hypertension. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2018, 315, L951-L964.	1.3	10
1017	Pulmonary endarterectomy and the cost of patient refusal. European Respiratory Journal, 2018, 52, 1801581.	3.1	2
1018	Oxygen therapy may worsen the survival rate in rats with monocrotaline-induced pulmonary arterial hypertension. PLoS ONE, 2018, 13, e0204254.	1.1	5
1019	Exhaled Nitric Oxide and Exhaled Breath Temperature as Potential Biomarkers in Patients with Pulmonary Hypertension. BioMed Research International, 2018, 2018, 1-9.	0.9	8
1020	The impact of post-pulmonary embolism syndrome and its possible determinants. Thrombosis Research, 2018, 171, 84-91.	0.8	40
1021	Should we use the oral selective IP receptor agonist selexipag offâ€label in children with pulmonary arterial hypertension?. Pulmonary Circulation, 2018, 8, 1-4.	0.8	9
1022	Intravenous sildenafil acutely improves hemodynamic response to exercise in patients with connective tissue disease. PLoS ONE, 2018, 13, e0203947.	1.1	1
1023	Left Ventricular Diastolic Dysfunction Predicts Mortality in Patients With Systemic Sclerosis. Journal of the American College of Cardiology, 2018, 72, 1804-1813.	1.2	78
1025	NLRC3: A Novel Noninvasive Biomarker for Pulmonary Hypertension Diagnosis. , 2018, 9, 843.		7
1026	Exercise Stress Echocardiography in Degenerative Mitral Regurgitation. Circulation: Cardiovascular Imaging, 2018, 11, e008263.	1.3	4
1027	Pulmonary Artery Stiffness by Cardiac Magnetic Resonance Imaging Predicts Major Adverse Cardiovascular Events in patients with Chronic Obstructive Pulmonary Disease. Scientific Reports, 2018, 8, 14447.	1.6	19

#	Article	IF	Citations
1028	Reversal of pulmonary arterial hypertension in POEMS syndrome with thalidomide: a case report. European Heart Journal - Case Reports, 2018, 2, yty051.	0.3	0
1029	Update on the epidemiology, risk factors, and disease outcomes of systemic sclerosis. Best Practice and Research in Clinical Rheumatology, 2018, 32, 223-240.	1.4	75
1030	Cologne consensus conference on pulmonary hypertension â€“ Update 2018. International Journal of Cardiology, 2018, 272, 1-3.	0.8	10
1031	Prognostic relevance of the right ventricular myo-mechanical index (RV-MMI) in patients with precapillary pulmonary hypertension. Open Heart, 2018, 5, e000903.	0.9	0
1032	Safe and effective exercise training for patients with pulmonary arterial hypertension: putting current evidence into clinical practice. Expert Review of Respiratory Medicine, 2018, 12, 965-977.	1.0	5
1033	Dynamics of high-sensitivity cardiac troponin T during therapy with balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension. PLoS ONE, 2018, 13, e0204683.	1.1	15
1034	Prevalence and Prognosis of Portopulmonary Hypertension in 223 Liver Transplant Recipients. Canadian Respiratory Journal, 2018, 2018, 1-6.	0.8	21
1035	Associations between diabetes mellitus and pulmonary hypertension in chronic respiratory disease patients. PLoS ONE, 2018, 13, e0205008.	1.1	12
1036	Maprotiline Prevents Monocrotaline-Induced Pulmonary Arterial Hypertension in Rats. Frontiers in Pharmacology, 2018, 9, 1032.	1.6	4
1037	Acute and Chronic Pulmonary Embolism: Perspectives on Diagnosis and Management. , 2018, , 355-366.		1
1039	Long-term survival in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: Insights from a referral center in Portugal. Revista Portuguesa De Cardiologia (English) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5		2
1040	Lessons from pulmonary hypertension registries. Revista Portuguesa De Cardiologia (English Edition), 2018, 37, 759-761.	0.2	0
1041	Pulmonary arterial hypertension in congenital heart disease. Continuing Cardiology Education, 2018, 4, 23-33.	0.4	7
1042	RV adaptation to increased afterload in congenital heart disease and pulmonary hypertension. PLoS ONE, 2018, 13, e0205196.	1.1	13
1043	Pictorial review of the pulmonary vasculature: from arteries to veins. Insights Into Imaging, 2018, 9, 971-987.	1.6	18
1044	Vasoplegia After Surgical Left Ventricular Restoration: 2-Year Follow-Up. Annals of Thoracic Surgery, 2018, 106, 1371-1378.	0.7	4
1045	Pulmonary Arterial Hypertension and Hereditary Haemorrhagic Telangiectasia. International Journal of Molecular Sciences, 2018, 19, 3203.	1.8	32
1046	Impact of Left Ventricular Diastolic Dysfunction and Biomarkers on Pulmonary Hypertension in Patients with Severe Aortic Stenosis. Medicina (Lithuania), 2018, 54, 63.	0.8	9

#	Article	IF	Citations
1047	Pulmonary hypertension-targeted therapies in heart failure: A systematic review and meta-analysis. PLoS ONE, 2018, 13, e0204610.	1.1	13
1048	Right atrial to left atrial volume index ratio is associated with increased mortality in patients with pulmonary hypertension. Echocardiography, 2018, 35, 1729-1735.	0.3	10
1049	Treatment Patterns and Associated Health Care Costs Before and After Treatment Initiation Among Pulmonary Arterial Hypertension Patients in the United States. Journal of Managed Care & Specialty Pharmacy, 2018, 24, 834-842.	0.5	31
1050	The Accuracy of a Large V Wave in the Pulmonary Capillary Wedge Pressure Waveform for Diagnosing Current Mitral Regurgitation. Cardiology, 2018, 141, 46-51.	0.6	5
1051	Atrial septal defect and exercise capacity: value of cardio-pulmonary exercise test in assessment and follow-up. Journal of Thoracic Disease, 2018, 10, S2864-S2873.	0.6	5
1052	Stress ECHO beyond coronary artery disease. Is it the holy grail of cardiovascular imaging?. Clinical Cardiology, 2018, 41, 1600-1610.	0.7	4
1053	Isolated DLco/VA reduction in systemic sclerosis patients: a new patient subset?. Clinical Rheumatology, 2018, 37, 3365-3371.	1.0	2
1054	Transition from treprostinil to selexipag in patients with pulmonary arterial hypertension: Case series. American Journal of Health-System Pharmacy, 2018, 75, 1877-1881.	0.5	18
1055	Risk assessment in patients with systemic sclerosis and pulmonary arterial hypertension. European Respiratory Journal, 2018, 52, 1801745.	3.1	5
1056	Endothelin-receptor antagonists in the management of pulmonary arterial hypertension: where do we stand?. Vascular Health and Risk Management, 2018, Volume 14, 253-264.	1.0	33
1057	Echocardiography during preload stress for evaluation of right ventricular contractile reserve and exercise capacity in pulmonary hypertension. Echocardiography, 2018, 35, 1997-2004.	0.3	6
1058	Pulmonary Arterial Hypertension Medical Management of the Adult Patient with Congenital Heart Disease. Cardiovascular Innovations and Applications, 2018, 3, .	0.1	0
1059	Microarray Analysis in Pulmonary Hypertensive Rat Heart after Simvastatin Treatment. The Ewha Medical Journal, 2018, 41, 53.	0.1	0
1060	The Relation of Dependency and the Predictive Potential of Several Factors Possibly Involved in Determining Pulmonary Hypertension in Gravesâ€™ Disease. Pakistan Journal of Medical Sciences, 2018, 34, 583-589.	0.3	0
1061	Echocardiographic evaluation of the right ventricular dimension and systolic function in dogs with pulmonary hypertension. Journal of Veterinary Internal Medicine, 2018, 32, 1541-1548.	0.6	37
1062	Right Ventricular Functional Improvement after Pulmonary Rehabilitation Program in Patients with COPD Determined by Speckle Tracking Echocardiography. Arquivos Brasileiros De Cardiologia, 2018, 111, 375-381.	0.3	5
1063	Right heart dysfunction. Journal of Cardiovascular Medicine, 2018, 19, 613-623.	0.6	10
1064	Initial Riociguat Monotherapy and Transition from Sildenafil to Riociguat in Patients with Idiopathic Pulmonary Arterial Hypertension: Influence on Right Heart Remodeling and Right Ventricularâ€“Pulmonary Arterial Coupling. Lung, 2018, 196, 745-753.	1.4	21

#	Article	IF	Citations
1065	Tolerability and clinical efficacy of inhaled treprostinil in patients with group 1 pulmonary arterial hypertension. Therapeutic Advances in Chronic Disease, 2018, 9, 171-177.	1.1	2
1066	Titration of pulmonary arterial hypertension therapeutics: Experience-based recommendations. Respiratory Medicine, 2018, 143, 139-146.	1.3	7
1067	Comorbidities of IPF: How do they impact on prognosis. Pulmonary Pharmacology and Therapeutics, 2018, 53, 6-11.	1.1	13
1068	Pulmonary vasodilator therapies are of no benefit in pulmonary hypertension due to left heart disease: A meta-analysis. International Journal of Cardiology, 2018, 273, 213-220.	0.8	26
1069	Use of direct oral anticoagulants for chronic thromboembolic pulmonary hypertension. Clinics, 2018, 73, e216.	0.6	19
1070	Management of Severe Pulmonary Hypertensive Disease for Surgical and Nonsurgical Procedures. International Anesthesiology Clinics, 2018, 56, e28-e55.	0.3	4
1071	TGF-Î² and BMPR2 Signaling in PAH: Two Black Sheep in One Family. International Journal of Molecular Sciences, 2018, 19, 2585.	1.8	78
1072	High levels of healthcare utilization prior to diagnosis in idiopathic pulmonary arterial hypertension support the feasibility of an early diagnosis algorithm: the SPHInX project. Pulmonary Circulation, 2018, 8, 1-9.	0.8	21
1073	The Regulation of Pulmonary Vascular Tone by Neuropeptides and the Implications for Pulmonary Hypertension. Frontiers in Physiology, 2018, 9, 1167.	1.3	28
1074	Mucine-1 Is Related to Cell-Mediated Immunoexpression and Blood Pressure in Pulmonary Artery in Pulmonary Arterial Hypertension (PAH): Preliminary Results. Advances in Experimental Medicine and Biology, 2018, 1072, 275-280.	0.8	1
1075	Risk-stratified outcomes with initial combination therapy in pulmonary arterial hypertension: Application of the REVEAL risk score. Journal of Heart and Lung Transplantation, 2018, 37, 1410-1417.	0.3	15
1076	Right Ventricular Hypertrophy and Dilation in Patients With Human Immunodeficiency Virus in the Absence of Clinical or Echocardiographic Pulmonary Hypertension. Journal of Cardiac Failure, 2018, 24, 583-593.	0.7	3
1077	Rivaroxaban and macitentan can be coadministered without dose adjustment but the combination of rivaroxaban and St John's wort should be avoided. British Journal of Clinical Pharmacology, 2018, 84, 2903-2913.	1.1	17
1078	Lessons from pulmonary hypertension registries. Revista Portuguesa De Cardiologia, 2018, 37, 759-761.	0.2	1
1079	Histone demethylase JARID1B regulates proliferation and migration of pulmonary arterial smooth muscle cells in mice with chronic hypoxia-induced pulmonary hypertension via nuclear factor-kappa B (NFkB). Cardiovascular Pathology, 2018, 37, 8-14.	0.7	13
1080	Prevalence of primary SjÃ¶grenâ€™s syndrome in patients undergoing evaluation for pulmonary arterial hypertension. PLoS ONE, 2018, 13, e0197297.	1.1	11
1081	Targeted therapy of pulmonary arterial hypertension: Updated recommendations from the Cologne Consensus Conference 2018. International Journal of Cardiology, 2018, 272, 37-45.	0.8	56
1082	General measures and supportive therapy for pulmonary arterial hypertension: Updated recommendations from the Cologne Consensus Conference 2018. International Journal of Cardiology, 2018, 272, 30-36.	0.8	32

#	Article	IF	Citations
1083	Exercise right heart catheterisation before and after pulmonary endarterectomy in patients with chronic thromboembolic disease. European Respiratory Journal, 2018, 52, 1800458.	3.1	57
1084	Clinical and genetic characteristics of pulmonary arterial hypertension in Lebanon. BMC Medical Genetics, 2018, 19, 89.	2.1	16
1085	Decoupling Between Diastolic Pulmonary Arterial Pressure and Pulmonary Arterial Wedge Pressure at Incremental Left Ventricular Assist Device (LVAD) Speeds Is Associated With Worse Prognosis After LVAD Implantation. Journal of Cardiac Failure, 2018, 24, 575-582.	0.7	19
1086	Chronic thromboembolic pulmonary hypertension (CTEPH): Updated Recommendations from the Cologne Consensus Conference 2018. International Journal of Cardiology, 2018, 272, 69-78.	0.8	140
1087	Decompensated right heart failure, intensive care and perioperative management in patients with pulmonary hypertension: Updated recommendations from the Cologne Consensus Conference 2018. International Journal of Cardiology, 2018, 272, 46-52.	0.8	33
1089	Histopathologic Analysis in Sudden Infant and Child Deaths. Academic Forensic Pathology, 2018, 8, 492-538.	0.3	4
1090	Clinical and genetic associations with prostacyclin response in pulmonary arterial hypertension. Pulmonary Circulation, 2018, 8, 1-9.	0.8	5
1091	A subclinical high tricuspid regurgitation pressure gradient independent of the mean pulmonary artery pressure is a risk factor for the survival after living donor liver transplantation. BMC Gastroenterology, 2018, 18, 62.	0.8	7
1092	The crucial impact of iron deficiency definition for the course of precapillary pulmonary hypertension. PLoS ONE, 2018, 13, e0203396.	1.1	24
1093	Serum Chloride Levels Track With SurvivalÂin Patients With Pulmonary ArterialÂHypertension. Chest, 2018, 154, 541-549.	0.4	24
1094	Beta1-adrenoceptor antagonist, metoprolol attenuates cardiac myocyte Ca2+ handling dysfunction in rats with pulmonary artery hypertension. Journal of Molecular and Cellular Cardiology, 2018, 120, 74-83.	0.9	25
1095	Right atrial mechanics provide useful insight in pediatric pulmonary hypertension. Pulmonary Circulation, 2018, 8, 1-10.	0.8	8
1096	Exercise-based evaluations and interventions for pulmonary hypertension with connective tissue disorders. Expert Review of Respiratory Medicine, 2018, 12, 615-622.	1.0	3
1097	Chronic Thromboembolic PulmonaryÂHypertension. Journal of the American College of Cardiology, 2018, 71, 2468-2486.	1.2	132
1098	Haemodynamics, dyspnoea, and pulmonary reserve in heart failure with preserved ejection fraction. European Heart Journal, 2018, 39, 2810-2821.	1.0	180
1099	MRI-derived Regional Biventricular Function in Patients with Chronic Thromboembolic Pulmonary Hypertension Before and After Pulmonary Endarterectomy. Academic Radiology, 2018, 25, 1540-1547.	1.3	15
1100	Reply: Can treprostinil-induced early gastrointestinal side effects serve as predictors of pulmonary arterial hypertension prognosis?. International Journal of Cardiology, 2018, 264, 188.	0.8	0
1101	Cardioprotection Induced by Activation of GPER in Ovariectomized Rats With Pulmonary Hypertension. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2018, 73, 1158-1166.	1.7	17

#	Article	IF	Citations
1102	Computational Fluid Dynamics Modeling of the Human Pulmonary Arteries with Experimental Validation. Annals of Biomedical Engineering, 2018, 46, 1309-1324.	1.3	20
1103	Characteristics and survival data from Latvian pulmonary hypertension registry: comparison of prospective pulmonary hypertension registries in Europe. Pulmonary Circulation, 2018, 8, 1-9.	0.8	30
1104	Chronic thromboembolic pulmonary hypertension: Reversal of pulmonary hypertension but not sleep disordered breathing following pulmonary endarterectomy. International Journal of Cardiology, 2018, 264, 147-152.	0.8	8
1105	A disease looking for innovative drugs: The case of pulmonary arterial hypertension. European Journal of Internal Medicine, 2018, 55, 47-51.	1.0	3
1106	Dual endothelinâ€1 receptor antagonism attenuates pleteletâ€mediated derangements of blood coagulation in Eisenmenger syndrome. Journal of Thrombosis and Haemostasis, 2018, 16, 1572-1579.	1.9	9
1107	Partitioning of pulmonary vascular resistances in group 2 pulmonary hypertension: insightful suggestions for bridging haemodynamics to underlying mechanisms. European Respiratory Journal, 2018, 51, 1800816.	3.1	1
1108	Dual-energy CT (DECT) lung perfusion in pulmonary hypertension: concordance rate with V/Q scintigraphy in diagnosing chronic thromboembolic pulmonary hypertension (CTEPH). European Radiology, 2018, 28, 5100-5110.	2.3	102
1109	Association of hemodynamics during caesarean section, outcomes after caesarean section and hormone changes with different anesthesia in pregnant women with severe pulmonary arterial hypertension. Experimental and Therapeutic Medicine, 2018, 15, 4731-4736.	0.8	6
1110	Pulmonary Hypertension: Good Intentions, But a Questionable Approach. Annals of the American Thoracic Society, 2018, 15, 664-666.	1.5	3
1111	Characterization of fibroblasts from hypertrophied right ventricle of pulmonary hypertensive rats. Pflugers Archiv European Journal of Physiology, 2018, 470, 1405-1417.	1.3	8
1112	Reference values and correlates of right atrial volume in healthy adults by twoâ€dimensional echocardiography. Echocardiography, 2018, 35, 1097-1107.	0.3	8
1113	Pulmonary hypertension due to left heart disease: diagnostic and prognostic value of CT in chronic systolic heart failure. European Radiology, 2018, 28, 4643-4653.	2.3	16
1115	When the Right Is Not Doing Right: The Role of Strain Imaging in Pulmonary Arterial Hypertension. Canadian Journal of Cardiology, 2018, 34, 962-964.	0.8	2
1116	Effects of Riociguat on Right Ventricular Remodelling in Chronic Thromboembolic Pulmonary Hypertension Patients: A Prospective Study. Canadian Journal of Cardiology, 2018, 34, 1137-1144.	0.8	9
1117	Orthopnea and pulmonary hypertension. Treat the underlying disease. Respiratory Medicine Case Reports, 2018, 24, 105-107.	0.2	2
1118	Global longitudinal strain measured by speckle tracking identifies subclinical heart involvement in patients with systemic sclerosis. European Journal of Preventive Cardiology, 2018, 25, 1598-1606.	0.8	38
1119	Right heart catheterisation is still a fundamental part of the follow-up assessment of pulmonary arterial hypertension. European Respiratory Journal, 2018, 52, 1800738.	3.1	15
1120	Contemporary survival of patients with pulmonary arterial hypertension and congenital systemic to pulmonary shunts. PLoS ONE, 2018, 13, e0195092.	1.1	15

#	Article	IF	Citations
1121	Reproducibility and Utility of the 6-minute Walk Test in Systemic Sclerosis. Journal of Rheumatology, 2018, 45, 1273-1280.	1.0	17
1122	Effects of Fasudil on Patients with Pulmonary Hypertension Associated with Left Ventricular Heart Failure with Preserved Ejection Fraction: A Prospective Intervention Study. Canadian Respiratory Journal, 2018, 2018, 1-7.	0.8	15
1123	Lack of a Tricuspid Regurgitation Doppler Signal and Pulmonary Hypertension by Invasive Measurement. Journal of the American Heart Association, 2018, 7, .	1.6	53
1124	Aggressive combination therapy for treatment of systemic sclerosis-associated pulmonary hypertension. Journal of Scleroderma and Related Disorders, 2018, 3, 30-38.	1.0	4
1125	Serial imaging after pulmonary embolism and correlation with functional limitation at 12Âmonths: Results of the ELOPE Study. Research and Practice in Thrombosis and Haemostasis, 2018, 2, 670-677.	1.0	23
1126	The importance of left heart disease as a cause of pulmonary hypertension in COPD. Hellenic Journal of Cardiology, 2018, 59, 166-167.	0.4	3
1127	Phenotyping pulmonary hypertension in systemic sclerosis: a moving target. Pulmonary Circulation, 2018, 8, 1-2.	0.8	1
1128	Nonâ€invasive right ventricular load adaptability indices in patients with sclerodermaâ€associated pulmonary arterial hypertension. Pulmonary Circulation, 2018, 8, 1-11.	0.8	22
1129	Pulmonary Arterial Hypertension Affects the Rat Gut Microbiome. Scientific Reports, 2018, 8, 9681.	1.6	56
1130	Exercise unmasks distinct pathophysiologic features in heart failure with preserved ejection fraction and pulmonary vascular disease. European Heart Journal, 2018, 39, 2825-2835.	1.0	165
1131	Sequential treatment with riociguat and balloon pulmonary angioplasty for patients with inoperable chronic thromboembolic pulmonary hypertension. Pulmonary Circulation, 2018, 8, 1-7.	0.8	44
1132	Association Between BMI and Obesity With Survival in Pulmonary Arterial Hypertension. Chest, 2018, 154, 872-881.	0.4	43
1133	Pulmonary Arterial Hypertension Specific Therapy in Patients with Combined Post- and Precapillary Pulmonary Hypertension. Pulmonary Medicine, 2018, 2018, 1-7.	0.5	3
1134	Right Ventricle Remodeling and Function in Scleroderma Patients. BioMed Research International, 2018, 2018, 1-9.	0.9	9
1135	ECG Markers of Hemodynamic Improvement in Patients with Pulmonary Hypertension. BioMed Research International, 2018, 2018, 1-10.	0.9	13
1136	Advances in the management of cardiovascular disease during pregnancy. Future Cardiology, 2018, 14, 269-272.	0.5	2
1137	Eisenmenger Syndrome. , 2018, , 528-544.		1
1138	The Right Heart International Network (RIGHT-NET). Heart Failure Clinics, 2018, 14, 443-465.	1.0	15

#	Article	IF	Citations
1139	Inhibition of CRTH2-mediated Th2 activation attenuates pulmonary hypertension in mice. Journal of Experimental Medicine, 2018, 215, 2175-2195.	4.2	48
1140	Pulmonary Circulation on the Crossroads Between the Left and Right Heart in Systemic Sclerosis. Heart Failure Clinics, 2018, 14, 271-281.	1.0	8
1141	Pulmonary Hypertension and Heart Failure. Heart Failure Clinics, 2018, 14, 297-309.	1.0	11
1142	Chronic Right Heart Failure. Heart Failure Clinics, 2018, 14, 413-423.	1.0	5
1143	Identifying At-Risk Patients with Combined Pre- and Postcapillary Pulmonary Hypertension Using Interventricular Septal Angle at Cardiac MRI. Radiology, 2018, 289, 61-68.	3.6	27
1144	The Evolving Role of MRI in Pulmonary Hypertension Evaluation: A Noninvasive Approach from Diagnosis to Follow-up. Radiology, 2018, 289, 69-70.	3.6	3
1145	Current Knowledge and Recent Advances of Right Ventricular Molecular Biology and Metabolism from Congenital Heart Disease to Chronic Pulmonary Hypertension. BioMed Research International, 2018, 2018, 1-10.	0.9	16
1146	Health-Related Quality of Life in Pulmonary Hypertension and Its Clinical Correlates: A Cross-Sectional Study. BioMed Research International, 2018, 2018, 1-10.	0.9	26
1147	Daily Chronic Intermittent Hypobaric Hypoxia Does Not Induce Chronic Increase in Pulmonary Arterial Pressure Assessed by Echocardiography. Canadian Respiratory Journal, 2018, 2018, 1-8.	0.8	0
1148	Heart Failure in Adult Congenital Heart Disease. Congenital Heart Disease in Adolescents and Adults, 2018, , .	0.2	0
1149	Psychometric Validation of the Pulmonary Arterial Hypertension-Symptoms and Impact (PAH-SYMPACT) Questionnaire. Chest, 2018, 154, 848-861.	0.4	41
1150	Three-Dimensional Echocardiography for the Assessment of Right Ventriculo-Arterial Coupling. Journal of the American Society of Echocardiography, 2018, 31, 905-915.	1.2	39
1151	Increased right atrial volume measured with cardiac magnetic resonance is associated with worse clinical outcome in patients with preâ€capillary pulmonary hypertension. ESC Heart Failure, 2018, 5, 864-875.	1.4	21
1152	Behavior of right atrial strain in high systolic pulmonary artery pressure. Echocardiography, 2018, 35, 1557-1563.	0.3	4
1153	Inhibition of BET Proteins Reduces Right Ventricle Hypertrophy and Pulmonary Hypertension Resulting from Combined Hypoxia and Pulmonary Inflammation. International Journal of Molecular Sciences, 2018, 19, 2224.	1.8	10
1154	Mortality and prognostic factors in Chinese patients with systemic lupus erythematosus. Lupus, 2018, 27, 1742-1752.	0.8	41
1155	The role of echocardiography in the diagnostic workâ€up of pulmonary hypertension. Continuing Cardiology Education, 2018, 4, 13-22.	0.4	1
1156	Right Heart Catheterization. , 2018, , 79-89.		0

#	Article	IF	Citations
1157	Pulmonary manifestations of systemic lupus erythematosus and SjÃ¶gren's syndrome. Current Opinion in Rheumatology, 2018, 30, 449-464.	2.0	24
1158	Partial anomalous pulmonary venous connection in a 72-year-old woman: A case report. SAGE Open Medical Case Reports, 2018, 6, 2050313X1878764.	0.2	1
1159	Plasma levels of high density lipoprotein cholesterol and outcomes in chronic thromboembolic pulmonary hypertension. PLoS ONE, 2018, 13, e0197700.	1.1	14
1160	Cefminox, a Dual Agonist of Prostacyclin Receptor and Peroxisome Proliferator-Activated Receptor-Gamma Identified by Virtual Screening, Has Therapeutic Efficacy against Hypoxia-Induced Pulmonary Hypertension in Rats. Frontiers in Pharmacology, 2018, 9, 134.	1.6	16
1161	Biomarkers for Pulmonary Vascular Remodeling in Systemic Sclerosis: A Pathophysiological Approach. Frontiers in Physiology, 2018, 9, 587.	1.3	32
1162	Inflammatory Mediators Drive Adverse Right Ventricular Remodeling and Dysfunction and Serve as Potential Biomarkers. Frontiers in Physiology, 2018, 9, 609.	1.3	42
1163	Pulmonary Arterial Hypertension: Iron Matters. Frontiers in Physiology, 2018, 9, 641.	1.3	20
1164	Diagnosing and grading heart failure with tomographic perfusion lung scintigraphy: validation with right heart catheterization. ESC Heart Failure, 2018, 5, 902-910.	1.4	12
1165	Clinical and Hemodynamic Correlates of Pulmonary Arterial Stiffness in Incident, Untreated Patients With Idiopathic Pulmonary Arterial Hypertension. Chest, 2018, 154, 882-892.	0.4	10
1166	ORAI Channels as Potential Therapeutic Targets in Pulmonary Hypertension. Physiology, 2018, 33, 261-268.	1.6	15
1167	Acute Heart Failure Management. Korean Circulation Journal, 2018, 48, 463.	0.7	16
1168	Drug-induced pulmonary arterial hypertension: a primer for clinicians and scientists. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2018, 314, L967-L983.	1.3	32
1169	E/Eâ€² and D-shaped Left Ventricle Severity in Patients with Increased Pulmonary Artery Pressure. Journal of Cardiovascular Imaging, 2018, 26, 85.	0.2	2
1170	Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension. CardioVascular and Interventional Radiology, 2018, 41, 1826-1839.	0.9	6
1171	Is it possible to apply the treat-to-target strategy in primary SjÃ¶grenâ€™s syndrome-associated pulmonary arterial hypertension?. Clinical Rheumatology, 2018, 37, 2989-2998.	1.0	5
1172	Management dilemmas in pulmonary arterial hypertension associated with congenital heart disease. Pulmonary Circulation, 2018, 8, 1-12.	0.8	15
1173	NOX4 expression and distal arteriolar remodeling correlate with pulmonary hypertension in COPD. BMC Pulmonary Medicine, 2018, 18, 111.	0.8	26
1174	Diagnosis, Treatment, and Prevention of Cardiovascular Toxicity Related to Anti-Cancer Treatment in Clinical Practice: An Opinion Paper from the Working Group on Cardio-Oncology of the Korean Society of Echocardiography. Journal of Cardiovascular Imaging, 2018, 26, 1.	0.8	24

#	Article	IF	Citations
1175	The value of speckle-tracking echocardiography in identifying right heart dysfunction in patients with chronic thromboembolic pulmonary hypertension. International Journal of Cardiovascular Imaging, 2018, 34, 1895-1904.	0.7	15
1176	Anticoagulant treatment in patients with pulmonary arterial hypertension associated with systemic sclerosis: More shadows than lights. Journal of Scleroderma and Related Disorders, 2018, 3, 39-42.	1.0	4
1177	â€œGuidelines Recommendations on the Treatment of Tricuspid Regurgitation. Where Are We and Where Do We Go With Transcatheter Valve Interventionâ€• Frontiers in Cardiovascular Medicine, 2018, 5, 37.	1.1	6
1178	Pulmonary Hypertension in Aortic and Mitral Valve Disease. Frontiers in Cardiovascular Medicine, 2018, 5, 40.	1.1	68
1179	Pulmonary Artery Size in Interstitial Lung Disease and Pulmonary Hypertension: Association with Interstitial Lung Disease Severity and Diagnostic Utility. Frontiers in Cardiovascular Medicine, 2018, 5, 53.	1.1	29
1180	Using Omics to Understand and Treat Pulmonary Vascular Disease. Frontiers in Medicine, 2018, 5, 157.	1.2	21
1181	Incremental Shuttle Walking Test Distance Is Reduced in Patients With Pulmonary Hypertension in World Health Organisation Functional Class I. Frontiers in Medicine, 2018, 5, 172.	1.2	4
1182	Pathophysiology and Diagnosis of Pulmonary Hypertension Due to Left Heart Disease. Frontiers in Medicine, 2018, 5, 174.	1.2	20
1183	A pilot randomised controlled trial investigating a mindfulness-based stress reduction (MBSR) intervention in individuals with pulmonary arterial hypertension (PAH): the PATHWAYS study. Pilot and Feasibility Studies, 2018, 4, 78.	0.5	14
1185	HIF Oxygen Sensing Pathways in Lung Biology. Biomedicines, 2018, 6, 68.	1.4	22
1186	Pulmonary Arterial Hypertension: Pathophysiology and Treatment. Diseases (Basel, Switzerland), 2018, 6, 38.	1.0	89
1187	Definition and Management of Segmental Pulmonary Hypertension. Journal of the American Heart Association, 2018, 7, .	1.6	41
1188	Have Noninvasive Imaging Studies Supplanted the Need for Invasive Hemodynamics: Lessons Learned from Lymphangioleiomyomatosis. Journal of the American Society of Echocardiography, 2018, 31, 902-904.	1.2	1
1189	The pharmacological treatment of chronic comorbidities in COPD: mind the gap!. Pulmonary Pharmacology and Therapeutics, 2018, 51, 48-58.	1.1	10
1190	EP4 Agonist L-902,688 Suppresses EndMT and Attenuates Right Ventricular Cardiac Fibrosis in Experimental Pulmonary Arterial Hypertension. International Journal of Molecular Sciences, 2018, 19, 727.	1.8	22
1191	Utility of D-shaped Left Ventricle and Mitral E/Eâ€² in Patients with Pulmonary Hypertension. Journal of Cardiovascular Imaging, 2018, 26, 59.	0.2	0
1192	Incidence and risk factors of chronic thromboembolic pulmonary hypertension following venous thromboembolism, a populationâ€based cohort study in England. Pulmonary Circulation, 2018, 8, 1-10.	0.8	40
1193	The Sugen 5416/Hypoxia Mouse Model of Pulmonary Arterial Hypertension. Methods in Molecular Biology, 2018, 1816, 243-252.	0.4	17

#	Article	IF	Citations
1194	Impact of the initiation of balloon pulmonary angioplasty program on referral of patients with chronic thromboembolic pulmonary hypertension to surgery. Journal of Heart and Lung Transplantation, 2018, 37, 1102-1110.	0.3	20
1195	Predictors of poor outcome in patients with pulmonary arterial hypertension: A single center study. PLoS ONE, 2018, 13, e0193245.	1.1	10
1196	Chronic Pulmonary Artery Embolization Models in Large Animals. Methods in Molecular Biology, 2018, 1816, 353-366.	0.4	1
1197	Modeling Pulmonary Hypertension: A Pig Model of Postcapillary Pulmonary Hypertension. Methods in Molecular Biology, 2018, 1816, 367-383.	0.4	6
1198	Pulmonary hypertension in chronic heart failure: definitions, advances, and unanswered issues. ESC Heart Failure, 2018, 5, 755-763.	1.4	17
1199	Factors associated with development and mortality of pulmonary hypertension in systemic lupus erythematosus patients. Lupus, 2018, 27, 1769-1777.	0.8	18
1200	A Multifaceted Approach to Pulmonary Hypertension in Adults With Congenital Heart Disease. Progress in Cardiovascular Diseases, 2018, 61, 320-327.	1.6	6
1201	Age, risk and outcomes in idiopathic pulmonary arterial hypertension. European Respiratory Journal, 2018, 51, 1800629.	3.1	9
1202	Characteristics of exercise capacity in female systemic lupus erythematosus associated pulmonary arterial hypertension patients. BMC Cardiovascular Disorders, 2018, 18, 56.	0.7	3
1203	The association of the N-terminal pro-brain-type natriuretic peptide response to exercise with disease severity in therapy-naive pulmonary arterial hypertension: a cohort study. Respiratory Research, 2018, 19, 8.	1.4	5
1204	Tricuspid flow and regurgitation in congenital heart disease and pulmonary hypertension: comparison of 4D flow cardiovascular magnetic resonance and echocardiography. Journal of Cardiovascular Magnetic Resonance, 2018, 20, 5.	1.6	32
1205	A stepwise composite echocardiographic score predicts severe pulmonary hypertension in patients with interstitial lung disease. ERJ Open Research, 2018, 4, 00124-2017.	1.1	16
1206	Genetic analyses in a cohort of 191 pulmonary arterial hypertension patients. Respiratory Research, 2018, 19, 87.	1.4	22
1207	Using all-cause mortality to define severe RV dilation with RV/LV volume ratio. Scientific Reports, 2018, 8, 7200.	1.6	13
1208	Fibrocytes are increased in lung and peripheral blood of patients with idiopathic pulmonary fibrosis. Respiratory Research, 2018, 19, 90.	1.4	43
1209	Muscular and extramuscular clinical features of patients with anti-PM/Scl autoantibodies. Neurology, 2018, 90, e2068-e2076.	1.5	76
1210	Study on the clinical efficacy of specific phosphodiesterase inhibitor in patients with pulmonary hypertension due to left heart disease. Experimental and Therapeutic Medicine, 2018, 16, 1175-1186.	0.8	2
1211	Hypercoagulability in Pulmonary Hypertension. Clinics in Chest Medicine, 2018, 39, 595-603.	0.8	18

#	Article	IF	Citations
1212	CHST3 and CHST13 polymorphisms as predictors of bosentan-induced liver toxicity in Japanese patients with pulmonary arterial hypertension. Pharmacological Research, 2018, 135, 259-264.	3.1	6
1213	Pulmonary Hypertension and Its Response to Treatment in a Patient with Kyphosis-related Alveolar Hypoventilation. Internal Medicine, 2018, 57, 1003-1006.	0.3	3
1214	Interventions and mechanisms of Nâ€'acetylcysteine on monocrotalineâ€'induced pulmonary arterial hypertension. Experimental and Therapeutic Medicine, 2018, 15, 5503-5509.	0.8	4
1215	El tratamiento de elecciÃ³n en la hipertensiÃ³n pulmonar tromboembÃ³lica crÃ³nica: la tromboendarterectomÃa pulmonar. Cirugia Cardiovascular, 2018, 25, 73-76.	0.1	1
1216	ECG derived ventricular gradient exceeds echocardiography in the early detection of pulmonary hypertension in scleroderma patients. International Journal of Cardiology, 2018, 273, 203-206.	0.8	10
1217	Systematic review and meta-analysis of interventions tested in animal models of pulmonary hypertension. Vascular Pharmacology, 2018, 110, 55-63.	1.0	11
1218	The importance of right ventricular function in patients with pulmonary arterial hypertension. Expert Review of Respiratory Medicine, 2018, 12, 809-815.	1.0	4
1219	Pulmonary vascular resistance versus pulmonary artery pressure for predicting right ventricular remodeling and functional tricuspid regurgitation. Echocardiography, 2018, 35, 1736-1745.	0.3	6
1220	Hemodynamic and Histopathologic Benefits of Early Treatment with Macitentan in a Rat Model of Pulmonary Arterial Hypertension. Korean Circulation Journal, 2018, 48, 839.	0.7	9
1221	2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. European Heart Journal, 2018, 39, 3165-3241.	1.0	1,396
1222	Pulmonary arterial hypertension in Latin America: epidemiological data from local studies. BMC Pulmonary Medicine, 2018, 18, 106.	0.8	21
1223	Role of extracellular matrix in the pathogenesis of pulmonary arterial hypertension. American Journal of Physiology - Heart and Circulatory Physiology, 2018, 315, H1322-H1331.	1.5	137
1224	Can computer assisted analysis of a standard 12â€'lead ECG be used for early diagnosis and monitoring of disease progression in pulmonary hypertension?. International Journal of Cardiology, 2018, 273, 221-222.	0.8	1
1225	Pulmonary hypertension in adults with congenital heart disease: Updated recommendations from the Cologne Consensus Conference 2018. International Journal of Cardiology, 2018, 272, 79-88.	0.8	46
1226	Long-term survival in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: Insights from a referral center in Portugal. Revista Portuguesa De Cardiologia, 2018, 37, 749-757.	0.2	13
1227	Favorable course of previously undiagnosed Methylmalonic Aciduria with Homocystinuria (cblC type) presenting with pulmonary hypertension and aHUS in a young child: a case report. Italian Journal of Pediatrics, 2018, 44, 90.	1.0	8
1228	Exercise pulmonary haemodynamic response predicts outcomes in fibrotic lung disease. European Respiratory Journal, 2018, 52, 1801015.	3.1	6
1229	Echocardiographic assessment of pulmonary hypertension: a guideline protocol from the British Society of Echocardiography. Echo Research and Practice, 2018, 5, G11-G24.	0.6	174

#	Article	IF	Citations
1230	Balloon pulmonary angioplasty is a promising option in thalassemic patients with inoperable chronic thromboembolic pulmonary hypertension. Journal of Thrombosis and Thrombolysis, 2018, 46, 516-520.	1.0	3
1231	Inhibition of Shp2 ameliorates monocrotaline-induced pulmonary arterial hypertension in rats. BMC Pulmonary Medicine, 2018, 18, 130.	0.8	17
1232	Relation of Right Atrial Mechanics to Functional Capacity in Patients With Systemic Sclerosis. American Journal of Cardiology, 2018, 122, 1249-1254.	0.7	8
1233	Right Atrial Function Predicts Clinical Outcome in Patients with Precapillary Pulmonary Hypertension. Journal of the American Society of Echocardiography, 2018, 31, 1137-1145.	1.2	12
1234	Elevated Pulmonary Pressureâ€"Get With the Right Group. JAMA Internal Medicine, 2018, 178, 1414.	2.6	0
1235	Management of Pulmonary Hypertension. Heart Failure Clinics, 2018, 14, 545-551.	1.0	4
1236	Switching inhaled iloprost formulations in patients with pulmonary arterial hypertension: the VENTASWITCH Trial. Pulmonary Circulation, 2018, 8, 1-7.	0.8	5
1237	Noninvasive determination of the pulmonary artery input impedance. Medical Hypotheses, 2018, 120, 7-13.	0.8	0
1238	Efficacy and safety of oral targeted therapies in pulmonary arterial hypertension: a metaâ€anᴀlysis of randomized clinical trials. Pulmonary Circulation, 2018, 8, 1-11.	0.8	6
1239	Balloon pulmonary angioplasty â€" efficient therapy of chronic thromboembolic pulmonary hypertension in the patient with advanced sarcoidosis â€" a case report. BMC Pulmonary Medicine, 2018, 18, 139.	0.8	4
1240	Spectral Computed Tomography Angiography With a Gadolinium-based Contrast Agent. Journal of Thoracic Imaging, 2018, 33, 246-253.	0.8	10
1241	Primary and Secondary Pulmonary Hypertension. , 2018, , 285-314.		0
1242	Right Heart Involvement in Hepatic Diseases. , 2018, , 475-488.		0
1243	Chest X-ray in Right Heart Disease. , 2018, , 541-559.		1
1244	Echocardiography of Right Heart. , 2018, , 561-571.		0
1245	Non-recommended dosing of direct oral anticoagulants in the treatment of acute pulmonary embolism is related to an increased rate of adverse events. Journal of Thrombosis and Thrombolysis, 2018, 46, 283-291.	1.0	11
1246	Relevance of the TAPSE/PASP ratio in pulmonary arterial hypertension. International Journal of Cardiology, 2018, 266, 229-235.	0.8	154
1247	Use of TAPSE/PASP ratio in pulmonary arterial hypertension: An easy shortcut in a congested road. International Journal of Cardiology, 2018, 266, 242-244.	0.8	41

#	Article	IF	Citations
1248	Modern treatment to reduce pulmonary arterial pressure in pulmonary arterial hypertension. Journal of Cardiology, 2018, 72, 466-472.	0.8	30
1249	Heart failure with preserved ejection fraction: from mechanisms to therapies. European Heart Journal, 2018, 39, 2780-2792.	1.0	250
1250	A potential therapeutic role for angiotensin-converting enzyme 2 in human pulmonary arterial hypertension. European Respiratory Journal, 2018, 51, 1702638.	3.1	183
1251	Residual pulmonary hypertension after pulmonary endarterectomy: A meta-analysis. Journal of Thoracic and Cardiovascular Surgery, 2018, 156, 1275-1287.	0.4	62
1252	Prognostic relevance of elevated pulmonary arterial pressure assessed non-invasively: Analysis in a large patient cohort with invasive measurements in near temporal proximity. PLoS ONE, 2018, 13, e0191206.	1.1	3
1253	The role of platelets in the development and progression of pulmonary arterial hypertension. Advances in Medical Sciences, 2018, 63, 312-316.	0.9	22
1254	Pulmonary hypertension registry of Kerala, India (PRO-KERALA) â€" Clinical characteristics and practice patterns. International Journal of Cardiology, 2018, 265, 212-217.	0.8	8
1255	Different forms of pulmonary hypertension in a family with clinical and genetic evidence for hereditary hemorrhagic teleangectasia type 2. Pulmonary Circulation, 2018, 8, 1-4.	0.8	4
1256	Chronic thromboembolic pulmonary hypertension after acute pulmonary embolism: to screen or not to screen?. European Respiratory Journal, 2018, 51, 1800440.	3.1	3
1257	Increasing quality of life in pulmonary arterial hypertension: is there a role for nutrition?. Heart Failure Reviews, 2018, 23, 711-722.	1.7	15
1258	Acute hemodynamic changes by breathing hypoxic and hyperoxic gas mixtures in pulmonary arterial and chronic thromboembolic pulmonary hypertension. International Journal of Cardiology, 2018, 270, 262-267.	0.8	30
1259	Neopterin as a Biomarker in Patients with Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension. Respiration, 2018, 96, 222-230.	1.2	12
1260	Defining outcomes following congenital diaphragmatic hernia using standardised clinical assessment and management plan (SCAMP) methodology within the CDH EURO consortium. Pediatric Research, 2018, 84, 181-189.	1.1	48
1261	Pulmonary hypertension in congenital heart disease. Future Cardiology, 2018, 14, 343-353.	0.5	53
1262	Predictors of residual tricuspid regurgitation after percutaneous closure of atrial septal defect. European Heart Journal Cardiovascular Imaging, 2019, 20, 225-232.	0.5	9
1263	Pulmonary Arterial Hypertension: A Case Study in FDA Expedited Program Designations. Therapeutic Innovation and Regulatory Science, 2019, 53, 264-269.	0.8	2
1264	Abnormal Ventilationâ€"Perfusion Scan Is Associated with Pulmonary Hypertension in Sickle Cell Adults. Journal of Nuclear Medicine, 2019, 60, 86-92.	2.8	13
1265	Evolving use of natriuretic peptide receptor type-C as part of strategies for the treatment of pulmonary hypertension due to left ventricle heart failure. International Journal of Cardiology, 2019, 281, 172-178.	0.8	9

#	Article	IF	Citations
1266	Treatment Barriers in Portopulmonary Hypertension. Hepatology, 2019, 69, 431-443.	3.6	34
1267	Health-related quality of life, treatment adherence and psychosocial support in patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension. Chronic Respiratory Disease, 2019, 16, 147997231878790.	1.0	24
1268	Idiopathic hypereosinophilic syndrome with pulmonary hypertension. Pulmonary Circulation, 2019, 9, 1-4.	0.8	0
1269	Platelet and coagulation disorders in newly diagnosed patients with pulmonary arterial hypertension. Platelets, 2019, 30, 646-651.	1.1	18
1270	Prognostic Importance of Increased Right Ventricular Afterload in Orthotopic Liver Transplantation Recipients With Endstage Cirrhosis. Heart Lung and Circulation, 2019, 28, 893-900.	0.2	5
1271	Soporte circulatorio con oxigenador extracorpÃ³reo de membrana durante el embarazo en la enfermedad venooclusiva pulmonar. Revista Espanola De Cardiologia, 2019, 72, 174-175.	0.6	3
1272	Transition from postâ€capillary pulmonary hypertension to combined preâ€and postâ€capillary pulmonary hypertension in swine: a key role for endothelin. Journal of Physiology, 2019, 597, 1157-1173.	1.3	23
1273	Balloon atrial septostomy in severe precapillary pulmonary hypertension: A single-center experience. Hellenic Journal of Cardiology, 2019, 60, 384-386.	0.4	4
1275	Increased Pulmonary-Systemic Pulse Pressure Ratio Is Associated With Increased Mortality in Group 1 Pulmonary Hypertension. Heart Lung and Circulation, 2019, 28, 1059-1066.	0.2	3
1276	Pulmonary arterial hypertension in patient treated for multiple sclerosis with 4â€aminopyridine. Fundamental and Clinical Pharmacology, 2019, 33, 127-129.	1.0	6
1277	Pulmonary arterial stiffness assessed by cardiovascular magnetic resonance imaging is a predictor of mild pulmonary arterial hypertension. International Journal of Cardiovascular Imaging, 2019, 35, 1881-1892.	0.7	26
1278	Pulmonary vascular disease in the setting of heart failure with preserved ejection fraction. Trends in Cardiovascular Medicine, 2019, 29, 207-217.	2.3	20
1279	Pharmacological therapy in adult congenital heart disease: growing need, yet limited evidence. European Heart Journal, 2019, 40, 1049-1056.	1.0	23
1280	Impaired Blood Rheology in Pulmonary Arterial Hypertension. Heart Lung and Circulation, 2019, 28, 1067-1073.	0.2	10
1281	French Society of Cardiology guidelines on exercise tests (part 2): Indications for exercise tests in cardiac diseases. Archives of Cardiovascular Diseases, 2019, 112, 56-66.	0.7	18
1282	Right ventricular function in elite male athletes meeting the structural echocardiographic task force criteria for arrhythmogenic right ventricular cardiomyopathy. Journal of Sports Sciences, 2019, 37, 306-312.	1.0	8
1283	Influence of riociguat treatment on pulmonary arterial hypertension. Herz, 2019, 44, 637-643.	0.4	5
1284	Longâ€term changes of resting and exercise right ventricular systolic performance in patients with chronic thromboembolic pulmonary hypertension following pulmonary thromboendarterectomy â€“ A twoâ€dimensional and threeâ€dimensional echocardiographic study. Echocardiography, 2019, 36, 1656-1665.	0.3	8

#	Article	IF	Citations
1285	Pulmonary arterial hypertension in interferonophaties: a case report and a review of the literature. Pulmonary Circulation, 2019, 9, 1-4.	0.8	9
1286	Sex-specific differences and survival in patients with idiopathic pulmonary arterial hypertension 2008â€“2016. ERJ Open Research, 2019, 5, 00075-2019.	1.1	16
1287	Effect of Transcriptional Regulator ID3 on Pulmonary Arterial Hypertension and Hereditary Hemorrhagic Telangiectasia. International Journal of Vascular Medicine, 2019, 2019, 1-8.	0.4	2
1288	Acute Deterioration of Pulmonary Arterial Hypertension (PAH) in a Patient with Neurofibromatosis Type 1 (NF1). Case Reports in Cardiology, 2019, 2019, 1-4.	0.1	0
1289	Serum uric acid as a marker of disease risk, severity, and survival in systemic sclerosisâ€related pulmonary arterial hypertension. Pulmonary Circulation, 2019, 9, 1-9.	0.8	32
1290	Decrease in Cerebral Oxygen Saturation During the 6-Minute Walk Test in Pediatric Pulmonary Arterial Hypertension. Pediatric Cardiology, 2019, 40, 1494-1502.	0.6	0
1292	Intervening with the Nitric Oxide Pathway to Alleviate Pulmonary Hypertension in Pulmonary Vein Stenosis. Journal of Clinical Medicine, 2019, 8, 1204.	1.0	9
1293	Effect of Combination Therapy of Endothelin Receptor Antagonist and Phosphodiesterase-5 Inhibitor on Clinical Outcome and Pulmonary Haemodynamics in Patients with Pulmonary Arterial Hypertension: A Meta-Analysis. Clinical Drug Investigation, 2019, 39, 1031-1044.	1.1	8
1294	Diastolic Pulmonary Gradient as a Predictor of Right Ventricular Failure After Left Ventricular Assist Device Implantation. Journal of the American Heart Association, 2019, 8, e012073.	1.6	21
1295	Effects of AntagomiRs on Different Lung Diseases in Human, Cellular, and Animal Models. International Journal of Molecular Sciences, 2019, 20, 3938.	1.8	13
1296	Increased prevalence of small airways dysfunction in patients with systemic sclerosis as determined by impulse oscillometry. Rheumatology, 2019, 59, 641-649.	0.9	7
1297	The Right Atrium. , 2019, , 309-322.		0
1298	Pulmonary Pathology in Rheumatic Disease. Clinics in Chest Medicine, 2019, 40, 667-677.	0.8	6
1299	The expression of survivin in irreversible pulmonary arterial hypertension rats and its value in evaluating the reversibility of pulmonary arterial hypertension secondary to congenital heart disease. Pulmonary Circulation, 2019, 9, 204589401985948.	0.8	8
1300	Simplified risk stratification for pulmonary arterial hypertension associated with connective tissue disease. Clinical Rheumatology, 2019, 38, 3619-3626.	1.0	5
1301	Right ventricular dimension index by cardiac magnetic resonance for prognostication in connective tissue diseases and pulmonary hypertension. Rheumatology, 2019, 59, 622-633.	0.9	2
1302	Comparison of Different Methods to Estimate Cardiac Index in Pulmonary Arterial Hypertension. Circulation, 2019, 140, 705-707.	1.6	22
1303	Anti-inflammatory nutrition with high protein attenuates cardiac and skeletal muscle alterations in a pulmonary arterial hypertension model. Scientific Reports, 2019, 9, 10160.	1.6	10

#	Article	IF	Citations
1304	Associations of left ventricular systolic dysfunction with the factors among Thai patients on peritoneal dialysis: a cross-sectional study. BMC Nephrology, 2019, 20, 257.	0.8	6
1305	Systolic Dysfunction in Systemic Sclerosis: Prevalence and Prognostic Implications. ACR Open Rheumatology, 2019, 1, 258-266.	0.9	10
1306	Pulmonary hypertension and valvular heart disease. Herz, 2019, 44, 491-501.	0.4	18
1307	Pulmonary hypertension in HFpEF and HFrEF: Pathophysiology, diagnosis, treatment approaches. Herz, 2019, 44, 483-490.	0.4	13
1308	Â¿Puede causar derrame pleural la insuficiencia cardiaca derecha?. Archivos De Bronconeumologia, 2019, 55, 453-454.	0.4	2
1309	Vena cava backflow and right ventricular stiffness in pulmonary arterial hypertension. European Respiratory Journal, 2019, 54, 1900625.	3.1	25
1310	Exertion during a hypoxia altitude simulation test helps identify potential cardiac decompensation. Respirology Case Reports, 2019, 7, e00450.	0.3	0
1311	Pulmonary Hypertension in Advanced Heart Failure: Assessment and Management of the Failing RV and LV. Current Heart Failure Reports, 2019, 16, 119-129.	1.3	7
1312	Paeonol protects mitochondrial injury and prevents pulmonary vascular remodeling in hypoxia. Respiratory Physiology and Neurobiology, 2019, 268, 103252.	0.7	7
1314	Electrocardiographic Criteria of Right Ventricular Hypertrophy in Patients with Chronic Thromboembolic Pulmonary Hypertension after Balloon Pulmonary Angioplasty. Internal Medicine, 2019, 58, 2139-2144.	0.3	16
1315	Impact of Severe Pulmonary Arterial Hypertension on the Left Heart and Prognostic Implications. Journal of the American Society of Echocardiography, 2019, 32, 1128-1137.	1.2	20
1316	Pulmonary hypertension with dasatinib and other tyrosine kinase inhibitors. Pulmonary Circulation, 2019, 9, 1-6.	0.8	24
1317	Right Heart Catheterization Further Confirms Successful Transition from Parenteral Prostanoid to Oral Selexipag. Archivos De Bronconeumologia, 2019, 55, 393-394.	0.4	0
1318	2019 updated consensus statement on the diagnosis and treatment of pediatric pulmonary hypertension: The European Pediatric Pulmonary Vascular Disease Network (EPPVDN), endorsed by AEPC, ESPR and ISHLT. Journal of Heart and Lung Transplantation, 2019, 38, 879-901.	0.3	266
1319	The Clinical Value of Proposed Risk Stratification Tools in Pediatric Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 1312-1315.	2.5	18
1320	Tracking Impact of Interstitial Lung Disease in Systemic Sclerosis in a Complete Nationwide Cohort. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 1258-1266.	2.5	146
1321	HDL Cholesterol as a Marker of Disease Severity and Prognosis in Patients with Pulmonary Arterial Hypertension. International Journal of Molecular Sciences, 2019, 20, 3514.	1.8	17
1322	Cardiac sympathetic dysfunction in pulmonary arterial hypertension: lesson from leftâ€sided heart failure. Pulmonary Circulation, 2019, 9, 1-10.	0.8	13

#	Article	IF	Citations
1323	Vasoreactive Pulmonary Arterial Hypertension Manifesting With Misleading Epileptic Seizure: Diagnostic and Treatment Pitfalls. Frontiers in Pediatrics, 2019, 7, 262.	0.9	1
1324	Assessment of Risk of Disease Progression in Pulmonary Arterial Hypertension: Insights from an International Survey of Clinical Practice. Advances in Therapy, 2019, 36, 2351-2363.	1.3	14
1325	Hepatocyte growth factor plays a particular role in progression of overall cardiac damage in experimental pulmonary hypertension. International Journal of Medical Sciences, 2019, 16, 854-863.	1.1	8
1326	Long-term Prognostic Significance of Admission Tricuspid Regurgitation Pressure Gradient in Hospitalized Patients With Heart Failure With Preserved Ejection Fraction: A Report From the Japanese Real-World Multicenter Registry. Journal of Cardiac Failure, 2019, 25, 978-985.	0.7	12
1327	Quality of life and functional limitations after pulmonary embolism and its prognostic relevance. Journal of Thrombosis and Haemostasis, 2019, 17, 1923-1934.	1.9	39
1329	Orphan drug development: the increasing role of clinical pharmacology. Journal of Pharmacokinetics and Pharmacodynamics, 2019, 46, 395-409.	0.8	12
1330	NPS2390, a selective calcium-sensing receptor antagonist controls the phenotypic modulation of hypoxic human pulmonary arterial smooth muscle cells by regulating autophagy. Journal of Translational Internal Medicine, 2019, 7, 59-68.	1.0	15
1331	Cardiac Changes in Patients on Long-Term Parenteral Nutrition. Nutrients, 2019, 11, 1587.	1.7	3
1332	Efficacy and Safety of the Use of Pulmonary Arterial Hypertension Pharmacotherapy in Patients with Pulmonary Hypertension Secondary to Left Heart Disease: A Systematic Review. Pharmacotherapy, 2019, 39, 929-945.	1.2	9
1333	Circulating Plasma Metabolomic Profiles Differentiate Rodent Models of Pulmonary Hypertension and Idiopathic Pulmonary Arterial Hypertension Patients. American Journal of Hypertension, 2019, 32, 1109-1117.	1.0	15
1334	Usefulness of ventilatory gas analysis for the non-invasive evaluation of the severity of chronic thromboembolic pulmonary hypertension. International Journal of Cardiology, 2019, 296, 149-154.	0.8	3
1335	Irreversible oxidative post-translational modifications in heart disease. Expert Review of Proteomics, 2019, 16, 681-693.	1.3	21
1336	Current organization of specialist pulmonary hypertension clinics: results of an international survey. Pulmonary Circulation, 2019, 9, 204589401985561.	0.8	3
1337	Sensors for detecting pulmonary diseases from exhaled breath. European Respiratory Review, 2019, 28, 190011.	3.0	72
1338	Heart disease and pregnancy: State of the art. Revista Portuguesa De Cardiologia (English Edition), 2019, 38, 373-383.	0.2	4
1339	The left atrial substrate plays a significant role in the development of complex atrial tachycardia in patients with precapillary pulmonary hypertension. BMC Cardiovascular Disorders, 2019, 19, 157.	0.7	11
1340	Patient assessment and selection for pulmonary rehabilitation. Respirology, 2019, 24, 844-853.	1.3	18
1341	Impact of adenotonsilectomy on nasal airflow and pulmonary blood pressure in mouth breathing children. International Journal of Pediatric Otorhinolaryngology, 2019, 125, 82-86.	0.4	11

#	Article	IF	Citations
1342	High rates of medication adherence in patients with pulmonary arterial hypertension: An integrated specialty pharmacy approach. PLoS ONE, 2019, 14, e0217798.	1.1	26
1343	Use of levosimendan in acute and advanced heart failure: short review on available real-world data . Therapeutics and Clinical Risk Management, 2019, Volume 15, 765-772.	0.9	10
1345	Physical activity in incident patients with pulmonary arterial and chronic thromboembolic hypertension. Lung, 2019, 197, 617-625.	1.4	12
1346	Heart rate variability in pulmonary hypertension with and without sleep apnea. Heliyon, 2019, 5, e02034.	1.4	2
1347	Macitentan for the treatment of portopulmonary hypertension (PORTICO): a multicentre, randomised, double-blind, placebo-controlled, phase 4 trial. Lancet Respiratory Medicine,the, 2019, 7, 594-604.	5.2	119
1348	Pulmonary Hypertension and Exercise. Clinics in Chest Medicine, 2019, 40, 459-469.	0.8	10
1349	Prognostic Implications of Baseline Pulmonary Vascular Resistance Determined by Transthoracic Echocardiography Before Transcatheter Aortic Valve Replacement. Journal of the American Society of Echocardiography, 2019, 32, 737-743.e1.	1.2	6
1351	Correlation of gene expression and clinical parameters identifies a set of genes reflecting LV systolic dysfunction and morphological alterations. Physiological Genomics, 2019, 51, 356-367.	1.0	18
1352	Red Cell Distribution Width and Platelet Count as Biomarkers of Pulmonary Arterial Hypertension in Patients with Connective Tissue Disorders. Disease Markers, 2019, 2019, 1-7.	0.6	20
1353	Detection of Pulmonary Hypertension with Systolic Pressure Estimated by Doppler Echocardiography. International Heart Journal, 2019, 60, 836-844.	0.5	13
1354	Prognostic Value of the Echocardiographic Probability of Pulmonary Hypertension in Patients with Acute Decompensated Heart Failure. Journal of Clinical Medicine, 2019, 8, 1684.	1.0	5
1355	Severe pulmonary hypertension and reduced right ventricle systolic function associated with maternal mortality in pregnant uncorrected congenital heart diseases. Pulmonary Circulation, 2019, 9, 1-9.	0.8	15
1356	Predictive Value of Novel Inflammation-Based Biomarkers for Pulmonary Hypertension in the Acute Exacerbation of Chronic Obstructive Pulmonary Disease. Analytical Cellular Pathology, 2019, 2019, 1-9.	0.7	21
1357	Safety and tolerability of macitentan in the management of pulmonary arterial hypertension: an update . Drug, Healthcare and Patient Safety, 2019, Volume 11, 71-85.	1.0	14
1359	Indications for lung transplant referral and listing. Journal of Thoracic Disease, 2019, 11, S1708-S1720.	0.6	15
1360	Prediction of One-Year Mortality Based upon A New Staged Mortality Risk Model in Patients with Aortic Stenosis Undergoing Transcatheter Valve Replacement. Journal of Clinical Medicine, 2019, 8, 1642.	1.0	1
1361	Adaptation and Validation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) for Croatia. Acta Clinica Croatica, 2019, 58, 3-12.	0.1	14
1362	Comparison of Pulmonary Artery Pressure Measurement With Doppler Echocardiography or With Right Heart Catheterization in Patients With Congenital Heart Disease. Frontiers in Pediatrics, 2019, 7, 421.	0.9	4

#	Article	IF	Citations
1363	Dopplerâ€Derived Renal Venous Stasis Index in the Prognosis of Right Heart Failure. Journal of the American Heart Association, 2019, 8, e013584.	1.6	66
1364	Echocardiographic features of Fabry cardiomyopathyâ€"Comparison with hypertrophyâ€matched sarcomeric hypertrophic cardiomyopathy. Echocardiography, 2019, 36, 2041-2049.	0.3	8
1365	Thyroid Dysfunction in Patients with Pulmonary Artery Hypertension (PAH): The Effect of Therapies Affecting the Prostanoid Pathway. Lung, 2019, 197, 761-768.	1.4	7
1366	Monocrotaline-induced pulmonary arterial hypertension: Time-course of injury and comparative evaluation of macitentan and Y-27632, a Rho kinase inhibitor. European Journal of Pharmacology, 2019, 865, 172777.	1.7	11
1367	Evaluating heart function in patients with POEMS syndrome. Echocardiography, 2019, 36, 1997-2003.	0.3	3
1368	Diagnostic and Prognostic Significance of Serum Levels of SeP (Selenoprotein P) in Patients With Pulmonary Hypertension. Arteriosclerosis, Thrombosis, and Vascular Biology, 2019, 39, 2553-2562.	1.1	12
1370	Novel EIF2AK4 mutations in histologically proven pulmonary capillary hemangiomatosis and hereditary pulmonary arterial hypertension. BMC Medical Genetics, 2019, 20, 176.	2.1	8
1371	Left Ventricular Morphology and Function as a Determinant of Pulmonary Hypertension in Patients with Severe Aortic Stenosis: Cardiovascular Magnetic Resonance Imaging Study. Medicina (Lithuania), 2019, 55, 711.	0.8	3
1372	Targeting the endothelin system: a step towards a precision medicine approach in heart failure with preserved ejection fraction?. European Heart Journal, 2019, 40, 3718-3720.	1.0	8
1373	Pulmonary Hypertension and Thoracic Surgery: Impact and Treatment Options. Current Anesthesiology Reports, 2019, 9, 436-445.	0.9	1
1374	Comparison of 4D Flow MRI to 2D Flow MRI in the pulmonary arteries in healthy volunteers and patients with pulmonary hypertension. PLoS ONE, 2019, 14, e0224121.	1.1	25
1375	Can Right Heart Failure Cause Pleural Effusion?. Archivos De Bronconeumologia, 2019, 55, 453-454.	0.4	2
1376	Longitudinal clinical outcomes in a real-world population of patients with idiopathic pulmonary fibrosis: the PROOF registry. Respiratory Research, 2019, 20, 231.	1.4	18
1377	Early treatment with ambrisentan of mildly elevated mean pulmonary arterial pressure associated with systemic sclerosis: a randomized, controlled, double-blind, parallel group study (EDITA study). Arthritis Research and Therapy, 2019, 21, 217.	1.6	34
1378	A machine learning approach for the prediction of pulmonary hypertension. PLoS ONE, 2019, 14, e0224453.	1.1	49
1379	Management of acutely decompensated chronic thromboembolic pulmonary hypertension in late pregnancy: a case report. BMC Pregnancy and Childbirth, 2019, 19, 365.	0.9	7
1380	MiRNA let-7b promotes the development of hypoxic pulmonary hypertension by targeting ACE2. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2019, 316, L547-L557.	1.3	53
1382	Identifying chronic thromboembolic pulmonary hypertension through the French national hospital discharge database. PLoS ONE, 2019, 14, e0214649.	1.1	11

#	Article	IF	Citations
1383	6-minute walking test: a useful tool in the management of heart failure patients. Therapeutic Advances in Cardiovascular Disease, 2019, 13, 175394471987008.	1.0	156
1384	Hypoxic Pulmonary Vasoconstriction and the Diffusing Capacity in Pulmonary Hypertension Secondary to Idiopathic Pulmonary Fibrosis. Journal of the American Heart Association, 2019, 8, e013310.	1.6	11
1386	Pulmonary Arterial Hypertension and Therapeutic Interventions. International Journal of Angiology, 2019, 28, 080-092.	0.2	4
1387	Differentiating Precapillary From Postcapillary Pulmonary Hypertension. Circulation, 2019, 140, 712-714.	1.6	32
1388	Right Heart Catheterizationâ€"Background, Physiological Basics, and Clinical Implications. Journal of Clinical Medicine, 2019, 8, 1331.	1.0	28
1389	Effect of beraprost on pulmonary hypertension due to left ventricular systolic dysfunction. Medicine (United States), 2019, 98, e14965.	0.4	4
1390	Pulmonary Artery Denervation: Update on Clinical Studies. Current Cardiology Reports, 2019, 21, 124.	1.3	11
1391	Clinical Value of Asymmetrical Dimethylarginine Detection in Patients with Connective Tissue Disease-Associated Pulmonary Arterial Hypertension. Cardiology Research and Practice, 2019, 2019, 1-8.	0.5	7
1392	Selexipag in the management of pulmonary arterial hypertension: an update . Drug, Healthcare and Patient Safety, 2019, Volume 11, 55-64.	1.0	8
1393	Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension: Initial Single-Center Experience. Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2019, 3, 311-318.	1.2	29
1395	2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). European Respiratory Journal, 2019, 54, 1901647.	3.1	806
1396	Disability and its clinical correlates in pulmonary hypertension measured through the World Health Organization Disability Assessment Schedule 2.0: a prospective, observational study. Jornal Brasileiro De Pneumologia, 2019, 45, e20170355.	0.4	2
1397	Can intestinal microbiota and circulating microbial products contribute to pulmonary arterial hypertension?. American Journal of Physiology - Heart and Circulatory Physiology, 2019, 317, H1093-H1101.	1.5	26
1398	ALDH2 (Aldehyde Dehydrogenase 2) Protects Against Hypoxia-Induced Pulmonary Hypertension. Arteriosclerosis, Thrombosis, and Vascular Biology, 2019, 39, 2303-2319.	1.1	51
1399	Hospital burden of pulmonary arterial hypertension in France. PLoS ONE, 2019, 14, e0221211.	1.1	9
1400	Twelve-Year Survival in a Patient With Systemic Sclerosisâ€"Associated Pulmonary Arterial Hypertension on Nifedipine Monotherapy. Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2019, 3, 376-379.	1.2	1
1401	Non-traditional exercises in rehabilitation programmes for symptomatic patients with peripheral artery disease. European Journal of Preventive Cardiology, 2019, 26, 1623-1624.	0.8	0
1402	Endothelin 1 Is Associated with Heart Failure Hospitalization and Long-Term Mortality in Patients with Heart Failure with Preserved Ejection Fraction and Pulmonary Hypertension. Cardiology, 2019, 143, 124-133.	0.6	20

#	Article	IF	Citations
1403	Clinical outcomes stratified by baseline functional class after initial combination therapy for pulmonary arterial hypertension. Respiratory Research, 2019, 20, 208.	1.4	16
1404	The Fibrosis-4 Index Is Useful for Predicting Mortality in Patients with Pulmonary Hypertension due to Left Heart Disease. International Heart Journal, 2019, 60, 1147-1153.	0.5	7
1405	Optimizing the Personalized, Risk-Adjusted Management of Pulmonary Embolism: An Integrated Clinical Trial Programme. Hamostaseologie, 2019, 39, 117-127.	0.9	4
1406	A Retrospective Analysis of Adherence to Risk Evaluation and Mitigation Strategies Requirements for Pulmonary Arterial Hypertension Drugs. Hospital Pharmacy, 2019, 54, 309-313.	0.4	5
1407	Assessing pulmonary hypertension in COPD. Is there a role for computed tomography? . International Journal of COPD, 2019, Volume 14, 2065-2079.	0.9	13
1408	The Prognostic Value of Soluble ST2 in Adults with Pulmonary Hypertension. Journal of Clinical Medicine, 2019, 8, 1517.	1.0	14
1409	Recommendations from the Association for European Paediatric and Congenital Cardiology for training in pulmonary hypertension. Cardiology in the Young, 2019, 29, 1323-1327.	0.4	5
1410	Advances in Management of Pulmonary Hypertension Associated with Systemic Sclerosis. , 2019, , .		1
1411	Patients with pulmonary arterial hypertension with and without cardiovascular risk factors: Results from the AMBITION trial. Journal of Heart and Lung Transplantation, 2019, 38, 1286-1295.	0.3	62
1412	Bosentan or Macitentan Therapy in Chronic Thromboembolic Pulmonary Hypertension?. Lung, 2019, 197, 753-760.	1.4	7
1413	LncRNA Tug1 involves in the pulmonary vascular remodeling in mice with hypoxic pulmonary hypertension via the microRNA-374c-mediated Foxc1. Life Sciences, 2019, 237, 116769.	2.0	45
1414	The FGL2 prothrombinase contributes to the pathological process of experimental pulmonary hypertension. Journal of Applied Physiology, 2019, 127, 1677-1687.	1.2	12
1415	Safety and Efficacy of Ambrisentanâ€“Phosphodiesterase Type 5 (PDE5) Inhibitor Combination Therapy for Japanese Pulmonary Arterial Hypertension Patients in Real-World Clinical Practice. Circulation Reports, 2019, 1, 268-275.	0.4	2
1416	Treprostinil for the treatment of chronic thromboembolic pulmonary hypertension. Expert Review of Respiratory Medicine, 2019, 13, 807-813.	1.0	1
1417	Diagnostic accuracy of lung ultrasound for identification of elevated left ventricular filling pressure. International Journal of Cardiology, 2019, 281, 62-68.	0.8	35
1418	A Combined Targeted and Whole Exome Sequencing Approach Identified Novel Candidate Genes Involved in Heritable Pulmonary Arterial Hypertension. Scientific Reports, 2019, 9, 753.	1.6	24
1419	Sildenafil for Pulmonary Hypertension in the Early Postoperative Period After Mitral Valve Surgery. Journal of Cardiothoracic and Vascular Anesthesia, 2019, 33, 1648-1656.	0.6	11
1420	The association of estimated whole blood viscosity with hemodynamic parameters and prognosis in patients with heart failure. Biomarkers in Medicine, 2019, 13, 69-82.	0.6	9

#	Article	IF	Citations
1421	Diagnosis and treatment of pediatric pulmonary arterial hypertension. Expert Review of Cardiovascular Therapy, 2019, 17, 161-175.	0.6	8
1422	Exercise cardiovascular magnetic resonance imaging allows differentiation of low-risk pulmonary arterial hypertension. Journal of Heart and Lung Transplantation, 2019, 38, 627-635.	0.3	10
1423	Interstitial lung disease associated with systemic sclerosis (SSc-ILD). Respiratory Research, 2019, 20, 13.	1.4	160
1424	Echocardiographic evaluation of left ventricular filling pressures in patients with pulmonary hypertension. International Journal of Cardiovascular Imaging, 2019, 35, 861-868.	0.7	6
1425	Development of best practice recommendations for the safe use of pulmonary hypertension pharmacotherapies using a modified Delphi method. American Journal of Health-System Pharmacy, 2019, 76, 153-165.	0.5	8
1426	Pulmonary arterial hypertension in connective tissue disorders: Pathophysiology and treatment. Experimental Biology and Medicine, 2019, 244, 120-131.	1.1	41
1427	Deciphering the Potential Pharmaceutical Mechanism of GUI-ZHI-FU-LING-WAN on Systemic Sclerosis based on Systems Biology Approaches. Scientific Reports, 2019, 9, 355.	1.6	13
1428	Fatal rightâ€sided heart failure due to leukostasis in a patient with leukemic transformation of myelodysplastic syndrome. Clinical Case Reports (discontinued), 2019, 7, 115-119.	0.2	3
1429	SEOM clinical guidelines on cardiovascular toxicity (2018). Clinical and Translational Oncology, 2019, 21, 94-105.	1.2	20
1430	Prognostic impact of chronic obstructive pulmonary disease on adverse prognosis in hospitalized heart failure patients with preserved ejection fraction â€“ A report from the JASPER registry. Journal of Cardiology, 2019, 73, 459-465.	0.8	19
1431	Pulmonary Artery Denervation Significantly Increases 6-Min Walk Distance for Patients With Combined Pre- and Post-Capillary Pulmonary Hypertension AssociatedÂWithÂLeft HeartÂFailure. JACC: Cardiovascular Interventions, 2019, 12, 274-284.	1.1	65
1432	Golden Ratio and the Proportionality Between Pulmonary Pressure Components in Pulmonary Arterial Hypertension. Chest, 2019, 155, 991-998.	0.4	13
1433	Pulmonary Artery Denervation. JACC: Cardiovascular Interventions, 2019, 12, 285-288.	1.1	6
1434	Realâ€life data on Selexipag for the treatment of pulmonary hypertension. Pulmonary Circulation, 2019, 9, 1-8.	0.8	11
1435	Beneficial Effects of Imatinib in a Patient with Suspected Pulmonary Veno-Occlusive Disease. Tohoku Journal of Experimental Medicine, 2019, 247, 69-73.	0.5	11
1436	Imaging of Pulmonary Artery. , 2019, , 235-267.		0
1437	Aortic stenosis prognosis in older patients: frailty is a strong marker of early congestive heart failure admissions. European Geriatric Medicine, 2019, 10, 483-491.	1.2	3
1438	Initial experience in children with the use of macitentan in pulmonary arterial hypertension after side effects with other endothelin receptor antagonists. Progress in Pediatric Cardiology, 2019, 52, 55-56.	0.2	3

#	Article	IF	Citations
1439	The ADAMTS13â€“VWF axis is dysregulated in chronic thromboembolic pulmonary hypertension. European Respiratory Journal, 2019, 53, 1801805.	3.1	31
1440	Risk classification of pulmonary arterial hypertension by echocardiographic combined assessment of pulmonary vascular resistance and right ventricular function. Heart and Vessels, 2019, 34, 1789-1800.	0.5	5
1441	Evaluating the extent of patient-centred care in a selection of ESC guidelines. European Heart Journal Quality of Care & Clinical Outcomes, 2019, 6, 55-61.	1.8	4
1442	Integrating Data From Randomized Controlled Trials and Observational Studies to Assess Survival in Rare Diseases. Circulation: Cardiovascular Quality and Outcomes, 2019, 12, e005095.	0.9	8
1443	Baseline history of patients using selexipag for pulmonary arterial hypertension. Therapeutic Advances in Respiratory Disease, 2019, 13, 175346661984377.	1.0	4
1444	Threshold of Pulmonary Hypertension Associated With Increased Mortality. Journal of the American College of Cardiology, 2019, 73, 2660-2672.	1.2	80
1445	Pulmonary hypertension in patients with a subaortic right ventricle: prevalence, impact and management. Heart, 2019, 105, 1471-1478.	1.2	20
1446	Automatic quantitative analysis of pulmonary vascular morphology in CT images. Medical Physics, 2019, 46, 3985-3997.	1.6	12
1447	Efficacy and Safety of Udenafil for the Treatment of Pulmonary Arterial Hypertension: a Placebo-controlled, Double-blind, Phase IIb Clinical Trial. Clinical Therapeutics, 2019, 41, 1499-1507.	1.1	13
1448	Eisenmenger syndrome and other types of pulmonary arterial hypertension related to adult congenital heart disease. Expert Review of Cardiovascular Therapy, 2019, 17, 449-459.	0.6	13
1449	A focus on riociguat in the treatment of pulmonary arterial hypertension. Basic and Clinical Pharmacology and Toxicology, 2019, 125, 202-214.	1.2	16
1450	miRNA-PDGFRB/HIF1A-lncRNA CTEPHA1 Network Plays Important Roles in the Mechanism of Chronic Thromboembolic Pulmonary Hypertension. International Heart Journal, 2019, 60, 924-937.	0.5	13
1451	Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations. European Journal of Heart Failure, 2019, 21, 715-731.	2.9	446
1452	Doppler estimates of pulmonary vascular resistance to phenotype pulmonary hypertension in heart failure. International Journal of Cardiovascular Imaging, 2019, 35, 1465-1472.	0.7	7
1453	Cardiopatia e gravidez â€“ o estado da arte. Revista Portuguesa De Cardiologia, 2019, 38, 373-383.	0.2	6
1454	Analysis of Biphasic Right Ventricular Outflow Doppler Waveform in Patients with Pulmonary Hypertension. International Heart Journal, 2019, 60, 108-114.	0.5	1
1455	Imaging for screening cardiovascular involvement in patients with systemic rheumatologic diseases: more questions than answers. European Heart Journal Cardiovascular Imaging, 2019, 20, 967-978.	0.5	8
1456	Oral treprostinil use in children: a multicenter, observational experience. Pulmonary Circulation, 2019, 9, 204589401986213.	0.8	11

#	Article	IF	Citations
1457	Balloon Pulmonary Angioplasty in Patients With Chronic Thromboembolic Pulmonary Hypertensionã€€â€• A Systematic Review and Meta-Analysis â€•. Circulation Journal, 2019, 83, 1660-1667.	0.7	34
1458	Simple and noninvasive method to estimate right ventricular operating stiffness based on echocardiographic pulmonary regurgitant velocity and tricuspid annular plane movement measurements during atrial contraction. International Journal of Cardiovascular Imaging, 2019, 35, 1871-1880.	0.7	3
1459	Mean platelet volume as a predictor of pulmonary hypertension in patients with stable COPD . International Journal of COPD, 2019, Volume 14, 1099-1108.	0.9	13
1460	The impact of left ventricular ejection fraction on heart failure patients with pulmonary hypertension. Heart and Lung: Journal of Acute and Critical Care, 2019, 48, 502-506.	0.8	1
1461	The additive value of echocardiographic pulmonary to left atrial global strain ratio in the diagnosis of pulmonary hypertension. International Journal of Cardiology, 2019, 292, 205-210.	0.8	8
1462	Pulmonary Hypertension Due to Left Heart Disease: an Update. Current Cardiology Reports, 2019, 21, 62.	1.3	13
1463	Lung Disease in Antiphospholipid Syndrome. Seminars in Respiratory and Critical Care Medicine, 2019, 40, 278-294.	0.8	10
1464	Compromised left atrial function and increased size predict raised cavity pressure: a systematic review and metaâ€•analysis. Clinical Physiology and Functional Imaging, 2019, 39, 297-307.	0.5	18
1465	Intravenous treprostinil as an add-on therapy in patients with pulmonary arterial hypertension. Journal of Heart and Lung Transplantation, 2019, 38, 748-756.	0.3	29
1466	The utility of point-of-care ultrasound right-sided cardiac markers as a screening test for moderate to severe pulmonary hypertension in dogs. Veterinary Journal, 2019, 250, 6-13.	0.6	18
1467	Acute vasoreactivity testing in pediatric idiopathic pulmonary arterial hypertension: an international survey on current practice. Pulmonary Circulation, 2019, 9, 1-9.	0.8	7
1468	Cost savings with a novel algorithm for early detection of systemic sclerosisâ€•related pulmonary arterial hypertension: alternative scenario analyses. Internal Medicine Journal, 2019, 49, 781-785.	0.5	4
1469	Asymmetric Dimethylarginine at Sea Level Is a Predictive Marker of Hypoxic Pulmonary Arterial Hypertension at High Altitude. Frontiers in Physiology, 2019, 10, 651.	1.3	20
1470	Computed tomographic and clinical features of pulmonary veno-occlusive disease: raising the radiologist's awareness. Clinical Radiology, 2019, 74, 655-662.	0.5	14
1471	The natural matching of harmonic responses in the pulmonary circulation. Journal of Physiology, 2019, 597, 3853-3865.	1.3	4
1472	Challenges in pulmonary hypertension associated with left heart disease. Expert Review of Cardiovascular Therapy, 2019, 17, 461-472.	0.6	2
1473	Preimplant Phosphodiesterase-5 Inhibitor Use Is Associated With Higher Rates of Severe Early Right Heart Failure After Left Ventricular Assist Device Implantation. Circulation: Heart Failure, 2019, 12, e005537.	1.6	38
1474	A Change in Focus. Circulation: Cardiovascular Imaging, 2019, 12, e009186.	1.3	1

#	Article	IF	Citations
1475	Transection of the cervical sympathetic trunk inhibits the progression of pulmonary arterial hypertension via ERK-1/2 Signalling. Respiratory Research, 2019, 20, 121.	1.4	12
1476	Pulmonary Vascular Dynamics. , 2019, 9, 1081-1100.		5
1477	Use of direct oral anticoagulants prevents increase in pulmonary vascular resistance and incidence of clinical worsening in patients with chronic thromboembolic pulmonary hypertension. Thrombosis Research, 2019, 180, 43-46.	0.8	10
1478	Pulmonary tumor thrombotic microangiopathy: a systematic review. Pulmonary Circulation, 2019, 9, 1-13.	0.8	65
1479	COPD and heart failure: differential diagnosis and comorbidity. Herz, 2019, 44, 502-508.	0.4	25
1480	Medical Therapy for Heart Failure Associated With Pulmonary Hypertension. Circulation Research, 2019, 124, 1551-1567.	2.0	45
1481	A Phase I Study to Show the Relative Bioavailability and Bioequivalence of Fixed-Dose Combinations of Ambrisentan and Tadalafil in Healthy Subjects. Clinical Therapeutics, 2019, 41, 1110-1127.	1.1	1
1482	Balloon pulmonary angioplasty for symptomatic chronic thromboembolic disease without pulmonary hypertension at rest. International Journal of Cardiology, 2019, 289, 116-118.	0.8	48
1483	Triglyceride-to-High-Density Lipoprotein Cholesterol Ratio and Systemic Inflammation in Patients with Idiopathic Pulmonary Arterial Hypertension. Medical Science Monitor, 2019, 25, 746-753.	0.5	18
1484	Effect of domiciliary oxygen therapy on exercise capacity and quality of life in patients with pulmonary arterial or chronic thromboembolic pulmonary hypertension: a randomised, placebo-controlled trial. European Respiratory Journal, 2019, 54, 1900276.	3.1	26
1485	Reduced peripheral blood superoxide dismutase 2 expression in sickle cell disease. Annals of Hematology, 2019, 98, 1561-1572.	0.8	10
1486	Impact of Pulmonary Artery-to-Aorta Ratio by CT on the Clinical Outcome in Heart Failure. Journal of Cardiac Failure, 2019, 25, 886-893.	0.7	5
1487	Immunotherapy of Endothelin-1 Receptor Type A for Pulmonary Arterial Hypertension. Journal of the American College of Cardiology, 2019, 73, 2567-2580.	1.2	38
1488	Balloon Pulmonary Angioplasty (Percutaneous Transluminal PulmonaryÂAngioplasty) for ChronicÂThromboembolic PulmonaryÂHypertension. JACC: Cardiovascular Interventions, 2019, 12, 1382-1388.	1.1	67
1489	Advanced Pulmonary Hypertension Due to Congenital Double-shunt Successfully Treated with Surgical Repair and Up-front Combination Therapy. Internal Medicine, 2019, 58, 1301-1305.	0.3	0
1490	Pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension incidence in Latvia in 2018. European Journal of Internal Medicine, 2019, 65, e9-e10.	1.0	5
1491	Evaluating a strategy of PAH therapy pre-treatment in patients with atrial septal defects and pulmonary arterial hypertension to permit safe repair (â€œtreat-and-repairâ€). International Journal of Cardiology, 2019, 291, 142-144.	0.8	10
1493	Prognostic value and diagnostic properties of the diastolic pulmonary pressure gradient in patients with pulmonary hypertension and left heart disease. International Journal of Cardiology, 2019, 290, 138-143.	0.8	12

#	Article	IF	Citations
1494	Chronic obstructive pulmonary disease and the early stage of cor pulmonale: A perspective in treatment with pulmonary arterial hypertension-approved drugs. Respiratory Investigation, 2019, 57, 325-329.	0.9	13
1496	Pulmonary Hypertension Parameters Assessment by Electrocardiographically Gated Computed Tomography. Journal of Thoracic Imaging, 2019, 34, 329-337.	0.8	8
1497	Impaired Cardiovascular Magnetic Resonanceâ€“Derived Rapid Semiautomated Right Atrial Longitudinal Strain Is Associated With Decompensated Hemodynamics in Pulmonary Arterial Hypertension. Circulation: Cardiovascular Imaging, 2019, 12, e008582.	1.3	48
1498	Restrictive atrial communication in right and left heart failure. Translational Pediatrics, 2019, 8, 133-139.	0.5	8
1499	Imaging of Pulmonary Hypertension. Chest, 2019, 156, 211-227.	0.4	33
1500	Use of Cardiac Imaging to Evaluate Cardiac Function and Pulmonary Hemodynamics in Patients with Heart Failure. Current Cardiology Reports, 2019, 21, 53.	1.3	2
1501	Noninvasive estimation of pulmonary vascular resistance improves portopulmonary hypertension screening in liver transplant candidates. Clinical Transplantation, 2019, 33, e13585.	0.8	8
1502	Pulmonary hypertension and right ventricular function in Nigerian children with sickle cell anaemia. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2019, 113, 489-496.	0.7	1
1503	Clinical characteristics of pulmonary hypertension patients living in plain and highâ€altitude regions. Clinical Respiratory Journal, 2019, 13, 485-492.	0.6	8
1504	Temporal shifts in fluid in pulmonary hypertension with and without sleep apnea. Journal of Sleep Research, 2019, 28, e12863.	1.7	4
1505	Opposite alterations of endothelin-1 in lung and pulmonary artery mirror gene expression of bone morphogenetic protein receptor 2 in experimental pulmonary hypertension. Experimental Lung Research, 2019, 45, 30-41.	0.5	4
1506	Analysis of pulmonary hypertension patient survival after treatment in referral center (data of first) Tj ETQq1 1 0.784314 rgBT /Overlo	0.8	9
1507	The incremental shuttle walk test predicts mortality in nonâ€group 1 pulmonary hypertension: results from the ASPIRE Registry. Pulmonary Circulation, 2019, 9, 1-9.	0.8	7
1508	Riociguat for the treatment of transthyretin cardiac amyloidosis: data from a named patient use program in Austria. Pulmonary Circulation, 2019, 9, 1-9.	0.8	1
1509	Use of Balloon Atrial Septostomy in Patients With Advanced Pulmonary Arterial Hypertension. Chest, 2019, 156, 53-63.	0.4	42
1510	Pulmonary vasculitis mimicking chronic thromboembolic disease. BMJ Case Reports, 2019, 12, e228409.	0.2	3
1511	Setting the international standard for longitudinal follow-up of patients with systemic sclerosis: a Delphi-based expert consensus on core clinical features. RMD Open, 2019, 5, e000826.	1.8	35
1512	Will Pulmonary Artery Denervation Really Have a Place in the Armamentarium of the Pulmonary Hypertension Specialist?. JACC: Cardiovascular Interventions, 2019, 12, 799-800.	1.1	2

#	Article	IF	Citations
1513	Incidence and prognosis of heart failure in persons with type 2 diabetes compared with individuals without diabetes â€“ a nation-wide study from Finland in 1996â€“2012. Annals of Medicine, 2019, 51, 174-181.	1.5	5
1514	State of the art: utility of multi-energy CT in the evaluation of pulmonary vasculature. International Journal of Cardiovascular Imaging, 2019, 35, 1509-1524.	0.7	19
1515	â€œTreat-to-closeâ€• Non-repairable ASD-PAH in the adult. International Journal of Cardiology, 2019, 291, 127-133.	0.8	35
1516	Sildenafil enhances central hemodynamic responses to exercise, but not V̀Ì‡<scp>o</scp>_{2peak}, in people with diabetes mellitus. Journal of Applied Physiology, 2019, 127, 1-10.	1.2	1
1517	Function of Adipose-Derived Mesenchymal Stem Cells in Monocrotaline-Induced Pulmonary Arterial Hypertension through miR-191 via Regulation of BMPR2. BioMed Research International, 2019, 2019, 1-12.	0.9	17
1518	Pulmonary hypertension subjects exhibit right ventricular transient exertional dilation during supine exercise stress echocardiography. Pulmonary Circulation, 2019, 9, 1-10.	0.8	7
1519	Intravascular B-cell lymphoma: case report of a rare cause of pulmonary arterial hypertension. European Heart Journal - Case Reports, 2019, 3, yty150.	0.3	2
1520	Pulmonary Hypertension in Children with Sickle Cell Disease: a Review of the Current Literature. Current Pediatrics Reports, 2019, 7, 33-44.	1.7	0
1521	Right atrial function for the prediction of prognosis in connective tissue disease-associated pulmonary arterial hypertension: a study with two-dimensional speckle tracking. International Journal of Cardiovascular Imaging, 2019, 35, 1637-1649.	0.7	9
1522	Advances in targeted therapy for chronic thromboembolic pulmonary hypertension. Heart Failure Reviews, 2019, 24, 949-965.	1.7	15
1523	Echocardiographic assessment of pulmonary arterial stiffness in human immunodeficiency virusâ€infected patients. Echocardiography, 2019, 36, 1123-1131.	0.3	14
1524	Right ventricular function after cardiac surgery: the diagnostic and prognostic role of echocardiography. Heart Failure Reviews, 2019, 24, 625-635.	1.7	39
1525	A Concerning Trend for Patients With Pulmonary Hypertension in the Era of Evidence-Based Medicine. Circulation, 2019, 139, 1861-1864.	1.6	23
1526	Laparoscopic Rectopexy in a Patient With Pulmonary Hypertension Associated With Scleroderma: A Case Report. A&A Practice, 2019, 12, 313-316.	0.2	1
1527	Energy Metabolism in the Failing Right Ventricle: Limitations of Oxygen Delivery and the Creatine Kinase System. International Journal of Molecular Sciences, 2019, 20, 1805.	1.8	13
1528	Guidelines and Recommendations Towards Evidence-Based Management of Systemic Sclerosis. Current Treatment Options in Rheumatology, 2019, 5, 115-126.	0.6	1
1529	The Use of Risk Assessment Tools and Prognostic Scores in Managing Patients with Pulmonary Arterial Hypertension. Current Hypertension Reports, 2019, 21, 45.	1.5	20
1530	Silibinin efficacy in a rat model of pulmonary arterial hypertension using monocrotaline and chronic hypoxia. Respiratory Research, 2019, 20, 79.	1.4	17

#	Article	IF	Citations
1531	Balloon pulmonary angioplasty attenuates sleep apnea in patients with chronic thromboembolic pulmonary hypertension. Heart and Lung: Journal of Acute and Critical Care, 2019, 48, 321-324.	0.8	3
1532	Development of renal function during staged balloon pulmonary angioplasty for inoperable chronic thromboembolic pulmonary hypertension. Scandinavian Journal of Clinical and Laboratory Investigation, 2019, 79, 268-275.	0.6	16
1533	Endothelialâ€"Mesenchymal Transition Drives Expression of CD44 Variant and xCT in Pulmonary Hypertension. American Journal of Respiratory Cell and Molecular Biology, 2019, 61, 367-379.	1.4	27
1534	Association of PET-measured myocardial flow reserve with echocardiography-estimated pulmonary artery systolic pressure in patients with hypertrophic cardiomyopathy. PLoS ONE, 2019, 14, e0212573.	1.1	3
1535	Hemodynamic Evaluation and Echocardiography in the Oncologic Intensive Care Unit. , 2019, , 1-21.		0
1536	Pulmonary Arterial Hypertension in HIV. , 2019, , 159-170.		0
1537	The Critically Ill Pregnant ACHD Patient. Congenital Heart Disease in Adolescents and Adults, 2019, , 337-358.	0.2	1
1538	Pulmonary Hypertension in an Oncologic Intensive Care Unit. , 2019, , 1-23.		0
1539	Diagnosis of pulmonary hypertension using spectral-detector CT. International Journal of Cardiology, 2019, 285, 80-85.	0.8	14
1540	Imaging Risk in Multisystem Inflammatory Diseases. JACC: Cardiovascular Imaging, 2019, 12, 2517-2537.	2.3	11
1541	The Creation of an Interatrial Right-To-Left Shunt in Patients with Severe, Irreversible Pulmonary Hypertension: Rationale, Devices, Outcomes. Current Cardiology Reports, 2019, 21, 31.	1.3	15
1542	Pulmonary hypertension in left heart disease: The need to continue to explore. International Journal of Cardiology, 2019, 288, 132-134.	0.8	3
1543	Long-term clinical value and outcome of riociguat in chronic thromboembolic pulmonary hypertension. IJC Heart and Vasculature, 2019, 22, 163-168.	0.6	23
1544	Biomarkers in clinical management of pulmonary hypertension: has the emperor no clothes? A call for action. Biomarkers in Medicine, 2019, 13, 235-238.	0.6	4
1545	Udenafil as a Therapeutic Option for Pulmonary Arterial Hypertension. Korean Circulation Journal, 2019, 49, 361.	0.7	2
1546	Physical activity and quality of life in patients with pulmonary hypertension. European Respiratory Journal, 2019, 53, 1900028.	3.1	9
1547	Echocardiography in Pulmonary Arterial Hypertension. Current Cardiology Reports, 2019, 21, 22.	1.3	15
1548	Mid-term outcome of severe tricuspid regurgitation: are there any differences according to mechanism and severity?. European Heart Journal Cardiovascular Imaging, 2019, 20, 1035-1042.	0.5	66

#	Article	IF	Citations
1549	Pulmonary Circulation. Lessons From the ICU, 2019, , 49-64.	0.1	0
1550	Differences in pulmonary arterial flow hemodynamics between children and adults with pulmonary arterial hypertension as assessed by 4D-flow CMR studies. American Journal of Physiology - Heart and Circulatory Physiology, 2019, 316, H1091-H1104.	1.5	20
1551	Commentary: Chronic thromboembolic pulmonary hypertension in Austria and Japan: The Sound of Music meets Madame Butterfly. Journal of Thoracic and Cardiovascular Surgery, 2019, 158, 615-616.	0.4	0
1552	Key inflammatory pathways underlying vascular remodeling in pulmonary hypertension. Herz, 2019, 44, 130-137.	0.4	13
1553	The feasibility and clinical implication of tricuspid regurgitant velocity and pulmonary flow acceleration time evaluation for pulmonary pressure assessment during exercise stress echocardiography. European Heart Journal Cardiovascular Imaging, 2019, 20, 1027-1034.	0.5	24
1554	Muscular and extramuscular features of myositis patients with anti-U1-RNP autoantibodies. Neurology, 2019, 92, e1416-e1426.	1.5	36
1555	Combination Therapy of Pulmonary Arterial Hypertension with Vardenafil and Macitentan Assessed in a Human Ex Vivo Model. Cardiovascular Drugs and Therapy, 2019, 33, 287-295.	1.3	3
1556	Noninvasive Cardiovascular Imaging: Emergence of a Powerful Tool for Early Identification of Cardiovascular Risk in People Living With HIV. Canadian Journal of Cardiology, 2019, 35, 260-269.	0.8	6
1557	Right Ventricular Size and Function in Chronic Heart Failure. Heart Failure Clinics, 2019, 15, 205-217.	1.0	8
1558	The Use of Transthoracic Echocardiogram to Quantify Pulmonary Vascular Resistance in Patients with Systemic Sclerosis. Journal of Rheumatology, 2019, 46, 1495-1501.	1.0	0
1559	Right ventricular basal inflow and outflow tract diameters overestimate right ventricular size in subjects with sigmoid-shaped interventricular septum: a study using three-dimensional echocardiography. International Journal of Cardiovascular Imaging, 2019, 35, 1211-1219.	0.7	4
1560	The complexity of pulmonary hypertension. Hemodialysis International, 2019, 23, 287-287.	0.4	0
1561	Management of Pulmonary Arterial Hypertension in the ICU. Journal of Pharmacy Practice, 2019, 32, 303-313.	0.5	8
1562	Statement on imaging and pulmonary hypertension from the Pulmonary Vascular Research Institute (PVRI). Pulmonary Circulation, 2019, 9, 1-32.	0.8	96
1564	Role of RASEF hypermethylation in cigarette smoke-induced pulmonary arterial smooth muscle remodeling. Respiratory Research, 2019, 20, 52.	1.4	10
1566	Polysplenia Syndrome as a Risk Factor for Early Progression of Pulmonary Hypertension. Circulation Journal, 2019, 83, 831-836.	0.7	7
1567	Pulmonary Edema Following Initiation of Parenteral Prostacyclin Therapy for Pulmonary Arterial Hypertension. Chest, 2019, 156, 45-52.	0.4	5
1568	Normal ventilation/perfusion lung scan in patients with extensive chronic thromboembolism pulmonary hypertension: A case report. Radiology Case Reports, 2019, 14, 510-513.	0.2	4

#	Article	IF	Citations
1570	Distinct plasma gradients of microRNAâ€204Âin the pulmonary circulation of patients suffering from WHO Groups I and II pulmonary hypertension. Pulmonary Circulation, 2019, 9, 1-12.	0.8	17
1571	Commentary: On the levels of patient selection in registry-based randomized controlled trials. Trials, 2019, 20, 100.	0.7	10
1572	Identifying Patients with Pulmonary Arterial Hypertension Using Administrative Claims Algorithms. Annals of the American Thoracic Society, 2019, 16, 797-806.	1.5	29
1573	Predicting Survival in Patients With Pulmonary Arterial Hypertension. Chest, 2019, 156, 323-337.	0.4	408
1574	Can patients be discharged after VSD closure?. International Journal of Cardiology, 2019, 282, 45-46.	0.8	0
1575	Cardiac Magnetic Resonance Imaging-Based Right Ventricular Strain Analysis for Assessment of Coupling and Diastolic Function in Pulmonary Hypertension. JACC: Cardiovascular Imaging, 2019, 12, 2155-2164.	2.3	75
1576	Outcome of pregnancies in women with pulmonary hypertension: a singleâ€centre experience from South India. BJOG: an International Journal of Obstetrics and Gynaecology, 2019, 126, 43-49.	1.1	15
1577	Levels of Evidence Supporting American College of Cardiology/American Heart Association and European Society of Cardiology Guidelines, 2008-2018. JAMA - Journal of the American Medical Association, 2019, 321, 1069.	3.8	144
1578	Bioinformatics and Drug Discovery. Methods in Molecular Biology, 2019, , .	0.4	2
1579	Pulmonary hypertension associated with left heart disease: efforts to improve the meaning of haemodynamic phenotypes. European Respiratory Journal, 2019, 53, 1801894.	3.1	0
1580	A Bayesian Network Approach to Disease Subtype Discovery. Methods in Molecular Biology, 2019, 1939, 299-322.	0.4	2
1581	Cheyne-Stokes respiration related oscillations in cardiopulmonary hemodynamics in patients with heart failure. International Journal of Cardiology, 2019, 289, 76-82.	0.8	21
1582	Combined automated 3D volumetry by pulmonary CT angiography and echocardiography for detection of pulmonary hypertension. European Radiology, 2019, 29, 6059-6068.	2.3	20
1583	Right ventricular outflow tract velocity time integral-to-pulmonary artery systolic pressure ratio: a non-invasive metric of pulmonary arterial compliance differs across the spectrum of pulmonary hypertension. Pulmonary Circulation, 2019, 9, 204589401984197.	0.8	11
1584	Peripartum outcomes in a large population of women with pulmonary arterial hypertension associated with congenital heart disease. European Journal of Preventive Cardiology, 2019, 26, 1067-1076.	0.8	31
1586	Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary circulation in patients with systemic sclerosis. Advances in Medical Sciences, 2019, 64, 309-314.	0.9	1
1587	Association of electrocardiographic left and right ventricular hypertrophy with physical fitness of military males: The CHIEF study. European Journal of Sport Science, 2019, 19, 1214-1220.	1.4	30
1588	Pulmonary arterial hypertension outcomes upon endothelin-1 receptor antagonist switch to macitentan. Journal of International Medical Research, 2019, 47, 2177-2186.	0.4	7

#	Article	IF	Citations
1589	Correlation of Right Ventricular Wall Stress With Plasma B-Type Natriuretic Peptide Levels in Patients With Pulmonary Hypertension. Circulation Journal, 2019, 83, 1278-1285.	0.7	8
1590	Association of N-Terminal Pro Brain Natriuretic Peptide and Long-Term Outcome in Patients With Pulmonary Arterial Hypertension. Circulation, 2019, 139, 2440-2450.	1.6	67
1591	Mitochondrial function remains impaired in the hypertrophied right ventricle of pulmonary hypertensive rats following short duration metoprolol treatment. PLoS ONE, 2019, 14, e0214740.	1.1	13
1592	Treatment of severe idiopathic pulmonary fibrosisâ€"is sildenafil the next (in)stage?. Journal of Thoracic Disease, 2019, 11, 339-340.	0.6	1
1593	Real-Life Experience with Selexipag as an Add-On Therapy to Oral Combination Therapy in Patients with Pulmonary Arterial or Distal Chronic Thromboembolic Pulmonary Hypertension: A Retrospective Analysis. Lung, 2019, 197, 353-360.	1.4	9
1594	The new haemodynamic definition of pulmonary hypertension: evidence prevails, finally!. European Respiratory Journal, 2019, 53, 1900038.	3.1	44
1595	2018 TSOC guideline focused update on diagnosis and treatment of pulmonary arterial hypertension. Journal of the Formosan Medical Association, 2019, 118, 1584-1609.	0.8	27
1596	Genetics and clinics: current applications, limitations, and future developments. European Heart Journal Supplements, 2019, 21, B7-B14.	0.0	0
1597	Do radiologists detect chronic thromboembolic disease on computed tomography?. Acta Radiologica, 2019, 60, 1576-1583.	0.5	29
1598	Guidelines for the Treatment of Pulmonary Hypertension (JCS 2017/JPCPHS 2017). Circulation Journal, 2019, 83, 842-945.	0.7	132
1599	Global weighted LBP based entropy features for the assessment of pulmonary hypertension. Pattern Recognition Letters, 2019, 125, 35-41.	2.6	36
1600	Critical Care of Patients After Pulmonary Thromboendarterectomy. Journal of Cardiothoracic and Vascular Anesthesia, 2019, 33, 3110-3126.	0.6	7
1601	Exercise-Based Rehabilitation to Improve Exercise Capacity and Quality of Life in Pulmonary Arterial Hypertension. Physical Therapy, 2019, 99, 1126-1131.	1.1	2
1602	Screening Echocardiography and Brain Natriuretic Peptide Levels Predict Late Pulmonary Hypertension in Infants with Bronchopulmonary Dysplasia. Pediatric Cardiology, 2019, 40, 973-979.	0.6	14
1603	Angioplastia pulmonar en hipertensiÃ³n pulmonar tromboembÃ³lica crÃ³nica. Un Ãºltimo pero eficaz recurso. REC: CardioClinics, 2019, 54, 57-59.	0.1	0
1604	Circulating biomarkers in chronic thromboembolic pulmonary hypertension. Pulmonary Circulation, 2019, 9, 1-13.	0.8	13
1605	Effects of oxygen therapy in a pediatric normoxemic patient with pulmonary arterial hypertension and congenital heart disease. Pulmonary Circulation, 2019, 9, 1177_2045894019.	0.8	2
1606	Right heart in pulmonary hypertension: from adaptation to failure. Pulmonary Circulation, 2019, 9, 1-20.	0.8	36

#	Article	IF	Citations
1607	Subclinical thyroid dysfunction is associated with adverse prognosis in heart failure patients with reduced ejection fraction. BMC Cardiovascular Disorders, 2019, 19, 83.	0.7	32
1608	Cancer incidence in patients with pre-capillary pulmonary hypertension. Journal of Heart and Lung Transplantation, 2019, 38, 778-780.	0.3	4
1609	Tricuspid Regurgitation. JACC: Cardiovascular Imaging, 2019, 12, 605-621.	2.3	91
1610	Pulmonary Hypertension. Medical Clinics of North America, 2019, 103, 413-423.	1.1	43
1611	Dasatinib-induced pulmonary arterial hypertension complicated with scleroderma: a case report. European Heart Journal - Case Reports, 2019, 3, ytz025.	0.3	2
1612	RhoA-Rho associated kinase signaling leads to renin-angiotensin system imbalance and angiotensin converting enzyme 2 has a protective role in acute pulmonary embolism. Thrombosis Research, 2019, 176, 85-94.	0.8	24
1613	Effects of vasopressin during a pulmonary hypertensive crisis induced by acute hypoxia inÂaÂratÂmodel of pulmonary hypertension. British Journal of Anaesthesia, 2019, 122, 437-447.	1.5	23
1614	The prevalence of pulmonary hypertension in Cavalier King Charles spaniels compared with other breeds with myxomatous mitral valve disease. Journal of Veterinary Cardiology, 2019, 23, 21-31.	0.3	4
1615	Pulmonary transit time from contrast echocardiography and cardiac magnetic resonance imaging: Comparison between modalities and the impact of region of interest characteristics. Echocardiography, 2019, 36, 119-124.	0.3	5
1616	Dendritic Cell Subsets and Effector Function in Idiopathic and Connective Tissue Disease-Associated Pulmonary Arterial Hypertension. Frontiers in Immunology, 2019, 10, 11.	2.2	30
1617	Meta-analysis of use of balloon pulmonary angioplasty in patients with inoperable chronic thromboembolic pulmonary hypertension. International Journal of Cardiology, 2019, 291, 134-139.	0.8	37
1618	Pregnancy still contraindicated in pulmonary arterial hypertension related to congenital heart disease: True or false?. European Journal of Preventive Cardiology, 2019, 26, 1064-1066.	0.8	7
1619	Acute Iloprost Inhalation Improves Right Ventricle Function in Pulmonary Artery Hypertension: A Cardiac Magnetic Resonance Study. Frontiers in Pharmacology, 2018, 9, 1550.	1.6	12
1620	Metabolic Alterations in Cardiopulmonary Vascular Dysfunction. Frontiers in Molecular Biosciences, 2018, 5, 120.	1.6	20
1621	Resting and Exercise Doppler Hemodynamics. Heart Failure Clinics, 2019, 15, 229-239.	1.0	1
1622	Galectin-3: A Harbinger of Reactive Oxygen Species, Fibrosis, and Inflammation in Pulmonary Arterial Hypertension. Antioxidants and Redox Signaling, 2019, 31, 1053-1069.	2.5	29
1623	Molecular Research in Chronic Thromboembolic Pulmonary Hypertension. International Journal of Molecular Sciences, 2019, 20, 784.	1.8	19
1624	Current and Emerging Technologies for Cardiovascular Imaging. Series in Bioengineering, 2019, , 13-59.	0.3	0

#	Article	IF	Citations
1625	Doubleâ€lung versus heartâ€lung transplantation for precapillary pulmonary arterial hypertension: a 24â€year singleâ€center retrospective study. Transplant International, 2019, 32, 717-729.	0.8	29
1626	Pulmonary Endarterectomy in Latvia: A National Experience. Medicina (Lithuania), 2019, 55, 18.	0.8	3
1627	Comprehensive threeâ€dimensional morphology of neoangiogenesis in pulmonary venoâ€occlusive disease and pulmonary capillary hemangiomatosis. Journal of Pathology: Clinical Research, 2019, 5, 108-114.	1.3	10
1628	Computed tomography-measured pulmonary artery to aorta ratio and EUTOS score for detecting dasatinib-induced pulmonary arterial hypertension. International Journal of Cardiovascular Imaging, 2019, 35, 1435-1442.	0.7	6
1629	Living With Severe Pulmonary Arterial Hypertension Without an Infusion Pump? Selexipag has a Role to Play. Archivos De Bronconeumologia, 2019, 55, 102-103.	0.4	1
1630	Deep-learning cardiac motion analysis for human survival prediction. Nature Machine Intelligence, 2019, 1, 95-104.	8.3	179
1631	Milrinone in Adult Cardiac Surgery: More Evidence Is Needed to Support Routine Inhalation Administration. Journal of Cardiothoracic and Vascular Anesthesia, 2019, 33, 674-676.	0.6	2
1632	Microparticles in systemic sclerosis: Potential proâ€inflammatory mediators and pulmonary hypertension biomarkers. Respirology, 2019, 24, 675-683.	1.3	18
1633	Treatment of pulmonary arterial hypertension with the dual endothelin receptor antagonist macitentan: clinical evidence and experience. Therapeutic Advances in Respiratory Disease, 2019, 13, 175346661882344.	1.0	17
1634	Advanced interstitial lung fibrosis with emphysema and pulmonary hypertension with no evidence for interstitial lung disease on high resolution CT. Pulmonary Circulation, 2019, 9, 204589401983221.	0.8	1
1635	Sildenafil for bronchopulmonary dysplasia and pulmonary hypertension: a metaâ€analysis. Pulmonary Circulation, 2019, 9, 1-8.	0.8	26
1636	Parameters associated with outcome in pediatric patients with congenital heart disease and pulmonary hypertension subjected to combined vasodilator and surgical treatments. Pulmonary Circulation, 2019, 9, 1-13.	0.8	9
1637	Chronic Thromboembolic Pulmonary Hypertension: Endovascular Treatment. Korean Circulation Journal, 2019, 49, 214.	0.7	6
1638	Cardiovascular Adaptations and Complications. , 2019, , 939-952.		0
1639	Non-invasive Estimation of Right Atrial Pressure Using Inferior Vena Cava Echography. Ultrasound in Medicine and Biology, 2019, 45, 1331-1337.	0.7	13
1640	Berberine attenuates hypoxiaâ€induced pulmonary arterial hypertension via bone morphogenetic protein and transforming growth factorâ€i² signaling. Journal of Cellular Physiology, 2019, 234, 17482-17493.	2.0	26
1641	Pharmacology of theÂPulmonary Circulation. , 2019, , 165-179.		0
1642	Therapeutic potential of phosphodiesterase type 5 inhibitors in heart failure with preserved ejection fraction and combined post- and pre-capillary pulmonary hypertension. International Journal of Cardiology, 2019, 283, 152-158.	0.8	38

#	Article	IF	Citations
1643	Highâ€risk pregnancy in a patient with pulmonary arterial hypertension due to congenital heart disease (PAHâ€CHD) with temporary shunt inversion and deoxygenation. Pulmonary Circulation, 2019, 9, 1-4.	0.8	5
1644	Pulmonary arterial hypertension in systemic lupus erythematosus based on a CSTARâ€PAH study: Baseline characteristics and risk factors. International Journal of Rheumatic Diseases, 2019, 22, 921-928.	0.9	26
1645	Pathophysiology, incidence, management, and consequences of cardiac arrhythmia in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. Pulmonary Circulation, 2019, 9, 1-15.	0.8	24
1646	Pulmonary Artery Elastic Properties After Balloon Pulmonary Angioplasty in Patients With Inoperable Chronic Thromboembolic Pulmonary Hypertension. Canadian Journal of Cardiology, 2019, 35, 422-429.	0.8	16
1647	P118â€…Defining a minimal clinically important difference in CAMPHOR. , 2019, , .		0
1648	Impact of pulmonary hypertension on outcome in patients with moderate or severe tricuspid regurgitation. Open Heart, 2019, 6, e001104.	0.9	5
1649	Systemic sclerosis: state of the art on clinical practice guidelines. RMD Open, 2019, 4, e000782.	1.8	91
1650	OP0067â€…UTILITY OF RISK STRATIFICATION IN PREDICTING OUTCOMES OF INITIAL MONOTHERAPY VERSUS COMBINATION THERAPY IN PULMONARY ARTERIAL HYPERTENSION ASSOCIATED WITH CONNECTIVE TISSUE DISEASE: A POST-HOC ANALYSIS OF THE AMBITION STUDY. , 2019, , .		0
1651	OP0068â€…ABATACEPT IN EARLY DIFFUSE CUTANEOUS SYSTEMIC SCLEROSISâ€" RESULTS OF A PHASE 2 INVESTIGATOR-INITIATED, MULTICENTER, DOUBLE-BLIND RANDOMIZED PLACEBO-CONTROLLED TRIAL. , 2019, , .		1
1653	Screening Of Pulmonary Hypertension in Methamphetamine Abusers (SOPHMA): rationale and design of a multicentre, cross-sectional study. BMJ Open, 2019, 9, e027193.	0.8	5
1654	The obesity paradox in pulmonary arterial hypertension: the Scottish perspective. ERJ Open Research, 2019, 5, 00241-2019.	1.1	10
1655	Echocardiographic score for prediction of pulmonary hypertension at catheterization. Journal of Cardiovascular Medicine, 2019, 20, 809-815.	0.6	6
1656	Pulmonary arterial hypertension: the case for a bioelectronic treatment. Bioelectronic Medicine, 2019, 5, 20.	1.0	15
1657	The Effects of Hydroxyurea Therapy on the Six-Minute Walk Distance in Patients with Adult Sickle Cell Anemia: An Echocardiographic Study . Journal of Blood Medicine, 2019, Volume 10, 443-452.	0.7	3
1658	Pulmonary Vascular Morphology Associated With Gas Exchange in Systemic Sclerosis Without Lung Fibrosis. Journal of Thoracic Imaging, 2019, 34, 373-379.	0.8	7
1659	Echocardiographic evaluations of right ventriculoâ€"arterial coupling in experimental and clinical pulmonary hypertension. Physiological Reports, 2019, 7, e14322.	0.7	14
1660	Might Nailfold Capillaroscopy Be a â€œProxyâ€• for Lung Involvement in Connective Tissue Diseases?. Journal of Rheumatology, 2019, 46, 1061-1063.	1.0	13
1661	Learning from registries in pulmonary arterial hypertension: pitfalls and recommendations. European Respiratory Review, 2019, 28, 190050.	3.0	39

#	Article	IF	Citations
1662	Early Detection of Pulmonary Hypertension in Connective Tissue Disease. Journal of Rheumatic Diseases, 2019, 26, 1.	0.4	1
1663	Pulmonary Artery Hypertension after Arteriovenous Fistula Creation Subsequently Resolved by Closure of the Fistula. Journal of St Marianna University, 2019, 10, 109-114.	0.1	0
1664	The era of clinical application of gene diagnosis in cardiovascular diseases is coming. Chronic Diseases and Translational Medicine, 2019, 5, 214-220.	0.9	2
1666	Pulmonary hypertension and chronic lung disease: where are we headed?. European Respiratory Review, 2019, 28, 190065.	3.0	19
1667	CT parenchymal lung changes in pulmonary hypertension. Clinical Radiology, 2019, 74, e18.	0.5	0
1668	Phosphodiesterase 5 inhibitors for pulmonary hypertension. The Cochrane Library, 2019, 2019, CD012621.	1.5	70
1669	What's next after the clot? Residual pulmonary vascular obstruction after pulmonary embolism: From imaging finding to clinical consequences. Thrombosis Research, 2019, 184, 67-76.	0.8	15
1670	Eisenmenger Syndrome: A Multisystem Disorderâ€"Do Not Destabilize the Balanced but Fragile Physiology. Canadian Journal of Cardiology, 2019, 35, 1664-1674.	0.8	23
1671	Exploring a physiotherapy wellâ€being review to deliver communityâ€based rehabilitation in patients with pulmonary hypertension. Pulmonary Circulation, 2019, 9, 1-9.	0.8	5
1672	Chronic thromboembolic pulmonary hypertension suspicion after pulmonary embolism in cancer patients. Respiratory Medicine and Research, 2019, 76, 34-37.	0.4	3
1673	Sildenafil for Pulmonary Arterial Hypertension. American Journal of Therapeutics, 2019, 26, e520-e526.	0.5	39
1674	Therapeutic Challenges And Advances In The Management Of Systemic Sclerosis-Related Pulmonary Arterial Hypertension (SSc-PAH) . Therapeutics and Clinical Risk Management, 2019, Volume 15, 1427-1442.	0.9	10
1675	Screening strategies for pulmonary arterial hypertension. European Heart Journal Supplements, 2019, 21, K9-K20.	0.0	44
1676	Management of pulmonary arterial hypertension in patients aged over 65 years. European Heart Journal Supplements, 2019, 21, K29-K36.	0.0	9
1677	The practical management of fluid retention in adults with right heart failure due to pulmonary arterial hypertension. European Heart Journal Supplements, 2019, 21, K46-K53.	0.0	14
1678	My life with pulmonary arterial hypertension: a patient perspective. European Heart Journal Supplements, 2019, 21, K54-K59.	0.0	6
1679	Beyond the World Symposium on Pulmonary Hypertension: practical management of pulmonary arterial hypertension and evolving concepts. European Heart Journal Supplements, 2019, 21, K1-K3.	0.0	1
1680	The revised definition of pulmonary hypertension: exploring the impact on patient management. European Heart Journal Supplements, 2019, 21, K4-K8.	0.0	55

#	Article	IF	Citations
1681	Pulmonary arterial hypertension populations of special interest: portopulmonary hypertension and pulmonary arterial hypertension associated with congenital heart disease. European Heart Journal Supplements, 2019, 21, K37-K45.	0.0	16
1682	The Biological Bases of Group 2 Pulmonary Hypertension. International Journal of Molecular Sciences, 2019, 20, 5884.	1.8	18
1683	Current Treatment Strategies and Nanoparticle-Mediated Drug Delivery Systems for Pulmonary Arterial Hypertension. International Journal of Molecular Sciences, 2019, 20, 5885.	1.8	16
1685	Pulmonary Arterial Hypertension: a Pharmacotherapeutic Update. Current Cardiology Reports, 2019, 21, 141.	1.3	51
1686	Orotracheal treprostinil administration attenuates bleomycinâ€induced lung injury, vascular remodeling, and fibrosis in mice. Pulmonary Circulation, 2019, 9, 1-14.	0.8	23
1687	The economic burden of systemic sclerosis related pulmonary arterial hypertension in Australia. BMC Pulmonary Medicine, 2019, 19, 226.	0.8	5
1688	Prognostic value of cardiopulmonary exercise testing in patients with systemic sclerosis. BMC Pulmonary Medicine, 2019, 19, 230.	0.8	24
1690	COUNTERPOINT: Should Initial Combination Therapy Be the Standard of Care in Pulmonary Arterial Hypertension? No. Chest, 2019, 156, 1043-1045.	0.4	1
1691	Pulmonary Hypertension with Valvular Heart Disease: When to Treat the Valve Disease and When to Treat the Pulmonary Hypertension. Current Cardiology Reports, 2019, 21, 151.	1.3	11
1692	Healthcare utilization, medical expenditure, and mortality in Korean patients with pulmonary hypertension. BMC Pulmonary Medicine, 2019, 19, 189.	0.8	0
1693	Global longitudinal strain is a hallmark of cardiac damage in mitral regurgitation: the Italian arm of the European Registry of mitral regurgitation (EuMiClip). Cardiovascular Ultrasound, 2019, 17, 28.	0.5	8
1694	Pregnancy in adults with congenital heart disease. Cardiovascular Diagnosis and Therapy, 2019, 9, S416-S423.	0.7	6
1695	Pulmonary hypertension in pediatrics. A feasible approach to bridge the gap between real world and guidelines. Journal of Maternal-Fetal and Neonatal Medicine, 2021, 34, 3820-3826.	0.7	6
1696	Abnormal pulmonary artery systolic pressure response after exercise in systemic sclerosis patients. Medicine (United States), 2019, 98, e14342.	0.4	3
1697	Pulmonary hypertension with massive megalosplenia. Medicine (United States), 2019, 98, e14594.	0.4	1
1698	Retrospective observational analysis of hospital discharge database to characterize primary pulmonary hypertension and its outcomes in Spain from 2004 to 2015. Medicine (United States), 2019, 98, e15518.	0.4	4
1699	Multivariable models for the diagnosis of pulmonary hypertension. Journal of Cardiovascular Medicine, 2019, 20, 816-817.	0.6	0
1700	Treatment of chronic thromboembolic pulmonary hypertension in a multidisciplinary team. Therapeutic Advances in Respiratory Disease, 2019, 13, 175346661989152.	1.0	25

#	Article	IF	Citations
1701	The prognostic value of DLCO and pulmonary blood flow in patients with pulmonary hypertension. Pulmonary Circulation, 2019, 9, 1-9.	0.8	13
1702	Matrix metalloproteinase 7Âin diagnosis and differentiation of pulmonary arterial hypertension. Pulmonary Circulation, 2019, 9, 1-8.	0.8	18
1703	Echocardiographic estimation of right ventricular wall tension: haemodynamic comparison and longâ€term followâ€up. Pulmonary Circulation, 2019, 9, 1-8.	0.8	5
1704	Higher plasma fibroblast growth factor 23 levels are associated with a higher risk profile in pulmonary arterial hypertension. Pulmonary Circulation, 2019, 9, 1-9.	0.8	10
1705	Anticoagulation in pulmonary arterial hypertension: a decision analysis. Pulmonary Circulation, 2019, 9, 1-12.	0.8	5
1706	Preoperative platelet count, preoperative hemoglobin concentration and deep hypothermic circulatory arrest duration are risk factors for acute kidney injury after pulmonary endarterectomy: a retrospective cohort study. Journal of Cardiothoracic Surgery, 2019, 14, 220.	0.4	8
1707	Thermodilution vs estimated Fick cardiac output measurement in an elderly cohort of patients: A single-centre experience. PLoS ONE, 2019, 14, e0226561.	1.1	10
1708	Which Needle in Which Haystack? Multisystem Care for Pulmonary Hypertension Patients. Annals of the American Thoracic Society, 2019, 16, 979-981.	1.5	0
1709	The Effects of a 10-wk Outpatient Pulmonary Rehabilitation Program on Exercise Performance, Muscle Strength, Soluble Biomarkers, and Quality of Life in Patients With Pulmonary Hypertension. Journal of Cardiopulmonary Rehabilitation and Prevention, 2019, 39, 397-402.	1.2	12
1710	Impact of obstructive sleep apnea on pulmonary hypertension in patients with chronic obstructive pulmonary disease. Chinese Medical Journal, 2019, 132, 1272-1282.	0.9	20
1711	JCS 2017/JHFS 2017 Guideline on Diagnosis and Treatment of Acute and Chronic Heart Failureã€€â€• Digest Version â€•. Circulation Journal, 2019, 83, 2084-2184.	0.7	446
1712	The burden of comorbidities in pulmonary arterial hypertension. European Heart Journal Supplements, 2019, 21, K21-K28.	0.0	37
1713	Pulmonary Hypertension and Pregnancy. Obstetrics and Gynecology, 2019, 134, 974-987.	1.2	36
1714	Chronic thromboembolic pulmonary hypertension (CTEPH): what do we know about it? A comprehensive review of the literature. Journal of Cardiovascular Medicine, 2019, 20, 159-168.	0.6	17
1715	Utilising artificial intelligence to determine patients at risk of a rare disease: idiopathic pulmonary arterial hypertension. Pulmonary Circulation, 2019, 9, 1-9.	0.8	35
1717	ACOG Practice Bulletin No. 212: Pregnancy and Heart Disease. Obstetrics and Gynecology, 2019, 133, e320-e356.	1.2	248
1718	Right ventricular dysfunction is associated with the development of chronic thromboembolic pulmonary hypertension but not with mortality post-acute pulmonary embolism. Medicine (United) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	0.4	8
1719	Bilateral lung transplantation after caesarean section in pregnancy with severe pulmonary arterial hypertension. Medicine (United States), 2019, 98, e18109.	0.4	5

#	Article	IF	Citations
1720	Cardiopulmonary exercise testing and echocardiographic exam: an useful interaction. Cardiovascular Ultrasound, 2019, 17, 29.	0.5	24
1721	Inflammatory Basis of Pulmonary Arterial Hypertension. Anesthesiology, 2019, 131, 898-907.	1.3	20
1722	Clinical phenotypes and outcomes of precapillary pulmonary hypertension of sickle cell disease. European Respiratory Journal, 2019, 54, 1900585.	3.1	15
1725	Pulmonary Arterial Hypertension In Systemic Sclerosis: Challenges In Diagnosis, Screening And Treatment . Open Access Rheumatology: Research and Reviews, 2019, Volume 11, 323-333.	0.8	14
1726	Un an aprÃ¨s le congrÃ¨s mondial, quels changements dans la prise en charge de lâ€™hypertension pulmonaire ?. Revue Des Maladies Respiratoires Actualites, 2019, 11, 123-128.	0.0	0
1727	Transcriptome-wide analysis associates ID2 expression with combined pre- and post-capillary pulmonary hypertension. Scientific Reports, 2019, 9, 19572.	1.6	11
1728	Correlation of native T1 mapping with right ventricular function and pulmonary haemodynamics in patients with chronic thromboembolic pulmonary hypertension before and after balloon pulmonary angioplasty. European Radiology, 2019, 29, 1565-1573.	2.3	28
1729	Classification of Pulmonary Arterial Hypertension by Genetic and Familial Testing. Revista Espanola De Cardiologia (English Ed), 2019, 72, 591-593.	0.4	0
1730	Prognostic value of right ventricular longitudinal strain in patients with pulmonary hypertension: a systematic review and meta-analysis. European Heart Journal Cardiovascular Imaging, 2019, 20, 475-484.	0.5	49
1731	Recurrent chest pain and dyspnoea in a patient with pulmonary arterial hypertension. Acta Clinica Belgica, 2019, 74, 292-295.	0.5	1
1732	Evaluation of Macitentan in Patients With Eisenmenger Syndrome. Circulation, 2019, 139, 51-63.	1.6	83
1733	Hypertension artÃ©rielle pulmonaire associÃ©e Ã la prise de lÃ©flunomideÂ: 4Âcas. Revue Du Rhumatisme (Edition Francaise), 2019, 86, 199-202.	0.0	0
1734	Pulmonary arterial hypertension in a multiâ€ethnic Asian population: Characteristics, survival and mortality predictors from a 14â€year followâ€up study. Respirology, 2019, 24, 162-170.	1.3	32
1735	Development of Pulmonary Arterial Hypertension in a Patient Treated with Qing-Dai (Chinese Herbal) Tj ETQq1 1 0.784314 rgBT /Over	0.3	17
1736	C-Arm computed tomography (CACT)-guided balloon pulmonary angioplasty (BPA): Evaluation of patient safety and peri- and post-procedural complications. European Radiology, 2019, 29, 1276-1284.	2.3	22
1737	The added value of cardiopulmonary exercise testing in the follow-up of pulmonary arterial hypertension. Journal of Heart and Lung Transplantation, 2019, 38, 306-314.	0.3	32
1738	Insights into the pulmonary vascular complications of heart failure with preserved ejection fraction. Journal of Physiology, 2019, 597, 1143-1156.	1.3	18
1739	TGFÎ² and BMPRII signalling pathways in the pathogenesis of pulmonary arterial hypertension. Drug Discovery Today, 2019, 24, 703-716.	3.2	64

#	Article	IF	Citations
1740	Characterization of Right Ventricular Deformation in Pulmonary Arterial Hypertension Using Three-Dimensional Principal Strain Analysis. Journal of the American Society of Echocardiography, 2019, 32, 385-393.	1.2	21
1741	Prescription patterns of direct oral anticoagulants in pulmonary embolism: A prospective multicenter French registry. Thrombosis Research, 2019, 174, 27-33.	0.8	9
1742	New drugs in preclinical and early stage clinical development in the treatment of heart failure. Expert Opinion on Investigational Drugs, 2019, 28, 51-71.	1.9	15
1743	Deterioration in right ventricular structure and function over time in patients with heart failure and preserved ejection fraction. European Heart Journal, 2019, 40, 689-697.	1.0	190
1744	Abnormal Nailfold Capillaroscopy Is Common in Patients with Connective Tissue Disease and Associated with Abnormal Pulmonary Function Tests. Journal of Rheumatology, 2019, 46, 1109-1116.	1.0	18
1745	Idiopathic Pulmonary Fibrosis for Cardiologists: Differential Diagnosis, Cardiovascular Comorbidities, and Patient Management. Advances in Therapy, 2019, 36, 298-317.	1.3	18
1746	Critical Care Management of theÂAdult with Eisenmenger Syndrome and Pulmonary Arterial Hypertension Related to Congenital Heart Disease. Congenital Heart Disease in Adolescents and Adults, 2019, , 273-297.	0.2	0
1747	Interstitial Lung Disease and Other Pulmonary Manifestations in Connective Tissue Diseases. Mayo Clinic Proceedings, 2019, 94, 309-325.	1.4	78
1748	Anti-RNA binding protein positivity in idiopathic interstitial pneumonia. Respiratory Medicine, 2019, 146, 23-27.	1.3	1
1749	Redox Biology of Peroxisome Proliferator-Activated Receptor-Î³ in Pulmonary Hypertension. Antioxidants and Redox Signaling, 2019, 31, 874-897.	2.5	20
1750	Incomplete echocardiographic recovery at 6Âmonths predicts long-term sequelae after intermediate-risk pulmonary embolism. A post-hoc analysis of the Pulmonary Embolism Thrombolysis (PEITHO) trial. Clinical Research in Cardiology, 2019, 108, 772-778.	1.5	44
1751	EmPHasis-10 score for the assessment of quality of life in various types of pulmonary hypertension and its relation to outcome. European Journal of Preventive Cardiology, 2019, 26, 1338-1340.	0.8	25
1752	Safety and tolerability of transition from inhaled treprostinil to oral selexipag in pulmonary arterial hypertension: Results from the TRANSIT-1 study. Journal of Heart and Lung Transplantation, 2019, 38, 43-50.	0.3	25
1753	Pulmonary Hypertension in Women. Heart Failure Clinics, 2019, 15, 137-145.	1.0	11
1754	Impact of concurrent tricuspid regurgitation on mortality after transcatheter aorticâ€valve implantation. Catheterization and Cardiovascular Interventions, 2019, 93, 946-953.	0.7	10
1755	Pulmonary Hypertension Predicts Adverse Outcomes in Renal Patients: A Systematic Review and Metaâ€Analysis. Therapeutic Apheresis and Dialysis, 2019, 23, 369-384.	0.4	12
1756	Current understanding and perioperative management of pediatric pulmonary hypertension. Paediatric Anaesthesia, 2019, 29, 441-456.	0.6	30
1758	Hemodynamic changes after acute fluid loading in patients with systemic sclerosis without pulmonary hypertension. Pulmonary Circulation, 2019, 9, 1-6.	0.8	11

#	Article	IF	Citations
1759	Prolonged QRS duration as a predictor of right ventricular dysfunction after balloon pulmonary angioplasty. International Journal of Cardiology, 2019, 280, 176-181.	0.8	19
1760	Treatment patterns, healthcare resource utilization, and healthcare costs among patients with pulmonary arterial hypertension in a realâ€world US database. Pulmonary Circulation, 2019, 9, 1-12.	0.8	34
1761	Pulmonary artery denervation improves hemodynamics and cardiac function in pulmonary hypertension secondary to heart failure. Pulmonary Circulation, 2019, 9, 204589401881629.	0.8	17
1762	Rab6A GTPase contributes to phenotypic modulation in pulmonary artery smooth muscle cells under hypoxia. Journal of Cellular Biochemistry, 2019, 120, 7858-7867.	1.2	5
1763	Value of lung perfusion scintigraphy in patients with idiopathic pulmonary arterial hypertension: a patchy pattern to consider. Pulmonary Circulation, 2019, 9, 1-7.	0.8	8
1764	Prevalence of pulmonary hypertension in peritoneal dialysis patients: a meta-analysis. International Urology and Nephrology, 2019, 51, 175-180.	0.6	2
1765	Subcutaneous treprostinil for the treatment of severe non-operable chronic thromboembolic pulmonary hypertension (CTREPH): a double-blind, phase 3, randomised controlled trial. Lancet Respiratory Medicine,the, 2019, 7, 239-248.	5.2	116
1766	Residual high intrapulmonary shunt fraction limits exercise capacity in patients treated with balloon pulmonary angioplasty. Heart and Vessels, 2019, 34, 868-874.	0.5	7
1767	Proximal pulmonary arterial wall disease in patients with persistent pulmonary hypertension after successful leftâ€sided valve replacement according to the hemodynamic phenotype. Pulmonary Circulation, 2019, 9, 1-10.	0.8	4
1768	Frequency and etiology of pulmonary hypertension in patients with myeloproliferative neoplasms. European Journal of Haematology, 2019, 102, 227-234.	1.1	15
1769	How to evaluate patients with congenital heart disease-related pulmonary arterial hypertension. Expert Review of Cardiovascular Therapy, 2019, 17, 11-18.	0.6	12
1770	Assessment of reversibility in pulmonary arterial hypertension and congenital heart disease. Heart, 2019, 105, 276-282.	1.2	37
1771	Decreased biventricular longitudinal strain in patients with systemic sclerosis is mainly caused by pulmonary hypertension and not by systemic sclerosis per se. Clinical Physiology and Functional Imaging, 2019, 39, 215-225.	0.5	20
1772	Reduced Right Ventricular Output Reserve in Patients With Systemic Sclerosis and Mildly Elevated Pulmonary Artery Pressure. Arthritis and Rheumatology, 2019, 71, 805-816.	2.9	25
1774	Therapy for Pulmonary Arterial Hypertension in Adults. Chest, 2019, 155, 565-586.	0.4	216
1776	Mechanical Ventilation and Advanced Respiratory Support in the Cardiac Intensive Care Unit. , 2019, , 548-557.e5.		0
1777	Traumatic Pulmonary Hypertension Secondary to Arteriovenous Fistula and Remote Gunshot Wound. Canadian Journal of Cardiology, 2019, 35, 229.e11-229.e13.	0.8	2
1778	Non-Invasive Assessment of Intravascular Pressure Gradients: A Review of Current and Proposed Novel Methods. Diagnostics, 2019, 9, 5.	1.3	9

#	Article	IF	Citations
1779	Serial pulmonary vascular resistance assessment in patients late after ventricular septal defect repair. International Journal of Cardiology, 2019, 282, 38-43.	0.8	3
1780	Multimodality treatment for chronic thromboembolic pulmonary hypertension. International Journal of Cardiology, 2019, 278, 238-239.	0.8	0
1781	Risk Factors for Mitral Valve Surgery: Atrial Fibrillation and Pulmonary Hypertension. Seminars in Cardiothoracic and Vascular Anesthesia, 2019, 23, 57-69.	0.4	6
1782	Perfusion Scintigraphy in Diagnosis and Management of Thromboembolic Pulmonary Hypertension. Radiographics, 2019, 39, 169-185.	1.4	28
1783	Mortality in US veterans with pulmonary hypertension: a retrospective analysis of survival by subtype and baseline factors. Pulmonary Circulation, 2019, 9, 1-12.	0.8	20
1784	Clinical and hemodynamic benefit of macitentan and riociguat upfront combination in patients with pulmonary arterial hypertension. Pulmonary Circulation, 2019, 9, 1-8.	0.8	19
1785	Nailfold capillaroscopy as a risk factor for pulmonary arterial hypertension in systemic lupus erythematosus patients. Advances in Rheumatology, 2019, 59, 1.	0.8	28
1786	Prognostic role of traditional cardiovascular risk factors in patients with idiopathic pulmonary arterial hypertension. Archives of Medical Science, 2019, 15, 1397-1406.	0.4	14
1787	Prevalence, determinants, and prognostic significance of exercise-induced pulmonary hypertension in patients with hypertrophic cardiomyopathy. International Journal of Cardiovascular Imaging, 2019, 35, 837-844.	0.7	12
1788	Selexipag treatment for pulmonary arterial hypertension associated with congenital heart disease after defect correction: insights from the randomised controlled GRIPHON study. European Journal of Heart Failure, 2019, 21, 352-359.	2.9	40
1789	Effect of pulmonary artery denervation in postcapillary pulmonary hypertension: results of a randomized controlled translational study. Basic Research in Cardiology, 2019, 114, 5.	2.5	16
1790	Living With Severe Pulmonary Arterial Hypertension Without an Infusion Pump? Selexipag has a Role to Play. Archivos De Bronconeumologia, 2019, 55, 102-103.	0.4	3
1791	The burden of at-home preparation of lyophilized parenteral medications: an analysis of contributing factors and implications for chronic disease patients and caregivers. Expert Opinion on Drug Delivery, 2019, 16, 187-198.	2.4	2
1792	Biomechanical Forces and Oxidative Stress: Implications for Pulmonary Vascular Disease. Antioxidants and Redox Signaling, 2019, 31, 819-842.	2.5	27
1793	The impact of trisomy 21 on treatment modalities and outcome in adults with congenital heart disease in Switzerland. Pulmonary Circulation, 2019, 9, 1-8.	0.8	0
1794	Clinical presentation of existential distress in pulmonary arterial hypertension. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2019, 3, 56-62.	0.2	4
1795	Pulmonary Arterial Wedge Pressure at Rest and During Exercise in Healthy Adults: A Systematic Review and Meta-analysis. Journal of Cardiac Failure, 2019, 25, 114-122.	0.7	25
1796	Diagnosis of Pulmonary Hypertension with Cardiac MRI: Derivation and Validation of Regression Models. Radiology, 2019, 290, 61-68.	3.6	43

#	Article	IF	Citations
1797	Exercise physiology in pulmonary hypertension patients with and without congenital heart disease. European Journal of Preventive Cardiology, 2019, 26, 86-93.	0.8	18
1798	Discordance between Imaging Modalities in the Evaluation of Chronic Thromboembolic Pulmonary Hypertension: A Combined Experience from Two Academic Medical Centers. Annals of the American Thoracic Society, 2019, 16, 277-280.	1.5	3
1799	The evolving role of cardiac magnetic resonance in primary mitral regurgitation: ready for prime time?. European Heart Journal Cardiovascular Imaging, 2019, 20, 123-130.	0.5	17
1800	Increasing mixed venous oxygen saturation is a predictor of improved renal function after balloon pulmonary angioplasty in patients with chronic thromboembolic pulmonary hypertension. Heart and Vessels, 2019, 34, 688-697.	0.5	10
1801	17Î²-estradiol preserves right ventricular function in rats with pulmonary arterial hypertension: an echocardiographic and histochemical study. International Journal of Cardiovascular Imaging, 2019, 35, 441-450.	0.7	9
1802	Echocardiographic right ventricular strain from multiple apical views is superior for assessment of right ventricular systolic function. Clinical Physiology and Functional Imaging, 2019, 39, 168-176.	0.5	11
1803	Cardio-pulmonary MRI for detection of treatment response after a single BPA treatment session in CTEPH patients. European Radiology, 2019, 29, 1693-1702.	2.3	27
1804	Pulmonary hypertension in left heart disease. Archives of Medical Science, 2019, 15, 262-273.	0.4	23
1805	Nasally Inhaled Nitric Oxide for Sudden Right-Sided Heart Failure in the Intensive Care Unit: NO Time Like the Present. Journal of Cardiothoracic and Vascular Anesthesia, 2019, 33, 648-650.	0.6	2
1806	Update of screening and diagnostic modalities for connective tissue disease-associated pulmonary arterial hypertension. Seminars in Arthritis and Rheumatism, 2019, 48, 1059-1067.	1.6	30
1807	Haemodynamic mechanisms and longâ€term prognostic impact of pulmonary hypertension in patients with severe aortic stenosis undergoing valve replacement. European Journal of Heart Failure, 2019, 21, 172-181.	2.9	50
1808	Value of tissueâ€tracking tricuspid annular plane by speckleâ€tracking echocardiography for the assessment of right ventricular systolic dysfunction. Echocardiography, 2019, 36, 110-118.	0.3	7
1809	Advances in medical therapy for pulmonary arterial hypertension. Current Opinion in Cardiology, 2019, 34, 98-103.	0.8	7
1810	Clinical and hemodynamic factors in predicting response to fluid challenge during right heart catheterization. Pulmonary Circulation, 2019, 9, 1-7.	0.8	5
1811	Risk stratification and medical therapy of pulmonary arterial hypertension. European Respiratory Journal, 2019, 53, 1801889.	3.1	614
1812	Pathophysiology of the right ventricle andÂof the pulmonary circulation in pulmonary hypertension: an update. European Respiratory Journal, 2019, 53, 1801900.	3.1	315
1813	Intensive care, right ventricular support and lung transplantation in patients with pulmonary hypertension. European Respiratory Journal, 2019, 53, 1801906.	3.1	144
1814	Clinical trial design and new therapies for pulmonary arterial hypertension. European Respiratory Journal, 2019, 53, 1801908.	3.1	142

#	Article	IF	Citations
1815	Prognostic value of multiple repeated biomarkers in pulmonary arterial hypertension associated with congenital heart disease. European Journal of Heart Failure, 2019, 21, 249-251.	2.9	0
1816	Systemic thrombolysis in haemodynamically unstable pulmonary embolism: The earlier the better?. Thrombosis Research, 2019, 173, 117-123.	0.8	11
1817	Hemodynamics of the diastolic pressure gradients in acute heart failure: implications for the diagnosis of preâ€capillary pulmonary hypertension in left heart disease. Pulmonary Circulation, 2019, 9, 1-9.	0.8	5
1818	Diagnosing and Managing Pulmonary and Right-Sided Heart Disease: Pulmonary Hypertension, Right Ventricular Outflow Pathology, and Sleep Apnea. , 2019, , 231-248.		0
1819	Therapeutic Options for Patients With Idiopathic Pulmonary Fibrosis. , 2019, , 113-126.		0
1820	Development and Validation of a Questionnaire to Measure Patientâ€™s Experiences of Health Care in Pulmonary Arterial Hypertension Outpatient Clinics. Heart Lung and Circulation, 2019, 28, 1074-1081.	0.2	4
1821	Echocardiographic surrogates of right atrial pressure in pulmonary hypertension. Heart and Vessels, 2019, 34, 477-483.	0.5	5
1822	Clinical Effects of Syncope on Disease Severity and Adverse Outcomes in Children with Idiopathic and Heritable Pulmonary Arterial Hypertension. Pediatric Cardiology, 2019, 40, 209-214.	0.6	8
1823	Pulmonary Hypertension Induced by Anticancer Drugs. Current Clinical Pathology, 2019, , 133-139.	0.0	1
1824	Right Heart Catheterisation: How To Do It. Heart Lung and Circulation, 2019, 28, e71-e78.	0.2	18
1825	Hospitalisations for heart failure predict mortality in pulmonary hypertension related to congenital heart disease. Heart, 2019, 105, 465-469.	1.2	9
1826	Use of Vena Cava Filters and Venous Access Devices. , 2019, , 594-635.		1
1827	Real-life experience of inhaled iloprost for patients with pulmonary arterial hypertension: Insights from the Spanish REHAP registry. International Journal of Cardiology, 2019, 275, 158-164.	0.8	11
1828	Transitioning Parenteral or Inhaled Treprostinil to Oral Treprostinil Diolamine: Case Series and Review of the Literature. Journal of Pharmacy Practice, 2019, 32, 599-604.	0.5	6
1829	Extracorporeal Membrane Oxygenation Support During Pregnancy in Pulmonary Veno-occlusive Disease. Revista Espanola De Cardiologia (English Ed), 2019, 72, 174-175.	0.4	1
1830	Increased platelet content of SDF-1alpha is associated with worse prognosis in patients with pulmonary prterial hypertension. Platelets, 2019, 30, 445-451.	1.1	8
1831	Pulmonary Hypertension in Patients WithÂSevere Aortic Stenosis: PrognosticÂImpact After TranscatheterÂAortic Valve Replacement. JACC: Cardiovascular Imaging, 2019, 12, 591-601.	2.3	73
1832	miRâ€1 is increased in pulmonary hypertension and downregulates Kv1.5 channels in rat pulmonary arteries. Journal of Physiology, 2019, 597, 1185-1197.	1.3	51

#	Article	IF	Citations
1833	Prognostic impact of right bundle branch block in hospitalized patients with idiopathic dilated cardiomyopathy: a single-center cohort study. Journal of International Medical Research, 2020, 48, 030006051880147.	0.4	4
1834	Longterm Efficacy and Safety of Monotherapy versus Combination Therapy in Systemic Sclerosisâ€“associated Pulmonary Arterial Hypertension: A Retrospective RESCLE Registry Study. Journal of Rheumatology, 2020, 47, 89-98.	1.0	11
1835	Pulmonary Artery Involvement in Patients with Takayasu Arteritis. Journal of Rheumatology, 2020, 47, 264-272.	1.0	38
1836	Pulmonary hypertension with a low cardiac index requires a higher PaO 2 level to avoid tissue hypoxia. Respirology, 2020, 25, 97-103.	1.3	4
1837	Putting machine learning into motion: applications in cardiovascular imaging. Clinical Radiology, 2020, 75, 33-37.	0.5	17
1838	Cellular inflammation in pulmonary hypertension: Detailed analysis of lung and right ventricular tissue, circulating immune cells and effects of a dual endothelin receptor antagonist. Clinical Hemorheology and Microcirculation, 2020, 73, 497-522.	0.9	11
1839	Pulmonary hypertension and right ventricular remodeling in HFpEF and HFrEF. Heart Failure Reviews, 2020, 25, 85-91.	1.7	12
1840	Forkhead box M1 transcription factor: a novel target for pulmonary arterial hypertension therapy. World Journal of Pediatrics, 2020, 16, 113-119.	0.8	4
1841	Patients with severe aortic stenosis and coexisting pulmonary hypertension treated by transapical transcatheter aortic valve replacementâ€”Is there a need for increased attention?. Catheterization and Cardiovascular Interventions, 2020, 95, 1001-1008.	0.7	2
1842	Unique wreath-like smooth muscle proliferation of the pulmonary vasculature in pulmonary veno-occlusive disease versus pulmonary arterial hypertension. Journal of the Formosan Medical Association, 2020, 119, 300-309.	0.8	4
1843	Whole blood viscosity in systemic sclerosis: a potential biomarker of pulmonary hypertension?. Clinical Rheumatology, 2020, 39, 49-56.	1.0	11
1844	Cardiovascular manifestations of sickle cell disease. European Heart Journal, 2020, 41, 1365-1373.	1.0	25
1845	The role of cardiac imaging in the management of non-ischemic cardiovascular diseases in human immunodeficiency virus infection. Journal of Nuclear Cardiology, 2020, 27, 801-818.	1.4	0
1846	Clinical diagnostic value of circulating serum miR-509-3p in pulmonary arterial hypertension with congenital heart disease. Hellenic Journal of Cardiology, 2020, 61, 26-30.	0.4	13
1847	Medication adherence, hospitalization, and healthcare resource utilization and costs in patients with pulmonary arterial hypertension treated with endothelin receptor antagonists or phosphodiesterase typeâ€5Âinhibitors. Pulmonary Circulation, 2020, 10, 1-11.	0.8	15
1848	Right Ventricular to Left Ventricular Ratio atÂCT Pulmonary Angiogram Predicts Mortality in Interstitial Lung Disease. Chest, 2020, 157, 89-98.	0.4	30
1849	A novel secreted-cAMP pathway inhibits pulmonary hypertension via a feed-forward mechanism. Cardiovascular Research, 2020, 116, 1500-1513.	1.8	15
1850	Lower urinary tract symptoms in systemic sclerosis: a detailed investigation. Rheumatology, 2020, 59, 1315-1324.	0.9	8

#	Article	IF	Citations
1851	No indication for right heart catheterisation for patients with isolated severe obstructive sleep apnoea syndrome according to a guideline-recommended approach. European Journal of Preventive Cardiology, 2020, 27, 2212-2215.	0.8	0
1852	Poor outcomes in carriers of the RNF213 variant (p.Arg4810Lys) with pulmonary arterial hypertension. Journal of Heart and Lung Transplantation, 2020, 39, 103-112.	0.3	25
1853	Effects of HIV Infection on Pulmonary Artery Pressure in Children. Global Heart, 2019, 14, 367.	0.9	3
1854	Treatment Discontinuation or Interruption in Pulmonary Arterial Hypertension. Journal of Cardiovascular Pharmacology and Therapeutics, 2020, 25, 131-141.	1.0	15
1855	Risk Reduction and Right Heart Reverse Remodeling by Upfront Triple Combination Therapy in Pulmonary ArterialÂHypertension. Chest, 2020, 157, 376-383.	0.4	97
1856	Realâ€life data of direct anticoagulant use, bleeding risk and venous thromboembolism recurrence in chronic thromboembolic pulmonary hypertension patients: an observational retrospective study. Pulmonary Circulation, 2020, 10, 1-10.	0.8	31
1857	Using Transitional Changes on Highâ€Resolution Computed Tomography to Monitor the Impact of Cyclophosphamide or Mycophenolate Mofetil on Systemic Sclerosisâ€"Related Interstitial Lung Disease. Arthritis and Rheumatology, 2020, 72, 316-325.	2.9	14
1858	Hemodynamic Effects of Pulmonary Arterial Hypertension-Specific Therapy in Patients With Heart Failure With Preserved Ejection Fraction and With Combined Post- and Precapillay Pulmonary Hypertension. Journal of Cardiac Failure, 2020, 26, 26-34.	0.7	11
1859	Adult congenital heart disease with pulmonary arterial hypertension: mechanisms and management. Heart Failure Reviews, 2020, 25, 773-794.	1.7	4
1860	Passive leg-lifting in heart failure patients predicts exercise-induced rise in left ventricular filling pressures. Clinical Research in Cardiology, 2020, 109, 498-507.	1.5	13
1861	Urgent lung transplantation in acute fibrinous and organizing pneumonia: a sliding door or a new perspective?. General Thoracic and Cardiovascular Surgery, 2020, 68, 136-141.	0.4	3
1862	A single-centre, placebo-controlled, double-blind randomised cross-over study of nebulised iloprost in patients with Eisenmenger syndrome: A pilot study. International Journal of Cardiology, 2020, 299, 131-135.	0.8	12
1863	A case of suspected portal-pulmonary hypertension due to hepatitis C virus infection. Clinical Journal of Gastroenterology, 2020, 13, 90-96.	0.4	2
1864	Comment on: Update of screening and diagnostic modalities for connective tissue disease-associated pulmonary arterial hypertension. Seminars in Arthritis and Rheumatism, 2020, 50, E3.	1.6	0
1865	Prolonged pulmonary pulse transit time is associated with symptoms in patients with significant mitral stenosis and sinus rhythm. Journal of Clinical Ultrasound, 2020, 48, 38-44.	0.4	5
1866	Nailfold Videocapillaroscopy in Systemic Sclerosisâ€"related Pulmonary Arterial Hypertension: A Systematic Literature Review. Journal of Rheumatology, 2020, 47, 888-895.	1.0	24
1867	2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). European Heart Journal, 2020, 41, 543-603.	1.0	2,426
1868	Growth differentiation factor-15 as candidate predictor for mortality in adults with pulmonary hypertension. Heart, 2020, 106, 467-473.	1.2	14

#	Article	IF	Citations
1869	The Role of Noninvasive Endpoints in Predicting Long-Term Outcomes in Pulmonary Arterial Hypertension. Lung, 2020, 198, 65-86.	1.4	10
1870	Cardiopulmonary exercise testing in a combined screening approach to individuate pulmonary arterial hypertension in systemic sclerosis. Rheumatology, 2020, 59, 1581-1586.	0.9	22
1871	Pulmonary hypertension is associated with increased nonrelapse mortality after allogeneic hematopoietic cell transplantation for myelofibrosis. Bone Marrow Transplantation, 2020, 55, 877-883.	1.3	13
1872	Effectiveness of epoprostenol in the management of pulmonary arterial hypertension: findings of an Australian retrospective chart review. Internal Medicine Journal, 2020, 50, 1377-1384.	0.5	2
1873	Interaction between PGI2 and ET-1 pathways in vascular smooth muscle from Group-III pulmonary hypertension patients. Prostaglandins and Other Lipid Mediators, 2020, 146, 106388.	1.0	5
1874	Prognostic value of hemodynamics and comorbidities in pulmonary hypertension due to advanced heart failure. Heart and Lung: Journal of Acute and Critical Care, 2020, 49, 158-164.	0.8	2
1875	Management of age-associated medical complications in patients with Î²-thalassemia. Expert Review of Hematology, 2020, 13, 85-94.	1.0	18
1876	Sex-related differences in exercise performance and outcome of patients with hypertrophic cardiomyopathy. European Journal of Preventive Cardiology, 2020, 27, 1821-1831.	0.8	15
1877	Association Between Right Ventricular Contractile Function and Cardiac Events in Isolated Postcapillary and Combined Pre- and Postcapillary Pulmonary Hypertension. Journal of Cardiac Failure, 2020, 26, 43-51.	0.7	5
1878	Bronchodilation induced by PGE 2 is impaired in Group III pulmonary hypertension. British Journal of Pharmacology, 2020, 177, 161-174.	2.7	13
1879	Sexâ€specific differences in chronic thromboembolic pulmonary hypertension. Results from the European CTEPH registry. Journal of Thrombosis and Haemostasis, 2020, 18, 151-161.	1.9	42
1880	Automatic Remasking of Digital Subtraction Angiography Images in Pulmonary Angiography. Journal of Digital Imaging, 2020, 33, 531-537.	1.6	2
1881	Cyclophilin A as a biomarker for the therapeutic effect of balloon angioplasty in chronic thromboembolic pulmonary hypertension. Journal of Cardiology, 2020, 75, 415-423.	0.8	2
1882	A multicenter study of anticoagulation in operable chronic thromboembolic pulmonary hypertension. Journal of Thrombosis and Haemostasis, 2020, 18, 114-122.	1.9	81
1883	Retrospective Validation of the REVEAL 2.0ÂRisk Score With the Australian and NewÂZealand Pulmonary Hypertension Registry Cohort. Chest, 2020, 157, 162-172.	0.4	23
1884	Comparative effectiveness of pulmonary arterial hypertension drugs in treatment-naive patients: a network meta-analysis. Journal of Comparative Effectiveness Research, 2020, 9, 7-22.	0.6	6
1885	Retrospective Database Analysis of Treatment Patterns Among Patients with Pulmonary Arterial Hypertension. Pulmonary Therapy, 2020, 6, 79-92.	1.1	8
1886	Circulating NEDD9 is increased in pulmonary arterial hypertension: A multicenter, retrospective analysis. Journal of Heart and Lung Transplantation, 2020, 39, 289-299.	0.3	19

#	Article	IF	Citations
1887	Pulmonary hypertension after shunt closure in patients with simple congenital heart defects. International Journal of Cardiology, 2020, 308, 28-32.	0.8	36
1888	ACC/AHA/ASE/HRS/ISACHD/SCAI/SCCT/SCMR/SOPE 2020 Appropriate Use Criteria for Multimodality Imaging During the Follow-Up Care of Patients With Congenital Heart Disease. Journal of the American College of Cardiology, 2020, 75, 657-703.	1.2	93
1889	Ambulatory Transition from Parenteral Prostanoid to Inhaled Treprostinil in Patients with Pulmonary Arterial Hypertension. Lung, 2020, 198, 53-58.	1.4	3
1890	Balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension. Cardiovascular Intervention and Therapeutics, 2020, 35, 130-141.	1.2	26
1891	Evolution of Patients with Pulmonary Arterial Hypertension Starting Macitentan After the Discontinuation of Other Endothelin-Receptor Antagonists: Results of a Retrospective Study. American Journal of Cardiovascular Drugs, 2020, 20, 481-487.	1.0	6
1892	What's in a prick? Vaccines and the cardiovascular system. Hellenic Journal of Cardiology, 2020, 61, 233-240.	0.4	1
1893	Long-term changes of right ventricular myocardial deformation and remodeling studied by cardiac magnetic resonance imaging in patients with chronic thromboembolic pulmonary hypertension following pulmonary thromboendarterectomy. International Journal of Cardiology, 2020, 300, 282-288.	0.8	19
1894	Current status of long-term prognosis among all subtypes of pulmonary hypertension in Japan. International Journal of Cardiology, 2020, 300, 228-235.	0.8	27
1895	â€œThe post-pulmonary syndrome - results of echocardiographic driven follow up after acute pulmonary embolismâ€• Thrombosis Research, 2020, 186, 30-35.	0.8	26
1896	The role of cardiopulmonary exercise testing and training in patients with pulmonary hypertension: making the case for this assessment and intervention to be considered a standard of care. Expert Review of Respiratory Medicine, 2020, 14, 317-327.	1.0	5
1897	Echocardiography reporting of pulmonary hypertension and subsequent referral to a specialty clinic. Echocardiography, 2020, 37, 8-13.	0.3	2
1898	Biomarkers and Right Ventricular Dysfunction. Critical Care Clinics, 2020, 36, 141-153.	1.0	14
1899	Ultrafast Ultrasound Imaging in PediatricÂand Adult Cardiology. JACC: Cardiovascular Imaging, 2020, 13, 1771-1791.	2.3	54
1900	Long noncoding RNAs: emerging roles in pulmonary hypertension. Heart Failure Reviews, 2020, 25, 795-815.	1.7	21
1901	Results of an Expert Consensus Survey on the Treatment of Pulmonary Arterial Hypertension With Oral Prostacyclin Pathway Agents. Chest, 2020, 157, 955-965.	0.4	26
1902	Pulmonary Hypertension Subtypes and Mortality in CKD. American Journal of Kidney Diseases, 2020, 75, 713-724.	2.1	32
1903	Risk factors for chronic thromboembolic pulmonary hypertension â€“ Importance of thyroid disease and function. Thrombosis Research, 2020, 185, 20-26.	0.8	9
1904	Systemic endothelial glycocalyx and aortic stiffness are preserved in pulmonary arterial hypertension. Hellenic Journal of Cardiology, 2020, 61, 288-290.	0.4	3

#	Article	IF	Citations
1905	Progression of nailfold capillaroscopic patterns and correlation with organ involvement in systemic sclerosis: a 12 year study. Rheumatology, 2020, 59, 1051-1058.	0.9	27
1906	Linking lncRNAs to regulation, pathogenesis, and diagnosis of pulmonary hypertension. Critical Reviews in Clinical Laboratory Sciences, 2020, 57, 181-195.	2.7	3
1907	A Bayesian Network Meta-analysis of Add-on Drug Therapies Specific for Pulmonary Arterial Hypertension. Annals of Pharmacotherapy, 2020, 54, 423-433.	0.9	3
1908	Clinical and Prognostic Values of ALBI Score in Patients With Acute Heart Failure. Heart Lung and Circulation, 2020, 29, 1328-1337.	0.2	28
1909	Extracorporeal Membrane Oxygenation in the Perioperative Care of the Lung Transplant Patient. Seminars in Cardiothoracic and Vascular Anesthesia, 2020, 24, 45-53.	0.4	18
1910	Biomarker-specific differences between transpulmonary and peripheral arterialâ€“venous blood sampling in patients with pulmonary hypertension. Biomarkers, 2020, 25, 131-136.	0.9	2
1911	Primary pulmonary arterial hypertension: Protocol to assess comprehensively in the rat the response to pharmacologic treatments. MethodsX, 2020, 7, 100771.	0.7	1
1912	PPARÎ³ is a gatekeeper for extracellular matrix and vascular cell homeostasis. Current Opinion in Nephrology and Hypertension, 2020, 29, 171-179.	1.0	38
1913	Intensity and quality of exertional dyspnoea in patients with stable pulmonary hypertension. European Respiratory Journal, 2020, 55, 1802108.	3.1	24
1914	Association between resting painless ST-segment depression with sudden cardiac death in middle-aged population: A prospective cohort study. International Journal of Cardiology, 2020, 301, 1-6.	0.8	4
1915	Diagnosis of pulmonary hypertension by noninvasive methods in hematopoietic cell transplant patients with myelofibrosis. Bone Marrow Transplantation, 2020, 55, 1681-1683.	1.3	4
1916	Pulmonary Hypertension Is a Potentially Reversible Contraindication to Cardiac Transplantation. ASAIO Journal, 2020, 66, e67-e67.	0.9	1
1917	Pulmonary hypertension detection by computed tomography pulmonary transit time in heart failure with reduced ejection fraction. European Heart Journal Cardiovascular Imaging, 2020, 21, 1291-1298.	0.5	16
1918	Right Ventricular Function and Long-Term Outcome in Sepsis: A Retrospective Cohort Study. Shock, 2020, 53, 537-543.	1.0	17
1919	Haemodynamic phenotypes and survival in patients with systemic sclerosis: the impact of the new definition of pulmonary arterial hypertension. Annals of the Rheumatic Diseases, 2020, 79, 370-378.	0.5	60
1920	The importance of right ventricular evaluation in risk assessment and therapeutic strategies: Raising the bar in pulmonary arterial hypertension. International Journal of Cardiology, 2020, 301, 183-189.	0.8	40
1921	Cocaine Use and Pulmonary Hypertension. American Journal of Cardiology, 2020, 125, 282-288.	0.7	13
1922	Endothelin-1, cardiac morphology, and heart failure: the MESA angiogenesis study. Journal of Heart and Lung Transplantation, 2020, 39, 45-52.	0.3	12

#	Article	IF	Citations
1923	Safety and efficacy of balloon pulmonary angioplasty in chronic thromboembolic pulmonary hypertension in the Netherlands. Netherlands Heart Journal, 2020, 28, 81-88.	0.3	24
1924	Activated Endothelial TGFÎ²1 Signaling Promotes Venous Thrombus Nonresolution in Mice Via Endothelin-1. Circulation Research, 2020, 126, 162-181.	2.0	37
1925	Chronic Thromboembolic Pulmonary Hypertension-Management Strategies and Outcomes. Journal of Cardiothoracic and Vascular Anesthesia, 2020, 34, 2513-2523.	0.6	15
1926	Effects of Pulmonary Hypertension on Exercise Capacity in Patients With Chronic Obstructive Pulmonary Disease. Archivos De Bronconeumologia, 2020, 56, 499-505.	0.4	8
1927	Clinical ultrasonography in systemic autoimmune diseases. Revista Clínica Espanõla, 2020, 220, 297-304.	0.3	0
1928	Acute Respiratory Failure in Interstitial Lung Disease Complicated by Pulmonary Hypertension. Respiratory Medicine, 2020, 161, 105825.	1.3	0
1929	Early post-transplant elevated pulmonary artery pressure predicts adverse outcome in cardiac recipients. IJC Heart and Vasculature, 2020, 26, 100438.	0.6	3
1930	Characteristics of Japanese elderly patients with pulmonary arterial hypertension. Pulmonary Circulation, 2020, 10, 1-13.	0.8	6
1931	Clinical implications of partial anomalous pulmonary venous connection: a rare cause of severe pulmonary arterial hypertension. Pulmonary Circulation, 2020, 10, 1-5.	0.8	4
1932	Nocturnal hypoxia in patients with idiopathic pulmonary arterial hypertension. Pulmonary Circulation, 2020, 10, 1-7.	0.8	5
1933	Prognostic value of sixâ€minute walk distance at a South American pulmonary hypertension referral center. Pulmonary Circulation, 2020, 10, 1-6.	0.8	3
1934	The changing face of pulmonary hypertension diagnosis: a historical perspective on the influence of diagnostics and biomarkers. Pulmonary Circulation, 2020, 10, 1-26.	0.8	17
1935	Outpatient specialist clinics for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension in the Nordic countries. Pulmonary Circulation, 2020, 10, 1-7.	0.8	2
1936	Effects of pulmonary endarterectomy on pulmonary hemodynamics in chronic thromboembolic pulmonary hypertension, evaluated by interventricular septum curvature. Pulmonary Circulation, 2020, 10, 1-9.	0.8	3
1937	Connexin-43 is a promising target for pulmonary hypertension due to hypoxaemic lung disease. European Respiratory Journal, 2020, 55, 1900169.	3.1	12
1938	Trans-Rightâ€“Ventricle and Transpulmonary MicroRNA Gradients in Human Pulmonary Arterial Hypertension*. Pediatric Critical Care Medicine, 2020, 21, 340-349.	0.2	21
1939	Right Heart Catheterization-Related Complications. Cardiology in Review, 2020, 28, 36-41.	0.6	32
1940	Is There Value in Repeating Inhaled Nitric Oxide Vasoreactivity Tests in Patients with Pulmonary Arterial Hypertension?. Lung, 2020, 198, 87-94.	1.4	7

#	Article	IF	Citations
1941	ERS Scientific Working Group 09.04, â€œPsychologists and behavioural scientistsâ€: the next step towards multidisciplinary respiratory care. European Respiratory Journal, 2020, 56, 2001881.	3.1	1
1942	Insulin-like growth factor binding protein-2: a new circulating indicator of pulmonary arterial hypertension severity and survival. BMC Medicine, 2020, 18, 268.	2.3	15
1943	Pathological Mechanisms and Potential Therapeutic Targets of Pulmonary Arterial Hypertension: A Review. , 2020, 11, 1623.		29
1944	Coagulation Profiles of Pulmonary Arterial Hypertension Patients, Assessed by Non-Conventional Hemostatic Tests and Markers of Platelet Activation and Endothelial Dysfunction. Diagnostics, 2020, 10, 758.	1.3	13
1945	Computed Tomography Angiographyâ€“Based Pulmonary Artery Volumetry as a Diagnostic Tool for Pulmonary Hypertension. Journal of Computer Assisted Tomography, 2020, 44, 681-686.	0.5	1
1946	The Value of C-Arm Computed Tomography in Addition to Conventional Digital Subtraction Angiography in the Diagnostic Work-up of Patients with Suspected Chronic Thromboembolic Pulmonary Hypertension: An Update of 300 Patients. Academic Radiology, 2022, 29, S1-S10.	1.3	6
1947	A lung graph model for the radiological assessment of chronic thromboembolic pulmonary hypertension in CT. Computers in Biology and Medicine, 2020, 125, 103962.	3.9	6
1948	Structural and hemodynamic properties of murine pulmonary arterial networks under hypoxia-induced pulmonary hypertension. Proceedings of the Institution of Mechanical Engineers, Part H: Journal of Engineering in Medicine, 2020, 234, 1312-1329.	1.0	11
1949	Longâ€term chronic intermittent hypoxia: a particular form of chronic highâ€altitude pulmonary hypertension. Pulmonary Circulation, 2020, 10, 5-12.	0.8	18
1950	Current clinical utilization of risk assessment tools in pulmonary arterial hypertension: a descriptive survey of facilitation strategies, patterns, and barriers to use in the United States. Pulmonary Circulation, 2020, 10, 1-10.	0.8	9
1951	Comparative effectiveness of endothelin receptor antagonists on mortality in patients with pulmonary arterial hypertension in a US Medicare population: a retrospective database analysis. Pulmonary Circulation, 2020, 10, 204589402095415.	0.8	1
1952	Right ventriculoâ€“pulmonary arterial uncoupling and poor outcomes in pulmonary arterial hypertension. Pulmonary Circulation, 2020, 10, 1-11.	0.8	5
1953	Evaluation of codeâ€based algorithms to identify pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension patients in large administrative databases. Pulmonary Circulation, 2020, 10, 1-10.	0.8	13
1954	Novel composite clinical endpoints and risk scores used in clinical trials in pulmonary arterial hypertension. Pulmonary Circulation, 2020, 10, 1-11.	0.8	12
1955	BMPR2 Promoter Variants Effect Gene Expression in Pulmonary Arterial Hypertension Patients. Genes, 2020, 11, 1168.	1.0	3
1956	New Insights Into Heat Shock Protein 90 in the Pathogenesis of Pulmonary Arterial Hypertension. Frontiers in Physiology, 2020, 11, 1081.	1.3	3
1957	Evaluation and management of pulmonary arterial hypertension. Respiratory Medicine, 2020, 171, 106099.	1.3	43
1958	Single-center prognostic validation of the risk assessment of the 2015 ESC/ERS guidelines in patients with pulmonary arterial hypertension in Japan. Canadian Journal of Physiology and Pharmacology, 2020, 98, 653-658.	0.7	2

#	Article	IF	Citations
1959	Borneol-mediated vardenafil hydrochloride patch for pediatric pulmonary arterial hypertension: Preparation, characterization and in vivo study. International Journal of Pharmaceutics, 2020, 591, 119864.	2.6	6
1960	The role of macrophages in pulmonary hypertension: Pathogenesis and targeting. International Immunopharmacology, 2020, 88, 106934.	1.7	16
1961	Cardiovascular disease in women: insights from magnetic resonance imaging. Journal of Cardiovascular Magnetic Resonance, 2020, 22, 71.	1.6	19
1962	Pulmonary hypertension associated with left-sided heart failure. Current Opinion in Cardiology, 2020, 35, 610-619.	0.8	13
1963	Upregulation of miR-361-3p suppresses serotonin-induced proliferation in human pulmonary artery smooth muscle cells by targeting SERT. Cellular and Molecular Biology Letters, 2020, 25, 45.	2.7	11
1964	Genetic Evaluation in a Cohort of 126 Dutch Pulmonary Arterial Hypertension Patients. Genes, 2020, 11, 1191.	1.0	12
1965	Comparison of Outcomes in Adults With Ventricular Septal Defect Closed Earlier in Life Versus Those in Whom the Defect Was Never Closed. American Journal of Cardiology, 2020, 133, 139-147.	0.7	6
1966	Effects of Pulmonary Hypertension on Exercise Capacity in Patients With Chronic Obstructive Pulmonary Disease. Archivos De Bronconeumologia, 2020, 56, 499-505.	0.4	6
1967	Looking Rightward in Acute Left Heart Failure. Journal of Cardiac Failure, 2020, 26, 821-823.	0.7	0
1968	Can anticoagulants improve the survival rate for patients with idiopathic pulmonary arterial hypertension? A systematic review and meta-analysis. Thrombosis Research, 2020, 196, 251-256.	0.8	10
1969	The beneficial effects of angiotensin-converting enzyme II (ACE2) activator in pulmonary hypertension secondary to left ventricular dysfunction. International Journal of Medical Sciences, 2020, 17, 2594-2602.	1.1	9
1970	Successful treatment for a patient with chronic thromboembolic pulmonary hypertension comorbid with essential thrombocythemia with the JAK2 V617F mutation by balloon pulmonary angioplasty. Respiratory Medicine Case Reports, 2020, 31, 101235.	0.2	2
1971	Predictors of infection-related rehospitalization in heart failure patients and its impact on long-term survival. Journal of Cardiovascular Medicine, 2020, 21, 889-896.	0.6	6
1972	Implementation of a systematic comprehensive geriatric assessment for elderly patients suspected of pulmonary hypertension. Respiratory Medicine and Research, 2020, 78, 100785.	0.4	0
1973	Pulmonary hypertension due to left heart disease with pulmonary arterial wedge pressure â‰¥15â€¯mmâ€¯Hg. Herz, 2020, 46, 209-214.	0.4	1
1974	Pulmonary capillary hemangiomatosis-predominant vasculopathy in a patient with rheumatoid arthritis-associated interstitial lung disease: An autopsy report. Respiratory Medicine Case Reports, 2020, 31, 101215.	0.2	0
1975	Multimodality Imaging of Pulmonary Hypertension. Current Treatment Options in Cardiovascular Medicine, 2020, 22, 1.	0.4	0
1977	Effects of macitentan and tadalafil monotherapy or their combination on the right ventricle and plasma metabolites in pulmonary hypertensive rats. Pulmonary Circulation, 2020, 10, 1-16.	0.8	9

#	Article	IF	Citations
1978	Chronic thromboembolic pulmonary hypertension mimicking coronary artery disease. Pulmonary Circulation, 2020, 10, 1-2.	0.8	0
1979	Role of biomarkers in evaluation, treatment and clinical studies of pulmonary arterial hypertension. Pulmonary Circulation, 2020, 10, 1-17.	0.8	16
1980	Poor outcome of patients with pulmonary arterial hypertension with insufficient response to phosphodiesteraseâ€5Âinhibitors alone or in combination with other specific therapy: a registryâ€based study. Pulmonary Circulation, 2020, 10, 1-9.	0.8	0
1981	Burden of pulmonary hypertension in patients with portal hypertension in the United States: a retrospective database study. Pulmonary Circulation, 2020, 10, 1-9.	0.8	6
1982	Large Granular Lymphocyte Leukemia and Precapillary Pulmonary Hypertension. Chest, 2020, 158, 2602-2609.	0.4	5
1983	Idiopathic pulmonary arterial hypertension phenotypes determined by cluster analysis from the COMPERA registry. Journal of Heart and Lung Transplantation, 2020, 39, 1435-1444.	0.3	104
1984	Upfront triple oral combination therapy including selexipag in a high-risk patient with idiopathic pulmonary arterial hypertension: a case report. European Heart Journal - Case Reports, 2020, 4, 1-5.	0.3	2
1985	Resolving the Ionotropic P2X4 Receptor Mystery Points towards a New Therapeutic Target for Cardiovascular Diseases. International Journal of Molecular Sciences, 2020, 21, 5005.	1.8	16
1986	Increased levels of platelet-derived microparticles in pulmonary hypertension. Thrombosis Research, 2020, 195, 120-124.	0.8	13
1987	Atrial fibrillation and atrial tachycardia in patients with chronic thromboembolic pulmonary hypertension treated with pulmonary endarterectomy. European Heart Journal Supplements, 2020, 22, F30-F37.	0.0	9
1988	Predicting the Risk of Adverse Events in Pregnant Women With Congenital Heart Disease. Journal of the American Heart Association, 2020, 9, e016371.	1.6	24
1989	Plasma adrenomedullin peptides and precursor levels in pulmonary arterial hypertension disease severity and risk stratification. Pulmonary Circulation, 2020, 10, 1-9.	0.8	8
1990	Elevated plasma endocan and BOC in heart failure patients decrease after heart transplantation in association with improved hemodynamics. Heart and Vessels, 2020, 35, 1614-1628.	0.5	7
1991	Echocardiographic Evaluation of Left Ventricular Filling Pressure in Patients With Heart Failure With Preserved Ejection Fraction: Usefulness of Inferior Vena Cava Measurements and 2016 EACVI/ASE Recommendations. Journal of Cardiac Failure, 2020, 26, 507-514.	0.7	10
1992	The features of rare pathogenic BMPR2 variants in pulmonary arterial hypertension: Comparison between patients and reference population. International Journal of Cardiology, 2020, 318, 138-143.	0.8	3
1993	Guidelines for the Treatment of Pulmonary Arterial Hypertension. Lung, 2020, 198, 581-596.	1.4	37
1995	The Conundrum of Right Ventricular Remodeling and Outcome in Pulmonary Hypertension. Circulation: Cardiovascular Imaging, 2020, 13, e011208.	1.3	2
1996	Safety and efficacy of transitioning from the combination of bosentan and sildenafil to alternative therapy in patients with pulmonary arterial hypertension. Pulmonary Circulation, 2020, 10, 1-8.	0.8	4

#	Article	IF	Citations
1997	Neurofibromatosis-associated pulmonary hypertension: an ominous duo. BMJ Case Reports, 2020, 13, e234976.	0.2	1
1998	Efficacy and safety of ambrisentan in Chinese patients with connective tissue disease-pulmonary arterial hypertension: a post-hoc analysis. BMC Cardiovascular Disorders, 2020, 20, 339.	0.7	1
1999	The outcome of pulmonary hypertension and its association with pulmonary artery dilatation. Netherlands Heart Journal, 2020, 28, 645-655.	0.3	4
2000	Venookklusive Erkrankung: Eine gezielte vasoaktive Therapie als BrÃ¼cke zur Lungentransplantation. Karger Kompass Pneumologie, 2020, 8, 142-143.	0.0	0
2001	Elevated plasma sRAGE and IGFBP7 in heart failure decrease after heart transplantation in association with haemodynamics. ESC Heart Failure, 2020, 7, 2340-2353.	1.4	10
2002	Pulmonary Hypertension in TranscatheterÂMitral Valve Repair for Secondary Mitral Regurgitation. Journal of the American College of Cardiology, 2020, 76, 2595-2606.	1.2	27
2003	Prognostic importance of Kidney, Heart and Interstitial lung diseases (KHI triad) in PH: A machine learning study. Archives of Cardiovascular Diseases, 2020, 113, 630-641.	0.7	3
2004	Hemodynamic and Clinical Implications of Impaired Pulmonary Vascular Reserve in the Fontan Circulation. Journal of the American College of Cardiology, 2020, 76, 2755-2763.	1.2	36
2005	Mitochondria-Associated Endoplasmic Reticulum Membranes in Cardiovascular Diseases. Frontiers in Cell and Developmental Biology, 2020, 8, 604240.	1.8	69
2006	P53 in the impaired lungs. DNA Repair, 2020, 95, 102952.	1.3	25
2007	Emerging therapies for right ventricular dysfunction and failure. Cardiovascular Diagnosis and Therapy, 2020, 10, 1735-1767.	0.7	13
2008	Update on noninvasive imaging of right ventricle dysfunction in pulmonary hypertension. Cardiovascular Diagnosis and Therapy, 2020, 10, 1604-1624.	0.7	16
2009	Treatment of right ventricular dysfunction and heart failure in pulmonary arterial hypertension. Cardiovascular Diagnosis and Therapy, 2020, 10, 1659-1674.	0.7	19
2010	Safety and efficacy of the endothelin receptor antagonist macitentan in pediatric pulmonary hypertension. Cardiovascular Diagnosis and Therapy, 2020, 10, 1675-1685.	0.7	14
2011	BKCa Channel Activation Attenuates the Pathophysiological Progression of Monocrotaline-Induced Pulmonary Arterial Hypertension in Wistar Rats. Cardiovascular Drugs and Therapy, 2021, 35, 719-732.	1.3	8
2012	Evaluation of right ventricular performance and impact of continuous positive airway pressure therapy in patients with obstructive sleep apnea living at high altitude. Scientific Reports, 2020, 10, 20186.	1.6	10
2013	Micro-RNA Analysis in Pulmonary Arterial Hypertension. JACC Basic To Translational Science, 2020, 5, 1149-1162.	1.9	24
2014	Epigenetic Regulation of Pulmonary Arterial Hypertension-Induced Vascular and Right Ventricular Remodeling: New Opportunities?. International Journal of Molecular Sciences, 2020, 21, 8901.	1.8	16

#	Article	IF	Citations
2016	Neurohormonal Modulation as a Therapeutic Target in Pulmonary Hypertension. Cells, 2020, 9, 2521.	1.8	4
2017	Development of a New International Antiphospholipid Syndrome Classification Criteria Phase I/II Report: Generation and Reduction of Candidate Criteria. Arthritis Care and Research, 2021, 73, 1490-1501.	1.5	60
2018	Cardiovascular Hoarseness (Ortner's Syndrome): A Pictorial Review. Current Problems in Diagnostic Radiology, 2021, 50, 749-754.	0.6	16
2019	Relationship between calcifications and structural lesions on hand radiography and axial calcifications on CT-scan. Medicine (United States), 2020, 99, e22443.	0.4	7
2020	Higher Incidence of Atrial Fibrillation in Left Ventricular-to-Right Atrial Shunt Patients. Frontiers in Physiology, 2020, 11, 580624.	1.3	2
2021	Surgery for Pulmonary Vascular Disease. , 2020, , 113-117.		1
2022	Predictive Factor for COVID-19 Worsening: Insights for High-Sensitivity Troponin and D-Dimer and Correlation With Right Ventricular Afterload. Frontiers in Medicine, 2020, 7, 586307.	1.2	34
2023	A successful case of heart transplantation concurrent with pulmonary thromboendarterectomy. Perfusion (United Kingdom), 2021, 36, 879-882.	0.5	0
2024	Impact of patient characteristics and perceived barriers on referral to exercise rehabilitation among patients with pulmonary hypertension in the United States. Pulmonary Circulation, 2020, 10, 1-9.	0.8	4
2025	Elevated Circulatory Levels of Microparticles Are Associated to Lung Fibrosis and Vasculopathy During Systemic Sclerosis. Frontiers in Immunology, 2020, 11, 532177.	2.2	13
2026	DDCIâ€01, a novel long acting phospdiesteraseâ€5Âinhibitor, attenuated monocrotalineâ€induced pulmonary hypertension in rats. Pulmonary Circulation, 2020, 10, 1-10.	0.8	0
2027	Effect of Coronavirus Disease 2019 in Pulmonary Circulation. The Particular Scenario of Precapillary Pulmonary Hypertension. Diagnostics, 2020, 10, 548.	1.3	21
2028	Macrophage migration inhibitory factor and chemokine RANTES in young pediatric patients with congenital cardiac communications: Relation to hemodynamic parameters and the presence of Down syndrome. Cytokine, 2020, 134, 155192.	1.4	1
2029	An update on sarcoidosis-associated pulmonary hypertension. Current Opinion in Pulmonary Medicine, 2020, 26, 582-590.	1.2	17
2030	Pulmonary arterial hypertension: closing the gap in congenital heart disease. Current Opinion in Pulmonary Medicine, 2020, 26, 422-428.	1.2	7
2031	Pulmonary arterial hypertension screening practices in scleroderma patients among Canadian rheumatologists. Journal of Scleroderma and Related Disorders, 2020, 5, 237-241.	1.0	2
2032	Do the remodeling effects of sacubitril/valsartan treatment depend upon heart failure duration?. Journal of Cardiovascular Medicine, 2020, 21, 682-687.	0.6	10
2033	Tibetan patients with hepatic hydatidosis can tolerate hypoxic environment without incident increase of pulmonary hypertension: an echocardiography study. International Journal of Cardiovascular Imaging, 2020, 36, 2139-2144.	0.7	0

#	Article	IF	Citations
2034	Predictive Value of Pulmonary Arterial Compliance in Systemic Lupus Erythematosus Patients With Pulmonary Arterial Hypertension. Hypertension, 2020, 76, 1161-1168.	1.3	8
2035	Assessment of Severity in Chronic Thromboembolic Pulmonary Hypertension by Quantitative Parameters of Dual-Energy Computed Tomography. Journal of Computer Assisted Tomography, 2020, 44, 578-585.	0.5	13
2036	Novel doseâ€"response analyses of treprostinil in pulmonary arterial hypertension and its effects on sixâ€minute walk distance and hospitalizations. Pulmonary Circulation, 2020, 10, 1-12.	0.8	7
2037	Improving adherence to pulmonary hypertension screening in patients with systemic sclerosis: Overcoming the provider-level barriers. Journal of Scleroderma and Related Disorders, 2020, 5, 219-223.	1.0	1
2038	Association of Preoperative Mixed Venous Oxygen Saturation with Postoperative Segmental Pulmonary Hypertension in Pulmonary Atresia with Ventricular Septal Defect and Major Aortopulmonary Collaterals. Pediatric Cardiology, 2020, 41, 1689-1696.	0.6	0
2039	Identification of Long Noncoding RNA H19 as a New Biomarker and Therapeutic Target in Right Ventricular Failure in Pulmonary Arterial Hypertension. Circulation, 2020, 142, 1464-1484.	1.6	96
2040	Gut microbiota modification suppresses the development of pulmonary arterial hypertension in an SU5416/hypoxia rat model. Pulmonary Circulation, 2020, 10, 1-10.	0.8	32
2041	Comparative effectiveness of oral prostacyclin pathway drugs on hospitalization in patients with pulmonary hypertension in the United States: a retrospective database analysis. Pulmonary Circulation, 2020, 10, 204589402091183.	0.8	5
2042	Antiâ€synthetase syndromeâ€associated pulmonary venoâ€occlusive disease. Pulmonary Circulation, 2020, 10, 1-4.	0.8	5
2043	Effects of exercise rehabilitation training on patients with pulmonary hypertension. Pulmonary Circulation, 2020, 10, 1-8.	0.8	5
2044	Pulmonary arterial hypertension and heart failure with preserved ejection fraction: are they so discordant?. Cardiovascular Diagnosis and Therapy, 2020, 10, 534-545.	0.7	5
2045	Longâ€term outcomes in pulmonary arterial hypertension by functional class: a metaâ€analysis of randomized controlled trials and observational registries. Pulmonary Circulation, 2020, 10, 1-10.	0.8	5
2046	Evidence synthesis in pulmonary arterial hypertension: a systematic review and critical appraisal. BMC Pulmonary Medicine, 2020, 20, 202.	0.8	4
2047	A promising approach for screening pulmonary hypertension based on frontal chest radiographs using deep learning: A retrospective study. PLoS ONE, 2020, 15, e0236378.	1.1	21
2048	The dangerous and contradictory prognostic significance of PVR<3WU when TAPSE<16mm in postcapillary pulmonary hypertension. ESC Heart Failure, 2020, 7, 2398-2405.	1.4	4
2049	Evolution of blood biomarker levels following percutaneous atrial septal defect closure in adults. IJC Heart and Vasculature, 2020, 30, 100582.	0.6	3
2050	Supervised Exercise Training in Patients with Chronic Thromboembolic Pulmonary Hypertension as Early Follow-Up Treatment after Pulmonary Endarterectomy: A Prospective Cohort Study. Respiration, 2020, 99, 577-588.	1.2	18
2051	High plasma adiponectin is associated with increased pulmonary blood flow and reduced right ventricular function in patients with pulmonary hypertension. BMC Pulmonary Medicine, 2020, 20, 204.	0.8	2

#	Article	IF	Citations
2052	Impact of Combined Pre and Postcapillary Pulmonary Hypertension on Survival after Transcatheter Aortic Valve Implantation. American Journal of Cardiology, 2020, 131, 60-66.	0.7	19
2053	Global Right Heart Assessment with Speckle-Tracking Imaging Improves the Risk Prediction of a Validated Scoring System in Pulmonary Arterial Hypertension. Journal of the American Society of Echocardiography, 2020, 33, 1334-1344.e2.	1.2	14
2054	Chronic Obstructive Pulmonary Disease and Lung Transplantation. Seminars in Respiratory and Critical Care Medicine, 2020, 41, 862-873.	0.8	1
2055	Use of Treprostinil in Pediatric Pulmonary Hypertension: Case Reports and Review of the Literature. Journal of Cardiovascular Pharmacology, 2020, 76, 23-31.	0.8	6
2056	Thrombocytopenia During Prostacyclin Analogue Therapies of Pulmonary Arterial Hypertensionâ€"Possible Pathomechanisms and Implications. Journal of Cardiovascular Pharmacology, 2020, 75, 421-425.	0.8	2
2057	Increased Levels of Runt-Related Transcription Factor 2 Are Associated With Poor Survival of Patients With Idiopathic Pulmonary Arterial Hypertension. American Journal of Men's Health, 2020, 14, 155798832094545.	0.7	8
2058	Prevalence and risk factors of high echocardiographic probability of pulmonary hypertension in myeloproliferative neoplasms patients. International Journal of Hematology, 2020, 112, 631-639.	0.7	2
2059	Use of Anticoagulants in Patients with Pulmonary Hypertension. Hamostaseologie, 2020, 40, 348-355.	0.9	15
2060	Risk assessment in severe pulmonary hypertension due to interstitial lung disease. Journal of Heart and Lung Transplantation, 2020, 39, 1118-1125.	0.3	15
2061	Effect and mechanism of prophylactic use of tadalafil during pregnancy on l-NAME-induced preeclampsia-like rats. Placenta, 2020, 99, 35-44.	0.7	10
2062	Essential aspects of the followâ€up after acute pulmonary embolism: An illustrated review. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 958-968.	1.0	33
2063	New developments in adult congenital heart disease. Netherlands Heart Journal, 2020, 28, 44-49.	0.3	8
2064	Sarcoidosis-Associated Pulmonary Hypertension. Seminars in Respiratory and Critical Care Medicine, 2020, 41, 659-672.	0.8	11
2065	Imaging in mitral stenosis. Current Opinion in Cardiology, 2020, 35, 445-453.	0.8	1
2066	Perioperative management of patients with undergoing durable mechanical circulatory support. Annals of Translational Medicine, 2020, 8, 830-830.	0.7	4
2067	Combination of F-ASO and Targeted Medical Therapy in Patients With Secundum ASD and Severe PAH. JACC: Cardiovascular Interventions, 2020, 13, 2024-2034.	1.1	16
2068	Atrial Septal Defect Closure in Patients With Pulmonary Hypertension. JACC: Cardiovascular Interventions, 2020, 13, 2035-2037.	1.1	2
2069	Predicting the outcomes of pulmonary hypertension is aÂbreathtaking task. Netherlands Heart Journal, 2020, 28, 623-624.	0.3	0

#	Article	IF	Citations
2071	Current Understanding of Circulating Biomarkers in Pulmonary Hypertension Due to Left Heart Disease. Frontiers in Medicine, 2020, 7, 570016.	1.2	5
2072	Acute effects of intravenous pimobendan administration in dog models of chronic precapillary pulmonary hypertension. Journal of Veterinary Cardiology, 2020, 32, 16-27.	0.3	8
2073	Echocardiographic Findings Among Virally Suppressed HIV-Infected Aging Asians Compared with HIV-Negative Individuals. Journal of Acquired Immune Deficiency Syndromes (1999), 2020, 85, 379-386.	0.9	3
2074	Red blood cell distribution width in addition to N-terminal prohormone of B-type natriuretic peptide concentration improves assessment of risk of cardiovascular events in adult patients with congenital heart disease. Archives of Cardiovascular Diseases, 2020, 113, 607-616.	0.7	2
2075	Decreased activation of ataxia telangiectasia mutatedÂ(ATM) in monocytesâ€‚from patients with systemic sclerosis. Rheumatology, 2020, 59, 3961-3970.	0.9	0
2076	Regional Right Ventricular Abnormalities Implicate Distinct Pathophysiological Conditions in Patients With Chronic Thromboembolic Pulmonary Hypertension. Journal of the American Heart Association, 2020, 9, e018096.	1.6	3
2077	E3 Ubiquitin ligase NEDD4 familyâ€˜regulatory network in cardiovascular disease. International Journal of Biological Sciences, 2020, 16, 2727-2740.	2.6	39
2078	Efficacy of the thromboxane receptor antagonist NTP42 alone, or in combination with sildenafil, in the sugen/hypoxia-induced model of pulmonary arterial hypertension. European Journal of Pharmacology, 2020, 889, 173658.	1.7	7
2079	Distinct patterns of soluble leukocyte activation markers are associated with etiology and outcomes in precapillary pulmonary hypertension. Scientific Reports, 2020, 10, 18540.	1.6	2
2081	Continuous and Noninvasive Estimation of Right Ventricle Systolic Blood Pressure Using Heart Sound Signal by Deep Bidirectional LSTM Network. Applied Sciences (Switzerland), 2020, 10, 5466.	1.3	3
2082	Riociguat in the Treatment of Chronic Thromboembolic Pulmonary Hypertension: An Evidence-Based Review of Its Place in Therapy . Core Evidence, 2020, Volume 15, 31-40.	4.7	6
2083	Mycophenolate Mofetil Improves Exercise Tolerance in Systemic Sclerosis Patients with Interstitial Lung Disease: A Pilot Study. Rheumatology and Therapy, 2020, 7, 1037-1044.	1.1	2
2084	Purinergic Dysfunction in Pulmonary Arterial Hypertension. Journal of the American Heart Association, 2020, 9, e017404.	1.6	16
2085	Prediction of Prognostic Hemodynamic Indices in Pulmonary Hypertension Using Non-Invasive Parameters. Diagnostics, 2020, 10, 644.	1.3	3
2086	Expanding Applications of Pulmonary MRI in the Clinical Evaluation of Lung Disorders: Fleischner Society Position Paper. Radiology, 2020, 297, 286-301.	3.6	95
2087	Exercise Hemodynamics in the Prognosis of Patients with Pulmonary Arterial Hypertension. Respiration, 2020, 99, 678-685.	1.2	2
2088	Echocardiography in Autoimmune Rheumatic Diseases for Diagnosis and Prognosis of Cardiovascular Complications. Medicina (Lithuania), 2020, 56, 445.	0.8	5
2089	Cardiac Magnetic Resonance Imaging in Pulmonary Arterial Hypertension: Ready for Clinical Practice and Guidelines?. Current Heart Failure Reports, 2020, 17, 181-191.	1.3	5

#	Article	IF	Citations
2090	How to interpret echocardiogram reports. InnovAiT, 2020, 13, 589-596.	0.0	0
2091	Altitude Travel in Patients With Pulmonary Hypertension: Randomized Pilot-Trial Evaluating Nocturnal Oxygen Therapy. Frontiers in Medicine, 2020, 7, 502.	1.2	9
2092	ACC/AHA/ASE/HRS/ISACHD/SCAI/SCCT/SCMR/SOPE 2020 Appropriate Use Criteria for Multimodality Imaging During the Follow-Up Care of Patients With Congenital Heart Disease. Journal of the American Society of Echocardiography, 2020, 33, e1-e48.	1.2	26
2093	Therapeutic Benefit of the Association of Lodenafil with Mesenchymal Stem Cells on Hypoxia-induced Pulmonary Hypertension in Rats. Cells, 2020, 9, 2120.	1.8	4
2094	Outcomes of Atrioseptostomy with Stenting in Patients with Pulmonary Arterial Hypertension from a Large Single-Institution Cohort. Diagnostics, 2020, 10, 725.	1.3	10
2095	Association between right atrial area measured by echocardiography and prognosis among pulmonary arterial hypertension: a systematic review and meta-analysis. BMJ Open, 2020, 10, e031316.	0.8	12
2096	A Case Report of a Patient With Pulmonary Arterial Hypertension Transitioned From Inhaled Iloprost to Selexipag. Journal of Pharmacy Practice, 2021, 34, 980-983.	0.5	2
2097	Automatic Diagnosis of Chronic Thromboembolic Pulmonary Hypertension Based on Volumetric Data from SPECT Ventilation and Perfusion Images. Applied Sciences (Switzerland), 2020, 10, 5360.	1.3	2
2098	Echocardiographic Diagnosis of Postcapillary Pulmonary Hypertension: A RIGHT1 Substudy. Hearts, 2020, 1, 38-49.	0.4	1
2099	Focused Update on Pulmonary Hypertension in Childrenâ€"Selected Topics of Interest for the Adult Cardiologist. Medicina (Lithuania), 2020, 56, 420.	0.8	1
2100	Therapeutic options for chronic kidney disease-associated pulmonary hypertension. Current Opinion in Nephrology and Hypertension, 2020, 29, 497-507.	1.0	2
2101	Prevalence and characteristics of portopulmonary hypertension in cirrhotic patients who underwent both hepatic vein and pulmonary artery catheterization. Hepatology Research, 2020, 50, 1244-1254.	1.8	18
2102	The Role and Regulation of Pulmonary Artery Smooth Muscle Cells in Pulmonary Hypertension. International Journal of Hypertension, 2020, 2020, 1-10.	0.5	9
2103	Inpatient Palliative Care Use in Patients With Pulmonary Arterial Hypertension. Chest, 2020, 158, 2568-2578.	0.4	20
2104	Impact of Tricuspid Regurgitation on Clinical Outcomes. Journal of the American College of Cardiology, 2020, 76, 1305-1314.	1.2	63
2105	The V̇I‡<scp>e</scp>/V̇I‡<scp>co</scp>₂ slope: a useful tool to evaluate the physiological status of children with congenital heart disease. Journal of Applied Physiology, 2020, 129, 1102-1110.	1.2	15
2106	Severe pulmonary arterial hypertension and interstitial pneumonia related to systemic lupus erythematosus successfully treated with mycophenolate mofetil: A novel case report. Lupus, 2020, 29, 1955-1960.	0.8	5
2107	Perioperative CTEPH patient monitoring with 2D phase-contrast MRI reflects clinical, cardiac and pulmonary perfusion changes after pulmonary endarterectomy. PLoS ONE, 2020, 15, e0238171.	1.1	6

#	Article	IF	Citations
2108	Nitric Oxide Stroke Volume Index as a New Hemodynamic Prognostic Parameter for Patients with Pulmonary Arterial Hypertension. Journal of Clinical Medicine, 2020, 9, 2939.	1.0	2
2109	Phosphodiesterase 5 inhibitor sildenafil in patients with heart failure with preserved ejection fraction and combined pre- and postcapillary pulmonary hypertension: a randomized open-label pilot study. BMC Cardiovascular Disorders, 2020, 20, 408.	0.7	26
2110	Implication of Potassium Channels in the Pathophysiology of Pulmonary Arterial Hypertension. Biomolecules, 2020, 10, 1261.	1.8	27
2111	Implication of Hemodynamic Assessment during Durable Left Ventricular Assist Device Support. Medicina (Lithuania), 2020, 56, 413.	0.8	1
2112	Diagnosis and Management of Patients with Heart Failure with Preserved Ejection Fraction (HFpEF): Current Perspectives and Recommendations . Therapeutics and Clinical Risk Management, 2020, Volume 16, 769-785.	0.9	16
2113	Galectin-3, GDF-15, and sST2 for the assessment of disease severity and therapy response in patients suffering from inoperable chronic thromboembolic pulmonary hypertension. Biomarkers, 2020, 25, 578-586.	0.9	19
2114	Anesthesia for pulmonary veno-occlusive disease: the dilemma and what we should know as anesthesiologists. Medicine (United States), 2020, 99, e21517.	0.4	1
2115	Exacerbated inflammatory signaling underlies aberrant response to BMP9 in pulmonary arterial hypertension lung endothelial cells. Angiogenesis, 2020, 23, 699-714.	3.7	22
2116	Imaging assessment of mitral and aortic regurgitation: current state of the art. Heart, 2020, 106, 1769-1776.	1.2	6
2117	CT-Based Biomarkers for Prediction of Chronic Thromboembolic Pulmonary Hypertension After an Acute Pulmonary Embolic Event. American Journal of Roentgenology, 2020, 215, 800-806.	1.0	16
2118	Pulmonary hypertension in majority countries: opportunities amidst challenges. Current Opinion in Pulmonary Medicine, 2020, 26, 373-383.	1.2	9
2119	Effect of ambrisentan on echocardiographic and Doppler measures from patients in China with pulmonary arterial hypertension. Expert Review of Cardiovascular Therapy, 2020, 18, 643-649.	0.6	1
2120	The usefulness of subxiphoid view in the evaluation of acceleration time and pulmonary hypertension in ICU patients. Echocardiography, 2020, 37, 1345-1352.	0.3	3
2121	Adherence to disease-specific drug treatment among patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension. ERJ Open Research, 2020, 6, 00299-2020.	1.1	23
2122	Clinical trial design in phase 2 and 3 trials for pulmonary hypertension. Pulmonary Circulation, 2020, 10, 1-10.	0.8	5
2123	â€˜Tired, afraid, breathlessâ€‰â€¦â€‰.â€™ An international survey of the exercise experience for people living with pulmonary hypertension. Pulmonary Circulation, 2020, 10, 1-10.	0.8	14
2124	Assessment of the REPLACE study composite endpoint in riociguatâ€treated patients in the PATENT study. Pulmonary Circulation, 2020, 10, 1-8.	0.8	4
2125	Patients with Single-Ventricle Physiology over the Age of 40 Years. Journal of Clinical Medicine, 2020, 9, 4085.	1.0	12

#	Article	IF	Citations
2126	Prevalence and outcomes of pulmonary hypertension after percutaneous closure of atrial septal defect: a systematic review and meta-analysis. European Respiratory Review, 2020, 29, 200099.	3.0	8
2127	Schistosomiasis Pulmonary Arterial Hypertension. Frontiers in Immunology, 2020, 11, 608883.	2.2	22
2128	Mid-regional pro-atrial natriuretic peptide and copeptin as indicators of disease severity and therapy response in CTEPH. ERJ Open Research, 2020, 6, 00356-2020.	1.1	6
2129	Physical Activity and Mental Health of Patients with Pulmonary Hypertension during the COVID-19 Pandemic. Journal of Clinical Medicine, 2020, 9, 4023.	1.0	14
2130	Targeted Drugs for Treatment of Pulmonary Arterial Hypertension: Past, Present, and Future Perspectives. Journal of Medicinal Chemistry, 2020, 63, 15153-15186.	2.9	20
2131	LOW UTILIZATION OF PROSTACYCLIN THERAPY PRIOR TO DEATH AMONG MEDICARE PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION. Chest, 2020, 158, A2164-A2165.	0.4	1
2132	REASONS FOR REFUSING PARENTERAL THERAPY: A QUALITATIVE STUDY OF PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION. Chest, 2020, 158, A2274.	0.4	0
2133	Echocardiography to Screen for Pulmonary Hypertension in CKD. Kidney International Reports, 2020, 5, 2275-2283.	0.4	4
2134	Commentary: Transplanting the powerhouse of the cell to enhance cardiopulmonary repair. Journal of Thoracic and Cardiovascular Surgery, 2020, , .	0.4	0
2135	A Randomized Study of Safety and Efficacy of Two Doses of Ambrisentan to Treat Pulmonary Arterial Hypertension in Pediatric Patients Aged 8 Years up to 18 Years. Journal of Pediatrics: X, 2020, 5, 100055.	1.1	1
2136	Toward Better Reproducibility in Experimental Research on New Agents for Pulmonary Hypertension. An Analysis of Data from Four Hundred Animal Studies. Cardiovascular Drugs and Therapy, 2021, 35, 707-718.	1.3	5
2137	Deep learning to predict elevated pulmonary artery pressure in patients with suspected pulmonary hypertension using standard chest X ray. Scientific Reports, 2020, 10, 19311.	1.6	28
2138	Proof that exercise works, now itâ€™s time for optimizing delivery to our patients with pulmonary hypertension. European Heart Journal, 2020, 42, 2296-2298.	1.0	5
2139	Non-invasive pulmonary artery pressure estimation by electrical impedance tomography in a controlled hypoxemia study in healthy subjects. Scientific Reports, 2020, 10, 21462.	1.6	11
2140	Cardiac manifestations of rheumatological disease: a synopsis for the cardiologist. Heart, 2021, 107, 1173-1181.	1.2	8
2141	Serum biomarker analysis at the protein level on pulmonary hypertension secondary to old anterior myocardial infarction. Pulmonary Circulation, 2020, 10, 1-13.	0.8	2
2142	Diagnostic utility of subâ€maximum cardiopulmonary exercise testing in the ambulatory setting for heart failure with preserved ejection fraction. Pulmonary Circulation, 2020, 10, 1-10.	0.8	10
2143	Peri-operative right ventricular dysfunctionâ€”the anesthesiologistâ€™s view. Cardiovascular Diagnosis and Therapy, 2020, 10, 1725-1734.	0.7	5

#	Article	IF	Citations
2144	Oral drugs used to treat persistent pulmonary hypertension of the newborn. Expert Review of Clinical Pharmacology, 2020, 13, 1295-1308.	1.3	5
2145	Kidney failure after lung transplantation in systemic scleroderma: a case report with literature review. Renal Replacement Therapy, 2020, 6, .	0.3	1
2146	Galectin-3 Plasma Levels Are Associated with Risk Profiles in Pulmonary Arterial Hypertension. Diagnostics, 2020, 10, 857.	1.3	4
2147	Pulmonary thromboendarterectomy in Portugal: Initial experience. Revista Portuguesa De Cardiologia, 2020, 39, 505-512.	0.2	6
2148	Right Atrial Pressure During Exercise Predicts Survival in Patients With Pulmonary Hypertension. Journal of the American Heart Association, 2020, 9, e018123.	1.6	8
2149	Pulmonary Hypertension Due to Left Heart Disease. Hypertension, 2020, 75, 1397-1408.	1.3	56
2150	Initial combination therapy of macitentan and tadalafil in pulmonary arterial hypertension. European Respiratory Journal, 2020, 56, 2000673.	3.1	35
2151	Long-term real world clinical outcomes of macitentan therapy in chronic thromboembolic pulmonary hypertension. Respiratory Medicine, 2020, 167, 105966.	1.3	6
2152	Selexipag treatment in patients with systemic sclerosisâ€“associated pulmonary arterial hypertension in clinical practice, a case series. Journal of Scleroderma and Related Disorders, 2020, 5, NP7-NP11.	1.0	2
2153	Risk assessment in PAH using quantitative CMR tricuspid regurgitation: relation to heart catheterization. ESC Heart Failure, 2020, 7, 1653-1663.	1.4	4
2154	Left ventricular assist devices in patients eligible for heart transplant with irreversible pulmonary hypertension. Revista Espanola De Cardiologia (English Ed), 2020, 73, 583-586.	0.4	0
2155	Turning the Oxygen Dial: Balancing the Highs and Lows. Trends in Cell Biology, 2020, 30, 516-536.	3.6	41
2156	Serum N-terminal pro-B-type natriuretic peptide levels are associated with left atrial dilation, resting left ventricular outflow tract gradient, and pulmonary hypertension in patients with hypertrophic cardiomyopathy. Postepy W Kardiologii Interwencyjnej, 2020, 16, 97-101.	0.1	0
2157	Early Intervention of Tongxinluo (é€šå¿ƒç»œ) on Right Ventricular Function Assessed by Echocardiography in Rats with Pulmonary Arterial Hypertension Induced by Monocrotaline. Chinese Journal of Integrative Medicine, 2020, 26, 913-920.	0.7	5
2158	BNP/NT-proBNP in pulmonary arterial hypertension: time for point-of-care testing?. European Respiratory Review, 2020, 29, 200009.	3.0	51
2159	Cardiac function and pulmonary hypertension in Central Asian highlanders at 3250â€…m. European Respiratory Journal, 2020, 56, 1902474.	3.1	22
2160	Supervised pulmonary hypertension exercise rehabilitation (SPHERe): study protocol for a multi-centre randomised controlled trial. BMC Pulmonary Medicine, 2020, 20, 143.	0.8	4
2161	Increased myocardial oxygen consumption rates are associated with maladaptive right ventricular remodeling and decreased event-free survival in heart failure patients. Journal of Nuclear Cardiology, 2021, 28, 2784-2795.	1.4	8

#	Article	IF	Citations
2162	Early SurgicalÂClosure of Atrial Septal Defect Improves Clinical Status of Symptomatic Young Children with Underlying Pulmonary Abnormalities. Pediatric Cardiology, 2020, 41, 1115-1124.	0.6	7
2163	Challenges and Special Aspects of Pulmonary Hypertension in Middle- to Low-Income Regions. Journal of the American College of Cardiology, 2020, 75, 2463-2477.	1.2	29
2164	Exercise and fluid challenge during right heart catheterisation for evaluation of dyspnoea. Pulmonary Circulation, 2020, 10, 1-9.	0.8	9
2165	Adenosine and the Cardiovascular System: The Good and the Bad. Journal of Clinical Medicine, 2020, 9, 1366.	1.0	52
2166	Selexipag for the treatment of children with pulmonary arterial hypertension: First multicenter experience in drug safety and efficacy. Journal of Heart and Lung Transplantation, 2020, 39, 695-706.	0.3	34
2167	Severe Pulmonary Hypertension Management Across Europe (PHAROS): an ERS Clinical Research Collaboration. European Respiratory Journal, 2020, 55, 2001047.	3.1	3
2168	Exercise Echocardiography as a Screening Tool in Systemic Sclerosis. Journal of Rheumatology, 2020, 47, 643-645.	1.0	2
2169	Disease severityâ€"related alterations of cardiac microRNAs in experimental pulmonary hypertension. Journal of Cellular and Molecular Medicine, 2020, 24, 6943-6951.	1.6	8
2170	Clinical characteristics and survival of Chinese patients diagnosed with pulmonary arterial hypertension who carry BMPR2 or EIF2KAK4 variants. BMC Pulmonary Medicine, 2020, 20, 150.	0.8	6
2171	Comparison of Balloon Pulmonary Angioplasty and Pulmonary Vasodilators for Inoperable Chronic Thromboembolic Pulmonary Hypertension: A Systematic Review and Meta-Analysis. Scientific Reports, 2020, 10, 8870.	1.6	22
2172	Implantable system for treprostinil: a realâ€world patient experience study. Pulmonary Circulation, 2020, 10, 1-10.	0.8	7
2173	Pulmonary hypertension with adult respiratory distress syndrome: prevalence, clinical impact, and association with central venous pressure. Pulmonary Circulation, 2020, 10, 1-8.	0.8	8
2174	Silibinin Upregulates CXCR4 Expression in Cultured Bone Marrow Cells (BMCs) Especially in Pulmonary Arterial Hypertension Rat Model. Cells, 2020, 9, 1276.	1.8	10
2175	Myeloproliferative Diseases as Possible Risk Factor for Development of Chronic Thromboembolic Pulmonary Hypertensionâ€"A Genetic Study. International Journal of Molecular Sciences, 2020, 21, 3339.	1.8	13
2176	Pulmonary Hypertension in Adults with Congenital Heart Disease: Real-World Data from the International COMPERA-CHD Registry. Journal of Clinical Medicine, 2020, 9, 1456.	1.0	21
2177	Axial pulmonary trunk diameter variations during the cardiac cycle. Surgical and Radiologic Anatomy, 2020, 42, 1279-1285.	0.6	2
2178	Incorporation of renal function in mortality risk assessment for pulmonary arterial hypertension. Journal of Heart and Lung Transplantation, 2020, 39, 675-685.	0.3	11
2179	Secondary Pulmonary Hypertension Among Patients Qualified for Lung Transplantation: Single-Center Study. Transplantation Proceedings, 2020, 52, 2101-2109.	0.3	0

#	Article	IF	Citations
2180	Multicentre randomised controlled trial of balloon pulmonary angioplasty and riociguat in patients with chronic thromboembolic pulmonary hypertension: protocol for the MR BPA study. BMJ Open, 2020, 10, e028831.	0.8	17
2181	Familial Recurrent Myocarditis Triggered by Exercise in Patients With a Truncating Variant of the Desmoplakin Gene. Journal of the American Heart Association, 2020, 9, e015289.	1.6	39
2183	Reduced pulmonary vascular reserve during stress echocardiography in confirmed pulmonary hypertension and patients at risk of overt pulmonary hypertension. International Journal of Cardiovascular Imaging, 2020, 36, 1831-1843.	0.7	4
2184	Predictive model of bosentan-induced liver toxicity in Japanese patients with pulmonary arterial hypertension. Canadian Journal of Physiology and Pharmacology, 2020, 98, 625-628.	0.7	2
2185	Role of Gas6 and TAM Receptors in the Identification of Cardiopulmonary Involvement in Systemic Sclerosis and Scleroderma Spectrum Disorders. Disease Markers, 2020, 2020, 1-8.	0.6	7
2186	Decoupling Between Diastolic Pulmonary Artery and Pulmonary Capillary Wedge Pressures Is Associated With Right Ventricular Dysfunction and Hemocompatibilityâ€Related Adverse Events in Patients With Left Ventricular Assist Devices. Journal of the American Heart Association, 2020, 9, e014801.	1.6	10
2187	Pulmonary vascular resistance as a potential marker of reactive pulmonary hypertension reduction following sildenafil therapy in patients disqualified from orthotopic heart transplantation. Advances in Medical Sciences, 2020, 65, 298-303.	0.9	0
2188	Echocardiographic Findings in Patients With COVID-19 Pneumonia. Canadian Journal of Cardiology, 2020, 36, 1203-1207.	0.8	130
2189	Impact of Inferior Venae Cava Assessment in Tetralogy of Fallot. CJC Open, 2020, 2, 129-134.	0.7	1
2190	DLNO/DLCO ratio evolution under targeted therapy in patients with pulmonary hypertension. Respiratory Physiology and Neurobiology, 2020, 279, 103467.	0.7	0
2191	Transitions between infused and oral prostacyclin pathway agents in pulmonary arterial hypertension: key considerations. Pulmonary Circulation, 2020, 10, 1-7.	0.8	5
2192	Editorial: Drug Development and Target Discovery in Pulmonary Vascular Diseases. Frontiers in Pharmacology, 2020, 11, 660.	1.6	2
2193	CAMPHOR score: patient-reported outcomes are improved by pulmonary endarterectomy in chronic thromboembolic pulmonary hypertension. European Respiratory Journal, 2020, 56, 1902096.	3.1	28
2194	Autoantibodies to stratify systemic sclerosis patients into clinically actionable subsets. Autoimmunity Reviews, 2020, 19, 102583.	2.5	25
2195	Congenital heart disease with pulmonary artery hypertension in an Asian cohort-initial report from TACHYON (TAiwan congenital heart disease associated with pulmonarY arterial hypertension) registry. International Journal of Cardiology, 2020, 317, 49-55.	0.8	6
2196	Dyspnea in antiphospholipid syndrome: Beyond pulmonary embolism. Revista Portuguesa De Cardiologia (English Edition), 2020, 39, 47.e1-47.e5.	0.2	0
2197	Virtual Histology to Evaluate Mechanisms of Pulmonary Artery Lumen Enlargement in Response to Balloon Pulmonary Angioplasty in Chronic Thromboembolic Pulmonary Hypertension. Journal of Clinical Medicine, 2020, 9, 1655.	1.0	8
2198	Management of adult patients with PAH in Spain: current practice, resources, and needs (AIRE17 Study). REC: CardioClinics, 2020, 55, 147-154.	0.1	2

#	Article	IF	Citations
2199	Interleukin-32 in systemic sclerosis, a potential new biomarker for pulmonary arterial hypertension. Arthritis Research and Therapy, 2020, 22, 127.	1.6	18
2200	Pulmonary Arterial Hypertensionâ€"Symptoms and Impact Questionnaire: feasibility of utilizing oneâ€day versus sevenâ€day symptom reporting. Pulmonary Circulation, 2020, 10, 1-9.	0.8	5
2201	Right ventricular function parameters in pulmonary hypertension: echocardiography vs. cardiac magnetic resonance. BMC Cardiovascular Disorders, 2020, 20, 259.	0.7	15
2202	Changes in REVEAL risk score in patients with pulmonary arterial hypertension treated with macitentan in clinical practice: results from the PRACMA study. BMC Pulmonary Medicine, 2020, 20, 154.	0.8	1
2203	Rightâ€sided cardiac disease: no longer the â€˜dark side of the heartâ€™. European Journal of Heart Failure, 2020, 22, 1226-1229.	2.9	1
2204	Long-term changes of exercise hemodynamics and physical capacity in chronic thromboembolic pulmonary hypertension after pulmonary thromboendarterectomy. International Journal of Cardiology, 2020, 317, 181-187.	0.8	6
2205	Biomedical invasive pressure sensor coatings: calibration and waveform perspectives. Journal of Medical Engineering and Technology, 2020, 44, 203-209.	0.8	2
2206	Effects of Different Types of Exercise Training on Pulmonary Arterial Hypertension: A Systematic Review. Journal of Clinical Medicine, 2020, 9, 1689.	1.0	14
2207	Surgical and Percutaneous Interventions for Chronic Thromboembolic Pulmonary Hypertension. Cardiology Clinics, 2020, 38, 257-268.	0.9	5
2208	The Role of Multimodality Imaging in Right Ventricular Failure. Cardiology Clinics, 2020, 38, 203-217.	0.9	3
2209	The tricuspid annular plane systolic excursion to systolic pulmonary artery pressure index: Association with all-cause mortality in patients with moderate or severe tricuspid regurgitation. International Journal of Cardiology, 2020, 317, 176-180.	0.8	18
2210	Pulmonary hypertension due to left heart disease: diagnostic value of pulmonary artery distensibility. European Radiology, 2020, 30, 6204-6212.	2.3	8
2211	Attitudes towards exercise among medical specialists who manage patients with pulmonary hypertension. Pulmonary Circulation, 2020, 10, 1-12.	0.8	6
2212	Role of Cardiovascular CT in Pulmonary Hypertension. Current Radiology Reports, 2020, 8, 1.	0.4	0
2213	Children and Adolescents with Pulmonary Arterial Hypertension: Baseline and Follow-Up Data from the Polish Registry of Pulmonary Hypertension (BNP-PL). Journal of Clinical Medicine, 2020, 9, 1717.	1.0	14
2214	â€œPureâ€•severe aortic stenosis without concomitant valvular heart diseases: echocardiographic and pathophysiological features. International Journal of Cardiovascular Imaging, 2020, 36, 1917-1929.	0.7	8
2215	Chronic Thromboembolic Pulmonary Hypertension Secondary to Thrombophilia and Incidentally Diagnosed Atrial Septal Defect. JACC: Case Reports, 2020, 2, 658-661.	0.3	1
2216	Pregnancy outcomes in patients with pulmonary arterial hypertension. Medicine (United States), 2020, 99, e20285.	0.4	32

#	Article	IF	Citations
2217	Spermine promotes pulmonary vascular remodelling and its synthase is a therapeutic target for pulmonary arterial hypertension. European Respiratory Journal, 2020, 56, 2000522.	3.1	39
2218	Prognostic Value of Right Ventricular Two-Dimensional and Three-Dimensional Speckle-Tracking Strain in Pulmonary Arterial Hypertension: Superiority of Longitudinal Strain over Circumferential and Radial Strain. Journal of the American Society of Echocardiography, 2020, 33, 985-994.e1.	1.2	37
2219	Does combination therapy work in chronic thromboembolic pulmonary hypertension?. IJC Heart and Vasculature, 2020, 29, 100544.	0.6	3
2220	Design of the Î²3-Adrenergic Agonist Treatment in Chronic Pulmonary Hypertension Secondary to HeartÂFailureÂTrial. JACC Basic To Translational Science, 2020, 5, 317-327.	1.9	12
2221	Lipid Accumulation in Hearts Transplanted From Nondiabetic Donors to Diabetic Recipients. Journal of the American College of Cardiology, 2020, 75, 1249-1262.	1.2	41
2222	Dyspnea in antiphospholipid syndrome: Beyond pulmonary embolism. Revista Portuguesa De Cardiologia, 2020, 39, 47.e1-47.e5.	0.2	1
2223	Clinical characteristics, diagnosis, and risk stratification of pulmonary hypertension in severe tricuspid regurgitation and implications for transcatheter tricuspid valve repair. European Heart Journal, 2020, 41, 2785-2795.	1.0	117
2224	Finding concordance in discord: the value of discordant invasive and echocardiographic pulmonary artery pressure measurements with severe tricuspid regurgitation. European Heart Journal, 2020, 41, 2796-2798.	1.0	14
2225	Effects of adopting the Global Lung Function Initiative 2017 reference equations on the interpretation of carbon monoxide transfer factor. European Respiratory Journal, 2020, 55, 1901905.	3.1	9
2226	Echocardiographic predictors of stress induced right ventricular diastolic dysfunction in non-severe chronic obstructive pulmonary disease. Journal of Cardiology, 2020, 76, 163-170.	0.8	0
2227	Oxygen therapy for pulmonary arterial hypertension: We need to rethink and investigate. Respirology, 2020, 25, 470-471.	1.3	4
2228	Pleuroparenchymal fibroelastosis in patients with idiopathic pulmonary fibrosis. Respirology, 2020, 25, 1046-1052.	1.3	24
2229	Phenotype and outcome of pulmonary arterial hypertension patients carrying a TBX4 mutation. European Respiratory Journal, 2020, 55, 1902340.	3.1	40
2231	Medication Adherence and Healthcare Costs Among Patients with Pulmonary Arterial Hypertension Treated with Oral Prostacyclins: A Retrospective Cohort Study. Drugs - Real World Outcomes, 2020, 7, 229-239.	0.7	10
2232	A randomized controlled trial on inspiratory muscle training in pulmonary hypertension: Effects on respiratory functions, functional exercise capacity, physical activity, and quality of life. Heart and Lung: Journal of Acute and Critical Care, 2020, 49, 381-387.	0.8	20
2233	Portopulmonary hypertension in the current era of pulmonary hypertension management. Journal of Hepatology, 2020, 73, 130-139.	1.8	78
2234	Diagnosis of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism. European Respiratory Journal, 2020, 55, 2000189.	3.1	55
2235	Accuracy of right atrial pressure estimation using a multi-parameter approach derived from inferior vena cava semi-automated edge-tracking echocardiography: a pilot study in patients with cardiovascular disorders. International Journal of Cardiovascular Imaging, 2020, 36, 1213-1225.	0.7	14

#	Article	IF	Citations
2236	Association Between Cardiac Injury and Mortality in Hospitalized Patients Infected With Avian Influenza A (H7N9) Virus. Critical Care Medicine, 2020, 48, 451-458.	0.4	74
2237	mmu_circ_0000790 Is Involved in Pulmonary Vascular Remodeling in Mice with HPH via MicroRNA-374c-Mediated FOXC1. Molecular Therapy - Nucleic Acids, 2020, 20, 292-307.	2.3	29
2238	Biomarkers in pulmonary arterial hypertension: Moving closer toward precision medicine?. Journal of Heart and Lung Transplantation, 2020, 39, 287-288.	0.3	5
2239	Diagnosis and Management of Pulmonary Hypertension in Patients With CKD. American Journal of Kidney Diseases, 2020, 75, 935-945.	2.1	25
2240	Comparison of inhaled nitric oxide with aerosolized prostacyclin or analogues for the postoperative management of pulmonary hypertension: a systematic review and meta-analysis. Annals of Medicine, 2020, 52, 120-130.	1.5	6
2241	Chronic thromboembolic disease following pulmonary embolism: time for a fresh look at old clot. European Respiratory Journal, 2020, 55, 1901934.	3.1	11
2242	Serum High-Density Lipoprotein Cholesterol is Significantly Associated with the Presence and Severity of Pulmonary Arterial Hypertension: A Retrospective Cross-Sectional Study. Advances in Therapy, 2020, 37, 2199-2209.	1.3	10
2243	Pulmonary thromboembolism with computed tomography defined chronic thrombus is associated with higher mortality. Pulmonary Circulation, 2020, 10, 1-8.	0.8	2
2244	Addition of a bilateral access form of peripheral extracorporeal membrane oxygenation rescued a patient with idiopathic pulmonary arterial hypertension who developed circulatory collapse immediately after childbirth. Pulmonary Circulation, 2020, 10, 1-3.	0.8	2
2245	Atrial arrhythmias in chronic lung diseaseâ€associated pulmonary hypertension. Pulmonary Circulation, 2020, 10, 1-13.	0.8	10
2246	Imaging of Chronic Thromboembolic Disease. Lung, 2020, 198, 245-255.	1.4	15
2247	Diffusing Capacity Is an Independent Predictor of Outcomes in Pulmonary Hypertension Associated With COPD. Chest, 2020, 158, 722-734.	0.4	24
2248	Invasive Hemodynamic Staging Classification of Cardiac Damage in Patients With Aortic Stenosis Undergoing Valve Replacement. Canadian Journal of Cardiology, 2020, 36, 1667-1674.	0.8	24
2249	Recurrent but Preventable Pulseless Electrical Activity Arrest. Circulation: Heart Failure, 2020, 13, e006781.	1.6	1
2250	David's procedure for pulmonary artery aneurysm. Journal of Cardiac Surgery, 2020, 35, 942-945.	0.3	8
2251	Association of Disease Subtype and Duration with Echocardiographic Evidence of Pulmonary Hypertension in Myeloproliferative Neoplasm. Medical Principles and Practice, 2020, 29, 486-491.	1.1	2
2252	Population pharmacokinetics of riociguat and its metabolite in patients with chronic thromboembolic pulmonary hypertension from routine clinical practice. Pulmonary Circulation, 2020, 10, 1-11.	0.8	1
2253	Characteristics of Chronic Obstructive Pulmonary Disease Patients with Pulmonary Hypertension Assessed by Echocardiography in a Three-Year Observational Cohort Study . International Journal of COPD, 2020, Volume 15, 487-499.	0.9	9

#	Article	IF	Citations
2254	Metacognitive Therapy for Adjustment Disorder in a Patient With Newly Diagnosed Pulmonary Arterial Hypertension: A Case Report. Frontiers in Psychology, 2020, 11, 143.	1.1	11
2255	Prognostic implications of inferior vena cava haemodynamics in ambulatory patients with tetralogy of Fallot. ESC Heart Failure, 2020, 7, 2589-2596.	1.4	5
2256	Diastolic function of the left and right ventricles of the heart in outpatients with arterial hypertension. Echocardiography, 2020, 37, 1014-1020.	0.3	2
2257	Ethical considerations of thoracic transplant and circulatory support during the COVID-19 pandemic: A closer look at pulmonary vascular disease. Journal of Heart and Lung Transplantation, 2020, 39, 852-853.	0.3	0
2258	Cardiovascular Risk in Systemic Sclerosis. Current Treatment Options in Rheumatology, 2020, 6, 282-298.	0.6	0
2259	Novel Insight into How Nurses Working at PH Specialist Clinics in Sweden Perceive Their Work. Healthcare (Switzerland), 2020, 8, 180.	1.0	1
2260	Remodeling Matrix Synthesis in a Rat Model of Aortocaval Fistula and the Cyclic Stretch: Impaction in Pulmonary Arterial Hypertension-Congenital Heart Disease. International Journal of Molecular Sciences, 2020, 21, 4676.	1.8	4
2261	Relationships between Pulmonary Hypertension Risk, Clinical Profiles, and Outcomes in Dilated Cardiomyopathy. Journal of Clinical Medicine, 2020, 9, 1660.	1.0	7
2262	Overexpression of PD-1 on Peripheral Blood Lymphocytes in Patients with Idiopathic Pulmonary Arterial Hypertension and Its Association with High Viral Loads of Epstein-Barr Virus and Poor Clinical Parameters. Journal of Clinical Medicine, 2020, 9, 1966.	1.0	10
2263	National trends and inpatient outcomes of pulmonary arterial hypertension related hospitalizations â€“ Analysis of the National Inpatient Sample Database. International Journal of Cardiology, 2020, 319, 131-138.	0.8	7
2264	Off-label use of pulmonary vasodilators after left ventricular assist device implantation: Calling in the evidence. , 2020, 214, 107619.		12
2265	Pulmonary hypertension: The diagnostic and prognostic value of novel imaging techniques. Hellenic Journal of Cardiology, 2020, 61, 71-72.	0.4	0
2266	Balloon atrial septostomy and transition of subcutaneous to intravenous prostacyclin infusion for rescuing advanced right heart failure in idiopathic pulmonary arterial hypertension: a case report. European Heart Journal - Case Reports, 2020, 4, 1-5.	0.3	3
2267	Rapid transition from oral selexipag to parenteral treprostinil in a patient with mixed-etiology pulmonary hypertension. American Journal of Health-System Pharmacy, 2020, 77, 1208-1212.	0.5	1
2268	Rapid disease progress in a PVOD patient carrying a novel EIF2AK4 mutation: a case report. BMC Pulmonary Medicine, 2020, 20, 186.	0.8	7
2269	Pulmonary artery to ascending aorta ratio by echocardiography: A strong predictor for presence and severity of pulmonary hypertension. PLoS ONE, 2020, 15, e0235716.	1.1	12
2270	The failing right ventricle: Where do we go from here. Acta Physiologica, 2020, 229, e13523.	1.8	2
2271	Isolated Exercise-Induced Pulmonary Hypertension Associates with Higher Cardiovascular Risk in Scleroderma Patients. Journal of Clinical Medicine, 2020, 9, 1910.	1.0	8

#	Article	IF	Citations
2272	Limitations of right ventricular annular parameters in the early postoperative period following pulmonary endarterectomy: an observational study. Interactive Cardiovascular and Thoracic Surgery, 2020, 31, 191-198.	0.5	4
2273	Pulmonary Hypertension Phenotypes in Systemic Sclerosis: The Right Diagnosis for the Right Treatment. International Journal of Molecular Sciences, 2020, 21, 4430.	1.8	20
2274	Right Ventricle Mechanics and Function during Stress in Patients with Asymptomatic Primary Moderate to Severe Mitral Regurgitation and Preserved Left Ventricular Ejection Fraction. Medicina (Lithuania), 2020, 56, 303.	0.8	0
2275	Selenium and Copper as Biomarkers for Pulmonary Arterial Hypertension in Systemic Sclerosis. Nutrients, 2020, 12, 1894.	1.7	23
2276	Serum soluble suppression of tumorigenicityâ€2 level associates with severity of pulmonary hypertension associated with uncorrected atrial septal defect. Pulmonary Circulation, 2020, 10, 1-8.	0.8	4
2277	Addressing Reduced Laboratory-Based Pulmonary Function Testing During a Pandemic. Chest, 2020, 158, 2502-2510.	0.4	63
2278	Evaluation of the Impact of an Echocardiographic Diagnosis of Pulmonary Hypertension on Patient Outcomes. CJC Open, 2020, 2, 328-336.	0.7	6
2279	Coronary artery fistula in adults: Incidence and appearance on cardiac computed tomography and comparison of detectability and hemodynamic effects with those on transthoracic echocardiography. Journal of Cardiology, 2020, 76, 593-600.	0.8	10
2280	Evaluation and Comparison of Quantitative Right Ventricular Strain Assessment by Cardiac Magnetic Resonance in Pulmonary Hypertension Using Feature Tracking and Deformable Registration Algorithms. Academic Radiology, 2021, 28, e306-e313.	1.3	3
2281	Pharmacology of Pulmonary Arterial Hypertension: An Overview of Current and Emerging Therapies. ACS Pharmacology and Translational Science, 2020, 3, 598-612.	2.5	12
2282	Association of clinical predictors with recurrence of atrial fibrillation after catheter ablation. Annals of Noninvasive Electrocardiology, 2020, 25, e12787.	0.5	7
2283	Systemic Arterial Stiffness in New Diagnosed Idiopathic Pulmonary Arterial Hypertension Patients . Vascular Health and Risk Management, 2020, Volume 16, 29-39.	1.0	10
2284	BET Signaling: A Novel Therapeutic Target for Pulmonary Hypertension?. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 1313-1313.	2.5	1
2285	The Right Ventricleâ€"You May Forget It, But It Will Not Forget You. Journal of Clinical Medicine, 2020, 9, 432.	1.0	18
2286	Systemic Consequences of Pulmonary Hypertension and Right-Sided Heart Failure. Circulation, 2020, 141, 678-693.	1.6	139
2287	Treatment of pulmonary hypertension with riociguat: a review of current evidence and future perspectives. Expert Opinion on Pharmacotherapy, 2020, 21, 1145-1155.	0.9	7
2288	Transition protocol from subcutaneous treprostinil to intravenous epoprostenol in deteriorating patients with pulmonary arterial hypertension. International Journal of Cardiology, 2020, 306, 187-189.	0.8	3
2289	Monitoring pulmonary pressures during longâ€term continuousâ€flow left ventricular assist device and fixed pulmonary hypertension: redefining alleged pathophysiological mechanisms?. ESC Heart Failure, 2020, 7, 702-704.	1.4	3

#	Article	IF	Citations
2290	Pathobiology of pulmonary artery hypertension: role of long non-coding RNAs. Cardiovascular Research, 2020, 116, 1937-1947.	1.8	41
2291	Multidimensional tracking of phenotypes and organ involvement in a complete nationwide systemic sclerosis cohort. Rheumatology, 2020, 59, 2920-2929.	0.9	28
2292	ACVIM consensus statement guidelines for the diagnosis, classification, treatment, and monitoring of pulmonary hypertension in dogs. Journal of Veterinary Internal Medicine, 2020, 34, 549-573.	0.6	143
2294	Electrical Stimulation-Guided Approach to Pulmonary Artery Catheter Ablation in Patients with Idiopathic Pulmonary Arterial Hypertension: A Pilot Feasibility Study with a 12-Month Follow-Up. BioMed Research International, 2020, 2020, 1-7.	0.9	11
2295	Effects of balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension on remodeling in right-sided heart. International Journal of Cardiovascular Imaging, 2020, 36, 1053-1060.	0.7	9
2296	Clinical implications of idiopathic pulmonary arterial hypertension phenotypes defined by cluster analysis. Journal of Heart and Lung Transplantation, 2020, 39, 310-320.	0.3	31
2297	Protective Effect of Statins on Pulmonary Hypertension in Chronic Obstructive Pulmonary Disease Patients: A Nationwide Retrospective, Matched Cohort Study. Scientific Reports, 2020, 10, 3104.	1.6	11
2298	Sex differences of hemodynamics during acute vasoreactivity testing to predict the outcomes of chronic thromboembolic pulmonary hypertension. Clinical Respiratory Journal, 2020, 14, 611-621.	0.6	5
2299	Remodeling of the pulmonary artery in idiopathic pleuroparenchymal fibroelastosis. Scientific Reports, 2020, 10, 306.	1.6	6
2300	Outcomes of Pulmonary Arterial Hypertension Are Improved in a SpecialtyÂCare Center. Chest, 2020, 158, 330-340.	0.4	18
2301	Increased main pulmonary artery diameter and main pulmonary artery to ascending aortic diameter ratio in smokers undergoing lung cancer screening. Clinical Imaging, 2020, 63, 16-23.	0.8	8
2302	Identification of a pulmonary arterial hypertension (PAH) patient cohort and study of its burden of illness in Programme de MÃ©dicalisation des SystÃ¨mes d'information (PMSI). International Journal of Cardiology, 2020, 306, 175-180.	0.8	6
2303	Cardiac Magnetic Resonance Imaging in Pulmonary Hypertension. Chest, 2020, 157, 470.	0.4	0
2304	Prolargin and matrix metalloproteinaseâ€2 in heart failure after heart transplantation and their association with haemodynamics. ESC Heart Failure, 2020, 7, 224-235.	1.4	9
2305	Aetiology and outcomes of severe right ventricular dysfunction. European Heart Journal, 2020, 41, 1273-1282.	1.0	42
2306	Treatment of Vascular Thrombosis in Antiphospholipid Syndrome: An Update. Hamostaseologie, 2020, 40, 031-037.	0.9	8
2307	Response. Chest, 2020, 157, 471.	0.4	1
2308	Right ventricular end-systolic remodeling index in the assessment of pediatric pulmonary arterial hypertension. The European Pediatric Pulmonary Vascular Disease Network (EPPVDN). Pediatric Research, 2020, 88, 285-292.	1.1	11

#	Article	IF	Citations
2309	Elevated plasma tyrosine kinases VEGF-D and HER4 in heart failure patients decrease after heart transplantation in association with improved haemodynamics. Heart and Vessels, 2020, 35, 786-799.	0.5	9
2310	Chemotherapy Improved Pulmonary Arterial Hypertension in a Patient with Chronic-Active Epstein-Barr Virus Infection. International Heart Journal, 2020, 61, 191-194.	0.5	3
2311	Genetic Predisposition to High-Altitude Pulmonary Edema. High Altitude Medicine and Biology, 2020, 21, 28-36.	0.5	21
2312	Cardiac Catheterization versus Echocardiography for Monitoring Pulmonary Pressure: A Prospective Study in Patients with Connective Tissue Disease-Associated Pulmonary Arterial Hypertension. Diagnostics, 2020, 10, 49.	1.3	7
2313	The challenge of an expanded therapeutic window in pulmonary hypertension. Nature Reviews Cardiology, 2020, 17, 195-197.	6.1	9
2314	Characterization of Patients with Pulmonary Arterial Hypertension: Data from the Polish Registry of Pulmonary Hypertension (BNP-PL). Journal of Clinical Medicine, 2020, 9, 173.	1.0	38
2315	Risk assessment in pulmonary arterial hypertension: Insights from the GRIPHON study. Journal of Heart and Lung Transplantation, 2020, 39, 300-309.	0.3	39
2316	Pregnancy in a Patient With Tetralogy of Fallot and Borderline Pulmonary Arterial Hypertension. JACC: Case Reports, 2020, 2, 91-95.	0.3	0
2317	Management of reproductive health in patients with pulmonary hypertension. American Journal of Obstetrics & Gynecology MFM, 2020, 2, 100087.	1.3	0
2318	Relationship between Bâ€type natriuretic peptide and invasive haemodynamics in patients with severe aortic valve stenosis. ESC Heart Failure, 2020, 7, 577-587.	1.4	17
2319	Impact of Preoperative Measurement of Right Heart Chambers in the Evaluation of Pulmonary Hypertension Following Aortic Valve Replacement. Chest, 2020, 157, 1597-1605.	0.4	3
2321	Pulmonary veno-occlusive disease: a probably underdiagnosed cause of pulmonary hypertension in systemic sclerosis. Clinical Rheumatology, 2020, 39, 1687-1691.	1.0	6
2322	Outcome after heartâ€“lung or lung transplantation in patients with Eisenmenger syndrome. Heart, 2020, 106, 127-132.	1.2	22
2323	Assessment of right ventricular function in advanced heart failure with nonischemic dilated cardiomyopathy: insights of right ventricular elastance. Journal of Cardiovascular Medicine, 2020, 21, 134-143.	0.6	5
2324	Marked Reduction of Pulmonary Artery Pressure After Registration for Lung Transplantation Is Associated With Long-Term Survival in Patients With Pulmonary Arterial Hypertensionã€€â€• Cohort Study â€•. Circulation Journal, 2020, 84, 245-251.	0.7	6
2325	Prognostic impact of right ventricular mass change in patients with idiopathic pulmonary arterial hypertension. International Journal of Cardiology, 2020, 304, 172-174.	0.8	5
2326	Classification of Pulmonary Hypertension in CKD. American Journal of Kidney Diseases, 2020, 75, 690-692.	2.1	0
2327	Diagnostic accuracy of CT pulmonary angiography in suspected pulmonary hypertension. European Radiology, 2020, 30, 4918-4929.	2.3	29

#	Article	IF	Citations
2328	Clinical heterogeneity of Pulmonary Arterial Hypertension associated with variants in TBX4. PLoS ONE, 2020, 15, e0232216.	1.1	21
2329	Quality of initial anticoagulant treatment and risk of CTEPH after acute pulmonary embolism. PLoS ONE, 2020, 15, e0232354.	1.1	9
2330	Ventilatory power, a cardiopulmonary exercise testing parameter for the prediction of pulmonary hypertension at right heart catheterization. IJC Heart and Vasculature, 2020, 28, 100513.	0.6	1
2331	Lower Plasma Melatonin Levels Predict Worse Long-Term Survival in Pulmonary Arterial Hypertension. Journal of Clinical Medicine, 2020, 9, 1248.	1.0	8
2332	Influence of long-standing pulmonary arterial hypertension and its severity on pulmonary artery aneurysm development. Heart and Vessels, 2020, 35, 1290-1298.	0.5	1
2333	Autopsy in adults with congenital heart disease (ACHD). Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 476, 797-820.	1.4	10
2334	Associations between functional tricuspid regurgitation and long-term outcomes for patients with pulmonary hypertension. International Journal of Cardiovascular Imaging, 2020, 36, 1261-1269.	0.7	3
2335	Molecular Profiling of Vascular Remodeling in Chronic Pulmonary Disease. American Journal of Pathology, 2020, 190, 1382-1396.	1.9	9
2336	Risk Stratification of Acute Pulmonary Embolism and Determining the Effect on Chronic Cardiopulmonary Complications: The REACH Study. TH Open, 2020, 04, e45-e50.	0.7	11
2337	SPARCL1 as a biomarker of maladaptive right ventricular remodelling in pulmonary hypertension. Biomarkers, 2020, 25, 290-295.	0.9	11
2338	Prognostic factors of pulmonary hypertension associated with connective tissue disease: pulmonary artery size measured by chest CT. Rheumatology, 2020, 59, 3221-3228.	0.9	10
2339	Regional right ventricular longitudinal systolic strain for detection of severely impaired right ventricular performance in pulmonary hypertension. Echocardiography, 2020, 37, 592-600.	0.3	3
2340	Partial anomalous pulmonary venous drainage in patients presenting with suspected pulmonary hypertension: A series of 90 patients from the ASPIRE registry. Respirology, 2020, 25, 1066-1072.	1.3	10
2341	Idiopathic Pulmonary Arterial Hypertension and Pulmonary Arterial Hypertension Associated With Congenital Heart Disease in Chinese Children: Similarities, Differences, and Prognostic Factors. Frontiers in Pediatrics, 2020, 8, 106.	0.9	3
2342	Combined Methods (Formal Adjusted Indirect Comparison, Meta-Analysis and Principal Component) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 Patients With Pulmonary Arterial Hypertension. Frontiers in Pharmacology, 2020, 11, 400.	1.6	6
2343	Right Ventricular Function in Chronic Heart Failure: From the Diagnosis to the Therapeutic Approach. Journal of Cardiovascular Development and Disease, 2020, 7, 12.	0.8	13
2344	Transitioning from Preclinical to Clinical Heart Failure with Preserved Ejection Fraction: A Mechanistic Approach. Journal of Clinical Medicine, 2020, 9, 1110.	1.0	19
2345	Modified Model for End-Stage Liver Disease Is an Indicator of the Ineffectiveness of Sildenafil Treatment in Patients With Advanced Heart Failure and Increased Pulmonary Vascular Resistance. Transplantation Proceedings, 2020, 52, 2440-2446.	0.3	1

#	Article	IF	Citations
2346	Effects of active commuting on cardiovascular risk factors: GISMOâ€"a randomized controlled feasibility study. Scandinavian Journal of Medicine and Science in Sports, 2020, 30, 15-23.	1.3	14
2347	Management of Pulmonary Arterial Hypertension in Patients with Systemic Sclerosis . Integrated Blood Pressure Control, 2020, Volume 13, 15-29.	0.4	24
2348	Intravascular Ultrasound Pulmonary Artery Denervation to Treat Pulmonary Arterial Hypertension (TROPHY1). JACC: Cardiovascular Interventions, 2020, 13, 989-999.	1.1	47
2349	Subclinical progression of systemic sclerosis-related cardiomyopathy. European Journal of Preventive Cardiology, 2020, 27, 1876-1886.	0.8	9
2350	Assessment of lung glucose uptake in patients with systemic lupus erythematosus pulmonary arterial hypertension: a quantitative FDG-PET imaging study. Annals of Nuclear Medicine, 2020, 34, 407-414.	1.2	11
2351	Right ventricular mechanical pattern in patients undergoing mitral valve surgery: a predictor of postâ€operative dysfunction?. ESC Heart Failure, 2020, 7, 1246-1256.	1.4	24
2353	Suspected myocardial injury in patients with COVID-19: Evidence from front-line clinical observation in Wuhan, China. International Journal of Cardiology, 2020, 311, 116-121.	0.8	360
2354	Methods to improve the yield of right heart catheterization in pulmonary hypertension. Respiratory Medicine: X, 2020, 2, 100015.	1.4	5
2355	Long-term treatment of pulmonary arterial hypertension with macitentan in Japanese patients. Current Medical Research and Opinion, 2020, 36, 921-928.	0.9	4
2356	The relationship between Tâ€wave peakâ€toâ€end interval and hemodynamic parameters in patients with pulmonary arterial hypertension. Annals of Noninvasive Electrocardiology, 2020, 25, e12764.	0.5	4
2357	Lysophosphatidic acid promotes thrombus stability by inducing rapid formation of neutrophil extracellular traps: A new mechanism of thrombosis. Journal of Thrombosis and Haemostasis, 2020, 18, 1952-1964.	1.9	21
2358	Contemporary look at extracorporeal membrane oxygenation as a bridge to reoperative lung transplantation in the United States â€" a retrospective study. Transplant International, 2020, 33, 895-901.	0.8	7
2359	Balloon pulmonary angioplasty for inoperable chronic thromboembolic pulmonary hypertension: the UK experience. Open Heart, 2020, 7, e001144.	0.9	54
2360	Home initiation of chronic non-invasive ventilation in COPD patients with chronic hypercapnic respiratory failure: a randomised controlled trial. Thorax, 2020, 75, 244-252.	2.7	121
2361	Exercise right heart catheterization before and after balloon pulmonary angioplasty in inoperable patients with chronic thromboembolic pulmonary hypertension. Pulmonary Circulation, 2020, 10, 1-9.	0.8	9
2362	Chronic thromboembolic disease following pulmonary embolism: more work ahead. European Respiratory Journal, 2020, 55, 2000229.	3.1	5
2363	Nocturnal hypercapnia with daytime normocapnia in patients with advanced pulmonary arterial hypertension awaiting lung transplantation. PLoS ONE, 2020, 15, e0227775.	1.1	2
2364	Value of Hemodynamic Monitoring in Patients With Cardiogenic Shock Undergoing Mechanical Circulatory Support. Circulation, 2020, 141, 1184-1197.	1.6	123

#	Article	IF	Citations
2365	Diastolic Pulmonary Artery to Pulmonary Capillary Wedge Pressure Difference: A Predictor of Outcome After Left Ventricular Assist Device Implantation. Journal of the American Heart Association, 2020, 9, e016110.	1.6	3
2366	Care of patients with pulmonary arterial hypertension during the coronavirus (COVIDâ€19) pandemic. Pulmonary Circulation, 2020, 10, 1-7.	0.8	50
2367	Mendelian randomisation analysis of red cell distribution width in pulmonary arterial hypertension. European Respiratory Journal, 2020, 55, 1901486.	3.1	26
2368	The COngenital HeARt Disease in adult and Pulmonary Hypertension (COHARD-PH) registry: a descriptive study from single-center hospital registry of adult congenital heart disease and pulmonary hypertension in Indonesia. BMC Cardiovascular Disorders, 2020, 20, 163.	0.7	12
2369	NTP42, a novel antagonist of the thromboxane receptor, attenuates experimentally induced pulmonary arterial hypertension. BMC Pulmonary Medicine, 2020, 20, 85.	0.8	19
2370	Potential Molecular Pathways Related to Pulmonary Artery Aneurysm Development: Lessons to Learn from the Aorta. International Journal of Molecular Sciences, 2020, 21, 2509.	1.8	7
2371	Hemodynamic profile of patients with severe aortic valve stenosis and atrial fibrillation versus sinus rhythm. International Journal of Cardiology, 2020, 311, 39-45.	0.8	14
2372	Six-minute walk distance in healthy young adults. Respiratory Medicine, 2020, 165, 105933.	1.3	43
2373	Preoperative C-reactive protein predicts early postoperative outcomes after pulmonary endarterectomy in patients with chronic thromboembolic pulmonary hypertension. Journal of Thoracic and Cardiovascular Surgery, 2021, 161, 1532-1542.e5.	0.4	7
2374	Clinical Evaluation and Diagnosis of Rheumatic Heart Disease. , 2021, , 69-106.		0
2375	The Renal Resistive Index: A New Biomarker for the Follow-up of Vascular Modifications in Systemic Sclerosis. Journal of Rheumatology, 2021, 48, 241-246.	1.0	7
2376	Tricuspid regurgitation pressure gradient identifies prognostically relevant worsening renal function in acute heart failure. European Heart Journal Cardiovascular Imaging, 2021, 22, 203-209.	0.5	6
2377	Identification of Differentially Expressed Genes Associated with Idiopathic Pulmonary Arterial Hypertension by Integrated Bioinformatics Approaches. Journal of Computational Biology, 2021, 28, 79-88.	0.8	16
2378	Prognostic role of PET/MRI hybrid imaging in patients with pulmonary arterial hypertension. Heart, 2021, 107, 54-60.	1.2	12
2379	The role of mechanotransduction in heart failure pathobiologyâ€"a concise review. Heart Failure Reviews, 2021, 26, 981-995.	1.7	7
2380	Portopulmonary hypertension: prognosis and management in the current treatment era â€“ results from the REHAP registry. Internal Medicine Journal, 2021, 51, 355-365.	0.5	30
2381	Pulmonary hypertension in bronchopulmonary dysplasia. Pediatric Research, 2021, 89, 446-455.	1.1	103
2382	5-Year prognostic value of the right ventricular strain-area loop in patients with pulmonary hypertension. European Heart Journal Cardiovascular Imaging, 2021, 22, 188-195.	0.5	13

#	Article	IF	Citations
2383	Risk stratification in chronic thromboembolic pulmonary hypertension predicts survival. Scandinavian Cardiovascular Journal, 2021, 55, 43-49.	0.4	21
2384	Plasma insulin-like growth factor binding protein 1 in pulmonary arterial hypertension. Scandinavian Cardiovascular Journal, 2021, 55, 35-42.	0.4	4
2385	Cardio-pulmonary involvement in pulmonary arterial hypertension: A perfusion and innervation scintigraphic evaluation. Journal of Nuclear Cardiology, 2021, 28, 546-556.	1.4	3
2386	Prevalence and risk factors for Pulmonary Hypertension associated with chronic Myeloproliferative Neoplasms. European Journal of Haematology, 2021, 106, 250-259.	1.1	7
2387	The role of the combination of echo-HRCT score as a tool to evaluate the presence of pulmonary hypertension in idiopathic pulmonary fibrosis. Internal and Emergency Medicine, 2021, 16, 941-947.	1.0	4
2388	Normative Reference Values of Cardiac Output by Pulsed-Wave Doppler Echocardiography in Adults. American Journal of Cardiology, 2021, 140, 128-133.	0.7	20
2389	Laser speckle contrast analysis predicts major vascular complications and mortality of patients with systemic sclerosis. Rheumatology, 2021, 60, 1850-1857.	0.9	15
2390	Synopsis from Expanding Applications of Pulmonary MRI in the Clinical Evaluation of Lung Disorders. Chest, 2021, 159, 492-495.	0.4	12
2391	Anticoagulation in Pulmonary Arterial Hypertension: Do We Know the Answer?. Current Problems in Cardiology, 2021, 46, 100738.	1.1	8
2392	Tricuspid valve diseases: Interventions on the forgotten heart valve. Journal of Cardiac Surgery, 2021, 36, 219-228.	0.3	3
2393	Altered cardiac repolarisation in highlanders with highâ€altitude pulmonary hypertension during wakefulness and sleep. Journal of Sleep Research, 2021, 30, e13153.	1.7	2
2394	A Fluid Challenge Test for the Diagnosis of Occult Heart Failure. Chest, 2021, 159, 791-797.	0.4	19
2395	Portopulmonary hypertension: An unfolding story. Clinics and Research in Hepatology and Gastroenterology, 2021, 45, 101492.	0.7	3
2396	New insights of tricuspid regurgitation: a large-scale prospective cohort study. European Heart Journal Cardiovascular Imaging, 2021, 22, 196-202.	0.5	53
2397	Outcomes of Pulmonary Endarterectomy Operation Concomitant with Cardiac Procedures. Thoracic and Cardiovascular Surgeon, 2021, 69, 279-283.	0.4	3
2398	Predictors of shortâ€and longâ€term outcomes of patients undergoing transcatheter mitral valve edgeâ€toâ€edge repair. Catheterization and Cardiovascular Interventions, 2021, 97, E390-E401.	0.7	7
2399	How should a physician approach the pharmacological management of chronic thromboembolic pulmonary hypertension?. Expert Opinion on Pharmacotherapy, 2021, 22, 557-563.	0.9	2
2400	Efficacy and safety of balloon pulmonary angioplasty in patients with inoperable chronic thromboembolic pulmonary hypertension. Journal of the Formosan Medical Association, 2021, 120, 947-955.	0.8	10

#	Article	IF	Citations
2401	Myocardial deformation assessment in patients with precapillary pulmonary hypertension: A cardiac magnetic resonance study. Diagnostic and Interventional Imaging, 2021, 102, 153-161.	1.8	8
2402	First in vivo assessment of RAS-Q technology as lung support device for pulmonary hypertension. International Journal of Artificial Organs, 2021, 44, 243-250.	0.7	1
2403	Invasive monitoring and dosing strategy to mitigate risks of general anaesthesia in a patient with connective tissue disease and pulmonary arterial hypertension. QJM - Monthly Journal of the Association of Physicians, 2021, 114, 206-208.	0.2	1
2404	Right cardiac involvement in lung diseases: a multimodality approach from diagnosis to prognostication. Journal of Internal Medicine, 2021, 289, 440-449.	2.7	7
2405	Impact of Right Ventricular Dysfunction on Mortality in Patients Hospitalized With COVID-19, According to Race. CJC Open, 2021, 3, 91-100.	0.7	43
2406	Malnutrition is independently associated with an increased risk of major cardiovascular events in adult patients with congenital heart disease. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 481-488.	1.1	6
2407	The Association of CT-measured Cardiac Indices with Lung Involvement and Clinical Outcome in Patients with COVID-19. Academic Radiology, 2021, 28, 8-17.	1.3	32
2408	Midâ€term followâ€up of balloon pulmonary angioplasty for inoperable chronic thromboembolic pulmonary hypertension: An experience in Latin America. Catheterization and Cardiovascular Interventions, 2021, 97, E748-E757.	0.7	7
2409	Top End Pulmonary Hypertension Study: Understanding Epidemiology, Therapeutic Gaps and Prognosis in Remote Australian Setting. Heart Lung and Circulation, 2021, 30, 507-515.	0.2	1
2410	CILP1 as a biomarker for right ventricular maladaptation in pulmonary hypertension. European Respiratory Journal, 2021, 57, 1901192.	3.1	15
2411	Multidimensional assessment and cluster analysis for idiopathic pulmonary arterial hypertension phenotyping. Journal of Heart and Lung Transplantation, 2021, 40, 166-167.	0.3	3
2412	Assessment of pulmonary arterial stiffness in patients with cirrhosis: A prospective cohort study. Echocardiography, 2021, 38, 57-63.	0.3	6
2413	Riociguat: Clinical research and evolving role in therapy. British Journal of Clinical Pharmacology, 2021, 87, 2645-2662.	1.1	18
2414	Pregnant with pulmonary arterial hypertension â€“ Can we handle the pressure?. International Journal of Cardiology, 2021, 328, 180-181.	0.8	0
2415	Congestive nephropathy: a neglected entity? Proposal for diagnostic criteria and future perspectives. ESC Heart Failure, 2021, 8, 183-203.	1.4	82
2416	Impact of a volume challenge on haemodynamics and prognosis in patients with severe aortic stenosis. ESC Heart Failure, 2021, 8, 508-517.	1.4	4
2417	Respiratory changes in biometry of suprarenal inferior vena cava in patients with varicose veins of lower extremities. Phlebology, 2021, 36, 313-321.	0.6	5
2419	Cardiovascular disorders in patients with congenital portosystemic shunts: 23 years of experience in a tertiary referral centre. Archives of Cardiovascular Diseases, 2021, 114, 221-231.	0.7	11

#	Article	IF	Citations
2420	Pulmonary hypertension in connective tissue diseases, new evidence and challenges. European Journal of Clinical Investigation, 2021, 51, e13453.	1.7	28
2421	Prognostic value of late gadolinium enhancement mass index in patients with pulmonary arterial hypertension. Advances in Medical Sciences, 2021, 66, 28-34.	0.9	7
2422	Left main coronary artery compression in pulmonary hypertension. Catheterization and Cardiovascular Interventions, 2021, 97, E956-E966.	0.7	10
2423	Balloon pulmonary angioplasty reverse right ventricular remodelling and dysfunction in patients with inoperable chronic thromboembolic pulmonary hypertension: a systematic review and meta-analysis. European Radiology, 2021, 31, 3898-3908.	2.3	15
2424	Cardiovascular Magnetic Resonance in Right Heart and Pulmonary Circulation Disorders. Heart Failure Clinics, 2021, 17, 57-75.	1.0	3
2425	Intracardiac and Vascular Hemodynamics with Cardiovascular Magnetic Resonance in Heart Failure. Heart Failure Clinics, 2021, 17, 135-147.	1.0	0
2426	The prevalence and incidence rate of pulmonary arterial hypertension in systemic sclerosis: Systematic review and meta-analysis. Autoimmunity Reviews, 2021, 20, 102713.	2.5	23
2427	The Value of Hemodynamic Measurements or Cardiac MRI in the Follow-up of Patients With Idiopathic Pulmonary Arterial Hypertension. Chest, 2021, 159, 1575-1585.	0.4	18
2428	Pulmonary Hypertension Due to Left Heart Diseaseâ€"A Practical Approach to Diagnosis and Management. Canadian Journal of Cardiology, 2021, 37, 572-584.	0.8	9
2429	Portopulmonary Hypertension: Prevalence, Clinical and Hemodynamic Features. Current Problems in Cardiology, 2021, 46, 100747.	1.1	13
2430	Practical guidance for echocardiography for cancer therapeutics-related cardiac dysfunction. Journal of Echocardiography, 2021, 19, 1-20.	0.4	14
2431	Sacubitril/valsartan treatment relieved the progression of established pulmonary hypertension in rat model and its mechanism. Life Sciences, 2021, 266, 118877.	2.0	12
2432	Imaging the adult with simple shunt lesions: position paper from the EACVI and the ESC WG on ACHD. Endorsed by AEPC (Association for European Paediatric and Congenital Cardiology). European Heart Journal Cardiovascular Imaging, 2021, 22, e58-e70.	0.5	10
2433	Macitentan in infants and children with pulmonary hypertensive vascular disease. Feasibility, tolerability and practical issues â€“ a singleâ€centre experience. Pulmonary Circulation, 2021, 11, 1-10.	0.8	7
2434	Evaluation of microvasculopathy using dualâ€energy computed tomography in patients with chronic thromboembolic pulmonary hypertension. Pulmonary Circulation, 2021, 11, 1-9.	0.8	10
2435	Influence of advanced pulmonary vascular remodeling on accuracy of echocardiographic parameters of left ventricular filling pressure. Pulmonary Circulation, 2021, 11, 1-12.	0.8	2
2436	Epidemiology of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: identification of the most accurate estimates from a systematic literature review. Pulmonary Circulation, 2021, 11, 1-12.	0.8	84
2437	Cardio-pulmonary-exercise testing, stress-induced right ventricular diastolic dysfunction and exercise capacity in non-severe chronic obstructive pulmonary disease. Pulmonology, 2021, 27, 194-207.	1.0	0

#	Article	IF	Citations
2438	Longitudinal changes in risk status in pulmonary arterial hypertension. ESC Heart Failure, 2021, 8, 680-690.	1.4	8
2439	Unrecognized pulmonary arterial hypertension in hospitalized patients. International Journal of Cardiovascular Imaging, 2021, 37, 1237-1243.	0.7	6
2440	AAV1-Mediated shRNA Knockdown of SASH1 in Rat Bronchus Attenuates Hypoxia-Induced Pulmonary Artery Remodeling. Human Gene Therapy, 2021, 32, 796-805.	1.4	2
2441	Reply to: â€œManagement of portopulmonary hypertension: What is more important, PAH severity or liver disease severity?â€. Journal of Hepatology, 2021, 74, 238-239.	1.8	0
2442	Long-term Outcomes After Pulmonary Endarterectomy in 499 Patients Over a 20-Year Period. Annals of Thoracic Surgery, 2021, 111, 1585-1592.	0.7	14
2443	Diastolic and systolic right ventricular diameters for predicting pulmonary hypertension in children with congenital heart disease. Clinical Imaging, 2021, 70, 67-73.	0.8	2
2444	Relative incidence and predictors of pulmonary arterial hypertension complicating type 2 diabetes: The Fremantle Diabetes Study Phase I. Journal of Diabetes and Its Complications, 2021, 35, 107773.	1.2	1
2445	Two cases of chronic obstructive pulmonary disease with undetectable diffusing capacity for carbon monoxide. Respiratory Investigation, 2021, 59, 145-148.	0.9	0
2447	Pulmonary arterial pressure and nasal obstruction in mouthâ€breathing children: Similarities between adenotonsillar hypertrophy and allergic rhinitis. International Forum of Allergy and Rhinology, 2021, 11, 128-135.	1.5	6
2448	Plasma irisin levels are associated with hemodynamic and clinical outcome in idiopathic pulmonary arterial hypertension patients. Internal and Emergency Medicine, 2021, 16, 625-632.	1.0	4
2449	Efficacy and safety of sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: a double-blind, randomised, placebo-controlled, phase 2b trial. Lancet Respiratory Medicine,the, 2021, 9, 85-95.	5.2	96
2450	Concealed role of red blood cells in pathogenesis of pulmonary arterial hypertension: Decreased red blood cell nitric oxide generation and effect of Rho-Kinase inhibitor fasudil. Clinical Hemorheology and Microcirculation, 2021, 76, 535-548.	0.9	4
2451	Accuracy and sensitivity of three-dimensional echocardiography to detect changes in right ventricular volumes: comparison study with cardiac magnetic resonance. International Journal of Cardiovascular Imaging, 2021, 37, 493-502.	0.7	1
2452	Valved reverse Potts shunt in a case of pulmonary hypertension due to pulmonary veno-occlusive disease. Indian Journal of Thoracic and Cardiovascular Surgery, 2021, 37, 89-92.	0.2	0
2453	2020 ESC Guidelines for the management of adult congenital heart disease. European Heart Journal, 2021, 42, 563-645.	1.0	971
2454	2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease. European Heart Journal, 2021, 42, 17-96.	1.0	830
2455	Upfront triple combination therapy in severe paediatric pulmonary arterial hypertension. European Respiratory Journal, 2021, 57, 2001120.	3.1	22
2456	An evaluation of selexipag for the treatment of pulmonary hypertension. Expert Opinion on Pharmacotherapy, 2021, 22, 29-36.	0.9	5

#	Article	IF	Citations
2457	Development and Validation of an Abridged Version of the REVEAL 2.0 Risk Score Calculator, REVEAL Lite 2, for Use in Patients With Pulmonary Arterial Hypertension. Chest, 2021, 159, 337-346.	0.4	137
2458	Risk factors for right ventricular dysfunction in patients with lymphangioleiomyomatosis. International Journal of Cardiovascular Imaging, 2021, 37, 439-448.	0.7	1
2459	MR 4D flow-based mean pulmonary arterial pressure tracking in pulmonary hypertension. European Radiology, 2021, 31, 1883-1893.	2.3	23
2460	A case series of transcatheter Potts Shunt creation in a pediatric population affected with refractory pulmonary artery hypertension: focus on the role of ECMO. Perfusion (United Kingdom), 2021, 36, 415-420.	0.5	4
2461	An Evaluation of the Learning Curve in Pulmonary Endarterectomy Using Propensity Score Matching. Thoracic and Cardiovascular Surgeon, 2021, 69, 284-292.	0.4	0
2462	Computed tomography appearances of the lung parenchyma in pulmonary hypertension. British Journal of Radiology, 2021, 94, 20200830.	1.0	6
2463	Efficacy and Safety of Long-Term Oral Bosentan in Different Types of Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis. American Journal of Cardiovascular Drugs, 2021, 21, 181-191.	1.0	2
2464	Effect of Normobaric Hypoxia on Exercise Performance in Pulmonary Hypertension. Chest, 2021, 159, 757-771.	0.4	15
2465	The incidence rate of pulmonary arterial hypertension and scleroderma renal crisis in systemic sclerosis patients with digital ulcers on endothelin antagonist receptors (ERAs) and phosphodiesterase-5 inhibitors (PDE5i). Rheumatology, 2021, 60, 872-880.	0.9	4
2466	Associated factors of early-onset pulmonary hypertension and clinical difference between early- and late-onset pulmonary hypertension in Thai systemic sclerosis. Modern Rheumatology, 2021, 31, 649-656.	0.9	2
2467	Reply to the Letter to the Editor Entitled â€œPrognostic Value of Elevated Pulmonary Artery Systolic Pressure on Short Term in Patients With Acute Myocardial Infarctionâ€• Angiology, 2021, 72, 200-201.	0.8	0
2468	Cor pulmonale: the role of traditional and advanced echocardiography in the acute and chronic settings. Heart Failure Reviews, 2021, 26, 263-275.	1.7	11
2469	The role of chemokines and chemokine receptors in pulmonary arterial hypertension. British Journal of Pharmacology, 2021, 178, 72-89.	2.7	40
2470	First steps in imaging the right ventricle with iodine-123-metaiodobenzylguanidine (123I-MIBG) and cadmium-zinc-telluride technology. Journal of Nuclear Cardiology, 2021, 28, 557-559.	1.4	0
2471	Combinations of cardiac and non-cardiac predictors for prognoses in patients with acute heart failure. European Heart Journal Quality of Care & Clinical Outcomes, 2021, 7, 83-96.	1.8	7
2472	Predictive value of non-invasive right ventricle to pulmonary circulation coupling in systemic lupus erythematosus patients with pulmonary arterial hypertension. European Heart Journal Cardiovascular Imaging, 2021, 22, 111-118.	0.5	22
2473	Asymptomatic aortic stenosis in a geriatric population. The role of frailty and comorbidity inÂmortality. Revista Espanola De Cardiologia (English Ed), 2021, 74, 167-174.	0.4	2
2474	A case of pulmonary arterial hypertension complicated by anti-neutrophil cytoplasmic antibody-associated vasculitis and systemic sclerosis. Immunological Medicine, 2021, 44, 263-269.	1.4	1

#	Article	IF	Citations
2475	Right Ventricular Response to Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension. , 2021, , 137-156.		0
2476	Pregnancy and Cardiovascular Disease. , 2021, , 403-435.		1
2477	Understanding the perspective of patients with pulmonary arterial hypertension: looking beyond health-related quality of life. Therapeutic Advances in Rare Disease, 2021, 2, 263300402098616.	0.3	0
2478	Editorial commentary: Pulmonary hypertension in patients with aortic stenosis. Trends in Cardiovascular Medicine, 2022, 32, 82-83.	2.3	0
2479	The mechanism of ions in pulmonary hypertension. Pulmonary Circulation, 2021, 11, 1-20.	0.8	2
2480	Initial triple therapy in pulmonary arterial hypertension: coming of age and rejuvenated. European Respiratory Journal, 2021, 57, 2004258.	3.1	0
2481	A Rare Case of Adult Aortopulmonary Window Combined with Anomalous Origin of the Right Pulmonary Artery from the Aorta Leading to Eisenmenger Syndrome. Journal of International Medical Research, 2021, 49, 030006052098465.	0.4	2
2482	Chronic thromboembolic pulmonary hypertension: evaluation of V/Q SPECT/CT and V/Q Quotient SPECT findings with postoperative results of pulmonary endarterectomy. Nuclear Medicine Communications, 2021, 42, 369-377.	0.5	1
2483	Infection, atherothrombosis and thromboembolism beyond the COVID-19 disease: what similar in physiopathology and researches. Aging Clinical and Experimental Research, 2021, 33, 273-278.	1.4	5
2484	Use of selexipag in a teenage patient with pulmonary arterial hypertension. Annals of Pediatric Cardiology, 2021, 14, 75.	0.2	4
2485	Regional shape, global function and mechanics in right ventricular volume and pressure overload conditions: a three-dimensional echocardiography study. International Journal of Cardiovascular Imaging, 2021, 37, 1289-1299.	0.7	19
2486	Radiological differences between chronic thromboembolic pulmonary disease (CTEPD) and chronic thromboembolic pulmonary hypertension (CTEPH). European Radiology, 2021, 31, 6230-6238.	2.3	10
2487	Triple oral combination therapy with macitentan, riociguat, and selexipag for pulmonary arterial hypertension. Therapeutic Advances in Respiratory Disease, 2021, 15, 175346662199504.	1.0	16
2488	Lessons from the short- and mid-term outcome of medical rehabilitation in adults with congenital heart disease. Cardiovascular Diagnosis and Therapy, 2021, 11, 1416-1431.	0.7	0
2489	Ambulatory prostanoid therapy: safe reduction in duration of inpatient training. European Journal of Cardiovascular Nursing, 2021, 20, 547-555.	0.4	0
2491	The prevalence and clinical outcome of supraventricular tachycardia in different etiologies of pulmonary hypertension. PLoS ONE, 2021, 16, e0245752.	1.1	17
2492	CardioRheumatology. , 2021, , 481-503.		0
2493	Pulmonary Hypertension - Glimpse from an Upper Window Can Help!. Journal of the Indian Academy of Echocardiography & Cardiovascular Imaging, 2021, 5, 70.	0.0	0

#	Article	IF	Citations
2494	Systemic Sclerosis. , 2021, , 129-141.		0
2495	Improved low-risk criteria scores for combination therapy of sildenafil and generic bosentan in patients with congenital heart disease with severe pulmonary hypertension: A prospective open label study. JRSM Cardiovascular Disease, 2021, 10, 204800402098221.	0.4	3
2496	Risk assessment in precapillary pulmonary hypertension: a comparative analysis. Respiratory Research, 2021, 22, 28.	1.4	6
2497	Perforation of pulmonary arteries during transluminal balloon angioplasty. Kardiologicheskii Vestnik, 2021, 16, 56.	0.1	0
2498	Altered TGFÎ²/SMAD Signaling in Human and Rat Models of Pulmonary Hypertension: An Old Target Needs Attention. Cells, 2021, 10, 84.	1.8	16
2499	Rescue balloon pulmonary angioplasty for life-threatening acute pulmonary embolism on chronic thromboembolic pulmonary hypertension patients. Respiratory Medicine Case Reports, 2021, 33, 101415.	0.2	2
2500	Selexipag as Add-on Therapy for Patients with Pulmonary Arterial Hypertension Associated with Congenital Heart Disease: A Single-Center Retrospective Study. Congenital Heart Disease, 2021, 16, 233-244.	0.0	3
2501	Pulmonary Artery Thermodilution. , 2021, , 51-59.		0
2502	Arrhythmias in Right-Heart Failure due to Pulmonary Hypertension. , 2021, , 331-348.		0
2503	Interactive Roles of CaMKII/Ryanodine Receptor Signaling and Inflammation in Lung Diseases. Advances in Experimental Medicine and Biology, 2021, 1303, 305-317.	0.8	1
2504	A pilot study of oral treprostinil pharmacogenomics and treatment persistence in patients with pulmonary arterial hypertension. Therapeutic Advances in Respiratory Disease, 2021, 15, 175346662110136.	1.0	4
2505	Prediction of long-term survival in patients with transfusion-dependent hemoglobinopathies: Insights from cardiac imaging and ferritin. Hellenic Journal of Cardiology, 2021, 62, 429-438.	0.4	1
2506	Underfilling decreases left ventricular function in pulmonary arterial hypertension. International Journal of Cardiovascular Imaging, 2021, 37, 1745-1755.	0.7	9
2507	Practice patterns of pulmonary hypertension secondary to left heart disease among pediatric pulmonary hypertension providers. Pulmonary Circulation, 2021, 11, 1-8.	0.8	3
2509	Chronic thromboembolic pulmonary hypertension due to an implantable cardioverter-defibrillator's lead thrombosis. Hellenic Journal of Cardiology, 2021, 62, 488-489.	0.4	0
2510	Longâ€term outcomes of pregnant women with pulmonary hypertension diagnosed by echocardiography: a retrospective cohort study in a single center from China. Pulmonary Circulation, 2021, 11, 1-8.	0.8	9
2511	Evaluation of hemodynamic parameters among patients with myeloproliferative neoplasms and suspected pulmonary hypertension. Leukemia and Lymphoma, 2021, 62, 1458-1465.	0.6	2
2512	Pulmonary Artery Dilatation Is a Common Finding in a Coronary Artery CT Angiography Population. In Vivo, 2021, 35, 2177-2185.	0.6	2

#	Article	IF	Citations
2513	Pulmonary Hypertension in Heart Failure. International Journal of Heart Failure, 2021, 3, 147.	0.9	5
2514	Radiological Findings in Multidetector Computed Tomography (MDCT) of Hereditary and Sporadic Pulmonary Veno-Occlusive Disease: Certainties and Uncertainties. Diagnostics, 2021, 11, 141.	1.3	6
2515	The efficacy of bosentan combined with vardenafil in the treatment of postoperative pulmonary hypertension in children with congenital heart disease. Medicine (United States), 2021, 100, e23896.	0.4	5
2516	Prognostic value of main pulmonary artery diameter to ascending aorta diameter ratio in patients with advanced heart failure. Acta Cardiologica, 2021, 76, 1108-1116.	0.3	4
2517	Lung Transplantation for Pulmonary Hypertension. Organ and Tissue Transplantation, 2021, , 1-12.	0.0	0
2519	The value of cardiopulmonary exercise testing in the diagnosis of pulmonary hypertension. Journal of Thoracic Disease, 2021, 13, 178-188.	0.6	8
2520	Advances in nutritional status of patients with connective tissue-associated pulmonary hypertension. E3S Web of Conferences, 2021, 233, 02002.	0.2	0
2521	Impact of Face Masks on 6â€Minute Walk Test in Healthy Volunteers. Pulmonary Circulation, 2021, 11, 1-3.	0.8	12
2522	Screening of key biomarkers and immune infiltration in Pulmonary Arterial Hypertension via integrated bioinformatics analysis. Bioengineered, 2021, 12, 2576-2591.	1.4	11
2523	Perspectives of bilateral thoracic sympathectomy for treatment of heart failure. Clinics, 2021, 76, e3248.	0.6	0
2524	Preexistent chronic disorders, often directly affecting pregnancy. , 2021, , 99-174.		0
2525	Characteristics and outcomes of patients with chronic thromboembolic pulmonary hypertension in the era of modern therapeutic approaches: data from the Polish multicenter registry (BNP-PL). Therapeutic Advances in Chronic Disease, 2021, 12, 204062232110029.	1.1	21
2526	Movement-based mind-body interventions for cardiac rehabilitation: An updated systematic review of randomized controlled trials. Tzu Chi Medical Journal, 2021, 34, 49-54.	0.4	0
2527	Right ventricular end-systolic remodeling index on cardiac magnetic resonance imaging: comparison with other functional markers in patients with chronic thromboembolic pulmonary hypertension. Quantitative Imaging in Medicine and Surgery, 2021, 12, 0-0.	1.1	2
2528	Left-Heart Failure and Its Effects on the Right Heart. , 2021, , 157-162.		0
2529	Concomitant tricuspid regurgitation severity and its secondary reduction determine long-term prognosis after transcatheter mitral valve edge-to-edge repair. Clinical Research in Cardiology, 2021, 110, 676-688.	1.5	24
2530	Comparative analysis on the anti-inflammatory/immune effect of mesenchymal stem cell therapy for the treatment of pulmonary arterial hypertension. Scientific Reports, 2021, 11, 2012.	1.6	12
2531	Effects of bevacizumab administration on the hypoxia - induced pulmonary hypertension rat model. Turkish Journal of Medical Sciences, 2021, , .	0.4	2

#	Article	IF	Citations
2532	Right-Heart Reverse Remodeling During Treatment for Pulmonary Hypertension. , 2021, , 291-299.		0
2533	Optimization of surgical timing of congenital diaphragmatic hernia using the quantified flow patterns of patent ductus arteriosus. Pediatric Surgery International, 2021, 37, 197-203.	0.6	6
2534	Persistent Pulmonary Hypertension in Corrected Valvular Heart Disease: Hemodynamic Insights and Longâ€Term Survival. Journal of the American Heart Association, 2021, 10, e019949.	1.6	18
2535	Pulmonary arterial hypertensionâ€associated genetic variants in combined postâ€capillary and preâ€capillary pulmonary hypertension: a case report. Pulmonary Circulation, 2021, 11, 1-5.	0.8	0
2536	Anti-PL-7 antibody positive antisynthetase syndrome diagnosed after the onset of pulmonary hypertension and right-sided heart failure. Rheumatology, 2021, 60, e277-e279.	0.9	1
2537	Clinical evaluation of pulmonary hypertension using patient-reported outcomes: a cross-sectional study. BMC Pulmonary Medicine, 2021, 21, 48.	0.8	1
2538	Long-Term Effect of an Exercise Training Program on Physical Functioning and Quality of Life in Pulmonary Hypertension: A Randomized Controlled Trial. BioMed Research International, 2021, 2021, 1-12.	0.9	5
2539	Right ventricular load and contractility in HIV-associated pulmonary hypertension. PLoS ONE, 2021, 16, e0243274.	1.1	7
2540	State-of-the-Art Review: Anatomical and Imaging Considerations During Transcatheter Tricuspid Valve Repair Using an Annuloplasty Approach. Frontiers in Cardiovascular Medicine, 2021, 8, 619605.	1.1	7
2541	Transcatheter pulmonary denervation in patients with left heart failure with reduced ejection fraction and combined precapillary and postcapillary pulmonary hypertension: A prospective single center experience. Catheterization and Cardiovascular Interventions, 2021, 98, 588-594.	0.7	5
2542	Critical care outcomes in patients with pre-existing pulmonary hypertension: insights from the ASPIRE registry. ERJ Open Research, 2021, 7, 00046-2021.	1.1	15
2543	Resultados ClÃnicos e HemodinÂ¢micos de Longo Prazo apÃ³s o Transplante de CoraÃ§Ã£o em Pacientes PrÃ©-Tratados com Sildenafil. Arquivos Brasileiros De Cardiologia, 2021, 116, 219-226.	0.3	7
2544	Caging the dragon: Research approach to COVIDâ€19â€“related thrombosis. Research and Practice in Thrombosis and Haemostasis, 2021, 5, 278-290.	1.0	14
2545	Change of right ventricular systolic pressure can indicate dasatinibâ€induced pulmonary arterial hypertension in chronic myeloid leukemia. Cancer Medicine, 2021, 10, 1515-1524.	1.3	1
2546	Experience of chronic thromboembolic pulmonary hypertension (CTEPH) in two cases with scleroderma and immunopathogenesis overview: Case report. Journal of Surgery and Medicine, 2021, 5, 1-1.	0.0	1
2547	Natural course of tricuspid regurgitation and prognostic implications. Open Heart, 2021, 8, e001529.	0.9	21
2548	Repeatability and sensitivity to change of non-invasive end points in PAH: the RESPIRE study. Thorax, 2021, 76, 1032-1035.	2.7	13
2549	Pulmonology approach in the investigation of chronic unexplained dyspnea. Jornal Brasileiro De Pneumologia, 2021, 47, e20200406.	0.4	3

#	Article	IF	Citations
2550	The Growing Role of Echocardiography in Pulmonary Arterial Hypertension Risk Stratification: The Missing Piece. Journal of Clinical Medicine, 2021, 10, 619.	1.0	13
2551	BenefÃcios do exercÃcio fÃsico na hipertensÃ£o arterial pulmonar associada Ã cardiopatia congÃªnita nÃ£o corrigida. Scientia Medica, 2021, 31, e38061.	0.1	0
2552	DIAGNOSIS AND MANAGEMENT OF PULMONARY EMBOLISM EURASIAN ASSOCIATION OF CARDIOLOGY (EAC) CLINICAL PRACTICE GUIDELINES (2021). Eurasian Heart Journal, 2021, , 44-77.	0.2	12
2553	The multifaceted problem of pulmonary arterial hypertension in systemic sclerosis. Lancet Rheumatology, The, 2021, 3, e149-e159.	2.2	11
2554	Autoimmune hypophysitis as a cause of adrenocorticotropic hormone deficiency in pulmonary arterial hypertension: a case report. European Heart Journal - Case Reports, 2021, 5, ytab117.	0.3	1
2555	Determinants and Management of the Postâ€“Pulmonary Embolism Syndrome. Seminars in Respiratory and Critical Care Medicine, 2021, 42, 299-307.	0.8	22
2556	Balloon pulmonary angioplasty vs. pulmonary endarterectomy in patients with chronic thromboembolic pulmonary hypertension: aÂsystematic review and meta-analysis. Heart Failure Reviews, 2021, 26, 897-917.	1.7	16
2557	Validity of the Modified Dyspnea Index for the Frenchâ€“Canadian Population. Journal of Nursing Measurement, 2021, 29, 121-139.	0.2	0
2558	Recent advances in the management of pulmonary arterial hypertension: lessons from the upfront combination of ambrisentan and tadalafil. Expert Review of Respiratory Medicine, 2021, 15, 493-504.	1.0	2
2559	Correlation Between Perfusion Abnormalities Extent in Ventilation/Perfusion SPECT/CT with Hemodynamic Parameters in Patients with Chronic Thromboembolic Pulmonary Hypertension. Molecular Imaging and Radionuclide Therapy, 2021, 30, 28-33.	0.3	3
2560	Obesity paradox in pulmonary hypertension due to left ventricular systolic dysfunction. Herz, 2021, 46, 575-580.	0.4	3
2561	Motion Reduction for C-Arm Computed Tomography of the Pulmonary Arteries: Image Quality of a Motion Correction Algorithm in Patients with Chronic Thromboembolic Hypertension During Balloon Pulmonary Angioplasty. RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren, 2021, 193, 1074-1080.	0.7	2
2562	Outcome Measures Used in Studies of Rehabilitation in Pulmonary Hypertension. Annals of the American Thoracic Society, 2021, 18, 321-335.	1.5	3
2563	Comparison of levosimendan, NO, and inhaled iloprost for pulmonary hypertension reversibility assessment in heart transplant candidates. ESC Heart Failure, 2021, 8, 908-917.	1.4	7
2564	Prognostic Value of Early Risk Stratification in Pediatric Pulmonary Arterial Hypertension. Transplantation Proceedings, 2021, 53, 1439-1442.	0.3	3
2565	Anesthetic protocol for right ventricular dysfunction management in heart transplantation: systematic review, development and validation. BMC Anesthesiology, 2021, 21, 46.	0.7	3
2566	Case Report of a 23â€yearâ€old first gravida presenting with breathlessness and oxygen saturation of 80%. Clinical Case Reports (discontinued), 2021, 9, 1307-1311.	0.2	0
2567	Association between splenectomy and chronic thromboembolic pulmonary hypertension: a systematic review and meta-analysis. BMJ Open, 2021, 11, e038385.	0.8	3

#	Article	IF	Citations
2568	Cardiac reserve by 6-minute walk stress echocardiography in systemic sclerosis. Open Heart, 2021, 8, e001559.	0.9	3
2569	Severe tricuspid regurgitation: prognostic role of right heart remodelling and pulmonary hypertension. European Heart Journal Cardiovascular Imaging, 2022, 23, 246-254.	0.5	12
2570	Digital Health Technology and Telemedicine-Based Hospital and Home Programs in Pulmonary Medicine During the COVID-19 Pandemic. American Journal of Therapeutics, 2021, 28, e217-e223.	0.5	15
2571	Evolution of patients with chronic thromboembolic pulmonary hypertension treated by balloon pulmonary angioplasty, according to their anticoagulant regimens. Heart and Vessels, 2021, 36, 910-915.	0.5	6
2572	Temporarily switching from oral to intravenous selexipag in patients with pulmonary arterial hypertension: safety, tolerability, and pharmacokinetic results from an open-label, phase III study. Respiratory Research, 2021, 22, 34.	1.4	3
2573	Multimodality cardiovascular imaging in pulmonary embolism. Cardiology Journal, 2021, 28, 150-160.	0.5	2
2574	Effects of Dual Initial Combination Therapy With Macitentan Plus Riociguat or Macitentan Plus Selexipag on Hemodynamics in Patients With Pulmonary Arterial Hypertension (SETOUCHI-PH Study)ã€€â€• Protocol of a Multicenter Randomized Control Trial â€•. Circulation Reports, 2021, 3, 105-109.	0.4	3
2575	The diagnostic and prognostic role of amino-terminal pro-brain type natriuretic peptides in pediatric cardiac diseases and pulmonary hypertension. Heart Vessels and Transplantation, 0, 5, 21.	0.0	0
2576	A prediction model of simple echocardiographic variables to screen for potentially correctable shunts in adult patients with pulmonary arterial hypertension associated with atrial septal defects: a cross-sectional study. International Journal of Cardiovascular Imaging, 2021, 37, 1551-1562.	0.7	1
2577	Chronic Thromboembolic Pulmonary Hypertension Due to Popliteal Vein Aneurysm. International Medical Case Reports Journal, 2021, Volume 14, 101-106.	0.3	1
2578	Preload dependence of pulmonary haemodynamics and right ventricular performance. Clinical Research in Cardiology, 2021, 110, 591-600.	1.5	1
2579	Electrophysiological study and radiofrequency ablation of hemodynamically-instable ventricular arrhythmias in a patient with pulmonary hypertension. Medicine (United States), 2021, 100, e24896.	0.4	0
2581	The clinical significance and prognostic value of right ventricular wall tension in moderate or severe tricuspid regurgitation. Future Cardiology, 2021, 17, 1371-1379.	0.5	0
2582	A novel echocardiographic method for estimation of pulmonary artery wedge pressure and pulmonary vascular resistance. ESC Heart Failure, 2021, 8, 1216-1229.	1.4	22
2583	A specialised cardiorespiratory team approach in the intensive care management of COVID-19 patients: benefit on mortality, diagnosis and management. Clinical Medicine, 2021, 21, 101-106.	0.8	6
2584	The clinical characteristics, treatment, and survival of portopulmonary hypertension in Japan. BMC Pulmonary Medicine, 2021, 21, 89.	0.8	7
2585	Pulmonary Hypertension Associated With Respiratory Diseasesã€€â€• Which Patients Should Be Treated With Pulmonary Arterial Hypertension-Targeted Therapies? â€•. Circulation Journal, 2021, 85, 343-344.	0.7	0
2586	Multiparametric vs. Inferior Vena Cavaâ€“Based Estimation of Right Atrial Pressure. Frontiers in Cardiovascular Medicine, 2021, 8, 632302.	1.1	6

#	Article	IF	Citations
2587	Left ventricular diastolic dysfunction in non-severe chronic obstructive pulmonary disease â€“ a step forward in cardiovascular comorbidome. PLoS ONE, 2021, 16, e0247940.	1.1	5
2588	Prognostic value of indexed pulmonary artery diameter assessed by cardiac magnetic resonance imaging in patients with acute heart failure. Revista Espanola De Cardiologia (English Ed), 2021, 74, 267-269.	0.4	0
2589	Pulmonary Disease, Pulmonary Hypertension and Atrial Fibrillation. Cardiac Electrophysiology Clinics, 2021, 13, 141-153.	0.7	14
2590	Multi-Institutional Prospective Cohort Study of Patients With Pulmonary Hypertension Associated With Respiratory Diseases. Circulation Journal, 2021, 85, 333-342.	0.7	10
2591	From Health-Related Quality of Life (HRQoL) of Patients with Pulmonary Hypertension to Patient Experience with the Care Received: Should We Be More Aware of Current Patient Needs?. Advances in Therapy, 2021, 38, 1860-1875.	1.3	3
2592	Acute pulmonary hypertension and shortâ€term outcomes in severe Covidâ€19 patients needing intensive care. Acta Anaesthesiologica Scandinavica, 2021, 65, 761-769.	0.7	30
2593	The Transcription Factor C/EBPÎ² Promotes HFL-1 Cell Migration, Proliferation, and Inflammation by Activating lncRNA HAS2-AS1 in Hypoxia. Frontiers in Cell and Developmental Biology, 2021, 9, 651913.	1.8	6
2594	Increased Mortality in Patients With Preoperative and Persistent Postoperative Pulmonary Hypertension Undergoing Mitral Valve Surgery for Mitral Regurgitation: A Cohort Study. Journal of the American Heart Association, 2021, 10, e018394.	1.6	6
2595	Contemporary Pharmacotherapeutic Approach in Pulmonary Arterial Hypertension. Clinics in Chest Medicine, 2021, 42, 125-131.	0.8	2
2596	Pulmonary angioplasty: A step further in the continuously changing landscape of chronic thromboembolic pulmonary hypertension management. European Journal of Radiology, 2021, 136, 109562.	1.2	3
2597	Respiratory and peripheral muscle involvement in patients with pulmonary arterial hypertension due to congenital heart diseases. Monaldi Archives for Chest Disease, 2021, 91, .	0.3	0
2598	Management of Patients With Venous Thromboembolism After the Initial Treatment Period. Journal of the American Board of Family Medicine, 2021, 34, 409-419.	0.8	3
2599	The contemporary pulmonary artery catheter. Part 2: measurements, limitations, and clinical applications. Journal of Clinical Monitoring and Computing, 2022, 36, 17-31.	0.7	28
2601	Validation of the REVEAL Prognostic Models in Systemic Lupus Erythematosus-Associated Pulmonary Arterial Hypertension. Frontiers in Medicine, 2021, 8, 618486.	1.2	3
2602	Atrial flow regulator for drugâ€resistant pulmonary hypertension in a young child. Catheterization and Cardiovascular Interventions, 2021, 97, E830-E834.	0.7	10
2603	Chronic thromboembolic pulmonary hypertension risk score evaluation and validation (CTEPH) Tj ETQq1 1 0.784314 rgBT /Overlock 1 Minerva Cardiology and Angiology, 2021, , .	0.4	0
2604	Mildly Elevated Pulmonary Arterial Pressure Is Associated With a High Risk of Progression to Pulmonary Hypertension and Increased Mortality: A Systematic Review and Metaâ€Analysis. Journal of the American Heart Association, 2021, 10, e018374.	1.6	11
2605	Pharmacological Interventions for Pulmonary Involvement in Rheumatic Diseases. Pharmaceuticals, 2021, 14, 251.	1.7	2

#	Article	IF	Citations
2606	Electrical impedance tomography in pulmonary arterial hypertension. PLoS ONE, 2021, 16, e0248214.	1.1	6
2607	Pulmonary Hemodynamics and Ventilation in Patients With COVID-19-Related Respiratory Failure and ARDS. Journal of Intensive Care Medicine, 2021, 36, 655-663.	1.3	6
2608	Longâ€Term Outcomes in Patients With Connective Tissue Diseaseâ€“Associated Pulmonary Arterial Hypertension in the Modern Treatment Era: Metaâ€Analyses of Randomized, Controlled Trials and Observational Registries. Arthritis and Rheumatology, 2021, 73, 837-847.	2.9	26
2609	High CD200 Expression on T CD4+ and T CD8+ Lymphocytes as a Non-Invasive Marker of Idiopathic Pulmonary Hypertensionâ€“Preliminary Study. Journal of Clinical Medicine, 2021, 10, 950.	1.0	2
2610	Respiratory Manifestations in Systemic Lupus Erythematosus. Pharmaceuticals, 2021, 14, 276.	1.7	19
2611	An interesting case of progressive dyspnoea and diffuse mediastinal adenopathy in a 25-year-old man. Breathe, 2021, 17, 200289.	0.6	0
2612	The role of cardiopulmonary exercise test in identifying pulmonary veno-occlusive disease. European Respiratory Journal, 2021, 57, 2100115.	3.1	5
2613	Sex Differences in Ischemic Stroke Outcomes in Patients With Pulmonary Hypertension. Journal of the American Heart Association, 2021, 10, e019341.	1.6	9
2614	Pharmacological treatment of idiopathic pulmonary fibrosis and fibrosing interstitial lung diseases: current trends and future directions. Precision and Future Medicine, 2021, 5, 31-40.	0.5	2
2615	Valor pronÃ³stico del diÃ¡metro indexado de la arteria pulmonar mediante resonancia magnÃ©tica cardiaca en pacientes con insuficiencia cardiaca aguda. Revista Espanola De Cardiologia, 2021, 74, 267-269.	0.6	0
2616	Pulmonary Arterial Hypertension in Hospitalized Patients With Polycythemia VeraÂ(from the National) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	0.7	2
2617	Therapeutic Evaluation of Antibody-Based Targeted Delivery of Interleukin 9 in Experimental Pulmonary Hypertension. International Journal of Molecular Sciences, 2021, 22, 3460.	1.8	8
2619	Effects of a reduced-sodium added-potassium salt substitute on blood pressure in rural Indian hypertensive patients: a randomized, double-blind, controlled trial. American Journal of Clinical Nutrition, 2021, 114, 185-193.	2.2	36
2620	Non-invasive early exclusion of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism: the InShape II study. Thorax, 2021, 76, 1002-1009.	2.7	41
2621	Prognostic Significance of Systemic Arterial Stiffness Evaluated by Cardio-Ankle Vascular Index in Patients with Idiopathic Pulmonary Hypertension. Vascular Health and Risk Management, 2021, Volume 17, 77-93.	1.0	7
2622	Right Ventricular-Pulmonary Arterial Coupling and Outcomes in Heart Failure and Valvular Heart Disease. Structural Heart, 2021, 5, 128-139.	0.2	3
2623	Endostatin and Vascular Endothelial Growth Factor-A₁₆₅b May Contribute to Classification of Pulmonary Hypertension. Circulation Reports, 2021, 3, 161-169.	0.4	4
2624	Pulmonary Vascular Resistance Measurement Remains Keystone in Congenital Heart Disease Management. Frontiers in Cardiovascular Medicine, 2021, 8, 607104.	1.1	0

#	Article	IF	Citations
2625	Echocardiographic Evaluation of Cardiac Status in Patients with Chronic Obstructive Pulmonary Disease. Bangladesh Medical Research Council Bulletin, 2021, 46, 204-210.	0.1	0
2626	Heart disease in women: a narrative review. Anaesthesia, 2021, 76, 118-130.	1.8	23
2627	Macrophage-derived PDGF-B induces muscularization in murine and human pulmonary hypertension. JCI Insight, 2021, 6, .	2.3	35
2628	The PREdictor of MAlnutrition in Systemic Sclerosis (PREMASS) Score: A Combined Index to Predict 12 Months Onset of Malnutrition in Systemic Sclerosis. Frontiers in Medicine, 2021, 8, 651748.	1.2	7
2629	Comparison of cardiovascular and psychological profile of young military men after COVID-19 with and without pneumonia. Russian Journal of Cardiology, 2021, 26, 4321.	0.4	2
2630	3-year Follow-up Results of Abant Izzet Baysal University Training and Research Hospital Patients with Pulmonary Hypertension. Turkish Journal of Internal Medicine, 0, , .	0.3	0
2631	Fluidâ€“structure interaction in a fully coupled three-dimensional mitralâ€“atriumâ€“pulmonary model. Biomechanics and Modeling in Mechanobiology, 2021, 20, 1267-1295.	1.4	7
2632	Autoimmune Polyendocrine Syndrome Complicated by Pulmonary Hypertension. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2021, 21, 561-565.	0.6	1
2633	Indication of the prognosis of pulmonary hypertension by using CMR function parameters. European Radiology, 2021, 31, 7121-7131.	2.3	0
2634	Early risk prediction in idiopathic versus connective tissue disease-associated pulmonary arterial hypertension: call for a refined assessment. ERJ Open Research, 2021, 7, 00854-2020.	1.1	14
2635	Combination Therapy in Pulmonary Arterial Hypertensionâ€”Targeting the Nitric Oxide and Prostacyclin Pathways. Journal of Cardiovascular Pharmacology and Therapeutics, 2021, 26, 107424842110065.	1.0	16
2636	Left ventricular diastolic dysfunction and diseases severity contribute to impaired exercise capacity in systemic lupus erythematosus. Lupus, 2021, 30, 1154-1162.	0.8	2
2637	Cardiovascular magnetic resonanceâ€assessed fast global longitudinal strain parameters add diagnostic and prognostic insights in right ventricular volume and pressure loading disease conditions. Journal of Cardiovascular Magnetic Resonance, 2021, 23, 38.	1.6	14
2638	Prediction Models and Scores in Pulmonary Hypertension: A Review. Current Pharmaceutical Design, 2021, 27, 1266-1276.	0.9	2
2639	Cardiopulmonary Exercise Testing Is an Accurate Tool for the Diagnosis of Pulmonary Arterial Hypertension in Scleroderma Related Diseases. Pharmaceuticals, 2021, 14, 342.	1.7	4
2640	Transthoracic Right Heart Echocardiography for the Intensivist. Journal of Intensive Care Medicine, 2021, 36, 1098-1109.	1.3	8
2641	Associations of the Prognostic Nutritional Index with the Cardiac Function and Survival after Cardiac Resynchronization Therapy. Internal Medicine, 2021, 60, 985-991.	0.3	3
2642	Characterization of a Cohort of Patients with Chronic Thromboembolic Pulmonary Hypertension from Northeastern Colombia (REHINO Study). Journal of Respiration, 2021, 1, 105-113.	0.4	0

#	Article	IF	Citations
2643	Pulmonary Hypertension Complicating Pregnancy. Current Pulmonology Reports, 2021, 10, 71-83.	0.5	5
2644	The Genetic Pathways Underlying Immunotherapy in Dilated Cardiomyopathy. Frontiers in Cardiovascular Medicine, 2021, 8, 613295.	1.1	9
2645	The Efficacy and Safety of Pulmonary Vasodilators in Pediatric Pulmonary Hypertension (PH): A Systematic Review and Meta-analysis. Frontiers in Pharmacology, 2021, 12, 668902.	1.6	3
2646	Chronic Thromboembolic Pulmonary Hypertension â€“ What Have We Learned From Large Animal Models. Frontiers in Cardiovascular Medicine, 2021, 8, 574360.	1.1	6
2647	Balloon pulmonary angioplasty in chronic thromboembolic pulmonary hypertension. Cardiovascular Intervention and Therapeutics, 2022, 37, 60-65.	1.2	4
2648	Risk prediction in medically treated chronic thromboembolic pulmonary hypertension. BMC Pulmonary Medicine, 2021, 21, 128.	0.8	5
2649	Feasibility of semi-recumbent bicycle exercise Doppler echocardiography for the evaluation of the right heart and pulmonary circulation unit in different clinical conditions: the RIGHT heart international NETwork (RIGHT-NET). International Journal of Cardiovascular Imaging, 2021, 37, 2151-2167.	0.7	6
2650	JCS/JHFS 2021 Statement on Palliative Care in Cardiovascular Diseases. Circulation Journal, 2021, 85, 695-757.	0.7	16
2651	Inflammatory Mechanisms in the Pathogenesis of Pulmonary Arterial Hypertension: Recent Advances. , 2021, 11, 1805-1829.		5
2652	Right ventricular stroke work index by echocardiography in adult patients with pulmonary arterial hypertension. BMC Cardiovascular Disorders, 2021, 21, 219.	0.7	1
2653	Role of Osteopontin as a Potential Biomarker of Pulmonary Arterial Hypertension in Patients with Systemic Sclerosis and Other Connective Tissue Diseases (CTDs). Pharmaceuticals, 2021, 14, 394.	1.7	10
2654	Correlation of echocardiographic probability of pulmonary hypertension with maternal outcomes in pregnant women with elevated right ventricular systolic pressure. Echocardiography, 2021, 38, 760-766.	0.3	2
2655	The benefit of exerciseâ€based rehabilitation programs in patients with pulmonary hypertension: a systematic review and metaâ€analysis of randomized controlled trials. Pulmonary Circulation, 2021, 11, 1-8.	0.8	8
2656	Circulating regulators of the wingless pathway in precapillary pulmonary hypertension. Respirology, 2021, 26, 574-581.	1.3	4
2657	Pulmonary arterial hypertension in pregnancyâ€”a systematic review of outcomes in the modern era. Pulmonary Circulation, 2021, 11, 1-9.	0.8	34
2658	A minimal clinically important difference measured by the Cambridge Pulmonary Hypertension Outcome Review for patients with idiopathic pulmonary arterial hypertension. Pulmonary Circulation, 2021, 11, 1-9.	0.8	4
2659	Body Habitus Considerations During Right Heart Catheterization. CJC Open, 2021, 3, 1108-1116.	0.7	2
2660	What are the echocardiographic findings of acute right ventricular strain that suggest pulmonary embolism?. Anaesthesia, Critical Care & Pain Medicine, 2021, 40, 100852.	0.6	27

#	Article	IF	Citations
2661	Inhaled pulmonary vasodilators: a narrative review. Annals of Translational Medicine, 2021, 9, 597-597.	0.7	21
2662	PULMONER ARTERÄ°YEL HÄ°PERTANSÄ°YON TEDAVÄ°SÄ°NDE GÃœNCEL YAKLAÅžIMLAR. Ankara Universitesi Eczaciljk Fakultesi Dergisi, 0, , .	0.2	0
2663	Giant pulmonary artery aneurysm caused by sibutramine-associated pulmonary arterial hypertension: First case in the literature. Anatolian Journal of Cardiology, 2021, 25, 512-514.	0.5	2
2664	Assessment of right ventricular reserve utilizing exercise provocation in systemic sclerosis. International Journal of Cardiovascular Imaging, 2021, 37, 2137-2147.	0.7	11
2665	A Simplified Diagnostic and Therapeutic Approach to Pulmonary Hypertension. Current Problems in Cardiology, 2022, 47, 100857.	1.1	1
2666	Pulmonary Hypertension in Association with Lung Disease: Quantitative CT and Artificial Intelligence to the Rescue? State-of-the-Art Review. Diagnostics, 2021, 11, 679.	1.3	15
2667	Right Ventricular Dysfunction in Patients With COVID-19: A Systematic Review and Meta-analysis. Journal of Cardiothoracic and Vascular Anesthesia, 2021, 35, 3319-3324.	0.6	45
2668	Transplant-associated thrombotic microangiopathy: theoretical considerations and a practical approach to an unrefined diagnosis. Bone Marrow Transplantation, 2021, 56, 1805-1817.	1.3	51
2669	Sotatercept for the Treatment of Pulmonary Arterial Hypertension. New England Journal of Medicine, 2021, 384, 1204-1215.	13.9	224
2670	Difficult diagnostics of a rare cause of pulmonary hypertension: a case report. Russian Journal of Cardiology, 0, 26, 4209.	0.4	0
2671	Pulmonary Hypertension. Annals of Internal Medicine, 2021, 174, ITC49-ITC64.	2.0	68
2673	Vascular endothelial injury assessed with functional techniques in systemic sclerosis patients with pulmonary arterial hypertension versus systemic sclerosis patients without pulmonary arterial hypertension: a systematic review and meta-analysis. Rheumatology International, 2021, 41, 1045-1053.	1.5	10
2674	Glutaminolysis: A Driver of Vascular and Cardiac Remodeling in Pulmonary Arterial Hypertension. Frontiers in Cardiovascular Medicine, 2021, 8, 667446.	1.1	9
2676	Differential diagnosis of arrhythmogenic cardiomyopathy: phenocopies versus disease variants. Minerva Medica, 2021, 112, 269-280.	0.3	13
2677	Left Ventricular Diastolic Dysfunction and Pulmonary Hypertension: Outcomes in SAVR. Thoracic and Cardiovascular Surgeon, 2021, , .	0.4	0
2678	Relation of Body Mass Index to Adverse Right Ventricular Mechanics. American Journal of Cardiology, 2021, 144, 137-142.	0.7	4
2679	Management of Women With Congenital or Inherited Cardiovascular Disease From Pre-Conception Through Pregnancy andÂPostpartum. Journal of the American College of Cardiology, 2021, 77, 1778-1798.	1.2	49
2680	Evaluation of the clinical efficacy and safety of nitric oxide synthesized from room air in the postoperative period of cardiac surgery. Translational Medicine, 2021, 8, 38-50.	0.1	5

#	Article	IF	Citations
2681	Direct oral anticoagulants in chronic thromboembolic pulmonary hypertension. Journal of Thrombosis and Thrombolysis, 2021, 52, 791-796.	1.0	6
2682	Commercial Air Travel for Passengers With Cardiovascular Disease: Recommendations for Less Common Conditions, Considerations for Venous Thromboembolism, and General Guidance. Current Problems in Cardiology, 2021, 46, 100782.	1.1	1
2683	Patient and disease characteristics of the first 500 patients with pulmonary arterial hypertension treated with selexipag in real-world settings from SPHERE. Journal of Heart and Lung Transplantation, 2021, 40, 279-288.	0.3	10
2684	New measures of right ventricle-pulmonary artery coupling in heart failure: An all-cause mortality echocardiographic study. International Journal of Cardiology, 2021, 329, 234-241.	0.8	13
2685	Management of arrhythmias in pulmonary hypertension. Journal of Interventional Cardiac Electrophysiology, 2021, 62, 219-229.	0.6	2
2686	Validity of echocardiographic tricuspid regurgitation gradient to screen for new definition of pulmonary hypertension. EClinicalMedicine, 2021, 34, 100822.	3.2	22
2687	Pulmonary hypertension and cardiovascular mortality in end-stage kidney disease: still some way to go before conclusive evidence. International Urology and Nephrology, 2021, , 1.	0.6	0
2688	Loss of immune homeostasis in patients with idiopathic pulmonary arterial hypertension. Thorax, 2021, 76, 1209-1218.	2.7	12
2689	Impact of targeted pulmonary arterial hypertension therapy in patients with combined post- and precapillary pulmonary hypertension. American Heart Journal, 2021, 235, 74-81.	1.2	3
2690	Prevalence of Pulmonary Hypertension in an Unselected Community-Based Population: A Retrospective Echocardiographic Studyâ€"RES-PH Study. Journal of Personalized Medicine, 2021, 11, 489.	1.1	2
2691	Pulmonary arterial hypertension unveils itself: a cancer-like progression â€" a case report. European Heart Journal - Case Reports, 2021, 5, ytab149.	0.3	1
2692	Prevalence of Mental Disorders and Impact on Quality of Life in Patients With Pulmonary Arterial Hypertension. Frontiers in Psychiatry, 2021, 12, 667602.	1.3	30
2693	Impact of Parthanatos on the Increased Risk of Onset and Mortality in Male Patients With Pulmonary Hypertension. American Journal of Men's Health, 2021, 15, 155798832110294.	0.7	5
2694	Consensus document on optimal management of patients with common arterial trunk. Cardiology in the Young, 2021, 31, 915-939.	0.4	1
2695	Parasympathetic modulation withdrawal improves functional capacity in pulmonary arterial hypertension. Respiratory Physiology and Neurobiology, 2021, 287, 103620.	0.7	1
2696	Pulmonary Arterial Remodeling Is Related to the Risk Stratification and Right Ventricular-Pulmonary Arterial Coupling in Patients With Pulmonary Arterial Hypertension. Frontiers in Physiology, 2021, 12, 631326.	1.3	4
2697	Glycated ACE2 receptor in diabetes: open door for SARS-COV-2 entry in cardiomyocyte. Cardiovascular Diabetology, 2021, 20, 99.	2.7	67
2698	A decrease in tricuspid regurgitation pressure gradient associates with favorable outcome in patients with heart failure. ESC Heart Failure, 2021, 8, 2826-2836.	1.4	4

#	Article	IF	Citations
2699	Offâ€label use of PAHâ€targeted medications approved for adults and their financial coverage by health insurances are vital for children with pulmonary hypertension. European Journal of Clinical Investigation, 2021, 51, e13571.	1.7	1
2700	Clinical Impact of the New Definition of Precapillary Pulmonary Hypertension. Chest, 2021, 159, 1995-1997.	0.4	11
2701	Impact of right ventricular work and pulmonary arterial compliance on peak exercise oxygen uptake in idiopathic pulmonary arterial hypertension. International Journal of Cardiology, 2021, 331, 230-235.	0.8	2
2702	Cardiovascular magnetic resonance predicts all-cause mortality in pulmonary hypertension associated with heart failure with preserved ejection fraction. International Journal of Cardiovascular Imaging, 2021, 37, 3019-3025.	0.7	12
2703	Refractory pleural effusion as a rare complication of pulmonary vascular stenosis induced by fibrosing mediastinitis: a case report and literature review. Journal of International Medical Research, 2021, 49, 030006052110100.	0.4	6
2704	Animal models of pulmonary hypertension: Getting to the heart of the problem. British Journal of Pharmacology, 2022, 179, 811-837.	2.7	31
2705	S100A6, Calumenin and Cytohesin 2 as Biomarkers for Cutaneous Involvement in Systemic Sclerosis Patients: A Case Control Study. Journal of Personalized Medicine, 2021, 11, 368.	1.1	5
2706	Periprocedural safety and outcome after pump implantation for intravenous treprostinil administration in patients with pulmonary arterial hypertension. BMC Pulmonary Medicine, 2021, 21, 164.	0.8	2
2707	Lung ultrasonography for long-term follow-up of COVID-19 survivors compared to chest CT scan. Respiratory Medicine, 2021, 181, 106384.	1.3	32
2708	Cardiac Manifestations in a Group of Romanian Patients with Gaucher Disease Type 1 (a Monocentric) Tj ETQq1 1 0.784314 rgBT /Ov	1.3	2
2709	Heart failure and pulmonary hypertension in a patient with partial anomalous pulmonary venous return and hyperthyroidism. Journal of Cardiovascular Medicine, 2021, Publish Ahead of Print, e15-e17.	0.6	0
2711	Right ventricular diastolic dysfunction and failure: a review. Heart Failure Reviews, 2022, 27, 1077-1090.	1.7	6
2712	Treatment Strategy Options in Inoperable Chronic Thromboembolic Pulmonary Hypertension Patients. Rational Pharmacotherapy in Cardiology, 2021, 17, 278-285.	0.3	0
2713	EACVI survey on the evaluation of left ventricular diastolic function. European Heart Journal Cardiovascular Imaging, 2021, 22, 1098-1105.	0.5	12
2714	Pulmonary arterial hyper-tension in a patient with hereditary hemorrhagic telangiectasia and family gene analysis: A case report. World Journal of Clinical Cases, 2021, 9, 3079-3089.	0.3	1
2715	The effects of oral pulmonary vasodilator therapy on poor candidates for fenestration closure in patients with a fontan circulation. International Journal of Cardiology Congenital Heart Disease, 2021, 3, 100090.	0.2	0
2716	Multimodal assessment of right ventricle overload-metabolic and clinical consequences in pulmonary arterial hypertension. Journal of Cardiovascular Magnetic Resonance, 2021, 23, 49.	1.6	11
2717	PTBP1 Targets ILK to Regulate the Hypoxia-Induced Phenotypic Transformation of Pulmonary Artery Smooth Muscle Cells. Drug Design, Development and Therapy, 2021, Volume 15, 2025-2033.	2.0	8

#	Article	IF	Citations
2718	Consensus document on optimal management of patients with common arterial trunk. European Journal of Cardio-thoracic Surgery, 2021, 60, 7-33.	0.6	7
2719	PULMONARY ARTERIAL HYPERTENSION: REGIONAL HEALTH CARE OPPORTUNITIES. Eurasian Heart Journal, 2021, , 84-91.	0.2	0
2721	Transcatheter Closure of Atrial Septal Defect Associated With Pulmonary Artery Hypertension using Fenestrated Devices. American Journal of Cardiology, 2021, 147, 122-128.	0.7	5
2722	Pregnancy in PAH: Emotions versus reality. Journal of Heart and Lung Transplantation, 2021, 40, 394-395.	0.3	1
2723	Iatrogenic perforation of a pulmonary artery side branchâ€"a case report. European Heart Journal - Case Reports, 2021, 5, ytab199.	0.3	2
2724	Association of Lymphangiogenic Factors With Pulmonary Arterial Hypertension in Systemic Sclerosis. Arthritis and Rheumatology, 2021, 73, 1277-1287.	2.9	4
2725	The relationship between retinal microcirculation and right heart catheterization and echocardiography findings in patients with idiopathic pulmonary arterial hypertension. Microcirculation, 2021, 28, e12704.	1.0	2
2726	Left Ventricular Hypertrophic Change Indicating Poor Prognosis in Patients With Normal-Flow, Low-Gradient Severe Aortic Stenosis With Preserved Left Ventricular Ejection Fraction. Circulation Reports, 2021, 3, 345-353.	0.4	2
2727	In-vitro performance of a single-chambered total artificial heart in a Fontan circulation. Journal of Artificial Organs, 2021, , 1.	0.4	0
2728	Cardiac Magnetic Resonance Evaluation of Pulmonary Arterial Hypertension. JACC: Cardiovascular Imaging, 2021, 14, 943-946.	2.3	0
2729	Prevalence of elevated right ventricular pressure in children with obstructive sleep apnea syndrome undergoing pulmonary hypertension screening. Journal of Clinical Sleep Medicine, 2021, 17, 2225-2232.	1.4	9
2730	Effect of Living Environment Factors on Quality of Life in Patients With Chronic Thromboembolic Pulmonary Hypertension After Completion of Balloon Pulmonary Angioplastyã€€â€• A Cross-Sectional Study â€•. Circulation Reports, 2021, 3, 279-285.	0.4	0
2731	High Right Ventricular Afterload during Exercise in Patients with Pulmonary Arterial Hypertension. Journal of Clinical Medicine, 2021, 10, 2024.	1.0	3
2732	May We Use Non-Invasive Indices of Aortic Stiffness and Endothelial Glycocalyx as Biomarkers for Idiopathic Pulmonary Artery Hypertension Follow-Up?. Medicina (Lithuania), 2021, 57, 558.	0.8	0
2733	Echocardiography in Pulmonary Arterial Hypertension: Is It Time to Reconsider Its Prognostic Utility?. Journal of Clinical Medicine, 2021, 10, 2826.	1.0	12
2734	Interstitial lung diseases and pulmonary hypertension. Journal of Radiological Review, 2021, 8, .	0.1	1
2735	Cardiovascular complications in cystic fibrosis: A review of the literature. Journal of Cystic Fibrosis, 2022, 21, 18-25.	0.3	25
2736	Hydrogen Sulfide Metabolism and Pulmonary Hypertension. Cells, 2021, 10, 1477.	1.8	15

#	Article	IF	Citations
2737	Efficacy of treat-and-repair strategy for atrial septal defect with pulmonary arterial hypertension. Heart, 2021, , heartjnl-2021-319096.	1.2	8
2738	Application of [18F]FLTâ€PET in pulmonary arterial hypertension: a clinical study in pulmonary arterial hypertension patients and unaffected bone morphogenetic protein receptor type 2Âmutation carriers. Pulmonary Circulation, 2021, 11, 1-9.	0.8	1
2739	Pulmonary arterial hypertension associated with congenital heart disease: lessons learnt from the large Turkish Nationwide Registry (THALES). Pulmonary Circulation, 2021, 11, 1-10.	0.8	5
2740	Risk Factors of Thrombotic Complications and Antithrombotic Therapy in Paediatric Cardiosurgical Patients. Acta Biomedica Scientifica, 2021, 6, 81-91.	0.1	0
2741	Pulmonary arterial hypertension patients display normal kinetics of clot formation using thrombelastography. Pulmonary Circulation, 2021, 11, 1-9.	0.8	3
2742	Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial. Lancet Respiratory Medicine,the, 2021, 9, 573-584.	5.2	85
2743	Pulmonary hypertension in interstitial lung disease: screening, diagnosis and treatment. Current Opinion in Pulmonary Medicine, 2021, 27, 396-404.	1.2	16
2744	Clinical characteristics and survival of patients with three major connective tissue diseases associated with pulmonary hypertension: A study from China. Experimental and Therapeutic Medicine, 2021, 22, 925.	0.8	5
2745	Electrocardiogram Alarm for Mediastinum Metastasis in a Patient With Lung Cancer. JAMA Internal Medicine, 2021, 181, 859.	2.6	2
2746	Therapeutic Challenges and Emerging Treatment Targets for Pulmonary Hypertension in Left Heart Disease. Journal of the American Heart Association, 2021, 10, e020633.	1.6	13
2747	Screening for the early detection of pulmonary arterial hypertension in patients with systemic sclerosis: A systematic review and meta-analysis of long-term outcomes. Seminars in Arthritis and Rheumatism, 2021, 51, 495-512.	1.6	12
2748	Serum Liberation of Fetal Fibronectin Variants in Patients with Pulmonary Hypertension: ED-A+ Fn as Promising Novel Biomarker of Pulmonary Vascular and Right Ventricular Myocardial Remodeling. Journal of Clinical Medicine, 2021, 10, 2559.	1.0	0
2749	Role of 3D echocardiographyâ€determined atrial volumes in distinguishing between preâ€capillary and postâ€capillary pulmonary hypertension. ESC Heart Failure, 2021, 8, 3975-3983.	1.4	5
2750	Association between Initial Treatment Strategy and Long-Term Survival in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 842-854.	2.5	94
2751	The role of imaging in pulmonary hypertension. Cardiovascular Diagnosis and Therapy, 2021, 11, 859-880.	0.7	5
2752	Anti-inflammatory role and mechanism of microRNA-92b-3p in the progression of hypoxic pulmonary hypertension. Life Sciences, 2021, , 119725.	2.0	1
2753	Epoprostenol for the treatment of pulmonary arterial hypertension. Expert Review of Clinical Pharmacology, 2021, 14, 1005-1013.	1.3	6
2754	Cardiac index predicts long-term outcomes in patients with heart failure. PLoS ONE, 2021, 16, e0252833.	1.1	6

#	Article	IF	Citations
2755	2020 KSC/KATRD Guideline for the Diagnosis and Treatment of Pulmonary Hypertension: Executive Summary. Tuberculosis and Respiratory Diseases, 2022, 85, 1-10.	0.7	6
2756	Long-term clinical course and outcome in patients with primary SjÃ¶gren syndrome-associated interstitial lung disease. Scientific Reports, 2021, 11, 12827.	1.6	11
2758	Establishing expert consensus for the optimal approach to holistic risk-management in pulmonary arterial hypertension: a Delphi process and narrative review. Expert Review of Respiratory Medicine, 2021, 15, 1493-1503.	1.0	0
2759	The Value of Heart Rhythm Complexity in Identifying High-Risk Pulmonary Hypertension Patients. Entropy, 2021, 23, 753.	1.1	4
2760	Impaired Myocardial Function Is Prognostic for Severe Respiratory Failure in the Course of COVID-19 Infection. Frontiers in Cardiovascular Medicine, 2021, 8, 584108.	1.1	7
2761	Pulmonary Complications in Cystic Fibrosis: Past, Present, and Future. Chest, 2021, 160, 1232-1240.	0.4	8
2762	Comparative Effectiveness of Exercise Training for Patients With Chronic Thromboembolic Pulmonary Hypertension After Pulmonary Endarterectomy: A Systematic Review and Meta-Analysis. Frontiers in Cardiovascular Medicine, 2021, 8, 664984.	1.1	1
2763	Pulmonary arterial hypertension associated with systemic scleroderma. Klinicheskaia Meditsina, 2021, 99, 68-74.	0.2	0
2764	KDOQI US Commentary on the 2020 KDIGO Clinical Practice Guideline on the Evaluation and Management of Candidates for Kidney Transplantation. American Journal of Kidney Diseases, 2021, 77, 833-856.	2.1	7
2765	A novel approach to perioperative risk assessment for patients with pulmonary hypertension. ERJ Open Research, 2021, 7, 00257-2021.	1.1	6
2766	Protecting the Injured Right Ventricle in COVID-19 Acute Respiratory Distress Syndrome: Can Clinicians Personalize Interventions and Reduce Mortality?. Journal of Cardiothoracic and Vascular Anesthesia, 2021, 35, 3325-3330.	0.6	3
2767	Successful treatment of pulmonary hypertension following hematopoietic stem cell transplant with a single oral tadalafil: a case report. Pulmonary Circulation, 2021, 11, 1-5.	0.8	3
2768	Nonsteroidal Mineralocorticoid Receptor Antagonists: Exploring Role in Cardiovascular Disease. Journal of Cardiovascular Pharmacology, 2021, 77, 685-698.	0.8	3
2769	Profiling and Molecular Mechanism Analysis of Long Non-Coding RNAs and mRNAs in Pulmonary Arterial Hypertension Rat Models. Frontiers in Pharmacology, 2021, 12, 709816.	1.6	8
2770	Right ventricular adaptation to pressure-overload: Differences between chronic thromboembolic pulmonary hypertension and idiopathic pulmonary arterial hypertension. Journal of Heart and Lung Transplantation, 2021, 40, 458-466.	0.3	14
2771	Treatment of pulmonary hypertension in patients with Hereditary Hemorrhagic Telangiectasia â€“ A case series and systematic review. Pulmonary Pharmacology and Therapeutics, 2021, 68, 102033.	1.1	6
2772	Does pulmonary artery pulsatility index predict mortality in pulmonary arterial hypertension?. ESC Heart Failure, 2021, 8, 3835-3844.	1.4	5
2773	Parenteral Prostanoids in Pediatric Pulmonary Arterial Hypertension: Start Early, Dose High, Combine. Annals of the American Thoracic Society, 2022, 19, 227-237.	1.5	16

#	Article	IF	Citations
2774	Pulmonary endarterectomy. Indian Journal of Thoracic and Cardiovascular Surgery, 2021, 37, 662-672.	0.2	0
2775	Soluble ST2 and mixed venous oxygen saturation for prediction of mortality in patients with pulmonary hypertension. Journal of Thoracic Disease, 2021, 13, 3478-3488.	0.6	2
2776	Acute effects of inhaled iloprost on intracardiac conduction in patients with pulmonary arterial hypertension. Herz, 2021, , 1.	0.4	0
2777	Prevalence and risk factors for left ventricular diastolic dysfunction in systemic sclerosis: a multi-center study of CRDC cohort in China. Clinical Rheumatology, 2021, 40, 4589-4596.	1.0	4
2778	Perinatal Management and Long-Term Follow-up of a Primipara With Severe Pulmonary Arterial Hypertension Associated With Systemic Lupus Erythematosus. Journal of Cardiothoracic and Vascular Anesthesia, 2021, , .	0.6	1
2779	Radiofrequency Catheter Ablation of Supraventricular Tachycardia in Patients With Pulmonary Hypertension: Feasibility and Long-Term Outcome. Frontiers in Physiology, 2021, 12, 674909.	1.3	5
2781	Perspective of Pulmonary Rehabilitation Centers in Latin America. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2021, 18, 401-405.	0.7	2
2782	Pulmonary Hypertension - A Distinct Perspective. Journal of Evidence Based Medicine and Healthcare, 2021, 8, 2349-2362.	0.0	0
2783	Pulmonary Hypertension in Patients with Common Variable Immunodeficiency. Journal of Clinical Immunology, 2021, 41, 1549-1562.	2.0	3
2784	2020 Chinese expert-based consensus on the diagnosis and treatment of connective tissue disease associated pulmonary arterial hypertension. Rheumatology and Immunology Research, 2021, 2, 63-78.	0.2	0
2785	Transition from IV epoprostenol to oral treprostinil in a patient with group 1 pulmonary arterial hypertension. American Journal of Health-System Pharmacy, 2021, , .	0.5	1
2786	Echocardiographic Changes and Long-Term Clinical Outcomes in Pediatric Patients With Pulmonary Arterial Hypertension Treated With Bosentan for 72 Weeks: A Post-hoc Analysis From the FUTURE 3 Study. Frontiers in Pediatrics, 2021, 9, 681538.	0.9	1
2787	Screening for Pulmonary Hypertension in Systemic Sclerosisâ€"A Primer for Cardio-Rheumatology Clinics. Diagnostics, 2021, 11, 1013.	1.3	2
2788	Is the maternal risk of pregnancy acceptable in patients with moderate pulmonary hypertension?. Pulmonary Circulation, 2021, 11, 1-2.	0.8	1
2789	Haemodynamic effects of PAH-targeted therapies in pulmonary hypertension due to lung disease: A systematic review and meta-analysis. Pulmonary Pharmacology and Therapeutics, 2021, 68, 102036.	1.1	4
2790	Contemporary review in the multi-modality imaging evaluation and management of tricuspid regurgitation. Cardiovascular Diagnosis and Therapy, 2021, 11, 804-817.	0.7	4
2791	Intravenous prostanoids in systemic sclerosis-associated pulmonary arterial hypertension: a single-centre experience. Rheumatology, 2021, , .	0.9	2
2792	The effect of docosahexaenoic acid on predicting the survival of patients with idiopathic pulmonary arterial hypertension. Annals of Translational Medicine, 2021, 9, 995-995.	0.7	3

#	Article	IF	Citations
2793	Accuracy of echocardiographic estimates of pulmonary artery pressures in pulmonary hypertension: insights from the KARUM hemodynamic database. International Journal of Cardiovascular Imaging, 2021, 37, 2637-2645.	0.7	9
2794	Recent advancements in pulmonary arterial hypertension and right heart failure research: overview of selected abstracts from ATS2020 and emerging COVIDâ€19 research. Pulmonary Circulation, 2021, 11, 1-13.	0.8	2
2795	A pilot cohort study assessing the feasibility of complete revascularization with balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension. PLoS ONE, 2021, 16, e0254770.	1.1	7
2796	Management of Pulmonary Hypertension Due to Chronic Lung Disease. Methodist DeBakey Cardiovascular Journal, 2021, 17, 124.	0.5	3
2797	Under Pressure: Right Heart Catheterization and Provocative Testing for Diagnosing Pulmonary Hypertension. Methodist DeBakey Cardiovascular Journal, 2021, 17, 92.	0.5	3
2798	Selective Segmental Pulmonary Angiography: Anatomical, Technical and Safety Aspects of a Must-Learn Technique in Times of Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension. Journal of Clinical Medicine, 2021, 10, 3358.	1.0	2
2799	Accelerated right heart failure due to lung resection in the setting of chronic respiratory failure. Journal of Cardiology Cases, 2021, 25, 42-45.	0.2	0
2800	Heart failure following transcatheter aortic valve replacement. Expert Review of Cardiovascular Therapy, 2021, 19, 695-709.	0.6	8
2801	Wedge Pressure vs Left Ventricular End-Diastolic Pressure for Pulmonary Hypertension Classification and Prognostication in Severe Aortic Stenosis. CJC Open, 2021, 3, 1428-1437.	0.7	5
2802	Translational Sciences in Cardiac Failure Secondary to Arteriovenous Fistula in Hemodialysis Patients. Annals of Vascular Surgery, 2021, 74, 431-449.	0.4	2
2803	Pulmonary Artery 18F-Fluorodeoxyglucose Uptake by PET/CMR as a Marker of PulmonaryÂHypertension in Sarcoidosis. JACC: Cardiovascular Imaging, 2022, 15, 108-120.	2.3	8
2804	Haemodynamic effects of riociguat in CTEPH and PAH: a 10-year observational study. ERJ Open Research, 2021, 7, 00082-2021.	1.1	3
2806	Current strategies for managing chronic thromboembolic pulmonary hypertension: results of the worldwide prospective CTEPH Registry. ERJ Open Research, 2021, 7, 00850-2020.	1.1	65
2807	Man With Respiratory Distress and Facial Swelling. Annals of Emergency Medicine, 2021, 78, 55.	0.3	0
2808	Favorable Pregnancy Outcomes in Women With Well-Controlled Pulmonary Arterial Hypertension. Frontiers in Medicine, 2021, 8, 689764.	1.2	20
2809	Echocardiographic Assessment of Right Ventricularâ€“Arterial Coupling in Predicting Prognosis of Pulmonary Arterial Hypertension Patients. Journal of Clinical Medicine, 2021, 10, 2995.	1.0	14
2811	Impact of the new definition of pulmonary hypertension according to world symposium of pulmonary hypertension 2018 on diagnosis of post-capillary pulmonary hypertension. International Journal of Cardiology, 2021, 335, 105-110.	0.8	10
2812	Pathophysiology of Heart Failure with Preserved Ejection Fraction. Heart Failure Clinics, 2021, 17, 327-335.	1.0	16

#	Article	IF	Citations
2813	Changes in the Pulmonary Artery Wave Reflection in Dogs with Experimentally-Induced Acute Pulmonary Embolism and the Effect of Vasodilator. Animals, 2021, 11, 1977.	1.0	12
2814	Is pulmonary vascular resistance index better than pulmonary vascular resistance in predicting outcomes in pulmonary arterial hypertension?. Journal of Heart and Lung Transplantation, 2021, 40, 614-622.	0.3	4
2815	Pregnancy and pulmonary arterial hypertension: a case series and literature review. American Journal of Obstetrics & Gynecology MFM, 2021, 3, 100358.	1.3	16
2816	Carbohydrate Antigen 125 Is a Biomarker of the Severity and Prognosis of Pulmonary Hypertension. Frontiers in Cardiovascular Medicine, 2021, 8, 699904.	1.1	4
2817	Pulmonary angiosarcoma: A case report of surgical treatment. Journal of Cardiac Surgery, 2021, 36, 3936-3938.	0.3	0
2818	Quality of life in ambulatory pulmonary arterial hypertension in connective tissue diseases and its relationship with risk stratification. Pulmonary Circulation, 2021, 11, 1-8.	0.8	1
2819	Short-Term Impact of Iron Deficiency in Different Subsets of Patients with Precapillary Pulmonary Hypertension from an Eastern European Pulmonary Hypertension Referral Center. International Journal of General Medicine, 2021, Volume 14, 3355-3366.	0.8	4
2820	Effectiveness and safety of a simple home-based rehabilitation program in pulmonary arterial hypertension: an interventional pilot study. BMC Sports Science, Medicine and Rehabilitation, 2021, 13, 79.	0.7	8
2821	Echocardiographic assessment of the right ventricle in COVID-19: a systematic review. International Journal of Cardiovascular Imaging, 2021, 37, 3499-3512.	0.7	15
2822	ISHLT consensus document on lung transplantation in patients with connective tissue disease: Part II: Cardiac, surgical, perioperative, operative, and post-operative challenges and management statements. Journal of Heart and Lung Transplantation, 2021, 40, 1267-1278.	0.3	1
2823	Management of Pulmonary Hypertension in Left Heart Disease. Methodist DeBakey Cardiovascular Journal, 2021, 17, 115.	0.5	7
2824	Evaluation and Management of Pulmonary Arterial Hypertension in Congenital Heart Disease. Methodist DeBakey Cardiovascular Journal, 2021, 17, 145.	0.5	4
2825	Cyclic GMP modulating drugs in cardiovascular diseases: mechanism-based network pharmacology. Cardiovascular Research, 2022, 118, 2085-2102.	1.8	23
2826	Acute right ventricular failure in COVID-19 infection: A case series. Journal of Cardiology Cases, 2021, 24, 45-48.	0.2	10
2827	Exercise tolerance and quality of life in hemodynamically partially improved patients with chronic thromboembolic pulmonary hypertension treated with balloon pulmonary angioplasty. PLoS ONE, 2021, 16, e0255180.	1.1	9
2828	Non-invasive Assessment of Pulmonary Artery Wave Reflection in Dogs With Suspected Pulmonary Hypertension. Frontiers in Veterinary Science, 2021, 8, 659194.	0.9	6
2829	Pulmonary Hypertension in Patients With Heart Failure With Mid-Range Ejection Fraction. Frontiers in Cardiovascular Medicine, 2021, 8, 694240.	1.1	4
2830	Efficacy and safety of balloon pulmonary angioplasty for residual pulmonary hypertension after pulmonary endarterectomy. International Journal of Cardiology, 2021, 334, 105-109.	0.8	19

#	Article	IF	Citations
2831	Acute Hemodynamic Effect of Acetazolamide in Patients With Pulmonary Hypertension Whilst Breathing Normoxic and Hypoxic Gas: A Randomized Cross-Over Trial. Frontiers in Medicine, 2021, 8, 681473.	1.2	4
2832	A study on echocardiographic findings in hospitalized patients with connective tissue diseases. Scandinavian Journal of Rheumatology, 2022, 51, 142-151.	0.6	2
2833	Time-trends and predictors of interhospital transfers and 30-day rehospitalizations after acute coronary syndrome from 2000-2015. PLoS ONE, 2021, 16, e0255134.	1.1	0
2834	Cardiovascular phenotypes predict clinical outcomes in sickle cell disease: An echocardiographyâ€based cluster analysis. American Journal of Hematology, 2021, 96, 1166-1175.	2.0	5
2835	Accuracy of echocardiography in pulmonary hypertension: thinking outside of the box beyond the Achillesâ€™ heel of right atrial pressure estimation. International Journal of Cardiovascular Imaging, 2021, 37, 2647-2649.	0.7	0
2836	Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. Journal of Heart and Lung Transplantation, 2021, 40, 1349-1379.	0.3	293
2837	Relationship Between Time From Diagnosis and Morbidity/Mortality in Pulmonary Arterial Hypertension. Chest, 2021, 160, 277-286.	0.4	21
2838	Effect of Breathing Oxygen-Enriched Air on Exercise Performance in Patients With Pulmonary Hypertension Due to Heart Failure With Preserved Ejection Fraction: A Randomized, Placebo-Controlled, Crossover Trial. Frontiers in Medicine, 2021, 8, 692029.	1.2	2
2839	A young lady with dyspnoea: Quest for the cause. Monaldi Archives for Chest Disease, 2021, , .	0.3	0
2840	Novel Treatment Pathways in Pulmonary Arterial Hypertension. Methodist DeBakey Cardiovascular Journal, 2021, 17, 29.	0.5	6
2841	The Evolution of Risk Assessment in Pulmonary Arterial Hypertension. Methodist DeBakey Cardiovascular Journal, 2021, 17, 134.	0.5	0
2842	Potential of Câ€Xâ€C motif chemokine ligand 1/8/10/12 as diagnostic and prognostic biomarkers in idiopathic pulmonary arterial hypertension. Clinical Respiratory Journal, 2021, 15, 1302-1309.	0.6	7
2843	The evaluation of right ventricle dyssynchrony by speckle tracking echocardiography in systemic sclerosis patients. Journal of Clinical Ultrasound, 2021, 49, 895-902.	0.4	6
2844	A model for estimating the health economic impact of earlier diagnosis of chronic thromboembolic pulmonary hypertension. ERJ Open Research, 2021, 7, 00719-2020.	1.1	14
2845	Gender features of structural and functional changes of the heart and levels of copeptin and NTproBNP in patients with acute Q-myocardial infarction in the presence of pulmonary hypertension. ZaporoÅ¾skij Medicinskij Å½urnal, 2021, 23, 480-484.	0.0	0
2846	Right coronary artery diastolic perfusion pressure on outcome of patients with left heart failure and pulmonary hypertension. ESC Heart Failure, 2021, 8, 4086-4092.	1.4	2
2847	Comparative Transcriptional Analysis of Pulmonary Arterial Hypertension Associated With Three Different Diseases. Frontiers in Cell and Developmental Biology, 2021, 9, 672159.	1.8	6
2848	Clinical significance of pulmonary hypertension in patients with constrictive pericarditis. Heart, 2021, 107, 1651-1656.	1.2	2

#	Article	IF	Citations
2849	Evaluation, Diagnosis, and Classification of Pulmonary Hypertension. Methodist DeBakey Cardiovascular Journal, 2021, 17, 86.	0.5	14
2850	TIFA protein expression is associated with pulmonary arterial hypertension. Scientific Reports, 2021, 11, 14140.	1.6	1
2851	Biomarkers for possible early detection and progression of idiopathic pulmonary fibrosis. Minerva Respiratory Medicine, 2021, 60, .	0.1	2
2852	Peripheral Arterial Stiffness in Acute Pulmonary Embolism and Pulmonary Hypertension at Short-Term Follow-Up. Journal of Clinical Medicine, 2021, 10, 3008.	1.0	1
2853	Practical approaches to exercise testing. Medical Herald of the South of Russia, 2021, 12, 22-27.	0.2	1
2854	Evaluating of Red Blood Cell Distribution Width, Comorbidities and Electrocardiographic Ratios as Predictors of Prognosis in Patients with Pulmonary Hypertension. Diagnostics, 2021, 11, 1297.	1.3	2
2855	Right Ventricular Dysfunction and Its Association With Mortality in Coronavirus Disease 2019 Acute Respiratory Distress Syndrome*. Critical Care Medicine, 2021, 49, 1757-1768.	0.4	44
2856	Inotropic therapies in heart failure and cardiogenic shock: an educational review. European Heart Journal: Acute Cardiovascular Care, 2021, 10, 676-686.	0.4	13
2857	Assessment of cardiac arrhythmias using long-term continuous monitoring in patients with pulmonary hypertension. International Journal of Cardiology, 2021, 334, 110-115.	0.8	8
2858	Chronic thromboembolic pulmonary hypertension: a review. Singapore Medical Journal, 2021, 62, 318-325.	0.3	4
2859	Echocardiography in Pulmonary Arterial Hypertension: Comprehensive Evaluation and Technical Considerations. Journal of Clinical Medicine, 2021, 10, 3229.	1.0	18
2860	Deep radiomics-based survival prediction in patients with chronic obstructive pulmonary disease. Scientific Reports, 2021, 11, 15144.	1.6	14
2861	Controlling the flow balance: In vitro characterization of a pulsatile total artificial heart in preload and afterload sensitivity. Artificial Organs, 2022, 46, 71-82.	1.0	3
2862	Translation, cross-cultural adaptation, reliability, and validity of the Turkish version of the Duke Activity Status Index in patients with pulmonary hypertension. Pulmonology, 2021, , .	1.0	0
2863	Impact of the new pulmonary hypertension definition on <scp>longâ€term</scp> mortality in patients with severe aortic stenosis undergoing valve replacement. Clinical Cardiology, 2021, 44, 1276-1285.	0.7	11
2864	Critical Care Management of Decompensated Right Heart Failure in Pulmonary Arterial Hypertension Patients â€“ An Ongoing Approach. The Journal of Critical Care Medicine, 2021, 7, 170-183.	0.3	3
2865	The Role of Exercise Doppler Echocardiography to Unmask Pulmonary Arterial Hypertension in Selected Patients with Systemic Sclerosis and Equivocal Baseline Echocardiographic Values for Pulmonary Hypertension. Diagnostics, 2021, 11, 1200.	1.3	8
2866	Selonsertib in adults with pulmonary arterial hypertension (ARROW): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Respiratory Medicine,the, 2022, 10, 35-46.	5.2	17

#	Article	IF	Citations
2867	Long term prognosis in patients with pulmonary hypertension undergoing catheter ablation for supraventricular tachycardia. Scientific Reports, 2021, 11, 16176.	1.6	5
2868	New progress in elucidating the relationship between cancer therapy and cardiovascular toxicity. BioScience Trends, 2021, 15, 211-218.	1.1	5
2869	Inhibition of the prolyl isomerase Pin1 improves endothelial function and attenuates vascular remodelling in pulmonary hypertension by inhibiting TGF-Î² signalling. Angiogenesis, 2022, 25, 99-112.	3.7	8
2871	Chronic Thromboembolic Pulmonary Hypertension Mimicking Acute Pulmonary Embolism: A Case Report. American Journal of Case Reports, 2021, 22, e933031.	0.3	2
2872	Impact of Right Ventricular Function on Left Ventricular Torsion and Ventricular Deformations in Pulmonary Artery Hypertension Patients. Cardiovascular & Hematological Disorders Drug Targets, 2021, 21, 78-86.	0.2	1
2873	Management of Pregnancy in Lupus. Rheumatic Disease Clinics of North America, 2021, 47, 441-455.	0.8	6
2874	Simultaneous Measurement of Lung Diffusing Capacity and Pulmonary Hemodynamics Reveals Exertional Alveolarâ€Capillary Dysfunction in Heart Failure With Preserved Ejection Fraction. Journal of the American Heart Association, 2021, 10, e019950.	1.6	9
2875	Vaso reactivity test using inhaled nitric oxide for pulmonary arterial hypertension accompanied by severe interstitial lung disease attributed to systemic sclerosis: A case report. Journal of Cardiology Cases, 2021, 25, 144-148.	0.2	0
2876	Hemodynamics Prior to Valve Replacement for Severe Aortic Stenosis and Pulmonary Hypertension during Long-Term Follow-Up. Journal of Clinical Medicine, 2021, 10, 3878.	1.0	1
2878	Natural Course of the Diffusing Capacity of the Lungs for Carbon Monoxide in COPD. Chest, 2021, 160, 481-490.	0.4	16
2879	A randomized placebo-control trial of the acute effects of oxygen supplementation on exercise hemodynamics, autonomic modulation, and brain oxygenation in patients with pulmonary hypertension. Respiratory Physiology and Neurobiology, 2021, 290, 103677.	0.7	3
2880	Congestive heart failure associated with POEMS syndrome that was adequately distinguished from cardiac amyloidosis: a case report and literature review. Annals of Translational Medicine, 2021, 9, 1266-1266.	0.7	1
2881	Oxidative Stress, Kinase Activation, and Inflammatory Pathways Involved in Effects on Smooth Muscle Cells During Pulmonary Artery Hypertension Under Hypobaric Hypoxia Exposure. Frontiers in Physiology, 2021, 12, 690341.	1.3	26
2882	Predicting the Risk of Pulmonary Arterial Hypertension in Systemic Lupus Erythematosus: A Chinese Systemic Lupus Erythematosus Treatment and Research Group Cohort Study. Arthritis and Rheumatology, 2021, 73, 1847-1855.	2.9	18
2883	Topic-Based, Recent Literature Review on Pulmonary Hypertension. Mayo Clinic Proceedings, 2021, 96, 3109-3121.	1.4	6
2884	Novel Experimental Therapies for Treatment of Pulmonary Arterial Hypertension. Journal of Experimental Pharmacology, 2021, Volume 13, 817-857.	1.5	15
2885	Complete Atrioventricular Septal Defects after the Age of 40 Years. Journal of Clinical Medicine, 2021, 10, 3665.	1.0	1
2886	Impact of septal myectomy on diastolic function in patients with obstructive hypertrophic cardiomyopathy. Journal of Thoracic Disease, 2021, 13, 4925-4934.	0.6	2

#	Article	IF	Citations
2887	Secundum Type Atrial Septal Defect in Patients with Trisomy 21â€"Therapeutic Strategies, Outcome, and Survival: A Nationwide Study of the German National Registry for Congenital Heart Defects. Journal of Clinical Medicine, 2021, 10, 3807.	1.0	2
2888	The angiostatic peptide endostatin enhances mortality risk prediction in pulmonary arterial hypertension. ERJ Open Research, 2021, 7, 00378-2021.	1.1	5
2889	Relationship Between Endogenous Hydrogen Sulfide and Pulmonary Vascular Indexes on High-Resolution Computed Tomography in Patients with Chronic Obstructive Pulmonary Disease. International Journal of COPD, 2021, Volume 16, 2279-2289.	0.9	6
2890	Osteopontin and galectin-3 as biomarkers of maladaptive right ventricular remodelingÂin pulmonary hypertension. Biomarkers in Medicine, 2021, 15, 1021-1034.	0.6	6
2891	Eplerenone Improves Pulmonary Vascular Remodeling and Hypertension by Inhibition of the Mineralocorticoid Receptor in Endothelial Cells. Hypertension, 2021, 78, 456-465.	1.3	13
2893	Cardiac catheterization in pediatric pulmonary hypertension: a systematic and practical approach. Cardiovascular Diagnosis and Therapy, 2021, 11, 1102-1110.	0.7	3
2894	Systemic sclerosis-associated pulmonary arterial hypertension in children. Cardiovascular Diagnosis and Therapy, 2021, 11, 1137-1143.	0.7	6
2895	Evidence for Multiple Origins of De Novo Formed Vascular Smooth Muscle Cells in Pulmonary Hypertension: Challenging the Dominant Model of Pre-Existing Smooth Muscle Expansion. International Journal of Environmental Research and Public Health, 2021, 18, 8584.	1.2	0
2896	Development of theÂPulmonary Hypertension Functional Classification Self-Report: a patient version adapted from the World Health Organization Functional Classification measure. Health and Quality of Life Outcomes, 2021, 19, 202.	1.0	14
2897	Value of standard echocardiography at the bedside for COVID-19 patients in intensive care units: a Japanese single-center analysis. Journal of Medical Ultrasonics (2001), 2021, 48, 595-603.	0.6	1
2898	Myocardial adaptation and exercise performance in patients with pulmonary arterial hypertension assessed with patient-specific computer simulations. American Journal of Physiology - Heart and Circulatory Physiology, 2021, 321, H865-H880.	1.5	1
2899	Deep Learning for Detection of Elevated Pulmonary Artery Wedge Pressure Using Standard Chest X-Ray. Canadian Journal of Cardiology, 2021, 37, 1198-1206.	0.8	17
2900	Metabolic Syndrome Mediates ROS-miR-193b-NFYAâ€"Dependent Downregulation of Soluble Guanylate Cyclase and Contributes to Exercise-Induced Pulmonary Hypertension in Heart Failure With Preserved Ejection Fraction. Circulation, 2021, 144, 615-637.	1.6	44
2902	Experiences with pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension at multiple centers in Taiwan. Journal of the Formosan Medical Association, 2022, 121, 604-612.	0.8	5
2903	Integrated Cardiopulmonary MRI Assessment of Pulmonary Hypertension. Journal of Magnetic Resonance Imaging, 2021, , .	1.9	7
2904	Transplantation for pulmonary arterial hypertension with congenital heart disease: Impact on outcomes of the current therapeutic approach including a high-priority allocation program. American Journal of Transplantation, 2021, 21, 3388-3400.	2.6	3
2905	Analysis of right ventricular flow with 4-dimensional flow cardiovascular magnetic resonance imaging in patients with pulmonary arterial hypertension. Quantitative Imaging in Medicine and Surgery, 2021, 11, 3655-3665.	1.1	8
2906	Covid-19-induced pulmonary hypertension in children, and the use of phosphodiesterase-5 inhibitors. F1000Research, 0, 10, 792.	0.8	0

#	Article	IF	Citations
2907	Pregnancy in women with an inferior vena cava filter: a tertiary center experience and overview of the literature. Blood Advances, 2021, 5, 4044-4053.	2.5	4
2908	Pulmonary Hypertension in Patients With COPD. Chest, 2021, 160, 678-689.	0.4	55
2909	Pulmonary vascular resistance in children and adults. When should we index for body surface area?. International Journal of Cardiology Congenital Heart Disease, 2021, 4, 100133.	0.2	0
2910	Pulmonary hypertension in patients with chronic myeloid leukemia. Medicine (United States), 2021, 100, e26975.	0.4	3
2911	Pharmacological Alteration of Cellular Mechanical Properties in Pulmonary Arterial Smooth Muscle Cells of Idiopathic Pulmonary Arterial Hypertension. Cardiology Research, 2021, 12, 231-237.	0.5	2
2912	Impact of Pulmonary Hypertension on In-Hospital Outcomes and 30-Day Readmissions Following Percutaneous Coronary Interventions. Mayo Clinic Proceedings, 2021, 96, 2058-2066.	1.4	3
2913	Altitude exposure in pediatric pulmonary hypertensionâ€"are we ready for (flight) recommendations?. Cardiovascular Diagnosis and Therapy, 2021, 11, 1122-1136.	0.7	4
2914	Pulmonary hypertension phenotypes in patients with systemic sclerosis. European Respiratory Review, 2021, 30, 210053.	3.0	27
2915	Potential role of an athlete-focused echocardiogram in sports eligibility. World Journal of Cardiology, 2021, 13, 271-297.	0.5	21
2916	Exploring Functional Differences between the Right and Left Ventricles to Better Understand Right Ventricular Dysfunction. Oxidative Medicine and Cellular Longevity, 2021, 2021, 1-21.	1.9	5
2917	Waitlist and post-transplant outcomes for eisenmenger syndrome: A comparison of transplant strategies. Journal of Heart and Lung Transplantation, 2021, 40, 841-849.	0.3	5
2918	The phenotype of myositis patients with anti-Ku autoantibodies. Seminars in Arthritis and Rheumatism, 2021, 51, 728-734.	1.6	13
2919	HipertensÃ£o pulmonar tromboembÃ³lica crÃ³nica: experiÃªncia inicial de doentes submetidos a tromboendarterectomia pulmonar. Revista Portuguesa De Cardiologia, 2021, 40, 741-752.	0.2	3
2920	Use of the Prostacyclin Receptor Agonist Selexipag in Patients With Pulmonary Arterial Hypertension Associated With Eisenmenger Syndrome. Canadian Journal of Cardiology, 2021, 37, 1286-1288.	0.8	4
2921	Diagnostic Delays and Characteristics of Pediatric Pulmonary Hypertension Presenting as Syncope. Clinical Pediatrics, 2021, 60, 443-446.	0.4	2
2922	Soluble Receptor for Advanced Glycation End Products (sRAGE) Is a Sensitive Biomarker in Human Pulmonary Arterial Hypertension. International Journal of Molecular Sciences, 2021, 22, 8591.	1.8	7
2923	Nonresponse to Acute Vasodilator Challenge and Prognosis in Heart Failure With Pulmonary Hypertension. Journal of Cardiac Failure, 2021, 27, 869-876.	0.7	4
2924	Exercise-induced pulmonary hypertension in HIV patients: Association with poor clinical and immunological status. Vascular Pharmacology, 2021, 139, 106888.	1.0	4

#	Article	IF	Citations
2925	Evaluation and management of patients with chronic thromboembolic pulmonary hypertension - consensus statement from the ISHLT. Journal of Heart and Lung Transplantation, 2021, 40, 1301-1326.	0.3	36
2926	Chronic Thromboembolic Pulmonary Hypertension: the Bedside. Current Cardiology Reports, 2021, 23, 147.	1.3	6
2927	Right Ventricular Function Predicts Adverse Clinical Outcomes in Patients With Chronic Thromboembolic Pulmonary Hypertension: A Three-Dimensional Echocardiographic Study. Frontiers in Medicine, 2021, 8, 697396.	1.2	5
2928	Role of the Immune System Elements in Pulmonary Arterial Hypertension. Journal of Clinical Medicine, 2021, 10, 3757.	1.0	20
2929	WNT5B promotes vascular smooth muscle cell dedifferentiation via mitochondrial dynamics regulation in chronic thromboembolic pulmonary hypertension. Journal of Cellular Physiology, 2022, 237, 789-803.	2.0	8
2930	Left Main Coronary Artery Stent Destructuring by a Pulmonary Artery Aneurysm. Cardiovascular Revascularization Medicine, 2022, 40, 246-248.	0.3	0
2931	Computer modeling to predict balloon pulmonary angioplasty success. American Journal of Physiology - Heart and Circulatory Physiology, 2021, 321, H567-H568.	1.5	0
2932	Sex Differences in Chronic Thromboembolic Pulmonary Hypertension. Treatment Options over Time in a National Referral Center. Journal of Clinical Medicine, 2021, 10, 4251.	1.0	4
2933	Sensitivity and Specificity of pulmonary artery pressure measurement in echocardiography and correlation with right heart catheterization. Journal of the Saudi Heart Association, 2021, 33, 228-336.	0.2	4
2934	Balloon pulmonary angioplasty protocol in a Portuguese pulmonary hypertension expert center. Revista Portuguesa De Cardiologia, 2021, 40, 653-665.	0.2	9
2935	Pretransplant Right Ventricular Dysfunction Is Associated With Increased Mortality After Heart Transplantation: A Hard Inheritance to Overcome. Journal of Cardiac Failure, 2022, 28, 259-269.	0.7	9
2936	Balloon pulmonary angioplasty protocol in a Portuguese pulmonary hypertension expert center. Revista Portuguesa De Cardiologia (English Edition), 2021, 40, 653-665.	0.2	0
2937	Balloon pulmonary angioplasty â€“ welcome to chronic thromboembolic pulmonary hypertension treatment. Revista Portuguesa De Cardiologia (English Edition), 2021, 40, 667-668.	0.2	0
2938	Liver dysfunction in idiopathic pulmonary arterial hypertension: prevalence, characteristics and prognostic significance, a retrospective cohort study in China. BMJ Open, 2021, 11, e045165.	0.8	2
2939	In search of pulmonary hypertension treatments: Effect of 17Î²-estradiol on PGI2 pathway in human pulmonary artery. Prostaglandins Leukotrienes and Essential Fatty Acids, 2021, 172, 102321.	1.0	1
2940	Sarcopenia in young adults with congenital heart disease. JCSM Rapid Communications, 2022, 5, 77-85.	0.6	1
2941	Oxygen inhalation can selectively dilate pulmonary arteries in patients with chronic thromboembolic pulmonary hypertension before balloon angioplasty. Journal of Cardiology, 2022, 79, 265-269.	0.8	5
2942	Correlation of Pulse Wave Transit Time with Pulmonary Artery Pressure in a Porcine Model of Pulmonary Hypertension. Biomedicines, 2021, 9, 1212.	1.4	4

#	Article	IF	Citations
2943	Postmortem diagnosis of pulmonary tumor thrombotic microangiopathy with rapid exacerbation in a patient with gastric cancer: a case report. International Journal of Emergency Medicine, 2021, 14, 53.	0.6	1
2944	A more effective alternative to the 6-minute walk test for the assessment of functional capacity in patients with pulmonary hypertension. European Journal of Physical and Rehabilitation Medicine, 2021, 57, 645-652.	1.1	4
2945	Advances in the management of pulmonary arterial hypertension. Journal of Investigative Medicine, 2021, 69, 1270-1280.	0.7	19
2946	Chest pain in a patient with pulmonary arterial hypertension. Revista Portuguesa De Cardiologia, 2022, 41, 73-80.	0.2	0
2947	Serum cartilage oligomeric matrix protein is decreased in patients with pulmonary hypertension: a potential protective factor. Pulmonary Circulation, 2021, 11, 1-6.	0.8	3
2948	Prevalence, Incidence and Associates of Pulmonary Hypertension Complicating Type 2 Diabetes: Insights from the Fremantle Diabetes Study Phase 2 and National Echocardiographic Database of Australia. Journal of Clinical Medicine, 2021, 10, 4503.	1.0	3
2949	Successful Transcollateral Bidirectional Balloon Pulmonary Angioplasty in a Patient With Chronic Thromboembolic Pulmonary Hypertension. JACC: Cardiovascular Interventions, 2021, 14, e281-e282.	1.1	1
2950	Value of echocardiography using knowledge-based reconstruction in determining right ventricular volumes in pulmonary sarcoidosis: comparison with cardiac magnetic resonance imaging. International Journal of Cardiovascular Imaging, 2021, , 1.	0.7	0
2951	Determinants and protective associations of the lupus low disease activity state in a prospective Chinese cohort. Clinical Rheumatology, 2022, 41, 357-366.	1.0	10
2952	The expression profiling of microRNA in systemic sclerosis-associated pulmonary arterial hypertension. Annals of Translational Medicine, 2021, 9, 1458-1458.	0.7	2
2953	Changing of pulmonary artery diameter in accordance with severity of COVID-19 (assessment based on) Tj ETQq0 0 0 rgBT /Overlock 10	0.3	1
2954	Sex Differences, Estrogen Metabolism and Signaling in the Development of Pulmonary Arterial Hypertension. Frontiers in Cardiovascular Medicine, 2021, 8, 719058.	1.1	15
2955	Magnetic resonance relaxometry of the liver - a new imaging biomarker to assess right heart failure in pulmonary hypertension. Journal of Heart and Lung Transplantation, 2022, 41, 86-94.	0.3	5
2956	Updates in Systemic Sclerosis Treatment and Applicability to Pediatric Scleroderma. Rheumatic Disease Clinics of North America, 2021, 47, 757-780.	0.8	5
2957	Clinical features and survival in Takayasuâ€™s arteritis-associated pulmonary hypertension: a nationwide study. European Heart Journal, 2021, 42, 4298-4305.	1.0	19
2958	Causal relation of tricuspid regurgitation for heart failure outcomes: a mediation analysis of echocardiographic predictors. European Heart Journal Open, 2021, 1, .	0.9	2
2959	Mechanosensitivity in Pulmonary Circulation: Pathophysiological Relevance of Stretch-Activated Channels in Pulmonary Hypertension. Biomolecules, 2021, 11, 1389.	1.8	16
2960	How We Would Treat Our Own Pulmonary Hypertension if We Needed to Undergo Cardiac Surgery. Journal of Cardiothoracic and Vascular Anesthesia, 2022, 36, 1540-1548.	0.6	5

#	Article	IF	Citations
2961	Reduced-Dose Intravenous Thrombolysis for Acute Intermediateâ€“High-risk Pulmonary Embolism: Rationale and Design of the Pulmonary Embolism International THrOmbolysis (PEITHO)-3 trial. Thrombosis and Haemostasis, 2022, 122, 857-866.	1.8	35
2962	Diffuse Alveolar Hemorrhage: A Case of Overlap Syndrome of ANCA-Associated Vasculitis in Diffuse Systemic Sclerosis. Archivos De Bronconeumologia, 2021, 57, 602-604.	0.4	0
2963	Takayasu arteritis-associated pulmonary hypertension. European Heart Journal, 2021, 42, 4306-4308.	1.0	5
2964	Pulmonary hypertension is associated with an increased incidence of NAFLD: A retrospective cohort study of 18,910 patients. Journal of Internal Medicine, 2021, 290, 886-893.	2.7	7
2965	Effect of sildenafil added to antifibrotic treatment in idiopathic pulmonary fibrosis. Scientific Reports, 2021, 11, 17824.	1.6	5
2966	Ferric carboxymaltose in patients with pulmonary arterial hypertension and iron deficiency: a longâ€term study. Journal of Cachexia, Sarcopenia and Muscle, 2021, 12, 1501-1512.	2.9	18
2967	Utility of Computed Tomographic Angiography for Pulmonary Hypertension Assessment in a Cohort of West Highland White Terriers With or Without Canine Idiopathic Pulmonary Fibrosis. Frontiers in Veterinary Science, 2021, 8, 732133.	0.9	1
2968	Accuracy and diagnostic performance of doppler echocardiography to estimate mean pulmonary artery pressure in heart failure. Echocardiography, 2021, 38, 1624-1631.	0.3	1
2969	Guiding interventions for secondary tricuspid regurgitation. Cardiology in Review, 2021, Publish Ahead of Print, .	0.6	1
2970	Usefulness of acute vasoreactivity testing to decide shunt closure. International Journal of Cardiology Congenital Heart Disease, 2021, , 100228.	0.2	0
2971	Mediating effect of social support on the relationship between illness concealment and depression symptoms in patients with pulmonary arterial hypertension. Heart and Lung: Journal of Acute and Critical Care, 2021, 50, 706-713.	0.8	3
2972	Echocardiography Monitoring of Pulmonary Hypertension after Pediatric Hematopoietic Stem Cell Transplantation: Pediatric Pulmonary Arterial Hypertension and Pulmonary Veno-Occlusive Disease after Hematopoietic Stem Cell Transplantation. Transplantation and Cellular Therapy, 2021, 27, 786.e1-786.e8.	0.6	2
2973	The longitudinal use of EmPHasis-10 and CAMPHOR questionnaire health-related quality of life scores in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. Respiratory Medicine, 2021, 186, 106525.	1.3	9
2974	New score scale for assessing the risk of establishing chronic heart failure with preserved ejection fraction. Medical Visualization, 2021, 25, 83-96.	0.1	1
2975	Balloon pulmonary angioplasty â€“ welcome to chronic thromboembolic pulmonary hypertension treatment. Revista Portuguesa De Cardiologia, 2021, 40, 667-668.	0.2	0
2976	Case Report: BMPR2-Targeted MinION Sequencing as a Tool for Genetic Analysis in Patients With Pulmonary Arterial Hypertension. Frontiers in Cardiovascular Medicine, 2021, 8, 711694.	1.1	1
2977	Low-Dose Dobutamine Stress Echocardiography for the Early Detection of Pulmonary Arterial Hypertension in Selected Patients with Systemic Sclerosis Whose Resting Echocardiography Is Non-Diagnostic for Pulmonary Hypertension. Journal of Clinical Medicine, 2021, 10, 3972.	1.0	2
2978	The association of left ventricular histologically verified myocardial fibrosis with pulmonary hypertension in severe aortic stenosis. Perfusion (United Kingdom), 2023, 38, 165-171.	0.5	5

#	Article	IF	Citations
2979	Plasma ADAMTS13 and von Willebrand factor in diagnosis and prediction of prognosis in pulmonary arterial hypertension. Pulmonary Circulation, 2021, 11, 1-15.	0.8	5
2980	Early symptomatic benefit indicates long-term prognosis after transcatheter mitral valve edge-to-edge repair in functional and degenerative etiology. International Journal of Cardiology, 2021, 344, 141-146.	0.8	2
2981	Physical Examination for the Detection of Pulmonary Hypertension: A Systematic Review. Cureus, 2021, 13, e18020.	0.2	1
2982	May-Thurner Anatomy in Patients With Chronic Thromboembolic Pulmonary Hypertension. JACC: Cardiovascular Interventions, 2021, 14, 1940-1946.	1.1	7
2983	Minute ventilation/carbon dioxide production in congenital heart disease. European Respiratory Review, 2021, 30, 200178.	3.0	0
2984	Mineralocorticoid receptors in pulmonary hypertension and right heart failure: From molecular biology to therapeutic targeting. , 2022, 231, 107987.		8
2985	Noninvasive Risk Score to Screen for Pulmonary Hypertension With Elevated Pulmonary Vascular Resistance in Diseases of Chronic Volume Overload. American Journal of Cardiology, 2021, 159, 113-120.	0.7	0
2986	A Mobile Health Intervention to Increase Physical Activity in Pulmonary Arterial Hypertension. Chest, 2021, 160, 1042-1052.	0.4	16
2987	Right ventricular and cyclic guanosine monophosphate signalling abnormalities in stages B and C of heart failure with preserved ejection fraction. ESC Heart Failure, 2021, , .	1.4	4
2988	Fear of COVID-19, Anxiety and Depression in Patients with Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension during the Pandemic. Journal of Clinical Medicine, 2021, 10, 4195.	1.0	17
2989	Reverse remodeling of tricuspid valve morphology and function in chronic thromboembolic pulmonary hypertension patients following pulmonary thromboendarterectomy: a cardiac magnetic resonance imaging and invasive hemodynamic study. BMC Cardiovascular Disorders, 2021, 21, 450.	0.7	7
2990	Validation of the 2016 ASE/EACVI Guideline for Diastolic Dysfunction in Patients With Unexplained Dyspnea and a Preserved Left Ventricular Ejection Fraction. Journal of the American Heart Association, 2021, 10, e021165.	1.6	23
2991	Clinical characteristics and prognosis analysis of idiopathic and hereditary pulmonary hypertension patients with ACVRL1 gene mutations. Pulmonary Circulation, 2021, 11, 1-8.	0.8	6
2992	Potassium (K+) channels in the pulmonary vasculature: Implications in pulmonary hypertension Physiological, pathophysiological and pharmacological regulation. , 2021, 225, 107835.		19
2993	A case of pulmonary arterial hypertension with V/Q SPECT / CT that showed localized uptake of 99mTc just below the pleura and a unique distribution. Respirology Case Reports, 2021, 9, e0847.	0.3	0
2994	Hyperuricemia in patients with pulmonary hypertension: A study in a tertiary care center. IP Indian Journal of Immunology and Respiratory Medicine, 2021, 6, 173-177.	0.1	0
2995	Recomendaciones para la atenciÃ³n de pacientes con insuficiencia cardiaca y COVID-19. Archivos De Cardiologia De Mexico, 2021, 90, 26-32.	0.1	2
2996	Pulmonary hypertension associated with busulfan. Pulmonary Circulation, 2021, 11, 1-12.	0.8	3

#	Article	IF	Citations
2997	Characteristics and in-hospital outcomes of patients undergoing balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension: a time-trend analysis from the Japanese nationwide registry. Open Heart, 2021, 8, e001721.	0.9	8
2998	Pulmonary Rehabilitation in 2021. JAMA - Journal of the American Medical Association, 2021, 326, 969.	3.8	14
2999	Impact of Three Different Algorithms for the Screening of SSc-PAH and Comparison with the Decisions of a Multidisciplinary Team. Diagnostics, 2021, 11, 1738.	1.3	7
3000	Use of Epoprostenol in the Treatment of Pulmonary Arterial Hypertension. Cureus, 2021, 13, e18191.	0.2	1
3001	Right Side of the Heart Pulmonary Circulation Unit Involvement in Left-Sided Heart Failure. Chest, 2022, 161, 535-551.	0.4	9
3002	Diffuse Alveolar Hemorrhage: A Case of Overlap Syndrome of ANCA-Associated Vasculitis in Diffuse Systemic Sclerosis. Archivos De Bronconeumologia, 2021, 57, 602-604.	0.4	0
3003	Pulmonary Hypertension: A Predictor of Lung Cancer Prognosis?. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 1112-1113.	2.5	1
3004	COVID-19 as a cause of chronic pulmonary hypertension: pathophysiological rationale and potential of instrumental investigations. Cardiovascular Therapy and Prevention (Russian Federation), 2021, 20, 2844.	0.4	7
3005	Soluble Guanylate Cyclase Stimulators in Heart Failure. Cureus, 2021, 13, e17781.	0.2	6
3006	Multimodal Approach of Isolated Pulmonary Vasculitis: A Single-Institution Experience. Annals of Thoracic Surgery, 2022, 114, 1253-1261.	0.7	4
3007	Extractos de los documentos de posicionamientos y recomendaciones mexicanas en enfermedades cardiovasculares y COVID-19. Archivos De Cardiologia De Mexico, 2021, 90, 100-110.	0.1	1
3008	Positioning imatinib for pulmonary arterial hypertension: A phase I/II design comprising dose finding and singleâ€arm efficacy. Pulmonary Circulation, 2021, 11, 1-12.	0.8	5
3009	Catheter-based therapies in acute and chronic pulmonary embolism. Current Opinion in Cardiology, 2021, 36, 704-710.	0.8	2
3011	Effect of riociguat on right ventricular function in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. Journal of Heart and Lung Transplantation, 2021, 40, 1172-1180.	0.3	9
3012	Serial right heart catheter assessment between balloon pulmonary angioplasty sessions identify procedural factors that influence response to treatment. Journal of Heart and Lung Transplantation, 2021, 40, 1223-1234.	0.3	23
3014	2020 guide for the diagnosis and treatment of interstitial lung disease associated with connective tissue disease. Respiratory Investigation, 2021, 59, 709-740.	0.9	45
3015	Superior vena cava obstruction and pulmonary artery involvement as rare findings of immunoglobulin G4-related disease. Journal of Cardiology Cases, 2021, 24, 195-198.	0.2	0
3016	Decoupling Between Pulmonary Artery Diastolic and Wedge Pressure Following Transcatheter Aortic Valve Replacement. Circulation Journal, 2021, , .	0.7	2

#	Article	IF	Citations
3017	Cardiac acoustic biomarkers as surrogate markers to diagnose the phenotypes of pulmonary hypertension: an exploratory study. Heart and Vessels, 2022, 37, 593-600.	0.5	2
3018	Clinical Phenotypes of Sarcoidosis-Associated Pulmonary Hypertension. Heart Lung and Circulation, 2021, 30, 1502-1508.	0.2	4
3019	Incidence, prevalence and long-term progression of Goh algorithm rated interstitial lung disease in systemic sclerosis in two independent cohorts in flanders: A retrospective cohort study. Seminars in Arthritis and Rheumatism, 2021, 51, 969-976.	1.6	8
3020	Efficacy and safety of a 12-week outpatient pulmonary rehabilitation program in Post-PE Syndrome. Thrombosis Research, 2021, 206, 66-75.	0.8	24
3021	Effects of sildenafil on right ventricle remodelling in Portopulmonary hypertension. Pulmonary Pharmacology and Therapeutics, 2021, 70, 102071.	1.1	11
3022	Three- Versus Two-Drug Therapy for Patients With Newly Diagnosed Pulmonary ArterialÂHypertension. Journal of the American College of Cardiology, 2021, 78, 1393-1403.	1.2	90
3023	Disrupted PI3K subunit p110Î± signaling protects against pulmonary hypertension and reverses established disease in rodents. Journal of Clinical Investigation, 2021, 131, .	3.9	12
3024	Identification of novel metabolic signatures potentially involved in the pathogenesis of COPD associated pulmonary hypertension. Metabolomics, 2021, 17, 94.	1.4	4
3025	Association between the albuminâ€“bilirubin (ALBI) score and severity of portopulmonary hypertension (PoPH): A dataâ€mining analysis. Hepatology Research, 2021, 51, 1207-1218.	1.8	15
3026	Management of severe idiopathic pulmonary hypertension in a patient with acute liver failure treated with liver transplantation. Journal of Liver Transplantation, 2021, 4, 100040.	0.2	1
3027	Healthâ€related quality of life and hospitalizations in chronic thromboembolic pulmonary hypertension versus idiopathic pulmonary arterial hypertension: an analysis from the Pulmonary Hypertension Association Registry (PHAR). Pulmonary Circulation, 2021, 11, 1-11.	0.8	3
3028	Veno-venous extracorporeal membrane oxygenation in pulmonary arterial hypertension - Bridging to recovery. Respiratory Medicine and Research, 2021, 80, 100848.	0.4	0
3029	Inflammatory markers in Eisenmenger syndrome and their association with clinical outcomes. A cross-sectional comparative study. International Journal of Cardiology, 2021, 342, 34-38.	0.8	2
3030	Group 1 Clinical Features and Treatment. , 2022, , 616-632.		0
3031	Role of Screening in Sleep Disordered Breathing (SDB). , 2022, , 86-100.		0
3032	Biomarkers in Pulmonary Hypertension. , 2022, , 597-604.		0
3033	Pulmonary Complications of Lung Cancer Therapies. , 2022, , 931-949.		0
3034	Diagnosis and management of lung involvement in systemic lupus erythematosus and SjÃ¶grenâ€™s syndrome: a literature review. Therapeutic Advances in Musculoskeletal Disease, 2021, 13, 1759720X2110406.	1.2	11

#	Article	IF	Citations
3035	Right heart chambers geometry and function in patients with the atrial and the ventricular phenotypes of functional tricuspid regurgitation. European Heart Journal Cardiovascular Imaging, 2022, 23, 930-940.	0.5	46
3036	Palliative Care in Pulmonary Arterial Hypertension. Respiratory Medicine, 2021, , 255-279.	0.1	0
3037	HFpEF without elevated right ventricular systolic pressure is a favorable prognostic indicator in patients with IPF requiring hospitalization for heart failure. PLoS ONE, 2021, 16, e0245778.	1.1	1
3038	Health Disparities in Pulmonary Arterial Hypertension and the Impact of the COVID-19 Pandemic. Advances in Pulmonary Hypertension, 2021, 20, 6-15.	0.1	5
3039	Danish translation and linguistic validation of the multidimensional dyspnea profile. European Clinical Respiratory Journal, 2021, 8, 1905498.	0.7	2
3040	Galectin-3 Promotes ROS, Inflammation, and Vascular Fibrosis in Pulmonary Arterial Hypertension. Advances in Experimental Medicine and Biology, 2021, 1303, 13-32.	0.8	12
3041	Invasive Hemodynamic Assessment in Heart Failure With Preserved Ejection Fraction. , 2021, , 93-105.		0
3042	Identification of Potential Risk Genes and the Immune Landscape of Idiopathic Pulmonary Arterial Hypertension via Microarray Gene Expression Dataset Reanalysis. Genes, 2021, 12, 125.	1.0	7
3043	Comorbidities of Chronic Obstructive Pulmonary Disease and Their Affect on Hospitalization of Patients in a Tertiary Care Hospital. Journal of Community Hospital Internal Medicine Perspectives, 2021, 11, 120-123.	0.4	7
3044	[11C]meta-hydroxyephedrine PET evaluation in experimental pulmonary arterial hypertension: Effects of carvedilol of right ventricular sympathetic function. Journal of Nuclear Cardiology, 2021, 28, 407-422.	1.4	1
3045	Assessment of pulmonary arterial hemodynamic and vascular changes by pulmonary pulse transit time in patients with human immunodeficiency virus infection. Journal of Cardiovascular Echography, 2021, 31, 6.	0.1	1
3046	Clinical Outcome of Closure of a Small Atrial Septal Defect in a Patient with Pulmonary Arterial Hypertension. Internal Medicine, 2021, , .	0.3	0
3047	A multicentric quality-control study of exercise Doppler echocardiography of the right heart and the pulmonary circulation. The RIGHT Heart International NETwork (RIGHT-NET). Cardiovascular Ultrasound, 2021, 19, 9.	0.5	7
3048	Optimism for Interstitial Lung Diseaseâ€“Associated Pulmonary Hypertension?. New England Journal of Medicine, 2021, 384, 376-377.	13.9	5
3049	Human ex vivo lung perfusion: a novel model to study human lung diseases. Scientific Reports, 2021, 11, 490.	1.6	15
3050	Proteomic analysis of pulmonary arterial hypertension. Therapeutic Advances in Chronic Disease, 2021, 12, 204062232110473.	1.1	4
3051	Relevance of Machine Learning to Cardiovascular Imaging. Advances in Medical Technologies and Clinical Practice Book Series, 2021, , 78-99.	0.3	0
3052	Plasma proteoglycan prolargin in diagnosis and differentiation of pulmonary arterial hypertension. ESC Heart Failure, 2021, 8, 1230-1243.	1.4	6

#	Article	IF	Citations
3053	State-of-the-art MR Imaging for Thoracic Diseases. Magnetic Resonance in Medical Sciences, 2022, 21, 212-234.	1.1	7
3054	The Odyssey from Symptom to Diagnosis of Pulmonary Hypertension from the Patients and Spouses Perspective. Journal of Primary Care and Community Health, 2021, 12, 215013272110292.	1.0	11
3055	Unique Features of Cardiovascular Pharmacology in Pregnancy and Lactation. , 2021, , 437-478.		0
3056	The Pursuit of Risk Assessment and Stratification Tools in Pulmonary Arterial Hypertension. Chest, 2021, 159, 14-16.	0.4	1
3057	The 2019 European guidelines on pulmonary embolism illustrated with the aid of an exemplary case report. European Heart Journal - Case Reports, 2021, 5, ytaa542.	0.3	1
3058	A multicenter retrospective study of patients with pulmonary hypertension transitioned from inhaled to oral treprostinil. Pulmonary Circulation, 2021, 11, 1-11.	0.8	0
3059	Pulmonary hypertension - Basics. Medical Journal of Dr D Y Patil Vidyapeeth, 2021, .	0.0	0
3060	Pulmonary Hypertension (PH) and the Role of Transcatheter Atrial Flow Regulator (AFR) Device Implantation. , 2021, , 445-452.		0
3061	Imaging in Diagnosis of Systemic Sclerosis. Journal of Clinical Medicine, 2021, 10, 248.	1.0	13
3062	Bioinformatic exploration of the immune related molecular mechanism underlying pulmonary arterial hypertension. Bioengineered, 2021, 12, 3137-3147.	1.4	8
3065	Prognostic value of oxygen saturation and heart rate during six-minute walk test in pediatric pulmonary hypertension. Turkish Journal of Medical Sciences, 2021, 51, 1833-1840.	0.4	0
3066	Liver Failure and the Lungs. , 2021, , 103-112.		0
3067	Predictive role of perioperative neutrophil to lymphocyte ratio in pediatric congenital heart disease associated with pulmonary arterial hypertension. BMC Surgery, 2021, 21, 3.	0.6	9
3068	In systemic sclerosis, the TAPSE/sPAP ratio can be used in addition to the DETECT algorithm for pulmonary arterial hypertension diagnosis. Rheumatology, 2022, 61, 2450-2456.	0.9	10
3069	Prostacyclin for pulmonary arterial hypertension. The Cochrane Library, 2019, 2019, CD012785.	1.5	32
3070	Haemodynamic effects and potential clinical implications of inhaled nitric oxide during right heart catheterization in heart transplant candidates. ESC Heart Failure, 2020, 7, 673-681.	1.4	10
3071	Lung. , 2019, , 131-152.		4
3073	Risk Factors for Pulmonary Hypertension in Adults After Atrial Septal Defect Closure. American Journal of Cardiology, 2019, 123, 1336-1342.	0.7	8

#	Article	IF	Citations
3074	Pulmonary Hypertension with Left Heart Disease: Prevalence, Temporal Shifts in Etiologies andÂOutcome. American Journal of Medicine, 2017, 130, 1272-1279.	0.6	32
3075	Artificial intelligence for early prediction of pulmonary hypertension using electrocardiography. Journal of Heart and Lung Transplantation, 2020, 39, 805-814.	0.3	55
3076	Transcatheter closure of atrial septal defect in the elderly: Early outcomes and mid-term follow-up. International Journal of Cardiology Congenital Heart Disease, 2020, 1, 100058.	0.2	5
3077	Pulmonary arterial hypertension specific therapy: The old and the new. , 2020, 214, 107576.		38
3080	Pulmonary hypertension in aortic valve stenosis. Trends in Cardiovascular Medicine, 2022, 32, 73-81.	2.3	20
3081	Cardiac natriuretic peptides. Nature Reviews Cardiology, 2020, 17, 698-717.	6.1	262
3082	Transplant Operative Considerations in Pulmonary Hypertension With Severe Right Heart Failure. Seminars in Thoracic and Cardiovascular Surgery, 2020, 32, 1024-1029.	0.4	3
3083	Pulmonary hypertension in pregnancy: experience from 45 cases at a tertiary care center. Journal of Maternal-Fetal and Neonatal Medicine, 2020, , 1-6.	0.7	8
3084	Two patients with mixed connective tissue disease complicated by pulmonary arterial hypertension showing contrasting responses to pulmonary vasodilators. Modern Rheumatology Case Reports, 2020, 4, 253-261.	0.3	1
3085	Contemporary use of Selexipag in pulmonary arterial hypertension associated with congenital heart disease: a case series. European Heart Journal - Case Reports, 2020, 4, 1-7.	0.3	5
3086	Combination therapy with pulmonary arterial hypertension targeted drugs and immunosuppression can be a useful strategy for sarcoidosis-associated pulmonary hypertension: a case report. European Heart Journal - Case Reports, 2021, 5, ytaa454.	0.3	3
3087	Oxygen and pulmonary arterial hypertension: effects, mechanisms, and therapeutic benefits. European Journal of Preventive Cardiology, 2021, 28, 127-136.	0.8	8
3088	Transesophageal echocardiography for perioperative management in thoracic surgery. Current Opinion in Anaesthesiology, 2021, 34, 7-12.	0.9	3
3089	Pulmonary hypertension in heart failure. Current Opinion in Cardiology, 2021, 36, 205-210.	0.8	7
3090	Cardiac Magnetic Resonanceâ€“Derived Indexed Volumes and Volume Ratios of the Cardiac Chambers Discriminating Group 2 Pulmonary Hypertension From Other World Health Organization Groups. Journal of Computer Assisted Tomography, 2021, 45, 59-64.	0.5	4
3091	Vascular and Parenchymal Enhancement Assessment by Dual-Phase Dual-Energy CT in the Diagnostic Investigation of Pulmonary Hypertension. Radiology: Cardiothoracic Imaging, 2020, 2, e200009.	0.9	5
3092	Novel Molecular Mechanisms of Pulmonary Hypertension: A Search for Biomarkers and Novel Drug Targetsâ€”From Bench to Bed Site. Oxidative Medicine and Cellular Longevity, 2020, 2020, 1-17.	1.9	17
3093	MicroRNA-140-5p and SMURF1 regulate pulmonary arterial hypertension. Journal of Clinical Investigation, 2016, 126, 2495-2508.	3.9	119

#	Article	IF	Citations
3094	Transition from selexipag to oral treprostinil in a patient with pulmonary arterial hypertension. Pulmonary Circulation, 2020, 10, 1-3.	0.8	4
3095	Virtual echocardiography screening tool to differentiate hemodynamic profiles in pulmonary hypertension. Pulmonary Circulation, 2020, 10, 1-10.	0.8	11
3096	Pharmacokinetics and tolerability of LIQ861, a novel dryâ€powder formulation of treprostinil. Pulmonary Circulation, 2020, 10, 1-9.	0.8	9
3097	Oral iron supplementation with ferric maltol in patients with pulmonary hypertension. European Respiratory Journal, 2020, 56, 2000616.	3.1	22
3098	Screening for pulmonary arterial hypertension in adults carrying a BMPR2 mutation. European Respiratory Journal, 2021, 58, 2004229.	3.1	50
3099	Response to exercise in patients with pulmonary arterial hypertension treated with combination therapy. ERJ Open Research, 2021, 7, 00725-2020.	1.1	3
3100	Risk stratification and prognostic factors in patients with pulmonary arterial hypertension and comorbidities a cross-sectional cohort study with survival follow-up. Respiratory Research, 2020, 21, 127.	1.4	14
3101	Use of ultrasound-measured internal jugular vein collapsibility index to determine static intracardiac pressures in patients with presumed pulmonary hypertension. Annals of Intensive Care, 2019, 9, 124.	2.2	6
3102	Heart and lung transplantation in pulmonary arterial hypertension related to congenital heart disease: an unusual indication. Journal of Congenital Cardiology, 2020, 4, .	0.5	1
3103	Therapeutics in pulmonary hypertension. , 2019, , 313-322.		2
3104	Pulmonary Artery Pressure as a Treatment Target to Improve the Prognosis of Idiopathic Pulmonary Arterial Hypertensionã€€â€• Insight From a Cohort From Two Japanese Pulmonary Hypertension Centers â€•. Circulation Reports, 2020, 2, 249-254.	0.4	3
3105	How COVID-19 Affected the Introduction of Telemedicine and Patient Reported Outcomes Among Patients With Pulmonary Hypertensionã€€â€• A Report From a Referral Center in Japan â€•. Circulation Reports, 2020, 2, 526-530.	0.4	6
3106	Balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension: State of the art. World Journal of Clinical Cases, 2020, 8, 2679-2702.	0.3	23
3107	Pulmonary vascular dysfunction among people aged over 65 years in the community in the Atherosclerosis Risk In Communities (ARIC) Study: A cross-sectional analysis. PLoS Medicine, 2020, 17, e1003361.	3.9	7
3108	Circulating Angiopoietin-1 Is Not a Biomarker of Disease Severity or Prognosis in Pulmonary Hypertension. PLoS ONE, 2016, 11, e0165982.	1.1	10
3109	Use of ECG and Other Simple Non-Invasive Tools to Assess Pulmonary Hypertension. PLoS ONE, 2016, 11, e0168706.	1.1	27
3110	Association between six-minute walk distance and long-term outcomes in patients with pulmonary arterial hypertension: Data from the randomized SERAPHIN trial. PLoS ONE, 2018, 13, e0193226.	1.1	33
3111	Synergistic interaction between a PDE5 inhibitor (sildenafil) and a new adenosine A2A receptor agonist (LASSBio-1359) improves pulmonary hypertension in rats. PLoS ONE, 2018, 13, e0195047.	1.1	8

#	Article	IF	Citations
3112	PULMONARY ARTERIAL HYPERTENSION IN SYSTEMIC CONNECTIVE TISSUE DISEASES: THE CURRENT STATE OF THE PROBLEM. Nauchno-Prakticheskaya Revmatologiya, 2018, 56, 474-485.	0.2	4
3113	Multidisciplinary Perioperative Management of Pulmonary Arterial Hypertension in Patients Undergoing Noncardiac Surgery. Southern Medical Journal, 2018, 111, 64-73.	0.3	12
3114	Atrial Septal Defect as Unexpected Cause of Pulmonary Artery Hypertension. Texas Heart Institute Journal, 2018, 45, 42-44.	0.1	2
3115	Pre-Operative Sildenafil for Patients With Pulmonary Hypertension Undergoing Mitral Valve Surgery: A Systematic Review and Meta-Analysis. Cardiology Research, 2019, 10, 369-377.	0.5	11
3116	Phosphodiesterase-5 Inhibitors Improve Clinical Outcomes, Exercise Capacity and Pulmonary Hemodynamics in Patients With Heart Failure With Reduced Left Ventricular Ejection Fraction: A Meta-Analysis. Journal of Clinical Medicine Research, 2017, 9, 488-498.	0.6	28
3117	Preliminary results from a nationwide adult cardiology perspective for pulmonary hypertension: RegiStry on clInical outcoMe and sUrvival in pulmonaRy hypertension Groups (SIMURG). Anatolian Journal of Cardiology, 2017, 18, 242-250.	0.5	13
3118	A Retrospective study of children with pulmonary arterial hypertension: A single center experience. Anatolian Journal of Cardiology, 2018, 20, 41-47.	0.5	9
3119	Ambrisentan induced severe asymptomatic thrombocytopenia: a case report. Anatolian Journal of Cardiology, 2020, 24, 285-286.	0.5	1
3120	Micro <scp>RNA</scp> â€483 amelioration of experimental pulmonary hypertension. EMBO Molecular Medicine, 2020, 12, e11303.	3.3	35
3121	Tricuspid regurgitation and the right ventricle in risk stratification and timing of intervention. Echo Research and Practice, 2019, 6, R26-R40.	0.6	35
3122	Normal Reference Intervals for Cardiac Dimensions and Function for Use in Echocardiographic Practice: A Guideline from the British Society of Echocardiography. Echo Research and Practice, 2020, 7, G1-G18.	0.6	89
3123	Echocardiographic Assessment of the Right Heart in Adults: A Practical Guideline from the British Society of Echocardiography. Echo Research and Practice, 2020, 7, G19-G41.	0.6	108
3124	Novel Goal-Directed Hemodynamic Optimization Therapy Based on Major Vasopressor during Corrective Cardiac Surgery in Patients with Severe Pulmonary Arterial Hypertension: A Pilot Study. Heart Surgery Forum, 2016, 19, 297.	0.2	3
3125	Atrial Arrhythmias in Pulmonary Hypertension: Pathogenesis, Prognosis and Management. Arrhythmia and Electrophysiology Review, 2018, 7, 43.	1.3	68
3126	Pulmonary Hypertension in Heart Failure Patients. Cardiac Failure Review, 2020, 6, e05.	1.2	7
3127	Treatment Selection in Pulmonary Arterial Hypertension: Phosphodiesterase Type 5 Inhibitors versus Soluble Guanylate Cyclase Stimulator. European Cardiology Review, 2018, 13, 35.	0.7	12
3128	Echocardiography in adults. Journal of Ultrasonography: Official Publication of Polish Ultrasound Society / Red Nacz Iwona SudoÅ‚-SzopiÅ„ska, 2019, 19, 54-61.	0.7	2
3129	Baseline pulmonary hypertension in heart transplant recipients: 9 years of experience at Almazov National Medical Research Centre. Vestnik Transplantologii I Iskusstvennykh Organov, 2020, 21, 7-13.	0.1	1

#	Article	IF	Citations
3130	Cryoablation method for pulmonary artery sympathetic denervation in patients with pulmonary hypertension secondary to left sided heart disease: interventional technique, safety and results of the hospital phase. Russian Journal of Cardiology, 2019, , 29-35.	0.4	4
3131	Contribution of the Institute of Clinical Cardiology named after A.L. Myasnikov in the studying the problem of pulmonary hypertension. Kardiologicheskii Vestnik, 2018, 13, 4.	0.1	2
3132	Reperfusion Pulmonary Oedema as a Complication of Balloon Angioplasty of the Pulmonary Artery in Patients with Chronic Thromboembolic Pulmonary Hypertension. Flebologiya, 2017, 11, 243.	0.2	3
3133	Pulmonary endarterectomy under prolonged circulatory arrest in patient with chronic thromboembolic pulmonary hypertension. Kardiologiya I Serdechno-Sosudistaya Khirurgiya, 2018, 11, 63.	0.1	1
3136	Role of Echocardiography in the Intensive Care Unit: Overview of the Most Common Clinical Scenarios. Journal of Patient-centered Research and Reviews, 2018, 5, 239-243.	0.6	3
3137	Pulmonary artery ganglionic plexi radiofrequency ablation using non-fluoroscopic navigation for the treatment of pulmonary hypertension: a pilot study. Complex Issues of Cardiovascular Diseases, 2019, 7, 36-46.	0.3	2
3138	sGC Stimulators and Activators. International Cardiovascular Forum Journal, 0, 18, .	1.1	2
3142	Riociguat and sildenafil for pulmonary hypertension: similarity and difference. Pulmonologiya, 2016, 26, 85-91.	0.2	9
3143	RNA sequencing analysis of monocrotaline-induced PAH reveals dysregulated chemokine and neuroactive ligand receptor pathways. Aging, 2020, 12, 4953-4969.	1.4	19
3144	Lung tissue remodelling in MCT-induced pulmonary hypertension: a proposal for a novel scoring system and changes in extracellular matrix and fibrosis associated gene expression. Oncotarget, 2016, 7, 81241-81254.	0.8	13
3145	5-HT induces PPAR Î³ reduction and proliferation of pulmonary artery smooth muscle cells via modulating GSK-3Î²/Î²-catenin pathway. Oncotarget, 2017, 8, 72910-72920.	0.8	6
3146	Antithrombotic therapy in patients with pulmonary arterial hypertension. Arterial Hypertension (Russian Federation), 2019, 25, 25-33.	0.1	3
3147	Recommendations on the diagnosis and management of pulmonary hypertension during COVID-19 pandemic. Arterial Hypertension (Russian Federation), 2020, 26, 343-355.	0.1	1
3148	On the possibility to increase sensitivity of diagnostic tests for fixed pulmonary hypertension in heart transplant candidates. AlÊ¹manah KliniÄeskoj Mediciny, 2019, 47, 212-220.	0.2	2
3149	ï¼œEditors' Choiceï¼ž Pulmonary Hypertension: Diagnosis, Management, and Treatment. Nagoya Journal of Medical Science, 2019, 81, 19-30.	0.6	15
3150	Acute vasoreactivity testing predicts outcome of idiopathic pulmonary arterial hypertension patients with a negative acute response. Annals of Translational Medicine, 2020, 8, 1650-1650.	0.7	2
3151	Pulmonary hypertension: a long-term risk stratifier in primary mitral regurgitation. Annals of Translational Medicine, 2016, 4, 541-541.	0.7	2
3152	CardioMEMS: where we are and where can we go?. Annals of Translational Medicine, 2019, 7, 418-418.	0.7	19

#	Article	IF	Citations
3153	Arterial Events in Patients with Chronic Myeloid Leukemia Receiving Treatment with Second Generation Tyrosine Kinase Inhibitors. Klinicheskaya Onkogematologiya/Clinical Oncohematology, 2016, 9, 474-484.	0.1	2
3154	Heart transplantation in patients with hypertrophic cardiomyopathy. Global Cardiology Science & Practice, 2018, 2018, 32.	0.3	2
3155	The role of genomics and genetics in pulmonary arterial hypertension. Global Cardiology Science & Practice, 2020, 2020, e202013.	0.3	5
3156	PULMONER HÄ°PERTANSÄ°YONLU BÄ°REYLERDE KÄ°NEZYOFOBÄ°. Turkish Journal of Physiotherapy and Rehabilitation, 2019, 30, 168-175.	0.5	3
3157	VALIDITY AND RELIABILITY OF THE 6-MINUTE PEGBOARD RING TEST IN PATIENTS WITH PULMONARY HYPERTENSION. Turkish Journal of Physiotherapy and Rehabilitation, 2020, 31, 210-217.	0.5	2
3158	Treatment Considerations for Pulmonary Arterial Hypertension and Assessment of Treatment Response. Advances in Pulmonary Hypertension, 2018, 16, 120-124.	0.1	1
3159	Risk Assessment in Pulmonary Arterial Hypertension Patients: The Long and Short of it. Advances in Pulmonary Hypertension, 2018, 16, 125-135.	0.1	12
3160	PH Professional Network: Team-Based Care for Professionals in Pulmonary Hypertension. Advances in Pulmonary Hypertension, 2018, 16, 95-96.	0.1	1
3161	Center-based Care for Pulmonary Hypertension: A European Perspective. Advances in Pulmonary Hypertension, 2018, 16, 170-174.	0.1	5
3162	Palliative Care and Advance Care Planning in Pulmonary Hypertension. Advances in Pulmonary Hypertension, 2018, 17, 15-19.	0.1	6
3163	Tyrosine Kinase Inhibitorâ€“Induced Pulmonary Arterial Hypertension. Advances in Pulmonary Hypertension, 2018, 17, 69-74.	0.1	3
3164	PH Professional Network: The Burden of Prior Authorization for Pulmonary Hypertension Medications: A Practical Guide for Managing the Process. Advances in Pulmonary Hypertension, 2018, 17, 126-131.	0.1	5
3165	Challenges in the Patient With Pulmonary Hypertension and Atrial Septal Defect: Understanding When and How to Close the Defect. Advances in Pulmonary Hypertension, 2019, 18, 10-13.	0.1	3
3166	Treating Pulmonary Arterial Hypertension With Exercise: The Role of Rehabilitative Medicine. Advances in Pulmonary Hypertension, 2019, 18, 56-62.	0.1	5
3167	Ask the Expert: A Regulatory Perspective on Clinical Trials for Pulmonary Arterial Hypertension. Advances in Pulmonary Hypertension, 2020, 19, 62-65.	0.1	1
3168	New Drugs, Therapeutic Strategies, and Future Direction for the Treatment of Pulmonary Arterial Hypertension. Current Medicinal Chemistry, 2019, 26, 2844-2864.	1.2	23
3169	The Role of Antithrombotic Therapy in Heart Failure. Current Pharmaceutical Design, 2020, 26, 2735-2761.	0.9	1
3170	Cardiovascular Disease in Antiphospholipid Syndrome. Current Vascular Pharmacology, 2020, 18, 538-548.	0.8	6

#	Article	IF	Citations
3171	Cardiovascular Disease in Patients with Chronic Obstructive Pulmonary Disease, Obstructive Sleep Apnoea Syndrome and Overlap Syndrome. Current Vascular Pharmacology, 2020, 19, 285-300.	0.8	15
3172	Effects of Pulmonary Hypertension and Right Ventricular Function in Short and Long-Term Kidney Function. Current Cardiology Reviews, 2018, 15, 3-11.	0.6	12
3173	Pulmonary rehabilitation in moderate pulmonary hypertension. Australasian Medical Journal, 2018, 11, .	0.1	1
3174	Evaluation of Clinical Outcomes and Simultaneous Digital Tracking of Daily Physical Activity, Heart Rate, and Inhalation Behavior in Patients With Pulmonary Arterial Hypertension Treated With Inhaled Iloprost: Protocol for the Observational VENTASTEP Study. JMIR Research Protocols, 2019, 8, e12144.	0.5	6
3175	The Shared Pathogenesis of Pulmonary Artery Hypertension. ACI (Acta Cardiologia Indonesiana), 2018, 4, 22.	0.0	4
3176	Four-Dimensional Flow Magnetic Resonance Imaging for Cardiovascular Imaging: from Basic Concept to Clinical Application. Cardiovascular Imaging Asia, 2018, 2, 85.	0.1	6
3177	GCH1åŸºå›åœ¨è—æ—é«˜åŽŸé€‚åº”ä¸å‘æŒ¥ä½œç”¨. Zoological Research, 2017, 38, 155-162.	0.9	14
3178	Rationale and proposal for cardio-oncology services in Italy. Journal of Cardiovascular Medicine, 2020, Publish Ahead of Print, .	0.6	4
3179	Pulmonary complications in patients with liver cirrhosis. Journal of Translational Internal Medicine, 2020, 8, 150-158.	1.0	19
3180	SUBTRACTION PULMONARY ANGIOGRAPHY IN DIAGNOSIS OF CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION. Medical Visualization, 2018, , 40-49.	0.1	1
3181	The state of the microcirculation of the skin in patients with pulmonary hypertension due to congenital heart defects. Regional Blood Circulation and Microcirculation, 2018, 17, 65-70.	0.1	2
3182	Pulmonary arterial hypertension in Russia: six-year observation analysis of the National Registry. Terapevticheskii Arkhiv, 2019, 91, 25-31.	0.2	27
3184	Beyond Thrombosis: the Role of Platelets in Pulmonary Hypertension. SciMedicine Journal, 2020, 2, 243-271.	1.5	20
3185	Current and emerging therapeutic approaches to pulmonary hypertension. Reviews in Cardiovascular Medicine, 2020, 21, 163.	0.5	51
3187	Pulmonary Hypertension. Deutsches Ärzteblatt International, 2017, 114, 73-84.	0.6	87
3188	Stress echocardiography for left ventricular diastolic dysfunction detection in patients with non-severe chronic obstructive pulmonary disease: a cross-sectional study. Croatian Medical Journal, 2019, 60, 449-457.	0.2	4
3189	The Clinical Efficacy of Pulmonary Hypertension-Specific Agents in Idiopathic Pulmonary Fibrosis: Systematic Review and Meta-Analysis of Randomized Controlled Clinical Trials. Journal of Korean Medical Science, 2020, 35, e48.	1.1	6
3190	Echocardiography for the Assessment of Pulmonary Hypertension and Congenital Heart Disease in the Young. Diagnostics, 2021, 11, 49.	1.3	7

#	Article	IF	Citations
3191	Tetralogy of Fallot or Pulmonary Atresia with Ventricular Septal Defect after the Age of 40 Years: A Single Center Study. Journal of Clinical Medicine, 2020, 9, 1533.	1.0	5
3192	Bedside Ultrasound in Assessment of 510 Severe and Critical Patients with COVID-19 Pneumonia in Wuhan, China. Advanced Ultrasound in Diagnosis and Therapy, 2020, 4, 60.	0.1	4
3193	Anxiety and depression in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: Results from a Chinese survey. Experimental and Therapeutic Medicine, 2020, 19, 3124-3132.	0.8	17
3194	Metformin prevents the development of monocrotalineâ€'induced pulmonary hypertension by decreasing serum levels of big endothelinâ€'1. Experimental and Therapeutic Medicine, 2020, 20, 149.	0.8	15
3195	Role of m6A RNA methylation in cardiovascular disease (Review). International Journal of Molecular Medicine, 2020, 46, 1958-1972.	1.8	154
3196	Current status of pulmonary arterial hypertension in Korea. Korean Journal of Internal Medicine, 2019, 34, 696-707.	0.7	10
3197	Evaluating suspected pulmonary hypertension: A structured approach. Cleveland Clinic Journal of Medicine, 2018, 85, 468-480.	0.6	5
3198	Pulmonary Arterial Hypertension and Pregnancy: Single Center Experience in Current Era of Targeted Therapy. Korean Circulation Journal, 2019, 49, 545.	0.7	7
3199	A review of imaging modalities in pulmonary hypertension. Annals of Thoracic Medicine, 2017, 12, 61.	0.7	51
3200	Severe pulmonary hypertension and right ventricular failure. Indian Journal of Anaesthesia, 2017, 61, 753.	0.3	8
3201	Incidence of chronic thromboembolic pulmonary hypertension in Thammasat University Hospital. Lung India, 2018, 35, 373.	0.3	6
3202	Balloon pulmonary angioplasty relieves haemodynamic stress towards untreated-side pulmonary vasculature and improves its resistance in patients with chronic thromboembolic pulmonary hypertension. EuroIntervention, 2018, 13, 2069-2076.	1.4	8
3203	Pulmonary artery denervation using catheter-based ultrasonic energy. EuroIntervention, 2019, 15, 722-730.	1.4	17
3204	Percutaneous treatment of chronic thromboembolic pulmonary hypertension (CTEPH). EuroIntervention, 2016, 12, X35-X43.	1.4	10
3205	Reversibility of Pulmonary Hypertension Following Surgical Atrial Septal Defect Closure in Children with Down Syndrome. Journal of Cardiovascular Imaging, 2019, 27, 247.	0.2	5
3206	Noninvasive model including right ventricular speckle tracking for the evaluation of pulmonary hypertension. World Journal of Cardiology, 2016, 8, 472.	0.5	4
3207	Dual-energy computed tomographic imaging of pulmonary hypertension. Swiss Medical Weekly, 2016, 146, w14328.	0.8	9
3208	Pulmonary hypertension in patients with Philadelphia-negative myeloproliferative neoplasms: a single-center retrospective analysis of 225 patients. Blood Research, 2020, 55, 77-84.	0.5	3

#	Article	IF	Citations
3209	Pharmacological treatment of pulmonary fibrosis. Journal of the Korean Medical Association, 2020, 63, 47.	0.1	4
3210	Frequency of pulmonary hypertension in transthoracic echocardiography screening is not increased in Takayasu arteritis: Experience from a single center in Turkey. European Journal of Rheumatology, 2018, 5, 249-253.	1.3	7
3211	The perpetual sword of Damocles: Cardiac involvement in systemic sclerosis and the role of non-invasive imaging modalities in medical decision making. European Journal of Rheumatology, 2020, 7, 203-211.	1.3	13
3212	Exercise Program Improves Functional Capacity and Quality of Life in Uncorrected Atrial Septal Defect-Associated Pulmonary Arterial Hypertension: A Randomized-Control Pilot Study. Annals of Rehabilitation Medicine, 2020, 44, 468-480.	0.6	2
3213	Increased systemic arterial stiffness in patients with chronic thromboembolic pulmonary hypertension. Cardiology Journal, 2020, 27, 742-748.	0.5	8
3214	Effects of cardiopulmonary rehabilitation on pulmonary arterial hypertension: A prospective, randomized study. Turkish Journal of Physical Medicine and Rehabilitation, 2019, 65, 278-286.	1.1	6
3215	Successful Lung Transplant After Prolonged Extracorporeal Membrane Oxygenation (ECMO) in a Child With Pulmonary Hypertension: A Case Report. Research in Cardiovascular Medicine, 2016, 5, e32545.	0.2	7
3216	The Correlation Between Uric Acid Level and Right Heart Catheterization Findings in Pulmonary Hypertension. Multidisciplinary Cardiovascular Annals, 2019, 10, .	0.2	1
3217	Early Assessment of Right Ventricular Function in Systemic Lupus Erythematosus Patients using Strain and Strain Rate Imaging. Arquivos Brasileiros De Cardiologia, 2018, 111, 75-81.	0.3	9
3218	Position Statement on Indications of Echocardiography in Adults - 2019. Arquivos Brasileiros De Cardiologia, 2019, 113, 135-181.	0.3	14
3219	Comprehensive Exercise Capacity and Quality of Life Assessments Predict Mortality in Patients with Pulmonary Arterial Hypertension. Acta Cardiologica Sinica, 2019, 35, 55-64.	0.1	8
3220	Outcomes of Pulmonary Endarterectomy for Chronic Thromboembolic Pulmonary Hypertension at a Single Center in Taiwan. Acta Cardiologica Sinica, 2019, 35, 153-164.	0.1	11
3221	Riociguat Improves Pulmonary Hemodynamics in Patients with Inoperable Chronic Thromboembolic Pulmonary Hypertension. Acta Cardiologica Sinica, 2020, 36, 64-71.	0.1	7
3222	Gene Mutation Annotation and Pedigree for Pulmonary Arterial Hypertension Patients in Han Chinese Patients. Global Heart, 2021, 16, 70.	0.9	2
3223	Preprocedural frailty is strongly associated with symptoms after balloon pulmonary angioplasty. Global Health & Medicine, 2022, 4, 45-51.	0.6	1
3225	Neuroprotective effects of dynamic bubble trap use in patients undergoing pulmonary endarterectomy: a two-arm randomized controlled trial. Journal of Thoracic Disease, 2021, 13, 5807-5817.	0.6	1
3226	High-intensity interval training and pulmonary hemodynamics in COPD with hypoxemia. European Clinical Respiratory Journal, 2021, 8, 1984642.	0.7	4
3227	Clinical and physiological characteristics of, medically treated, chronic thromboembolic pulmonary hypertension patients in Saudi Arabia: A single center experience. Annals of Thoracic Medicine, 2021, 16, 347.	0.7	2

#	Article	IF	Citations
3228	Cardio-Oncology. UNIPA Springer Series, 2021, , 309-325.	0.1	0
3229	Detection of patients with chronic thromboembolic pulmonary hypertension by volumetric iodine quantification in the lungâ€"a case control study. Quantitative Imaging in Medicine and Surgery, 2022, 12, 1121-1129.	1.1	5
3230	Noninvasive prediction of pulmonary hemodynamics in chronic thromboembolic pulmonary hypertension by electrocardiogram-gated computed tomography. European Journal of Radiology Open, 2021, 8, 100384.	0.7	3
3231	Effect of a day-trip to altitude (2500â€...m) on exercise performance in pulmonary hypertension: randomised crossover trial. ERJ Open Research, 2021, 7, 00314-2021.	1.1	11
3232	Optimization of specific therapy for pulmonary hypertension: the possibilities of riociguat. Terapevticheskii Arkhiv, 2021, 93, 1117-1124.	0.2	5
3234	Takotsubo syndrome after palliative transcatheter treatment of acquired aortic stenosis in patient with congenital ventricular septal defect. Case report. Terapevticheskii Arkhiv, 2021, 93, 1078-1085.	0.2	0
3235	Evidence base for specific pulmonary vasodilators in adults with congenital heart disease. Terapevticheskii Arkhiv, 2021, 93, 1106-1116.	0.2	3
3236	Depiction of mosaic perfusion in chronic thromboembolic pulmonary hypertension (CTEPH) on C-arm computed tomography compared to computed tomography pulmonary angiogram (CTPA). Scientific Reports, 2021, 11, 20042.	1.6	0
3237	Temporal trends in pulmonary arterial hypertension: results from the COMPERA registry. European Respiratory Journal, 2022, 59, 2102024.	3.1	57
3238	â€œIt is the fear of exercise that stops meâ€•â€“ attitudes and dimensions influencing physical activity in pulmonary hypertension patients. Pulmonary Circulation, 2021, 11, 1-9.	0.8	2
3239	Clinical efficacy, safety, tolerability, and survival outcome of long-term inhaled iloprost treatment in the management of pulmonary arterial hypertension: Data from prospective multicenter observational OPTION study. , 2021, 25, 721-732.		2
3240	Bioequivalence and food effect of a fixedâ€dose combination of macitentan and tadalafil: Adaptive design in the COVIDâ€19 pandemic. Pharmacology Research and Perspectives, 2021, 9, e00846.	1.1	2
3241	Digital Tracking of Physical Activity, Heart Rate, and Inhalation Behavior in Patients With Pulmonary Arterial Hypertension Treated With Inhaled Iloprost: Observational Study (VENTASTEP). Journal of Medical Internet Research, 2021, 23, e25163.	2.1	6
3242	The breath print represents a novel biomarker of malnutrition in pulmonary arterial hypertension: a proofâ€ofâ€concept study. Journal of Parenteral and Enteral Nutrition, 2021, 45, 1645-1652.	1.3	2
3243	Mortality trends in pulmonary arterial hypertension in Canada: a temporal analysis of survival per ESC/ERS guideline era. European Respiratory Journal, 2022, 59, 2101552.	3.1	27
3244	Predictors of Mortality in Critically Ill Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Frontiers in Medicine, 2021, 8, 762004.	1.2	4
3245	Real-World Analysis of Treatment Patterns Among Hospitalized Patients with Pulmonary Arterial Hypertension. Pulmonary Therapy, 2021, 7, 575-590.	1.1	3
3246	A pragmatic approach to risk assessment in pulmonary arterial hypertension using the 2015 European Society of Cardiology/European Respiratory Society guidelines. Open Heart, 2021, 8, e001725.	0.9	3

#	Article	IF	Citations
3247	Early combination of pulmonary vasodilators prevents chronic kidney disease progression in connective tissue diseaseâ€associated pulmonary hypertension. International Journal of Rheumatic Diseases, 2021, 24, 1419-1426.	0.9	0
3248	Sex Differences in Pulmonary Hypertension. Frontiers in Aging, 2021, 2, .	1.2	13
3249	Schistosome-Associated Pulmonary Arterial Hypertension: A Review Emphasizing Pathogenesis. Frontiers in Cardiovascular Medicine, 2021, 8, 724254.	1.1	7
3250	Subphenotyping of Patients With Aortic Stenosis by Unsupervised Agglomerative Clustering of Echocardiographic and Hemodynamic Data. JACC: Cardiovascular Interventions, 2021, 14, 2127-2140.	1.1	21
3251	Ventilation/perfusion (V/Q) scanning in contemporary patients with pulmonary embolism: utilization rates and predictors of use in a multinational study. Journal of Thrombosis and Thrombolysis, 2022, 53, 829-840.	1.0	6
3252	Liver fibrosis index as a novel prognostic factor in patients with pulmonary arterial hypertension. Heart and Vessels, 2022, 37, 601-608.	0.5	4
3253	Clinical Conundrum: To Deliver or Not To Deliver a Patient With Pulmonary Edema and Preeclampsia. Journal of Obstetrics and Gynaecology Canada, 2021, 43, 1170-1172.	0.3	1
3254	Clinical application of pulmonary vascular resistance in patients with pulmonary arterial hypertension. Journal of Cardiothoracic Surgery, 2021, 16, 311.	0.4	3
3255	Impaired endothelium-dependent and endothelium-independent systemic vasodilatory reserve in pulmonary hypertension regardless the clinical group: A generalized dysfunction beyond the pulmonary arteries?. , 2021, 25, 733-740.		2
3256	Prognostic value of an echocardiographic index reflecting right ventricular operating stiffness in patients with heart failure. Heart and Vessels, 2022, 37, 583-592.	0.5	0
3257	Evaluation of Pulmonary Hypertension Using <scp>4D</scp> Flow <scp>MRI</scp>. Journal of Magnetic Resonance Imaging, 2022, 56, 234-245.	1.9	18
3258	Catheter-Directed Therapies in Patients with Pulmonary Embolism: Predictive Factors of In-Hospital Mortality and Long-Term Follow-Up. Journal of Clinical Medicine, 2021, 10, 4716.	1.0	0
3259	Vasodilator therapy for pulmonary hypertension in children: a national study of patient characteristics and current treatment strategies. Pulmonary Circulation, 2021, 11, 1-8.	0.8	5
3261	Chronic thromboembolic pulmonary hypertension in an obese patient with type 2 diabetes mellitus. Sibirskij Å¾urnal KliniÄeskoj I Ã¨ksperimentalÊ¹noj Mediciny, 2021, 36, 154-160.	0.1	0
3262	Chronic thromboembolic pulmonary hypertension after an acute pulmonary embolism: fundamental concepts of diagnosis and review of current treatment options. Russian Journal of Cardiology, 2021, 26, 4588.	0.4	0
3266	Systemic arterial properties in pulmonary hypertension. Pulmonary Circulation, 2021, 11, 1-3.	0.8	0
3267	Deep Vein Thrombosis in Intravenous Drug Users: An Invisible Global Health Burden. Cureus, 2021, 13, e18457.	0.2	5
3268	Cardiac biomarkers as indicators of right ventricular dysfunction and recovery in chronic thromboembolic pulmonary hypertension patients after balloon pulmonary angioplasty therapy â€“ a cardiac magnetic resonance imaging cohort study. Pulmonary Circulation, 2021, 11, 1-10.	0.8	0

#	Article	IF	Citations
3269	Plasma tumour and metabolism related biomarkers AMBP, LPL and Glyoxalase I differentiate heart failure with preserved ejection fraction with pulmonary hypertension from pulmonary arterial hypertension. International Journal of Cardiology, 2021, 345, 68-76.	0.8	12
3270	Sex and survival following pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension: a Scandinavian observational cohort study. Pulmonary Circulation, 2021, 11, 1-9.	0.8	8
3271	Case report: Stepwise transition from subcutaneous treprostinil to epoprostenol in high-risk pulmonary arterial hypertension. European Heart Journal - Case Reports, 2021, 5, ytaa578.	0.3	2
3273	The Polish adaptation of the CAMbridge Pulmonary Hypertension Outcome Review (CAMPHOR). Cardiology Journal, 2020, 27, 608-615.	0.5	1
3274	PH Grand Rounds: Confronting the Challenge of Sarcoidosis-Associated Pulmonary Hypertension. Advances in Pulmonary Hypertension, 2015, 14, 166-169.	0.1	0
3275	Pulmonary Hypertension in Chronic Myeloproliferative Disorders. Advances in Pulmonary Hypertension, 2015, 14, 150-154.	0.1	0
3276	Combined Heart Transplants. , 2016, , 379-391.		0
3278	Cardiac Issues in Adolescents with Congenital Heart Disease. Congenital Heart Disease in Adolescents and Adults, 2016, , 15-26.	0.2	0
3279	Microvolt T-wave alternans profiles in patients with pulmonary arterial hypertension compared to patients with left ventricular systolic dysfunction and a group of healthy volunteers. Anatolian Journal of Cardiology, 2016, 16, 825-830.	0.5	3
3280	Diagnostic Challenges in Pediatric Pulmonary Hypertension. Advances in Pulmonary Hypertension, 2016, 15, 76-81.	0.1	0
3281	Pulmonary Arterial Hypertension: â€œA Journey to Lung Transplantâ€• Advances in Pulmonary Hypertension, 2016, 15, 39-44.	0.1	0
3282	Pulmonary Vascular Resistance in Patients With Pulmonary Hypertension: Importance of the Quadratic Velocity-Pressure Relationshipã€€â€“ Reply â€“. Circulation Journal, 2016, 80, 2563-2564.	0.7	0
3283	Editor's Memo. Advances in Pulmonary Hypertension, 2016, 15, 58-58.	0.1	0
3284	AnÃsthesie bei Patienten mit Cor pulmonale. , 2016, , 1-3.		0
3285	The perspectives of application of statins under pulmonary hypertension. Rossiiskii Meditsinskii Zhurnal: Organ Ministerstva Zdravookhraneniia RSFSR, 2016, 22, 36-42.	0.1	0
3286	The role of echocardiography in prognosis and clinical complication risk prediction in patients with acute pulmonary embolism. Intervencni A Akutni Kardiologie, 2016, 15, 8-16.	0.0	0
3287	"Grey zone" of vasoreactivity during acute vasodilator testing in patients with pulmonary hypertension. Systemic Hypertension, 2016, 13, 73-76.	0.1	0
3288	Management of orthopedic patients with hypertension in the perioperative period (literature review). Ortopediiï¸aï¸¡, Travmatologiiï¸aï¸¡ I Protezirovanie, 2016, .	0.0	0

#	Article	IF	Citations
3291	Grundlagen der Pneumologie. , 2017, , 1-38.		0
3292	An Uncommon Severe Case of Pulmonary Hypertension - From Genetic Testing to Benefits of Home Anticoagulation Monitoring. Acta Marisiensis - Seria Medica, 2016, 62, 426-429.	0.3	0
3293	Angiologie. , 2017, , 315-370.		0
3294	Is pulmonary artery pressure a trigger of adverse outcome in mitral regurgitation?. Annals of Translational Medicine, 2016, 4, 498-498.	0.7	0
3295	Non-Group 1 Pulmonary Hypertension Associated With Systemic Sclerosis: An Under-studied Patient Population. Advances in Pulmonary Hypertension, 2017, 16, 68-75.	0.1	0
3296	Leitsymptom Dyspnoe, LeistungsschwÃche. , 2017, , 115-226.		0
3297	PH Grand Rounds: When Pulmonary Arterial Hypertension Is Complicated by Pericardial Disease. Advances in Pulmonary Hypertension, 2017, 15, 198-200.	0.1	1
3298	Systemic Sclerosis and Other Connective Tissue Diseases. Advances in Pulmonary Hypertension, 2017, 16, 55-60.	0.1	0
3299	Gaps and Controversies of New Treatment Recommendations in Recent Pulmonary Hypertension Guidelines: What We Know and What We Don't. Advances in Pulmonary Hypertension, 2017, 16, 20-25.	0.1	0
3300	Training and Recommendations for Exercise. Congenital Heart Disease in Adolescents and Adults, 2017, , 305-314.	0.2	0
3301	Mechanical Circulatory Support as Bridge to Candidacy. , 2017, , 149-158.		0
3302	Whatever Happened to Oral Monotherapy?. Advances in Pulmonary Hypertension, 2017, 15, 190-192.	0.1	0
3304	Segmental Pulmonary Hypertension. Congenital Heart Disease in Adolescents and Adults, 2017, , 69-89.	0.2	0
3305	Indications for Lung Transplantation. , 2017, , 1-20.		0
3306	Pulmonary Hypertension in Patients with Chronic Obstructive Pulmonary Disease: A Review for Definition, Epidemiology, Pathology, and Diagnosis. General Medicine (Los Angeles, Calif), 2017, 05, .	0.2	2
3307	Cardiovasculaire pathologie in de geriatrische revalidatie. , 2017, , 241-255.		0
3308	Pulmonary Hypertension in Left Heart Disease. , 2017, , 341-369.		0
3309	Pulmonary Vasodilators in Patients with Pulmonary Arterial Hypertension Related to Congenital Heart Disease. Congenital Heart Disease in Adolescents and Adults, 2017, , 253-266.	0.2	1

#	Article	IF	Citations
3310	PAH in Patients with Prevalent Systemicâ€“Pulmonary Shunts and PAH in Patients with Small Cardiac Defects. Congenital Heart Disease in Adolescents and Adults, 2017, , 45-60.	0.2	2
3311	Operator Safety Zone During the Nitric Oxide Inhalation Vasoreactivity Test for Pulmonary Hypertension Patients. Advanced Biomedical Engineering, 2017, 6, 88-94.	0.4	0
3312	Physical Examination and Electrocardiography in Patients with Pulmonary Arterial Hypertension Due to Congenital Heart Disease: Initial Clinical Assessment. Congenital Heart Disease in Adolescents and Adults, 2017, , 121-148.	0.2	0
3313	Post-capillary Pulmonary Hypertension in ACHD. Congenital Heart Disease in Adolescents and Adults, 2017, , 105-117.	0.2	0
3314	ASDs and PFO. , 2017, , 411-523.		0
3315	Selection of Infusion Prostacyclin Therapy in Pulmonary Arterial Hypertension: Not Just a Last Resort. Advances in Pulmonary Hypertension, 2017, 16, 14-19.	0.1	0
3316	Prognostication in PAHâ€“CHD. Congenital Heart Disease in Adolescents and Adults, 2017, , 315-328.	0.2	0
3319	Evaluation of end-tidal CO2 pressure at the anaerobic threshold for detecting and assessing pulmonary hypertension. Heart and Vessels, 2017, 32, 1350-1357.	0.5	2
3320	Pulmonary Arterial Hypertension. , 2017, , .		0
3321	Pulmonary arterial hypertension - diagnosis and treatment. Intervencni A Akutni Kardiologie, 2017, 16, 63-68.	0.0	0
3322	Case of successful treatment of a high risk acute tele with hypothony in a patient with polymorbid pathology. Pain Anesthesia and Intensive Care, 2017, .	0.1	0
3323	Ultrasound diagnostic opportunities in pulmonology. Pulmonologiya, 2017, 27, 283-290.	0.2	1
3324	ANTIBIOGRAM STUDY AND ANTIBIOTIC USE EVALUATION USING GYSSEN METHOD IN PATIENTS WITH DIABETIC FOOT. Folia Medica Indonesiana, 2017, 52, 198.	0.1	2
3325	Management of thromboembolism-in-transit with pulmonary embolism. Journal of Animal Science and Technology, 2017, 4, ERP-17-0043.	0.8	4
3327	Right heart catheterization for hemodynamic evaluation of pulmonary hypertension. Bukovinian Medical Herald, 2017, 21, 114-119.	0.1	0
3328	Basic Science and Clinical Trials: Accelerating the Future. Advances in Pulmonary Hypertension, 2018, 17, 148-152.	0.1	0
3329	ACUTE RIGHT VENTRICULAR FAILURE. Messenger of Anesthesiology and Resuscitation, 2018, 15, 74-86.	0.1	8
3330	Cardiac Manifestations of Cancer and Their Management. , 2018, , 181-197.		0

#	Article	IF	Citations
3331	Initial isolated Takayasu's arteritis of bilateral pulmonary artery branches with severe pulmonary hypertension: A case report. Biomedical Research (Aligarh, India), 2018, 29, .	0.1	0
3332	Results of a Clinical Trial to Determine the Efficacy, Safety, and Tolerability of Intravenous Drip Infusion Therapy of a New Epoprostenol Formulation in Japanese Children with Pulmonary Arterial Hypertension. Nihon Shoni Junkanki Gakkai Zasshi = Pediatric Cardiology and Cardiac Surgery, 2018, 34, 30-38.	0.0	0
3333	OBSOLETE: Pulmonary Arterial Hypertension. , 2018, , .		0
3334	An overlooked aspect in the assessment of systolic pulmonary arterial pressure in female patients with hyperthyroidism. Anatolian Journal of Cardiology, 2018, 21, 54-55.	0.5	0
3335	PH experience in an expert university hospital. Anatolian Journal of Cardiology, 2018, 20, 35-40.	0.5	5
3336	Patient characteristics and outcome of end-stage lung diseases referred for lung transplantation in North India. Lung India, 2018, 35, 290.	0.3	6
3337	Pulmonary Vascular Disease: Specific Evaluation and Timing for Listing Eligible Patients to Receive Lung Transplantation and Management of the Pre-lung Transplant Patient. , 2018, , 71-84.		0
3338	THE CLINICAL INTELLECTION DEVELOPMENT (BASED ON CBCR MODEL) IN INTERNAL MEDICINE BY CLINICAL CASE EXAMPLE: PRELIMINARY PULMONARY HYPERTENSION. Bulletin of Problems Biology and Medicine, 2018, 1, 226.	0.0	0
3339	Right Ventricular Evaluation with Speckle Tracking Echocardiography in COPD after a Pulmonary Rehabilitation Program. Arquivos Brasileiros De Cardiologia, 2018, 111, 382-383.	0.3	0
3340	Stimulants and Pulmonary Arterial Hypertension: An Update. Advances in Pulmonary Hypertension, 2018, 17, 49-54.	0.1	4
3342	Single- and Bilateral Lung Transplantation: Indications, Contraindications, Evaluation, and Requirements for Patients to Be Considered Eligible. , 2018, , 17-40.		0
3343	Echocardiographic evolution of pulmonary hypertension in female patients with hyperthyroidism. Anatolian Journal of Cardiology, 2018, 20, 174-181.	0.5	9
3344	Drug Therapy in Adult Congenital Heart Disease Heart Failure. Congenital Heart Disease in Adolescents and Adults, 2018, , 187-200.	0.2	1
3345	PH Professional Network: Roadmap to Accreditation: Practical Aspects. Advances in Pulmonary Hypertension, 2018, 16, 195-200.	0.1	0
3346	Pulmonary Arterial Hypertension. Congenital Heart Disease in Adolescents and Adults, 2018, , 129-142.	0.2	0
3347	Clinical Presentation with High Penetrance in a Korean Family with Pulmonary Arterial Hypertension Associated with a BMPR2 Intron 3 Splice Site Pathogenic Variant. Laboratory Medicine Online, 2018, 8, 119.	0.0	0
3349	Indications for Lung Transplantation. , 2018, , 759-778.		0
3350	The Value of Right Ventricular Dysfunction and Right Ventricular-Pulmonary Artery Coupling in Chronic Heart Failure: The Role of Echocardiography. Kardiologiya, 2018, 17, 82-90.	0.3	5

#	Article	IF	Citations
3351	Cardiopulmonary Complications of Cirrhosis. , 2018, , 281-292.e5.		0
3352	OBSOLETE: Pulmonary Hypertension Associated with Left-Sided Heart Disease. , 2018, , .		0
3353	Echocardiographic Evaluation of Pulmonary Hypertension. Journal of the Indian Academy of Echocardiography & Cardiovascular Imaging, 2018, 2, 95-105.	0.0	1
3354	I. Diagnosis and Examination of Pulmonary Hypertension; 2. Estimation by Echocardiographic Parameters in Patients with Pulmonary Hypertension. The Journal of the Japanese Society of Internal Medicine, 2018, 107, 202-207.	0.0	0
3355	Overview of Pulmonary Hypertension and Nice Classification. The Journal of the Japanese Society of Internal Medicine, 2018, 107, 191-194.	0.0	0
3356	Systemic sclerosis in 2017. Vnitrni Lekarstvi, 2018, 64, 146-154.	0.1	1
3357	The importance of psychosocial factors in management of pulmonary arterial hypertension patients. Kardiologia Polska, 2018, 76, 529-535.	0.3	2
3358	Hemodynamic effects of the vasodilation in different vascular regions on patients with severe left ventricle systolic dysfunction. Regional Blood Circulation and Microcirculation, 2018, 17, 32-38.	0.1	0
3359	Combination therapy is a new standard for treatment of pulmonary arterial hypertension. Terapevticheskii Arkhiv, 2018, 90, 72-80.	0.2	5
3360	ENDOVASCULAR TREATMENT OF THE RESIDUAL THROMBOEMBOLIC PULMONARY HYPERTENSION AFTER PULMONARY THROMBENDARTERECTOMY WITH THE DENERVATION SYSTEM SYMPLICITY. Cardiovascular Therapy and Prevention (Russian Federation), 2018, 17, 43-48.	0.4	3
3361	CONTEMPORARY STRATEGY OF PULMONARY HYPERTENSION MANAGEMENT IN PEDIATRICS. Cardiovascular Therapy and Prevention (Russian Federation), 2018, 17, 101-124.	0.4	4
3362	EXPERIENCE OF USING THE NONÂSELECTIVE ENDOTHELIN RECEPTOR ANTAGONIST MACITENTAN IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION. Cardiovascular Therapy and Prevention (Russian) Tj ETQq1 1 0.784314 rgBT /Overlock	0.4	3
3363	Fibrobronchoskopijos galimybÄ—s diagnozuojant plauÄ¡Å³ ligas. Pulmonology and Allergology, 2018, 2, .	0.0	0
3364	Atypical Presentation of Cardiac Tamponade as a Cause of Acute Liver Injury: Case Report and Review of Literature. Cureus, 2018, 10, e2779.	0.2	4
3365	INFLUENCE OF PULMONARY HYPERTENSION ON CLINICAL COURSE AND PROGNOSIS OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE. Russian Journal of Cardiology, 2018, , 173-179.	0.4	1
3366	Association between MDR1 gene polymorphism and clinical course of pediatric pulmonary arterial hypertension. Romanian Journal of Laboratory Medicine, 2018, 26, 305-312.	0.1	3
3367	Treatment and Palliation of Symptoms in Patients With Advanced Pulmonary Arterial Hypertension. Advances in Pulmonary Hypertension, 2018, 17, 20-24.	0.1	1
3368	Organization and Delivery of Palliative Care for Pulmonary Arterial Hypertension: Case-based Discussion. Advances in Pulmonary Hypertension, 2018, 17, 11-14.	0.1	0

#	Article	IF	Citations
3369	RETROSPECTIVE EFFICACY ANALYSIS OF ACUTE VASOREACTIVE TEST AS A CRITERIA FOR SURGERY IN CHILDREN WITH INBORN LEFT-TO-RIGHT BLOOD SHUNTING AND PULMONARY ARTERIAL HYPERTENSION. Russian Journal of Cardiology, 2018, , 41-46.	0.4	0
3370	Case report: Life-saving pulmonary endarterectomy for a young female with primary antiphospholipid syndrome complicated by severe chronic thromboembolic pulmonary hypertension. Seminars in Cardiovascular Medicine, 2018, 24, 1-8.	0.3	0
3371	A complex case of pulmonary hypertension associated with portal hypertension. Hypertension, 2018, .	0.2	0
3372	ÐŸÐžÐÐ£Ð¨Ð•ÐÐ¯ Ð‘ÐÐ›ÐÐ¡Ð£ ÐŸÐÐž-Ð¢Ð•ÐŸÐÐžÐ¢Ð˜Ð—ÐÐŸÐÐ›Ð¬Ð¯ Ð¦ Ð˜Ð¢ÐžÐšÐŠÐ†ÐÐ†Ð’ Ð£ ÐŸÐÐ¦Ð†Ð„ÐÐ¢Ð’ Ð		
3373	Lung Transplantation for Pulmonary Arterial Hypertension. , 2019, , 163-172.		0
3375	StratÃ©gies thÃ©rapeutiques dans lâ€™hypertension pulmonaire : peut-on encore faire mieux ?. Revue Des Maladies Respiratoires Actualites, 2018, 10, 144-148.	0.0	0
3376	Prevalence of pulmonary arterial hypertension in the Camerino area of central Italy and savings resulting from generic bosentan. European Journal of Hospital Pharmacy, 2020, 27, 100-102.	0.5	2
3378	Impact of nitrate therapy on the expression of caveolin-1 and its phosphorylated isoform in lungs in the model of monocrotaline induced pulmonary hypertension. European Pharmaceutical Journal, 2018, 65, 4-7.	0.2	0
3380	Recovery of Respiratory Function After Coronary Artery Bypass Graft Surgery Using Pep-Therapy. Multidisciplinary Cardiovascular Annals, 2018, 10, .	0.2	2
3382	Management of patients with pulmonary arterial hypertension against of systemic sclerodermia (part) Tj ETQq1 1 0.784314 rgBT /Ov	0.1	0
3383	Characterization of Pulmonary Arterial Hypertension Using Right Ventricular Regional Curvedness Derived From CMR Imaging. , 0, , .		0
3384	Estimation of Endostatin level in pulmonary arterial hypertension patients and its relation with some parameters. Current Issues in Pharmacy and Medical Sciences, 2018, 31, 170-179.	0.1	0
3385	The use of stress test in patients after coronary artery bypass grafting to assess the effectiveness of surgery, determination of rehabilitation possibilities and prognosis. Bulletin of Siberian Medicine, 2018, 17, 221-228.	0.1	1
3386	MYOCARDIAL PERFUSION AND NEUROTROPIC SINGLE-PHOTON EMISSION COMPUTED TOMOGRAPHY FEATURES IN PATIENTS WITH PRIMARY PULMONARY HYPERTENSION. Vestnik Rentgenologii I Radiologii, 2018, 99, 244-252.	0.1	4
3388	Drug Induced Pulmonary Arterial Hypertension. Interni Medicina Pro Praxi, 2018, 20, 259-264.	0.0	0
3390	Cardiovascular Magnetic Resonance Assessment of Right Ventricular Anatomy and Function. , 2019, , 454-468.e4.		1
3391	Postoperative acute respiratory failure in cardiac surgery. Khirurgiya, 2019, , 5.	0.0	3
3392	Pulmonary Hypertension in General Cardiology Practice. Arquivos Brasileiros De Cardiologia, 2019, 113, 419-428.	0.3	4

#	Article	IF	Citations
3393	AnÃsthesie bei Patienten mit Cor pulmonale. Springer Reference Medizin, 2019, , 1663-1665.	0.0	0
3394	Moving Beyond the Endothelium is Still Challenging-Complex Interplay between Endothelin and Reactive Oxygen Species in Pulmonary Arterial Hypertension. Korean Circulation Journal, 2019, 49, 877.	0.7	0
3395	Pulmonary Artery. , 2019, , 529-533.e2.		0
3396	Improvement of Left Ventricular Ejection Fraction and Pulmonary Hypertension Are Significant Prognostic Factors in Heart Failure with Reduced Ejection Fraction Patients. Journal of Cardiovascular Imaging, 2019, 27, 257.	0.2	3
3397	Pregnancy in Patients with Pulmonary Arterial Hypertension â€œTo Deliver, or Not to Deliver: That Is the Questionâ€• Korean Circulation Journal, 2019, 49, 555.	0.7	0
3398	Pneumologie. , 2019, , 457-525.		0
3399	Risk Assessment and Survival of Pulmonary Hypertension Patients: Multicenter Experience in Turkey. Anatolian Journal of Cardiology, 2019, 21, 322-330.	0.5	3
3400	Assessment of Right Ventricular Function by Tissue Doppler Imaging in Pulmonary Arterial Hypertensive Rat. The Ewha Medical Journal, 2019, 42, 39.	0.1	0
3401	Perioperative management of patients with chronic heart failure. Russian Journal of Anesthesiology and Reanimatology /Anesteziologiya I Reanimatologiya, 2019, , 5.	0.2	6
3402	Consequences of Altered Cardiac Activity on Brain Activity. , 2019, , 1-15.		0
3403	Pulmonary Hypertension and the Right Ventricle: The Roles of Mitochondrial Reactive Oxygen Species in Causing Further Right Ventricular Mitochondrial Changes. , 2019, , 539-549.		2
3405	Pulmonale Hypertonie bei Kindern und Jugendlichen. Springer Reference Medizin, 2019, , 1-6.	0.0	0
3406	Diagnostic Work-Up of Pulmonary Hypertension â€“ Think About Shunt Flow! A Case Report. American Journal of Case Reports, 2019, 20, 154-158.	0.3	1
3407	Algorithms of systemic scleroderma treatment with the predominant heart lesion, pulmonary arterial hypertension and interstitial lung disease according to modern guidelines. Hypertension, 2019, .	0.2	0
3408	NON INVASIVE DIAGNOSIS AND ASSESSMENT OF THE SEVERITY OF PULMONARY HYPERTENSION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE. Journal of Sulaimani Medical College, 2019, 9, 1-10.	0.0	0
3409	Subclinical biventricular systolic dysfunction in patients with systemic sclerosis. European Journal of Rheumatology, 2019, 6, 86-91.	1.3	2
3412	Hypertension artÃ©rielle pulmonaire au cours de la drÃ©panocytose : complication aiguÃ« ou chronique ?. Medecine Intensive Reanimation, 2019, 28, 339-342.	0.1	0
3413	Pulmonary arterial hypertension diagnosed during pregnancy â€“ echocardiography as a tool for management. Cardiologia Croatica, 2019, 14, 73-73.	0.0	0

#	Article	IF	Citations
3414	Balloon pulmonary angioplasty for patients with inoperable chronic thromboembolic pulmonary hypertension. Terapevticheskii Arkhiv, 2019, 91, 43-47.	0.2	2
3415	Pulmonary Endarterectomy and Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertensionã€€â€• Similar Effects on Health-Related Quality of Life â€•. Circulation Reports, 2019, 1, 228-234.	0.4	2
3416	Detection of systemic sclerosis in patients with pulmonary hypertension. Regional Blood Circulation and Microcirculation, 2019, 18, 48-54.	0.1	0
3417	INFLUENCE OF PULMONARY DENERVATION ON THE MECHANICAL FUNCTION OF THE RIGHT HEART CHAMBERS IN PATIENTS WITH PULMONARY HYPERTENSION. Complex Issues of Cardiovascular Diseases, 2019, 8, 49-57.	0.3	0
3418	Structural-functional features of the heart in patients with acute Q-myocardial infarction of the anterior wall of the left ventricle in the presence of pulmonary hypertension. ScienceRise: Medical Science, 2019, .	0.0	0
3419	ClasificaciÃ³n de la hipertensiÃ³n arterial pulmonar basada en el estudio genÃ©tico y familiar. Revista Espanola De Cardiologia, 2019, 72, 591-593.	0.6	0
3420	Goal-Oriented Sequential Combination Therapy Evaluated Using Cardiopulmonary Exercise Parameters for the Treatment of Newly Diagnosed Pulmonary Arterial Hypertensionã€€â€• Goal-Oriented Therapy Evaluated by Cardiopulmonary Exercise Testing for Pulmonary Arterial Hypertension (GOOD EYE) â€•. Circulation Reports, 2019, 1, 303-311.	0.4	3
3421	Perioperative anesthetic considerations in patients with pulmonary hypertension undergoing non-cardiac and non-obstetric surgeries. Medical Biological Science and Engineering, 2019, 2, 31-39.	0.5	3
3422	Ask the Expert: What Is the Exercise â€œPrescriptionâ€•That You Provide to Your Patients?. Advances in Pulmonary Hypertension, 2019, 18, 68-69.	0.1	0
3423	Right Ventricular Function in Heart Failure Patients with Normal Left Ventricular Size: Analysis by Conventional Echocardiographic Parameters and Magnetic Resonance Imaging. Multidisciplinary Cardiovascular Annals, 2019, 10, .	0.2	0
3424	Right Heart Catheterization Further Confirms Successful Transition from Parenteral Prostanoid to Oral Selexipag. Archivos De Bronconeumologia, 2019, 55, 393-394.	0.4	1
3425	Use of standard report of transthoracic echocardiography in clinical practice. UMJ Heart & Vessels, 2019, .	0.0	0
3426	Correlation between Echocardiography and Cardiac Catheterization for the Assessment of Pulmonary Hypertension in Pediatric Patients. Cureus, 2019, 11, e5511.	0.2	3
3427	Prognosis and its predictors for pulmonary hypertension associated with connective tissue diseases (data of the first Ukrainian register). Hypertension, 2019, .	0.2	0
3428	Pulmoner hipertansiyonlu hastalarda comet analizi ile deÄŸerlendirilen artmÄ±ÅŸ DNA hasarÄ±. Pamukkale Medical Journal, 0, , .	0.2	0
3429	Clinical Outcomes and Treatment Options in Patients With Pulmonary Hypertension Who Received Pulmonary Hypertension-Specific Drugsã€€â€• Single-Center Case Series â€•. Circulation Reports, 2019, 1, 389-395.	0.4	1
3430	Systemic Sclerosis (Scleroderma). , 2020, , 263-275.		0
3432	Long-Term Response to Vasoactive Treatment in a Case of Kyphoscoliosis-Associated Pulmonary Hypertension. American Journal of Case Reports, 2019, 20, 1505-1508.	0.3	2

#	Article	IF	Citations
3433	A Case of Right Ventricular Dysfunction with Right Ventricular Failure Secondary to Obesity Hypoventilation Syndrome. American Journal of Case Reports, 2019, 20, 1487-1491.	0.3	1
3434	Pulmonary Hypertension in an Oncologic Intensive Care Unit. , 2020, , 675-697.		0
3435	Pulmonary hypertension in a patient with kyphoscoliotic heart disease. Siberian Medical Journal, 2019, 34, 172-178.	0.3	0
3436	Pulmonary Hypertension: â€œYouÂTake My Breath Awayâ€•, 2020, , 525-534.		0
3437	The Analysis of Long-Term Results and Quality of Life in Patients with Massive Pulmonary Embolism in the Course of Treatment with Thrombolytic and Anticoagulant Drugs. Sklifosovsky Journal Emergency Medical Care, 2019, 8, 274-278.	0.3	1
3438	PH Professional Network: Bridging the Gap: A Multidisciplinary Approach to Transitions of Care. Advances in Pulmonary Hypertension, 2019, 18, 103-107.	0.1	0
3439	Pulmonary Hypertension Due to Left Heart Diseaseâ€"Combine or Not Combined? DPG In or Out? A Practical Approach to the Patient With Suspected Left Heart Disease. Advances in Pulmonary Hypertension, 2019, 18, 87-91.	0.1	1
3440	Valvular Heart Failure. , 2020, , 231-243.		0
3441	Proximal Pulmonary Artery Aneurysm Secondary to Suspected Pulmonary Hypertension Treated with Conservative Therapy in Limited Resource Setting. American Journal of Case Reports, 2019, 20, 1805-1811.	0.3	1
3442	Drug demand satisfaction of patients with idiopathic pulmonary arterial hypertension. Pacific Medical Journal, 2019, , 18-22.	0.0	0
3443	Relationship between right atrium area and right ventricular ejection fraction on magnetic resonance imaging: comparison with other prognostic markers in patients with pulmonary arterial hypertension. Radiologia Brasileira, 2019, 52, 351-355.	0.3	2
3444	Diagnosis of pulmonary embolism in patients with pulmonary hypertension (a case report). Pulmonologiya, 2019, 29, 620-624.	0.2	1
3446	A clinical case of radiofrequency pulmonary artery denervation for treatment of a patient with residual chronic thromboembolic pulmonary hypertension. Cardiovascular Therapy and Prevention (Russian Federation), 2019, 18, 121-125.	0.4	1
3447	Isolated Ventricular Septal Defect. , 2020, , 849-863.		1
3448	Leitsymptom Dyspnoe, LeistungsschwÃche. , 2020, , 117-229.		0
3449	Pulmonary hypertension in patients with sarcoidosis: A single center experience. Anatolian Journal of Cardiology, 2020, 25, 36-41.	0.5	2
3450	Echocardiography in the ICU. , 2020, , 1-24.		0
3451	Perioperative Nursing for Adult Congenital Heart Disease with Severe Pulmonary Arterial Hypertension. International Journal of Clinical Medicine, 2020, 11, 538-547.	0.1	0

#	Article	IF	Citations
3452	Neutrophil Extracellular Traps in Atherosclerosis and Thrombosis. Handbook of Experimental Pharmacology, 2020, , 405-425.	0.9	9
3453	Contemporary usefulness of pulmonary venous flow parameters to estimate left ventricular end-diastolic pressure on transthoracic echocardiography. International Journal of Cardiovascular Imaging, 2020, 36, 1699-1709.	0.7	5
3454	Role of echocardiography in screening for portopulmonary hypertension in liver transplant candidates: a meta-analysis. PeerJ, 2020, 8, e9243.	0.9	3
3455	Pulmonary arterial hypertension in the elderly: Clinical perspectives. Cardiology Journal, 2020, 27, 184-193.	0.5	5
3456	TÃ¼rkiyeâ€™de tersiyer bir merkezde sistemik skleroz hastalarÄ±nda pulmoner hipertansiyon taramasÄ±; kesitsel orjinal Ã§alÄ±Ÿma. Turkish Journal of Clinics and Laboratory, 0, , .	0.2	0
3458	EPC modulation, a new mechanism for CTEPH therapy?. International Journal of Cardiology, 2020, 307, 165.	0.8	0
3460	The cardiovascular system in idiopathic pulmonary fibrosis. , 2020, , 198-211.		0
3461	NT-proBNP increase during stress echocardiography predicts significant changes in ischemic mitral regurgitation severity in patients qualified for surgical revascularization. Cardiology Journal, 2020, , .	0.5	0
3462	Cardiovascular implications of pulmonary hypertension due to chronic respiratory diseases. , 2020, , 167-183.		0
3463	Machine learning for the diagnosis of pulmonary hypertension. Kardiologiya, 2020, 60, 96-101.	0.3	6
3465	EcografÃa clÃnica en las enfermedades autoinmunes sistÃ©micas. Revista Clinica Espanola, 2020, 220, 297-304.	0.2	3
3466	Respiratory failure in a cancer patient: pulmonary thrombotic microangiopathy. Clinical Medicine, 2020, 20, 430-432.	0.8	1
3469	Risk stratification in PAH. Global Cardiology Science & Practice, 2020, 2020, e202009.	0.3	0
3470	Anesthetic and Circulatory Management of Patients with Pulmonary Hypertension. The Journal of Japan Society for Clinical Anesthesia, 2020, 40, 520-526.	0.0	0
3471	Clonal hematopoiesis with JAK2V617F promotes pulmonary hypertension with ALK1 upregulation in lung neutrophils. Nature Communications, 2021, 12, 6177.	5.8	30
3472	Full recovery of right ventricular systolic function in children undergoing bilateral lung transplantation for severe PAH. Journal of Heart and Lung Transplantation, 2022, 41, 187-198.	0.3	10
3473	Chronic thromboembolic pulmonary hypertension in patients with antiphospholipid syndrome: Risk factors and management. Journal of Heart and Lung Transplantation, 2022, 41, 208-216.	0.3	5
3474	Non-Invasive Risk Prediction Based on Right Ventricular Function in Patients with Pulmonary Arterial Hypertension. Journal of Clinical Medicine, 2021, 10, 5130.	1.0	1

#	Article	IF	Citations
3475	Progressive fibrosing interstitial lung disease: prevalence and clinical outcome. Respiratory Research, 2021, 22, 282.	1.4	28
3476	The prognostic significance of the alterations of pulmonary hemodynamics in patients with pulmonary arterial hypertension: a meta-regression analysis of randomized controlled trials. Systematic Reviews, 2021, 10, 284.	2.5	5
3477	Right atrium enlargement is related to increased heart damage and mortality in well-controlled hypertension. Nutrition, Metabolism and Cardiovascular Diseases, 2022, 32, 420-428.	1.1	5
3478	Pulmonary hypertension in children with chronic bronchopulmonary pathology: a pulmonologistâ€™s perspective to the problem. Meditsinskiy Sovet, 2021, , 300-309.	0.1	0
3479	Ventilation-Perfusion Scan: A Primer for Practicing Radiologists. Radiographics, 2021, 41, 2047-2070.	1.4	5
3480	The European Rare Disease Network for HHT Frameworks for management of hereditary haemorrhagic telangiectasia in general and speciality care. European Journal of Medical Genetics, 2022, 65, 104370.	0.7	28
3481	Pulmonary manifestations of chronic liver disease: a comprehensive review. Annals of Gastroenterology, 2020, 33, 237-249.	0.4	13
3482	Pulmonale Hypertonie. Springer Reference Medizin, 2020, , 2095-2100.	0.0	0
3483	Akute und chronische Lungenembolie. , 2020, , 281-293.		0
3484	Comparative Analysis of Cardiovascular Disorders in Patients with Chronic Myeloid Leukemia on Tyrosine Kinase Inhibitor Therapy. Klinicheskaya Onkogematologiya/Clinical Oncohematology, 2020, 13, 104-111.	0.1	1
3485	Perioperative management of patients with valvular heart disease. Russian Journal of Anesthesiology and Reanimatology /Anesteziologiya I Reanimatologiya, 2020, , 6.	0.2	1
3486	Whole-Body Vibration Therapy in Patients with Pulmonary Hypertension and Right Heart Failure: Lessons from a Pilot Study. , 2020, , 355-362.		0
3487	Pulmonary Hemodynamics and Outcome in a Large Cohort of Patients with Sinus Venosus Septal Defect. Congenital Heart Disease, 2020, 15, 69-78.	0.0	0
3488	Exercise Training for Pulmonary Hypertension: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Biological Research for Nursing, 2021, 23, 442-454.	1.0	1
3489	Occult pulmonary arterial hypertension in patients with previous pulmonary tuberculosis. African Journal of Thoracic and Critical Care Medicine, 2020, 26, 133.	0.3	6
3490	Switching Strategy in the Management of Patients with Pulmonary Arterial Hypertension. The REPLACE Study Results. Rational Pharmacotherapy in Cardiology, 2020, 16, 1009-1016.	0.3	0
3491	Advanced therapies in Eisenmenger syndrome. Journal of Congenital Cardiology, 2020, 4, .	0.5	0
3492	Pulmonary arterial hypertension associated with congenital heart disease after defect repair: the effect of pregnancy. Journal of Congenital Cardiology, 2020, 4, .	0.5	0

#	Article	IF	Citations
3493	Chronisch-thromboembolische pulmonale Hypertonie: Strukturiertes kÃ¶rperliches Training nach pulmonaler Endarteriektomie. Karger Kompass Pneumologie, 2021, 9, 20-22.	0.0	0
3494	Selexipag for the treatment of pulmonary arterial hypertension. Expert Review of Respiratory Medicine, 2021, 15, 583-595.	1.0	4
3495	Pulmonary arterial hypertension associated with congenital heart disease: classification and pathophysiology. Journal of Congenital Cardiology, 2020, 4, .	0.5	3
3496	Strategies for the management of pulmonary arterial hypertension in patients with congenital heart disease. Journal of Congenital Cardiology, 2020, 4, .	0.5	5
3497	The progress of pulmonary artery denervation. Cardiology Journal, 2022, 29, 381-387.	0.5	4
3498	Pregnancy in pulmonary arterial hypertension associated with congenital heart disease: an illustrative case study. Journal of Congenital Cardiology, 2020, 4, .	0.5	0
3499	Adultsâ€™ experiences of living with pulmonary hypertension: a thematic synthesis of qualitative studies. BMJ Open, 2020, 10, e041428.	0.8	10
3500	Multimodality Imaging of Pulmonary Hypertension: Prognostication of Therapeutic Outcomes. Medical Radiology, 2021, , 225-257.	0.0	1
3501	Erythrocytosis and iron status in Eisenmenger syndrome: an illustrative case study. Journal of Congenital Cardiology, 2020, 4, .	0.5	0
3503	Echocardiographic Prevalence and Risk Predictors of Ventricular Dysfunction in Connective Tissue Disorders: Tertiary Care Hospital-Based Prospective Case-Control Study. Indian Journal of Clinical Cardiology, 2020, 1, 132-141.	0.3	0
3504	General management of pulmonary arterial hypertension associated with adult congenital heart disease. Journal of Congenital Cardiology, 2020, 4, .	0.5	0
3505	Increase in Pulmonary Artery Pressures. In Clinical Practice, 2021, , 101-109.	0.1	0
3506	Treatment of isolated tricuspid regurgitation in 2020: an update. Faculty Reviews, 2020, 9, 26.	1.7	2
3508	Safflower injection inhibits pulmonary arterial remodeling in a monocrotaline-induced pulmonary arterial hypertension rat model. Zeitschrift Fur Naturforschung - Section C Journal of Biosciences, 2021, 76, 27-34.	0.6	3
3509	Thrombotic Lesion of the Pulmonary Vessels in Patients with Pulmonary Embolism. Rational Pharmacotherapy in Cardiology, 2020, 16, 1002-1008.	0.3	0
3510	STRUCTURAL CHANGES OF THE PULMONARY ARTERIES AFTER BALLOON PULMONARY ANGIOPLASTY IN PATIENTS WITH CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION. Eurasian Heart Journal, 2020, , 12-20.	0.2	1
3511	Respiratory rate modulation improves symptoms in patients with pulmonary hypertension. SAGE Open Medicine, 2021, 9, 205031212110539.	0.7	0
3513	Assessment of Reversibility in Pulmonary Hypertension Related to Congenital Heart Disease by Using Biomarkers and Clinical Features. Congenital Heart Disease, 2022, 17, 87-97.	0.0	0

#	Article	IF	Citations
3514	Consequences of Altered Cardiac Activity on Brain Activity. , 2020, , 197-211.		0
3515	Brazilian Thoracic Society recommendations for the diagnosis and treatment of chronic thromboembolic pulmonary hypertension. Jornal Brasileiro De Pneumologia, 2020, 46, e20200204-e20200204.	0.4	3
3518	Inhalation therapy with nitric oxide synthesized from atmospheric air in the postoperative period of cardiac surgery in children: single-center retrospective cohort study. Alexander Saltanov Intensive Care Herald, 2021, , 98-107.	0.2	2
3519	Hemodynamic Evaluation and Echocardiography in the Oncologic Intensive Care Unit. , 2020, , 753-773.		0
3520	New treatment options for pulmonary arterial hypertension â€" the first selective IP-receptor agonist selexipag. Cardiovascular Therapy and Prevention (Russian Federation), 2019, 18, 80-87.	0.4	2
3521	Is the increase of uric acid associated with the components of the metabolic syndrome?. Seminars in Cardiovascular Medicine, 2020, 26, 7-13.	0.3	0
3523	Recomendaciones para la atenciÃ³n de pacientes con insuficiencia cardiaca y COVID-19. , 2020, 31, 190-196.		0
3524	Diagnosis, Indication and Timing. , 2020, , 1-62.		0
3525	Chronically Critically Ill Pediatric Cardiac Patient: Nursing Considerations. , 2020, , 1-12.		0
3526	Novel treatments for diastolic heart failure. , 2020, , 95-127.		0
3527	Geodesically Smoothed Tensor Features for Pulmonary Hypertension Prognosis Using the Heart and Surrounding Tissues. Lecture Notes in Computer Science, 2020, , 253-262.	1.0	6
3528	Late-Onset Pulmonary Hypertension After the Atrial Switch Procedure for Transposition of the Great Arteries. Congenital Heart Disease, 2020, 15, 483-493.	0.0	1
3529	PH Professional Network: Up, Up, and Away: Clinical Considerations for Altitude-Related Travel and Pulmonary Hypertension. Advances in Pulmonary Hypertension, 2020, 19, 80-82.	0.1	0
3530	Differential Diagnosis of Diffuse Pulmonary Disorders Using Genetics. Respiratory Medicine, 2020, , 11-23.	0.1	0
3531	Comprehensive Long-Term Follow up of Adults with Arterial Switch Operation â€" European Collaboration for Prospective Outcome Research in Congenital Heart disease (EPOCH-ASO)â€"Study Design and Protocols. Congenital Heart Disease, 2020, 15, 309-338.	0.0	1
3532	How Did The Updated Haemodynamic Definitions Affect The Frequency Of Pulmonary Hypertension In Patients With Systemic Sclerosis?. Anatolian Journal of Cardiology, 2020, 25, 30-35.	0.5	1
3533	Pulmonary Hypertension in Sickle Cell Disease: Current Controversies and Clinical Practices. Respiratory Medicine, 2020, , 123-134.	0.1	1
3534	IMAGING TECHNIQUES IN THE DIAGNOSIS OF PULMONARY HYPERTENSION. WiadomoÅ›ci Lekarskie, 2020, 73, 1867-1869.	0.1	0

#	Article	IF	Citations
3535	Cardiovascular Manifestation of Paediatric HIV Infection. , 2020, , 103-114.		0
3536	Right ventricular function in patients with pulmonary arterial hypertension associated with congenital heart disease with repaired and unrepaired defects; correlation of speckle tracking, conventional echocardiography and clinical parameters. Anatolian Journal of Cardiology, 2020, 23, 277-287.	0.5	3
3538	Isolated Postcapillary and Combined Pre- and Postcapillary Pulmonary Hypertension. Respiratory Medicine, 2020, , 61-70.	0.1	0
3539	Cost-utility analysis of Macitentan Vs. Bosentan in pulmonary atrial hypertension. Journal of Family Medicine and Primary Care, 2020, 9, 3634.	0.3	2
3541	Parenteral Prostacyclin Use in Pulmonary Arterial Hypertension. Respiratory Medicine, 2020, , 147-171.	0.1	0
3542	Indications and Contraindications in Lung Transplantation. , 2020, , 883-892.		0
3543	Echocardiographic Screening Methods for Pulmonary Hypertension: A Practical Review. Journal of Cardiovascular Imaging, 2020, 28, 1.	0.2	7
3544	Should oral combination therapy be the standard of care for pulmonary arterial hypertension?. Expert Review of Respiratory Medicine, 2020, 14, 341-343.	1.0	1
3545	The Failing Right Heart from Pulmonary Hypertension. Clinical Cases in Cardiology, 2020, , 147-169.	0.0	0
3546	Pulmonary Hypertension in Chronic Kidney Disease and End-Stage Renal Disease. Respiratory Medicine, 2020, , 173-194.	0.1	2
3547	Noninvasive predictors of functional capacity in patients with pulmonary hypertension due to congenital heart disease: A pilot echocardiography single-center study. Journal of Cardiovascular Echography, 2020, 30, 193.	0.1	0
3549	Medical, Endovascular, and Surgical Treatment of CTEPH. Respiratory Medicine, 2020, , 203-214.	0.1	0
3550	Screening for precapillary pulmonary hypertension in chronic myeloproliferative disorders: theÂrole ofÂN-terminal pro-B-type natriuretic peptide and vascular endothelial growth factor â€“ aÂpilot study. Archives of Medical Science, 2020, 17, 1628-1635.	0.4	0
3552	Successful Transition from Intravenous Epoprostenol to Oral Selexipag due to Effective Management of Side Effects in a Young Woman with Severe Idiopathic Pulmonary Arterial Hypertension. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences), 2020, 46, 77-83.	0.0	0
3554	Pulmoner Arteriyal Hipertansiyon HastalarÄ±nda Serum D vitamini DÃ¼zeyleri. Dicle Medical Journal, 0, , 216-222.	0.2	0
3555	Evaluation of Diagnostic Accuracy and Radiation Exposure of Dual-Energy Computed Tomography (DECT) in the Course of Chronic Thromboembolic Pulmonary Hypertension (CTEPH). RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren, 2021, 193, 1318-1326.	0.7	3
3556	Evaluation of the Results of Balloon Pulmonary Angioplasty in Patients with Chronic Distal Pulmonary Thromboembolic Disease and Pulmonary Hypertension. Indian Journal of Cardiovascular Disease in Women WINCARS, 0, 06, 157-164.	0.1	3
3557	Ethical Issues Regarding Off - Label Administration of Antibiotics. Journal of Intercultural Management and Ethics, 2020, 3, 29-38.	0.0	0

#	Article	IF	Citations
3560	Sleep-related breathing disorders in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. Arterial Hypertension (Russian Federation), 2020, 26, 85-93.	0.1	0
3561	Perioperative Management of Pulmonary Hypertension. A Review. The Journal of Critical Care Medicine, 2021, 7, 83-96.	0.3	6
3563	Outcomes and Risk Factors of Systolic Pulmonary Artery Pressure Progression in Patients with Systemic Rheumatic Diseases: Follow-up Results from a Korean Registry. Archives of Rheumatology, 2020, 35, 558-567.	0.3	0
3564	Chronic Thromboembolic Pulmonary Hypertensionâ€"Are Good Days Ahead?. Indian Journal of Cardiovascular Disease in Women WINCARS, 0, 06, 165-167.	0.1	0
3565	Long-Term Survival, Safety and Tolerability with Selexipag in Patients with Pulmonary Arterial Hypertension: Results from GRIPHON and its Open-Label Extension. Advances in Therapy, 2022, 39, 796-810.	1.3	12
3566	Iron Metabolism and Idiopathic Pulmonary Arterial Hypertension: New Insights from Bioinformatic Analysis. BioMed Research International, 2021, 2021, 1-27.	0.9	20
3567	Vascular remodeling of the small pulmonary arteries and measures of vascular pruning on computed tomography. Pulmonary Circulation, 2021, 11, 1-9.	0.8	6
3568	Fibrinolytic markers could be useful predictors of severity in patients with pulmonary arterial hypertension: a retrospective study. Thrombosis Journal, 2021, 19, 78.	0.9	2
3569	Sex and gender in pulmonary arterial hypertension. European Respiratory Review, 2021, 30, 200330.	3.0	31
3570	Incidence and predictors of de novo late-onset persistent atrial fibrillation in postoperative rheumatic heart disease patients (LOAF-RHD study). Journal of Interventional Cardiac Electrophysiology, 2022, 64, 621-628.	0.6	1
3571	Cutaneous Iontophoresis of Vasoactive Medications in Patients with Sclerodermaâ€•Associated Pulmonary Arterial Hypertension. Microcirculation, 2021, , e12734.	1.0	0
3572	Standardizing registry data to the OMOP Common Data Model: experience from three pulmonary hypertension databases. BMC Medical Research Methodology, 2021, 21, 238.	1.4	22
3573	COMPERA 2.0: a refined four-stratum risk assessment model for pulmonary arterial hypertension. European Respiratory Journal, 2022, 60, 2102311.	3.1	124
3574	Is There a Link Between Nailfold Videocapillaroscopy and Pulmonary Function Tests in Systemic Sclerosis Patients?. Journal of Clinical Rheumatology, 2022, 28, 26-32.	0.5	4
3575	The Impact of Clinical Treatment Plan of the New Definition of Precapillary Pulmonary Hypertension. Chest, 2021, 160, e540-e541.	0.4	0
3576	Novel Targets in a High-Altitude Pulmonary Hypertension Rat Model Based on RNA-seq and Proteomics. Frontiers in Medicine, 2021, 8, 742436.	1.2	0
3577	Mateâ€pair sequencing identifies a cryptic BMPR2 mutation in hereditary pulmonary arterial hypertension. Pulmonary Circulation, 2020, 10, 1-4.	0.8	1
3578	Overexpressed lncRNA AC068039.4 Contributes to Proliferation and Cell Cycle Progression of Pulmonary Artery Smooth Muscle Cells Via Sponging miR-26a-5p/TRPC6 in Hypoxic Pulmonary Arterial Hypertension. Shock, 2021, 55, 244-255.	1.0	14

#	Article	IF	Citations
3579	Pulmonary Vascular Disease Evaluation with Magnetic Resonance Angiography. Radiologic Clinics of North America, 2020, 58, 707-719.	0.9	3
3580	Preoperative balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension led to successful anesthetic management for total hysterectomy under general anesthesia: a case report. JA Clinical Reports, 2020, 6, 55.	0.2	1
3581	Galectin-3 plasma levels in adult congenital heart disease and the pressure overloaded right ventricle: reason matters. Biomarkers in Medicine, 2020, 14, 1197-1205.	0.6	3
3582	â€œPortraitâ€•of patients with idiopathic pulmonary hypertension and chronic thromboembolic pulmonary hypertension depending on comorbid status: current and prognosis features. Pulmonologiya, 2020, 30, 427-436.	0.2	5
3583	LesÃµes Plexiformes em Modelo Experimental de HipertensÃ£o Arterial Pulmonar Induzida por Monocrotalina. Arquivos Brasileiros De Cardiologia, 2020, 115, 480-490.	0.3	5
3584	Optimal Cut-Off of Tricuspid Regurgitation Velocity According to the New Definition of Pulmonary Hypertensionã€€â€• Its Use in Predicting Pulmonary Hypertension â€•. Circulation Reports, 2020, 2, 625-629.	0.4	3
3585	Risk assessment in patients with functional class II pulmonary arterial hypertension: Comparison of physician gestalt with ESC/ERS and the REVEAL 2.0 risk score. PLoS ONE, 2020, 15, e0241504.	1.1	12
3586	Quality of smoking cessation advice in guidelines of tobacco-related diseases: An updated systematic review. Clinical Medicine, 2020, 20, 551-559.	0.8	7
3587	Tratamiento de la embolia de pulmÃ³n. DetecciÃ³n de la hipertensiÃ³n pulmonar tromboembÃ³lica crÃ³nica. Revista Clinica Espanola, 2020, 220, 69-77.	0.2	0
3588	Pulmonary thromboendarterectomy in Portugal: Initial experience. Revista Portuguesa De Cardiologia (English Edition), 2020, 39, 505-512.	0.2	0
3590	Therapeutic use of oxygen in pulmonary arterial hypertension: a forgotten friend. European Journal of Preventive Cardiology, 2021, 28, 124-126.	0.8	0
3591	Cardiac catheterization in pulmonary hypertension: doing it right, with a catheter on the left. Cardiovascular Diagnosis and Therapy, 2020, 10, 1718-1724.	0.7	4
3592	How to select the appropriate candidate of pulmonary arterial hypertension: specific therapy in elderly patients with pulmonary hypertension. Journal of Geriatric Cardiology, 2017, 14, 17-19.	0.2	0
3593	Consecutive Sessions of Rescue Balloon Atrial Septostomy for an Idiopathic Pulmonary Arterial Hypertension Patient with Refractory Right Heart Failure - Usefulness of Intracardiac Echocardiography Guidance. Acta Cardiologica Sinica, 2017, 33, 310-314.	0.1	4
3594	Long-Term Survival of Patients with Pulmonary Arterial Hypertension at a Single Center in Taiwan. Acta Cardiologica Sinica, 2017, 33, 498-509.	0.1	19
3595	Relationship between Serum Uric Acid Levels and the Severity of Pulmonary Hypertension. Tanaffos, 2017, 16, 283-288.	0.5	6
3597	Exercise rehabilitation programmes for pulmonary hypertension: a systematic review of intervention components and reporting quality. BMJ Open Sport and Exercise Medicine, 2018, 4, e000400.	1.4	5
3598	Bendopnea and Its Clinical Importance in Outpatient Patients with Pulmonary Arterial Hypertension. Acta Cardiologica Sinica, 2018, 34, 518-525.	0.1	5

#	Article	IF	Citations
3599	Echocardiographic Parameters in Acute Pulmonary Edema. Current Health Sciences Journal, 2017, 43, 345-350.	0.2	0
3600	Author`s Reply. Anatolian Journal of Cardiology, 2019, 21, 55-56.	0.5	0
3601	Balloon Pulmonary Angioplasty in Chronic Pulmonary Thromboembolic Pulmonary Hypertension. Acta Cardiologica Sinica, 2019, 35, 183-187.	0.1	1
3602	Cardiovascular Effects of Tyrosine Kinase Inhibitors in Patients With Advanced Renal Cell Carcinoma at the VA San Diego Healthcare System. Federal Practitioner: for the Health Care Professionals of the VA, DoD, and PHS, 2019, 36, S18-S24.	0.6	0
3603	Approach to a patient with pulmonary hypertension. Journal of Geriatric Cardiology, 2019, 16, 478-481.	0.2	1
3604	The Relationship between Electrocardiographic Changes and Prognostic Factors in Severely Symptomatic Pulmonary Hypertension. Tanaffos, 2019, 18, 34-40.	0.5	2
3605	Removing an Entrapped Pigtail Catheter by Re-enforcing a Traditional Method. Tanaffos, 2019, 18, 84-87.	0.5	1
3606	Changed hemodynamics in acute vasoreactivity testing: prognostic predictors in chronic thromboembolic pulmonary hypertension. American Journal of Translational Research (discontinued), 2020, 12, 959-973.	0.0	1
3607	Predictive value of pulmonary function testing in the evaluation of pulmonary hypertension in sarcoidosis. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2018, 35, 308-316.	0.2	1
3608	A crucial role of endoplasmic reticulum stress in cellular responses during pulmonary arterial hypertension. American Journal of Translational Research (discontinued), 2020, 12, 1481-1490.	0.0	6
3609	Managing Pulmonary Hypertension in Times of COVID-19. Acta Cardiologica Sinica, 2020, 36, 394-395.	0.1	0
3610	Management of interstitial lung diseases: A consensus statement of the Indian Chest Society (ICS) and National College of Chest Physicians (NCCP). Lung India, 2020, 37, 359-378.	0.3	2
3611	Long-term outcomes of epoprostenol therapy in sarcoid associated pulmonary hypertension. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2020, 37, 184-191.	0.2	2
3612	Treatment of newly diagnosed sarcoid-associated pulmonary hypertension with ambrisentan and tadalafil combination therapy. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2020, 37, 234-238.	0.2	0
3613	Chronic thromboembolic pulmonary hypertension - still evolving. Global Cardiology Science & Practice, 2020, 2020, e202011.	0.3	1
3614	Management of Pulmonary Arterial Hypertension Patients with World Health Organization Functional Class II. Acta Cardiologica Sinica, 2020, 36, 583-587.	0.1	0
3615	Pulmonary hypertension concurrent with pericardial effusion and superior vena cava syndrome: who is the initiator?. Journal of Geriatric Cardiology, 2020, 17, 723-727.	0.2	0
3616	Exercise Capacity and Quality of Life in Pulmonary Arterial Hypertension. Acta Cardiologica Sinica, 2021, 37, 74-85.	0.1	0

#	Article	IF	Citations
3617	Impact of pulmonary perfusion defects by scintigraphy on pulmonary vascular resistances, functional capacity and right ventricular systolic function in patients with chronic thromboembolic pulmonary hypertension. American Journal of Nuclear Medicine and Molecular Imaging, 2021, 11, 20-26.	1.0	0
3618	Severe Acute Malnutrition among Unoperated Ethiopian Children with Congenital Heart Disease: A Wake-up Call to Reverse the Situation, A Retrospective Cross-Sectional Study. Ethiopian Journal of Health Sciences, 2020, 30, 707-714.	0.2	1
3619	Pulmonary capillary hemangiomatosis: a case series and review of literature. American Journal of Cardiovascular Disease, 2021, 11, 239-245.	0.5	0
3620	ï¼œEditors' Choiceï¼ž Differential effects of combination therapy on the components of the risk stratification table in patients with idiopathic or heritable pulmonary arterial hypertension in a Japanese population. Nagoya Journal of Medical Science, 2021, 83, 321-330.	0.6	0
3621	Prognostic Value of Right Ventricular Cardiac Power Output at Rest in Patients with Advanced Heart Failure. Acta Cardiologica Sinica, 2021, 37, 404-411.	0.1	0
3622	A Novel Approach to Left Ventricular Filling Pressure Assessment: The Role of Hemodynamic Forces Analysis. Frontiers in Cardiovascular Medicine, 2021, 8, 704909.	1.1	1
3623	Good response to pulmonary arterial hypertension-targeted therapy in 2 pulmonary veno-occlusive disease patients: A case report. Medicine (United States), 2021, 100, e27334.	0.4	0
3627	Additional prognostic value of echocardiographic follow-up in pulmonary hypertensionâ€"role of 3D right ventricular area strain. European Heart Journal Cardiovascular Imaging, 2022, 23, 1562-1572.	0.5	6
3628	Pulmonary hypertension in adults with congenital heart disease. Clinical phenotypes and outcomes in the advanced pulmonary vasodilator era. Heart and Lung: Journal of Acute and Critical Care, 2022, 51, 75-81.	0.8	2
3629	Cardiovascular Images in Neglected Tropical Diseases. , 2022, , 241-257.		0
3630	Schistosomiasis & Heart. , 2022, , 195-203.		0
3631	Pulmonary Hypertension Associated with Connective Tissue Disease. Cardiology Clinics, 2022, 40, 29-43.	0.9	8
3632	The role of endothelin II type A receptor (ETAR) in transplant injury. Transplant Immunology, 2022, 70, 101505.	0.6	9
3633	Pulmonary Hypertension in Adults with Congenital Heart Disease. Cardiology Clinics, 2022, 40, 55-67.	0.9	6
3634	The Pathobiology of Pulmonary Arterial Hypertension. Cardiology Clinics, 2022, 40, 1-12.	0.9	14
3635	Interventional Management of Chronic Thromboembolic Pulmonary Hypertension. Cardiology Clinics, 2022, 40, 103-114.	0.9	0
3636	Increased Pulmonary Arterial Compliance after Balloon Pulmonary Angioplasty Predicts Exercise Tolerance Improvement in Inoperable CTEPH Patients with Lower Pulmonary Arterial Pressure. Heart and Lung: Journal of Acute and Critical Care, 2022, 52, 8-15.	0.8	5
3637	Rehabilitation for Visceral Impairmentï¼šUpdate. The Japanese Journal of Rehabilitation Medicine, 2021, 58, 1092-1100.	0.0	0

#	Article	IF	Citations
3638	Chronic thromboembolic pulmonary hypertension: Initial experience of patients undergoing pulmonary thromboendarterectomy. Revista Portuguesa De Cardiologia (English Edition), 2021, 40, 741-752.	0.2	1
3639	Identification of a Novel Gene Correlated With Vascular Smooth Muscle Cells Proliferation and Migration in Chronic Thromboembolic Pulmonary Hypertension. Frontiers in Physiology, 2021, 12, 744219.	1.3	2
3640	Left atrial unloading with an 8Âmm septal cutting balloon to treat postcapillary pulmonary hypertension: a case report. ESC Heart Failure, 2021, , .	1.4	3
3641	Use of venous-venous extracorporeal membrane oxygenation in the treatment of postpartum pulmonary hypertension crisis. Perfusion (United Kingdom), 2023, 38, 401-404.	0.5	1
3642	Congenital heart disease: When simple becomes complex. Revista Portuguesa De Cardiologia, 2022, 41, 179.e1-179.e2.	0.2	0
3643	Critical care management of pulmonary arterial hypertension in pregnancy: the pre-, peri- and post-partum stages. Acute and Critical Care, 2021, 36, 286-293.	0.6	6
3644	Independent Association Between Occupational Exposure and Decline of FVC in Systemic Sclerosis. Chest, 2022, 161, 1011-1021.	0.4	4
3645	Serum Organ-Specific Anti-Heart and Anti-Intercalated Disk Autoantibodies as New Autoimmune Markers of Cardiac Involvement in Systemic Sclerosis: Frequency, Clinical and Prognostic Correlates. Diagnostics, 2021, 11, 2165.	1.3	7
3646	Prognostic value of right ventricular native T1 mapping in pulmonary arterial hypertension. PLoS ONE, 2021, 16, e0260456.	1.1	4
3647	Non-Coding RNA Networks in Pulmonary Hypertension. Frontiers in Genetics, 2021, 12, 703860.	1.1	8
3648	Selexipag and the pulmonary hypertension continuum. European Journal of Heart Failure, 2022, 24, 215-218.	2.9	3
3649	Echocardiography in the diagnostic evaluation and phenotyping of heart failure with preserved ejection fraction. Journal of Cardiology, 2022, 79, 679-690.	0.8	8
3651	The REPAIR Study. JACC: Cardiovascular Imaging, 2022, 15, 240-253.	2.3	28
3652	Construction of a Support Vector Machineâ€“Based Classifier for Pulmonary Arterial Hypertension Patients. Frontiers in Genetics, 2021, 12, 781011.	1.1	2
3653	Use of small pulmonary vascular alterations to identify different types of pulmonary hypertension: a quantitative computed tomography analysis. Journal of X-Ray Science and Technology, 2021, , 1-9.	0.7	1
3654	Expanding the Evidence of a Semi-Dominant Inheritance in GDF2 Associated with Pulmonary Arterial Hypertension. Cells, 2021, 10, 3178.	1.8	12
3655	Alternative RAS in Various Hypoxic Conditions: From Myocardial Infarction to COVID-19. International Journal of Molecular Sciences, 2021, 22, 12800.	1.8	4
3656	Prognostic Implications of Right Ventricular Function and Pulmonary Pressures Assessed by Echocardiography in Hospitalized Patients with COVID-19. Journal of Personalized Medicine, 2021, 11, 1245.	1.1	7

#	Article	IF	Citations
3657	The clinical characteristics of patients with pulmonary hypertension combined with obstructive sleep apnoea. BMC Pulmonary Medicine, 2021, 21, 378.	0.8	6
3658	Validity of the ESC Risk Assessment in Idiopathic Pulmonary Arterial Hypertension in China. Frontiers in Cardiovascular Medicine, 2021, 8, 745578.	1.1	2
3659	Chronic Thromboembolic Pulmonary Hypertension (CTEPH). , 2022, , 235-247.		0
3660	Right Ventricular Cardiac Power Output as a Mortality Predictor in Patients with Pulmonary Arterial Hypertension. Sakarya Medical Journal, 0, , .	0.1	0
3661	Iron in Cardiovascular Disease: Challenges and Potentials. Frontiers in Cardiovascular Medicine, 2021, 8, 707138.	1.1	27
3662	COVID-19 Vaccination in Patients with Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension: Safety Profile and Reasons for Opting against Vaccination. Vaccines, 2021, 9, 1395.	2.1	14
3663	A narrative review on adverse effects of dasatinib with a focus on pharmacotherapy of dasatinib-induced pulmonary toxicities. Blood Research, 2021, 56, 229-242.	0.5	19
3664	Importance of Tricuspid Regurgitation Velocity Threshold in Risk Assessment of Pulmonary Hypertension-Long-Term Outcome of Patients Submitted to Aortic Valve Replacement. Frontiers in Cardiovascular Medicine, 2021, 8, 720643.	1.1	1
3665	The impact of comorbidities on selexipag treatment effect in patients with pulmonary arterial hypertension: insights from the <scp>GRIPHON</scp> study. European Journal of Heart Failure, 2022, 24, 205-214.	2.9	22
3666	Survival of patients with idiopathic pulmonary fibrosis and pulmonary hypertension under therapy with nintedanib or pirfenidone. Internal and Emergency Medicine, 2022, 17, 815-822.	1.0	3
3667	The Role of Conjunctival Microvasculation Combined with Echocardiography in Evaluating Pulmonary Arterial Hypertension in Systemic Lupus Erythematosus. Disease Markers, 2021, 2021, 1-6.	0.6	5
3668	Right ventricular failure: a comorbidity or a clinical emergency?. Heart Failure Reviews, 2022, 27, 1779-1793.	1.7	3
3669	Impact of Pulmonary Artery Dilatation on Clinical Outcomes in Patients Undergoing Transcatheter Aortic Valve Replacement. JACC: Cardiovascular Interventions, 2021, 14, 2560-2569.	1.1	3
3670	Implication of proliferation gene biomarkers in pulmonary hypertension. Animal Models and Experimental Medicine, 2021, 4, 369-380.	1.3	11
3672	Factors Influencing the Evolution of Pulmonary Hypertension in Previously Healthy Subjects Recovering from a SARS-CoV-2 Infection. Journal of Clinical Medicine, 2021, 10, 5272.	1.0	5
3673	Non-cardiac surgery in patients with valvular heart disease. Heart, 2022, 108, 1171-1178.	1.2	4
3674	New prognostic markers in pulmonary arterial hypertension: CRP to albumin ratio and uric acid. Clinical Biochemistry, 2022, 100, 22-28.	0.8	11
3675	A Novel Non-Invasive Method for Estimating Elevated Pulmonary Vascular Resistance Based on Echocardiographic Assessment of Pulmonary Artery Wave Reflection. Circulation Journal, 2021, , .	0.7	2

#	Article	IF	Citations
3676	Predictors of pulmonary hypertension among children with atrial septal defects (ASD). Libyan Journal of Medicine, 2022, 17, 2007603.	0.8	0
3677	Plasma metabolomics in the perioperative period of defect repair in patients with pulmonary arterial hypertension associated with congenital heart disease. Acta Pharmacologica Sinica, 2022, 43, 1710-1720.	2.8	12
3678	Diffusing Capacity for Carbon Monoxide Predicts Response to Balloon Pulmonary Angioplasty in Patients With Inoperable Chronic Thromboembolic Pulmonary Hypertension. Frontiers in Cardiovascular Medicine, 2021, 8, 762267.	1.1	5
3679	Outcomes and prognostic factors of decompensated pulmonary hypertension in the intensive care unit. Respiratory Medicine, 2021, 190, 106685.	1.3	11
3680	Algorithms for the diagnosis and treatment of idiopathic pulmonary arterial hypertension. Hypertension, 2021, 14, 5-28.	0.2	0
3681	Measurement of Pulmonary Artery Wave Reflection Before and After Mitral Valvuloplasty in Canine Patients With Pulmonary Hypertension Caused by Myxomatous Mitral Valve Disease. Frontiers in Veterinary Science, 2021, 8, 773035.	0.9	2
3682	Pulmonary arterial hypertension associated with pulmonary arteriovenous malformations and pulmonary veno-occlusive disease: A devastating combination. Respiratory Medicine Case Reports, 2021, 34, 101564.	0.2	1
3683	Lowering Tricuspid Regurgitant Velocity Threshold to Identify aÂMean Pulmonary Artery Pressure â‰¥Â20ÂmmÂHg. Chest, 2021, 160, 2000-2002.	0.4	0
3684	Pulmonale Hypertonie: Was ist neu?. , 0, , .		0
3686	Management of interstitial lung diseases: A consensus statement of the Indian Chest Society (ICS) and National College of Chest Physicians (NCCP). Lung India, 2020, 37, 359.	0.3	9
3687	Pulmonary hypertension â€“ general considerations. Medic Ro, 2021, 5, 30.	0.0	0
3688	Surgical management of pulmonary endarterectomy avoiding deep hypothermia: the Pavia experience. Annals of Cardiothoracic Surgery, 2021, 11, 0-0.	0.6	0
3689	Data of modern registries on clinical course and prognosis of patients with idiopathic pulmonary arterial hypertension. Kardiologicheskii Vestnik, 2021, 16, 23.	0.1	1
3690	Pulmonary endarterectomy reoperation: frequency, risk factors and outcomes. Annals of Cardiothoracic Surgery, 2021, 11, 0-0.	0.6	0
3691	Chronic thromboembolic pulmonary hypertension: diagnosis, operability assessment and patient selection for pulmonary endarterectomy. Annals of Cardiothoracic Surgery, 2022, 11, 82-97.	0.6	9
3692	Impact and safety of balloon pulmonary angioplasty for elderly patients. Pulmonary Circulation, 2022, 12, e12009.	0.8	3
3693	Ventricular flow analysis and its association with exertional capacity in repaired tetralogy of Fallot: 4D flow cardiovascular magnetic resonance study. Journal of Cardiovascular Magnetic Resonance, 2022, 24, 4.	1.6	15
3694	Quantification of vortex flow in pulmonary arteries of patients with chronic thromboembolic pulmonary hypertension. European Journal of Radiology, 2022, 148, 110142.	1.2	10

#	Article	IF	Citations
3695	The value of ventricular gradient for predicting pulmonary hypertension and mortality in hemodialysis patients. Scientific Reports, 2022, 12, 456.	1.6	3
3696	The role of junctophilin proteins in cellular function. Physiological Reviews, 2022, 102, 1211-1261.	13.1	25
3697	Baseline PA/BSA ratio in patients undergoing transcatheter aortic valve replacement â€“ A novel CT-based marker for the prediction of pulmonary hypertension and outcome. International Journal of Cardiology, 2022, 348, 26-32.	0.8	3
3698	Association between myocardial fibrosis, as assessed with cardiac magnetic resonance T1 mapping, and persistent dyspnea after pulmonary embolism. IJC Heart and Vasculature, 2022, 38, 100935.	0.6	0
3699	Effects of BPA on right ventricular mechanical dysfunction in patients with inoperable CTEPH â€“ A cardiac magnetic resonance study. European Journal of Radiology, 2022, 147, 110111.	1.2	11
3700	Data on plasma tumour and metabolism related proteinsâ€™ potential in differentiation of HFpEF-PH from PAH and in prognosis of left heart failure patients with pulmonary hypertension. Data in Brief, 2022, 40, 107747.	0.5	0
3701	The therapeutic effect and mechanism of Rapamycin combined with HO-3867 on monocrotaline-induced pulmonary hypertension in rats. European Journal of Pharmaceutical Sciences, 2022, 170, 106102.	1.9	1
3702	Severe Acute Malnutrition among Unoperated Ethiopian Children with Congenital Heart Disease: A Wake-up Call to Reverse the Situation, A Retrospective Cross-Sectional Study. Ethiopian Journal of Health Sciences, 2020, 30, 707-714.	0.2	4
3703	Chronic thromboembolic pulmonary hypertension â€“ still evolving. Global Cardiology Science & Practice, 2020, 2020, e202011.	0.3	4
3704	Patterns of Pulmonary Hypertension in Patients with Chronic Kidney Disease. The Egyptian Journal of Hospital Medicine, 2020, 81, 2114-2119.	0.0	0
3705	Interventional Cardiology and Catheter-Based Interventions in Pregnancy. Cardiology in Review, 2022, 30, 24-30.	0.6	1
3706	Pulmonary endarterectomy in the octogenarian population: safety and outcomes. Journal of Cardiovascular Medicine, 2021, 22, 567-571.	0.6	10
3708	Anti-Obesity Medications: An Update for Canadian Physicians. Canadian Journal of General Internal Medicine, 2020, 15, 5-12.	0.6	0
3709	Systemic sclerosis and pulmonary arterial hypertension: A case report. Acta Facultatis Medicae Naissensis, 2021, 38, 390-398.	0.1	0
3710	BenefÃcios do exercÃcio fÃsico na hipertensÃ£o arterial pulmonar associada Ã cardiopatia congÃªnita nÃ£o corrigida. Scientia Medica, 2021, 31, e38061.	0.1	0
3711	2020 Clinical practice guidelines for Pulmonary hypertension, including chronic thromboembolic pulmonary hypertension. Russian Journal of Cardiology, 2022, 26, 4683.	0.4	29
3713	Good response to pulmonary arterial hypertension-targeted therapy in 2 pulmonary veno-occlusive disease patients. Medicine (United States), 2021, 100, e27334.	0.4	5
3714	Can serum 8-hydroxy-2'-deoxyguanosine levels reflect the severity of pulmonary arterial hypertension?. Revista Da AssociaÃ§Ã£o MÃ©dica Brasileira, 2021, 67, 1437-1442.	0.3	3

#	Article	IF	Citations
3715	The Roles of S100A4 and the EGF/EGFR Signaling Axis in Pulmonary Hypertension with Right Ventricular Hypertrophy. Biology, 2022, 11, 118.	1.3	3
3716	Epigenetic Mechanisms as Emerging Therapeutic Targets and Microfluidic Chips Application in Pulmonary Arterial Hypertension. Biomedicines, 2022, 10, 170.	1.4	7
3717	Perioperative Management of Pulmonary Hypertension During Cardiac Surgery: A Call for Interdisciplinary Networking.. Journal of Cardiothoracic and Vascular Anesthesia, 2022, , .	0.6	0
3718	Physiological aspects of cardiopulmonary dysanapsis on exercise in adults born preterm. Journal of Physiology, 2022, 600, 463-482.	1.3	20
3719	The Prognostic Impact of Serum Uric Acid on Disease Severity and 5-Year Mortality in Patients With Idiopathic Pulmonary Artery Hypertension. Frontiers in Medicine, 2022, 9, 805415.	1.2	7
3720	Cardiac manifestations in primary antiphospholipid syndrome and their association to antiphospholipid antibodiesâ€™ types and titersâ€”cross-sectional study of Serbian cohort. Clinical Rheumatology, 2022, , 1.	1.0	3
3721	Treatment of Portopulmonary Hypertension (PoPH): A review. Journal of Liver Transplantation, 2022, 6, 100071.	0.2	1
3722	Association of nutritional status and mortality risk in patients with primary pulmonary hypertension. Pulmonary Circulation, 2022, 12, e12018.	0.8	3
3723	Notch4 mediates vascular remodeling via ERK/JNK/P38 MAPK signaling pathways in hypoxic pulmonary hypertension. Respiratory Research, 2022, 23, 6.	1.4	17
3724	Right Ventricular Response to Acute Hypoxia Exposure: A Systematic Review. Frontiers in Physiology, 2021, 12, 786954.	1.3	1
3725	Pulmonary vascular resistance and compliance in pulmonary blood flow alterations in children with congenital heart disease. Heart and Vessels, 2022, , 1.	0.5	2
3726	Histologic and proteomic remodeling of the pulmonary veins and arteries in a porcine model of chronic pulmonary venous hypertension. Cardiovascular Research, 2023, 119, 268-282.	1.8	4
3727	Removing roadblocks in pulmonary circulation: centres of excellence and interhospital networks. EuroIntervention, 2022, 17, 1050-1051.	1.4	0
3728	Safety and tolerability of combination therapy with ambrisentan and tadalafil for the treatment of pulmonary arterial hypertension in children: Realâ€world experience. Pediatric Pulmonology, 2022, 57, 724-733.	1.0	7
3729	Evaluation of the effect of nitric oxide inhalation in the patients with chronic thromboembolic pulmonary hypertension or pulmonary disease during balloon pulmonary angioplasty. Pulmonary Circulation, 2022, 12, e12032.	0.8	2
3730	Plasma matrix metalloproteinase 2 is associated with severity and mortality in pulmonary arterial hypertension. Pulmonary Circulation, 2022, 12, e12041.	0.8	8
3731	Impact of additional selexipag on prostacyclin infusion analogs in patients with pulmonary arterial hypertension. Respiratory Medicine Case Reports, 2022, 36, 101592.	0.2	2
3732	Estimation of Elevated Systolic Pulmonary Artery Pressure Using Right Ventricular Isovolumic Relaxation Time. , 0, 32, 15-20.		0

#	Article	IF	Citations
3733	Imaging assessment of the right atrium: anatomy and function. European Heart Journal Cardiovascular Imaging, 2022, 23, 867-884.	0.5	17
3734	Comparing Diagnosis and Treatment of Pulmonary Hypertension Patients at a Pulmonary Hypertension Center versus Community Centers. Diseases (Basel, Switzerland), 2022, 10, 5.	1.0	5
3735	Utility of Plasma Volume Status in Ambulatory Patients with Pulmonary Hypertension. Pulmonary Circulation, 2022, 12, e12045.	0.8	1
3736	Utility of Automated Cardiac Chamber Volumetry by Non-Gated CT Pulmonary Angiography for Detection of Pulmonary Hypertension Using the 2018 Updated Hemodynamic Definition. American Journal of Roentgenology, 2022, , .	1.0	0
3737	An expert panel Delphi consensus statement on the use of palliative care in the management of patients with pulmonary arterial hypertension. Pulmonary Circulation, 2022, 12, e12003.	0.8	4
3738	Disease characteristics and clinical outcome over two decades from the Swiss pulmonary hypertension registry. Pulmonary Circulation, 2022, 12, e12001.	0.8	7
3739	Perfiles hemodinÃ¡micos de una serie de pacientes llevados a cateterismo cardÃ¡aco derecho. Experiencia de un centro de la ciudad de MedellÃ¡n, Colombia. Archivos De Cardiologia De Mexico, 2022, 92, 53-59.	0.1	0
3740	Eâ€REVEAL Lite 2.0 scoring for early prediction of disease progression in pulmonary arterial hypertension. Pulmonary Circulation, 2022, 12, e12026.	0.8	6
3741	Hemodynamic Evaluation of the Right Heart-Pulmonary Circulation Unit in Patients Candidate to Transjugular Intrahepatic Portosystemic Shunt. Journal of Clinical Medicine, 2022, 11, 461.	1.0	2
3742	Clinical impact of pulmonary hypertension on the outcomes of acute myocardial infarction patients with or without chronic obstructive pulmonary disease. Medicine (United States), 2022, 101, e28627.	0.4	0
3743	Epidemiology and outcomes of pulmonary hypertension in the cardiac intensive care unit. European Heart Journal: Acute Cardiovascular Care, 2022, 11, 230-241.	0.4	9
3744	An openâ€label, doseâ€escalation study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single doses of GSK2586881 in participants with pulmonary arterial hypertension. Pulmonary Circulation, 2022, 12, e12024.	0.8	8
3746	Long-Term Prognostic Impact of Right Ventricular Dysfunction in Patients with COVID-19. Journal of Personalized Medicine, 2022, 12, 162.	1.1	4
3747	A Case of Complex Pulmonary Hypertension: the Importance of Diagnostic Investigation. Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine, 2022, 16, 117954842110732.	0.5	0
3748	Cardiovascular magnetic resonance-derived left ventricular intraventricular pressure gradients among patients with precapillary pulmonary hypertension. European Heart Journal Cardiovascular Imaging, 2022, 24, 78-87.	0.5	7
3749	The clinical experience of macitentan in pulmonary hypertension in Indian cohort: 12-month follow-up. Lung India, 2022, 39, 12.	0.3	2
3750	Valvular Heart Disease in Patients with Chronic Kidney Disease. European Cardiology Review, 2022, 17, e02.	0.7	11
3751	Future perspective in diabetic patients with pre- and post-capillary pulmonary hypertension. Heart Failure Reviews, 2023, 28, 745-755.	1.7	3

#	Article	IF	Citations
3752	Pulmonary Hypertension in Pregnancy: A Positive Outcome with a Multidisciplinary Team and Individualized Treatment Plan. Journal of Cardiothoracic and Vascular Anesthesia, 2022, 36, 3403-3413.	0.6	1
3753	New strategy to resume and taper epoprostenol after lung transplant for pulmonary hypertension. General Thoracic and Cardiovascular Surgery, 2022, 70, 372-377.	0.4	5
3754	Diagnosis of pulmonary hypertension associated with congenital heart disease. Part 2. Echocardiography. Rossiyskiy Vestnik Perinatologii I Pediatrii, 2022, 66, 23-32.	0.1	3
3755	Long-Term Outcomes in Adult Patients With Pulmonary Hypertension After Percutaneous Closure of Atrial Septal Defects. Circulation: Cardiovascular Interventions, 2022, 15, CIRCINTERVENTIONS121011110.	1.4	3
3756	Heart Involvement in Systemic Sclerosis: the Role of Magnetic Resonance Imaging. Clinical Reviews in Allergy and Immunology, 2023, 64, 343-357.	2.9	6
3757	Association of Electrocardiographic Signs of Right Ventricular Hypertrophy and Clot Localization in Chronic Thromboembolic Pulmonary Hypertension. Journal of Clinical Medicine, 2022, 11, 625.	1.0	6
3758	Appropriate Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension Improves Right Ventricular Ejection Fraction via Lung Perfusion Scan. International Heart Journal, 2022, 63, 91-98.	0.5	1
3759	Haemoptysis in Pulmonary Arterial Hypertension Associated with Congenital Heart Disease: Insights on Pathophysiology, Diagnosis and Management. Journal of Clinical Medicine, 2022, 11, 633.	1.0	6
3760	the comparative effects of sacubitril/valsartan vs. enalapril on pulmonary hypertension due to heart failure with reduced ejection fraction. Pulmonary Circulation, 0, , .	0.8	3
3761	Use of Pulmonary Arterial Hypertension Therapies in Patients with a Fontan Circulation: Current Practice Across the United Kingdom. Journal of the American Heart Association, 2022, 11, e023035.	1.6	8
3762	Change in pulmonary arterial compliance and pulmonary pulsatile stress after balloon pulmonary angioplasty. , 2022, 26, 43-48.		5
3763	Computed tomography lung parenchymal descriptions in routine radiological reporting have diagnostic and prognostic utility in patients with idiopathic pulmonary arterial hypertension and pulmonary hypertension associated with lung disease. ERJ Open Research, 2022, 8, 00549-2021.	1.1	7
3764	Clinical impact of subcutaneous treprostinil in trisomy 21 patient with pulmonary arterial hypertension associated with CHD. Cardiology in the Young, 2022, 32, 1502-1504.	0.4	0
3765	Reproductive Issues and Pregnancy Implications in Systemic Sclerosis. Clinical Reviews in Allergy and Immunology, 2023, 64, 321-342.	2.9	6
3766	Association Between the Coronary Sinus Ostial Size and Atrioventricular Nodal Reentrant Tachycardia in Patients With Pulmonary Arterial Hypertension. Frontiers in Physiology, 2021, 12, 790077.	1.3	1
3767	Echocardiographic probability of pulmonary hypertension: a validation study. European Respiratory Journal, 2022, 60, 2102548.	3.1	27
3768	Determinants of altered left ventricular suction in pre-capillary pulmonary hypertension. European Heart Journal Cardiovascular Imaging, 2022, 23, 1399-1406.	0.5	2
3769	Post severe COVID-19 infection lung damages study. The experience of early three months multidisciplinary follow-up. Monaldi Archives for Chest Disease, 2022, , .	0.3	2

#	Article	IF	Citations
3770	Chronic Thromboembolic Pulmonary Hypertension: An Update. Diagnostics, 2022, 12, 235.	1.3	16
3771	Targeting Myadm to Intervene Pulmonary Hypertension on Rats Before Pregnancy Alleviates the Effect on Their Offspringâ€™s Cardiac-Cerebral Systems. Frontiers in Pharmacology, 2021, 12, 791370.	1.6	1
3772	GPR18-Mediated Relaxation of Human Isolated Pulmonary Arteries. International Journal of Molecular Sciences, 2022, 23, 1427.	1.8	7
3773	Different Cytokine Patterns in BMPR2-Mutation-Positive Patients and Patients With Pulmonary Arterial Hypertension Without Mutations and Their Influence on Survival. Chest, 2022, 161, 1651-1656.	0.4	2
3774	Identification of Crucial Hub Genes and Differential T Cell Infiltration in Idiopathic Pulmonary Arterial Hypertension Using Bioinformatics Strategies. Frontiers in Molecular Biosciences, 2022, 9, 800888.	1.6	7
3775	Clinical Value of FeNO for Pulmonary Hypertension Diagnosis in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease. Emergency Medicine International, 2022, 2022, 1-6.	0.3	1
3776	Does Age Matter? Pulmonary Endarterectomy in the Elderly Patient with CTEPH. Thoracic and Cardiovascular Surgeon, 2022, 70, 663-670.	0.4	8
3777	Treatment of heart failure with a preserved ejection fraction. Journal of the Korean Medical Association, 2022, 65, 18-25.	0.1	0
3778	Role of cardiopulmonary exercise test in the prediction of hemodynamic impairment in patients with pulmonary arterial hypertension. Pulmonary Circulation, 2022, 12, e12044.	0.8	6
3779	Nitric oxide: Clinical applications in critically ill patients. Nitric Oxide - Biology and Chemistry, 2022, 121, 20-33.	1.2	21
3780	The echocardiographic course of pretransplant pulmonary hypertension following kidney transplantation and associated outcomes. Pulmonary Circulation, 2022, 12, e12030.	0.8	1
3781	The Impact of Breathing Hypoxic Gas and Oxygen on Pulmonary Hemodynamics in Patients With Pulmonary Hypertension. Frontiers in Medicine, 2022, 9, 791423.	1.2	9
3782	In systemic sclerosis TAPSE/sPAP ratio is correlated with ventilatory efficiency and exercise capacity assessed by CPET. Clinical and Experimental Medicine, 2022, , 1.	1.9	2
3783	The Importance of Functional and Feature-Tracking Cardiac MRI Parameters in Prediction of Adverse Cardiac Events and Cardiac Mortality in Thalassemia Patients. Academic Radiology, 2022, 29, S91-S99.	1.3	3
3785	Cardiac dysfunction and mortality in critically ill patients with COVIDâ€19: A Swedish multicentre observational study. Acta Anaesthesiologica Scandinavica, 2022, 66, 606-614.	0.7	6
3786	Successful Transition from Intravenous Epoprostenol to Oral Selexipag and Inhaled Iloprost in a Case of Severe Pulmonary Arterial Hypertension Associated with Systemic Lupus Erythematosus. Modern Rheumatology Case Reports, 2022, , .	0.3	1
3787	Advances in treatment of chronic thromboembolic pulmonary hypertension. Thrombosis Research, 2022, 212, 30-37.	0.8	3
3788	The Role of Thyroid Disorders, Obesity, Diabetes Mellitus and Estrogen Exposure as Potential Modifiers for Pulmonary Hypertension. Journal of Clinical Medicine, 2022, 11, 921.	1.0	5

#	Article	IF	Citations
3790	Dynamic Changes in miR-21 Regulate Right Ventricular Dysfunction in Congenital Heart Disease-Related Pulmonary Arterial Hypertension. Cells, 2022, 11, 564.	1.8	4
3791	European Respiratory Society statement on long COVID follow-up. European Respiratory Journal, 2022, 60, 2102174.	3.1	81
3792	Echocardiographic Biventricular Coupling Index to Predict Precapillary Pulmonary Hypertension. Journal of the American Society of Echocardiography, 2022, 35, 715-726.	1.2	6
3793	Anxiety and Depression in Patients With Pulmonary Arterial Hypertension in Northwest China: A Cross-Sectional Study. Frontiers in Psychiatry, 2021, 12, 758120.	1.3	6
3794	A unique gut microbiota signature in pulmonary arterial hypertension: A pilot study. Pulmonary Circulation, 2022, 12, e12051.	0.8	7
3795	Acute and chronic exercise training in patients with Class II pulmonary hypertension: effects on haemodynamics and symptoms. ESC Heart Failure, 2022, , .	1.4	1
3796	A Meta-analysis of the efficacy of pulmonary artery denervation in the treatment of pulmonary hypertension. Heart and Lung: Journal of Acute and Critical Care, 2022, 53, 42-50.	0.8	4
3797	Obstructive sleep apnea and cardiovascular comorbidity: modern discordance in assessing the effectiveness of CPAP-therapy against the pathogenetic mechanisms and cardiovascular diseases. Pulmonologiya, 2021, 31, 799-807.	0.2	1
3798	The Role of Pulmonary Artery Wedge Pressure on the Incidence of Atrial Fibrillation and Atrial Tachycardias in Patients With Isolated Pre-capillary Pulmonary Hypertens. Physiological Research, 2021, 70, .	0.4	0
3799	Unmasking of left heart dilation following treatment for precapillary pulmonary hypertension. Canadian Veterinary Journal, 2021, 62, 1177-1180.	0.0	0
3800	Diagnostic accuracy, sensitivity, and specificity of CT pulmonary artery to aorta diameter ratio in screening for pulmonary hypertension in end-stage COPD patients. Croatian Medical Journal, 2021, 62, 446-445.	0.2	0
3801	Pulmonary vascular disease in pulmonary hypertension due to left heart disease: pathophysiologic implications. European Heart Journal, 2022, 43, 3417-3431.	1.0	50
3802	Cardiovascular Comorbidity in Patients Scheduled for TKA. , 2022, , 139-150.		1
3803	CILP1 as a biomarker for right ventricular dysfunction in patients with ischemic cardiomyopathy. Pulmonary Circulation, 2022, 12, e12062.	0.8	3
3804	An Overview of Methods for Detecting eIF2Î± Phosphorylation and the Integrated Stress Response. Methods in Molecular Biology, 2022, 2428, 3-18.	0.4	5
3805	Was Paul Wood wrong about pre-capillary pulmonary hypertension protecting against pulmonary congestion in left heart disease?. European Heart Journal, 2022, 43, 3432-3434.	1.0	6
3806	Echocardiographic Pulmonary to Left Atrial Ratio in Dogs (ePLAR): A Differential Marker of Pre- and Postcapillary Pulmonary Hypertension. American Journal of Animal and Veterinary Sciences, 2022, 17, 42-52.	0.2	0
3807	Leitsymptom Dyspnoe, LeistungsschwÃche. , 2022, , 121-242.		0

#	Article	IF	Citations
3808	Clinical Application of 4D Flow MR Imaging to Pulmonary Hypertension. Magnetic Resonance in Medical Sciences, 2022, 21, 309-318.	1.1	8
3809	Genetic cause of pulmonary veno-occlusive disease. Lung India, 2022, 39, 191.	0.3	1
3810	Heart-Rate Recovery at 1 Min After Exercise Predicts Response to Balloon Pulmonary Angioplasty in Patients With Inoperable Chronic Thromboembolic Pulmonary Hypertension. Frontiers in Cardiovascular Medicine, 2022, 9, 795420.	1.1	0
3811	A Case of Pulmonary Hypertension in a 67-Year-Old Woman with Thiamine Deficiency Following Partial Gastrectomy and Exacerbated by Diuretics. American Journal of Case Reports, 2022, 23, e935308.	0.3	2
3812	Cancer Risk in Pulmonary Hypertension Patients. Clinical Epidemiology, 2022, Volume 14, 173-177.	1.5	1
3813	Perifollicular Hypopigmentation in Systemic Sclerosis: Associations With Clinical Features and Internal Organ Involvement. Journal of Rheumatology, 2022, 49, 475-481.	1.0	3
3814	Right atrial and ventricular strain detects subclinical changes in right ventricular function in precapillary pulmonary hypertension. International Journal of Cardiovascular Imaging, 2022, 38, 1699-1710.	0.7	12
3815	Effect of a 12-week home-based exercise training program on aerobic capacity, muscle mass, liver and spleen stiffness, and quality of life in cirrhotic patients: a randomized controlled clinical trial. BMC Gastroenterology, 2022, 22, 66.	0.8	10
3816	Childhood Maltreatment, Mental Well-Being, and Healthy Lifestyle in Patients With Chronic Thromboembolic Pulmonary Hypertension. Frontiers in Psychiatry, 2022, 13, 821468.	1.3	1
3817	Interplay of Low-Density Lipoprotein Receptors, LRPs, and Lipoproteins inÂPulmonary Hypertension. JACC Basic To Translational Science, 2022, 7, 164-180.	1.9	23
3818	Risk prediction in pulmonary hypertension due to chronic heart failure: incremental prognostic value of pulmonary hemodynamics. BMC Cardiovascular Disorders, 2022, 22, 56.	0.7	0
3819	Prevalence, Risk Factors and Intervention for Depression and Anxiety in Pulmonary Hypertension: A Systematic Review and Meta-analysis. Frontiers in Medicine, 2022, 9, 765461.	1.2	9
3820	High prevalence of occult left ventricular diastolic dysfunction detected by exercise stress test in systemic sclerosis. Scientific Reports, 2022, 12, 2423.	1.6	4
3821	Comparative Study of Diagnostic Efficacy of Single Phase-Computed Tomography Pulmonary Angiography and Dual Phase-Computed Tomography Pulmonary Angiography in the Diagnosis of Pulmonary Embolism. Frontiers in Cardiovascular Medicine, 2022, 9, 846805.	1.1	2
3822	Spectral Detector CT-Derived Pulmonary Perfusion Maps and Pulmonary Parenchyma Characteristics for the Semiautomated Classification of Pulmonary Hypertension. Frontiers in Cardiovascular Medicine, 2022, 9, 835732.	1.1	3
3823	Nailfold capillaroscopy in SSc: innocent bystander or promising biomarker for novel severe organ involvement/progression?. Rheumatology, 2022, 61, 4384-4396.	0.9	10
3824	Earlyâ€onset and severe Pulmonary Arterial Hypertension due to a novel compound heterozygous association of rare VHL mutations: a case report and review of existing data.. Pulmonary Circulation, 0, , .	0.8	3
3825	Right Ventricular and Right Atrial Function Are Less Compromised in Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction: A Comparison With Pulmonary Arterial Hypertension With Similar Pressure Overload. Circulation: Heart Failure, 2022, 15, CIRCHEARTFAILURE121008726.	1.6	12

#	Article	IF	Citations
3826	Sexual and Reproductive Health in Women with Pulmonary Hypertension: A Qualitative Study. Archives of Sexual Behavior, 2022, 51, 1647-1657.	1.2	7
3827	Exercise stress echocardiography: Where are we now?. World Journal of Cardiology, 2022, 14, 64-82.	0.5	9
3828	Muscle training in patients with pulmonary hypertension. a narrative review. Colombia Medica, 2022, 52, e2015163.	0.7	1
3829	Solving the Pulmonary Hypertension Paradox in Patients With Severe TricuspidÂRegurgitation by Employing Artificial Intelligence. JACC: Cardiovascular Interventions, 2022, 15, 381-394.	1.1	12
3830	Dysregulated Immunity in Pulmonary Hypertension: From Companion to Composer. Frontiers in Physiology, 2022, 13, 819145.	1.3	8
3831	Sulforaphane Does Not Protect Right Ventricular Systolic and Diastolic Functions in Nrf2 Knockout Pulmonary Artery Hypertension Mice. Cardiovascular Drugs and Therapy, 2022, 36, 425-436.	1.3	8
3832	Larger pulmonary artery to ascending aorta ratios are associated with decreased survival of patients undergoing pulmonary endarterectomy. JTCVS Open, 2022, , .	0.2	0
3833	Serum markers of cardiac complications in a systemic sclerosis cohort. Scientific Reports, 2022, 12, 4661.	1.6	4
3834	Prostacyclin analogues decrease platelet aggregation but have no effect on thrombin generation, fibrin clot structure, and fibrinolysis in pulmonary arterial hypertension: PAPAYA coagulation. Platelets, 2022, 33, 1065-1074.	1.1	2
3835	Pulmonary artery denervation for pulmonary hypertension: a systematic review and meta-analysis of clinical studies. Arterial Hypertension (Russian Federation), 2022, 27, 628-641.	0.1	1
3836	The spectrum and prevalence of arrhythmia in different clinical pulmonary hypertension groups in Chinese population. Clinical Cardiology, 2022, 45, 495-502.	0.7	5
3837	Bi-level Positive Airway Pressure Versus Nasal CPAP for the Prevention of Extubation Failure in Infants After Cardiac Surgery. Respiratory Care, 2022, 67, 448-454.	0.8	2
3838	Characteristics, goalâ€oriented treatments and survival of pulmonary arterial hypertension in China: Insights from a national multicentre prospective registry. Respirology, 2022, 27, 517-528.	1.3	15
3839	Cardiovascular subphenotypes in patients with <scp>COVID</scp> â€19 pneumonitis whose lungs are mechanically ventilated: a singleâ€centre retrospective observational study. Anaesthesia, 2022, , .	1.8	16
3840	Treatment with neurohormonal inhibitors and prognostic outcome in pulmonary arterial hypertension with risk factors for left heart disease. World Journal of Critical Care Medicine, 2022, 11, 85-91.	0.8	1
3841	Platelet Activation Markers in Children with Pulmonary Arterial Hypertension Associated with Congenital Heart Disease. Pediatric Cardiology, 2022, 43, 1264-1270.	0.6	4
3842	Prevalence of Mental Disorders in Patients With Chronic Thromboembolic Pulmonary Hypertension. Frontiers in Psychiatry, 2022, 13, 821466.	1.3	7
3843	The Prognostic Value of Right Atrial and Right Ventricular Functional Parameters in Systemic Sclerosis. Frontiers in Cardiovascular Medicine, 2022, 9, 845359.	1.1	5

#	Article	IF	Citations
3844	Pulmonary thromboendarterectomy in chronic thromboembolic pulmonary hypertension: the Spanish experience. Annals of Cardiothoracic Surgery, 2022, 11, 151-160.	0.6	6
3845	Effect of Levosimendan on Acute Decompensated Right Heart Failure in Patients With Connective Tissue Disease-Associated Pulmonary Arterial Hypertension. Frontiers in Medicine, 2022, 9, 778620.	1.2	5
3846	Impact of interstitial lung disease on the survival of systemic sclerosis with pulmonary arterial hypertension. Scientific Reports, 2022, 12, 5289.	1.6	6
3847	Ring Finger Protein 213 in Moyamoya Disease With Pulmonary Arterial Hypertension: A Mini-Review. Frontiers in Neurology, 2022, 13, 843927.	1.1	1
3848	Flare rates and factors determining flare occurrence in patients with systemic lupus erythematosus who achieved low disease activity or remission: results from a prospective cohort study. Lupus Science and Medicine, 2022, 9, e000553.	1.1	4
3849	Marinobufagenin, left ventricular geometry and cardiac dysfunction in end-stage kidney disease patients. International Urology and Nephrology, 2022, 54, 2581-2589.	0.6	7
3850	Long-term mortality after pulmonary artery denervation stratified by baseline functional class in patients with pulmonary arterial hypertension. AsiaIntervention, 2022, 8, 58-68.	0.1	5
3851	sPAP/PAAT Ratio as a New Index of Pulmonary Vascular Load: A Study in Normal Subjects and Ssc Patients with and without PH. Pathophysiology, 2022, 29, 134-142.	1.0	0
3852	Gene panel diagnostics reveals new pathogenic variants in pulmonary arterial hypertension. Respiratory Research, 2022, 23, 74.	1.4	18
3853	The Value of Passive Leg Raise During Right Heart Catheterization in Diagnosing Heart Failure With Preserved Ejection Fraction. Circulation: Heart Failure, 2022, 15, CIRCHEARTFAILURE121008935.	1.6	26
3854	Metabolomics-based mechanism exploration of pulmonary arterial hypertension pathogenesis: novel lessons from explanted human lungs. Hypertension Research, 2022, 45, 990-1000.	1.5	5
3855	Management and prognosis of HIVâ€associated pulmonary arterial hypertension: 20 Years of evidence from the REHAP registry. Journal of Internal Medicine, 2022, 292, 116-126.	2.7	5
3856	Cardiovascular Imaging for Systemic Sclerosis Monitoring and Management. Frontiers in Cardiovascular Medicine, 2022, 9, 846213.	1.1	3
3857	Unmasking right ventricular-arterial uncoupling during fluid challenge in pulmonary hypertension. Journal of Heart and Lung Transplantation, 2022, 41, 345-355.	0.3	12
3858	Increased Levels of ICOS and ICOSL Are Associated to Pulmonary Arterial Hypertension in Patients Affected by Connective Tissue Diseases. Diagnostics, 2022, 12, 704.	1.3	3
3859	A case report of a long-term survivor after inadvertent ligation of left pulmonary artery during intended ductal ligation. European Heart Journal - Case Reports, 2022, 6, ytac127.	0.3	0
3860	Prediction of maximal oxygen uptake from 6-min walk test in pulmonary hypertension. ERJ Open Research, 2022, 8, 00664-2021.	1.1	1
3861	Thoracic Involvement in Systemic Autoimmune Rheumatic Diseases: Pathogenesis and Management. Clinical Reviews in Allergy and Immunology, 2022, 63, 472-489.	2.9	13

#	Article	IF	Citations
3862	Pulmonary embolus associated with a rare provoking factor: recreational nitrous oxide use. BMJ Case Reports, 2022, 15, e247315.	0.2	1
3863	High Betaine and Dynamic Increase of Betaine Levels Are Both Associated With Poor Prognosis of Patients With Pulmonary Hypertension. Frontiers in Cardiovascular Medicine, 2022, 9, 852009.	1.1	7
3864	Pulmonary endarterectomy: technique and pitfalls. Annals of Cardiothoracic Surgery, 2022, 11, 180-188.	0.6	4
3865	Oxygen Management in Heart Failure Patients. Indian Journal of Clinical Cardiology, 0, , 263246362210815.	0.3	0
3866	Incremental value of cardiopulmonary exercise testing in intermediate-risk pulmonary arterial hypertension. Journal of Heart and Lung Transplantation, 2022, 41, 780-790.	0.3	13
3867	An Overview of Different Techniques for Improving the Treatment of Pulmonary Hypertension Secondary in Systemic Sclerosis Patients. Diagnostics, 2022, 12, 616.	1.3	16
3868	Baseline Ratio of Soluble Fas/FasL Predicts Onset of Pulmonary Hypertension in Elder Patients Undergoing Maintenance Hemodialysis: A Prospective Cohort Study. Frontiers in Physiology, 2022, 13, 847172.	1.3	1
3869	The zinc transporter ZIP12 regulates monocrotaline-induced proliferation and migration of pulmonary arterial smooth muscle cells via the AKT/ERK signaling pathways. BMC Pulmonary Medicine, 2022, 22, 111.	0.8	10
3870	Heart failure in adults with congenital heart disease. International Journal of Cardiology, 2022, 357, 39-45.	0.8	17
3871	Comparison of fibrosing mediastinitis patients with vs. without markedly increased systolic pulmonary arterial pressure: a single-center retrospective study. BMC Cardiovascular Disorders, 2022, 22, 134.	0.7	0
3872	HipertensiÃ³n arterial pulmonar. Medicina ClÃnica, 2022, 158, 622-629.	0.3	11
3873	Eisenmenger syndrome with left main compression syndrome: a case report. BMC Cardiovascular Disorders, 2022, 22, 89.	0.7	2
3874	Soluble ST2 as a Potential Biomarker for Risk Assessment of Pulmonary Hypertension in Patients Undergoing TAVR?. Life, 2022, 12, 389.	1.1	4
3875	Sarcoidosis-associated pulmonary hypertension. , 2022, , 234-255.		0
3876	Identification of a Novel EIF2AK Variant and Genetics-Assisted Approach to Diagnosis of Pulmonary Capillary Hemangiomatosis. Lung, 2022, 200, 217-219.	1.4	1
3877	An unusual case of CTEPH treated by BPA in a patient with a single lung after cancer surgery. Pulmonary Circulation, 0, , .	0.8	1
3878	Therapeutic alternatives in chronic thromboembolic pulmonary hypertension: from pulmonary endarterectomy to balloon pulmonary angioplasty to medical therapy. State of the art from a multidisciplinary team. Annals of Cardiothoracic Surgery, 2022, 11, 120-127.	0.6	3
3879	Progression of Chronic Kidney Disease and All-Cause Mortality in Patients with Tricuspid Regurgitation. Diseases (Basel, Switzerland), 2022, 10, 16.	1.0	0

#	Article	IF	Citations
3880	Impaired biventricular contractile reserve in patients with diastolic dysfunction: insights from exercise stress echocardiography. European Heart Journal Cardiovascular Imaging, 2022, 23, 1042-1052.	0.5	3
3881	Renal Venous Stasis Index Reflects Renal Congestion and Predicts Adverse Outcomes in Patients With Heart Failure. Frontiers in Cardiovascular Medicine, 2022, 9, 772466.	1.1	10
3882	Diagnostic accuracy of automated 3D volumetry of cardiac chambers by CT pulmonary angiography for identification of pulmonary hypertension due to left heart disease. European Radiology, 2022, , 1.	2.3	3
3883	Echocardiography Nomogram for Predicting Survival among Chronic Lung Disease Patients with Severe Pulmonary Hypertension. Journal of Clinical Medicine, 2022, 11, 1603.	1.0	0
3884	Pulmonary Arterial Hypertension and Consecutive Right Heart Failure Lead to Liver Fibrosis. Frontiers in Cardiovascular Medicine, 2022, 9, 862330.	1.1	6
3885	Right Heart Chambers Longitudinal Strain Provides Enhanced Diagnosis and Categorization in Patients With Pulmonary Hypertension. Frontiers in Cardiovascular Medicine, 2022, 9, 841776.	1.1	0
3886	Pulmonary Artery Remodeling and Advanced Hemodynamics: Magnetic Resonance Imaging Biomarkers of Pulmonary Hypertension. Applied Sciences (Switzerland), 2022, 12, 3518.	1.3	4
3887	The paradox of pulmonary arterial hypertension in Italy in the COVID-19 era: is risk of disease progression around the corner?. European Respiratory Journal, 2022, 60, 2102276.	3.1	8
3888	Metacognitive Short-Term Intervention in Patients With Mental Disorders Following Cardiovascular Events. Frontiers in Psychiatry, 2022, 13, 812807.	1.3	1
3889	Worsening Dyspnea in Patients With Idiopathic Portal Hypertension. Chest, 2022, 161, e245-e248.	0.4	1
3890	Rationale and design of a screening study to detect schistosomiasisâ€associated pulmonary hypertension in Ethiopia and Zambia. Pulmonary Circulation, 2022, 12, e12072.	0.8	2
3891	Prognostic Role of Pulmonary Function in Patients With Heart Failure With Reduced Ejection Fraction. Journal of the American Heart Association, 2022, 11, e023422.	1.6	2
3892	Sustained Hemodynamic and Clinical Improvements for a Patient With Idiopathic Pulmonary Arterial Hypertension Over 1.5 Years After Balloon Atrial Septostomy: A Case Report. Frontiers in Cardiovascular Medicine, 2022, 9, 868123.	1.1	0
3893	Transthoracic Echocardiographic Predictive Probability of Pulmonary Hypertension in Liver Transplant candidates: Implications for Clinical Practice. Journal of Liver Transplantation, 2022, 7, 100090.	0.2	0
3894	Utilization of risk assessment tools in management of PAH: A PAH provider survey. Pulmonary Circulation, 2022, 12, e12057.	0.8	4
3895	Characteristics and prognostic significance of right heart remodeling and tricuspid regurgitation after pulmonary endarterectomy. Journal of Thoracic and Cardiovascular Surgery, 2024, 167, 658-667.e7.	0.4	2
3896	Impact of Esophageal Pressure Measurement on Pulmonary Hypertension Diagnosis in Patients With Obesity. Chest, 2022, 162, 684-692.	0.4	9
3897	Balloon pulmonary angioplasty in inoperable chronic thromboembolic pulmonary hypertension. BMJ Case Reports, 2022, 15, e247318.	0.2	1

#	Article	IF	Citations
3898	Mining the Plasma Proteome for Insights into the Molecular Pathology of Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 1449-1460.	2.5	19
3899	TGFâ€²² receptor mutations and clinical prognosis in Chinese Pediatric Patients with idiopathic/hereditary Pulmonary Arterial Hypertension. Pulmonary Circulation, 2022, 12, e12076.	0.8	2
3900	Severe Aortic Valve Stenosis and Pulmonary Hypertension: A Systematic Review of Non-Invasive Ways of Risk Stratification, Especially in Patients Undergoing Transcatheter Aortic Valve Replacement. Journal of Personalized Medicine, 2022, 12, 603.	1.1	5
3901	Maternal and fetal outcomes of pregnant women with pulmonary arterial hypertension associated with congenital heart disease in Beijing, China: A retrospective study. Pulmonary Circulation, 2022, 12, e12079.	0.8	9
3902	Two polymorphic gene loci associated with treprostinil dose in pulmonary arterial hypertension. Pharmacogenetics and Genomics, 2022, Publish Ahead of Print, .	0.7	1
3903	Prognostic Significance of Small Pulmonary Vessel Alteration Measured by Chest Computed Tomography in Connective Tissue Diseases With Pulmonary Arterial Hypertension. Journal of Thoracic Imaging, 0, Publish Ahead of Print, .	0.8	0
3904	Clinical characteristics of pulmonary hypertension in patients with pleuroparenchymal fibroelastosis. Respiratory Investigation, 2022, 60, 543-550.	0.9	2
3905	Pulmonary Hypertension in Adult Congenital Heart Disease in Asia: A Distinctive Feature of Complex Congenital Heart Disease. Journal of the American Heart Association, 2022, 11, e022596.	1.6	9
3906	The Glycobiology of Pulmonary Arterial Hypertension. Metabolites, 2022, 12, 316.	1.3	8
3907	Mechanisms of pulmonary vascular dysfunction in pulmonary hypertension and implications for novel therapies. American Journal of Physiology - Heart and Circulatory Physiology, 2022, 322, H702-H724.	1.5	22
3908	Extracellular vesicle-mediated bidirectional communication between heart and other organs. American Journal of Physiology - Heart and Circulatory Physiology, 2022, 322, H769-H784.	1.5	19
3909	Automated vortical blood flow-based estimation of mean pulmonary arterial pressure from 4D flow MRI. Magnetic Resonance Imaging, 2022, 88, 132-141.	1.0	6
3910	Effects of pulmonary rehabilitation on cardiac magnetic resonance parameters in patients with persistent dyspnea following pulmonary embolism. IJC Heart and Vasculature, 2022, 40, 100995.	0.6	2
3911	Maternal and fetal outcomes in pregnant women with pulmonary hypertension: The impact of left heart disease. International Journal of Cardiology Congenital Heart Disease, 2022, 8, 100354.	0.2	0
3912	Pulmonary hypertension is associated with an increased incidence of cancer diagnoses. Pulmonary Circulation, 0, , .	0.8	2
3914	Recent Advances and Current Topics on Therapeutic Approaches in Pulmonary Arterial Hypertension. Nihon Shoni Junkanki Gakkai Zasshi = Pediatric Cardiology and Cardiac Surgery, 2021, 37, 173-183.	0.0	0
3915	Perioperative approach to precapillary pulmonary hypertension in non-cardiac non-obstetric surgery. European Respiratory Review, 2021, 30, 210166.	3.0	6
3916	Persistent Pulmonary Hypertension: A Look Into the Future Therapy. Cureus, 2021, 13, e20377.	0.2	1

#	Article	IF	Citations
3917	An autopsy case of pulmonary arterial hypertension in an elderly patient with multimorbidity: a case report. European Heart Journal - Case Reports, 2022, 6, ytab527.	0.3	2
3918	Hospital costs of Balloon Pulmonary Angioplasty (BPA) procedure and management for CTEPH patients: An observational study based on the French national hospital discharge database (PMSI). PLoS ONE, 2021, 16, e0260483.	1.1	2
3919	Pulmonary Hypertension and COVID-19. Hamostaseologie, 2021, , .	0.9	8
3920	Chronic thromboembolic pulmonary hypertension: anticoagulation and beyond. Hematology American Society of Hematology Education Program, 2021, 2021, 478-484.	0.9	3
3921	Multidisciplinary Team Managements and Clinical Outcomes in Patients With Pulmonary Arterial Hypertension During the Perinatal Period. Frontiers in Cardiovascular Medicine, 2021, 8, 795765.	1.1	5
3922	Application of B-Type Natriuretic Peptide in Neonatal Diseases. Frontiers in Pediatrics, 2021, 9, 767173.	0.9	4
3924	Transition from epoprostenol to selexipag in a patient with systemic sclerosis and pulmonary hypertension during the postoperative period of colon cancer surgery: A case report. Journal of Scleroderma and Related Disorders, 2022, 7, 239719832110637.	1.0	0
3925	The role of matrix metalloproteinases in patients with pulmonary hypertension: data from a prospective study. BMC Cardiovascular Disorders, 2021, 21, 607.	0.7	3
3926	The Role of Pulmonary Artery Wedge Pressure on the Incidence of Atrial Fibrillation and Atrial Tachycardias in Patients With Isolated Pre-capillary Pulmonary Hypertension. Physiological Research, 2021, , 841-849.	0.4	4
3927	Vascular involvement in chronic thromboembolic pulmonary hypertension is associated with spirometry obstructive impairment. BMC Pulmonary Medicine, 2021, 21, 407.	0.8	7
3928	Severity of precapillary pulmonary hypertension: Predictive factor. Pulmonology, 2021, , .	1.0	1
3929	Diagnosis of pulmonary hypertension associated with congenital heart disease. Part 1. Definition, classification and initial examination of patients. Rossiyskiy Vestnik Perinatologii I Pediatrii, 2021, 66, 28-37.	0.1	2
3930	Preoperative evaluation of geriatric patients undergoing liver transplantation. Current Opinion in Anaesthesiology, 2022, 35, 96-104.	0.9	2
3931	Balloon pulmonary angioplasty combined with riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension (PRACTICE study): study protocol for a randomized controlled trial. Trials, 2021, 22, 957.	0.7	1
3932	Left Pulmonary Artery Coarctation Associated with Pneumonia and Pulmonary Hypertension in a Cat. Veterinary Sciences, 2021, 8, 325.	0.6	0
3933	Effect of Xuezhikang Therapy on Expression of Pulmonary Hypertension Related miR-638 in Patients With Low HDL-C Levels. Frontiers in Pharmacology, 2021, 12, 764046.	1.6	1
3934	Tolerancia al esfuerzo en la hipertensiÃ³n pulmonar. Archivos De Bronconeumologia, 2021, 58, 388-388.	0.4	0
3935	Pulmonary Hypertension Registry of Kerala, India (PRO-KERALA): One-year outcomes. Indian Heart Journal, 2022, 74, 34-39.	0.2	5

#	Article	IF	Citations
3937	MicroRNA-146-5p Promotes Pulmonary Artery Endothelial Cell Proliferation under Hypoxic Conditions through Regulating USP3. Disease Markers, 2021, 2021, 1-8.	0.6	7
3938	Left atrium reservoir function is central in patients with rheumatic mitral stenosis. International Journal of Cardiovascular Imaging, 2022, 38, 1257-1266.	0.7	3
3939	The clinical features of pulmonary artery involvement in Takayasu arteritis and its relationship with ischemic heart diseases and infection. Arthritis Research and Therapy, 2021, 23, 293.	1.6	11
3940	Senescence Alterations in Pulmonary Hypertension. Cells, 2021, 10, 3456.	1.8	11
3941	Pulmonary Arteriovenous Pressure Gradient and Time-Averaged Mean Velocity of Small Pulmonary Arteries Can Serve as Sensitive Biomarkers in the Diagnosis of Pulmonary Arterial Hypertension: A Preclinical Study by 4D-Flow MRI. Diagnostics, 2022, 12, 58.	1.3	0
3942	Circulating sLR11 levels predict severity of pulmonary hypertension due to left heart disease. PLoS ONE, 2021, 16, e0261753.	1.1	1
3943	Atypical presentation of cardiac tamponade in pulmonary hypertension: A case report and review of the literature. Clinical Case Reports (discontinued), 2021, 9, e05218.	0.2	1
3944	Exercise rehabilitation programmes for pulmonary hypertension: a systematic review of intervention components and reporting quality. BMJ Open Sport and Exercise Medicine, 2018, 4, e000400.	1.4	8
3946	Chronic thromboembolic pulmonary hypertension and impairment after pulmonary embolism: the FOCUS study. European Heart Journal, 2022, 43, 3387-3398.	1.0	69
3947	Advances in Pulmonary Artery Involvement in Takayasuâ€™s Arteritis. Advances in Clinical Medicine, 2022, 12, 2842-2849.	0.0	0
3948	Invasive hemodynamic assessments during exercise: normal patterns and clinical value. , 2022, , 545-563.		0
3949	Pulsatile hemodynamics and ventriculaâ€“arterial interactions in the pulmonary circulation: physiologic concepts. , 2022, , 883-897.		0
3950	Epigenetics and Vascular Disease. , 2022, , 475-510.		1
3951	Hidden systolic dysfunction of the right ventricle in patients with increased pulmonary vascular resistance 3 months after COVID-19 pneumonia. Kardiologiya, 2022, 62, 16-20.	0.3	4
3952	An evolutionary machine learning for pulmonary hypertension animal model from arterial blood gas analysis. Computers in Biology and Medicine, 2022, 146, 105529.	3.9	7
3953	Successful treatment with nilotinib after bosutinib-induced pulmonary arterial hypertension recurrence following dasatinib in chronic myeloid leukemia in chronic phase. Leukemia Research Reports, 2022, 17, 100312.	0.2	1
3954	Diagnosis and Treatment of Pulmonary Arterial Hypertension. JAMA - Journal of the American Medical Association, 2022, 327, 1379.	3.8	165
3956	End-Systolic Eccentricity Index Obtained by Enhanced Computed Tomography Is a Predictor of Pulmonary Vascular Resistance in Patients with Chronic Thromboembolic Pulmonary Hypertension. Life, 2022, 12, 593.	1.1	0

#	Article	IF	Citations
3957	Distinguishing exercise intolerance in earlyâ€stage pulmonary hypertension with invasive exercise hemodynamics: Rest V_E/VCO₂ and ETCO₂ identify pulmonary vascular disease. Clinical Cardiology, 2022, 45, 742-751.	0.7	6
3958	The hemodynamic characteristics of severe chronic lung disease referred for lung transplantation. Pulmonary Circulation, 0, , .	0.8	1
3959	Percutaneous Pulmonary Angioplasty forÂPatients With Takayasu Arteritis and Pulmonary Hypertension. Journal of the American College of Cardiology, 2022, 79, 1477-1488.	1.2	8
3960	Biventricular Myocardial Strain Analysis in Patients with Pulmonary Arterial Hypertension Using Cardiac Magnetic Resonance Tissue-Tracking Technology. Journal of Clinical Medicine, 2022, 11, 2230.	1.0	2
3961	Echocardiographic Characteristics of Patients with Antiâ€synthetase Syndrome. Pulmonary Circulation, 2022, 12, e12084.	0.8	1
3962	Structural and Hemodynamic Changes of the Right Ventricle in PH-HFpEF. International Journal of Molecular Sciences, 2022, 23, 4554.	1.8	4
3963	Right Ventricular Dyssynchrony Casts New Light on the Risk Stratification and Prediction of Prognosis in Patients With Pulmonary Hypertension. Circulation Journal, 2022, , .	0.7	0
3964	Portopulmonary hypertension and the risk of high right ventricular systolic pressure in liver transplant candidates. PLoS ONE, 2022, 17, e0267125.	1.1	4
3965	The Role of the Multidisciplinary Health Care Team in the Management of Patients with Systemic Sclerosis. Journal of Multidisciplinary Healthcare, 2022, Volume 15, 815-824.	1.1	6
3966	Metacognitions in Patients With Frequent Mental Disorders After Diagnosis of Pulmonary Arterial Hypertension. Frontiers in Psychiatry, 2022, 13, 812812.	1.3	2
3967	Hemodynamics of the right ventricle and the pulmonary circulation. Applications in Engineering Science, 2022, 10, 100102.	0.5	1
3973	Echocardiographyâ€defined pulmonary hypertension is an adverse prognostic factor for newly diagnosed multiple myeloma patients. Cancer Medicine, 2022, 11, 4182-4192.	1.3	3
3974	Accuracy of echocardiographic estimations of right heart pressures in adult heart transplant recipients. Clinical Cardiology, 2022, , .	0.7	3
3975	The treatment strategy of connective tissue disease associated pulmonary arterial hypertension: Evolving into the future. , 2022, 239, 108192.		7
3976	Noninvasive Assessment of Cardiopulmonary Reserve: Toward Early Detection of Pulmonary Vascular Disease. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 398-401.	2.5	5
3977	Pulmonary vascular volume is associated with DLCO and fibrotic score in idiopathic pulmonary fibrosis: an observational study. BMC Medical Imaging, 2022, 22, 76.	1.4	5
3984	Summary 2015 ESC guidelines. Acta Cardiologica, 2016, 71, 7-13.	0.3	3
3985	A Novel Approach to Left Ventricular Filling Pressure Assessment: The Role of Hemodynamic Forces Analysis. Frontiers in Cardiovascular Medicine, 2021, 8, 704909.	1.1	5

#	Article	IF	Citations
3986	Prognostic Power of Pulmonary Arterial Compliance Is Boosted by a Hemodynamic Unloading Test With Glyceryl Trinitrate in Heart Failure Patients With Post-capillary Pulmonary Hypertension. Frontiers in Cardiovascular Medicine, 2022, 9, 838898.	1.1	0
3990	Phenotypic clusters and survival analyses in interstitial pneumonia with myositis-specific autoantibodies.. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2022, 38, e2021047.	0.2	2
3991	Echocardiographic estimate of pulmonary artery pressure in sarcoidosis patients - real world data from a multi-national study.. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2022, 38, e2021032.	0.2	2
3993	Assessment of pulmonary artery pressures by various doppler echocardiographic parameters and its correlation with cardiac catheterization in patients with pulmonary hypertension. Heart Views, 2020, 21, 263.	0.1	2
4000	Regular Risk Assessment in Pulmonary Arterial Hypertension - A Whistleblower for Hidden Disease Progression.. Acta Cardiologica Sinica, 2022, 38, 113-123.	0.1	1
4002	Pneumologie. , 2022, , 465-540.		0
4004	High-circulating gut microbiota-dependent metabolite trimethylamine N-oxide is associated with poor prognosis in pulmonary arterial hypertension. European Heart Journal Open, 2022, 2, .	0.9	12
4005	Effect of Ground-Based Walk Training in Pulmonary Hypertension. American Journal of Cardiology, 2022, 174, 172-178.	0.7	1
4006	Anxiety, Depression and Quality of Life in Pulmonary Hypertension: A Comparison of Incident and Prevalent Cases. Respiration, 2022, 101, 784-792.	1.2	2
4007	Atrioventricular plane displacement and regional function to predict outcome in pulmonary arterial hypertension. International Journal of Cardiovascular Imaging, 2022, 38, 2235-2248.	0.2	1
4008	Differentiating pulmonary hypertension associated with protein kinase inhibitors. Pulmonary Circulation, 2022, 12, .	0.8	0
4009	Long-Term Survival of Adult Patients With Atrial Septal Defect With Regards to Defect Closure and Pulmonary Hypertension. Frontiers in Cardiovascular Medicine, 2022, 9, 867012.	1.1	4
4010	Noninvasive diagnosis of pulmonary hypertension with hyperpolarised ¹²⁹Xe magnetic resonance imaging and spectroscopy. ERJ Open Research, 2022, 8, 00035-2022.	1.1	4
4011	Cardiac complications in patients with COVID-19: a systematic review. Journal of Anesthesia, Analgesia and Critical Care, 2022, 2, .	0.5	3
4012	Exercise-Induced Pulmonary Hypertension Is Associated with High Cardiovascular Risk in Patients with HIV. Journal of Clinical Medicine, 2022, 11, 2447.	1.0	1
4013	Diagnostic value of miRNA expression and right ventricular echocardiographic functional parameters for chronic thromboembolic pulmonary hypertension with right ventricular dysfunction and injury. BMC Pulmonary Medicine, 2022, 22, 171.	0.8	3
4014	Evaluation of balloon pulmonary angioplasty using lung perfusion SPECT in patients with chronic thromboembolic pulmonary hypertension. Journal of Nuclear Cardiology, 2022, 29, 3392-3400.	1.4	5
4015	Changes in Inflammatory Markers in Patients with Chronic Thromboembolic Pulmonary Hypertension Treated with Balloon Pulmonary Angioplasty. Cells, 2022, 11, 1491.	1.8	2

#	Article	IF	Citations
4016	A comparative analysis on risk of pulmonary hypertension in children with Atrio-ventricular (AV) canal defect: a multi-centre study. African Health Sciences, 2022, 22, 220-6.	0.3	0
4017	Pulmonary hypertension in pregnancy and its effects on the fetus. Seminars in Fetal and Neonatal Medicine, 2022, , 101348.	1.1	2
4018	Drug-induced pulmonary artery hypertension. Kachestvennaya Klinicheskaya Praktika, 2022, , 53-63.	0.2	1
4019	[Translated article] Exercise Tolerance in Pulmonary Hypertension. Archivos De Bronconeumologia, 2022, , .	0.4	0
4020	Echocardiographic Evaluation of Initial Ambrisentan Plus Phosphodiesterase Type 5 Inhibitor on Right Ventricular Pulmonary Artery Coupling in Severe Pulmonary Arterial Hypertension Patients. Frontiers in Cardiovascular Medicine, 2022, 9, 843606.	1.1	4
4021	Right Ventricle to Pulmonary Artery Coupling Predicts the Risk Stratification in Patients With Systemic Sclerosis-Associated Pulmonary Arterial Hypertension. Frontiers in Cardiovascular Medicine, 2022, 9, .	1.1	1
4022	Realâ€world treatment patterns, healthcare resource utilization, and cost among adults with pulmonary arterial hypertension in the United States. Pulmonary Circulation, 2022, 12, .	0.8	5
4023	CXCL10 levels in diagnosis and improved hemodynamics in patients with chronic thromboembolic pulmonary hypertension undergoing balloon pulmonary angioplasty. Pulmonary Circulation, 2022, 12, .	0.8	4
4024	Quantification of Lung Perfusion Blood Volume in Dual-Energy Computed Tomography in Patients with Pulmonary Hypertension. Life, 2022, 12, 684.	1.1	0
4025	Mortality in Pulmonary Arterial Hypertension in the Modern Era: Early Insights From the Pulmonary Hypertension Association Registry. Journal of the American Heart Association, 2022, 11, e024969.	1.6	50
4026	Doppler trans-thoracic echocardiography for detection of pulmonary hypertension in adults. The Cochrane Library, 2022, 2022, CD012809.	1.5	5
4027	Evaluation of right ventricular myocardial strain in pulmonary arterial hypertension associated with atrial septal defect by cardiac magnetic resonance feature tracking. International Journal of Cardiovascular Imaging, 2022, 38, 2035-2045.	0.2	0
4028	Prognostic value of brain natriuretic peptides in patients with pulmonary arterial hypertension: A systematic review and meta-analysis. American Heart Journal, 2022, 250, 34-44.	1.2	13
4029	Performance of the Abbott Architect Immuno-Chemiluminometric NT-proBNP Assay. Diagnostics, 2022, 12, 1172.	1.3	6
4030	Association of Right Ventricular Afterload With Atrial Fibrillation Risk in Older Adults. Chest, 2022, 162, 884-893.	0.4	2
4031	Rituximab on lung, skin, and joint involvement in patients with systemic sclerosis: A case series study and review of the literature. International Journal of Rheumatic Diseases, 2022, 25, 755-768.	0.9	6
4032	Bilateral versus unilateral balloon pulmonary angioplasty for inoperable chronic thromboembolic pulmonary hypertension. Respiratory Research, 2022, 23, 117.	1.4	2
4033	Prognostic Value of Pulmonary Artery Pulsatility Index in Right Ventricle Failure-Related Mortality in Inoperable Chronic Thromboembolic Pulmonary Hypertension. Journal of Clinical Medicine, 2022, 11, 2735.	1.0	0

#	Article	IF	Citations
4035	Maternal and Fetal Outcomes in Adult Congenital Heart Disease. Journal of Cardiothoracic and Vascular Anesthesia, 2022, , .	0.6	1
4036	Comprehensive review on novel targets and emerging therapeutic modalities for pulmonary arterial Hypertension. International Journal of Pharmaceutics, 2022, 621, 121792.	2.6	16
4037	Multiple congenital visceral abnormalities as a rare cause of pulmonary arterial hypertension. Egyptian Heart Journal, 2022, 74, 34.	0.4	0
4038	Novel Approaches to Imaging the Pulmonary Vasculature and Right Heart. Circulation Research, 2022, 130, 1445-1465.	2.0	10
4039	Prevalence and Clinical Features of Portopulmonary Hypertension in Patients With Hepatic Cirrhosis: An Echocardiographic Study. Cureus, 2022, , .	0.2	0
4040	Cardiorespiratory Adaptation to Short-Term Exposure to Altitude vs. Normobaric Hypoxia in Patients with Pulmonary Hypertension. Journal of Clinical Medicine, 2022, 11, 2769.	1.0	6
4041	Interstitial Lung Disease in Rheumatoid Arthritis: A Practical Review. Frontiers in Medicine, 2022, 9, .	1.2	14
4044	Sinais de InjÃªria CardÃaca em Pacientes PediÃ¡tricos com COVID-19 Gravemente Enfermos: Uma ExperiÃªncia de Centro Ãšnico no Brasil. Arquivos Brasileiros De Cardiologia, 2022, 118, 937-945.	0.3	1
4045	Platelet, Fibrinolytic and Other Coagulation Abnormalities in Newly-Diagnosed Patients with Chronic Thromboembolic Pulmonary Hypertension. Diagnostics, 2022, 12, 1238.	1.3	7
4046	Prevalence, Genetic Background, andÂClinical Phenotype of CongenitalÂThrombophilia in ChronicÂThromboembolic PulmonaryÂHypertension. JACC Asia, 2022, 2, 247-255.	0.5	7
4047	Changes in the Characteristics and Initial Treatments of Pulmonary Hypertension Between 2008 and 2020 in Japan. JACC Asia, 2022, 2, 273-284.	0.5	10
4048	Right or Left HeartÂFailure. JACC Asia, 2022, 2, 244-246.	0.5	0
4049	Artificial Intelligence-Enabled Electrocardiogram Improves the Diagnosis and Prediction of Mortality in Patients With Pulmonary Hypertension. JACC Asia, 2022, 2, 258-270.	0.5	7
4050	Pulmonary Hypertension Caused by Fibrosing Mediastinitis. JACC Asia, 2022, 2, 218-234.	0.5	12
4051	Impact of grip strength and gait speed on exercise tolerance in patients with pulmonary hypertension without left heart disease. Heart and Vessels, 2022, 37, 1928-1936.	0.5	1
4052	Challenges in managing a critically ill patient with decompensated Eisenmenger syndrome. BMJ Case Reports, 2022, 15, e245549.	0.2	1
4053	Anomalous origin of the left pulmonary artery from the ascending thoracic aorta and a right patent ductus arteriosus associated with pulmonary hypertension in a woman of childbearing age: an unprecedented approach. BMJ Case Reports, 2022, 15, e247070.	0.2	1
4054	Quality of Life in Patients With Pulmonary Hypertension. Clinical Nursing Research, 2023, 32, 539-548.	0.7	1

#	Article	IF	Citations
4055	The added value of right ventricular function normalized for afterload to improve risk stratification of patients with pulmonary arterial hypertension. PLoS ONE, 2022, 17, e0265059.	1.1	15
4056	Adjunct ambrisentan therapy had clinical benefits in 5 dogs with sildenafil-refractory pulmonary hypertension.. Canadian Veterinary Journal, 2022, 63, 497-503.	0.0	0
4057	ERS International Congress 2021: highlights from the Pulmonary Vascular Diseases Assembly. ERJ Open Research, 2022, 8, 00665-2021.	1.1	2
4058	Association of residual pulmonary hypertension with survival after pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension. Pulmonary Circulation, 2022, 12, .	0.8	7
4059	Diagnostic Performance of Pulsed Doppler Ultrasound of the Common Femoral Vein to Detect Elevated Right Atrial Pressure in Pulmonary Hypertension. Journal of Cardiovascular Translational Research, 2023, 16, 141-151.	1.1	2
4060	Effects of sildenafil on symptoms and exercise capacity for heart failure with reduced ejection fraction and pulmonary hypertension (the <scp>SilHF</scp> study): a randomized placeboâ€controlled multicentre trial. European Journal of Heart Failure, 2022, 24, 1239-1248.	2.9	16
4061	A systematic review with meta-analysis of biomarkers for detection of pulmonary arterial hypertension. ERJ Open Research, 2022, 8, 00009-2022.	1.1	5
4062	Pulmonary Artery Pressure-Guided Telemonitoring Reduced Pulmonary Artery Pressure but Did Not Result in Higher Doses of Guideline-Directed Medical Therapyâ€“Observations from an Advanced Elderly German Heart Failure Cohort. Life, 2022, 12, 766.	1.1	0
4063	Beneficial Effects of Pulmonary Vasodilators on Pre-Capillary Pulmonary Hypertension in Patients with Chronic Kidney Disease on Hemodialysis. Life, 2022, 12, 780.	1.1	0
4064	Functional Alterations Due to COVID-19 Lung Lesionsâ€”Lessons From a Multicenter V/Q Scan-Based Registry. Clinical Nuclear Medicine, 2022, 47, e540-e547.	0.7	1
4065	Subgroup Analysis in Pulmonary Hypertension-Specific Therapy Clinical Trials: A Systematic Review. Journal of Personalized Medicine, 2022, 12, 863.	1.1	2
4066	miR-155-5p regulates hypoxia-induced pulmonary artery smooth muscle cell function by targeting PYGL. Bioengineered, 2022, 13, 12985-12997.	1.4	7
4067	Right heart failure: A narrative review for emergency clinicians. American Journal of Emergency Medicine, 2022, 58, 106-113.	0.7	7
4068	Complications of balloon pulmonary angioplasty for inoperable chronic thromboembolic pulmonary hypertension: Impact on the outcome. Journal of Heart and Lung Transplantation, 2022, 41, 1086-1094.	0.3	11
4069	Cardiac Adaptation to Prolonged High Altitude Migration Assessed by Speckle Tracking Echocardiography. Frontiers in Cardiovascular Medicine, 2022, 9, .	1.1	3
4070	The impact of atrial fibrillation and atrial tachycardias on the hemodynamic status of patients with pulmonary hypertension. Europace, 2022, 24, .	0.7	0
4071	Scleroderma-specific autoantibodies: Should they be included in the diagnostic work-up for SjÃ¶gren's syndrome?. Seminars in Arthritis and Rheumatism, 2022, 55, 152026.	1.6	4
4072	Left ventricular diastolic dysfunction in systemic sclerosis: Clinical, immunological and survival differences in the Spanish RESCLE registry. Seminars in Arthritis and Rheumatism, 2022, 55, 152033.	1.6	7

#	Article	IF	Citations
4073	Non-compact right ventricular myocardium â€“ diagnostic and clinical features: A review. Terapevticheskii Arkhiv, 2022, 94, 558-564.	0.2	0
4074	Antibody response to BNT162b2 SARS-CoV-2 mRNA vaccine in adult patients with systemic sclerosis. Clinical Rheumatology, 2022, 41, 2755-2763.	1.0	6
4075	Description of Two New Cases of AQP1 Related Pulmonary Arterial Hypertension and Review of the Literature. Genes, 2022, 13, 927.	1.0	5
4076	Assessment of pulmonary arterial stiffness in patients with systemic sclerosis without overt pulmonary hypertension. International Journal of Cardiovascular Imaging, 2022, 38, 2191-2197.	0.2	0
4077	An algorithm to identify cases of pulmonary arterial hypertension from the electronic medical record. Respiratory Research, 2022, 23, .	1.4	5
4078	Comparison of PCWP and LVEDP Measurements in Patients with Severe Aortic Stenosis Undergoing TAVIâ€"Same Same but Different?. Journal of Clinical Medicine, 2022, 11, 2978.	1.0	1
4079	Adenoviral vectors for cardiovascular gene therapy applications: a clinical and industry perspective. Journal of Molecular Medicine, 2022, 100, 875-901.	1.7	8
4080	Evaluation of pulmonary arterial stiffness and comparison with right ventricular functions in patients with cirrhosis preparing for liver transplantation. Journal of Clinical Ultrasound, 2022, 50, 749-755.	0.4	2
4081	Eurasian guidelines for the diagnosis and treatment of pulmonary hypertension associated with congenital heart defects in adults (2021). Eurasian Heart Journal, 2022, , 6-70.	0.2	1
4082	Current status and barriers in pulmonary hypertension care delivery in India: A qualitative analysis. Pulmonary Circulation, 2022, 12, .	0.8	1
4083	Chronic thromboembolic pulmonary hypertension: A 10-year analysis from a Portuguese referral center. Revista Portuguesa De Cardiologia, 2022, 41, 741-748.	0.2	1
4084	Cannabidiol Improves Antioxidant Capacity and Reduces Inflammation in the Lungs of Rats with Monocrotaline-Induced Pulmonary Hypertension. Molecules, 2022, 27, 3327.	1.7	11
4085	Association between Large Arteries Diameter and Heart Function in Subjects Free of Cardiovascular Diseases. Journal of Personalized Medicine, 2022, 12, 889.	1.1	2
4086	Cell death regulation by MAMs: from molecular mechanisms to therapeutic implications in cardiovascular diseases. Cell Death and Disease, 2022, 13, .	2.7	20
4087	Imbalanced prostanoid release mediates cigarette smoke-induced human pulmonary artery cell proliferation. Respiratory Research, 2022, 23, .	1.4	9
4088	Invasive Hemodynamic Assessment and Procedural Success of Transcatheter Tricuspid Valve Repairâ€"Important Factors for Right Ventricular Remodeling and Outcome. Frontiers in Cardiovascular Medicine, 2022, 9, .	1.1	7
4089	Managing pulmonary arterial hypertension: how to select and facilitate successful transplantation. Current Opinion in Organ Transplantation, 2022, 27, 169-176.	0.8	2
4090	Risk stratification in patients with pulmonary arterial hypertension at the time of listing for lung transplantation. Journal of Heart and Lung Transplantation, 2022, 41, 1285-1293.	0.3	6

#	Article	IF	Citations
4091	AMPK and the Challenge of Treating Hypoxic Pulmonary Hypertension. International Journal of Molecular Sciences, 2022, 23, 6205.	1.8	5
4092	Combined pre- and post-capillary pulmonary hypertension in left heart disease. Heart Failure Reviews, 2023, 28, 137-148.	1.7	7
4093	Pleuroparenchymal fibroelastosis in rheumatoid arthritis-associated interstitial lung disease. Respiratory Research, 2022, 23, .	1.4	5
4094	Computed tomography evaluation of pediatric pulmonary hypertension. Pediatric Radiology, 2022, 52, 1888-1894.	1.1	1
4095	A Brief Review on Gender Differences in Mexican-Mestizo Patients with Pulmonary Arterial Hypertension (PAH) at a Tertiary-Level Hospital. Current Problems in Cardiology, 2022, 47, 101275.	1.1	2
4096	To be or not to beâ€¦ treated with initial combination therapy, that is the (PAH) question. European Respiratory Journal, 2022, 59, 2200390.	3.1	2
4097	Clinically important changes in right ventricular volume and function in pulmonary arterial hypertension assessed with cardiac magnetic resonance imaging. Pulmonary Circulation, 2022, 12, .	0.8	3
4098	Cardiovascular Regulation During Acute Gravitational Changes with Exhaling on Exertion. International Journal of Sports Medicine, 0, , .	0.8	0
4099	Potential role of conventional and speckle-tracking echocardiography in the screening of structural and functional cardiac abnormalities in elderly individuals: Baseline echocardiographic findings from the LOOP study. PLoS ONE, 2022, 17, e0269475.	1.1	2
4100	Portopulmonary Hypertension: A Review of the Current Literature. Heart Lung and Circulation, 2022, , .	0.2	4
4101	Basic Hemodynamic Parameters. , 2022, , 463-474.		1
4102	Prognostic value of MELD-XI and MELD-Albumin scores in double valve replacement. Cardiology Plus, 2022, 7, 39-47.	0.2	1
4103	The effect of main pulmonary artery diameter on the prognosis of COVID-19 patients in the ICU. Journal of Health Sciences and Medicine, 2022, 5, 778-781.	0.0	0
4104	Decreased Peak Left Atrial Longitudinal Strain Is Associated with Persistent Pulmonary Hypertension Associated with Left Heart Disease. Journal of Clinical Medicine, 2022, 11, 3510.	1.0	0
4105	Pregnancy in Pulmonary Arterial Hypertension: A Multidisciplinary Approach. Journal of Cardiovascular Development and Disease, 2022, 9, 196.	0.8	6
4106	Profiles and treatment patterns of patients with pulmonary arterial hypertension on monotherapy at experienced centres. ESC Heart Failure, 2022, 9, 2873-2885.	1.4	5
4107	Increased Methyl-CpG-Binding Domain Protein 2 Promotes Cigarette Smoke-Induced Pulmonary Hypertension. Frontiers in Oncology, 0, 12, .	1.3	0
4108	Role of <scp>miR</scp>â€21â€5p/<scp>FilGAP</scp> axis in estradiol alleviating the progression of monocrotalineâ€induced pulmonary hypertension. Animal Models and Experimental Medicine, 2022, 5, 217-226.	1.3	10

#	Article	IF	Citations
4109	Pulmonary artery acceleration time accuracy for systolic pulmonary artery pressure estimation in critically ill patients. Ultrasound Journal, 2022, 14, .	1.3	6
4110	ISHLT consensus statement: Perioperative management of patients with pulmonary hypertension and right heart failure undergoing surgery. Journal of Heart and Lung Transplantation, 2022, 41, 1135-1194.	0.3	17
4111	Apela gene therapy alleviates pulmonary hypertension in rats. FASEB Journal, 2022, 36, .	0.2	3
4112	Systemic Blood Predictors of Elevated Pulmonary Artery Pressure Assessed by Non-invasive Echocardiography After Acute Exposure to High Altitude: A Prospective Cohort Study. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	2
4113	Non-Invasive Estimation of Right Atrial Pressure Using a Semi-Automated Echocardiographic Tool for Inferior Vena Cava Edge-Tracking. Journal of Clinical Medicine, 2022, 11, 3257.	1.0	3
4114	Pulmonary arterial hypertension. Medicina ClÃnica (English Edition), 2022, 158, 622-629.	0.1	4
4115	Iron deficiency and pulmonary arterial hypertension. Nutrition in Clinical Practice, 0, , .	1.1	1
4116	The Potential Application and Promising Role of Targeted Therapy in Pulmonary Arterial Hypertension. Biomedicines, 2022, 10, 1415.	1.4	4
4117	Progress of Pathogenesis in Pediatric Multifocal Atrial Tachycardia. Frontiers in Pediatrics, 0, 10, .	0.9	3
4118	Oxidative Stress and Antioxidative Therapy in Pulmonary Arterial Hypertension. Molecules, 2022, 27, 3724.	1.7	16
4119	Normalization of Four Different Types of Pulmonary Hypertension After Atrial Septal Defect Closure. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	0
4120	The role of serial right heart catheterization in risk stratification and management of pulmonary arterial hypertension. Expert Review of Cardiovascular Therapy, 2022, 20, 543-547.	0.6	3
4121	Noninvasively predicting pulmonary vascular resistance in chronic thromboembolic pulmonary hypertension. Pulmonary Circulation, 0, , .	0.8	0
4122	Alterations in right ventricular mechanics in patients with Behcetâ€™s disease. International Journal of Cardiovascular Imaging, 0, , .	0.2	0
4123	The frequency of pulmonary hypertension in chronic obstructive pulmonary disease of geriatric patients: a narrative literature review. The Egyptian Journal of Internal Medicine, 2022, 34, .	0.3	1
4124	Continuous cardiac monitoring in a patient with terminal pulmonary hypertension and eventual bilateral lung transplantation. BMJ Case Reports, 2022, 15, e248304.	0.2	0
4125	Whole Exome Sequencing of Patients With Heritable and Idiopathic Pulmonary Arterial Hypertension in Central Taiwan. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	3
4126	Immunosuppressive therapy in patients with connective tissue diseaseâ€associated pulmonary arterial hypertension: A systematic review. International Journal of Rheumatic Diseases, 2022, 25, 982-990.	0.9	7

#	Article	IF	Citations
4127	Telehealth: A winning weapon to face the COVID-19 outbreak for patients with pulmonary arterial hypertension. Vascular Pharmacology, 2022, 145, 107024.	1.0	2
4128	Porto-pulmonary arterial hypertension: Translation of pathophysiological concepts to the bedside. Vascular Pharmacology, 2022, 145, 107022.	1.0	3
4131	Evaluation of Lung Glucose Uptake with Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography/CT in Patients with Pulmonary Arterial Hypertension and Pulmonary Hypertension Due to Left Heart Disease. Annals of Nuclear Cardiology, 2022, , .	0.0	0
4134	Eurasian guidelines for the diagnosis and treatment of pulmonary hypertension associated with congenital heart defects in adults (2021). Eurasian Heart Journal, 2022, , 6-70.	0.2	0
4135	PULMONARY ARTERY INFLAMMATION IN NON-SPECIFIC AORTOARTERITIS. Review. Medical Science of Ukraine (MSU), 2022, 18, 55-68.	0.0	0
4136	Cardiac Effort to Compare Clinic and Remote 6-Minute Walk Testing in Pulmonary Arterial Hypertension. Chest, 2022, 162, 1340-1348.	0.4	4
4137	Relationship between ectopic calcifications and bone fragility depicted on computed tomography scan in 70 patients with systemic sclerosis. Journal of Scleroderma and Related Disorders, 0, , 239719832211044.	1.0	1
4138	Mortality risk factors in patients on waiting list for lung transplantation between 2005 and 2018: A single institutional experience. Journal of the Formosan Medical Association, 2022, , .	0.8	1
4139	Echocardiographic estimation of pulmonary hypertension in COVID-19Âpatients. Netherlands Heart Journal, 2022, 30, 510-518.	0.3	5
4140	Pulmonary Hypertension in Remote and Disadvantaged Population: Overcoming Unique Challenges for Improved Outcomes. Internal Medicine Journal, 0, , .	0.5	0
4141	Ventricular depolarization and repolarization variability in children with type 1 diabetes mellitus. Pediatrics International, 2022, 64, .	0.2	0
4142	Prognostic impact of follow-up pulmonary vascular resistance in pulmonary arterial hypertension. Open Heart, 2022, 9, e002054.	0.9	3
4143	Incidence and Risk Factors of Pulmonary Hypertension After Venous Thromboembolism: An Analysis of a Large Health Care Database. Journal of the American Heart Association, 2022, 11, .	1.6	7
4144	Exercise Rehabilitation Training in Patients With Pulmonary Hypertension: A Review. Heart Lung and Circulation, 2022, 31, 1341-1348.	0.2	2
4145	Pulmonary thromboembolic events in COVIDâ€19â€”A systematic literature review. Pulmonary Circulation, 2022, 12, .	0.8	9
4146	Post-Pulmonary Embolism Syndrome and Functional Outcomes after Acute Pulmonary Embolism. Seminars in Thrombosis and Hemostasis, 2023, 49, 848-860.	1.5	8
4147	Quantitative Assessment of Regional Pulmonary Transit Times in Pulmonary Hypertension. Journal of Magnetic Resonance Imaging, 0, , .	1.9	2
4148	Physical Activity in Pulmonary Arterial Hypertension during Pandemic COVID-19 and the Potential Impact of Mental Factors. International Journal of Environmental Research and Public Health, 2022, 19, 8343.	1.2	2

#	Article	IF	Citations
4149	Indian Guidelines on Nebulization Therapy. Indian Journal of Tuberculosis, 2022, , .	0.3	2
4150	Normal Echocardiographic Reference Values of the Right Ventricular to Left Ventricular Endsystolic Diameter Ratio and the Left Ventricular Endsystolic Eccentricity Index in Healthy Children and in Children With Pulmonary Hypertension. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	3
4151	Dynamics of 6-Minute Walk Distance as a Predictor of Efficiency Specific Pulmonary Vasodilators. Rational Pharmacotherapy in Cardiology, 2022, 18, 342-349.	0.3	1
4152	Main pulmonary artery diameter in combination with cardiovascular biomarkers: new possibilities to identify pulmonary hypertension in patients with severe aortic valve stenosis. Minerva Medica, 2024, 114, .	0.3	4
4153	Clinical assessment for pulmonary hypertension in interstitial lung disease. Internal Medicine Journal, 2023, 53, 1415-1422.	0.5	0
4155	Five year risk assessment and treatment patterns in patients with chronic thromboembolic pulmonary hypertension. ESC Heart Failure, 0, , .	1.4	1
4156	Direct oral anticoagulants in patients with chronic thromboembolic pulmonary hypertension and the presence of recent thrombus during pulmonary endarterectomy. Pulmonary Circulation, 2022, 12, .	0.8	9
4157	Drug-Drug Interactions in the Management of Patients With Pulmonary Arterial Hypertension. Chest, 2022, 162, 1360-1372.	0.4	10
4158	Prevalence of potential drugâ€drug interactions with disease specific treatments in patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension â€“ a registry study. Pulmonary Circulation, 0, , .	0.8	0
4159	Reversible Cardiac Hypertrophy in Pulmonary Arterial Hypertension Treated With High-Dose Epoprostenol. CJC Open, 2022, 4, 816-819.	0.7	1
4160	Distinct cardiovascular phenotypes are associated with prognosis in systemic sclerosis: a cardiovascular magnetic resonance study. European Heart Journal Cardiovascular Imaging, 2023, 24, 463-471.	0.5	7
4161	Long-Term Safety, Tolerability and Survival in Patients with Pulmonary Arterial Hypertension Treated with Macitentan: Results from the SERAPHIN Open-Label Extension. Advances in Therapy, 2022, 39, 4374-4390.	1.3	2
4162	Elucidating the Clinical Implications and Pathophysiology of Pulmonary Hypertension in Heart Failure With Preserved Ejection Fraction: A Call to Action: A Science Advisory From the American Heart Association. Circulation, 2022, 146, .	1.6	13
4163	Validation of the New Pediatric Pulmonary Hypertension Risk Score by <scp>CMR</scp> and Speckle Tracking Echocardiography. European Journal of Clinical Investigation, 0, , .	1.7	1
4164	Development of an Electronic Frailty Index for Predicting Mortality and Complications Analysis in Pulmonary Hypertension Using Random Survival Forest Model. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	4
4165	Cardiac risk stratification of the liver transplant candidate: A comprehensive review. World Journal of Transplantation, 2022, 12, 142-156.	0.6	4
4166	Demonstration of subclinical involvement with pulmonary arterial stiffness in patients with systemic sclerosis without overt pulmonary hypertension. International Journal of Cardiovascular Imaging, 2022, 38, 1813-1814.	0.2	0
4167	Right ventricular pressure overload related to residual thrombotic burden in patients 1Âyear after acute pulmonary embolism: From the Nagoya PE study. Thrombosis Research, 2022, 216, 113-119.	0.8	0

#	Article	IF	Citations
4168	Hotspots and frontiers in pulmonary arterial hypertension research: a bibliometric and visualization analysis from 2011 to 2020. Bioengineered, 2022, 13, 14667-14680.	1.4	11
4169	Prognostic Implications of the Novel Pulmonary Hypertension Definition in Patients with Aortic Stenosis after Transcatheter Valve Replacement. Journal of Clinical Medicine, 2022, 11, 4279.	1.0	3
4170	Long-term outcomes in distinct phenogroups of patients with primary mitral regurgitation undergoing valve surgery. Heart, 2023, 109, 305-313.	1.2	5
4171	Right ventricular strain related to pulmonary artery pressure predicts clinical outcome in patients with pulmonary arterial hypertension. European Heart Journal Cardiovascular Imaging, 2023, 24, 635-642.	0.5	15
4172	Prognostic meaning of right ventricular function and output reserve in patients with systemic sclerosis. Arthritis Research and Therapy, 2022, 24, .	1.6	4
4173	Efficacy and safety of edoxaban in patients with chronic thromboembolic pulmonary hypertension: protocol for a multicentre, randomised, warfarin-controlled, parallel group trial - KABUKI trial. BMJ Open, 2022, 12, e061225.	0.8	4
4174	INSPIRE: Safety and Tolerability of Inhaled LIQ861 (Treprostinil) in Pulmonary Arterial Hypertension (PAH). Pulmonary Circulation, 0, , .	0.8	2
4175	Cuando la simple comunicaciÃ³n interauricular no es tan simple. Revista De EcocardiografÃa PrÃ¡ctica Y Otras TÃ©cnicas De Imagen CardÃaca, 2016, , 39-43.	0.0	0
4176	Impact of Estimated Plasma Volume Status on Mortality in Right Heart Failure Patients: A Retrospective Cohort Study in Indonesia. Global Heart, 2022, 17, .	0.9	1
4177	Right ventricle remodeling in chronic thromboembolic pulmonary hypertension. Journal of Translational Internal Medicine, 2022, 10, 125-133.	1.0	8
4178	Predictors of pulmonary hypertension after atrial septal defect closure: Impact of atrial fibrillation. Turkish Journal of Thoracic and Cardiovascular Surgery, 2022, 30, 344-353.	0.2	1
4179	The diagnostic challenge of patients with anti-U1-RNP antibodies. Rheumatology International, 2023, 43, 509-521.	1.5	6
4180	Mixed venous oxygen tension is a crucial prognostic factor in pulmonary hypertension: a retrospective cohort study. BMC Pulmonary Medicine, 2022, 22, .	0.8	4
4181	Altered Lung Microbiome and Metabolome Profile in Children With Pulmonary Arterial Hypertension Associated With Congenital Heart Disease. Frontiers in Medicine, 0, 9, .	1.2	6
4182	Kynurenine metabolites predict survival in pulmonary arterial hypertension: A role for IL-6/IL-6RÎ±. Scientific Reports, 2022, 12, .	1.6	6
4183	Bioactive adrenomedullin for assessment of venous congestion in heart failure. ESC Heart Failure, 2022, 9, 3543-3555.	1.4	9
4184	Using deep learning to diagnose pulmonary hypertension. European Heart Journal Cardiovascular Imaging, 2022, 23, 1457-1458.	0.5	1
4185	Clinical Characteristics and Transplant-Free Survival Across the Spectrum of Pulmonary Vascular Disease. Journal of the American College of Cardiology, 2022, 80, 697-718.	1.2	22

#	Article	IF	Citations
4186	Optical coherence tomography angiography findings in patients with chronic thromboembolic pulmonary hypertension.. Retina, 2022, Publish Ahead of Print, .	1.0	3
4187	Metabolic reprogramming: A novel metabolic model for pulmonary hypertension. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	3
4188	2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. European Respiratory Journal, 2023, 61, 2200879.	3.1	445
4189	Preoperative Transthoracic Echocardiography Predicts Cardiac Complications in Elderly Patients with Coronary Artery Disease Undergoing Noncardiac Surgery. Clinical Interventions in Aging, 0, Volume 17, 1151-1161.	1.3	2
4190	Case Report: Clinical characteristics and genetic analysis of two patients with hereditary hemorrhagic telangiectasia. Frontiers in Genetics, 0, 13, .	1.1	0
4191	Farnesyl diphosphate synthase regulated endothelial proliferation and autophagy during rat pulmonary arterial hypertension induced by monocrotaline. Molecular Medicine, 2022, 28, .	1.9	5
4192	2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. European Heart Journal, 2022, 43, 3618-3731.	1.0	1,033
4193	2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery. European Heart Journal, 2022, 43, 3826-3924.	1.0	298
4194	Long non-coding RNAs: Modulators of phenotypic transformation in vascular smooth muscle cells. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	3
4195	Bibliometric study of soluble guanylate cyclase stimulators in cardiovascular research based on web of science from 1992 to 2021. Frontiers in Pharmacology, 0, 13, .	1.6	0
4196	Management of COVID-19 in Patients with Pulmonary Arterial Hypertension. Heart Failure Clinics, 2023, 19, 107-114.	1.0	4
4197	Pregnancy Considerations in the Multidisciplinary Care of Patients with Pulmonary Arterial Hypertension. Journal of Cardiovascular Development and Disease, 2022, 9, 260.	0.8	2
4198	Microvasculopathy Evaluated by Dual-Energy Computed Tomography in Patients with Chronic Thromboembolic Pulmonary Hypertension and Pulmonary Arterial Hypertension. Life, 2022, 12, 1232.	1.1	0
4199	Long-Term Study on Therapeutic Strategy for Treatment of Eisenmenger Syndrome Patients: A Case Series Study. Children, 2022, 9, 1217.	0.6	1
4201	Effects of remote haemodynamicâ€guided heart failure management in patients with different subtypes of pulmonary hypertension: insights from the <scp>MEMSâ€HF</scp> study. European Journal of Heart Failure, 2022, 24, 2320-2330.	2.9	14
4202	Echocardiographic assessment and clinical implication of functional tricuspid regurgitation in heart failure with reduced or preserved ejection fraction (ECLIPSE-HF). International Journal of Cardiovascular Imaging, 2022, 38, 2581-2591.	0.2	1
4204	CircGSAP regulates the cell cycle of pulmonary microvascular endothelial cells via the miR-942-5p sponge in pulmonary hypertension. Frontiers in Cell and Developmental Biology, 0, 10, .	1.8	5
4205	Variables associated with pulmonary hypertension screened by echocardiography in chronic myeloid leukemia patients on dasatinib therapy. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	0

#	Article	IF	Citations
4206	Association Between Circulating CD4+ T Cell Methylation Signatures of Network-Oriented SOCS3 Gene and Hemodynamics in Patients Suffering Pulmonary Arterial Hypertension. Journal of Cardiovascular Translational Research, 2023, 16, 17-30.	1.1	24
4208	The prevalence and survival of pulmonary hypertension due to left heart failure: A retrospective analysis of a multicenter prospective cohort study. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	2
4209	Use of sixâ€minute walking test to predict peak oxygen consumption in pulmonary vascular disease. Pulmonary Circulation, 2022, 12, .	0.8	2
4210	Frequency and predictors for chronic thromboembolic pulmonary hypertension after a first unprovoked pulmonary embolism: Results from PADIS studies. Journal of Thrombosis and Haemostasis, 2022, 20, 2850-2861.	1.9	5
4211	Impact of borderline pulmonary hypertension due to left heart failure on mortality in a multicenter registry study: A 3-year survivorship analysis. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	0
4212	The 6-min walk test as a primary end-point in interstitial lung disease. European Respiratory Review, 2022, 31, 220087.	3.0	16
4213	Adjusting Overall Survival Estimates of Macitentan in Pulmonary Arterial Hypertension After Treatment Switching: Results from the SERAPHIN Study. Advances in Therapy, 2022, 39, 4346-4358.	1.3	1
4214	Balloon pulmonary angioplasty versus riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension (RACE): a multicentre, phase 3, open-label, randomised controlled trial and ancillary follow-up study. Lancet Respiratory Medicine,the, 2022, 10, 961-971.	5.2	73
4215	Left atrial acceleration factor as a magnetic resonance 4D flow measure of mean pulmonary artery wedge pressure in pulmonary hypertension. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	3
4216	ER-stress-induced secretion of circulating glucose-regulated protein 78kDa (GRP78) ameliorates pulmonary artery smooth muscle cell remodelling. Cell Stress and Chaperones, 2022, 27, 561-572.	1.2	4
4217	Vasoreactive phenotype in children with pulmonary arterial hypertension and syncope. ERJ Open Research, 0, , 00223-2022.	1.1	0
4218	An explorative metabolomic analysis of the endothelium in pulmonary hypertension. Scientific Reports, 2022, 12, .	1.6	2
4219	Balloon pulmonary angioplasty versus riociguat in inoperable chronic thromboembolic pulmonary hypertension (MR BPA): an open-label, randomised controlled trial. Lancet Respiratory Medicine,the, 2022, 10, 949-960.	5.2	36
4220	The Variation in the Diastolic Period with Interventricular Septal Displacement and Its Relation to the Right Ventricular Function in Pulmonary Hypertension: A Preliminary Cardiac Magnetic Resonance Study. Diagnostics, 2022, 12, 1970.	1.3	1
4221	Cardiopulmonary exercise test: A 20-year (2002-2021) bibliometric analysis. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	4
4222	Veno-Arterial Extracorporeal Membrane Oxygenation Rescue in a Patient With Pulmonary Hypertension Presenting for Revision Total Hip Arthroplasty: A Case Report and Narrative Review. Cureus, 2022, , .	0.2	0
4223	Chronic Thromboembolic Pulmonary Hypertension: An Observational Study. Medicina (Lithuania), 2022, 58, 1094.	0.8	8
4224	Indications for Lung Transplantation and Patient Selection. Journal of Chest Surgery, 2022, 55, 255-264.	0.2	0

#	Article	IF	Citations
4225	Incremental value of preoperative right ventricular function in predicting moderate to severe acute kidney injury after heart transplantation. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	2
4226	Glycated ACE2 reduces anti-remodeling effects of renin-angiotensin system inhibition in human diabetic hearts. Cardiovascular Diabetology, 2022, 21, .	2.7	10
4227	Incremental prognostic value of left atrial strain in patients with heart failure. ESC Heart Failure, 2022, 9, 3942-3953.	1.4	7
4228	Medications for the treatment of pulmonary arterial hypertension: a systematic review and network meta-analysis. European Respiratory Review, 2022, 31, 220036.	3.0	9
4229	Chitinase 3 like 1 contributes to the development of pulmonary vascular remodeling in pulmonary hypertension. JCI Insight, 2022, 7, .	2.3	8
4230	Right Heart Catheterization (RHC): A Comprehensive Review of Provocation Tests and Hepatic Hemodynamics in Patients With Pulmonary Hypertension (PH). Current Problems in Cardiology, 2022, 47, 101351.	1.1	7
4232	The Impact of Pulmonary Hypertension on the Clinical Outcomes of Acute Myocardial Infarction after Percutaneous Coronary Intervention. Korean Journal of Medicine, 2022, 97, 257-270.	0.1	0
4233	Pulmonary arterial hypertension sensitive to calcium channel blocker, but not advanced pulmonary hypertension treatment: a case report. European Heart Journal - Case Reports, 2022, 6, .	0.3	1
4234	Cor Pulmonale Secondary to Severe Pulmonary Hypertension As the First Manifestation of Graves' Disease. Cureus, 2022, , .	0.2	0
4235	Usefulness of Pâ€wave peak time as an electrocardiographic parameter in predicting left ventricular diastolic dysfunction in patients with mitral regurgitation. Annals of Noninvasive Electrocardiology, 0, , .	0.5	1
4236	Expert consensus on liver transplantation perioperative evaluation and rehabilitation for acute-on-chronic liver failure. Liver Research, 2022, , .	0.5	0
4237	Maternal and Fetal Outcomes in Pregnant Women with Pulmonary Arterial Hypertension: A Single-Center Experience and Review of Current Literature. , 0, , .		2
4238	Computational models of ventricular mechanics and adaptation in response to right-ventricular pressure overload. Frontiers in Physiology, 0, 13, .	1.3	3
4239	Transcatheter mitral valve implantation versus conventional redo surgery for degenerated mitral valve prostheses and rings in a multicenter registry. Journal of Thoracic and Cardiovascular Surgery, 2024, 167, 957-964.	0.4	4
4240	Heart Failure with Preserved Ejection Fraction and Pulmonary Hypertension: Focus on Phosphodiesterase Inhibitors. Pharmaceuticals, 2022, 15, 1024.	1.7	1
4241	Riociguat and balloon pulmonary angioplasty improve prognosis in patients with inoperable chronic thromboembolic pulmonary Hypertension. Journal of Heart and Lung Transplantation, 2023, 42, 134-139.	0.3	17
4242	Recent advancements in pediatric cardiopulmonary bypass technology for better outcomes of pediatric cardiac surgery. The Cardiothoracic Surgeon, 2022, 30, .	0.2	2
4243	Riociguat in pulmonary hypertension and heart failure with preserved ejection fraction: the haemoDYNAMIC trial. European Heart Journal, 2022, 43, 3402-3413.	1.0	31

#	Article	IF	Citations
4244	Symptomatic and severe pulmonary hypertension due to hyperthyroidism. BMJ Case Reports, 2022, 15, e251120.	0.2	0
4245	The prognostic value of right ventricular ejection fraction by cardiovascular magnetic resonance in heart failure: A systematic review and meta-analysis. International Journal of Cardiology, 2022, 368, 94-103.	0.8	3
4247	Update on balloon pulmonary angioplasty for treatment of chronic thromboembolic pulmonary hypertension. Current Opinion in Pulmonary Medicine, 2022, 28, 369-374.	1.2	3
4248	Standardized incidence ratios and risk factors for cancer in patients with systemic sclerosis: Data from the Spanish Scleroderma Registry (RESCLE). Autoimmunity Reviews, 2022, 21, 103167.	2.5	7
4249	Genetic and functional analyses of TBX4 reveal novel mechanisms underlying pulmonary arterial hypertension. Journal of Molecular and Cellular Cardiology, 2022, 171, 105-116.	0.9	8
4250	Efficacy and safety of sequential combination therapy for pulmonary arterial hypertension: A meta-analysis of Randomized-Controlled Trials. Pulmonary Pharmacology and Therapeutics, 2022, 76, 102144.	1.1	1
4251	Use of Semiconductor Gas Sensors Made from Nanomaterials in Medicine. Journal of Contemporary Physics, 2022, 57, 263-273.	0.1	0
4252	Hereditary Hemorrhagic Telangiectasia: Genetics, Pathophysiology, Diagnosis, and Management. Journal of Clinical Medicine, 2022, 11, 5245.	1.0	9
4254	Cardiac and Pulmonary Vascular Dysfunction in Vitamin Dâ€“Deficient Bmpr2-Mutant Rats. American Journal of Respiratory Cell and Molecular Biology, 2022, 67, 402-405.	1.4	2
4255	Chronic Thromboembolic Pulmonary Hypertension in Females: Clinical Features and Survival. Journal of Cardiovascular Development and Disease, 2022, 9, 308.	0.8	2
4256	Sodium-glucose cotransporter-2 (SGLT2) expression in diabetic and non-diabetic failing human cardiomyocytes. Pharmacological Research, 2022, 184, 106448.	3.1	20
4257	A novel echocardiographic estimate of pulmonary vascular resistance employing the hydraulic analogy to Ohmâ€™s law. IJC Heart and Vasculature, 2022, 42, 101121.	0.6	0
4258	Pulmonary pressure recovery in idiopathic, hereditary and drug and toxin-induced pulmonary arterial hypertension: determinants and clinical impact. Vascular Pharmacology, 2022, 146, 107099.	1.0	4
4259	The potential benefit of rooibos (Aspalathus linearis) in pulmonary arterial hypertension: A short review. South African Journal of Botany, 2022, 150, 840-844.	1.2	3
4260	Pulmonary artery pressures and right ventricular dimensions of post-COVID-19 patients without previous significant cardiovascular pathology. Heart and Lung: Journal of Acute and Critical Care, 2023, 57, 75-79.	0.8	1
4261	A Comprehensive Review of Mechanical Circulatory Support Devices. Heart International, 2022, 16, 37.	0.4	16
4262	Middle to long-term outcomes of surgical repair for atrioventricular septal defect: a single-center study. Journal of Thoracic Disease, 2022, .	0.6	1
4263	Exercise for Systemic and Pulmonary Arterial Hypertension: Killing Two Birds with One Stone. Updates in Hypertension and Cardiovascular Protection, 2022, , 175-190.	0.1	0

#	Article	IF	Citations
4264	Treatment of advanced heart failure in adults with congenital heart disease: a narrative review and clinical cases. Cardiovascular Diagnosis and Therapy, 2022, 12, 727-743.	0.7	1
4265	NOTCH3 Mutations and CADASIL Phenotype in Pulmonary Arterial Hypertension Associated with Congenital Heart Disease. Congenital Heart Disease, 2022, .	0.0	0
4266	Intra-Airway Gene Delivery for Pulmonary Hypertension in Rodent Models. Methods in Molecular Biology, 2022, , 263-278.	0.4	0
4267	Long-term course of pulmonary arterial hypertension in adults with congenital heart disease under targeted therapy: a retrospective analysis of a single tertiary center. Cardiovascular Diagnosis and Therapy, 2022, 12, 655-670.	0.7	2
4268	Sleep-Disordered Breathing and Nocturnal Hypoxemia in Chronic Thromboembolic Pulmonary Hypertension and Chronic Thromboembolic Pulmonary Disease. SSRN Electronic Journal, 0, , .	0.4	0
4269	Open right hepatectomy in a patient with hepatocarcinoma and pulmonary hypertensionÂ. Journal of Cancer Prevention & Current Research, 2022, 13, 90-92.	0.1	0
4270	Prevalence, risk factors, and survival associated with pulmonary hypertension and heart failure among patients with underlying coronary artery disease: a national prospective, multicenter registry study in China. Chinese Medical Journal, 2022, 135, 1837-1845.	0.9	2
4271	The impact of the COVIDâ€19 pandemic on the care of pulmonary hypertension patients outside the Hubei province in China. Pulmonary Circulation, 2022, 12, .	0.8	1
4272	Association between income and likelihood of right heart catheterization in individuals with pulmonary hypertension: A US claims database analysis. Pulmonary Circulation, 2022, 12, .	0.8	0
4273	Medical Management of Chronic Thromboembolic Pulmonary Hypertension. Advances in Pulmonary Hypertension, 2022, 21, 88-92.	0.1	0
4274	HÄ°PERTANSÄ°YON TANISI ALAN HASTALARDA ANGÄ°OTENSÄ°NOJEN (AGT) GEN TARAMASI VE NUTRÄ°GENETÄ°K YAKLAÅžIMLAR. Turkish Journal of Clinics and Laboratory, 0, , .	0.2	0
4275	New progress in diagnosis and treatment of pulmonary arterial hypertension. Journal of Cardiothoracic Surgery, 2022, 17, .	0.4	6
4276	Novel predictor of pulmonary arterial hypertension: Monocyte to HDL cholesterol ratio. Medicine (United States), 2022, 101, e29973.	0.4	1
4277	Sotatercept for the treatment of pulmonary arterial hypertension: PULSAR open-label extension. European Respiratory Journal, 2023, 61, 2201347.	3.1	44
4278	Successful recovery after blade atrial septostomy in a child with pulmonary hypertensive crisis and cardiac arrest requiring extracorporeal cardiopulmonary resuscitation. Progress in Pediatric Cardiology, 2022, , 101572.	0.2	0
4279	Exercise MR-proANP unmasks latent right heart failure in CTEPH. Journal of Heart and Lung Transplantation, 2022, , .	0.3	2
4281	Identification of Signal Pathways and Hub Genes of Pulmonary Arterial Hypertension by Bioinformatic Analysis. Canadian Respiratory Journal, 2022, 2022, 1-12.	0.8	6
4282	Anticoagulation in pulmonary arterial hypertension - association with mortality, healthcare utilization, and quality of life: The Pulmonary Hypertension Association Registry (PHAR). Journal of Heart and Lung Transplantation, 2022, 41, 1808-1818.	0.3	4

#	Article	IF	Citations
4283	Association between right ventricular longitudinal strain and cardiovascular events in patients with cardiac sarcoidosis. Journal of Cardiology, 2022, 80, 549-556.	0.8	4
4284	Baseline Sex Differences in Pulmonary Arterial Hypertension Randomized Clinical Trials. Annals of the American Thoracic Society, 2023, 20, 58-66.	1.5	4
4285	Mechanical circulatory support devices and treatment strategies for right heart failure. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	4
4286	Covid-19-induced pulmonary hypertension in children, and the use of phosphodiesterase-5 inhibitors. F1000Research, 0, 10, 792.	0.8	0
4287	Exercise feature and predictor of prognosis in patients with pulmonary artery stenosisâ€associated pulmonary hypertension. ESC Heart Failure, 0, , .	1.4	1
4288	Pulmonary Hypertension in Sclerodermaâ€“ Evaluation and Management. Disease-a-Month, 2022, , 101468.	0.4	1
4289	Impact of cigarette smoking on rheumatoid arthritis-associated lung diseases: a retrospective case control study on clinical and radiological features and prognosis. Rheumatology International, 0, , .	1.5	0
4290	AÅŸikÃ¢r pulmoner hipertansiyonu olmayan sistemik sklerozlu hastalarda tÄ±rnak kapilaroskopi bulgularÄ± ve modifiye Rodnan skoru saÄŸ ventrikÃ¼l fonksiyonlarÄ±nda bozulma ile iliÅŸkilidir. Journal of Medicine and Palliative Care:, 2022, 3, 188-194.	0.0	0
4291	Indirect treatment comparison and cost-minimization analysis of riociguat versus selexipag in patients with pulmonary arterial hypertension. Expert Review of Pharmacoeconomics and Outcomes Research, 0, , 1-7.	0.7	0
4292	Role of Inferior Vena Cava Dynamics for Estimating Right Atrial Pressure in Congenital Heart Disease. Circulation: Cardiovascular Imaging, 2022, 15, .	1.3	2
4293	Atrial flutter and fibrillation in patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension in the ASPIRE registry: Comparison of rate versus rhythm control approaches. International Journal of Cardiology, 2023, 371, 363-370.	0.8	3
4294	Arrhythmic burden of adult survivors with repaired total anomalous pulmonary venous connection. , 2022, , .		1
4295	Predictive Value of the Transthoracic Echocardiography Index for Acute Kidney Injury after Cardiac Valve Surgery. Journal of Cardiovascular Development and Disease, 2022, 9, 316.	0.8	1
4296	The optimal exercise modality and intensity for hemodialysis patients incorporating Bayesian network meta-analysis and systematic review. Frontiers in Physiology, 0, 13, .	1.3	5
4297	The evolution of survival of pulmonary arterial hypertension over 15 years. Pulmonary Circulation, 2022, 12, .	0.8	8
4298	Vascular compression and pulmonary hypertension: the occupational context. Occupational and Environmental Medicine, 2022, 79, 721-722.	1.3	0
4299	Different response of the oxygen pathway in patients with chronic thromboembolic pulmonary hypertension treated with pulmonary endarterectomy versus balloon pulmonary angioplasty. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	0
4300	Echocardiographic changes after arteriovenous fistula creation in hemodialysis patients. Clinical Nephrology, 2022, 98, 229-238.	0.4	1

#	Article	IF	Citations
4301	Role of the electrocardiogram in the risk stratification of pulmonary hypertension. Heart, 2023, 109, 208-215.	1.2	4
4302	Elevated plasma WIFâ€1 levels are associated with worse prognosis in heart failure with pulmonary hypertension. ESC Heart Failure, 2022, 9, 4139-4149.	1.4	3
4303	Selexipag-based triple combination therapy improves prognosis in Chinese pulmonary arterial hypertension patients. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	3
4304	Right Heart Function in Cardiorenal Syndrome. Current Heart Failure Reports, 0, , .	1.3	0
4305	Targeting non-coding RNA H19: A potential therapeutic approach in pulmonary diseases. Frontiers in Pharmacology, 0, 13, .	1.6	4
4306	Angiopoietin 2 and hsCRP are associated with pulmonary hemodynamics and long-term mortality respectively in CTEPHâ€"Results from a prospective discovery and validation biomarker study. Journal of Heart and Lung Transplantation, 2023, 42, 398-405.	0.3	3
4307	Assessing Daily Life Physical Activity by Actigraphy in Pulmonary Arterial Hypertension. Chest, 2023, 163, 407-418.	0.4	7
4308	Interest of TAPSE/sPAP ratio for noninvasive pulmonary arterial hypertension risk assessment. Journal of Heart and Lung Transplantation, 2022, 41, 1761-1772.	0.3	19
4309	Survival benefit of overweight patients undergoing MitraClipÂ® procedure in comparison to normalâ€weight patients. Clinical Cardiology, 2022, 45, 1236-1245.	0.7	1
4310	NMR-Based Metabolomic Analysis of Plasma in Patients with Adult Congenital Heart Disease and Associated Pulmonary Arterial Hypertension: A Pilot Study. Metabolites, 2022, 12, 845.	1.3	5
4311	Conundrum of Classifying Subtypes of Pulmonary Hypertensionâ€"Introducing a Novel Approach to Classify â€œBorderlineâ€•Patients in a Population with Severe Aortic Stenosis Undergoing TAVI. Journal of Cardiovascular Development and Disease, 2022, 9, 294.	0.8	0
4312	Correlation between Pulmonary Artery Pressure and Vortex Duration Determined by 4D Flow MRI in Main Pulmonary Artery in Patients with Suspicion of Chronic Thromboembolic Pulmonary Hypertension (CTEPH). Journal of Clinical Medicine, 2022, 11, 5237.	1.0	2
4313	Management of the Critically Ill Patient with Pulmonary Arterial Hypertension and Right Heart Failure. Clinics in Chest Medicine, 2022, 43, 425-439.	0.8	3
4314	Diagnostic efficacy of ECG-derived ventricular gradient for the detection of chronic thromboembolic pulmonary hypertension in patients with acute pulmonary embolism. Journal of Electrocardiology, 2022, 74, 94-100.	0.4	0
4315	Comparative Prognostic Value of Parameters of Pulsatile Right Ventricular Afterload in Patients With Advanced Heart Failure Awaiting Heart Transplantation. American Journal of Cardiology, 2022, , .	0.7	0
4316	Regnase-1 Prevents Pulmonary Arterial Hypertension Through mRNA Degradation of Interleukin-6 and Platelet-Derived Growth Factor in Alveolar Macrophages. Circulation, 2022, 146, 1006-1022.	1.6	14
4317	Eisenmenger sendromlu bir hastada 11 yÄ±llÄ±k dÃ¶nemde bosentan monoterapisinin seri deÄŸerlendirmesi: Olgu takip raporu. , 0, , .		0
4318	Comparability between Computed Tomography Morphological Vascular Parameters and Echocardiography for the Assessment of Pulmonary Hypertension in Patients with Severe Aortic Valve Stenosisâ€"Results of a Multi-Center Study. Diagnostics, 2022, 12, 2363.	1.3	0

#	Article	IF	Citations
4319	Evaluation of the profile of circulating extracellular vesicles of different cell origin and their activity in patients with postthromboembolic syndrome. Translational Medicine, 2022, 9, 59-69.	0.1	0
4320	A study of the efficacy of sacubitril/valsartan plus dapagliflozin combination treatment in pulmonary arterial hypertension due to left heart disease. Perfusion (United Kingdom), 2023, 38, 1697-1704.	0.5	2
4321	Pulmonary Artery Denervation for Pulmonary Arterial Hypertension. JACC: Cardiovascular Interventions, 2022, 15, 2412-2423.	1.1	19
4322	Case report: The impact of percutaneous atrial septal defect closure in pulmonary hypertension with co-existing cor triatriatum sinister and multiple cardiac comorbidities. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	0
4323	Target organ expression and biomarker characterization of chemokine CCL21 in systemic sclerosis associated pulmonary arterial hypertension. Frontiers in Immunology, 0, 13, .	2.2	5
4324	Correlations of Computed Tomography Measurement of Distal Pulmonary Vascular Pruning with Airflow Limitation and Emphysema in COPD Patients. International Journal of COPD, 0, Volume 17, 2241-2252.	0.9	0
4325	Right Heart Catheterization in Pediatric Pulmonary Arterial Hypertension: Insights and Outcome from a Large Tertiary Center. Journal of Clinical Medicine, 2022, 11, 5374.	1.0	0
4326	Longâ€term outcome prediction for chronic thromboembolic pulmonary hypertension after pulmonary endarterectomy. Clinical Cardiology, 2022, 45, 1255-1263.	0.7	2
4327	Management of Idiopathic Pulmonary Arterial Hypertension in a Patient in Trinidad: A Case Report. Cureus, 2022, , .	0.2	0
4328	Cardiac response to changes in central venous sonomorphology: Mechanism of impaired heart relaxation in patients with varicose veins of lower extremities. Phlebology, 2022, 37, 644-650.	0.6	2
4329	A Right Heart Catheterization for the Diagnosis of Pulmonary Hypertension. Chest, 2022, 162, 511-513.	0.4	1
4330	EmPHasisâ€10 Healthâ€Related Quality of Life and Exercise Capacity in Chronic Thromboembolic Pulmonary Hypertension After Balloon Angioplasty. Journal of the American Heart Association, 2022, 11, .	1.6	2
4331	NBL1 Mediates Endothelial-to-Mesenchymal Transition in Pulmonary Arterial Hypertension Related to Congenital Heart Disease. American Journal of Respiratory Cell and Molecular Biology, 0, , .	1.4	2
4332	Early echocardiographic evaluation of right ventricular load adaptability after sequential combination treatment in pulmonary arterial hypertension. Herz, 0, , .	0.4	0
4335	Heart Failure After Right Ventricular Myocardial Infarction. Current Heart Failure Reports, 0, , .	1.3	3
4337	Biomarker-based approach to determine etiology and severity of pulmonary hypertension: Focus on microRNA. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	2
4338	The Consistent Effectiveness and Safety of Macitentan Therapies Across Idiopathic and Congenital Heart Disease-Associated PulmonaryArterial Hypertension: A Single-Center Experience. , 2022, 26, 778-787.		1
4339	Plasma Cell-Free DNA Predicts Survival and Maps Specific Sources of Injury in Pulmonary Arterial Hypertension. Circulation, 2022, 146, 1033-1045.	1.6	15

#	Article	IF	Citations
4340	Intraoperative Changes and Prognostic Implications of Pulmonary Hypertension in Hypertrophic Obstructive Cardiomyopathy Patients Undergoing Surgical Septal Myectomy. Journal of Thoracic and Cardiovascular Surgery, 2022, , .	0.4	1
4341	The impact of COVIDâ€19 pandemic on pulmonary hypertension: What have we learned?. Pulmonary Circulation, 2022, 12, .	0.8	4
4342	Psychometric properties of the sit-to-stand test for patients with pulmonary hypertension: A systematic review protocol. PLoS ONE, 2022, 17, e0275646.	1.1	0
4343	Current status of pulmonary artery denervation. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	0
4344	Iron Deficiency in Heart Failure and Pulmonary Hypertension. Current Treatment Options in Cardiovascular Medicine, 0, , .	0.4	0
4345	Association between right ventricular dysfunction and adverse cardiac events in mild COPD patients. European Journal of Clinical Investigation, 2023, 53, .	1.7	11
4346	An updated metaâ€analysis of hemodynamics markers of prognosis in patients with pulmonary hypertension due to left heart disease.. Pulmonary Circulation, 0, , .	0.8	3
4347	Efficacy of computed tomography in diagnosing pulmonary hypertension: A systematic review and meta-analysis. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	3
4348	Myocardial Work in Patients Hospitalized With COVIDâ€19: Relation to Biomarkers, COVIDâ€19 Severity, and Allâ€Cause Mortality. Journal of the American Heart Association, 2022, 11, .	1.6	2
4349	20-Year-Old Postpartum Woman With Hypoxia and Tachycardia. Mayo Clinic Proceedings, 2022, 97, 1936-1941.	1.4	0
4350	Non-pharmacologic autonomic neuromodulation for treatment of heart failure: A systematic review and meta-analysis of randomized controlled trials. Trends in Cardiovascular Medicine, 2024, 34, 101-107.	2.3	4
4351	Exercise Catheterization for Hemodynamic Evaluation of Adults with Coarctation of the Aorta. Congenital Heart Disease, 2022, 17, 605-615.	0.0	0
4352	Real-world evidence of subcutaneous treprostinil use in pulmonary arterial hypertension in Argentina. Therapeutic Advances in Respiratory Disease, 2022, 16, 175346662211327.	1.0	0
4353	Double <scp>Doppler Tei</scp> index combined with lung ultrasound to evaluate the right ventricular function and lung condition in neonates with pulmonary hypertension. Journal of Clinical Ultrasound, 2023, 51, 628-635.	0.4	3
4354	Association between Renal Function at Admission and COVID-19 in-Hospital Mortality in Southern Italy: Findings from the Prospective Multicenter Italian COVOCA Study. Journal of Clinical Medicine, 2022, 11, 6121.	1.0	7
4355	Role of cardiovascular computed tomography parameters and lungs findings in predicting severe COVID-19 patients: a single-centre retrospective study. Egyptian Journal of Radiology and Nuclear Medicine, 2022, 53, .	0.3	0
4356	Beneficial Effects of Low-Intensity Pulsed Ultrasound Therapy on Right Ventricular Dysfunction in Animal Models. JACC Basic To Translational Science, 2023, 8, 283-297.	1.9	2
4357	Vasoreactivity testing in pulmonary hypertension associated with congenital heart disease. Eurasian Heart Journal, 2022, , 58-64.	0.2	1

#	Article	IF	Citations
4358	Treatment pattern and clinical outcomes in portopulmonary hypertension: A database study in Japan. JGH Open, 0, , .	0.7	2
4359	Diagnostic and prognostic value of ventilatory power in pulmonary hypertension. Respiratory Research, 2022, 23, .	1.4	1
4361	Pharmacological counseling in hepatotoxicity induced by macitentan and selexipag: Âa case reportÂ. Journal of Medical Case Reports, 2022, 16, .	0.4	4
4362	Analysis of the dynamics of the daily variability of the sinus rhythm according to Holter monitoring to assess the effectiveness of treatment of patients with pulmonary hypertension. Medical Alphabet, 2022, , 29-35.	0.0	0
4363	Impact of Periprocedural Pulmonary Hypertension on Outcomes After Transcatheter Aortic Valve Replacement. Journal of the American College of Cardiology, 2022, 80, 1601-1613.	1.2	18
4364	Medication use by US patients with pulmonary hypertension associated with chronic obstructive pulmonary disease: a retrospective study of administrative data. BMC Pulmonary Medicine, 2022, 22, .	0.8	1
4365	Non-Invasive Assessment of Right Ventricle to Arterial Coupling for Prognosis Stratification of Fibrotic Interstitial Lung Diseases. Journal of Clinical Medicine, 2022, 11, 6115.	1.0	0
4366	Right ventricular failure in left heart disease: from pathophysiology to clinical manifestations and prognosis. Heart Failure Reviews, 2023, 28, 757-766.	1.7	10
4367	Mild pulmonary hemodynamic alterations in patients with systemic sclerosis: relevance of the new 2022 ESC/ERS definition of pulmonary hypertension and impact on mortality. Respiratory Research, 2022, 23, .	1.4	3
4368	Pulmonary hypertension due to high cardiac output. Respiratory Medicine, 2023, 206, 107034.	1.3	1
4369	Balloon pulmonary angioplasty can be an effective and safe therapeutic option in non-surgical elderly patients. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	3
4370	Native T1 Mapping-Based Radiomics for Noninvasive Prediction of the Therapeutic Effect of Pulmonary Arterial Hypertension. Diagnostics, 2022, 12, 2492.	1.3	1
4371	Unsolved problems in CDH follow-up. Frontiers in Pediatrics, 0, 10, .	0.9	1
4372	Prognostic role of pulmonary hemodynamics before transcatheter aortic valve replacement among patients with severe aortic stenosis. Journal of Heart and Lung Transplantation, 2023, 42, 275-282.	0.3	1
4373	Safety of macitentan for the treatment of pulmonary hypertension: Realâ€world experience from the OPsumitÂ® USers Registry (OPUS) and OPsumitÂ® Historical USers cohort (OrPHeUS). Pulmonary Circulation, 2022, 12, .	0.8	6
4374	Echocardiographic Prognostic Factors in Pulmonary Hypertension. , 0, , .		0
4375	Central versus Peripheral CTEPHâ€"Clinical and Hemodynamic Specifications. Medicina (Lithuania), 2022, 58, 1538.	0.8	1
4376	Lack of concordance between the different exercise test measures used in the risk stratification of patients with pulmonary arterial hypertension. Pulmonary Circulation, 2022, 12, .	0.8	4

#	Article	IF	Citations
4377	Surgical Repair of Truncus Arteriosus: A Long-Term Hemodynamic Assessment. World Journal for Pediatric & Congenital Heart Surgery, 2022, 13, 716-722.	0.3	0
4379	Lasso algorithm and support vector machine strategy to screen pulmonary arterial hypertension gene diagnostic markers. Scottish Medical Journal, 0, , 003693302211321.	0.7	1
4380	IMproving PULmonary hypertension Screening by Echocardiography: IMPULSE. Echo Research and Practice, 2022, 9, .	0.6	0
4381	Sox17 Deficiency Promotes Pulmonary Arterial Hypertension via HGF/c-Met Signaling. Circulation Research, 2022, 131, 792-806.	2.0	15
4382	NCAPG Promotes Pulmonary Artery Smooth Muscle Cell Proliferation as a Promising Therapeutic Target of Idiopathic Pulmonary Hypertension: Bioinformatics Analysis and Experiment Verification. International Journal of Molecular Sciences, 2022, 23, 11762.	1.8	3
4383	Leflunomide-induced pulmonary arterial hypertension in a young man with nephrotic syndrome: A case report. Frontiers in Pharmacology, 0, 13, .	1.6	1
4384	Artificial intelligence-enabled phenotyping of patients with severe aortic stenosis: on the recovery of extra-aortic valve cardiac damage after transcatheter aortic valve replacement. Open Heart, 2022, 9, e002068.	0.9	5
4385	Association between oxygen delivery and digital ulcers in systemic sclerosis. Microvascular Research, 2023, 145, 104449.	1.1	2
4386	Survival rate and predictors of 36-month mortality in patients with heart failure in Sub Saharan Africa: insights from the Douala Heart Failure Registry (Do-HF). Cardiovascular Diagnosis and Therapy, 2022, 12, 577-588.	0.7	0
4387	Bezoldâ€“Jarisch reflex mediated syncope in pulmonary arterial hypertension: An illustrative case series. Pulmonary Circulation, 2022, 12, .	0.8	0
4388	Patient selection for balloon pulmonary angioplasty: Sixâ€year results from a high volume PTE surgical center. Pulmonary Circulation, 2022, 12, .	0.8	9
4389	Skin disorders and interstitial lung disease: Part IIâ€”The spectrum of cutaneous diseases with lung disease association. Journal of the American Academy of Dermatology, 2023, 88, 767-782.	0.6	2
4390	Hypersensitivity Pneumonitis With and Without Autoimmune Features: A Clinical Comparative Analysis. Lung, 2022, 200, 763-771.	1.4	3
4391	Operability of atrial septal defect with borderline pulmonary vascular resistance index: A study in developing country. Frontiers in Surgery, 0, 9, .	0.6	0
4392	Impact of pulmonary hypertension on lung cancer management. Respiratory Medicine and Research, 2022, 82, 100964.	0.4	1
4393	Portopulmonary Hypertension in Nontransplanted Patients: Results of the Largest US Single-Institution Registry. Mayo Clinic Proceedings, 2022, 97, 2236-2247.	1.4	3
4394	Managing Cardiac Arrest Using Ultrasound. Annals of Emergency Medicine, 2023, 81, 532-542.	0.3	4
4395	Real-World Safety and Clinical Outcomes of Macitentan in Asian Patients with Pulmonary Arterial Hypertension: A Prospective Multicenter Study. Drugs - Real World Outcomes, 0, , .	0.7	0

#	Article	IF	Citations
4396	Oxidative stress in patients with pulmonary hypertension. Advances in Redox Research, 2022, 6, 100053.	0.9	1
4397	Pulmonary Veno-Occlusive Disease Versus Pulmonary Arterial Hypertension. , 2022, , 345-348.		0
4398	Pulmonary hypertension and associated outcomes in noncardiac surgery: A systematic review and meta-analysis. Heart and Lung: Journal of Acute and Critical Care, 2023, 58, 21-27.	0.8	2
4399	VisiÃ³n crÃtica de las guÃas de funciÃ³n diastÃ³lica: verdades y mentiras. Revista De EcocardiografÃa PrÃ¡ctica Y Otras TÃ©cnicas De Imagen CardÃaca, 2017, , 7-12.	0.0	0
4400	COMPARATIVE CLINICAL CHARACTERISTICS OF PATIENTS WITH VARIOUS FORMS OF PULMONARY ARTERIAL HYPERTENSION ASSOCIATED WITH CONGENITAL HEART DISEASE, ACCORDING TO THE CLINICAL CLASSIFICATION. Eurasian Heart Journal, 2019, , 108-121.	0.2	0
4401	CASE REPORT ON THE SUCCESSFUL USE OF A NEW SELECTIVE PROSTACYCLIN IP RECEPTOR AGONIST, SELEXIPAG, IN A PATIENT WITH IDIOPATHIC PULMONARY HYPERTENSION. Eurasian Heart Journal, 2019, , 144-155.	0.2	1
4404	Prevalence and Treatment Outcomes of Arrhythmias in Patients with Single Ventricle Physiology over the Age of 40 Years. Journal of Clinical Medicine, 2022, 11, 6568.	1.0	4
4405	Training programs in preclinical studies. The example of pulmonary hypertension. Systematic review and meta-analysis. PLoS ONE, 2022, 17, e0276875.	1.1	1
4406	Management of Interstitial Lung Diseases: A Consensus Statement of the Indian Chest Society and National College of Chest Physicians (India). The Indian Journal of Chest Diseases & Allied Sciences, 2022, 62, 73-98.	0.1	0
4407	Vagal nerve stimulation preserves right ventricular function in a rat model of right ventricular pressure overload. Pulmonary Circulation, 0, , .	0.8	1
4408	IL-11 system participates in pulmonary artery remodeling and hypertension in pulmonary fibrosis. Respiratory Research, 2022, 23, .	1.4	15
4409	Circulating markers of inflammation and angiogenesis and clinical outcomes across subtypes of pulmonary arterial hypertension. Journal of Heart and Lung Transplantation, 2023, 42, 173-182.	0.3	8
4410	Influence of Iron Deficiency on Clinical and Haemodynamic Parameters in Pulmonary Arterial Hypertension Cohorts. Heart Lung and Circulation, 2022, 31, 1594-1603.	0.2	3
4411	Impact and predictors of outcome of COVID-19 in pulmonary hypertension patients. Egyptian Journal of Bronchology, 2022, 16, .	0.3	0
4412	Prognostic Value of Hepatic Native T1 and Extracellular Volume Fraction in Patients with Pulmonary Arterial Hypertension. Journal of the American Heart Association, 2022, 11, .	1.6	2
4413	Long-term outcomes in health-related quality of life influence chronic disease management in patients with pulmonary hypertension. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	1
4414	Is combined use of radiofrequency ablation and balloon dilation the future of interatrial communications?. Expert Review of Cardiovascular Therapy, 0, , 1-9.	0.6	0
4415	Assessing jugular venous compliance with optical hemodynamic imaging by modulating intrathoracic pressure. Journal of Biomedical Optics, 2022, 27, .	1.4	0

#	Article	IF	Citations
4416	Association Between Copayment and Adherence to Medications for Pulmonary Arterial Hypertension. Journal of the American Heart Association, 2022, 11, .	1.6	1
4417	The original and two new derivative versions of the COMPERA 2.0 risk assessment model: useful tools for guiding balloon pulmonary angioplasty. Respiratory Research, 2022, 23, .	1.4	3
4418	PAH-specific therapy for pulmonary hypertension and interstitial lung disease: A systemic review and meta-analysis. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	2
4419	Management of pregnant patients with pulmonary arterial hypertension. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	2
4420	Incorporation of noninvasive assessments in risk prediction for pulmonary arterial hypertension. Pulmonary Circulation, 0, , .	0.8	0
4421	Pulmonary Arterial Hypertension: Emerging Principles of Precision Medicine across Basic Science to Clinical Practice. Reviews in Cardiovascular Medicine, 2022, 23, 378.	0.5	2
4422	Clinical Presentations and Multimodal Imaging Diagnosis in Chronic Thromboembolic Pulmonary Hypertension. Journal of Clinical Medicine, 2022, 11, 6678.	1.0	1
4423	Patient-specific and gene-corrected induced pluripotent stem cell-derived endothelial cells elucidate single-cell phenotype of pulmonary veno-occlusive disease. Stem Cell Reports, 2022, , .	2.3	0
4424	Increased biventricular hemodynamic forces in precapillary pulmonary hypertension. Scientific Reports, 2022, 12, .	1.6	1
4425	CircGSAP alleviates pulmonary microvascular endothelial cells dysfunction in pulmonary hypertension via regulating miR-27a-3p/BMPR2 axis. Respiratory Research, 2022, 23, .	1.4	9
4426	Pulmonary arterial hypertension incidence in Latvia in 2019. Pulmonary Circulation, 2022, 12, .	0.8	0
4427	Pulmonary hypertension in connective tissue diseases: epidemiology, pathogenesis, and treatment. Clinical Rheumatology, 2023, 42, 2601-2610.	1.0	7
4428	Pulmonary hypertension associated with left-sided heart disease. Swiss Medical Weekly, 2017, 147, w14395.	0.8	13
4429	A Case of Pulmonary Hypertension Associated with Diffuse Panbronchiolitis that Improved with Erythromycin and Home Oxygen Therapy. Internal Medicine, 2023, , .	0.3	0
4430	Pregnancy and Pulmonary Hypertension. Heart Failure Clinics, 2023, 19, 75-87.	1.0	9
4431	Impact of Hormonal-Anabolic Deficiencies in Idiopathic Pulmonary Arterial Hypertension. Heart Failure Clinics, 2023, 19, 115-123.	1.0	0
4432	CTEPH: A Kaiser Permanente Northern California Experience. Thrombosis Research, 2023, 221, 130-136.	0.8	2
4433	Mildly Elevated Pulmonary Hypertension. Heart Failure Clinics, 2023, 19, 1-9.	1.0	0

#	Article	IF	Citations
4434	Use of Oral Anticoagulant Drugs in Patients with Pulmonary Hypertension. Heart Failure Clinics, 2023, 19, 97-106.	1.0	0
4435	How to Treat Right Heart Failure. Tips for Clinicians in Everyday Practice. Heart Failure Clinics, 2023, 19, 125-135.	1.0	2
4436	Cardiopulmonary Exercise Testing in Pulmonary Arterial Hypertension. Heart Failure Clinics, 2023, 19, 35-43.	1.0	2
4437	Multidisciplinary Approach to Chronic Thromboembolic Pulmonary Hypertension: Role of Radiologists. Radiographics, 2023, 43, .	1.4	3
4438	Efficacy and safety of non-prostanoid prostacyclin receptor agonist for pulmonary hypertension: A meta-analysis. Pulmonary Pharmacology and Therapeutics, 2023, 78, 102182.	1.1	0
4439	Partial anomalous pulmonary venous return in adults: Insight into pulmonary hypertension. International Journal of Cardiology Congenital Heart Disease, 2023, 11, 100426.	0.2	1
4440	2022 Update of indications and contraindications for lung transplantation in France. Respiratory Medicine and Research, 2023, 83, 100981.	0.4	0
4441	Chest X-ray features facilitate screening for pulmonary hypertension caused by fibrosing mediastinitis. Therapeutic Advances in Chronic Disease, 2022, 13, 204062232211432.	1.1	1
4442	Nursing Care in the Outpatient and Hospital Setting. , 2022, , 71-95.		0
4443	Predictors of early response to balloon pulmonary angioplasty in patients with inoperable chronic thromboembolic pulmonary hypertension. Therapeutic Advances in Respiratory Disease, 2022, 16, 175346662211380.	1.0	0
4444	Higher body mass index is associated with a lower iloprost infusion rate tolerance and higher iloprost-related adverse events in patients with systemic sclerosis. Therapeutic Advances in Musculoskeletal Disease, 2022, 14, 1759720X2211371.	1.2	5
4445	Pulmonary Vasoreactivity. , 2022, , 353-377.		0
4446	Relevance of Machine Learning to Cardiovascular Imaging. , 2022, , 589-605.		0
4447	Longâ€term prognostic value of cardiac catheterization and acute vasodilator testing with inhaled iloprost in pediatric idiopathic pulmonary arterial hypertension. Pulmonary Circulation, 2022, 12, .	0.8	1
4448	Comparison of intravenous sildenafil with inhaled nitric oxide for acute vasodilator testing in pulmonary arterial hypertension. Pulmonary Circulation, 2022, 12, .	0.8	3
4449	Relationships between sexual function, mental health, and quality of life of female patients with pulmonary arterial hypertension associated with congenital heart disease. Pulmonary Circulation, 2022, 12, .	0.8	1
4450	The impact of atrial fibrillation and atrial tachycardias on the hemodynamic status of patients with pulmonary hypertension. Physiological Research, 2022, 71, 791-799.	0.4	1
4451	Nutritional status in pulmonary arterial hypertension. Pulmonary Circulation, 2022, 12, .	0.8	3

#	Article	IF	Citations
4452	Adaptive versus maladaptive right ventricular remodelling. ESC Heart Failure, 2023, 10, 762-775.	1.4	14
4454	The evolving landscape of pulmonary arterial hypertension clinical trials. Lancet, The, 2022, 400, 1884-1898.	6.3	25
4455	Palliative Care Perspectives of Patients with Pulmonary Arterial Hypertension. Annals of the American Thoracic Society, 0, , .	1.5	1
4456	Left Heart Disease Phenotype in Elderly Patients with Pulmonary Arterial Hypertension: Insights from the Italian PATRIARCA Registry. Journal of Clinical Medicine, 2022, 11, 7136.	1.0	5
4457	Comparison of hypoxia-induced pulmonary hypertension rat models caused by different hypoxia protocols. Experimental Lung Research, 0, , 1-11.	0.5	0
4459	Risk of bleeding associated with transbronchial biopsy using flexible bronchoscopy in patients with echocardiographic or chest CT evidence of pulmonary hypertension. BMC Pulmonary Medicine, 2022, 22, .	0.8	1
4460	The role of tolvaptan in pulmonary hypertension: A retrospective study. Medicine (United States), 2022, 101, e31587.	0.4	1
4461	Cardiac involvement in a Spanish unicentric prospective cohort of patients with systemic lupus erythematosus. Lupus, 0, , 096120332211412.	0.8	0
4462	ACR Appropriateness CriteriaÂ® Suspected Pulmonary Hypertension: 2022 Update. Journal of the American College of Radiology, 2022, 19, S502-S512.	0.9	3
4464	A signal recognition particle-related joint model of LASSO regression, SVM-RFE and artificial neural network for the diagnosis of systemic sclerosis-associated pulmonary hypertension. Frontiers in Genetics, 0, 13, .	1.1	3
4465	The Role of Bone Morphogenetic Protein Receptor Type 2 (BMPR2) and the Prospects of Utilizing Induced Pluripotent Stem Cells (iPSCs) in Pulmonary Arterial Hypertension Disease Modeling. Cells, 2022, 11, 3823.	1.8	4
4466	Correlation between CT Value on Lung Subtraction CT and Radioactive Count on Perfusion Lung Single Photon Emission CT in Chronic Thromboembolic Pulmonary Hypertension. Diagnostics, 2022, 12, 2895.	1.3	1
4467	Eosinophils protect against pulmonary hypertension through 14-HDHA and 17-HDHA. European Respiratory Journal, 2023, 61, 2200582.	3.1	5
4468	Pathophysiology and pathogenic mechanisms of pulmonary hypertension: role of membrane receptors, ion channels, and Ca²⁺ signaling. Physiological Reviews, 2023, 103, 1827-1897.	13.1	15
4469	Undiagnosed Atrial Septal Defect in the Setting of Comorbidities and Ventricular Failure: Seemingly Simple Disease with a Challenging Diagnosis. Case, 2022, , .	0.1	0
4470	Pulmonary hypertension in the primary care setting. The Prescriber, 2022, 33, 11-18.	0.1	0
4471	Dynamic aspects of ventricular interaction during exercise in HFpEF and in preâ€capillary pulmonary hypertension. ESC Heart Failure, 2023, 10, 650-660.	1.4	1
4472	From acute SARS-CoV-2 infection to pulmonary hypertension. Frontiers in Physiology, 0, 13, .	1.3	8

#	Article	IF	Citations
4473	Right ventricular energetic biomarkers from 4D Flow CMR are associated with exertional capacity in pulmonary arterial hypertension. Journal of Cardiovascular Magnetic Resonance, 2022, 24, .	1.6	3
4476	Assessment of morphological criteria for the efficiency of radiofrequency circumferential denervation of the pulmonary artery in the experiment (animals, pigs). Acta Biomedica Scientifica, 2022, 7, 131-142.	0.1	0
4478	JCS/JACR 2021 Guideline on Rehabilitation in Patients With Cardiovascular Disease. Circulation Journal, 2022, 87, 155-235.	0.7	64
4479	Evaluation of a digital health system (PAHcareâ„¢) for routine care of patients with pulmonary arterial hypertension: The CBS-PAH study protocol. Frontiers in Public Health, 0, 10, .	1.3	4
4480	Analysis of healthcare-associated infection in patients with pulmonary arterial hypertension associated with congenital heart disease in PICU: Evidence from a tertiary hospital in western China. Frontiers in Pediatrics, 0, 10, .	0.9	0
4481	The Role of Anti-U1 RNP Antibody in Connective Tissue Disease-Associated Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis. Journal of Clinical Medicine, 2023, 12, 13.	1.0	2
4482	Impact of diastolic pulmonary gradient and pulmonary artery pulse index on outcomes in heart transplant patientsâ€"Results from the Eurotransplant database. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	2
4483	The identification and verification of hub genes associated with pulmonary arterial hypertension using weighted gene co-expression network analysis. BMC Pulmonary Medicine, 2022, 22, .	0.8	3
4485	Treatment of Vascular Injury During Balloon Pulmonary Angioplasty in Patients With Chronic Thromboembolic Pulmonary Hypertension. JACC Asia, 2022, 2, 831-842.	0.5	4
4486	CTLA-4 Expression Is a Promising Biomarker of Idiopathic Pulmonary Arterial Hypertension and Allows Differentiation of the Type of Pulmonary Hypertension. International Journal of Molecular Sciences, 2022, 23, 15910.	1.8	4
4487	Development and validation of a risk nomogram model for predicting pulmonary hypertension in patients with stage 3â€"5 chronic kidney disease. International Urology and Nephrology, 0, , .	0.6	0
4488	Impact of Exercise-Induced Pulmonary Hypertension on Right Ventricular Function and on Worsening of Cardiovascular Risk in HIV Patients. Journal of Clinical Medicine, 2022, 11, 7349.	1.0	0
4489	Î²3 adrenergic agonist treatment in chronic pulmonary hypertension associated with heart failure (<scp>SPHEREâ€HF</scp>): a double blind, placeboâ€controlled, randomized clinical trial. European Journal of Heart Failure, 2023, 25, 373-385.	2.9	8
4490	Construction of a diagnostic signature and immune landscape of pulmonary arterial hypertension. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	1
4491	Biomarkers of haemodynamic severity of systemic sclerosis-associated pulmonary arterial hypertension by serum proteome analysis. Annals of the Rheumatic Diseases, 2023, 82, 365-373.	0.5	12
4492	Novel and emerging therapies in pulmonary arterial hypertension. Frontiers in Drug Discovery, 0, 2, .	1.1	1
4493	Correlation between the level of evidence and the class of recommendations concerning the pharmacological aspects of the Guidelines of the European Society of Cardiology. International Journal of Cardiology, 2023, 375, 119-123.	0.8	0
4494	Higher circulating Trimethylamine N-oxide levels are associated with worse severity and prognosis in pulmonary hypertension: a cohort study. Respiratory Research, 2022, 23, .	1.4	8

#	Article	IF	Citations
4496	Safety and efficacy of RT234 vardenafil inhalation powder on exercise parameters in pulmonary arterial hypertension: phase II, dose-escalation study design. Respiratory Research, 2022, 23, .	1.4	4
4497	Riociguat real-world use in patients with chronic thromboembolic pulmonary hypertension: A retrospective, observational cohort study in France. Respiratory Medicine and Research, 2023, 83, 100987.	0.4	0
4498	Pulmonary hypertension with a precapillary component in heart failure with preserved ejection fraction. Heart, 2023, 109, 626-633.	1.2	2
4499	Diagnosing heart failure with preserved ejection fraction with pulmonary vascular disease. Heart, 0, , heartjnl-2022-321984.	1.2	3
4500	Longâ€Term Clinical Outcomes in Patients With Severe Tricuspid Regurgitation. Journal of the American Heart Association, 2023, 12, .	1.6	3
4501	Current best clinical practices for monitoring of interstitial lung disease. Expert Review of Respiratory Medicine, 2022, 16, 1153-1166.	1.0	1
4502	Risk factors for portopulmonary hypertension in patients with cirrhosis: a prospective, multicenter study. Hepatology International, 0, , .	1.9	2
4503	Cytokines as prognostic biomarkers in pulmonary arterial hypertension. European Respiratory Journal, 2023, 61, 2201232.	3.1	7
4504	The Interplay between Conventional Cardiovascular Risk Factors and Health-Related Quality of Life in a Cohort of Working Young and Middle-Aged Adults: A Prospective Study. Life, 2022, 12, 2132.	1.1	0
4505	Characteristics of patients with rheumatic heart disease in a national referral hospital in Indonesia. Medical Journal of Indonesia, 2022, 31, 178-85.	0.2	4
4506	Peripheral Vascular Ageing in Pulmonary Arterial Hypertension as Assessed by Common Carotid Artery Intima Thickness and Intima/Media Thickness Ratio: An Investigation Using Non-Invasive High-Resolution Ultrasound. Heart Lung and Circulation, 2022, , .	0.2	2
4507	Lung diffusion capacity correlates with preâ€implant pulmonary hypertension and predicts outcome after LVAD implantation. ESC Heart Failure, 0, , .	1.4	2
4508	Right Ventricular Strain by Magnetic Resonance Feature Tracking Is Largely Afterload-Dependent and Does Not Reflect Contractility: Validation by Combined Volumetry and Invasive Pressure Tracings. Diagnostics, 2022, 12, 3183.	1.3	1
4509	USP15 promotes pulmonary vascular remodeling in pulmonary hypertension in a YAP1/TAZ-dependent manner. Experimental and Molecular Medicine, 2023, 55, 183-195.	3.2	4
4510	Semi-automatic thresholding of RV trabeculation improves repeatability and diagnostic value in suspected pulmonary hypertension. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	0
4511	Pregnancy outcomes in women with pulmonary hypertension: a retrospective study in China. BMC Pregnancy and Childbirth, 2023, 23, .	0.9	2
4512	Transplant-Associated Thrombotic Microangiopathy in the Context of Allogenic Hematopoietic Stem Cell Transplantation: Where We Stand. International Journal of Molecular Sciences, 2023, 24, 1159.	1.8	2
4513	Adherence and treatment patterns of disease-specific drugs among patients with pulmonary arterial hypertension: A nationwide, new-user cohort study. Frontiers in Pharmacology, 0, 13, .	1.6	1

#	Article	IF	Citations
4514	Outcomes of pregnant women hospitalized with unrepaired congenital heart disease: Insights from a multidisciplinary center in Vietnam. Obstetric Medicine, 0, , 1753495X2211488.	0.5	0
4515	Interventional Occlusion of Large Patent Ductus Arteriosus in Adults with Severe Pulmonary Hypertension. Journal of Clinical Medicine, 2023, 12, 354.	1.0	1
4516	Soluble guanylate cyclase stimulator riociguat in the palette of modern specific therapy for precapillary pulmonary hypertension: from the pathophysiological basis to the results of current research. Systemic Hypertension, 2023, 19, 45-52.	0.1	0
4517	Derivation of a Risk Score (REVEAL-ECHO) Based on Echocardiographic Parameters of Patients With Pulmonary Arterial Hypertension. Chest, 2023, 163, 1232-1244.	0.4	5
4518	Soluble Guanylyl Cyclase Activatorsâ€"Promising Therapeutic Option in the Pharmacotherapy of Heart Failure and Pulmonary Hypertension. Molecules, 2023, 28, 861.	1.7	8
4519	Efficacy and safety of endothelin receptor antagonists, phosphodiesterase type 5 Inhibitors, and prostaglandins in pediatric pulmonary arterial hypertension: A network meta-analysis. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	0
4520	Time to diagnosis of pulmonary hypertension and diagnostic burden: A retrospective analysis of nationwide US healthcare data. Pulmonary Circulation, 2023, 13, .	0.8	7
4521	The prognostic role of the echocardiographic tricuspid annular plane systolic excursion/systolic pulmonary arterial pressure (TAPSE/sPAP) ratio and its relationship with NT-proANP plasma level in systemic sclerosis. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	1
4522	Effect of 5 weeks of oral acetazolamide on patients with pulmonary vascular disease: A randomized, double-blind, cross-over trial. Pulmonology, 2023, , .	1.0	1
4523	Potential long-term effects of SARS-CoV-2 infection on the pulmonary vasculature: Multilayered cross-talks in the setting of coinfections and comorbidities. PLoS Pathogens, 2023, 19, e1011063.	2.1	7
4524	Swietenine Alleviates Vascular Remodelling by Enhancing Mitophagy of Pulmonary Arterial Smooth Muscle Cells in Experimental Pulmonary Hypertension. Canadian Journal of Cardiology, 2023, 39, 646-659.	0.8	1
4525	Impact of the New Classification of Pulmonary Hypertension in Patients With Advanced Respiratory Disease. Archivos De Bronconeumologia, 2023, , .	0.4	0
4526	Gaps in the Care of Pulmonary Hypertension: A Crossâ€Sectional Patient Simulation Study Among Practicing Cardiologists and Pulmonologists. Journal of the American Heart Association, 2023, 12, .	1.6	1
4527	Societal costs associated with pulmonary arterial hypertension: A study utilizing linked national registries. Pulmonary Circulation, 2023, 13, .	0.8	2
4528	Clinical characteristics of pulmonary hypertension patients who underwent right heart catheterization in Thailand: 5-year retrospective single-centre study. Lung India, 2023, 40, 42.	0.3	0
4529	Preexisting Chronic Thromboembolic Pulmonary Hypertension in Acute Pulmonary Embolism. Chest, 2023, 163, 923-932.	0.4	11
4531	Risk assessment validation in patients with pulmonary arterial hypertension: Data from a Southern Brazil Registry (RESPHIRAR Study). Pulmonary Circulation, 0, , .	0.8	0
4532	Pulmonary veno-occlusive disease in Sjogren's syndrome: a case report. BMC Pulmonary Medicine, 2023, 23, .	0.8	1

#	Article	IF	Citations
4533	Tolerability, safety and survival in patients with severe pulmonary arterial hypertension treated with intravenous epoprostenol (VeletriÂ®): a prospective, 6-months, open label, observational, non-interventional study. Respiratory Research, 2023, 24, .	1.4	3
4534	Ventilation Induces Changes in Pulse Wave Transit Time in the Pulmonary Artery. Biomedicines, 2023, 11, 182.	1.4	1
4535	Impact of the revised hemodynamic definition of pulmonary hypertension. Revista Espanola De Cardiologia (English Ed), 2023, , .	0.4	0
4536	Cost-Effectiveness Analysis of Macitentan in Comparison With Bosentan in the Treatment of Pulmonary Arterial Hypertension in Iran. Value in Health Regional Issues, 2023, 34, 78-85.	0.5	0
4537	Ventricular Function and Cardio-Ankle Vascular Index in Patients With Pulmonary Artery Hypertension. Vascular Health and Risk Management, 0, Volume 18, 889-904.	1.0	0
4538	Latent trajectory modelling of pulmonary artery pressure in systemic sclerosis: a retrospective cohort study. RMD Open, 2022, 8, e002673.	1.8	0
4539	Exhaled Air Metabolome Analysis for Pulmonary Arterial Hypertension Fingerprints Identificationâ€"The Preliminary Study. International Journal of Environmental Research and Public Health, 2023, 20, 503.	1.2	3
4540	Left Ventricular Fibrosis Assessment by Native T1, ECV, and LGE in Pulmonary Hypertension Patients. Diagnostics, 2023, 13, 71.	1.3	1
4541	Case Report: A Rare Manifestation of Pulmonary Arterial Hypertension in Ankylosing Spondylitis. Journal of Personalized Medicine, 2023, 13, 62.	1.1	2
4542	Antiphospholipid Syndrome and the Lungs. European Medical Journal (Chelmsford, England), 0, , 76-82.	3.0	2
4543	Different Causes of Functional Tricuspid Valve Regurgitation Are Linked to Differences in Tricuspid Valve and Right-Sided Heart Geometry and Function: 3D Echocardiography Study. Medicina (Lithuania), 2023, 59, 57.	0.8	2
4544	Piezo1, a novel therapeutic target to treat pulmonary arterial hypertension. Frontiers in Physiology, 0, 14, .	1.3	0
4546	Outcomes of Preprocedural Pulmonary Hypertension on All-Cause and Cardiac Mortality in Patients Undergoing Transcatheter Aortic Valve Implantation: A Systematic Review. Cureus, 2023, , .	0.2	0
4547	Contemporary interventional management of pulmonary embolism. Clinical Radiology, 2023, , .	0.5	1
4548	A North American, single-center experience implanting fenestrated atrial devices and atrial flow regulators into a heterogeneous group of pediatric pulmonary hypertension patients. Frontiers in Pediatrics, 0, 11, .	0.9	0
4549	Pulmonary Hypertension Phenotype Can Be Identified in Heart Failure with Reduced Ejection Fraction Using Echocardiographic Assessment of Pulmonary Artery Pressure with Supportive Use of Pressure Reflection Variables. Journal of the American Society of Echocardiography, 2023, , .	1.2	0
4550	Neurophysiological Mechanisms of Exertional Dyspnea in Post-Pulmonary Embolism Syndrome. Journal of Applied Physiology, 0, , .	1.2	0
4551	Case report: Thoughts on two cases of total anomalous pulmonary venous connection complicated with pulmonary artery hypertension. Frontiers in Cardiovascular Medicine, 0, 10, .	1.1	0

#	Article	IF	Citations
4553	The diagnostic and prognostic value of growth differentiation factorâ€15 in systemic lupus erythematosusâ€associated pulmonary arterial hypertension. Pulmonary Circulation, 2023, 13, .	0.8	2
4554	Hyperoxia improves exercise capacity in cardiopulmonary disease: a series of randomised controlled trials. ERJ Open Research, 2023, 9, 00563-2022.	1.1	1
4555	Novel Depiction of Collateral Flow in Chronic Thromboembolic Pulmonary Hypertension Using 4D Dynamic 82Rb PET/CT. Clinical Nuclear Medicine, 0, Publish Ahead of Print, .	0.7	0
4556	Neonatal outcomes in pregnant women with pulmonary arterial hypertension associated with heart disease. Pediatrics and Neonatology, 2023, , .	0.3	0
4557	Multimodality Imaging in HIV-Associated Cardiovascular Complications: A Comprehensive Review. International Journal of Environmental Research and Public Health, 2023, 20, 2201.	1.2	0
4558	Endothelial Dysfunction Syndromes after Allogeneic Stem Cell Transplantation. Cancers, 2023, 15, 680.	1.7	6
4559	Longâ€term exercise and pulmonary function outcomes in a contemporary cohort of children with congenital diaphragmatic hernia. Pediatric Pulmonology, 2023, 58, 1471-1480.	1.0	1
4560	è‚ºé«˜è¡€åœ§è¨ºç™‚ã®é€²æ©. The Journal of the Japanese Society of Internal Medicine, 2022, 111, 836-843.	0.0	0
4562	Frontline autologous stem cell transplantation in POEMS syndrome with pulmonary arterial hypertension. Journal of Cancer Research and Practice, 2023, 10, 34.	0.2	0
4563	Maternal Outcomes Among Pregnant Women With Congenital Heart Diseaseâ€“Associated Pulmonary Hypertension. Circulation, 2023, 147, 549-561.	1.6	6
4564	Differences in right ventricular function and response to targeted therapy between patients with IPAH and PAH-CHD. Frontiers in Pharmacology, 0, 14, .	1.6	0
4565	Predictors of pulmonary hypertension in patients with hypersensitivity pneumonitis. BMC Pulmonary Medicine, 2023, 23, .	0.8	3
4566	Shear Wave Dispersion Slope of the Liver Can Predict Adverse Outcomes in Patients with Pulmonary Hypertension. International Heart Journal, 2023, 64, 230-236.	0.5	1
4567	Case-Based Discussion:ÂEchocardiographic Assessment of Pulmonary Hypertension. Current Cardiovascular Imaging Reports, 2023, 16, 11-19.	0.4	0
4568	Inhibition of heterogeneous nuclear ribonucleoproteins A1 and oxidative stress reduces glycolysis via pyruvate kinase M2 in chronic thromboembolic pulmonary hypertension. Journal of Translational Internal Medicine, 2023, .	1.0	0
4569	Distribution of thrombus predicts severe reperfusion pulmonary edema after pulmonary endarterectomy. Asian Journal of Surgery, 2023, 46, 3766-3772.	0.2	0
4570	Prevalence of pulmonary hypertension in aortic regurgitation and its influence on outcomes. Heart, 2023, 109, 1310-1318.	1.2	8
4571	Sexually Transmitted Infections & the Heart. Current Problems in Cardiology, 2023, 48, 101629.	1.1	2

#	Article	IF	Citations
4572	The role of riociguat in combination therapies for pulmonary arterial hypertension. Respiratory Medicine, 2023, 211, 107196.	1.3	2
4573	A rare, life-threatening debut of pancreatic adenocarcinoma: Pulmonary tumor thrombotic microangiopathy. Current Problems in Cancer Case Reports, 2023, 10, 100238.	0.1	0
4574	Characteristics of Right Ventricular to Pulmonary Arterial Coupling and Association With Functional Status Among Older Aged Adults from the Multi-Ethnic Study of Atherosclerosis. American Journal of Cardiology, 2023, 196, 41-51.	0.7	1
4575	Association Between the Degree of Severity of Pulmonary Hypertension With the Presence of Pulmonary Artery Aneurysm: A Brief Updated Review for Clinicians. Current Problems in Cardiology, 2023, 48, 101645.	1.1	2
4576	Effect of preoperative pulmonary artery pressure on the prognosis of end-stage heart failure patients after heart transplantation. Journal of Cardiothoracic Surgery, 2023, 18, .	0.4	0
4579	Prognostic value of follow-up vasoreactivity test in pulmonary arterial hypertension. Journal of Cardiology, 2023, 82, 69-75.	0.8	3
4580	The Î²3â€adrenoreceptor agonist mirabegron for the treatment of combined preâ€and postâ€capillary <scp>pulmonary hypertension</scp>: new pathway or dead end?. European Journal of Heart Failure, 2023, 25, 386-388.	2.9	0
4581	Curcumol suppresses endothelial-to-mesenchymal transition via inhibiting the AKT/GSK3Î² signaling pathway and alleviates pulmonary arterial hypertension in rats. European Journal of Pharmacology, 2023, 943, 175546.	1.7	2
4582	Predictors of Improvement in Exercise Tolerance After Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension. Journal of the American Heart Association, 2023, 12, .	1.6	1
4583	Monitoring of mitralâ€and tricuspid valve interventions with <scp>CardioMEMS</scp> : Insights beyond imaging. European Journal of Clinical Investigation, 0, , .	1.7	0
4584	Hub Genes and Immune Cell Infiltration in Hypoxia-Induced Pulmonary Hypertension: Bioinformatics Analysis and In Vivo Validation. Combinatorial Chemistry and High Throughput Screening, 2023, 26, 2085-2097.	0.6	0
4585	Pulmonary vasodilator therapies in pulmonary arterial hypertension associated with CHD: a systematic review and network meta-analysis. Cardiology in the Young, 2023, 33, 2297-2311.	0.4	0
4586	Discussion on operation: To compare the curative effect of PMT and CDT in the treatment of middle and high risk stratified APE and the clinical application value of serum BNP, TnI and plasma DFR levelse. Frontiers in Surgery, 0, 10, .	0.6	0
4587	Shikonin improves pulmonary vascular remodeling in monocrotalineâ€induced pulmonary arterial hypertension via regulation of PKM2. Molecular Medicine Reports, 2023, 27, .	1.1	4
4588	Oxygenated hemoglobin as prognostic marker among patients with systemic sclerosis screened for pulmonary hypertension. Scientific Reports, 2023, 13, .	1.6	1
4589	Differential Diagnosis of Pulmonary Veno-Occlusive Disease and/or Pulmonary Capillary Hemangiomatosis after Identification of Two Novel EIF2AK4 Variants by Whole-Exome Sequencing. Molecular Syndromology, 2023, 14, 254-257.	0.3	0
4590	In-depth characterization of pulmonary arterial hypertension in mixed connective tissue disease: a French national multicentre study. Rheumatology, 2023, 62, 3261-3267.	0.9	5
4591	Lung Dysfunction and Chronic Kidney Disease: A Complex Network of Multiple Interactions. Journal of Personalized Medicine, 2023, 13, 286.	1.1	6

#	Article	IF	Citations
4592	Efficacy and Safety of Balloon Pulmonary Angioplasty for Patients With Chronic Thromboembolic Pulmonary Hypertension and Comorbid Chronic Obstructive Pulmonary Disease. Journal of the American Heart Association, 2023, 12, .	1.6	2
4594	Effect of High-Altitude Exposure on the Heart. , 2023, 3, 48-53.		0
4595	Adverse reactions after treatment with dasatinib in chronic myeloid leukemia: Characteristics, potential mechanisms, and clinical management strategies. Frontiers in Oncology, 0, 13, .	1.3	4
4596	Planned Extracorporeal Life Support Employment during Liver Transplantation: The Potential of ECMO and CRRT as Preventive Therapiesâ€"Case Reports and Literature Review. Journal of Clinical Medicine, 2023, 12, 1239.	1.0	2
4597	Usefulness of Systemic Venous Ultrasound Protocols in the Prognosis of Heart Failure Patients: Results from a Prospective Multicentric Study. Journal of Clinical Medicine, 2023, 12, 1281.	1.0	2
4598	Machine Learning Based on Computed Tomography Pulmonary Angiography in Evaluating Pulmonary Artery Pressure in Patients with Pulmonary Hypertension. Journal of Clinical Medicine, 2023, 12, 1297.	1.0	1
4600	The Lung Transplant Candidate, Indications, Timing, and Selection Criteria. Clinics in Chest Medicine, 2023, 44, 15-33.	0.8	0
4601	Effect of multidisciplinary team (MDT) centred on pregnant women with pulmonary hypertension on treatment and outcomes of pregnancy. BMC Pulmonary Medicine, 2023, 23, .	0.8	6
4602	Left Ventricular Filling Pressure in ChronicÂThromboembolic PulmonaryÂHypertension. Journal of the American College of Cardiology, 2023, 81, 653-664.	1.2	11
4603	Doppler Echocardiography Combined with NTproBNP/BNP in the Diagnosis of Pulmonary Artery Hypertension Associated with Congenital Heart Disease. Computational and Mathematical Methods in Medicine, 2023, 2023, 1-5.	0.7	0
4604	Long COVID-19 Syndrome Severity According to Sex, Time from the Onset of the Disease, and Exercise Capacityâ€"The Results of a Cross-Sectional Study. Life, 2023, 13, 508.	1.1	4
4605	Diagnosis and management of pulmonary hypertension in infants with bronchopulmonary dysplasia: a guide for paediatric respiratory specialists. Breathe, 2022, 18, 220209.	0.6	3
4606	Evaluation of right ventricular strain in two separate cohorts with precapillary pulmonary hypertension. Pulmonary Circulation, 2023, 13, .	0.8	1
4607	Pathophysiology and Treatment of Chronic Thromboembolic Pulmonary Hypertension. International Journal of Molecular Sciences, 2023, 24, 3979.	1.8	7
4608	Risk Factors of Exchange Blood Transfusion in Infants With Severe Pertussis. Clinical Pediatrics, 0, , 000992282311549.	0.4	0
4609	Surgical and Device Interventions in the Treatment of Chronic Thromboembolic Disease. Pulmonary Therapy, 0, , .	1.1	0
4610	Successful Eisenmenger syndromeâ€targeted drug therapy in pregnant women: a case series and literature review. BJOG: an International Journal of Obstetrics and Gynaecology, 0, , .	1.1	0
4611	Serum Biomarkers in Connective Tissue Disease-Associated Pulmonary Arterial Hypertension. International Journal of Molecular Sciences, 2023, 24, 4178.	1.8	6

#	Article	IF	Citations
4612	Evaluation of the European Society of Cardiology/European Respiratory Society derived three- and four-strata risk stratification models in pulmonary arterial hypertension: introducing an internet-based risk stratification calculator. European Heart Journal Open, 2023, 3, .	0.9	3
4613	Fibroblast growth factor 23 as a biomarker of right ventricular dysfunction in pulmonary hypertension. Clinical Research in Cardiology, 0, , .	1.5	1
4614	Right Ventricular Function During Exercise After Pulmonary Endarterectomy for Chronic Thromboembolic Pulmonary Hypertension. Journal of the American Heart Association, 2023, 12, .	1.6	2
4615	CT quantitative analysis of pulmonary changes in rheumatoid arthritis. Journal of X-Ray Science and Technology, 2023, , 1-9.	0.7	0
4616	Characteristics and risk factors of mortality in patients with systemic sclerosis-associated interstitial lung disease. Annals of Medicine, 2023, 55, 663-671.	1.5	4
4617	Development of pulmonary arterial hypertension following long-term Qing-Dai use for ulcerative colitis. Journal of Cardiology Cases, 2023, 27, 218-221.	0.2	2
4618	Clinical Course of Suspected Diagnosis of Pulmonary Tumor Thrombotic Microangiopathy: A 10-Year Experience of Rapid Progressive Right Ventricular Failure Syndrome in Advanced Cancer Patients. Korean Circulation Journal, 2023, 53, 170.	0.7	2
4619	Multi-Task Learning for Pulmonary Arterial Hypertension Prognosis Prediction Via Memory Drift and Prior Prompt Learning on 3D Chest CT. IEEE Journal of Biomedical and Health Informatics, 2023, , 1-12.	3.9	0
4620	Point-of-Care Ultrasonography in a Pulmonary Hypertension Clinic: A Randomized Pilot Study. Journal of Clinical Medicine, 2023, 12, 1752.	1.0	0
4622	Perioperative Decision-Making in Pulmonary Hypertension. Heart Lung and Circulation, 2023, 32, 454-466.	0.2	1
4623	Sarcoidosis-associated pulmonary hypertension. Sestrinska Rec, 2022, 25, 26-30.	0.1	0
4624	Balloon pulmonary angioplasty followed by pulmonary endarterectomy: Combination treatment for high-surgical-risk patients with chronic thromboembolic pulmonary hypertension. , 2023, 36, .		0
4625	Long-Term Outcomes of Patients With Pulmonary Embolism Managed With Endovascular Therapies Compared to Medical Therapy. , 2023, , 100602.		1
4626	Plasma Connective Tissue Growth Factor as a Biomarker of Pulmonary Arterial Hypertension Associated With Congenital Heart Disease in Adults. Circulation Journal, 2023, 87, 527-535.	0.7	0
4627	Characteristics, treatments and survival of pulmonary arterial hypertension associated with congenital heart disease in China: Insights from a national multicenter prospective registry. Journal of Heart and Lung Transplantation, 2023, 42, 974-984.	0.3	1
4628	Identifying risk factors for perioperative decline in right ventricular performance in cardiac surgery patients: a prospective observational study in a tertiary care hospital. BMJ Open, 2023, 13, e068598.	0.8	0
4629	Oxygen Therapy in Pulmonary Vascular Disease. Heart Failure Clinics, 2023, 19, e1-e11.	1.0	2
4630	Patient Satisfaction with a Dedicated Infusion Pump for Subcutaneous Treprostinil to Treat Pulmonary Arterial Hypertension. Journal of Personalized Medicine, 2023, 13, 423.	1.1	1

#	Article	IF	Citations
4631	Right Ventricular Energy Failure Predicts Mortality in Patients With Pulmonary Hypertension. American Journal of Cardiology, 2023, 193, 19-27.	0.7	1
4632	State-of-the-art evidence in the treatment of systemic sclerosis. Nature Reviews Rheumatology, 2023, 19, 212-226.	3.5	21
4634	Fluid management in septic patients with pulmonary hypertension, review of the literature. Frontiers in Cardiovascular Medicine, 0, 10, .	1.1	0
4635	Case report: High-dose epoprostenol therapy in pediatric patients with pulmonary hypertension and developmental lung disease. Frontiers in Pediatrics, 0, 11, .	0.9	0
4636	Proteomics- and Metabolomics-Based Analysis of Metabolic Changes in a Swine Model of Pulmonary Hypertension. International Journal of Molecular Sciences, 2023, 24, 4870.	1.8	0
4637	The ratio of TAPSE to PASP predicts prognosis in lung transplant candidates with pulmonary arterial hypertension. Scientific Reports, 2023, 13, .	1.6	3
4638	Idiopathic Pulmonary Arterial Hypertension in Paediatrics Represents Still a Serious Challenge: A Case Series Study. Children, 2023, 10, 518.	0.6	1
4639	Hypochromic red cells as a prognostic indicator of survival among patients with systemic sclerosis screened for pulmonary hypertension. Arthritis Research and Therapy, 2023, 25, .	1.6	3
4641	Pulmonary arterial hypertension associated with congenital heart disease: An omics study. Frontiers in Cardiovascular Medicine, 0, 10, .	1.1	0
4642	Pharmacology and Emerging Therapies for Group 3 Pulmonary Hypertension Due to Chronic Lung Disease. Pharmaceuticals, 2023, 16, 418.	1.7	1
4643	A Comprehensive Secondary Prevention Benchmark (2PBM) Score Identifying Differences in Secondary Prevention Care in Patients After Acute Coronary Syndrome. Journal of Cardiopulmonary Rehabilitation and Prevention, 2023, 43, 245-252.	1.2	0
4644	Native T1 mapping in early diffuse and limited systemic sclerosis, and its association with diastolic function. Journal of Cardiology, 2023, 82, 100-107.	0.8	1
4645	Anesthesia management in a patient with anomalous origin of left pulmonary artery from the descending aorta: A case report and literature review. Frontiers in Surgery, 0, 10, .	0.6	0
4646	Prognostic Value of Transthoracic Echocardiography in Children With Pulmonary Arterial Hypertension. Journal of the American Heart Association, 0, , .	1.6	0
4647	The correlation in echocardiogram to right heart catheterization in identifying pulmonary hypertension as a barrier to liver transplantation. American Journal of the Medical Sciences, 2023, 365, 496-501.	0.4	0
4648	Evaluation and Management of Pulmonary Hypertension in Noncardiac Surgery: A Scientific Statement From the American Heart Association. Circulation, 2023, 147, 1317-1343.	1.6	21
4649	<scp>European Society of Cardiology quality indicators</scp> for the care and outcomes of adults with pulmonary arterial hypertension. Developed in collaboration with the <scp>Heart Failure Association of the European Society of Cardiology</scp>. European Journal of Heart Failure, 2023, 25, 469-477.	2.9	4
4650	Impact of Rheumatic Process in Left and Right Ventricular Function in Patients with Mitral Regurgitation. Global Heart, 2023, 18, .	0.9	0

#	Article	IF	Citations
4651	Pathogenetic rationale for prostanoids and role of inhaled iloprost in the treatment of pulmonary hypertension. Kardiologicheskii Vestnik, 2023, 18, 23.	0.1	0
4652	Epiphenomenon or Prognostically Relevant Interventional Target? A Novel Proportionality Framework for Severe Tricuspid Regurgitation. Journal of the American Heart Association, 2023, 12, .	1.6	2
4653	Routine Rehabilitation as a Treatment Component for Patients With Pulmonary Arterial or Chronic Thromboembolic Pulmonary Hypertensions. Journal of Cardiopulmonary Rehabilitation and Prevention, 0, Publish Ahead of Print, .	1.2	0
4654	Animal Disease Models and Patient-iPS-Cell-Derived In Vitro Disease Models for Cardiovascular Biologyâ€"How Close to Disease?. Biology, 2023, 12, 468.	1.3	1
4655	CT measured pulmonary artery to ascending aorta ratio stratified by echocardiographically obtained systolic pulmonary artery pressure values for noninvasive detection of pulmonary hypertension in patients with severe aortic valve stenosis. Clinical Research in Cardiology, 2023, 112, 1394-1416.	1.5	3
4656	Association between cumulative dose of hydroxychloroquine and electrocardiographic abnormalities in patients with systemic lupus erythematosus. European Journal of Internal Medicine, 2023, 112, 70-76.	1.0	0
4657	Post-Pulmonary Embolism Impairment Six Months after Acute Pulmonary Embolism: A Prospective Registry. Vascular and Endovascular Surgery, 2023, 57, 665-672.	0.3	1
4658	Cardiopulmonary exercise testing during follow-up after acute pulmonary embolism. European Respiratory Journal, 2023, 61, 2300059.	3.1	11
4659	A Nomogram for Predicting 3-Year Mortality in Patients with Pulmonary Hypertension due to Left Heart Failure: A Retrospective Analysis of a Prospective Registry Study. Cardiology, 2023, 148, 161-172.	0.6	0
4660	Treatment effects of pulmonary artery denervation for pulmonary arterial hypertension stratified by REVEAL risk score: Results from PADN-CFDA trial. Journal of Heart and Lung Transplantation, 2023, , .	0.3	1
4661	Medications to Avoid When Treating Heart Failure. , 2023, , 285-306.		0
4662	Tricuspid regurgitation in elderly patients with acute heart failure: insights from the KCHF registry. ESC Heart Failure, 2023, 10, 1948-1960.	1.4	3
4663	Economic burden of illness among patients with pulmonary arterial hypertension (PAH) associated with connective tissue disorders (CTD). Pulmonary Circulation, 2023, 13, .	0.8	4
4664	Severity of functional tricuspid regurgitation is associated with mortality in patients with pulmonary hypertension in longâ€term followâ€up. Pulmonary Circulation, 2023, 13, .	0.8	2
4665	Assessment of diaphragmatic function by ultrasonography in patients with systemic sclerosis and its relation to clinical parameters. Wiener Klinische Wochenschrift, 0, , .	1.0	0
4666	Prevalence of pulmonary hypertension in aortic stenosis and its influence on outcomes. Heart, 2023, 109, 1319-1326.	1.2	6
4667	Plasma mid-regional proadrenomedullin level in children with pulmonary hypertension associated with CHD. Cardiology in the Young, 0, , 1-7.	0.4	0
4668	Current clinical understanding and effectiveness of portopulmonary hypertension treatment. Frontiers in Medicine, 0, 10, .	1.2	1

#	Article	IF	Citations
4669	Consensus on the assessment of systemic sclerosisâ€“associated primary heart involvement: World Scleroderma Foundation/Heart Failure Association guidance on screening, diagnosis, and follow-up assessment. Journal of Scleroderma and Related Disorders, 0, , 239719832311634.	1.0	3
4670	Novel Drugs for the Treatment of Pulmonary Arterial Hypertension: Where Are We Going?. Drugs, 0, , .	4.9	1
4672	Isovolumetric Contraction as a Marker of Ventricular Performance in Patients with Afterload Mismatch. Diagnostics, 2023, 13, 1366.	1.3	0
4673	Autoregulation: mediators and reninâ€“angiotensin system in diseases and treatments. Future Journal of Pharmaceutical Sciences, 2023, 9, .	1.1	1
4674	Chronic thromboembolic pulmonary hypertension and the post-pulmonary embolism (PE) syndrome. Vascular Medicine, 2023, 28, 348-360.	0.8	3
4675	Long-term outcome of chronic thromboembolic pulmonary hypertension using direct oral anticoagulants and warfarin: a Japanese prospective cohort study. Journal of Thrombosis and Haemostasis, 2023, 21, 2151-2162.	1.9	5
4676	Pulmonary Artery Strain PredictsÂPrognosis in PulmonaryÂArterialÂHypertension. JACC: Cardiovascular Imaging, 2023, 16, 1022-1034.	2.3	4
4677	PH Professional Network: Real-World Implementation: Nursing Role in Balancing the Art and Science of PAH Risk Assessment. Advances in Pulmonary Hypertension, 2023, 22, 79-82.	0.1	0
4678	Review of Advances on Management of Chronic Thromboembolic Pulmonary Hypertension. International Journal of Angiology, 0, , .	0.2	0
4679	Non-invasive detection of severe PH in lung disease using magnetic resonance imaging. Frontiers in Cardiovascular Medicine, 0, 10, .	1.1	3
4680	Pulmonary hypertension in systemic sclerosis with usual interstitial pneumonia. Internal and Emergency Medicine, 0, , .	1.0	0
4681	Incidence and prognostic significance of malignant arrhythmias during (repetitive) Holter electrocardiograms in patients with pulmonary hypertension. Frontiers in Cardiovascular Medicine, 0, 10, .	1.1	0
4682	Metabolic profiling of in vivo right ventricular function and exercise performance in pulmonary arterial hypertension. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2023, 324, L836-L848.	1.3	1
4683	Safety and effectiveness of standardized exercise training in patients with pulmonary hypertension associated with heart failure with preserved ejection fraction (TRAIN-HFpEF-PH): study protocol for a randomized controlled multicenter trial. Trials, 2023, 24, .	0.7	0
4684	Human Endogenous Retrovirus, SARS-CoV-2, and HIV Promote PAH via Inflammation and Growth Stimulation. International Journal of Molecular Sciences, 2023, 24, 7472.	1.8	3
4685	Effects of the Oral Angiotensin II Type 2 Receptor Agonist C21 in Sugen-Hypoxia Induced Pulmonary Hypertension in Rats. International Journal of Molecular Sciences, 2023, 24, 7478.	1.8	5
4686	Cardiovascular Effect of Epoprostenol and Intravenous Cardiac Drugs for Acute Heart Failure on Canine Pulmonary Hypertension. Veterinary Sciences, 2023, 10, 302.	0.6	0
4687	Value of NT-proBNP and Galectin-3 as Biomarkers in the Follow-Up of Asymptomatic Elderly Patients with Severe Aortic Stenosis. Journal of Clinical Medicine, 2023, 12, 2987.	1.0	1

#	Article	IF	Citations
4688	Right ventricular free wall longitudinal strain assessment using offline speckle tracking in COVID-19 patients requiring intensive medical care. Journal of Medical Ultrasonics (2001), 2023, 50, 417-425.	0.6	1
4689	Comparative evaluation of costs and healthcare resource utilization of oral selexipag versus inhaled treprostinil or oral treprostinil in patients with pulmonary arterial hypertension. Journal of Medical Economics, 2023, 26, 644-655.	1.0	0
4690	Assessment of the effect of two regimens of milrinone infusion in paediatric patients with pulmonary artery hypertension undergoing corrective cardiac procedure: A prospective observational study. Annals of Pediatric Cardiology, 2022, 15, 358.	0.2	1
4706	Understanding and Engineering the Pulmonary Vasculature. Advances in Experimental Medicine and Biology, 2023, , 247-264.	0.8	0
4710	Ãœberwachung der Beatmung. , 2023, , 379-410.		0
4722	Sport bei Patienten mit angeborenen Herzfehlern (inklusive rechtsventrikulÃren Vitien). , 2023, , 273-284.		0
4728	Connective Tissue Disease-Associated Interstitial Lung Disease. , 2023, , 661-691.		0
4737	Pulmonary Hypertension (Management). An algorithmic Approach. , 2023, , .		0
4795	Pulmonale Hypertonie. Springer Reference Medizin, 2023, , 1-30.	0.0	0
4796	Vascular Diseases. , 2023, , 417-436.		0
4803	Case report: Myocardial perfusion gated-SPECT in pulmonary artery hypertensionâ€"the Movahed's sign. Frontiers in Cardiovascular Medicine, 0, 10, .	1.1	0
4856	Overview of Pulmonary Arterial Hypertension in Pregnancy. Contemporary Cardiology, 2023, , 387-393.	0.0	0
4864	GanzkÃ¶rpervibrationstherapie bei Patienten mit pulmonaler Hypertonie und Rechtsherzinsuffizienz: Lehren aus einer Pilotstudie. , 2023, , 389-397.		0
4896	Pediatric Pulmonary Hypertension. , 2023, , 1-34.		0
4904	POCUS in Monitoring: Right Ventricular Function and Pulmonary Hypertension. , 2023, , 231-249.		0
4917	Characterization of pulmonary arterial stiffness using cardiac MRI. International Journal of Cardiovascular Imaging, 2024, 40, 425-439.	0.7	1
4923	The Role of Lung Ventilation/Perfusion Scan in the Management of Chronic Thromboembolic Pulmonary Hypertension. Nuclear Medicine and Molecular Imaging, 0, , .	0.6	1
4928	Recent developments in dry powder inhalation (DPI) formulations for lung-targeted drug delivery. Journal of Pharmaceutical Investigation, 0, , .	2.7	1

#	Article	IF	Citations
4939	Pulmonary Vascular Diseases. , 2023, , 191-200.		0
4952	Lung Transplantation for Pulmonary Artery Hypertension. , 0, , .		0
4960	Clinical Cases of Electrosonography in Patients with Shortness of Breath. , 2023, , 185-241.		0
4964	Pulmonary Vascular Disease. , 2023, , 225-243.		0
4968	Left heart disease in pulmonary hypertension. , 0, , .		0
4983	Begutachtung bei venÃ¶sen thromboembolischen Erkrankungen. Springer Reference Medizin, 2023, , 1-9.	0.0	0
4992	Pulmonale Hypertonie. Springer Reference Medizin, 2023, , 459-488.	0.0	0
5001	Imaging in Ventricular Septal Defect. , 2023, , 187-214.		0
5007	Eisenmenger Syndrome and Other Types of Pulmonary Arterial Hypertension Related to Congenital Heart Disease. , 2024, , 1-17.		0
5031	Erwachsene mit angeborenen Herzfehlern (EMAH). Springer Reference Medizin, 2023, , 1-31.	0.0	0
5063	Classification, Diagnosis, and Medical Treatment of Pulmonary HypertensionÂ. , 0, , .		0